<SEC-DOCUMENT>0001401914-20-000118.txt : 20201112
<SEC-HEADER>0001401914-20-000118.hdr.sgml : 20201112
<ACCEPTANCE-DATETIME>20201112160438
ACCESSION NUMBER:		0001401914-20-000118
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201112
DATE AS OF CHANGE:		20201112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Dare Bioscience, Inc.
		CENTRAL INDEX KEY:			0001401914
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				204139823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36395
		FILM NUMBER:		201306566

	BUSINESS ADDRESS:	
		STREET 1:		3655 NOBEL DRIVE
		STREET 2:		SUITE 260
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122
		BUSINESS PHONE:		858-926-7655

	MAIL ADDRESS:	
		STREET 1:		3655 NOBEL DRIVE
		STREET 2:		SUITE 260
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cerulean Pharma Inc.
		DATE OF NAME CHANGE:	20090714

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tempo Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20070604
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>dare-20200930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:9ad61a15-e285-44cc-ad2a-44a040d7fb22,g:5f0dd9b0-b13f-4c69-b05c-880a09202ba6,d:868f48d3ece34cfab595a46f6986b439--><html xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dare="http://darebioscience.com/20200930" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>dare-20200930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80L2ZyYWc6ZjI5OGViOWI0OTNhNGI0MmE2ODkxNWQzNDE4MjI1MDEvdGFibGU6MGUxMTU2OTU3MGI4NDY0M2EyODE0OTcxYjgxMWRmZmMvdGFibGVyYW5nZTowZTExNTY5NTcwYjg0NjQzYTI4MTQ5NzFiODExZGZmY18yLTEtMS0xLTA_1e086ec7-780d-40e4-a6dd-3c37bc13b5c4">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80L2ZyYWc6ZjI5OGViOWI0OTNhNGI0MmE2ODkxNWQzNDE4MjI1MDEvdGFibGU6MGUxMTU2OTU3MGI4NDY0M2EyODE0OTcxYjgxMWRmZmMvdGFibGVyYW5nZTowZTExNTY5NTcwYjg0NjQzYTI4MTQ5NzFiODExZGZmY180LTEtMS0xLTA_7d037d88-8186-44d8-b196-107b52cfc9fd">2020</ix:nonNumeric><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80L2ZyYWc6ZjI5OGViOWI0OTNhNGI0MmE2ODkxNWQzNDE4MjI1MDEvdGFibGU6MGUxMTU2OTU3MGI4NDY0M2EyODE0OTcxYjgxMWRmZmMvdGFibGVyYW5nZTowZTExNTY5NTcwYjg0NjQzYTI4MTQ5NzFiODExZGZmY181LTEtMS0xLTA_8e4eafeb-c4fd-446c-b432-6ce124003295">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80L2ZyYWc6ZjI5OGViOWI0OTNhNGI0MmE2ODkxNWQzNDE4MjI1MDEvdGFibGU6MGUxMTU2OTU3MGI4NDY0M2EyODE0OTcxYjgxMWRmZmMvdGFibGVyYW5nZTowZTExNTY5NTcwYjg0NjQzYTI4MTQ5NzFiODExZGZmY183LTEtMS0xLTA_7c8e6b50-3c93-41f9-8362-a1204438413b">0001401914</ix:nonNumeric><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80L2ZyYWc6ZjI5OGViOWI0OTNhNGI0MmE2ODkxNWQzNDE4MjI1MDEvdGFibGU6MGUxMTU2OTU3MGI4NDY0M2EyODE0OTcxYjgxMWRmZmMvdGFibGVyYW5nZTowZTExNTY5NTcwYjg0NjQzYTI4MTQ5NzFiODExZGZmY184LTEtMS0xLTA_c33cabd1-85cf-4804-b8fe-e978964f7a69">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81NS9mcmFnOjRhOTdjNWI4Y2ZjYzQ0ZDI5ZWUyYTA3NGZlYTcwNjgzL3RhYmxlOjA4MmJmMjk3ODYxNTRiYTk4ZjdkNmMyMDdjMGY1OTAzL3RhYmxlcmFuZ2U6MDgyYmYyOTc4NjE1NGJhOThmN2Q2YzIwN2MwZjU5MDNfMS0xLTEtMS0w_cbaf9acf-1f46-4f5d-a9e2-e57f2655c64a">us-gaap:OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81NS9mcmFnOjRhOTdjNWI4Y2ZjYzQ0ZDI5ZWUyYTA3NGZlYTcwNjgzL3RhYmxlOjA4MmJmMjk3ODYxNTRiYTk4ZjdkNmMyMDdjMGY1OTAzL3RhYmxlcmFuZ2U6MDgyYmYyOTc4NjE1NGJhOThmN2Q2YzIwN2MwZjU5MDNfMi0xLTEtMS0w_e450dd45-6e1c-4ce6-a80b-54086aadb951">us-gaap:OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81NS9mcmFnOjRhOTdjNWI4Y2ZjYzQ0ZDI5ZWUyYTA3NGZlYTcwNjgzL3RhYmxlOjA4MmJmMjk3ODYxNTRiYTk4ZjdkNmMyMDdjMGY1OTAzL3RhYmxlcmFuZ2U6MDgyYmYyOTc4NjE1NGJhOThmN2Q2YzIwN2MwZjU5MDNfMy0xLTEtMS0w_69a33745-9a1c-4e9e-971d-3fab9230fb83">us-gaap:OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="dare-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i49663014624147daaf0460b147931a88_I20201111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i541d1593a6734f80a2264c14bc99a339_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44cca179a4a34f1e858332eb7fcba586_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="id8c96646bea247b9938b381dd4090324_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4aae1fde8a24498b3bc6e50aff2d4e1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8afa8464781b49a39b4681faf83f4671_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0073ec1a844c45b1b12b82e642dd6a0d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84723044896e4ab9937bf3130967d6a7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88d2ffda43594518bae4aac3bbe0861d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i433a6eab314144b584233fa1098fc8b0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibed628a16b5f4ca89e9d282060d3f6a9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d54ca496ab242d283acce737c73d143_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i468d0e095ca5490b9de2575fd7a58a4e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i778d6dd4e63740179791957d7305f2d7_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9582df1f48a942c1843feec52a079e1b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib17d45f7c7314d7e8b1fcddab7ac50b4_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideedcc5e7e244a87ad925fd33a419342_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f7e83b86b284e20a0d23c9d195bdac6_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9145a313e1704334b699d500b0ae36f5_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i151cfac574024088b63a3767d69922af_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib72039df45d24401a53a53bc832e4837_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1cc1b354afd4948a85810f1bd926e05_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64f2c60cd7e34b7a8f98d5f6c6890113_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a5c11ea74534c2794d2172e3aa03449_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76559cf393ca49de9e7e135807775d99_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcd5510991654ecd9e8099e2226b8f7d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8703c6e447584c3a98ba5761b1da8b14_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57949e2187364d4a9adfe732ba2936e0_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if86e95ff8cf340409d913ec4b47d61aa_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib52fe01a8be246969cc36b76ea728405_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c6459561ac24633955667a0e138a61d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5b514c768bf44b98354f79ace769b2b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb45eeeb928743849e7b50bfe4b365b2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2787ea775c17482bae9bb54124be9c7a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b807e058c5c42409d7dfd94b4bd478f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaebd7d8309614a7e99f2a6f1bb3dafb1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i230e979e152146c681167c318df557ef_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i688bebc3cdcd4ca48392c35cf27fb782_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a5ba66df1e847c9a79436490357853b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78009fb2296d46f394545d697435837a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25c35de4c46a4497b5ac99d104d6962c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0a3948de04b49feb4074444bfe4c48a_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7acea1d9dc949cdb1eba8efb4698c44_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8280d4d773d546688557038d3b275d97_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49b5674e31f74d72ba13e82dac7e8633_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida47f40a6fe841c087027031cad177ba_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib92f3eb9ef0b48db84cc7350557622d2_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c547f1fe1484bc6a952437a3d10d9dd_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i449930a975d04b9ea1c18df54bf78b4b_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i353a8bedc0db4bee96fe2d31985e5160_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id22f3847410f44a987757fc5805190ca_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42ad961aed164f408dfab70f502a4e98_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia38cd88862524a25953e1e12fcbed8da_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20c1dd4c92ea492d812ea60776150735_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i368ed0b181144e64a2f66800be6d6815_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99271232f7ab4dc9b246dc5b7b11dcad_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4ff10b061754f5888a60896993775e5_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id40cf5fc96ed4ccdabbc1a27d10c3f5b_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf2e4de4cdd14243bd2e981a38608f20_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c0eb362b20e46349b240d667ece7a11_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9e90787a50b48e68e5848b83240c00e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaf82bec24924dfa8554c21c40d52902_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1138443634a2487caabd35c4a968772e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0593b34027c74956b65c17141dc3c7fe_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a4b2196c78848c28cbb2f6c038213dd_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i102d49b207054edeacf51fa8bd1a45a3_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a33072e23e94e97a50599beb8d9e67a_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3d4d54b0f7c4a229b25cbe2d9ad07e1_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>dare:segment</xbrli:measure></xbrli:unit><xbrli:context id="i17feaef906b24653ac55862eb815e6dc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61802997b9674fab8ffd3af8bfb3c702_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5ea3391305d40f1a09bb8baa7e4411b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9564923853734eb58d6d4aa1c93e63f2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf36c001049f4946aa8e0ca7818e0e67_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i237f1cb504f84950b23fc22b495fd451_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95e67fe471b24b518cb739618ce1fa5b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d74cf524f4149c68caa93d927c1dd50_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i073719e46a364115ad47c32863916d2b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28e27dfd8d1744fd931fe1123a4379d6_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:BayerHealthcareLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib620eb86663f4b8eb249d3ca45e8961f_D20200110-20200110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:BayerHealthcareLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-10</xbrli:startDate><xbrli:endDate>2020-01-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i675ccdafc7724770bc5f9d69ad53a137_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i663f6a3e47204c84a850cfb01668fd90_D20191205-20191205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-05</xbrli:startDate><xbrli:endDate>2019-12-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13d5e927223840e1ae39274dbb5609d3_D20200131-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-31</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic44f91cd00fb46e9b948e5acc2a670e9_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2508e3e579a94cdea63398846fa669b5_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9480befabfcf46ad88721e52ff929278_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib18fb0a15d48447fa6a79f7ea2a55a0f_D20191205-20191205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:HammockPharmaceuticalsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:AssignmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-05</xbrli:startDate><xbrli:endDate>2019-12-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib69e2f5dfaaa4c50b61ce358dfe41490_D20200131-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:HammockPharmaceuticalsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:AssignmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-31</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d27e115aa2d4aa195fb48879883d1a1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:HammockPharmaceuticalsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:AssignmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i389b47dad95042fe93f5c460e656a37d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:HammockPharmaceuticalsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:AssignmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84c418494d874dde87ff86a8ad8133ad_D20170301-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27a820732a994084bea4346080486a18_D20170301-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dare:UponReachingCertainWorldwideNetSalesMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i8f872d8e39ed4734a655cc6daabe747c_D20170301-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc98d29e798c45f386168a17588148ad_D20170301-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88ef2e92e2db432987e74cad75d700a3_D20180201-20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if910f6abc722476083f07bcc96a49f22_D20180201-20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ef6eb9665eb4b70a2eaa329f9ee2427_D20180201-20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75219243251d4cfb879a00b8d9c29575_D20180201-20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if58b7340a7a6466bb0aae7cb62f4cf97_D20180201-20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49b990efd5e94bda8624d4a3746d6795_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35e21a41a4f34efb9124460b6ace1b6e_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5cb9f4c567542a0a0afd091500582b8_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:SalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb3910bfa3544d7bb4cb75487de595bc_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:AdarePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:DevelopmentAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8e3c00cd33e4af2a7e1c65065c3b12b_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:AdarePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:DevelopmentAndOptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponSigningOfDevelopmentAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9aa0a2281ea41fc9868218205b55f9c_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:AdarePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:DevelopmentAndOptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d6c1e846f824bddaf958f3525ddafea_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:AdarePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:DevelopmentAndOptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i240f37dfb7c84e948e9a4cfed130cbc1_D20191130-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-30</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86cbc311d1df479cb96f4a597e179fe5_D20191120-20191120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-20</xbrli:startDate><xbrli:endDate>2019-11-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19e761cec8174fb4bcb03e95810a4853_I20191120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ad6893defad461fa065876a751e3690_I20191120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibec4b74376bf439b97a248a65f5b0eae_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i934a565bb58b4ec5acca2c91b69403b1_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a4aaadc8c3b47a6a160697edf8e4341_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6272459e3f90454cbd5e25ce85446ee8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">dare:PrivateDareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ab49a29689548b9833e3f0ae8c799b5_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2928b74a51bf456b8caf39b2a4cfa467_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e27560f58324d76aa01f67cbf138dc4_I20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91e3f089ee85463896dc24cc0479b252_I20180710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48b5c358a2b64cbf929fdc1e1a69614a_D20180710-20180710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-10</xbrli:startDate><xbrli:endDate>2018-07-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0e7f22b525c449280e635ae64efe397_D20200101-20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia09f304e0bb247cd9fb0ea915995673a_I20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6fbf357b1224eeb9a1eed68e2f55aff_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3721c96df454703ab043d1b9396afec_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i748cf08e328d4f8e88ce6250028b6f5c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaedce4b2446d4390afdde0c8b65ed211_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id30e47d05e2d4a89bd634aed60cdde96_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib435822bc7804f31be11690ccf5f9859_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b128d3f8bbe4c5482cb6f55c962c6aa_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9f7aa24af72476481534c2c2f333aba_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d8b23a6ddc647dd8a654ce4e72821b1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i164eef1d163e46c2afb6bc319807e895_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55a9907b8e8649348aa6657478dfe2cc_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3caed64836884e1cb8f9c5b521f55da0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea59aafe0f1745f7a971f2eaffe8481c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i452d4b20caeb47d2985cd2793d9a7eac_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic57e6d999ba14991863c6606b7f50384_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56d13a7ae7894e27975f5d3dc7ebf378_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2c303c2ae4943dd8fbcfc1e44714b26_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i416122ab3120493b993ec3ad05b96111_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a6ac70780144725885adc47194a94b4_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i868ac446cd6e4c439961eab65e3c6861_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60d87dbf215545a1b5c48615b58b820f_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia456760e828443768946d965d3e5d697_D20190412-20190412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-12</xbrli:startDate><xbrli:endDate>2019-04-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f7b9efd7dda44b2bec435609ae73e40_I20200422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">dare:LincolnParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bfaf2e8371745b2b5e46ebc3e913e82_D20200422-20200422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-22</xbrli:startDate><xbrli:endDate>2020-04-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd932424f77b4acfbcb47c05aacbb08a_D20200501-20200501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01002baf920d410fac2c775eac9c140e_I20200422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib32b7d0c93d34cbe804300d040f5b315_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5c15ea8e6c24d4b9e6b1c403108842f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie264785d23cd421d928dd14372cfabf0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08898414c3aa4894b7ad663dd58d2ddc_D20200422-20200422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-22</xbrli:startDate><xbrli:endDate>2020-04-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0955c43f6b5843e3b4a7d1e24a09a0ae_D20200422-20200422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-22</xbrli:startDate><xbrli:endDate>2020-04-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia927dba53c23411a8034d4380544fcb1_D20200422-20200422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-22</xbrli:startDate><xbrli:endDate>2020-04-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic533380ee2c447de91cd03aa8a73d217_I20200422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61a90f906d204892bcb7fb20f2f34ff8_I20200422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie54a63cb8870455387d630bcd302c82e_I20200421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i648dfc2b093f4a32a88926256f87782e_I20200422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic75ab5f711a541808c1cac6b1d2728cc_I20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0a8869e72f444d7a1483b278b655bd2_I20180215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201711Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8656d31612a94a26a509031e31dde229_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1285bc78ac34b519323112460b394f5_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2508825fce204dd18b05c1f2654f691a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic02e362243bc4544af3beee1e4271766_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd48642e50f1470c986bf4baf9540666_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i194102b3e8904dd394f4b80afaad69ba_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i856b85e65eba4389af62e53fcb4ddb88_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnAprilFourTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2f84c97f44e4cb286f9274ce4c5ce72_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnAprilFourTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife8c2ec7d4b44a57b608f2c92187d0d9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i637dd6b17c604a2b8aa23ef3d1d38219_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i8ad78d95daba4838b75da7b4df9b8b00_I20180701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5600cf051b646c18541fb6d7163c31b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07edbdfe23b14e1b882ecc8189596d12_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5eedf8fd854e4e299d621b34d7105036_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cd38b5d0d18443eb25f5b075faaf8d0_D20180101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec804f8af9ee49218d67d6fd78a4180c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantOvapreneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i160a0b42d86e4a8bbd0f05476b0f68e6_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantOvapreneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07b04c713b994fddb69fb22f61dcce47_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantOvapreneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee4d04ac7d154b5da7eff0fa25f65c41_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantOvapreneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa5514aaaa824b3aa79107f5c9c5d73d_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREFRT1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida0b6e85f82e4e608327c8ca8bc71f2d_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREFRT1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61ac128034e543f09fa5c2ccee686dd9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREFRT1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6eebb50c9aa442eb1c1e54f219936db_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREFRT1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e9574645f90496484a14992487f17b9_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareTrustFundAxis">dare:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08cd90f2ba3140dbb283240c624fe12e_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareTrustFundAxis">dare:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f10d1b26cc94a1fa3cb93ec8aedbb85_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareTrustFundAxis">dare:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i811a18ee61a041bcb8b2a9a6d171b9a6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:NationalInstitutesOfHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f2fd361955c4af0b36cfc82bd1dd299_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c48e9816275492c80d5c9b5987290e9_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fa32febc2e54647a6368e846d71b024_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd0fb129419e4ee29415f58d00c829e5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia980a0c4d8c2414ca34948ab72d9b74d_D20201001-20201111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:AtTheMarketEquityOfferingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic93f45ca4cb841cf9744ed2f4001e2a4_D20201001-20201111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-11-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i868f48d3ece34cfab595a46f6986b439_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGV4dHJlZ2lvbjpjYmI3NzIwZDNkZGE0ZmRjYWQwYzkwNDg2YzA0MDRkMF8xNzQ5_9e17a434-88f5-425a-a0ba-6bd51770ed16">10-Q</ix:nonNumeric></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6ZmE3YzY0YjlhNWRmNGQ2Zjk1YjZhYzRkMjI3NjUyZDkvdGFibGVyYW5nZTpmYTdjNjRiOWE1ZGY0ZDZmOTViNmFjNGQyMjc2NTJkOV8wLTAtMS0xLTA_b8e9ca27-6e51-450e-9859-7e31cd4adab1">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGV4dHJlZ2lvbjpjYmI3NzIwZDNkZGE0ZmRjYWQwYzkwNDg2YzA0MDRkMF8zMjk4NTM0ODg1MDk3_8c32770a-8174-4658-82ba-427dc52a8667">September 30, 2020</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center;text-indent:47.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6ZDI2NTBkMDk1ZmQ3NGNhOWJhN2MxOGIzN2QzOTIzODIvdGFibGVyYW5nZTpkMjY1MGQwOTVmZDc0Y2E5YmE3YzE4YjM3ZDM5MjM4Ml8wLTAtMS0xLTA_973efafb-afcd-4dc6-b272-e1d7aa91b66e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><img src="dare-20200930_g1.jpg" alt="dare-20200930_g1.jpg" style="height:106px;width:269px"/></div><div style="margin-bottom:5pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.994%"><tr><td style="width:1.0%"></td><td style="width:27.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF8wLTEtMS0xLTAvdGV4dHJlZ2lvbjozNTIzYzI1ZDA4NzM0OTkyOTZjNTgxYjNkZDg2NDFiNF81_c28aed9a-9cb2-48f5-b9d5-7d4780cbade6">DAR&#201; BIOSCIENCE, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Exact Name of Registrant as Specified in its Charter)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF8xLTAtMS0xLTAvdGV4dHJlZ2lvbjozMjAyZDQ5ZDU0MGY0NTFkOTE1YmQ2MGZkYjJlMDYyNV81_d64c901f-e8cb-41db-96de-1d6fa995ebe2">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or Other Jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commission File No. <ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF8xLTEtMS0xLTAvdGV4dHJlZ2lvbjpkODU1MjJjOTljMDM0MThjYjc2Y2MyNzE5ZmE3ZDllOV8yNA_4f544cfc-c5be-4158-bdd1-f94e7387a233">001-36395</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF8xLTItMS0xLTAvdGV4dHJlZ2lvbjphMzY1ZGM0YTQ5OTg0N2Q1OWNlMmVlODVmZTVjZGVmNl81_1b3e9f89-860b-4a21-8c5c-79ee4ee916ff">20-4139823</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identification No.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpmNDY0YWYyZTEzMTQ0YTUxOWI0ZjdlZGNmZTg1NTIyM181_e62c6400-582d-41b9-8626-fc80f195693f">3655 Nobel Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpmNDY0YWYyZTEzMTQ0YTUxOWI0ZjdlZGNmZTg1NTIyM185_083db6e2-0cd7-479a-8bb0-1588a3a68a0b">Suite 260</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpmNDY0YWYyZTEzMTQ0YTUxOWI0ZjdlZGNmZTg1NTIyM18xMg_e66b2dd6-fcbc-498e-878f-d65107b49fbe">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpmNDY0YWYyZTEzMTQ0YTUxOWI0ZjdlZGNmZTg1NTIyM18xNg_92a0e067-8449-48e1-9db0-f271ba8506be">CA</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF8zLTEtMS0xLTAvdGV4dHJlZ2lvbjo1YjEzNmIyZGY5YmY0MGNmODU2Nzk3ZDU2N2FlODExNV82_c4e563c4-ebb3-4a22-809d-11663132e256">858</ix:nonNumeric>) <ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF8zLTEtMS0xLTAvdGV4dHJlZ2lvbjo1YjEzNmIyZGY5YmY0MGNmODU2Nzk3ZDU2N2FlODExNV8xMA_3d73e358-ee00-4b8e-afc2-9e80e6f8cbc4">926-7655</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF8zLTItMS0xLTAvdGV4dHJlZ2lvbjplODI0NWNlZGViNDM0YjAyYjM1MWQzMGM3MjE1Zjc3NF81_8c88d8df-f0d7-4b95-befe-9ed11b0f08f2">92122</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Zip Code)</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Former name, former address and former fiscal year, if changed since last report)</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF84LTAtMS0xLTA_87ede753-553a-4670-b0ce-dd8405f10a09">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF84LTEtMS0xLTA_d5b62427-d99f-4f30-9514-7fe8f2ae4caf">DARE</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nasdaq Capital Market</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGV4dHJlZ2lvbjpjYmI3NzIwZDNkZGE0ZmRjYWQwYzkwNDg2YzA0MDRkMF8xNzQ2_08ddf95d-c9d5-4651-a352-9db6119168fd">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGV4dHJlZ2lvbjpjYmI3NzIwZDNkZGE0ZmRjYWQwYzkwNDg2YzA0MDRkMF8xNzQ3_b9addc52-4e8c-4c12-bebb-eb94d0aa31f2">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjQxYTQyNmVlMzhlNGNlODkyMWUxNzM4MTFkMTczZjcvdGFibGVyYW5nZTo2NDFhNDI2ZWUzOGU0Y2U4OTIxZTE3MzgxMWQxNzNmN18xLTAtMS0xLTA_a7a70b78-8624-4a2d-8e2d-52723ca69e4d">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" format="ixt:booleantrue" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjQxYTQyNmVlMzhlNGNlODkyMWUxNzM4MTFkMTczZjcvdGFibGVyYW5nZTo2NDFhNDI2ZWUzOGU0Y2U4OTIxZTE3MzgxMWQxNzNmN18xLTUtMS0xLTA_8ac95871-c8d9-4b98-8a19-ab65c5507b4f">x</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjQxYTQyNmVlMzhlNGNlODkyMWUxNzM4MTFkMTczZjcvdGFibGVyYW5nZTo2NDFhNDI2ZWUzOGU0Y2U4OTIxZTE3MzgxMWQxNzNmN18yLTItMS0xLTA_8b7a8a8a-3f66-41a7-a8b7-63cb72ec686c">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o </span></div><div style="margin-top:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGV4dHJlZ2lvbjpjYmI3NzIwZDNkZGE0ZmRjYWQwYzkwNDg2YzA0MDRkMF8xNzQ4_058826d5-b056-434b-9a5f-4e651af314a4">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x </span></div><div style="margin-top:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of November&#160;11, 2020, <ix:nonFraction unitRef="shares" contextRef="i49663014624147daaf0460b147931a88_I20201111" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGV4dHJlZ2lvbjpjYmI3NzIwZDNkZGE0ZmRjYWQwYzkwNDg2YzA0MDRkMF8xNjUy_f041bbd4-e12e-4c28-8bc7-49d853947d21">37,990,001</ix:nonFraction> shares of the Registrant&#8217;s Common Stock, par value $0.0001, were issued and outstanding.</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i868f48d3ece34cfab595a46f6986b439_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q, in particular &#8220;Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations,&#8221; of Part I. Financial Information, and the information incorporated by reference herein contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this report, including statements regarding our strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;design,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;could,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;contemplate,&#8221; project,&#8221; &#8220;target,&#8221; &#8220;tend to,&#8221; or the negative version of these words and similar expressions.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including those factors described in Part II, Item 1A, &#8220;Risk Factors,&#8221; in this report, and elsewhere in this report. Given these uncertainties, you should not place undue reliance on any forward-looking statement. The following factors are among those that may cause such differences:</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Inability to continue as a going concern;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Inability to raise additional capital, under favorable terms or at all, including as a result of the effects of the COVID-19 pandemic;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Inability to successfully attract partners and enter into collaborations relating to the development and/or commercialization of our product candidates on a timely basis or on acceptable terms, or at all;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">A decision by Bayer HealthCare LLC to discontinue its commercial interest in Ovaprene&#174; and/or to terminate our license agreement;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Inability or an increase in projected costs to timely develop, obtain regulatory approval for and commercialize our product candidates;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Failure or delay in starting, conducting and completing clinical trials or obtaining United States Food and Drug Administration, or FDA, or foreign regulatory approval for our product candidates in a timely manner, including as a result of matters beyond our control such as the effects related to geopolitical actions, natural disasters, or public health emergencies or pandemics, such as the COVID-19 pandemic;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">A change in the FDA Center assigned primary oversight responsibility for our combination product candidates;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">A change in regulatory requirements for our product candidates, including the development pathway pursuant to Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, or the FDA's 505(b)(2) pathway;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Unsuccessful clinical trial outcomes stemming from clinical trial designs, failure to enroll a sufficient number of patients, higher than anticipated patient dropout rates, failure to meet established clinical endpoints, undesirable side effects and other safety concerns;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Reaching a conclusion regarding the efficacy or safety of a product candidate following full evaluation of complete clinical study data that is materially different from topline study results we may report;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Communication from the FDA or another regulatory authority that it does not accept or agree with our assumptions, estimates, calculations, conclusions or analyses of clinical or nonclinical study data regarding a product candidate, or that it interprets or weighs the importance of study data differently than we have in a manner that negatively impacts the candidate's prospects for regulatory approval in a timely manner, or at all;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Negative publicity concerning the safety and efficacy of our product candidates, or of product candidates being developed by others that share characteristics similar to our candidates;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Inability to demonstrate sufficient efficacy of our product candidates;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to select or capitalize on the most scientifically, clinically or commercially promising or profitable indications or therapeutic areas for our product candidates due to limited financial resources;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Loss of our licensed rights to develop and commercialize a product candidate as a result of the termination of the underlying licensing agreement;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Monetary obligations and other requirements in connection with our exclusive, in-license agreements covering the patents and related intellectual property related to our product candidates, or our merger or asset purchase agreements relating to the acquisition of our product candidates;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Developments by our competitors that make our product candidates less competitive or obsolete;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Dependence on third parties to conduct nonclinical studies and clinical trials of our product candidates;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Dependence on third parties to supply and manufacture clinical trial materials and, if any of our candidates are approved, commercial product, including components of our products as well as the finished product, in accordance with current good manufacturing practices and in the quantities needed;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cyber-attacks, security breaches or similar events compromising our technology systems or the technology systems of third parties on which we rely; </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Interruptions in, or the complete shutdown of, the operations of third parties on which we rely, including clinical sites, manufacturers, suppliers, and other vendors, from matters beyond their control, such as the effects related to geopolitical actions, natural disasters, or public health emergencies or pandemics, such as the COVID-19 pandemic, and our lack of recourse against such third parties if their inability to perform is excused under the terms of our agreements with such parties;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Failure of our product candidates, if approved, to gain market acceptance or obtain adequate coverage for third party reimbursement;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">A reduction in demand for contraceptives caused by an elimination of current requirements that health insurance plans cover and reimburse certain FDA-cleared or approved contraceptive products without cost sharing;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Uncertainty as to whether health insurance plans will cover our product candidates even if we successfully develop and obtain regulatory approval for them;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Unfavorable or inadequate reimbursement rates for our product candidates set by the United States government and other third-party payers even if they become covered products under health insurance plans;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Difficulty in introducing branded products in a market made up of generic products;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Inability to adequately protect or enforce our, or our licensor&#8217;s, intellectual property rights;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Lack of patent protection for the active ingredients in certain of our product candidates which could expose those product candidates to competition from other formulations using the same active ingredients;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Higher risk of failure associated with product candidates in pre-clinical stages of development that may lead investors to assign them little to no value and make these assets difficult to fund;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Disputes or other developments concerning our intellectual property rights;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Actual and anticipated fluctuations in our quarterly or annual operating results;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Price and volume fluctuations in the stock market, and in our stock in particular, which could subject us to securities class-action litigation;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to maintain the listing of our common stock on the Nasdaq Capital Market or another nationally recognized exchange;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation or public concern about the safety of our potential products;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Strict government regulations on our business, including various fraud and abuse laws, including, without limitation, the U.S. federal Anti-Kickback Statute, the U.S. federal False Claims Act and the U.S. Foreign Corrupt Practices Act;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Regulations governing the production or marketing of our product candidates;</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Loss of, or inability to attract, key personnel; and</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Increased costs as a result of operating as a public company, and substantial time devoted by our management to compliance initiatives and corporate governance practices.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">All forward-looking statements in this report are current only as of the date of this report. We do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any statement is made or to reflect the occurrence of unanticipated events, except as required by law.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i868f48d3ece34cfab595a46f6986b439_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_13">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_16">Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_13">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_70">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_70">23</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_97">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_97">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_100">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_100">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_103">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_106">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_106">35</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_109">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_109">35</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_112">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_112">38</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_115">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_115">38</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_118">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_118">38</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_121">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_121">38</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_124">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_124">39</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_127">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i868f48d3ece34cfab595a46f6986b439_127">40</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i868f48d3ece34cfab595a46f6986b439_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I.&#160;&#160;&#160;&#160;FINANCIAL INFORMATION</span></div><div id="i868f48d3ece34cfab595a46f6986b439_16"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Consolidated Financial Statements (Unaudited)</span></div><div style="margin-top:10pt"><span><br/></span></div><div id="i868f48d3ece34cfab595a46f6986b439_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dar&#233; Bioscience, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfNC0xLTEtMS0w_b993d7e6-f240-413a-9141-8c227fc044a3">5,389,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfNC0zLTEtMS0w_9d94c6e5-2392-4e65-a4f1-4bc25d6c97b9">4,780,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfNS0xLTEtMS0w_008f138d-13b4-4959-84cb-38914649f86a">213,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfNS0zLTEtMS0w_bc9368d7-654d-4695-982c-86a1c7d038cd">555,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfNi0xLTEtMS0w_d5bd65ee-ff59-434b-9e94-f7bf43858848">1,381,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfNi0zLTEtMS0w_fd9da235-a639-418e-94e5-4debbdc3afdd">1,108,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfOC0xLTEtMS0w_52a4ab8c-3489-4716-8426-d43370d6f9ab">6,984,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfOC0zLTEtMS0w_8860ded9-275f-461c-a004-ea29b1514587">6,443,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfOS0xLTEtMS0w_524079a4-9206-4613-b72f-d3ae56964638">42,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfOS0zLTEtMS0w_d8d937df-dde2-49c0-9f0c-3d10bb6e866f">63,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTEtMS0xLTEtMA_d84c91b4-c24a-4b34-a3a5-89d520f2555d">634,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTEtMy0xLTEtMA_ab3a5661-2ef6-4705-9307-af54a3b000ed">935,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTItMS0xLTEtMA_e4c0e180-f3ac-4926-872d-34bcfc0c31d6">7,661,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTItMy0xLTEtMA_abeb7b38-b859-425d-a086-b588f0e17f72">7,442,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity (deficit)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTUtMS0xLTEtMA_c6e11362-6dae-4b66-913e-1bc6e8c47bfe">1,555,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTUtMy0xLTEtMA_3212e352-eb9b-4f52-9e7f-d85974130215">1,083,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTYtMS0xLTEtMA_3a117f44-fa24-4e42-8053-241b250943b9">2,454,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTYtMy0xLTEtMA_1fa77bd8-e56b-478f-9f01-49bd234fb952">2,098,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred grant funding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" format="ixt:numdotdecimal" name="dare:DeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTctMS0xLTEtMA_4af3ae84-4b60-4aab-9d52-aeadf993044c">2,178,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" format="ixt:numdotdecimal" name="dare:DeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTctMy0xLTEtMA_51d926db-160b-46ee-930c-4994cd125ef7">2,019,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTgtMS0xLTEtMA_300c2030-fb38-43d2-b741-96bdc3b4f6a3">367,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:NotesPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTgtMy0xLTEtMA_7e1d3bf4-879c-4d4b-a304-a65e9c54e999">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTktMS0xLTEtNjc2_4b8b772c-0272-492e-95d6-bab494ecaf82">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTktMy0xLTEtNjc2_f055295d-7abe-4d81-bb74-68a49550c75b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTktMS0xLTEtMA_39ab7436-11f0-4128-8b9e-6061fc71d64c">409,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTktMy0xLTEtMA_94ba8db5-8285-4ed6-8bd1-d24cd8f73ed9">410,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjAtMS0xLTEtMA_52704cc0-3e75-407b-9fa5-01abab7043d8">7,964,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjAtMy0xLTEtMA_56f99614-bfe3-44c5-91e4-77c720205d3a">5,612,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred license revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjEtMS0xLTEtMA_5d160c17-3fa4-41aa-9348-8a35daf4af90">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjEtMy0xLTEtMA_f21278ff-e1c9-4167-9581-11316862c3fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjItMS0xLTEtMA_bf20fd75-fa9b-4822-bbf3-c45e272d8f11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjItMy0xLTEtMA_66de9d80-70a2-4a61-84a0-250dbbd295a7">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities long-term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjMtMS0xLTEtMA_4bbea6df-2002-4932-81a7-eb9f3d08ed93">82,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjMtMy0xLTEtMA_e0498a04-7929-4ab4-9764-e5b27a0bc717">389,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjQtMS0xLTEtMA_5dd6d0c9-bacd-4e31-b1ca-55eedcade9fa">9,047,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjQtMy0xLTEtMA_713ef7eb-8a2b-4802-b597-f8cecdc2df78">7,001,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 8)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjUtMS0xLTEtMA_18397f76-16d7-4eda-9a36-ed18ac8dd553"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjUtMy0xLTEtMA_d5c21737-3c28-4353-a410-abd3899f6c4f"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders' equity (deficit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdiN2U4NGQwYWQ1NzQxMGFiYmRlNzcwYTQ1M2Q1NmUwXzIx_a25d9738-8dcf-49ed-8334-2f08d3e57ad8"><ix:nonFraction unitRef="usdPerShare" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdiN2U4NGQwYWQ1NzQxMGFiYmRlNzcwYTQ1M2Q1NmUwXzIx_a4a63956-6cdf-4c89-9b08-639b1b8470d7">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdiN2U4NGQwYWQ1NzQxMGFiYmRlNzcwYTQ1M2Q1NmUwXzM1_cc32efbf-fe5f-41a2-8bcc-de1083b26a70"><ix:nonFraction unitRef="shares" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdiN2U4NGQwYWQ1NzQxMGFiYmRlNzcwYTQ1M2Q1NmUwXzM1_ecb8e5e2-3fc8-49b9-adfd-d870510866fd">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdiN2U4NGQwYWQ1NzQxMGFiYmRlNzcwYTQ1M2Q1NmUwXzU3_52c0b1d1-1033-49e9-8dae-0fc2dad5a3ca"><ix:nonFraction unitRef="shares" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdiN2U4NGQwYWQ1NzQxMGFiYmRlNzcwYTQ1M2Q1NmUwXzU3_b298ac56-751c-4981-8d7a-a9c6403d1e59"><ix:nonFraction unitRef="shares" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdiN2U4NGQwYWQ1NzQxMGFiYmRlNzcwYTQ1M2Q1NmUwXzU3_b623bd62-269d-4035-9fa9-553341385b5d"><ix:nonFraction unitRef="shares" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdiN2U4NGQwYWQ1NzQxMGFiYmRlNzcwYTQ1M2Q1NmUwXzU3_ef4560c7-b3ec-47e4-a689-7972d0616479">None</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjctMS0xLTEtMA_7ba69eb7-6e17-4f70-8dd6-9f90e17edf80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjctMy0xLTEtMA_51aa3092-9c07-4c2f-b1e4-de45f73db3a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjJlMmVjOGM3ZGUwNzRlY2ViM2M3ZjhhNmY0YTU5MTE5XzE4_0ac7299e-a94c-404a-9656-d24c3cefde8c"><ix:nonFraction unitRef="usdPerShare" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjJlMmVjOGM3ZGUwNzRlY2ViM2M3ZjhhNmY0YTU5MTE5XzE4_e1cd2e7b-7fb5-4df5-a4e6-86e319eaaf55">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjJlMmVjOGM3ZGUwNzRlY2ViM2M3ZjhhNmY0YTU5MTE5XzMy_448ee0de-0838-4dc5-bc1c-d1cdb8bb62ae"><ix:nonFraction unitRef="shares" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjJlMmVjOGM3ZGUwNzRlY2ViM2M3ZjhhNmY0YTU5MTE5XzMy_4f542939-5f5a-4e95-96d5-ffb999f72874">120,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjJlMmVjOGM3ZGUwNzRlY2ViM2M3ZjhhNmY0YTU5MTE5XzU0_34b58967-b7ba-4361-86dd-73b7569b793e"><ix:nonFraction unitRef="shares" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjJlMmVjOGM3ZGUwNzRlY2ViM2M3ZjhhNmY0YTU5MTE5XzU0_6efb2c24-8872-4f6d-841e-11590d33bbc5">33,602,516</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjJlMmVjOGM3ZGUwNzRlY2ViM2M3ZjhhNmY0YTU5MTE5XzYx_503cf01f-e341-4444-be29-30dd8a4f53fb"><ix:nonFraction unitRef="shares" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjJlMmVjOGM3ZGUwNzRlY2ViM2M3ZjhhNmY0YTU5MTE5XzYx_acb4f585-ae7c-4a76-9859-66f19ce4a8b3">19,683,401</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjgtMS0xLTEtMA_7b41c73f-f6d0-4bd4-a8ca-b3e8cd197974">3,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjgtMy0xLTEtMA_057e8bc8-5627-4edb-abb7-5adda41ecba2">1,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjktMS0xLTEtMA_a8a090b7-e38d-4214-ae73-724397405e08">112,807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjktMy0xLTEtMA_b342c8ea-650e-4697-a90e-cb24a6c4eed0">102,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMzAtMS0xLTEtMA_291455ff-b150-41c9-b381-6a559cf0889b">61,712,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMzAtMy0xLTEtMA_98764828-2f91-428b-8a1d-956aceb86bd5">44,564,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMzEtMS0xLTEtMA_c322a0cc-c040-4ab6-9341-cdfd60e2d075">62,989,323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMzEtMy0xLTEtMA_338fbe93-810b-4b4c-8fd3-25ceb100da54">44,023,191</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total stockholders' equity (deficit)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMzItMS0xLTEtMA_ef0b8539-a07b-412e-afd8-f0b73456484f">1,385,888</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMzItMy0xLTEtMA_b9e7980d-e2e2-497e-8820-16a69d30ef0e">440,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and stockholders' equity (deficit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMzMtMS0xLTEtMA_98fcd469-cef3-45fb-8868-0377e32c1d3b">7,661,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMzMtMy0xLTEtMA_8b5b515d-1a86-4ee4-8996-4ba79e0eaa5e">7,442,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to interim consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i868f48d3ece34cfab595a46f6986b439_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dar&#233; Bioscience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMy0xLTEtMS0w_bbbfb1b2-6b2b-4c06-8b4a-6edbc58df7cc">1,353,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMy0zLTEtMS0w_e1fcd698-0c31-40fb-b174-129bb325740a">1,318,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMy01LTEtMS0w_93e5a820-425b-4a41-9722-69b549194ffc">4,772,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMy03LTEtMS0w_9694e157-54b4-4f25-a60e-6b62c9dc5cf4">3,903,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNC0xLTEtMS0w_811014ca-e113-4423-9ab7-ba6b2b1ac508">6,203,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNC0zLTEtMS0w_9d221d38-6b13-48c5-a597-ba43844299af">1,966,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNC01LTEtMS0w_2d0f8c03-9eee-4678-b31d-b0154f5b00d6">14,131,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNC03LTEtMS0w_73925c7e-c415-47db-8464-db1bcb2713d7">6,172,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License fees</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="dare:LicenseFee" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNS0xLTEtMS0w_8c29bfd9-93bc-45cf-8760-eebb09ead498">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="dare:LicenseFee" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNS0zLTEtMS0w_cc3bdf58-3feb-4e1e-a139-7e785c5ea688">133,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="dare:LicenseFee" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNS01LTEtMS0w_b33530af-6897-40c8-a907-feeeaeff27f7">58,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="dare:LicenseFee" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNS03LTEtMS0w_8c39a3f9-45ec-453c-bda3-8fff57386568">408,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNi0xLTEtMS0w_87eb8a7b-2ba6-47b2-9a03-6eea72fe2140">7,581,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNi0zLTEtMS0w_78b95280-113c-4e0a-a07f-9e898e7f7963">3,418,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNi01LTEtMS0w_0ba2b777-78ca-4e0d-a190-9087e64358ff">18,961,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNi03LTEtMS0w_70d32862-c558-4f2e-af4f-d0b8ee6b22f4">10,484,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNy0xLTEtMS0w_3d4f48ea-f152-4716-a86b-5125de0dc7c0">7,581,822</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNy0zLTEtMS0w_588d10bb-960a-4467-bf4a-90d596c62dad">3,418,549</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNy01LTEtMS0w_be6b8eb2-f774-460a-9b15-a8d5c62fed3f">18,961,722</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNy03LTEtMS0w_e266980a-fb82-47bf-a3ed-665c3b00c940">10,484,070</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="0" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfOC0xLTEtMS0w_1332b832-e987-4d2f-8956-c381ec9ff568">986</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfOC0zLTEtMS0w_c8c4bb0f-2c41-4d3a-b342-7236fb68cdbd">25,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfOC01LTEtMS0w_50c1bd6d-d123-4bd2-bb46-2809de83f3f9">2,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfOC03LTEtMS0w_568074ec-58f5-4eef-8589-87c29965429f">86,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfOS0xLTEtMS0w_8f41b3f3-bef1-4aa2-a438-5f447130fc47">7,582,808</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfOS0zLTEtMS0w_20f5e685-95e3-4d45-869f-216852afaa84">3,393,078</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfOS01LTEtMS0w_74a62076-f47d-43f9-a47d-1fb6c9035d5e">18,959,268</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfOS03LTEtMS0w_4b3b7bad-35bc-41a9-b596-9406fa4f7144">10,397,367</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend from trigger of down round provision feature</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTAtMS0xLTEtMA_3290649f-0feb-4f3f-a327-466b666a8e0c">6,863</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTAtMy0xLTEtMA_7316918c-f545-4df1-a083-704b1150deb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTAtNS0xLTEtMA_c6185c78-9828-4d61-8a0b-429be93c9dd7">6,863</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTAtNy0xLTEtMA_d0cae931-d974-48af-8943-44d23d21f928">789,594</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss to common shareholders</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTEtMS0xLTEtMA_0bd4bdec-8154-49b7-bcbe-2c489a2c05a9">7,589,671</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTEtMy0xLTEtMA_abe0178b-4c31-44e9-81b0-1eafa069a4ec">3,393,078</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTEtNS0xLTEtMA_b8e6811b-1747-44c6-802b-92b7c0d2e39c">18,966,131</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTEtNy0xLTEtMA_964f1878-a7a8-4857-b263-1702bde22dfd">11,186,961</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTItMS0xLTEtMA_3c8db855-aae7-4d6a-87b9-d1fbbb625770">672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTItMy0xLTEtMA_b991754f-2137-4938-876b-2b00fb86c904">15,378</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTItNS0xLTEtMA_34f8c993-bf7d-4f75-9cab-5c8f91acc1b1">10,182</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTItNy0xLTEtMA_6ddceee5-9225-4378-83f9-985e7d738db1">15,674</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTMtMS0xLTEtMA_a4c04c7e-6570-46d8-a08e-4c38d8b9796b">7,588,999</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTMtMy0xLTEtMA_bcfd4f48-47a1-48cf-8199-a1da1f3ab7d1">3,408,456</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTMtNS0xLTEtMA_94744f7b-13f4-4c0a-9ca9-c731acbc8998">18,976,313</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTMtNy0xLTEtMA_dc49fe28-d46a-4e20-b18b-7142cd6a5b23">11,202,635</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per common share - basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTQtMS0xLTEtMA_53cbfccd-7b97-4fb9-a00d-b2a52f0b30f5">0.24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTQtMy0xLTEtMA_abc8cd83-f4bf-4c72-898c-0778ad7db2fe">0.20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTQtNS0xLTEtMA_96836c11-63ac-4535-aba7-5994454ee7d9">0.69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTQtNy0xLTEtMA_ccbf204e-7156-4dc6-922c-d4f4fcdbebaa">0.76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTYtMS0xLTEtMA_7d7ae933-d989-45e9-85c8-7190740448fd">31,588,152</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTYtMy0xLTEtMA_04851193-fbe3-4b04-a775-c0c6b74b9ae8">16,683,411</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTYtNS0xLTEtMA_18e0537a-eb27-4c94-b439-53104f2cc9b2">27,381,508</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTYtNy0xLTEtMA_d0cb703f-fa2e-41b6-ab76-7273407748a1">14,756,213</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to interim consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i868f48d3ece34cfab595a46f6986b439_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dar&#233; Bioscience, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.019%"><tr><td style="width:1.0%"></td><td style="width:27.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.962%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.488%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">paid-in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">comprehensive</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">stockholders'</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib4aae1fde8a24498b3bc6e50aff2d4e1_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMy0xLTEtMS0w_868540ef-af52-4445-8fbb-f70a22d1900e">19,683,401</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4aae1fde8a24498b3bc6e50aff2d4e1_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMy0zLTEtMS0w_15005a43-87a6-4a45-8868-ae70f6cefec3">1,968</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8afa8464781b49a39b4681faf83f4671_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMy01LTEtMS0w_1fb0c6c9-7fef-49a4-974b-4a0412b99e76">44,564,674</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0073ec1a844c45b1b12b82e642dd6a0d_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMy03LTEtMS0w_f0b7c26b-2a29-4511-a582-2142c33cb1ed">102,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84723044896e4ab9937bf3130967d6a7_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMy05LTEtMS0w_d92342c2-2a0d-4656-85b4-93d48b8fb393">44,023,191</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMy0xMS0xLTEtMA_8242d08a-a805-418b-a634-8fb32da19aac">440,826</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88d2ffda43594518bae4aac3bbe0861d_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNC01LTEtMS0w_278f1ff8-f666-4768-800c-3e86fb5b96fa">160,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i433a6eab314144b584233fa1098fc8b0_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNC0xMS0xLTEtMA_f784bcad-c578-4e53-8300-2f48f536eed0">160,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibed628a16b5f4ca89e9d282060d3f6a9_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNS0xLTEtMS0w_430cf6a4-fc99-4d05-bbf8-ffc36dbabd86">3,308,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed628a16b5f4ca89e9d282060d3f6a9_D20200101-20200331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNS0zLTEtMS0w_bae013fa-6dea-46e5-858e-7c91e9b317b1">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88d2ffda43594518bae4aac3bbe0861d_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNS01LTEtMS0w_eacf3e65-d8ce-4088-a755-3a14ae238653">5,222,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i433a6eab314144b584233fa1098fc8b0_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNS0xMS0xLTEtMA_d1975014-385f-484f-9b35-c93fe9f471f4">5,222,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock from the exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibed628a16b5f4ca89e9d282060d3f6a9_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNi0xLTEtMS0w_21bc16cf-d57b-471c-8287-d0c8ac7c22ac">1,699,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed628a16b5f4ca89e9d282060d3f6a9_D20200101-20200331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNi0zLTEtMS0w_132e5d95-7107-43f8-9d8b-1af3f11bfbf0">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88d2ffda43594518bae4aac3bbe0861d_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNi01LTEtMS0w_f884d57c-3a89-428e-9218-b8c719489cc4">1,664,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i433a6eab314144b584233fa1098fc8b0_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNi0xMS0xLTEtMA_b185ece5-faee-42c5-8eea-65624c5cbe21">1,665,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibed628a16b5f4ca89e9d282060d3f6a9_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNy0xLTEtMS0w_59489566-6183-4907-bcdb-71fefc27b6c1">10,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed628a16b5f4ca89e9d282060d3f6a9_D20200101-20200331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNy0zLTEtMS0w_b413afff-304a-41e8-9e89-064f9a9a7a72">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i433a6eab314144b584233fa1098fc8b0_D20200101-20200331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNy0xMS0xLTEtMA_93fc1acf-3370-4a9e-afb1-b9b87bff212f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d54ca496ab242d283acce737c73d143_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfOC05LTEtMS0w_5af13f8b-bcd4-4065-b2a6-d929e2142963">4,252,248</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i433a6eab314144b584233fa1098fc8b0_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfOC0xMS0xLTEtMA_253fe2c5-8c93-45b7-a958-ce069f6e157d">4,252,248</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i468d0e095ca5490b9de2575fd7a58a4e_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfOS03LTEtMS0w_aa62e0d5-f5e0-4bfa-aab1-cf2836c409ce">22,944</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i433a6eab314144b584233fa1098fc8b0_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfOS0xMS0xLTEtMA_d9d82c7c-8cbb-4a87-ba19-e749f5bb53c7">22,944</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i778d6dd4e63740179791957d7305f2d7_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTAtMS0xLTEtMA_4d63f2b9-0c8e-4184-bcb2-03055443f97e">24,700,553</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778d6dd4e63740179791957d7305f2d7_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTAtMy0xLTEtMA_e552882d-cc0c-4093-9647-9aa1794f4e34">2,470</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582df1f48a942c1843feec52a079e1b_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTAtNS0xLTEtMA_3d41db21-ce6e-4913-9dbb-edccd4ce1c3b">51,612,721</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib17d45f7c7314d7e8b1fcddab7ac50b4_I20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTAtNy0xLTEtMA_319a29eb-bdc7-4b92-84bc-4955d28bd88e">125,569</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ideedcc5e7e244a87ad925fd33a419342_I20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTAtOS0xLTEtMA_a220c439-f31e-42fc-b319-b6eafcc5f155">48,275,439</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f7e83b86b284e20a0d23c9d195bdac6_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTAtMTEtMS0xLTA_a388eade-bfa2-4461-b1ad-3bd8f821b16b">3,214,183</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9145a313e1704334b699d500b0ae36f5_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTEtNS0xLTEtMA_547beef5-8ff2-47ef-b37c-d60cfdfdb649">186,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151cfac574024088b63a3767d69922af_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTEtMTEtMS0xLTA_d730005b-fd2e-4845-a409-1f82a6c8c673">186,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib72039df45d24401a53a53bc832e4837_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTItMS0xLTEtMA_58b118ef-9980-4159-917c-4381bd45f619">3,823,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib72039df45d24401a53a53bc832e4837_D20200401-20200630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTItMy0xLTEtMA_d6f121f1-145b-4c76-ac34-f1a43308bcdb">382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9145a313e1704334b699d500b0ae36f5_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTItNS0xLTEtMA_2ef5dca1-4721-4aaf-9e44-ab3560720617">4,021,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151cfac574024088b63a3767d69922af_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTItMTEtMS0xLTA_d1d1d577-f6aa-4c60-b282-2c5122808414">4,022,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1cc1b354afd4948a85810f1bd926e05_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTMtOS0xLTEtMA_0fa040f3-dbc3-42c3-8c2e-3517a2129ee7">7,124,213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i151cfac574024088b63a3767d69922af_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTMtMTEtMS0xLTA_424a5fc2-d445-422f-9256-b9752a3938e7">7,124,213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64f2c60cd7e34b7a8f98d5f6c6890113_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTQtNy0xLTEtMA_d62eda36-760c-4950-ac72-ef9539a3b32f">12,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151cfac574024088b63a3767d69922af_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTQtMTEtMS0xLTA_b2f57858-fe20-4575-99a5-3a79a6ab97e9">12,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a5c11ea74534c2794d2172e3aa03449_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTUtMS0xLTEtMA_5f7aad44-99f9-43a8-ab60-70443ef0c1a5">28,524,004</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a5c11ea74534c2794d2172e3aa03449_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTUtMy0xLTEtMA_e2d74b2c-c0ce-4eb1-b19f-dd62dec0010c">2,852</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76559cf393ca49de9e7e135807775d99_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTUtNS0xLTEtMA_d170cc65-e301-4e93-9fae-999716d52875">55,821,534</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd5510991654ecd9e8099e2226b8f7d_I20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTUtNy0xLTEtMA_0cb83553-2c4e-4898-86ee-e2806e7ced37">113,479</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8703c6e447584c3a98ba5761b1da8b14_I20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTUtOS0xLTEtMA_79f81884-1ab5-4b45-9950-a4b97a65ce00">55,399,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57949e2187364d4a9adfe732ba2936e0_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTUtMTEtMS0xLTA_e9f0c8e0-0927-47d3-bc83-4e32f7b61e02">311,255</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if86e95ff8cf340409d913ec4b47d61aa_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTYtNS0xLTEtOTAw_1043ee62-ffa9-40ba-a76f-1a4159b339b3">194,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTYtMTEtMS0xLTM2Nw_7c07fbbf-1217-4f36-ad19-2d06ee591832">194,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib52fe01a8be246969cc36b76ea728405_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTctMS0xLTEtMzY3_bd0f4835-0ea5-4aa2-95ba-cc24b87ce66a">4,666,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52fe01a8be246969cc36b76ea728405_D20200701-20200930" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTctMy0xLTEtMzY3_b5d55a05-28f0-4872-948a-d66eadbbbd0e">466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if86e95ff8cf340409d913ec4b47d61aa_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTctNS0xLTEtOTAw_568ca286-5b11-424c-bf88-5f3660754e17">5,277,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTctMTEtMS0xLTM2Nw_c4d98b17-19cd-4018-9c3d-b7479ba95209">5,277,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance cost on equity line paid in common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib52fe01a8be246969cc36b76ea728405_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="dare:StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTgtMS0xLTEtMjI3MA_d81df52a-7833-41dd-84fc-30394fbb3568">285,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52fe01a8be246969cc36b76ea728405_D20200701-20200930" decimals="0" name="dare:StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTgtMy0xLTEtMjI3MA_17485947-cc7f-4db1-a948-ca582dc41269">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if86e95ff8cf340409d913ec4b47d61aa_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="dare:StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTgtNS0xLTEtMjI3MA_84ca7e8f-8f91-4336-b21f-5669d47bcbb5">291,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="dare:StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTgtMTEtMS0xLTIyNzA_914b0f3e-1cba-4fdb-9982-33b71782165c">291,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock from the exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib52fe01a8be246969cc36b76ea728405_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTgtMS0xLTEtODY0_1739acc5-d04a-48ff-a752-b607fa8e5a83">126,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52fe01a8be246969cc36b76ea728405_D20200701-20200930" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTgtMy0xLTEtODY0_c0880108-85e8-416f-9b7f-b133e0c44941">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if86e95ff8cf340409d913ec4b47d61aa_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTgtNS0xLTEtOTAw_ba6a567a-cbf1-4285-a2bb-7f909defacaf">120,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTgtMTEtMS0xLTkwOA_6da591bb-b6bb-4629-93b3-6ad46699b39c">120,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend from trigger of down round provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if86e95ff8cf340409d913ec4b47d61aa_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTgtNS0xLTEtMzY3_28ee78e1-7862-4496-86c7-1b21c7344abe">6,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c6459561ac24633955667a0e138a61d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTgtOS0xLTEtMzY3_cc0fa563-e864-46c0-8755-abc6fb3015b8">6,863</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c6459561ac24633955667a0e138a61d_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTktOS0xLTEtMzY3_886cf810-c8af-47d0-8572-1e8d1d0e2f0b">7,582,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTktMTEtMS0xLTM2Nw_e0037ff1-5348-45da-a434-057d1ab1cb87">7,582,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5b514c768bf44b98354f79ace769b2b_D20200701-20200930" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMjAtNy0xLTEtNTcx_0091236c-a832-45a6-8663-8b2e80b4ceaa">672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMjAtMTEtMS0xLTM2Nw_74a7b6fb-bf32-41a0-aa8f-a8dfbdf3ca66">672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb45eeeb928743849e7b50bfe4b365b2_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMjEtMS0xLTEtMzY3_21391857-0049-4531-aa7a-35ea91d0ed3a">33,602,516</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb45eeeb928743849e7b50bfe4b365b2_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMjEtMy0xLTEtMzY3_b28a358d-6a74-45da-ab60-705fa6101f8b">3,360</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2787ea775c17482bae9bb54124be9c7a_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMjEtNS0xLTEtMzY3_560fc365-5abb-462f-bda4-9e4a3eb07319">61,712,882</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b807e058c5c42409d7dfd94b4bd478f_I20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMjEtNy0xLTEtMzY3_762c02f5-b4f1-4b29-856b-d482b8a407d1">112,807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaebd7d8309614a7e99f2a6f1bb3dafb1_I20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMjEtOS0xLTEtMzY3_abb8065e-d9a8-409b-9133-2b7761113003">62,989,323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMjEtMTEtMS0xLTM2Nw_2c5775ec-6ef0-47df-930e-650c4e3bdf46">1,385,888</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dar&#233; Bioscience, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.224%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">paid-in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">comprehensive</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">stockholders'</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i230e979e152146c681167c318df557ef_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMy0xLTEtMS00Mzk_83a01394-5242-4f71-8d5f-60efbb947aa6">11,422,161</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i230e979e152146c681167c318df557ef_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMy0zLTEtMS00Mzk_59e2d4a7-32e9-487f-a24a-72771a7e961d">1,143</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i688bebc3cdcd4ca48392c35cf27fb782_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMy01LTEtMS00Mzk_80c2fd69-c3d7-43b0-b076-cdd75e2b8541">35,791,972</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a5ba66df1e847c9a79436490357853b_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMy03LTEtMS00Mzk_6c2a5a0f-7ec1-4149-8238-53b203540ba3">96,728</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78009fb2296d46f394545d697435837a_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMy05LTEtMS00Mzk_e8ca86fc-f36e-4cd0-b690-6bfebc607607">28,969,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25c35de4c46a4497b5ac99d104d6962c_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMy0xMS0xLTEtNDM5_0156c829-612d-49c5-aa5c-18996b3d2718">6,726,620</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0a3948de04b49feb4074444bfe4c48a_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfNC01LTEtMS00Mzk_84f885d4-dddb-422a-9989-4c1ad69e8858">97,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7acea1d9dc949cdb1eba8efb4698c44_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfNC0xMS0xLTEtNDM5_0ee4091d-998c-4233-8127-ac4b822e41d6">97,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8280d4d773d546688557038d3b275d97_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfNS05LTEtMS00Mzk_4bb35c9f-a876-4a3d-ba93-4f8e09542842">3,051,840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7acea1d9dc949cdb1eba8efb4698c44_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfNS0xMS0xLTEtNDM5_a815fe83-76d8-4177-9bd1-09a6a9ae5731">3,051,840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49b5674e31f74d72ba13e82dac7e8633_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfNi03LTEtMS00Mzk_68c1e5bc-5bb3-4f7b-a4fc-acc1436ac2c6">7,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7acea1d9dc949cdb1eba8efb4698c44_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfNi0xMS0xLTEtNDM5_79cabfc6-24e4-4cf7-9e71-572f52e4d720">7,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida47f40a6fe841c087027031cad177ba_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfNy0xLTEtMS00Mzk_b67e87dc-02d6-4204-bbe8-3a381bc45509">11,422,161</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida47f40a6fe841c087027031cad177ba_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfNy0zLTEtMS00Mzk_a454ebd2-32f7-4897-b232-89a4765f3183">1,143</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib92f3eb9ef0b48db84cc7350557622d2_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfNy01LTEtMS00Mzk_c1b77104-b108-40ad-af8c-3ea925a69848">35,889,940</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c547f1fe1484bc6a952437a3d10d9dd_I20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfNy03LTEtMS00Mzk_6aeefa21-e49b-489b-89a3-132c8f92c844">89,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i449930a975d04b9ea1c18df54bf78b4b_I20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfNy05LTEtMS00Mzk_a7c79e30-8ae1-4c5b-94a1-52698ec58449">32,021,607</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i353a8bedc0db4bee96fe2d31985e5160_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfNy0xMS0xLTEtNDM5_30fb088a-0313-4c3e-aed0-5256833d0d81">3,780,369</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22f3847410f44a987757fc5805190ca_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfOC01LTEtMS00Mzk_112864eb-9751-4d65-9c4d-04af1e307bda">111,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42ad961aed164f408dfab70f502a4e98_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfOC0xMS0xLTEtNDM5_8007144c-ba50-4b33-80ca-60610473cefc">111,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock via public offering, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia38cd88862524a25953e1e12fcbed8da_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfOS0xLTEtMS00Mzk_ca33953d-f3ed-4a84-b55d-337bb6f14fd4">5,261,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia38cd88862524a25953e1e12fcbed8da_D20190401-20190630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfOS0zLTEtMS00Mzk_a62d2815-3772-4b5f-83f0-ece82065bafe">525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22f3847410f44a987757fc5805190ca_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfOS01LTEtMS00Mzk_edc2d01e-32f4-4602-b536-a3395540569f">5,151,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42ad961aed164f408dfab70f502a4e98_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfOS0xMS0xLTEtNDM5_514b4691-709a-4bcb-a599-0820aae5006f">5,151,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend from trigger of down round provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22f3847410f44a987757fc5805190ca_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTAtNS0xLTEtNDM5_2111d659-4216-438e-83a9-07daa9b55751">789,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20c1dd4c92ea492d812ea60776150735_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTAtOS0xLTEtNDM5_dbe974f4-af25-4659-9442-fee0340503f3">789,594</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20c1dd4c92ea492d812ea60776150735_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTEtOS0xLTEtNDM5_69e6fcf0-9e6d-4b01-b424-40c9cce4d0a1">3,952,450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42ad961aed164f408dfab70f502a4e98_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTEtMTEtMS0xLTQzOQ_a7c79edb-eceb-404a-adaa-6a7d23a121bc">3,952,450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i368ed0b181144e64a2f66800be6d6815_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTItNy0xLTEtNDM5_a6183701-b7f5-43c6-8920-40107e4415f6">7,917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42ad961aed164f408dfab70f502a4e98_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTItMTEtMS0xLTQzOQ_436c0d20-25b9-41a1-b4d6-5d6f6c6a72ad">7,917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99271232f7ab4dc9b246dc5b7b11dcad_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTMtMS0xLTEtNDM5_40bff04c-fcb5-4c7e-b72a-5abba40796e8">16,683,411</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99271232f7ab4dc9b246dc5b7b11dcad_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTMtMy0xLTEtNDM5_6f58102c-69ae-4532-b2a5-9213c6d6d9af">1,668</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4ff10b061754f5888a60896993775e5_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTMtNS0xLTEtNDM5_f2d6cb1d-0208-4b39-b05b-2f6d27ac8ccb">41,942,062</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id40cf5fc96ed4ccdabbc1a27d10c3f5b_I20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTMtNy0xLTEtNDM5_480200c2-e9a8-4f9f-b44c-f4dc3fdf99a0">97,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf2e4de4cdd14243bd2e981a38608f20_I20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTMtOS0xLTEtNDM5_2a962a44-4cf5-4b1e-aa28-3517fe018666">36,763,651</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c0eb362b20e46349b240d667ece7a11_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTMtMTEtMS0xLTQzOQ_98eaf2a4-6edf-4811-bff8-1e00d041cc76">5,083,055</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9e90787a50b48e68e5848b83240c00e_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTQtNS0xLTEtNDM5_0983cae1-727e-4a4c-a586-b8ef7bb82224">135,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTQtMTEtMS0xLTQzOQ_faf55608-897d-421b-bb62-7cf3e441143f">135,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifaf82bec24924dfa8554c21c40d52902_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTUtOS0xLTEtNDM5_b4797dca-7b9b-461f-b9f0-67009f792068">3,393,078</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTUtMTEtMS0xLTQzOQ_9ad5a4c5-546d-42f1-ab18-20011c1bd815">3,393,078</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1138443634a2487caabd35c4a968772e_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTYtNy0xLTEtNDM5_be3ddf79-b76a-471c-934b-93eac6409b84">15,378</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTYtMTEtMS0xLTQzOQ_de2f3428-f6d3-44db-a231-0bba5429113b">15,378</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0593b34027c74956b65c17141dc3c7fe_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTctMS0xLTEtNDM5_02a5eb5b-456e-40af-ac8e-326a50093638">16,683,411</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0593b34027c74956b65c17141dc3c7fe_I20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTctMy0xLTEtNDM5_87f037e9-d9c7-4f1c-b8fa-05dc8ef73753">1,668</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4b2196c78848c28cbb2f6c038213dd_I20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTctNS0xLTEtNDM5_dfde0a4c-2af5-40a0-a8a7-fddcc221ba82">42,077,455</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i102d49b207054edeacf51fa8bd1a45a3_I20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTctNy0xLTEtNDM5_88d4b07e-689b-438f-bf8a-1e644919f04d">112,402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a33072e23e94e97a50599beb8d9e67a_I20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTctOS0xLTEtNDM5_ef155dc6-2313-405e-8010-61279e926b12">40,156,729</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3d4d54b0f7c4a229b25cbe2d9ad07e1_I20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTctMTEtMS0xLTQzOQ_b1e85418-c69c-46b9-a1f8-f3b63bc540af">1,809,992</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to interim consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i868f48d3ece34cfab595a46f6986b439_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dar&#233; Bioscience, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMy0xLTEtMS0w_e41d0b6f-a805-4322-b941-7ce173cc9b37">18,959,268</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMy0zLTEtMS0w_cff9819b-b3c2-4109-898f-45fc9ded27fd">10,397,367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash adjustments reconciling net loss to operating cash flows:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfNS0xLTEtMS0w_961047f2-49e9-434b-a2d0-a5ae077d0744">36,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfNS0zLTEtMS0w_2fb3f002-96c1-48e0-8e57-023b61cb41e8">3,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfNi0xLTEtMS0w_35b3fb44-0202-4de4-8b9b-8f9511283fec">542,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfNi0zLTEtMS0w_830189bb-31cf-42b7-91f3-2795b89c5623">344,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash operating lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="dare:NonCashLeaseExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfNy0xLTEtMS0w_aa51bb00-145b-43e5-9138-ab912790b9a6">125,517</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="dare:NonCashLeaseExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfNy0zLTEtMS0w_4c0107cc-6b5b-4944-bd32-a378547e0f9e">19,914</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTAtMS0xLTEtMA_f03f205e-fce5-4a2c-ac6f-cc37d76226ba">341,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTAtMy0xLTEtMA_2a771e7c-daf3-4967-b0c9-d56f146790c1">6,802</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTEtMS0xLTEtMA_871821e4-0068-4108-bb2d-f65b15d40cca">18,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTEtMy0xLTEtMA_17eccf65-e735-4046-b1af-1a1c6e19b12b">367,409</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="dare:IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTMtMS0xLTEtMA_1ff777a8-f2a8-4ffb-839d-ebc0e92b5230">118,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="dare:IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTMtMy0xLTEtMA_15c92083-2f88-4033-b5f8-6e9d09b16bad">138,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTQtMS0xLTEtMA_1082d0e6-2489-413c-a2fa-68e8e68abe20">472,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTQtMy0xLTEtMA_81cac436-dbd9-4d8e-a94a-9c7fb5e53ee9">107,463</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTYtMS0xLTEtMA_2a1a105d-62d8-4a1f-a09b-67df8a1d1e69">355,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTYtMy0xLTEtMA_9291f2a1-60ae-466c-8d30-f24d42e4070d">905,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred grant funding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="dare:IncreaseDecreaseInDeferredGrantFunding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTctMS0xLTEtMA_e675f48e-89cc-48a8-be9d-67242afbcb16">158,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" format="ixt:zerodash" name="dare:IncreaseDecreaseInDeferredGrantFunding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTctMy0xLTEtMA_e348085d-c69e-4cdc-87f4-5305c7186e16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred license revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTgtMS0xLTEtMA_46c1af84-5cc2-4776-9f4f-87f3996ebd98">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTgtMy0xLTEtMA_9c5549e9-cf78-4035-8231-fab69b8e1651">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTktMS0xLTEtMA_02bce1e4-4206-49db-a319-93638aacda2d">16,041,176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTktMy0xLTEtMA_57458e7f-d6d3-4a62-b88b-977358e08466">9,506,797</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjEtMS0xLTEtMA_4e32469a-176b-4d3b-bb8d-20924b2c8cf9">15,246</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjEtMy0xLTEtMA_57205cf6-6988-4035-9f43-7c3984f7eddc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjItMS0xLTEtMA_9f95e08e-4a07-48d3-8ea8-3c6c32a7ecfe">15,246</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjItMy0xLTEtMA_ab6c1113-c860-48b3-9706-443b0f501622">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from issuance of common stock </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="dare:NetProceedsFromIssuanceOfCommonStockAndWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjQtMS0xLTEtMA_5615422d-5ce4-40e2-b933-59e3940d58be">14,522,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="dare:NetProceedsFromIssuanceOfCommonStockAndWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjQtMy0xLTEtMA_612d33a9-314b-46ff-beb2-625a9b4ebb18">5,151,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="dare:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjYtMS0xLTEtMA_f9ec4ce5-5cfb-4746-8155-24dbb9397374">1,785,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" format="ixt:zerodash" name="dare:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjYtMy0xLTEtMA_36252562-389c-4dce-ab35-01bbb3577baf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjctMS0xLTEtMA_11fec863-48ae-4fb0-999f-f076dc6955eb">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjctMy0xLTEtMA_620018f1-22be-45b0-b258-1ed9899d100c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjgtMS0xLTEtMA_4b8e645d-d361-48b0-9053-a4ee1c444cda">367,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjgtMy0xLTEtMA_ffaa488d-74c3-4334-8257-52915f56fb4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjktMS0xLTEtMA_8df18b91-62ef-4abf-8353-8de9a686eee0">16,675,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjktMy0xLTEtMA_dd26b1f9-0af5-42f1-8fc3-4e6e5ed74a94">5,151,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzAtMS0xLTEtMA_f577f8e4-b9bf-431a-9def-fdae759d2b87">10,182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzAtMy0xLTEtMA_9715e172-dbcb-4763-b92a-8a5c661e7085">15,674</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzEtMS0xLTEtMA_e7adb5f7-3e2f-4a7f-9955-d8e9cdfd53be">609,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzEtMy0xLTEtMA_09cf9855-c99e-43b6-970c-2d3ca5d7366f">4,370,769</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzItMS0xLTEtMA_858aca3e-7022-4f7f-8aad-70dca6f3f7d6">4,780,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25c35de4c46a4497b5ac99d104d6962c_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzItMy0xLTEtMA_a61534ec-46a2-4117-8fe4-28a70e3ae7ba">6,805,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzMtMS0xLTEtMA_7015cc58-3a11-4ec1-b735-e8fd0aa76032">5,389,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3d4d54b0f7c4a229b25cbe2d9ad07e1_I20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzMtMy0xLTEtMA_4e16921c-c978-4902-ae0e-cf1f39aa5fb4">2,435,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash operating and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzUtMS0xLTEtMA_58b3b055-166c-41d5-9d10-622bedeab871">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzUtMy0xLTEtMA_93572da9-5bd2-443d-b9dd-921294ec0f41">231,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance cost on equity paid in common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="dare:IssuanceCostOnEquityPaidInCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzYtMS0xLTEtMTg5MQ_a52d07fb-e1e7-4dc7-bf1f-60a74305e59e">291,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" format="ixt:zerodash" name="dare:IssuanceCostOnEquityPaidInCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzYtMy0xLTEtMTg5MQ_daee0f0d-f760-4adb-afa0-b09b3c8374e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend from trigger of down round provision feature</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzYtMS0xLTEtMA_ca6d778a-5237-4cb0-8bf7-d0242d6942c2">6,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzYtMy0xLTEtMA_b44de645-6a51-4390-b3f4-4cbfd92dffb1">789,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to interim consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i868f48d3ece34cfab595a46f6986b439_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dar&#233; Bioscience, Inc. and Subsidiaries</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div id="i868f48d3ece34cfab595a46f6986b439_34"></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNC9mcmFnOjYzNWQ2OTNhNDc1MjRkMGI4ZmM0N2RjOTBkYjQ1MjExL3RleHRyZWdpb246NjM1ZDY5M2E0NzUyNGQwYjhmYzQ3ZGM5MGRiNDUyMTFfMTE2OTM_72d39c16-509e-4aa5-b71a-3c21307126c0" continuedAt="i6a271a9d2d7342bea8d52c88b55b306e" escape="true">ORGANIZATION AND DESCRIPTION OF THE BUSINESS</ix:nonNumeric></span></div><ix:continuation id="i6a271a9d2d7342bea8d52c88b55b306e" continuedAt="i3affaf4a13ee4b84aaaa781bf5655b02"><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dar&#233; Bioscience, Inc. is a clinical-stage biopharmaceutical company committed to the acceleration of innovative products for women&#8217;s health. Dar&#233; Bioscience, Inc. and its wholly owned subsidiaries operate in <ix:nonFraction unitRef="segment" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNC9mcmFnOjYzNWQ2OTNhNDc1MjRkMGI4ZmM0N2RjOTBkYjQ1MjExL3RleHRyZWdpb246NjM1ZDY5M2E0NzUyNGQwYjhmYzQ3ZGM5MGRiNDUyMTFfMjYx_1264d0cf-46e5-4c1e-8bec-2a5ff1dff1d4">one</ix:nonFraction> segment. In this report, the &#8220;Company&#8221; refers collectively to Dar&#233; Bioscience, Inc. and its wholly owned subsidiaries, unless otherwise stated or the context otherwise requires.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is driven by a mission to identify, acquire and develop a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, fertility, and sexual and vaginal health. The Company's business strategy is to in-license or otherwise acquire the rights to differentiated product candidates in the Company's areas of focus, some of which have existing clinical proof-of-concept data, to take those candidates through mid- to late-stage clinical development, and to establish and leverage strategic partnerships to achieve commercialization.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since July 2017, the Company has assembled a portfolio of clinical-stage and pre-clinical-stage candidates. While the Company will continue to assess opportunities to expand its portfolio, its current focus is on advancing its existing product candidates through mid- and late-stages of clinical development or approval. The Company's portfolio includes three product candidates in advanced clinical development:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BV1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a novel thermosetting bioadhesive hydrogel formulated with clindamycin phosphate 2% to be administered in a single vaginally delivered application</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a first line treatment for bacterial vaginosis;</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Ovaprene&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a hormone-free, monthly vaginal contraceptive; and</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Sildenafil Cream</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a proprietary cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's portfolio also includes three product candidates in Phase 1 clinical development or that the Company believes are Phase 1-ready:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HRT1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a combination bio-identical estradiol and progesterone intravaginal ring for the treatment of menopausal symptoms, including vasomotor symptoms, as part of a hormone replacement therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or HRT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following menopause;</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FRT1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan; and</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VVA1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or VVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with hormone-receptor positive breast cancer.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's portfolio also includes these pre-clinical stage product candidates:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-LARC1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a combination product designed to provide long-acting, reversible contraception comprising an implantable, user-controlled wireless drug delivery system and levonorgestrel;</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">ORB-204 and ORB-214</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, injectable formulations of etonogestrel designed to provide contraception over 6-month and 12-month periods, respectively; and</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-RH1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a novel approach to non</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hormonal contraception for both men and women by targeting the CatSper ion channel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary operations have consisted of, and are expected to continue to consist of, product research and development and advancing its portfolio of product candidates through clinical development and regulatory approval. The Company expects that the majority of its development expenses for the remainder of 2020 and in 2021 will support the advancement of DARE-BV1, Ovaprene, and Sildenafil Cream, 3.6%.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3affaf4a13ee4b84aaaa781bf5655b02" continuedAt="i022f63f2229448a58eb69ac900e95c5a"><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not obtained any regulatory approvals for any of its product candidates, commercialized any of its product candidates or generated any product revenue. The Company is subject to several risks common to clinical-stage biopharmaceutical companies, including dependence on key employees as well as third-party licensors, partners and service providers, competition from other companies, the need to develop commercially viable products in a timely and cost-effective manner, and the need to obtain adequate additional capital to fund the development of product candidates. The Company is also subject to several risks common to other companies in the industry, including rapid technology change, regulatory approval of products, uncertainty of market acceptance of products, competition from substitute products and larger companies, compliance with government regulations, protection of proprietary technology, dependence on third parties, and product liability.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has prepared its interim consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. The Company has a history of losses from operations, expects negative cash flows from operations will continue for the foreseeable future, and expects that its net losses will continue for at least the next several years as it develops its existing product candidates and seeks to acquire, license or develop additional product candidates. These circumstances raise substantial doubt about the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty of the Company's ability to continue as a going concern.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company had an accumulated deficit of approximately $<ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNC9mcmFnOjYzNWQ2OTNhNDc1MjRkMGI4ZmM0N2RjOTBkYjQ1MjExL3RleHRyZWdpb246NjM1ZDY5M2E0NzUyNGQwYjhmYzQ3ZGM5MGRiNDUyMTFfNjAyNw_0f7a0b63-44c5-40f1-a87f-4735dd0cf634">63.0</ix:nonFraction> million and cash and cash equivalents of approximately $<ix:nonFraction unitRef="usd" contextRef="i17feaef906b24653ac55862eb815e6dc_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNC9mcmFnOjYzNWQ2OTNhNDc1MjRkMGI4ZmM0N2RjOTBkYjQ1MjExL3RleHRyZWdpb246NjM1ZDY5M2E0NzUyNGQwYjhmYzQ3ZGM5MGRiNDUyMTFfNjA3Nw_7742a6f6-b81e-4b90-a2ba-3edf8a6ed160">5.4</ix:nonFraction> million. The Company also had negative cash flow from operations of approximately $<ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNC9mcmFnOjYzNWQ2OTNhNDc1MjRkMGI4ZmM0N2RjOTBkYjQ1MjExL3RleHRyZWdpb246NjM1ZDY5M2E0NzUyNGQwYjhmYzQ3ZGM5MGRiNDUyMTFfNjE1NA_b0558bd5-f8c2-4b69-90f1-61b0c1a18c32">16.0</ix:nonFraction> million during the nine months ended September&#160;30, 2020. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is focused primarily on the development and commercialization of innovative products in women&#8217;s health. The Company will continue to incur significant research and development and other expenses related to these activities. If the clinical trials for any of the Company&#8217;s product candidates fail to produce successful results such that those product candidates do not advance in clinical development, then the Company&#8217;s business and prospects may suffer. Even if the product candidates advance in clinical development, they may fail to gain regulatory approval. Even if the product candidates are approved, they may fail to achieve market acceptance, and the Company may never become profitable. Even if the Company becomes profitable, it may not sustain profitability.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company's current operating plan estimates, the Company does not have sufficient cash to satisfy its working capital needs and other liquidity requirements over at least the next <ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" format="ixt-sec:durmonth" name="dare:PeriodofInsufficientCashandLiquidityRequirements" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNC9mcmFnOjYzNWQ2OTNhNDc1MjRkMGI4ZmM0N2RjOTBkYjQ1MjExL3RleHRyZWdpb246NjM1ZDY5M2E0NzUyNGQwYjhmYzQ3ZGM5MGRiNDUyMTFfNzE2Mw_3df2d038-0abb-4b5f-925e-ee374c895ea6">12</ix:nonNumeric> months from the date of issuance of the accompanying consolidated financial statements. The Company needs to raise substantial additional capital to continue to fund its operations and to successfully execute its current operating plan, including to continue the planned development of DARE-BV1, Ovaprene, and Sildenafil Cream, 3.6%.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently evaluating a variety of capital raising options, including equity and debt financings, government or other grant funding, collaborations and strategic alliances or other similar types of arrangements to cover its operating expenses, including the development of its product candidates and any future product candidates it may license or otherwise acquire. The amount and timing of the Company's capital needs have been and will continue to depend highly on many factors, including the product development programs the Company chooses to pursue and the pace and results of its clinical development efforts. If the Company raises capital through collaborations, strategic alliances or other similar types of arrangements, it may have to relinquish, on terms that are not favorable to the Company, rights to some of its technologies or product candidates it would otherwise seek to develop or commercialize. There can be no assurances that capital will be available when needed or that, if available, it will be obtained on terms favorable to the Company and its stockholders. Additionally, equity or debt financings may have a dilutive effect on the holdings of the Company's existing stockholders. If the Company cannot raise capital when needed, on favorable terms or at all, the Company will not be able to continue development of its product candidates, will need to reevaluate its planned operations and may need to delay, scale back or eliminate some or all of its development programs, reduce expenses, file for bankruptcy, reorganize, merge with another entity, or cease operations. If the Company becomes unable to continue as a going concern, the Company may have to liquidate its assets, and might realize significantly less than the values at which they are carried on its consolidated financial statements, and stockholders may lose all or part of their investment in the Company's common stock. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i022f63f2229448a58eb69ac900e95c5a">The effect of the COVID-19 pandemic and efforts to reduce the spread of COVID-19 remain a rapidly evolving and uncertain risk to the Company's business, operating results, financial condition and stock price. In large part, the extent to which the pandemic affects the Company will depend on future developments that are beyond its knowledge or control, including, but not limited to, the duration and severity of the pandemic, governmental and individual organization actions and policies implemented to reduce transmission of the disease or facilitate development of or access to therapies to treat or vaccinations to protect against the disease, governmental actions and policies to assist economic recovery, and the speed with which and degree to which normal economic and operating conditions resume. Infectious disease experts have cautioned that the U.S. may experience a substantial surge in cases and hospitalizations during the cooler months, which may lead the federal government and/or state governments to impose or re-impose stay-at-home orders and shutdowns of non-essential businesses in efforts to reduce the spread of the disease, such as those announced by the United Kingdom, Germany, France and other European countries in October 2020. The pandemic may increase the anticipated aggregate costs for the development of the Company's product candidates and may adversely impact the anticipated timelines for the development of the Company's product candidates by, among other things,&#160;causing disruptions in the supply chain for clinical supplies, delays in the commencement of clinical trials, delays in the timing and pace of subject enrollment in any ongoing clinical trials and lower than anticipated subject enrollment and completion rates, delays in the review and approval of the Company's regulatory submissions by regulatory agencies with respect to the Company's product candidates, and other unforeseen disruptions. The economic impact of the pandemic and the uncertainty and volatility in the capital markets it has caused, and may continue to cause, may negatively impact investor sentiment and the availability and cost of capital, and may adversely impact the Company's ability to raise capital when needed or on terms favorable to the Company and its stockholders to fund its development programs and operations.</ix:continuation> Given the high level of uncertainty regarding the duration and impact of the COVID-19 pandemic on the U.S. and global economies, workplace environments and capital markets, the Company is unable to assess the impact of the pandemic on its operations. The full extent to which the COVID-19 pandemic will impact the Company's business, results of operations, financial condition, clinical trials, and preclinical research and access to capital will depend on future developments that are highly uncertain.</span></div><div id="i868f48d3ece34cfab595a46f6986b439_37"></div><div style="margin-top:18pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfOTk5OQ_23a68426-14b5-46a6-a201-e5840afefe11" continuedAt="ibf6aad6d1854452786fb8bf2bc949c86" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="ibf6aad6d1854452786fb8bf2bc949c86" continuedAt="ic3e544e563c34e4b8247310c93d3dd1a"><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are described in Note 1 to the consolidated financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed with the Securities and Exchange Commission, or SEC on March 27, 2020. Since the date of those consolidated financial statements, there have been no material changes to the Company&#8217;s significant accounting policies, except for the accounting policies related to revenue recognition as described below.</span></div><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfMTAwMDU_34151567-dbad-4a35-a2c6-d445aa60185b" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X.&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#8217;s opinion, the accompanying interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying interim consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfMTAwMDI_a29d2647-592f-45d0-b7e3-6b63635b9c96" continuedAt="if0240250d4d24746972142b68c4240d1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use, or ROU, lease assets, current portion of lease obligations, and long-term lease obligations on the Company's consolidated balance sheets.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic3e544e563c34e4b8247310c93d3dd1a" continuedAt="i1e7a644e6f1d4e308ee40e5d83dcdea6"><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if0240250d4d24746972142b68c4240d1">ROU lease assets represent the Company's right to use an underlying asset for the lease term and lease obligations represent the Company's obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. If the lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset also includes any lease payments made and excludes lease incentives. The Company's lease terms may include options to extend or terminate the lease and the related payments are only included in the lease liability when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</ix:continuation> (See Note 7, Leased Properties.)</span></div><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfMTAwMDM_c2ae36cf-00df-43c0-a1b6-89b88d6e265e" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfOTk5Nw_d9aced9b-70d5-453b-870d-b27469f0397d" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#191c1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following tables present the classification within the fair value hierarchy of financial assets and liabilities that are remeasured on a recurring basis as of September&#160;30, 2020 and December&#160;31, 2019. There were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 2) as of September&#160;30, 2020.</span></div><div style="margin-bottom:5pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:477.75pt"><tr><td style="width:1.0pt"></td><td style="width:208.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61802997b9674fab8ffd3af8bfb3c702_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfNC0xLTEtMS0w_67ca1a40-51c8-40a7-b31e-815bcf518967">5,389,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ea3391305d40f1a09bb8baa7e4411b_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfNC0zLTEtMS0w_c98feb58-1a66-485d-b897-e55cdc8ecf1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9564923853734eb58d6d4aa1c93e63f2_I20200930" decimals="0" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfNC01LTEtMS0w_14e80330-9280-42c6-9e0b-3f620b127885">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf36c001049f4946aa8e0ca7818e0e67_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfNC03LTEtMS0w_ec950bb0-a28c-47cb-88ff-6c9eeff9b3c8">5,389,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61802997b9674fab8ffd3af8bfb3c702_I20200930" decimals="0" format="ixt:zerodash" name="dare:AssetAcquisitionContingentConsiderationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfNi0xLTEtMS0w_42832e19-e4b0-47f1-a04c-cb0b3adb55f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ea3391305d40f1a09bb8baa7e4411b_I20200930" decimals="0" format="ixt:zerodash" name="dare:AssetAcquisitionContingentConsiderationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfNi0zLTEtMS0w_3d7d588b-03bc-438d-b524-963473f781fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9564923853734eb58d6d4aa1c93e63f2_I20200930" decimals="0" format="ixt:numdotdecimal" name="dare:AssetAcquisitionContingentConsiderationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfNi01LTEtMS0w_97a8be8c-f579-40b9-98d6-22c3c83262fe">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf36c001049f4946aa8e0ca7818e0e67_I20200930" decimals="0" format="ixt:numdotdecimal" name="dare:AssetAcquisitionContingentConsiderationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfNi03LTEtMS0w_0c3fd969-0b1a-4434-8d89-6d57e40aa758">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i237f1cb504f84950b23fc22b495fd451_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfOS0xLTEtMS0w_69f20bf5-06df-4a5d-9476-02894f4ddc0a">4,780,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e67fe471b24b518cb739618ce1fa5b_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfOS0zLTEtMS0w_789e13ed-ea7d-4e4c-9660-3f85c5abafd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d74cf524f4149c68caa93d927c1dd50_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfOS01LTEtMS0w_41ad0423-5fd1-4637-ae06-256dff2ee9f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i073719e46a364115ad47c32863916d2b_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfOS03LTEtMS0w_6d4ea617-a28b-4b06-afee-5146c6660aa3">4,780,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other non-current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:26pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i237f1cb504f84950b23fc22b495fd451_I20191231" decimals="0" format="ixt:zerodash" name="dare:AssetAcquisitionContingentConsiderationNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfMTEtMS0xLTEtMA_770a2f4b-06dd-44fa-ad23-782d8bdfa697">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e67fe471b24b518cb739618ce1fa5b_I20191231" decimals="0" format="ixt:zerodash" name="dare:AssetAcquisitionContingentConsiderationNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfMTEtMy0xLTEtMA_a9a3224f-f4c7-457d-9e1c-d26a0ab3375b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d74cf524f4149c68caa93d927c1dd50_I20191231" decimals="0" format="ixt:numdotdecimal" name="dare:AssetAcquisitionContingentConsiderationNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfMTEtNS0xLTEtMA_1c6c29c4-3e17-4db9-89a5-e1d967516574">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i073719e46a364115ad47c32863916d2b_I20191231" decimals="0" format="ixt:numdotdecimal" name="dare:AssetAcquisitionContingentConsiderationNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfMTEtNy0xLTEtMA_cbc2a48a-acf0-4394-a1e2-ae81dd00895d">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfMjc0ODc3OTA3OTU1NA_658b467c-3008-458a-8559-db0655fcc595" continuedAt="i4c7a9253c0084910b4185d7fd51b5200" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue is accordance with Accounting Standards Codification, or ASC, Topic 606,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1e7a644e6f1d4e308ee40e5d83dcdea6"><ix:continuation id="i4c7a9253c0084910b4185d7fd51b5200"><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a contract with multiple performance obligations, the Company develops estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license&#160;to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from non-refundable, upfront fees allocated to the&#160;license when the&#160;license&#160;is transferred to the customer and the customer is able to use and benefit from the&#160;license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. To date, the Company has not recognized any license fee revenue resulting from any of its collaborative arrangements.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bayer License. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Company entered into a license agreement with Bayer HealthCare LLC, or Bayer, regarding the further development and commercialization of Ovaprene in the U.S. Upon execution of the agreement, the Company received a $<ix:nonFraction unitRef="usd" contextRef="i28e27dfd8d1744fd931fe1123a4379d6_D20200101-20200131" decimals="-5" format="ixt:numdotdecimal" name="dare:UpfrontLicenseFeePaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfODQ5OQ_aa0153e2-3a8c-4ac2-ac29-1733eca43a43">1.0</ix:nonFraction> million upfront non-refundable license fee payment from Bayer. Bayer, in its sole discretion, has the right to make the license effective by paying the Company an additional $<ix:nonFraction unitRef="usd" contextRef="i28e27dfd8d1744fd931fe1123a4379d6_D20200101-20200131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfODY2OA_b7a7c133-097a-4500-bab0-5137aa58e4f4">20.0</ix:nonFraction> million. The Company concluded that there was one significant performance obligation related to the $<ix:nonFraction unitRef="usd" contextRef="i28e27dfd8d1744fd931fe1123a4379d6_D20200101-20200131" decimals="-5" format="ixt:numdotdecimal" name="dare:UpfrontLicenseFeePaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfODc2Mw_aa0153e2-3a8c-4ac2-ac29-1733eca43a43">1.0</ix:nonFraction> million upfront payment: a distinct license to commercialize Ovaprene effective upon the receipt of the $<ix:nonFraction unitRef="usd" contextRef="i28e27dfd8d1744fd931fe1123a4379d6_D20200101-20200131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfODg2Mg_b7a7c133-097a-4500-bab0-5137aa58e4f4">20.0</ix:nonFraction> million fee. The $<ix:nonFraction unitRef="usd" contextRef="i28e27dfd8d1744fd931fe1123a4379d6_D20200101-20200131" decimals="-5" format="ixt:numdotdecimal" name="dare:UpfrontLicenseFeePaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfODg3NA_aa0153e2-3a8c-4ac2-ac29-1733eca43a43">1.0</ix:nonFraction> million upfront payment will be recorded as license revenue at the earlier of (1) the point in time the&#160;Company receives the $<ix:nonFraction unitRef="usd" contextRef="i28e27dfd8d1744fd931fe1123a4379d6_D20200101-20200131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfODk5NA_b7a7c133-097a-4500-bab0-5137aa58e4f4">20.0</ix:nonFraction> million fee, the license&#160;is transferred to Bayer and Bayer is able to use and benefit from the&#160;license and (2) the termination of the agreement. As of September&#160;30, 2020, neither of the foregoing had occurred. The $<ix:nonFraction unitRef="usd" contextRef="i28e27dfd8d1744fd931fe1123a4379d6_D20200101-20200131" decimals="-5" format="ixt:numdotdecimal" name="dare:UpfrontLicenseFeePaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfOTE4Nw_aa0153e2-3a8c-4ac2-ac29-1733eca43a43">1.0</ix:nonFraction> million payment is recorded as long term deferred revenue in the Company's consolidated balance sheet at September&#160;30, 2020.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will also be entitled to receive (a) milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="ib620eb86663f4b8eb249d3ca45e8961f_D20200110-20200110" decimals="-5" format="ixt:numdotdecimal" name="dare:MilestonePaymentsContingentAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfOTM2NA_96641c70-c39e-41d1-bcfa-a05270c33af2">310.0</ix:nonFraction> million related to the commercial sales of Ovaprene, if all such milestones are achieved, and (b) tiered royalties starting in the low double digits based on annual net sales of Ovaprene during a calendar year, subject to customary royalty reductions and offsets, and (c) a percentage of sublicense revenue.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential future payments for variable consideration, such as commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur. (See Note 3, License and Collaboration Agreements.)</span></div></ix:continuation><div id="i868f48d3ece34cfab595a46f6986b439_40"></div><div style="margin-bottom:6pt;margin-top:18pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTg2NTQ_7846afc3-3826-4bb9-bf3e-2ae997d7be3b" continuedAt="if789e8550aaf4aef97f8a11768c04e55" escape="true">LICENSE AND COLLABORATION AGREEMENTS</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if789e8550aaf4aef97f8a11768c04e55" continuedAt="if691d221353a447e8b18bebb8f4efd8c"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Out-License Agreements</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Bayer HealthCare License Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 10, 2020, the Company entered into a license agreement with Bayer, regarding the further development and commercialization of Ovaprene in the U.S. Under the agreement, the Company received a $<ix:nonFraction unitRef="usd" contextRef="i28e27dfd8d1744fd931fe1123a4379d6_D20200101-20200131" decimals="-5" format="ixt:numdotdecimal" name="dare:UpfrontLicenseFeePaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMzMx_aa0153e2-3a8c-4ac2-ac29-1733eca43a43">1.0</ix:nonFraction> million upfront non-refundable license fee payment from Bayer. If Bayer pays an additional $<ix:nonFraction unitRef="usd" contextRef="i28e27dfd8d1744fd931fe1123a4379d6_D20200101-20200131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfNDE3_b7a7c133-097a-4500-bab0-5137aa58e4f4">20.0</ix:nonFraction> million to the Company after Bayer receives and reviews the results of the pivotal clinical trial of Ovaprene, which payment Bayer may elect to make in its sole discretion, the license grant to Bayer to develop and commercialize Ovaprene for human contraception in the U.S. becomes effective. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone &amp; Royalty Payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company will be entitled to receive (a) a milestone payment in the low double-digit millions upon the first commercial sale of Ovaprene in the U.S. and escalating milestone payments based on annual net sales of Ovaprene during a calendar year, totaling up to $<ix:nonFraction unitRef="usd" contextRef="ib620eb86663f4b8eb249d3ca45e8961f_D20200110-20200110" decimals="-5" format="ixt:numdotdecimal" name="dare:MilestonePaymentsContingentAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTAwNQ_96641c70-c39e-41d1-bcfa-a05270c33af2">310.0</ix:nonFraction> million if all such milestones, including the first commercial sale, are achieved, (b) tiered royalties starting in the low double digits based on annual net sales of Ovaprene during a calendar year, subject to customary royalty reductions and offsets, and (c) a percentage of sublicense revenue.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Efforts.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company is responsible for the pivotal trial for Ovaprene and for its development and regulatory activities and has product supply obligations. Bayer is supporting the Company in development and regulatory activities by providing up to two full-time equivalents with expertise in clinical, regulatory, preclinical, commercial, CMC and product supply matters in an advisory capacity. After payment of the $<ix:nonFraction unitRef="usd" contextRef="i28e27dfd8d1744fd931fe1123a4379d6_D20200101-20200131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTcxOA_b7a7c133-097a-4500-bab0-5137aa58e4f4">20.0</ix:nonFraction> million fee, Bayer will be responsible for the commercialization of Ovaprene for human contraception in the U.S.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial term of the agreement, which is subject to automatic renewal terms, continues until the later of (a) the expiration of any valid claim covering the manufacture, use, sale or import of Ovaprene in the U.S.; or (b) 15 years from the first commercial sale of Ovaprene in the U.S. In addition to customary termination rights for both parties, Bayer may terminate the agreement at any time on 90 days' notice and the agreement will automatically terminate if the Company does not receive the $<ix:nonFraction unitRef="usd" contextRef="i28e27dfd8d1744fd931fe1123a4379d6_D20200101-20200131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMjMzMQ_b7a7c133-097a-4500-bab0-5137aa58e4f4">20.0</ix:nonFraction> million fee if and when due.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">In-License Agreements</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Hammock/MilanaPharm Assignment and License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the Company entered into (a) an Assignment Agreement with Hammock Pharmaceuticals, Inc., or the Assignment Agreement, and (b) a First Amendment to License Agreement with TriLogic Pharma, LLC and MilanaPharm LLC, or the License Amendment. Both agreements relate to the exclusive license agreement among Hammock, TriLogic and MilanaPharm dated as of January 9, 2017, or the MilanaPharm License Agreement. Under the Assignment Agreement and the MilanaPharm License Agreement, as amended by the License Amendment, the Company acquired an exclusive, worldwide license to develop and commercialize products for the diagnosis, treatment and prevention of human diseases or conditions in or through any intravaginal or urological applications. The licensed intellectual property relates to the hydrogel drug delivery platform of TriLogic and MilanaPharm known as TRI-726. In DARE-BV1, this proprietary technology is formulated with clindamycin, an antibiotic with FDA approval to treat certain bacterial infections, including bacterial vaginosis. In December 2019, the Company entered into amendments to each of the License Amendment and Assignment Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of other terms of the License Amendment, as amended:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company paid MilanaPharm: (1) $<ix:nonFraction unitRef="usd" contextRef="i675ccdafc7724770bc5f9d69ad53a137_D20191201-20191231" decimals="-3" format="ixt:numdotdecimal" name="dare:LicenseFee" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMzcyOA_c70b481c-f081-42fa-a7d5-c32c1e24e2de">25,000</ix:nonFraction> in connection with the execution of the License Amendment; (2) $<ix:nonFraction unitRef="usd" contextRef="i663f6a3e47204c84a850cfb01668fd90_D20191205-20191205" decimals="-3" format="ixt:numdotdecimal" name="dare:LicenseFeeToBePaidUponContingency" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMzc5NA_edfaec97-f454-4c5a-92d7-43ecf64fcae7">100,000</ix:nonFraction> on December 5, 2019; and (3) $<ix:nonFraction unitRef="usd" contextRef="i13d5e927223840e1ae39274dbb5609d3_D20200131-20200131" decimals="-3" format="ixt:numdotdecimal" name="dare:LicenseFeeToBePaidUponContingency" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMzgyNg_9e1d2b1d-5d18-46af-bc10-6904a4795aeb">110,000</ix:nonFraction> on January 31, 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will pay to MilanaPharm (1) up to $<ix:nonFraction unitRef="usd" contextRef="ic44f91cd00fb46e9b948e5acc2a670e9_D20191201-20191231" decimals="-3" format="ixt:numdotdecimal" name="dare:MilestonePaymentsContingentAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMzkxNg_fcbbcb58-39a2-4e67-a454-f6a274bef9ab">300,000</ix:nonFraction> in the aggregate upon achievement of certain clinical and regulatory development milestones, $<ix:nonFraction unitRef="usd" contextRef="i2508e3e579a94cdea63398846fa669b5_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="dare:MilestonePaymentsContingentAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfNDAxMg_652db27b-bab7-40a8-af3c-2b894bc2457f">50,000</ix:nonFraction> of which was paid during the second quarter of 2020, and (2) up to $<ix:nonFraction unitRef="usd" contextRef="i9480befabfcf46ad88721e52ff929278_D20200401-20200630" decimals="-4" format="ixt:numdotdecimal" name="dare:MilestonePaymentsContingentAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfNDA4Mg_1339835d-bc74-4401-85ed-6ea647edfb52">1.75</ix:nonFraction> million in the aggregate upon achieving certain commercial sales milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Sublicense Income.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will pay MilanaPharm a low double-digit percentage of all income received by the Company or its affiliates in connection with any sublicense granted to a third party for use outside of the United States, subject to certain exclusions.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if691d221353a447e8b18bebb8f4efd8c" continuedAt="i9ab887208ffd46f38b8c4586c3254a7b"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> After the commercial launch of licensed products and processes and during the royalty term, the Company will pay MilanaPharm high single-digit to low double-digit royalties based on annual worldwide net sales of licensed products and processes in accordance with the agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Efforts. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company must use commercially reasonable efforts and resources to (1) develop and commercialize at least one licensed product or process in the United States and at least one licensed product or process in Canada, the United Kingdom, France, Germany, Italy or Spain, and (2) continue to commercialize that product or process following the first commercial sale of a licensed product or process in the applicable jurisdiction.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unless earlier terminated, the license term continues until (1) on a licensed product-by-product (or process-by-process basis) and country-by-country basis, the date of expiration of the royalty term with respect to such licensed product (or process) in such country, and (2) the expiration of all applicable royalty terms under the MilanaPharm License Agreement with respect to all licensed products and processes in all countries. Upon expiration of the term with respect to any licensed product or process in a country (but not upon earlier termination of the MilanaPharm License Agreement), the licenses granted to the Company under the MilanaPharm License Agreement will convert automatically to an exclusive, fully paid-up, royalty-free, perpetual, non-terminable and irrevocable right and license under the licensed intellectual property.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to customary termination rights in favor of all parties, MilanaPharm may terminate the license solely with respect to a licensed product or process in a country if, after having launched such product or process in such country, the Company or its affiliates or sublicensees, (1) discontinue the sale of such product or process in such country and MilanaPharm notifies the Company of such termination within <ix:nonNumeric contextRef="i663f6a3e47204c84a850cfb01668fd90_D20191205-20191205" format="ixt-sec:durday" name="dare:LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfNjQzNg_48eec022-654e-4a40-9e6c-cb2d65e14b17">60</ix:nonNumeric> days of having first been notified by the Company of such discontinuation, or (2) (A) discontinue all commercially reasonable marketing efforts to sell, and discontinue all sales of, such product or process in such country for nine months or more, (B) fail to resume such commercially reasonable marketing efforts within <ix:nonNumeric contextRef="i663f6a3e47204c84a850cfb01668fd90_D20191205-20191205" format="ixt-sec:durday" name="dare:LicenseAgreementTerminationPeriodDueToPerformanceFailure" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfNjc1NQ_4a1b27df-5403-40c5-9bff-b5592aa077d4">120</ix:nonNumeric> days of having been notified of such failure by MilanaPharm, (C) fail to reasonably demonstrate a strategic justification for the discontinuation and failure to resume to MilanaPharm, and (D) MilanaPharm gives <ix:nonNumeric contextRef="i663f6a3e47204c84a850cfb01668fd90_D20191205-20191205" format="ixt-sec:durday" name="dare:LicenseAgreementNoticePeriodOfTermination" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfNjk2Mw_62c91511-809d-4636-974e-886579480f49">90</ix:nonNumeric> days&#8217; notice to the Company.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of other terms of the Assignment Agreement, as amended:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assignment; Technology Transfer</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Hammock assigned and transferred to the Company all of its right, title and interest in and to the MilanaPharm License Agreement and agreed to cooperate to transfer to the Company all of the data, materials and the licensed technology in its possession pursuant to a technology transfer plan to be agreed upon by the parties, with a goal for the Company to independently practice the licensed intellectual property as soon as commercially practical in order to develop and commercialize the licensed products and processes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fees</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company paid Hammock: (1) $<ix:nonFraction unitRef="usd" contextRef="ib18fb0a15d48447fa6a79f7ea2a55a0f_D20191205-20191205" decimals="INF" format="ixt:numdotdecimal" name="dare:LicenseFee" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfNzY2Nw_1cf44b58-9014-4072-a567-60afe611308b">250,000</ix:nonFraction> in connection with the execution of the Assignment Agreement; (2) $<ix:nonFraction unitRef="usd" contextRef="ib18fb0a15d48447fa6a79f7ea2a55a0f_D20191205-20191205" decimals="INF" format="ixt:numdotdecimal" name="dare:LicenseFeeToBePaidUponContingency" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfNzczNg_6ab75424-6843-426a-a159-225a162b11e9">125,000</ix:nonFraction> on December 5, 2019; and (3) $<ix:nonFraction unitRef="usd" contextRef="ib69e2f5dfaaa4c50b61ce358dfe41490_D20200131-20200131" decimals="INF" format="ixt:numdotdecimal" name="dare:LicenseFeeToBePaidUponContingency" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfNzc2OA_78556fd3-1da9-4458-990b-aac04d49c56a">137,500</ix:nonFraction> on January 31, 2020. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company will pay Hammock up to $<ix:nonFraction unitRef="usd" contextRef="i9d27e115aa2d4aa195fb48879883d1a1_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="dare:MilestonePaymentsContingentAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfNzg0OA_80f3d4f0-f965-48a2-aec0-90146e492a86">1.1</ix:nonFraction> million in the aggregate upon achievement of certain clinical and regulatory development milestones, $<ix:nonFraction unitRef="usd" contextRef="i389b47dad95042fe93f5c460e656a37d_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="dare:MilestonePayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMzI5ODUzNDkwMjQ3OA_969bd998-33c9-4b58-9e95-3351df042b0f">100,000</ix:nonFraction> of which was paid during the third quarter of 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Assignment Agreement will terminate upon the later of (1) completion of the parties' technology transfer plan, and (2) payment to Hammock of the last of the milestone payments.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ADVA-Tec License Agreement </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company entered into a license agreement with ADVA-Tec, Inc., under which the Company was granted the exclusive right to develop and commercialize Ovaprene for human contraceptive use worldwide. The Company must use commercially reasonable efforts to develop and commercialize Ovaprene.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will pay ADVA-Tec: (1) up to $<ix:nonFraction unitRef="usd" contextRef="i84c418494d874dde87ff86a8ad8133ad_D20170301-20170331" decimals="-5" format="ixt:numdotdecimal" name="dare:ResearchAndDevelopmentMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfODUyOQ_0ab03e77-fab3-4f58-8f0b-e9734a724b29">14.6</ix:nonFraction> million in the aggregate based on the achievement of specified development and regulatory milestones; and (2) up to $<ix:nonFraction unitRef="usd" contextRef="i27a820732a994084bea4346080486a18_D20170301-20170331" decimals="-5" format="ixt:numdotdecimal" name="dare:ResearchAndDevelopmentMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfODY0MA_4120a090-2b7a-4ccc-8e13-59a22d0ee8be">20.0</ix:nonFraction> million in the aggregate based on the achievement of certain worldwide net sales milestones.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  After the commercial launch of Ovaprene, the Company will pay ADVA-Tec royalties based on aggregate annual net sales of Ovaprene in specified regions, at a royalty rate that will vary between <ix:nonFraction unitRef="number" contextRef="i8f872d8e39ed4734a655cc6daabe747c_D20170301-20170331" decimals="INF" name="dare:PercentageOfRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfODk0Mg_0322846c-53f5-4213-8c0a-4ec344fb684e">1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ifc98d29e798c45f386168a17588148ad_D20170301-20170331" decimals="INF" name="dare:PercentageOfRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfODk0OQ_017bb3df-9e6d-478d-b592-c56979435409">10</ix:nonFraction>% and will increase based on various net sales thresholds. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9ab887208ffd46f38b8c4586c3254a7b" continuedAt="i5476cdfbc90648988dd69da454d9acc4"><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Unless earlier terminated, the license continues on a country-by-country basis until the later of the life of the licensed patents or final commercial sale of Ovaprene. In addition to customary termination rights for both parties: (A) the Company may terminate the agreement with or without cause in whole or on a country-by-country basis upon 60 days prior written notice; and (B) ADVA-Tec may terminate the agreement if (1) the Company develops or commercializes any non-hormonal ring-based vaginal contraceptive device competitive to Ovaprene or (2) if the Company fails to meet agreed upon efforts to commercialize Ovaprene.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">SST License and Collaboration Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into a license and collaboration agreement with Strategic Science &amp;&#160;Technologies-D,&#160;LLC and Strategic Science &amp; Technologies, LLC, referred to collectively as SST, under which the Company received an exclusive, royalty-bearing, sublicensable license to develop and commercialize the Licensed Product (as defined below), in all countries and geographic territories of the world, for all indications for women related to female sexual dysfunction and/or female reproductive health, or the Field of Use. The Licensed Product, is defined as SST&#8217;s proprietary topical formulation of sildenafil cream as it existed as of the effective date of the agreement, or any other topically applied pharmaceutical product containing sildenafil or a salt thereof as a pharmaceutically active ingredient, alone or with other active ingredients, but specifically excluding any product containing ibuprofen or any salt derivative of ibuprofen.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of other terms of this license and collaboration agreement:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invention Ownership.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company retains rights to inventions made by its employees, SST retains rights to inventions made by its employees, and each party will own a <ix:nonFraction unitRef="number" contextRef="i88ef2e92e2db432987e74cad75d700a3_D20180201-20180228" decimals="INF" name="dare:PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTA4NDY_a30d8210-d2e7-48b0-9098-d6a543b3787b">50</ix:nonFraction>% undivided interest in all joint inventions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Development Committee.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The parties will collaborate through a joint development committee that will determine the strategic objectives for, and generally oversee, the development efforts of both parties under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company must use commercially reasonable efforts to develop the Licensed Products in the Field of Use in accordance with a development plan in the agreement, and to commercialize the Licensed Products in the Field of Use. The Company is responsible for all reasonable internal and external costs and expenses incurred by SST in its performance of the development activities it must perform under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SST will be eligible to receive tiered royalties based on percentages of annual net sales of Licensed Products in the single digits to the mid double digits, subject to customary royalty reductions and offsets, and a percentage of sublicense revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SST will be eligible to receive payments (1) ranging from $<ix:nonFraction unitRef="usd" contextRef="if910f6abc722476083f07bcc96a49f22_D20180201-20180228" decimals="-5" format="ixt:numdotdecimal" name="dare:MilestonePaymentsContingentAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTE4OTg_dda4d2b4-bd29-4087-bdd2-c863cad5e52e">0.5</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i1ef6eb9665eb4b70a2eaa329f9ee2427_D20180201-20180228" decimals="-5" format="ixt:numdotdecimal" name="dare:MilestonePaymentsContingentAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTE5MDQ_a6dd61cd-6ea3-4435-a605-c1ecabe5dfc9">18.0</ix:nonFraction> million in the aggregate upon achieving certain clinical and regulatory milestones in the U.S. and worldwide, and (2) between $<ix:nonFraction unitRef="usd" contextRef="i75219243251d4cfb879a00b8d9c29575_D20180201-20180228" decimals="-5" format="ixt:numdotdecimal" name="dare:MilestonePaymentsContingentAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTIwMjM_2603c508-ed11-4228-a244-79cf89c6db95">10.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="if58b7340a7a6466bb0aae7cb62f4cf97_D20180201-20180228" decimals="-5" format="ixt:numdotdecimal" name="dare:MilestonePaymentsContingentAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTIwMjk_e00aab80-d38e-4ba1-b358-282728e676a5">100.0</ix:nonFraction> million in the aggregate upon achieving certain commercial sales milestones. If the Company enters into strategic development or distribution partnerships related to the Licensed Products, additional milestone payments would be due to SST.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Catalent JNP License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018,&#160;the Company entered into an exclusive license agreement with Catalent JNP, Inc. (formerly known as Juniper Pharmaceuticals, Inc., and which the Company refers to as Catalent), under which Catalent granted the Company (a) an exclusive, royalty-bearing worldwide license under certain patent rights, either owned by or exclusively licensed to Catalent, to make, have made, use, have used, sell, have sold, import and have imported products and processes; and (b) a non-exclusive, royalty-bearing worldwide license to use certain technological information owned by Catalent to make, have made, use, have used, sell, have sold, import and have imported products and processes. The Company is entitled to sublicense the rights granted to it under this agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Upfront Fee.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company paid a $<ix:nonFraction unitRef="usd" contextRef="i49b990efd5e94bda8624d4a3746d6795_D20180401-20180430" decimals="-3" format="ixt:numdotdecimal" name="dare:UpfrontLicenseFeePaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTMxMDA_0b633ba0-3e42-4848-8c78-2fe117fd381c">250,000</ix:nonFraction> non-creditable upfront license fee to Catalent in connection with the execution of the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annual Maintenance Fee.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will pay an annual license maintenance fee to Catalent on each anniversary of the date of the agreement, the amount of which was $<ix:nonFraction unitRef="usd" contextRef="i49b990efd5e94bda8624d4a3746d6795_D20180401-20180430" decimals="-3" format="ixt:numdotdecimal" name="dare:PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTMzNzA_a1de5eef-eb5d-4280-a335-95fd08ea68df">50,000</ix:nonFraction> for each of the first two years and will be $<ix:nonFraction unitRef="usd" contextRef="i49b990efd5e94bda8624d4a3746d6795_D20180401-20180430" decimals="-3" format="ixt:numdotdecimal" name="dare:PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTM0MDE_b095340b-7337-4231-9fc4-4c50329174cb">100,000</ix:nonFraction> thereafter, and which will be creditable against royalties and other payments due to Catalent in the same calendar year but may not be carried forward to any other year.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5476cdfbc90648988dd69da454d9acc4" continuedAt="ic9e93f59eda14a7db0d64dd6d539257d"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company must make potential future development and sales milestone payments of (1) up to $<ix:nonFraction unitRef="usd" contextRef="i35e21a41a4f34efb9124460b6ace1b6e_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="dare:MaximumPotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTM2ODc_abafb97c-94f3-4763-a0b3-fdca7b2e92f5">13.5</ix:nonFraction> million in the aggregate upon achieving certain clinical and regulatory milestones, and (2) up to $<ix:nonFraction unitRef="usd" contextRef="ie5cb9f4c567542a0a0afd091500582b8_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="dare:MaximumPotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTM3ODA_acd0ee01-33b8-4841-b4a9-943b9685ceff">30.3</ix:nonFraction> million in the aggregate upon achieving certain commercial sales milestones for each product or process covered by the licenses granted under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the royalty term, the Company will pay Catalent mid-single-digit to low double-digit royalties based on worldwide net sales of products and processes covered by the licenses granted under the agreement. In lieu of such royalty payments, the Company will pay Catalent a low double-digit percentage of all sublicense income the Company receives for the sublicense of rights under the agreement to a third party. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adare Development and Option Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, the Company entered into an exclusive development and option agreement with Adare Pharmaceuticals (formerly known as Orbis Biosciences, and which the Company refers to as Adare), for the development of long-acting injectable etonogestrel contraceptive with 6- and 12-month durations (ORB-204 and ORB-214, respectively). Under this agreement, the Company paid Adare $<ix:nonFraction unitRef="usd" contextRef="ibb3910bfa3544d7bb4cb75487de595bc_D20180301-20180331" decimals="-3" format="ixt:numdotdecimal" name="dare:ResearchAndDevelopmentMilestonePayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTQ3MTM_6e33af1c-684b-4a39-9805-0b3fac47b8f7">300,000</ix:nonFraction> to conduct the first stage of development work as follows: $<ix:nonFraction unitRef="usd" contextRef="ic8e3c00cd33e4af2a7e1c65065c3b12b_D20180301-20180331" decimals="-3" format="ixt:numdotdecimal" name="dare:ResearchAndDevelopmentMilestonePayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTQ3NzU_2c8ae335-34ea-4d6a-a27b-613fac10f0f9">150,000</ix:nonFraction> upon signing the agreement; $<ix:nonFraction unitRef="usd" contextRef="id9aa0a2281ea41fc9868218205b55f9c_D20180301-20180331" decimals="-3" format="ixt:numdotdecimal" name="dare:ResearchAndDevelopmentMilestonePayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTQ4MDY_07dc1a75-35e0-4984-859b-68155799fb04">75,000</ix:nonFraction> at the <ix:nonFraction unitRef="number" contextRef="id9aa0a2281ea41fc9868218205b55f9c_D20180301-20180331" decimals="INF" name="dare:PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTQ4MTY_f38578ba-3f88-4397-9d1b-027d7424dc15">50</ix:nonFraction>% completion point, not later than 6 months following the date the agreement was signed (which the Company paid in September 2018); and $<ix:nonFraction unitRef="usd" contextRef="i5d6c1e846f824bddaf958f3525ddafea_D20180301-20180331" decimals="-3" format="ixt:numdotdecimal" name="dare:ResearchAndDevelopmentMilestonePayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTQ5NTM_aba76411-63e0-4b65-a899-a9f1fcf89762">75,000</ix:nonFraction> upon delivery by Adare of the 6-month batch, not later than 11 months following the date the agreement was signed (which the Company paid in January 2019). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon Adare successfully completing the first stage of development work and achieving the predetermined target milestones for that stage, the Company will have <ix:nonNumeric contextRef="ibb3910bfa3544d7bb4cb75487de595bc_D20180301-20180331" format="ixt-sec:durday" name="dare:CommencementPeriodForStageTwoUponAchievementOfStageOne" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTUyNzI_768cede2-54e4-4f73-b4ce-043c8eb5952b">90</ix:nonNumeric> days to instruct Adare whether to commence the second stage of development work. Should the Company execute its option to proceed with the second stage, it will have to provide additional funding to Adare for such activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-clinical studies for the 6- and 12-month formulations have been completed, including establishing pharmacokinetics and pharmacodynamics profiles. The collaboration with Adare will continue to advance the program through formulation optimization with the goal of achieving sustained release over the target time period.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement provides the Company with an option to enter into a license agreement for ORB-204 and ORB-214 should development efforts be successful.</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Acquired Products</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Microchips Acquisition</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As further discussed in Note 4. Acquisition below, in November 2019, the Company completed its acquisition of Microchips (as defined below). The Company acquired Microchips to secure the rights to develop an implantable, user-controlled, long-acting reversible contraception method, now known as DARE-LARC1. The Company agreed to use commercially reasonable efforts to achieve specified development and regulatory objectives relating to the implantable contraceptive product in development by Microchips.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issued an aggregate of <ix:nonFraction unitRef="shares" contextRef="i240f37dfb7c84e948e9a4cfed130cbc1_D20191130-20191130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTY2MDQ_e62d8789-2f34-4ce5-93ba-ff2ff72d77ba">2,999,990</ix:nonFraction> shares of its common stock to the holders of shares of Microchips' capital stock outstanding immediately prior to the effective time of the merger. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also agreed to pay the following contingent consideration to the former Microchips stockholders: (a) up to $<ix:nonFraction unitRef="usd" contextRef="i86cbc311d1df479cb96f4a597e179fe5_D20191120-20191120" decimals="-5" format="ixt:numdotdecimal" name="dare:ResearchAndDevelopmentMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTY4NzU_1c67599a-f50d-4f19-8f84-ddd57167f4a3">46.5</ix:nonFraction> million contingent upon the achievement of specified funding, product development and regulatory milestones; (b) up to $<ix:nonFraction unitRef="usd" contextRef="i19e761cec8174fb4bcb03e95810a4853_I20191120" decimals="-5" format="ixt:numdotdecimal" name="dare:AssetAcquisitionContingentConsiderationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTY5ODk_7d2dacef-9a43-4d59-9736-2bc71a024e55">55.0</ix:nonFraction> million contingent upon the achievement of specified amounts of aggregate net sales of products incorporating the intellectual property acquired by the Company in the merger; (c) tiered royalty payments ranging from low single-digit to low double-digit percentages of annual net sales of such products, subject to customary provisions permitting royalty reductions and offset; and (d)&#160;a percentage of sublicense revenue related to such products. The Company agreed to use commercially reasonable efforts to achieve specified development and regulatory objectives relating to DARE-LARC1. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="i1ad6893defad461fa065876a751e3690_I20191120" decimals="-5" format="ixt:numdotdecimal" name="dare:AssetAcquisitionContingentConsiderationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTc2MDY_ea42d155-60f3-4692-a3dd-4f0205031aad">1.0</ix:nonFraction> million in contingent consideration associated with milestone payments it expects to become payable in the first half of 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic9e93f59eda14a7db0d64dd6d539257d" continuedAt="i3ef002ba9a13471ab8ca3bff689f0c6c"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pear Tree Acquisition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company completed its acquisition of Pear Tree Pharmaceuticals, Inc., or Pear Tree. The Company acquired Pear Tree to secure the rights to develop a proprietary vaginal formulation of tamoxifen, now known as DARE-VVA1, as a potential treatment for vulvar and vaginal atrophy.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company must make contingent payments to the Pear Tree former stockholders and their representatives, or the Holders, that are based on achieving certain clinical, regulatory and commercial milestones, which may be paid, in the Company&#8217;s sole discretion, in cash or shares of the Company&#8217;s common stock.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i3ef002ba9a13471ab8ca3bff689f0c6c" continuedAt="i99bcca73f04640849f7ebe62fe5ff33c">Royalty Payments</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i99bcca73f04640849f7ebe62fe5ff33c">. The Holders will be eligible to receive, subject to certain offsets, tiered royalties, including customary provisions permitting royalty reductions and offset, based on percentages of annual net sales of certain products subject to license agreements the Company assumed and a percentage of sublicense revenue.</ix:continuation> </span></div><div id="i868f48d3ece34cfab595a46f6986b439_43"></div><div style="margin-bottom:6pt;margin-top:18pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80My9mcmFnOjM5NzgxY2JjZmU1YzQ2YjdhYWFjNzAwYTVmNjIxYjNjL3RleHRyZWdpb246Mzk3ODFjYmNmZTVjNDZiN2FhYWM3MDBhNWY2MjFiM2NfMjI5OA_ecef9f8b-7f62-4956-974c-a6d106f1658a" continuedAt="i072d937d0a764c299cfdddf060221260" escape="true">ACQUISITION</ix:nonNumeric></span></div><ix:continuation id="i072d937d0a764c299cfdddf060221260" continuedAt="i188b61e4db9e48978ba4428188ef6f56"><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company acquired Microchips Biotech, Inc., or Microchips, via a merger transaction in which a wholly owned subsidiary of the Company, formed for purposes of this transaction, merged with and into Microchips</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Microchips survived as the Company&#8217;s wholly owned subsidiary. Microchips is developing a proprietary, implantable drug delivery system designed to store and precisely deliver numerous therapeutic doses over months and years on a schedule determined by the user and controlled via wireless remote. Microchips&#8217; lead product candidate is a pre-clinical stage contraceptive application of that technology that utilizes levonorgestrel, now known as DARE-LARC1.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issued an aggregate of <ix:nonFraction unitRef="shares" contextRef="i240f37dfb7c84e948e9a4cfed130cbc1_D20191130-20191130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80My9mcmFnOjM5NzgxY2JjZmU1YzQ2YjdhYWFjNzAwYTVmNjIxYjNjL3RleHRyZWdpb246Mzk3ODFjYmNmZTVjNDZiN2FhYWM3MDBhNWY2MjFiM2NfNzQ1_e62d8789-2f34-4ce5-93ba-ff2ff72d77ba">2,999,990</ix:nonFraction> shares of its common stock to the holders of shares of Microchips' capital stock outstanding immediately prior to the effective time of the merger. The transaction was valued at $<ix:nonFraction unitRef="usd" contextRef="ibec4b74376bf439b97a248a65f5b0eae_I20191130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80My9mcmFnOjM5NzgxY2JjZmU1YzQ2YjdhYWFjNzAwYTVmNjIxYjNjL3RleHRyZWdpb246Mzk3ODFjYmNmZTVjNDZiN2FhYWM3MDBhNWY2MjFiM2NfOTI2_9d9f126c-f6a4-4663-a906-b02fbe60ae78">2.4</ix:nonFraction> million, based on the fair value of the <ix:nonFraction unitRef="shares" contextRef="i240f37dfb7c84e948e9a4cfed130cbc1_D20191130-20191130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80My9mcmFnOjM5NzgxY2JjZmU1YzQ2YjdhYWFjNzAwYTVmNjIxYjNjL3RleHRyZWdpb246Mzk3ODFjYmNmZTVjNDZiN2FhYWM3MDBhNWY2MjFiM2NfOTYx_e62d8789-2f34-4ce5-93ba-ff2ff72d77ba">2,999,990</ix:nonFraction> shares issued of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibec4b74376bf439b97a248a65f5b0eae_I20191130" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80My9mcmFnOjM5NzgxY2JjZmU1YzQ2YjdhYWFjNzAwYTVmNjIxYjNjL3RleHRyZWdpb246Mzk3ODFjYmNmZTVjNDZiN2FhYWM3MDBhNWY2MjFiM2NfOTgx_c1168f79-37c6-4fb8-8c25-3d0d9412a526">0.79</ix:nonFraction> per share, which was the closing price per share of the Company's common stock on the date of closing. The shares were issued in exchange for Microchips&#8217; cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="ibec4b74376bf439b97a248a65f5b0eae_I20191130" decimals="-5" format="ixt:numdotdecimal" name="dare:BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80My9mcmFnOjM5NzgxY2JjZmU1YzQ2YjdhYWFjNzAwYTVmNjIxYjNjL3RleHRyZWdpb246Mzk3ODFjYmNmZTVjNDZiN2FhYWM3MDBhNWY2MjFiM2NfMTE2Nw_30c1f115-379e-4112-bebc-28234f6e59ea">6.1</ix:nonFraction> million, less net liabilities of $<ix:nonFraction unitRef="usd" contextRef="ibec4b74376bf439b97a248a65f5b0eae_I20191130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80My9mcmFnOjM5NzgxY2JjZmU1YzQ2YjdhYWFjNzAwYTVmNjIxYjNjL3RleHRyZWdpb246Mzk3ODFjYmNmZTVjNDZiN2FhYWM3MDBhNWY2MjFiM2NfMTE5NQ_0e6d5db4-e7e3-4f82-8531-029ac2126bff">3.5</ix:nonFraction> million and transaction costs of $<ix:nonFraction unitRef="usd" contextRef="i934a565bb58b4ec5acca2c91b69403b1_I20191130" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80My9mcmFnOjM5NzgxY2JjZmU1YzQ2YjdhYWFjNzAwYTVmNjIxYjNjL3RleHRyZWdpb246Mzk3ODFjYmNmZTVjNDZiN2FhYWM3MDBhNWY2MjFiM2NfMTIyMw_32ed8da9-6252-41d6-aa31-4e39848fcfc8">202,000</ix:nonFraction>, which was allocated based on the relative fair value of the assets acquired and liabilities assumed.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also agreed to pay certain contingent consideration payments, tiered royalty payments and a percentage of sublicense revenue as discussed in Note 3, Acquired Products&#8212;Microchips Acquisition, above.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i188b61e4db9e48978ba4428188ef6f56">The Company determined the transaction was accounted for as an asset acquisition as there were no outputs or substantive processes in existence as of the acquisition date. Transaction costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i934a565bb58b4ec5acca2c91b69403b1_I20191130" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80My9mcmFnOjM5NzgxY2JjZmU1YzQ2YjdhYWFjNzAwYTVmNjIxYjNjL3RleHRyZWdpb246Mzk3ODFjYmNmZTVjNDZiN2FhYWM3MDBhNWY2MjFiM2NfMjE3NA_32ed8da9-6252-41d6-aa31-4e39848fcfc8">202,000</ix:nonFraction> associated with the merger were included in the Company&#8217;s research and development expense in the fourth quarter of 2019.</ix:continuation> </span></div><div id="i868f48d3ece34cfab595a46f6986b439_46"></div><div style="margin-top:18pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMzM1MA_c45c2ccf-175c-44db-a52b-8617549995e4" continuedAt="ia0816a381c59496c970d92fabb1dbb62" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="ia0816a381c59496c970d92fabb1dbb62" continuedAt="if834d344359b4319b8dd29edb403a86c"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The 2015 Employee, Director and Consultant Equity Incentive Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the business combination transaction in July 2017 between the Company and Dar&#233; Bioscience Operations, Inc., a privately held Delaware corporation, or Private Dar&#233;, the Company assumed the Private Dar&#233; 2015 Employee, Director and Consultant Equity Incentive Plan, or the 2015 Private Dar&#233; Plan and each then outstanding award granted thereunder, which consisted of options and restricted stock. Based on the exchange ratio for the business combination transaction and after giving effect to the reverse stock split effected in connection with the closing of that transaction, the outstanding options and restricted stock awards granted under the 2015 Private Dar&#233; Plan were replaced with options to purchase <ix:nonFraction unitRef="shares" contextRef="i2a4aaadc8c3b47a6a160697edf8e4341_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfODI0_037d6a71-0ea4-4f55-ac59-232336463436">10,149</ix:nonFraction> shares of the Company&#8217;s common stock with a correspondingly adjusted exercise price and <ix:nonFraction unitRef="shares" contextRef="i6272459e3f90454cbd5e25ce85446ee8_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfOTE1_7a350a18-1402-49d0-9f3c-05c5d484c88f">223,295</ix:nonFraction> shares of the Company&#8217;s common stock. All of the options that were assumed were exercised as of September&#160;30, 2020. No awards may be granted under the 2015 Private Dar&#233; Plan following the closing of the business combination transaction.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2014 Employee Stock Purchase Plan, or the ESPP, became effective in April 2014, but no offering period has been initiated thereunder since January 2017 and there was <ix:nonFraction unitRef="usd" contextRef="i3ab49a29689548b9833e3f0ae8c799b5_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMTM1Mw_901bd7b5-243d-40f4-b7b4-5b42b27d6938"><ix:nonFraction unitRef="usd" contextRef="i2928b74a51bf456b8caf39b2a4cfa467_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMTM1Mw_c128eb01-df28-41a6-b70f-616220bed5f5">no</ix:nonFraction></ix:nonFraction> stock-based compensation related to the ESPP for the nine months ended September&#160;30, 2020 or September&#160;30, 2019.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if834d344359b4319b8dd29edb403a86c" continuedAt="i7d781899c53f4a48b9a44a5d0ff51604"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated 2014 Stock Incentive Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains the Amended and Restated 2014 Plan, or the Amended 2014 Plan, which provides for the grant of options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards to employees, officers and directors, and consultants and advisors. There were <ix:nonFraction unitRef="shares" contextRef="i4e27560f58324d76aa01f67cbf138dc4_I20180731" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMTc4Mw_88e62325-14a5-400f-bce5-2b534808411c">2,046,885</ix:nonFraction> shares of common stock authorized for issuance under the Amended 2014 Plan when it was approved by the Company's stockholders in July 2018. The number of authorized shares increases annually on the first day of each fiscal year until, and including, the fiscal year ending December 31, 2024 by the least of (i) <ix:nonFraction unitRef="shares" contextRef="i91e3f089ee85463896dc24cc0479b252_I20180710" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMjA5Nw_19987938-fee5-406c-9071-082a8fb7865b">2,000,000</ix:nonFraction>, (ii) <ix:nonFraction unitRef="number" contextRef="i48b5c358a2b64cbf929fdc1e1a69614a_D20180710-20180710" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMjEwNg_ef61eb04-b2bd-4760-af7b-b7a141547b7e">4</ix:nonFraction>% of the number of outstanding shares of common stock on such date, or (iii) an amount determined by the Company&#8217;s board of directors. On January 1, 2020, the number of authorized shares increased by <ix:nonFraction unitRef="shares" contextRef="id0e7f22b525c449280e635ae64efe397_D20200101-20200101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMjMwNQ_c00393a5-a333-4857-b7c5-fda8e2e69694">787,336</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="ia09f304e0bb247cd9fb0ea915995673a_I20200101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMjMxMQ_d442fadb-1a39-41f9-8375-d98f8ff9cfc3">1,411,481</ix:nonFraction>, which increase represented <ix:nonFraction unitRef="number" contextRef="id0e7f22b525c449280e635ae64efe397_D20200101-20200101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMjM0Mg_34056eeb-b636-4d3e-a5f6-cb55b814068b">4</ix:nonFraction>% of the number of outstanding shares of common stock on such date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Stock Option Activity</span></div><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMzM1MQ_c34488c8-753b-401d-ac62-e6ff613d8fdd" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes stock option activity under the Amended 2014 Plan, and related information for the nine months ended September&#160;30, 2020. The exercise price of all options granted during the nine months ended September&#160;30, 2020 was equal to the market value of the Company&#8217;s common stock on the date of grant. As of September&#160;30, 2020, unamortized stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMjc4Ng_f1ef6bf6-239f-4811-8944-a21b3c27cbe5">1,493,686</ix:nonFraction> will be amortized over a weighted average period of <ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" format="ixt-sec:duryear" name="dare:WeightedAverageAmortizationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMjg0MQ_d5eee951-593a-4a2f-abc4-5b603bfe5e4b">2.37</ix:nonNumeric> years. At September&#160;30, 2020, <ix:nonFraction unitRef="shares" contextRef="ie6fbf357b1224eeb9a1eed68e2f55aff_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMjg1Mg_8c3cc6fd-cb52-4b01-876c-71fa091dff2c">507,516</ix:nonFraction> shares of common stock were reserved for future awards granted under the Amended 2014 Plan.</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:376.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3721c96df454703ab043d1b9396afec_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfMS0xLTEtMS0w_6dbbf3db-8e82-4b6f-b765-dc52996e89fc">1,889,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id3721c96df454703ab043d1b9396afec_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfMS0zLTEtMS0w_c40d4dd1-0670-4cfd-9b37-21fedbe73be1">1.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i748cf08e328d4f8e88ce6250028b6f5c_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfMi0xLTEtMS0w_f0adfa26-3461-4ee6-bb20-bd518bdcdfdb">903,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i748cf08e328d4f8e88ce6250028b6f5c_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfMi0zLTEtMS0w_e06574ca-c91b-4c34-bc0b-5afc1c00f60c">1.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i748cf08e328d4f8e88ce6250028b6f5c_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfMy0xLTEtMS0w_c5aa8f10-fdb6-448e-b8a3-307f0e77d582">10,149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i748cf08e328d4f8e88ce6250028b6f5c_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfMy0zLTEtMS0w_79ac2bd7-651e-42cd-9ad5-eb0f7e9506ee">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i748cf08e328d4f8e88ce6250028b6f5c_D20200101-20200930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfNC0xLTEtMS0w_777618bb-df34-4caf-a037-27a1b8d81cd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i748cf08e328d4f8e88ce6250028b6f5c_D20200101-20200930" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfNC0zLTEtMS0w_cf8c0f0b-dcf7-4926-958f-0e78611f2363">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i748cf08e328d4f8e88ce6250028b6f5c_D20200101-20200930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfNS0xLTEtMS0w_149064ec-5dd5-4d15-b129-5c36ca42e28b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i748cf08e328d4f8e88ce6250028b6f5c_D20200101-20200930" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfNS0zLTEtMS0w_4bf3b03e-87b9-4c33-8d01-e32f06b7bdca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6fbf357b1224eeb9a1eed68e2f55aff_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfNi0xLTEtMS0w_f2f65486-47b8-4d66-92f5-b2dd1872af38">2,783,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie6fbf357b1224eeb9a1eed68e2f55aff_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfNi0zLTEtMS0w_deb0ca98-4d82-476e-8aba-dae4c8e645da">1.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6fbf357b1224eeb9a1eed68e2f55aff_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfNy0xLTEtMS0w_002d9bed-d1f9-4bbe-8a76-77cb766c01d2">1,038,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie6fbf357b1224eeb9a1eed68e2f55aff_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfNy0zLTEtMS0w_425fab91-3990-42e2-82e1-63f9d1790fd4">1.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense</span></div><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMzM1Mw_df365ec6-1a7a-4a07-a3c0-1def97db7a21" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense related to stock options granted to employees and directors recognized in the consolidated statement of operations is as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:238.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaedce4b2446d4390afdde0c8b65ed211_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjEwNGRkNjU4YzU5MjQ1MWNiMjgwMmNjZjZiZmQ0ZTQzL3RhYmxlcmFuZ2U6MTA0ZGQ2NThjNTkyNDUxY2IyODAyY2NmNmJmZDRlNDNfMi0xLTEtMS0w_226ad03a-8e0b-4c79-9858-c97f81cf92df">60,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id30e47d05e2d4a89bd634aed60cdde96_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjEwNGRkNjU4YzU5MjQ1MWNiMjgwMmNjZjZiZmQ0ZTQzL3RhYmxlcmFuZ2U6MTA0ZGQ2NThjNTkyNDUxY2IyODAyY2NmNmJmZDRlNDNfMi0zLTEtMS0w_98fa66ca-5f4d-4c4b-8cb7-79ba6feccb3e">27,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib435822bc7804f31be11690ccf5f9859_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjEwNGRkNjU4YzU5MjQ1MWNiMjgwMmNjZjZiZmQ0ZTQzL3RhYmxlcmFuZ2U6MTA0ZGQ2NThjNTkyNDUxY2IyODAyY2NmNmJmZDRlNDNfMi01LTEtMS0w_c3957cf3-62f0-4926-9cce-5237b0f24443">166,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b128d3f8bbe4c5482cb6f55c962c6aa_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjEwNGRkNjU4YzU5MjQ1MWNiMjgwMmNjZjZiZmQ0ZTQzL3RhYmxlcmFuZ2U6MTA0ZGQ2NThjNTkyNDUxY2IyODAyY2NmNmJmZDRlNDNfMi03LTEtMS0w_c4ba89fd-6c5f-4d8c-ba37-8b2d94e4b747">78,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9f7aa24af72476481534c2c2f333aba_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjEwNGRkNjU4YzU5MjQ1MWNiMjgwMmNjZjZiZmQ0ZTQzL3RhYmxlcmFuZ2U6MTA0ZGQ2NThjNTkyNDUxY2IyODAyY2NmNmJmZDRlNDNfMy0xLTEtMS0w_ad610be3-1ca9-4ba4-b156-729f80aeb0ea">134,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d8b23a6ddc647dd8a654ce4e72821b1_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjEwNGRkNjU4YzU5MjQ1MWNiMjgwMmNjZjZiZmQ0ZTQzL3RhYmxlcmFuZ2U6MTA0ZGQ2NThjNTkyNDUxY2IyODAyY2NmNmJmZDRlNDNfMy0zLTEtMS0w_d82e5d5d-86ce-468a-baa5-149f14f089c5">108,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i164eef1d163e46c2afb6bc319807e895_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjEwNGRkNjU4YzU5MjQ1MWNiMjgwMmNjZjZiZmQ0ZTQzL3RhYmxlcmFuZ2U6MTA0ZGQ2NThjNTkyNDUxY2IyODAyY2NmNmJmZDRlNDNfMy01LTEtMS0w_b25775ab-78bd-4e8f-a3ad-9cbd42b583d8">375,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55a9907b8e8649348aa6657478dfe2cc_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjEwNGRkNjU4YzU5MjQ1MWNiMjgwMmNjZjZiZmQ0ZTQzL3RhYmxlcmFuZ2U6MTA0ZGQ2NThjNTkyNDUxY2IyODAyY2NmNmJmZDRlNDNfMy03LTEtMS0w_9602d9af-4105-4f81-9842-74021000fc89">265,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3caed64836884e1cb8f9c5b521f55da0_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjEwNGRkNjU4YzU5MjQ1MWNiMjgwMmNjZjZiZmQ0ZTQzL3RhYmxlcmFuZ2U6MTA0ZGQ2NThjNTkyNDUxY2IyODAyY2NmNmJmZDRlNDNfNC0xLTEtMS0w_7d121887-0c8b-41e6-9d3d-78fbf2bf4ed2">194,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea59aafe0f1745f7a971f2eaffe8481c_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjEwNGRkNjU4YzU5MjQ1MWNiMjgwMmNjZjZiZmQ0ZTQzL3RhYmxlcmFuZ2U6MTA0ZGQ2NThjNTkyNDUxY2IyODAyY2NmNmJmZDRlNDNfNC0zLTEtMS0w_6e31885c-aef6-4c6f-b91d-a7980fb9bad1">135,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i452d4b20caeb47d2985cd2793d9a7eac_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjEwNGRkNjU4YzU5MjQ1MWNiMjgwMmNjZjZiZmQ0ZTQzL3RhYmxlcmFuZ2U6MTA0ZGQ2NThjNTkyNDUxY2IyODAyY2NmNmJmZDRlNDNfNC01LTEtMS0w_0c9806d0-3cfa-4106-8544-64d35962afd5">542,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic57e6d999ba14991863c6606b7f50384_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjEwNGRkNjU4YzU5MjQ1MWNiMjgwMmNjZjZiZmQ0ZTQzL3RhYmxlcmFuZ2U6MTA0ZGQ2NThjNTkyNDUxY2IyODAyY2NmNmJmZDRlNDNfNC03LTEtMS0w_2f245b6e-3e7c-4424-89f8-d6e0164fdb05">344,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7d781899c53f4a48b9a44a5d0ff51604"><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMzM1NA_3a922b11-6654-4559-9c83-32772540a27a" escape="true"><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in the Black-Scholes option-pricing model for stock options granted to employees and to directors in respect of board services during the three and nine months ended September&#160;30, 2020 are as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:373.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:36pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjYyZmZhOGZkNGQ5NDQ4YzZhMzBlZjk1MGU4ZWE0NWUwL3RhYmxlcmFuZ2U6NjJmZmE4ZmQ0ZDk0NDhjNmEzMGVmOTUwZThlYTQ1ZTBfMS0yLTEtMS0w_2beda1ea-b107-4cfe-9786-a8cb1c5f2af5">10.0</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjYyZmZhOGZkNGQ5NDQ4YzZhMzBlZjk1MGU4ZWE0NWUwL3RhYmxlcmFuZ2U6NjJmZmE4ZmQ0ZDk0NDhjNmEzMGVmOTUwZThlYTQ1ZTBfMS00LTEtMS0w_6bb7d3bd-15d7-4ca7-b5f1-b2d57fb22ff3">10.0</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjYyZmZhOGZkNGQ5NDQ4YzZhMzBlZjk1MGU4ZWE0NWUwL3RhYmxlcmFuZ2U6NjJmZmE4ZmQ0ZDk0NDhjNmEzMGVmOTUwZThlYTQ1ZTBfMi0yLTEtMS0w_8fd7cf50-cd87-455a-a2ed-bcc4aca76f44">0.71</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjYyZmZhOGZkNGQ5NDQ4YzZhMzBlZjk1MGU4ZWE0NWUwL3RhYmxlcmFuZ2U6NjJmZmE4ZmQ0ZDk0NDhjNmEzMGVmOTUwZThlYTQ1ZTBfMi00LTEtMS0w_4fe2947e-4803-43f8-92e9-d5787743cc77">0.82</ix:nonFraction>%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjYyZmZhOGZkNGQ5NDQ4YzZhMzBlZjk1MGU4ZWE0NWUwL3RhYmxlcmFuZ2U6NjJmZmE4ZmQ0ZDk0NDhjNmEzMGVmOTUwZThlYTQ1ZTBfMy0yLTEtMS0w_cb63681b-225b-430b-a377-213e6d1db42e">119</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjYyZmZhOGZkNGQ5NDQ4YzZhMzBlZjk1MGU4ZWE0NWUwL3RhYmxlcmFuZ2U6NjJmZmE4ZmQ0ZDk0NDhjNmEzMGVmOTUwZThlYTQ1ZTBfMy00LTEtMS0w_79b5b00e-02f5-421d-a4e3-694fc7741fe6">120</ix:nonFraction>%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="2" name="dare:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjYyZmZhOGZkNGQ5NDQ4YzZhMzBlZjk1MGU4ZWE0NWUwL3RhYmxlcmFuZ2U6NjJmZmE4ZmQ0ZDk0NDhjNmEzMGVmOTUwZThlYTQ1ZTBfNC0yLTEtMS0w_2eb3ae49-4e0d-496d-a35b-5264147eef60">0.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="2" name="dare:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjYyZmZhOGZkNGQ5NDQ4YzZhMzBlZjk1MGU4ZWE0NWUwL3RhYmxlcmFuZ2U6NjJmZmE4ZmQ0ZDk0NDhjNmEzMGVmOTUwZThlYTQ1ZTBfNC00LTEtMS0w_162c2c5e-b62d-40af-9697-f95588b19626">0.0</ix:nonFraction>%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjYyZmZhOGZkNGQ5NDQ4YzZhMzBlZjk1MGU4ZWE0NWUwL3RhYmxlcmFuZ2U6NjJmZmE4ZmQ0ZDk0NDhjNmEzMGVmOTUwZThlYTQ1ZTBfNS0yLTEtMS0w_0c2df28b-0aa3-4903-b8a4-2e5e756d09c3">0.0</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjYyZmZhOGZkNGQ5NDQ4YzZhMzBlZjk1MGU4ZWE0NWUwL3RhYmxlcmFuZ2U6NjJmZmE4ZmQ0ZDk0NDhjNmEzMGVmOTUwZThlYTQ1ZTBfNS00LTEtMS0w_03ece4d9-107b-432d-8adc-bde1d834e543">0.0</ix:nonFraction>%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of options granted</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjYyZmZhOGZkNGQ5NDQ4YzZhMzBlZjk1MGU4ZWE0NWUwL3RhYmxlcmFuZ2U6NjJmZmE4ZmQ0ZDk0NDhjNmEzMGVmOTUwZThlYTQ1ZTBfNi0yLTEtMS0w_93373611-6762-4753-93c9-570712354ae3">1.10</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjYyZmZhOGZkNGQ5NDQ4YzZhMzBlZjk1MGU4ZWE0NWUwL3RhYmxlcmFuZ2U6NjJmZmE4ZmQ0ZDk0NDhjNmEzMGVmOTUwZThlYTQ1ZTBfNi00LTEtMS0w_3c7f18d2-091d-4ac0-890b-07886179c568">1.00</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i868f48d3ece34cfab595a46f6986b439_49"></div><div style="margin-top:18pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfNTQzOQ_40eeb308-bfc0-400d-8092-37f4b306e00b" continuedAt="i54380a900984483ba8c8af392d572410" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="i54380a900984483ba8c8af392d572410" continuedAt="id95635a70fb44ff2912b58e0bedf5715"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATM Sales Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company entered into a common stock sales agreement under which the Company may sell shares of its common stock from time to time in &#8220;at-the-market&#8221; equity offerings (as defined in Rule 415 promulgated under the Securities Act of 1933, as amended). The Company will pay a commission of up to <ix:nonFraction unitRef="number" contextRef="i56d13a7ae7894e27975f5d3dc7ebf378_D20180101-20180131" decimals="INF" name="dare:PercentageOfAggregateCommission" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMzYy_205ce347-01b4-446d-8845-6c9eba74e933">3</ix:nonFraction>% of the gross proceeds of any common stock sold under this agreement plus certain legal expenses. The common stock sales agreement was amended in August 2018 to refer to the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-227019) that was filed to replace the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-206396) that expired on August 28, 2018.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="ic2c303c2ae4943dd8fbcfc1e44714b26_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTA5OTUxMTY1NjExMw_09934b43-1723-4053-9ecf-45a0f74f03a3">1,952,512</ix:nonFraction> shares under the common stock sales agreement for gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ic2c303c2ae4943dd8fbcfc1e44714b26_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTA5OTUxMTY1NjEyOA_faeac2df-e34f-4d8e-a1bc-507ea3632bd4">2.4</ix:nonFraction> million and incurred offering expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="ic2c303c2ae4943dd8fbcfc1e44714b26_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="dare:OfferingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTA5OTUxMTY1NjE0Mg_288ecdbe-9984-4e97-86d5-99b901cca8a8">82,000</ix:nonFraction>. During the nine months ended September&#160;30, 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="i416122ab3120493b993ec3ad05b96111_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfNzk1_2dc82996-f23c-4ba0-afa1-4cf1891511a0">7,916,092</ix:nonFraction> shares under the common stock sales agreement for gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i416122ab3120493b993ec3ad05b96111_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfODgw_4c5ef638-607d-492b-ae73-6d743136baf8">10.8</ix:nonFraction> million and incurred offering expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="i416122ab3120493b993ec3ad05b96111_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="dare:OfferingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfOTMx_4197cdb6-2acd-479a-aee7-ed4b5f243e7c">420,000</ix:nonFraction>. The Company did not sell any shares under this agreement during the three or nine months ended September&#160;30, 2019.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">April 2019 Underwritten Public Offering</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, the Company closed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i7a6ac70780144725885adc47194a94b4_D20190401-20190430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTEzMw_f995d03b-9b60-4aac-8ceb-cc7f74153c6b">4,575,000</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i868ac446cd6e4c439961eab65e3c6861_I20190430" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTE5Mw_99a38c56-271c-4c8c-8133-0aa893d1885b">1.10</ix:nonFraction> per share. The Company granted the underwriters a <ix:nonNumeric contextRef="i60d87dbf215545a1b5c48615b58b820f_D20190401-20190430" format="ixt-sec:durwordsen" name="dare:UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfNTQzNg_6c62d11c-8f7c-43af-bab1-bfc5851caf76">30-day</ix:nonNumeric> over-allotment option to purchase up to an additional <ix:nonFraction unitRef="shares" contextRef="ia456760e828443768946d965d3e5d697_D20190412-20190412" decimals="INF" format="ixt:numdotdecimal" name="dare:UnderwritersOptionToPurchaseAdditionalShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTMwNw_7dc0c2a9-0814-4a78-90ab-13b51eb9621d">686,250</ix:nonFraction> shares which was exercised in full on April 12, 2019. Including the over-allotment shares, the Company issued a total of <ix:nonFraction unitRef="shares" contextRef="i60d87dbf215545a1b5c48615b58b820f_D20190401-20190430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTQzMQ_24e91c9a-256d-4387-8dcd-6917fec9f09f">5,261,250</ix:nonFraction> shares in the underwritten public offering and received gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i60d87dbf215545a1b5c48615b58b820f_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="dare:GrossProceedsFromOfferingOfCommonStockAndWarrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTUyMg_2a20219b-ba2f-4b46-baa4-c2e2e6270833">5.8</ix:nonFraction> million and net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i60d87dbf215545a1b5c48615b58b820f_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTU1OQ_6b75a96a-a357-4a6f-849b-cb2fff3bceda">5.2</ix:nonFraction> million after deducting underwriting discounts and offering expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Line</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 22, 2020, the Company entered into a purchase agreement, or the Purchase Agreement, and a registration rights agreement with Lincoln Park Capital Fund, LLC, or Lincoln Park. Under the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to&#160;$<ix:nonFraction unitRef="usd" contextRef="i9f7b9efd7dda44b2bec435609ae73e40_I20200422" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjAxNw_e523b7cd-9e48-4967-8384-62b726b98132">15.0</ix:nonFraction> million&#160;of the Company&#8217;s common stock. Such sales of common stock by the Company may occur from time to time, at the Company&#8217;s sole discretion, subject to certain limitations, until May 19, 2023. On April 22, 2020, in accordance with the Purchase Agreement, the Company issued <ix:nonFraction unitRef="shares" contextRef="i8bfaf2e8371745b2b5e46ebc3e913e82_D20200422-20200422" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjI4OQ_34512f7d-5723-4a5d-a439-882866a21a38">285,714</ix:nonFraction> shares of its common stock, or the Commitment Shares, to Lincoln Park in consideration for its commitment to purchase shares under the Purchase Agreement. The Company filed a registration statement on Form S-1 (File No. 333-237954) to register the resale by Lincoln Park of up to <ix:nonFraction unitRef="shares" contextRef="icd932424f77b4acfbcb47c05aacbb08a_D20200501-20200501" decimals="INF" format="ixt:numdotdecimal" name="dare:SaleofStockMaximumAmountRegistered" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjU3Mg_a5e52ec9-cdc2-4b04-bc6c-f59dc9e8b560">7.5</ix:nonFraction> million shares of the Company's common stock issued or issuable to Lincoln Park under the Purchase Agreement, including the Commitment Shares, and such registration statement was declared effective by the SEC on May 12, 2020.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id95635a70fb44ff2912b58e0bedf5715" continuedAt="i419f1224263e4af98c71d008f6c64322"><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred legal, accounting, and other fees related to the Purchase Agreement of approximately $<ix:nonFraction unitRef="usd" contextRef="i01002baf920d410fac2c775eac9c140e_I20200422" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredOfferingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjg5OQ_953a15a3-c649-4c26-9431-89f2d4d4e67d">374,000</ix:nonFraction>. These costs are amortized and expensed as shares are sold under the Purchase Agreement and as of September&#160;30, 2020 there was approximately $<ix:nonFraction unitRef="usd" contextRef="ib32b7d0c93d34cbe804300d040f5b315_I20200930" decimals="-3" format="ixt:numdotdecimal" name="dare:DeferredOfferingCostsUnamortizedPortion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMzAxMw_38f1e838-90d9-49fa-a910-e55d5f992782">269,000</ix:nonFraction> of unamortized costs. During the three months ended September&#160;30, 2020, the Company sold, and Lincoln Park purchased, <ix:nonFraction unitRef="shares" contextRef="ic5c15ea8e6c24d4b9e6b1c403108842f_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTA5OTUxMTY1NjIyNg_92e88827-d562-492d-a016-e4d0aa429b30">3.0</ix:nonFraction> million shares under the Purchase Agreement for gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ic5c15ea8e6c24d4b9e6b1c403108842f_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTA5OTUxMTY1NjIzNw_6f5f4cd0-64e9-4dbb-a57e-574de6b08cd3">3.3</ix:nonFraction> million and incurred offering expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="ic5c15ea8e6c24d4b9e6b1c403108842f_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTA5OTUxMTY1NjI0Nw_d5ce60b6-acfd-4890-9a62-12576eb6bf41">83,000</ix:nonFraction>. During the nine months ended September&#160;30, 2020, the Company sold, and Lincoln Park purchased, <ix:nonFraction unitRef="shares" contextRef="ie264785d23cd421d928dd14372cfabf0_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMzExNQ_d54ec964-7922-4823-83c0-51450391e802">3,882,160</ix:nonFraction> shares under the Purchase Agreement for gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ie264785d23cd421d928dd14372cfabf0_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMzE5MA_7ab7240d-6252-44de-ae6a-bd136b931b3b">4.2</ix:nonFraction> million and incurred offering expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="ie264785d23cd421d928dd14372cfabf0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMzI0MQ_ea7c5860-f265-4915-8cf3-8f96c6823112">105,000</ix:nonFraction>.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Purchase Agreement, on any business day until May 19, 2023, the Company may direct Lincoln Park to purchase up to <ix:nonFraction unitRef="shares" contextRef="i08898414c3aa4894b7ad663dd58d2ddc_D20200422-20200422" decimals="INF" format="ixt:numdotdecimal" name="dare:RegularRepurchaseCommonStockIssuable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjc0ODc3OTA5ODQ2OQ_e4fcac14-854d-476d-90d6-a346b945a92b">200,000</ix:nonFraction> shares of common stock, each, a Regular Purchase. The Company may increase the share amount it directs Lincoln Park to purchase under a Regular Purchase to up to <ix:nonFraction unitRef="shares" contextRef="i0955c43f6b5843e3b4a7d1e24a09a0ae_D20200422-20200422" decimals="INF" format="ixt:numdotdecimal" name="dare:RegularPurchaseCommonStockIssuableIncreaseAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjc0ODc3OTA5ODQ3OA_12a8d756-165a-4ffb-a534-548f39533853">250,000</ix:nonFraction> shares or up to <ix:nonFraction unitRef="shares" contextRef="ia927dba53c23411a8034d4380544fcb1_D20200422-20200422" decimals="INF" format="ixt:numdotdecimal" name="dare:RegularPurchaseCommonStockIssuableIncreaseAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjc0ODc3OTA5ODQ4Nw_91cbed45-4fb7-4b4a-bf98-cbaeaa78401c">300,000</ix:nonFraction> shares if the closing sale price of the Company's common stock is not below $<ix:nonFraction unitRef="usdPerShare" contextRef="ic533380ee2c447de91cd03aa8a73d217_I20200422" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjc0ODc3OTA5ODQ5Ng_9f57ad0f-1dee-4ff6-9c75-369bc7cd2bab">1.50</ix:nonFraction> or $<ix:nonFraction unitRef="usdPerShare" contextRef="i61a90f906d204892bcb7fb20f2f34ff8_I20200422" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjc0ODc3OTA5ODUwMw_061e128b-6671-4e00-a4ef-41cd4d5fb113">3.00</ix:nonFraction>, respectively, on the business day on which the Company initiates the purchase, subject to adjustment for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction as provided in the Purchase Agreement. However, Lincoln Park&#8217;s maximum commitment in any single Regular Purchase may not exceed $<ix:nonFraction unitRef="shares" contextRef="i08898414c3aa4894b7ad663dd58d2ddc_D20200422-20200422" decimals="-5" format="ixt:numdotdecimal" name="dare:RegularPurchaseCommonStockIssuableMaximumAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjc0ODc3OTA5ODUxMA_c0eeba46-2bab-4642-8e39-5cab00db5bc8">1.0</ix:nonFraction>&#160;million. The purchase price per share for each Regular Purchase will be the lower of (i) the lowest sale price of the Company's common stock on the business day on which the Company initiates the purchase and (ii) the average of the three lowest closing sale prices of the Company's common stock during the 10-business day period immediately preceding the business day on which the Company initiates the purchase. In addition to Regular Purchases, the Company may also direct Lincoln Park to purchase other amounts of common stock as accelerated purchases and as additional accelerated purchases, subject to limits specified in the Purchase Agreement, at a purchase price per share calculated as specified in the Purchase Agreement, but in no case lower than the minimum price per share the Company stipulates in its notice to Lincoln Park initiating these purchases.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under applicable Nasdaq rules, the Company may not issue or sell to Lincoln Park under the Purchase Agreement more than <ix:nonFraction unitRef="shares" contextRef="i08898414c3aa4894b7ad663dd58d2ddc_D20200422-20200422" decimals="INF" format="ixt:numdotdecimal" name="dare:CommonStockExchangeCap" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjc0ODc3OTA5ODU5Nw_b3c3879e-1264-42bb-b08e-d8b93e1d2c33">4,941,089</ix:nonFraction> shares of its common stock, or the Exchange Cap, unless (i) the Company obtains stockholder approval to issue shares in excess of the Exchange Cap or (ii) the average price of all applicable sales of the Company's common stock to Lincoln Park under the Purchase Agreement equals or exceeds $<ix:nonFraction unitRef="usdPerShare" contextRef="ie54a63cb8870455387d630bcd302c82e_I20200421" decimals="4" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjc0ODc3OTA5ODYwOA_18cd0579-29eb-4bfa-8a6a-cfa47888a929">1.0117</ix:nonFraction> (which represents the closing sale price per share of the Company's common stock on the day before the Company entered into the Purchase Agreement, plus an incremental amount). In addition, the Company may not sell shares to Lincoln Park under the Purchase Agreement if such sale would result in Lincoln Park beneficially owning more than <ix:nonFraction unitRef="number" contextRef="i648dfc2b093f4a32a88926256f87782e_I20200422" decimals="4" name="dare:CommonStockExchangeCapPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjc0ODc3OTA5ODYxNw_b3ca39c1-44a4-4f18-a046-3cdc7128b540">9.99</ix:nonFraction>% of the Company's then outstanding shares of common stock. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company closed an underwritten public offering in connection with which the Company issued to the investors in that offering warrants that initially had an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic75ab5f711a541808c1cac6b1d2728cc_I20180228" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMzQ2Mw_2e26200c-189e-43b2-9349-926812515465">3.00</ix:nonFraction> per share and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are exercisable through February 2023.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrants include a price-based anti-dilution provision, which provides that, subject to certain limited exceptions, the exercise price of the warrants will be reduced each time the Company issues or sells (or is deemed to issue or sell) securities for a net consideration per share less than the exercise price of those warrants in effect immediately prior to such issuance or sale. In addition, subject to certain exceptions, if the Company issues, sells or enters into any agreement to issue or sell securities at a price which varies or may vary with the market price of the shares of the Company&#8217;s common stock, the warrant holders have the right to substitute such variable price for the exercise price of the warrant then in effect. These warrants are exercisable only for cash, unless a registration statement covering the shares issued upon exercise of the warrants is not effective, in which case the warrants may be exercised on a cashless basis. A registration statement covering the shares issued upon exercise of the warrants is currently effective. The Company estimated the fair value of the warrants as of February 15, 2018 to be approximately $<ix:nonFraction unitRef="usd" contextRef="ib0a8869e72f444d7a1483b278b655bd2_I20180215" decimals="-5" format="ixt:numdotdecimal" name="dare:EstimatedFairValueOfWarrantsRecordedInEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfNDY4Mw_79981409-6354-4af4-b264-003cb5da8a0a">3.0</ix:nonFraction> million which has been recorded in equity as of the grant date. The Company early adopted ASU 2017-11 as of January 1, 2018 and recorded the fair value of the warrants as equity. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019 and July 2020, in accordance with the price-based anti-dilution provision discussed above, the exercise price of these warrants was automatically reduced to $<ix:nonFraction unitRef="usdPerShare" contextRef="i8656d31612a94a26a509031e31dde229_D20190401-20190430" decimals="INF" name="us-gaap:WarrantExercisePriceDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfNTA5MA_52ea8c80-4d40-4b7a-bf01-adeb6b792e02">0.98</ix:nonFraction> per share and to $<ix:nonFraction unitRef="usdPerShare" contextRef="ia1285bc78ac34b519323112460b394f5_D20200701-20200731" decimals="INF" name="us-gaap:WarrantExercisePriceDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTA5OTUxMTYzNDg2Ng_2e005bf0-97aa-4c23-9979-7875040d886e">0.96</ix:nonFraction> per share, respectively, and as a result of the triggering of the anti-dilution provision, $<ix:nonFraction unitRef="usd" contextRef="i8656d31612a94a26a509031e31dde229_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfNTEwNw_a6840a46-19f7-4a06-901a-0107d79c496e">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia1285bc78ac34b519323112460b394f5_D20200701-20200731" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTA5OTUxMTY1Njc5Nw_dced395f-4fea-400c-8c11-278e81c5ba6f">6,863</ix:nonFraction>, respectively, was recorded to additional paid-in capital.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i419f1224263e4af98c71d008f6c64322"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2020, warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="dare:NumberOfCommonStockWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTY0OTI2NzQ3MDYzNA_670e63f3-d15a-4f9d-9d9e-c19b71cee947">126,000</ix:nonFraction> shares of common stock were exercised for gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTY0OTI2NzQ3MDY0NQ_51ad5ef9-c070-4a75-8bee-7b6134cb25f8">121,000</ix:nonFraction>. During the nine months ended September&#160;30, 2020, warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="dare:NumberOfCommonStockWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTA5OTUxMTYzNTQ0NA_22ec207b-6693-4fe0-b720-96ba17bb59c9">1,825,000</ix:nonFraction> shares of common stock were exercised for gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTA5OTUxMTYzNTQ4Mw_f49d2ab3-419f-49f4-a527-8b8f14fb9de6">1.8</ix:nonFraction> million. <ix:nonFraction unitRef="shares" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="dare:NumberOfCommonStockWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfNTMxMw_c7674514-7910-4f2b-a9bc-6c04bbe74e0a"><ix:nonFraction unitRef="shares" contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930" decimals="INF" format="ixt-sec:numwordsen" name="dare:NumberOfCommonStockWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfNTMxMw_fd761b2f-1fe0-4110-a83a-bb0b0a113746">No</ix:nonFraction></ix:nonFraction> warrants were exercised during the three or nine months ended September&#160;30, 2019. <ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfNTQzNw_db3df617-5835-4fde-9adf-6c925e8b49f0" continuedAt="i968d143a9320454ba913eb6c807176c6" escape="true">As of September&#160;30, 2020, the Company had the following warrants outstanding:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><ix:continuation id="i968d143a9320454ba913eb6c807176c6"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:169.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:19.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:18.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:118.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:18.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:157.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying<br/>Outstanding Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2508825fce204dd18b05c1f2654f691a_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfMS0wLTEtMS0w_9746a47a-e587-4c38-a4b1-0cebf634d1d8">2,906</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2508825fce204dd18b05c1f2654f691a_I20200930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfMS0zLTEtMS0w_56f38af8-1bc4-4f80-bed0-db75cd5fb5f5">120.40</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic02e362243bc4544af3beee1e4271766_D20200101-20200930" name="dare:ClassOfWarrantOrRightsWarrantsExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfMS01LTEtMS0w_25bd655b-d72a-481b-af36-ded462f8f8ab">2021-12-01</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd48642e50f1470c986bf4baf9540666_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfMi0wLTEtMS0w_49e63525-a0e7-499f-93d7-98dc23db604a">3,737</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd48642e50f1470c986bf4baf9540666_I20200930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfMi0zLTEtMS0w_2dcdca71-4a53-4b51-8599-7abb7eef1555">120.40</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i194102b3e8904dd394f4b80afaad69ba_D20200101-20200930" name="dare:ClassOfWarrantOrRightsWarrantsExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfMi01LTEtMS0w_2f4cfd1f-d8b2-45bc-aa78-19631188a99e">2021-12-06</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i856b85e65eba4389af62e53fcb4ddb88_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfMy0wLTEtMS0w_5758e304-66e8-44e6-8bab-7c2b3e59dad8">6,500</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i856b85e65eba4389af62e53fcb4ddb88_I20200930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfMy0zLTEtMS0w_d1227db3-1774-4088-b858-0f87246c9df1">10.00</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2f84c97f44e4cb286f9274ce4c5ce72_D20200101-20200930" name="dare:ClassOfWarrantOrRightsWarrantsExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfMy01LTEtMS0w_42e64e4f-deea-477d-ad19-1446a251c235">2026-04-04</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife8c2ec7d4b44a57b608f2c92187d0d9_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfNC0wLTEtMS0w_548556a0-9633-4e4c-9035-a4c8145817f3">1,895,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ife8c2ec7d4b44a57b608f2c92187d0d9_I20200930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfNC0zLTEtMS0w_3dd2b49b-729a-4a2d-97bb-d4e7af19d1b4">0.96</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i637dd6b17c604a2b8aa23ef3d1d38219_D20200101-20200930" name="dare:ClassOfWarrantOrRightsWarrantsExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfNC01LTEtMS0w_10b01c1f-e934-485b-9503-8db9b18b518a">2023-02-15</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfNS0wLTEtMS0w_2c5eb580-6570-4a44-8019-b8d1152426b5">1,908,643</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></ix:continuation></div></ix:continuation><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div id="i868f48d3ece34cfab595a46f6986b439_52"></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMjkwOA_a45ff46d-98ac-4e32-b564-cf4f8d8ef9ad" continuedAt="i4a6fedb5d93f4eb181295c398f4333eb" escape="true">LEASED PROPERTIES</ix:nonNumeric></span></div><ix:continuation id="i4a6fedb5d93f4eb181295c398f4333eb" continuedAt="ia207f6f737944325a14b3e6f8edbe75b"><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease for its corporate headquarters (<ix:nonFraction unitRef="sqft" contextRef="i8ad78d95daba4838b75da7b4df9b8b00_I20180701" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetRentableArea" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfNzk_311e0a92-ee1d-4b8d-8568-42aa17ee4282">3,169</ix:nonFraction> square feet of office space) commenced on July 1, 2018 and terminates on July 31, 2021. The Company has the option to extend the term of the lease for <ix:nonNumeric contextRef="i8ad78d95daba4838b75da7b4df9b8b00_I20180701" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMjMz_fc6ea49f-1698-45e4-ba95-a7c2e80c293b">one year</ix:nonNumeric>. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Microchips, which the Company acquired in November 2019, leases general office space in Lexington, Massachusetts and warehouse space in Billerica, Massachusetts. The Lexington lease commenced on July 1, 2013 and terminates on September 30, 2021. The Billerica lease commenced on October 1, 2016 and terminates on March 31, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under</span><span style="color:#191c1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the terms of each lease, the lessee pays base annual rent (subject to an annual fixed percentage increase), plus property taxes, and other normal and necessary expenses, such as utilities, repairs, and maintenance. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. The leases do not require material variable lease payments, residual value guarantees or restrictive covenants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The leases do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment. The Company uses an incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="i25c35de4c46a4497b5ac99d104d6962c_I20181231" decimals="2" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMTYyNQ_38f4bace-83ba-41cc-890a-60fd3c19db38">7</ix:nonFraction>% for operating leases that commenced prior to January 2019. The depreciable lives of operating leases and leasehold improvements are limited by the expected lease term.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, the Company reported operating lease ROU assets of approximately $<ix:nonFraction unitRef="usd" contextRef="ic5600cf051b646c18541fb6d7163c31b_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMTg2OA_f279365c-1bdb-4de1-b125-bbcce7fd2701">306,000</ix:nonFraction> in other non-current assets, and $<ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMTkwNA_90a3cf7d-ec2f-4c33-911d-b5d8bc8ee546">410,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMTkxMQ_23ca4cde-bb68-4734-93cb-6173964e5857">83,000</ix:nonFraction>, respectively, in current and non-current other liabilities on the consolidated balance sheet.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease costs were approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMjA1Ng_ec0e6fd9-a8fb-487e-a16f-fe4bc8ed72d3">76,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMjA2Mw_797d4bc5-384a-440c-8867-c547e26e6dd5">27,000</ix:nonFraction> for the three months ended&#160;September&#160;30, 2020 and September&#160;30, 2019, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMjEyMg_548fa047-0f8f-4c99-abd1-48f2d2817cc6">228,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMjEyOQ_87af783e-4d9c-480d-b1e5-377a395ad570">81,000</ix:nonFraction> for the nine months ended&#160;September&#160;30, 2020 and September&#160;30, 2019, respectively. Operating lease costs consist of monthly lease payments expense, common area maintenance and other repair and maintenance costs and are included in general and administrative expenses in the consolidated statement of operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities were approximately $<ix:nonFraction unitRef="usd" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMjUxMQ_81d49a2b-5bb8-46b3-9c4d-9f22eff804a6">111,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMjUxOA_6180b78b-f4db-41cf-8953-75b7e50ad32e">28,000</ix:nonFraction>&#160;for the three months ended&#160;September&#160;30, 2020 and September&#160;30, 2019, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMjU3Mw_5e8cdf35-632e-476b-af80-2cca319470e4">349,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMjU4MA_0c873478-fe7c-4283-b417-347bda757f82">81,000</ix:nonFraction> for the nine months ended&#160;September&#160;30, 2020 and September&#160;30, 2019, respectively. These amounts are included in operating activities in the consolidated statements of cash flows. Further, at September&#160;30, 2020, operating leases had a weighted average remaining lease term of <ix:nonNumeric contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMjgxMA_3e434a9b-e922-46f9-8d84-876eb3ee4ef6">1.14</ix:nonNumeric> years. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia207f6f737944325a14b3e6f8edbe75b"><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMjkwNg_ea46b2e6-41bc-4876-837f-6ec170660201" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, future minimum payments under the Company's operating leases are approximately:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:445.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RhYmxlOjU5OWY1ZGQxOTAyZDRhNGZiMTE4MTAwZDJhZGVhNjJhL3RhYmxlcmFuZ2U6NTk5ZjVkZDE5MDJkNGE0ZmIxMTgxMDBkMmFkZWE2MmFfMS0xLTEtMS0w_059310f8-17e8-4802-b83f-e731d43ffba1">112,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RhYmxlOjU5OWY1ZGQxOTAyZDRhNGZiMTE4MTAwZDJhZGVhNjJhL3RhYmxlcmFuZ2U6NTk5ZjVkZDE5MDJkNGE0ZmIxMTgxMDBkMmFkZWE2MmFfMi0xLTEtMS0w_3d630451-efd1-4b86-8f80-772788689258">363,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RhYmxlOjU5OWY1ZGQxOTAyZDRhNGZiMTE4MTAwZDJhZGVhNjJhL3RhYmxlcmFuZ2U6NTk5ZjVkZDE5MDJkNGE0ZmIxMTgxMDBkMmFkZWE2MmFfMy0xLTEtMS0w_0c20c4f9-ed7f-4429-a2a8-17e0834c7ee8">42,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RhYmxlOjU5OWY1ZGQxOTAyZDRhNGZiMTE4MTAwZDJhZGVhNjJhL3RhYmxlcmFuZ2U6NTk5ZjVkZDE5MDJkNGE0ZmIxMTgxMDBkMmFkZWE2MmFfNC0xLTEtMS0w_cdc846b9-c54e-4463-b475-18f9271b9249">517,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Difference between future minimum lease payments and discounted operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RhYmxlOjU5OWY1ZGQxOTAyZDRhNGZiMTE4MTAwZDJhZGVhNjJhL3RhYmxlcmFuZ2U6NTk5ZjVkZDE5MDJkNGE0ZmIxMTgxMDBkMmFkZWE2MmFfNS0xLTEtMS0w_b3d562ec-d79b-4d49-9572-07de6d72cfed">24,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RhYmxlOjU5OWY1ZGQxOTAyZDRhNGZiMTE4MTAwZDJhZGVhNjJhL3RhYmxlcmFuZ2U6NTk5ZjVkZDE5MDJkNGE0ZmIxMTgxMDBkMmFkZWE2MmFfNi0xLTEtMS0w_05733e16-c30e-4a6f-9a70-d6d627a33df1">493,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i868f48d3ece34cfab595a46f6986b439_58"></div><div style="margin-top:18pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="us-gaap:CommitmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81OC9mcmFnOjIxZjFjMzljOWFiNjQ3MDJhYjM0OGQ0ZjMwMGM5ZTgxL3RleHRyZWdpb246MjFmMWMzOWM5YWI2NDcwMmFiMzQ4ZDRmMzAwYzllODFfMTYzMw_3f0dd4d9-555d-467a-bf6a-44e1a0e78e4d" continuedAt="ifeb34916491c4e8a9e008a8bbcb75310" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="ifeb34916491c4e8a9e008a8bbcb75310"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Microchips, the Company agreed to pay contingent consideration based upon the achievement of specified funding, product development and regulatory milestones. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="ibec4b74376bf439b97a248a65f5b0eae_I20191130" decimals="-5" format="ixt:numdotdecimal" name="dare:AssetAcquisitionContingentConsiderationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81OC9mcmFnOjIxZjFjMzljOWFiNjQ3MDJhYjM0OGQ0ZjMwMGM5ZTgxL3RleHRyZWdpb246MjFmMWMzOWM5YWI2NDcwMmFiMzQ4ZDRmMzAwYzllODFfMjgx_119806c8-d2a5-484e-9e34-bab3a4045537">1.0</ix:nonFraction> million in contingent consideration liability associated with milestone payments expected to become payable in the first half of 2021 in its consolidated balance sheet at September&#160;30, 2020.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Payable</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, due to the economic uncertainty resulting from the impact of the COVID-19 pandemic on the Company's operations and to support its ongoing operations and retain all employees, the Company applied for a loan under the Paycheck Protection Program, or the PPP, of the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, administered by the U.S. Small Business Administration, or the SBA. The Company received a loan of approximately $<ix:nonFraction unitRef="usd" contextRef="i07edbdfe23b14e1b882ecc8189596d12_D20200401-20200430" decimals="-3" format="ixt:numdotdecimal" name="dare:CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81OC9mcmFnOjIxZjFjMzljOWFiNjQ3MDJhYjM0OGQ0ZjMwMGM5ZTgxL3RleHRyZWdpb246MjFmMWMzOWM5YWI2NDcwMmFiMzQ4ZDRmMzAwYzllODFfODk5_fe7de3d6-836c-4a11-9a06-b62e4a8bbe13">367,000</ix:nonFraction>. The loan matures in April 2022, bears interest at a rate of <ix:nonFraction unitRef="number" contextRef="i5eedf8fd854e4e299d621b34d7105036_I20200430" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81OC9mcmFnOjIxZjFjMzljOWFiNjQ3MDJhYjM0OGQ0ZjMwMGM5ZTgxL3RleHRyZWdpb246MjFmMWMzOWM5YWI2NDcwMmFiMzQ4ZDRmMzAwYzllODFfOTYz_03accac3-df63-422c-b8f3-7cb8b481bbac">1.00</ix:nonFraction>% per annum, is payable in equal monthly payments commencing in November 2020 through maturity and may be prepaid at any time prior to maturity with no prepayment penalties. Under the terms of the PPP, the loan proceeds could be used for "qualifying expenses" and, subject to specified limitations in the CARES Act and under the terms of the PPP, certain amounts of the loan, including accrued interest, may be forgiven if used for qualifying expenses. Qualifying expenses include payroll costs, costs used to continue group health care benefits, mortgage interest payments, rent payments, utility payments, and interest payments on other debt obligations incurred before February 15, 2020. In September 2020, the Company submitted its forgiveness application. The Company used the entire amount of the loan for payroll and rent costs, which the Company believes are expenses that constitute qualifying expenses, and the Company requested that the entire amount of the loan, including accrued interest, be forgiven. There can be no assurance that the loan will be forgiven, in whole or in part. Under current SBA guidance, it may take up to 90 days from the date the Company's loan forgiveness application is submitted to the SBA by the Company's lender for the SBA to make a determination with respect to the Company's loan forgiveness application . The Company recorded a note payable plus accrued interest for the loan in the amount of approximately $<ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="-3" format="ixt:numdotdecimal" name="dare:NotesPayableCurrentPlusAccruedInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81OC9mcmFnOjIxZjFjMzljOWFiNjQ3MDJhYjM0OGQ0ZjMwMGM5ZTgxL3RleHRyZWdpb246MjFmMWMzOWM5YWI2NDcwMmFiMzQ4ZDRmMzAwYzllODFfMTU5MQ_66366178-8519-4970-8cb5-f744072154ea">369,000</ix:nonFraction> in its consolidated balance sheet at September&#160;30, 2020.</span></div></ix:continuation><div id="i868f48d3ece34cfab595a46f6986b439_61"></div><div style="margin-top:18pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="dare:GrantAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMjQ4NA_5f9a72ec-575c-4a4c-8fa5-970e3019262c" continuedAt="ia4cf214d671a4d8b9e8271ced7bcb1d8" escape="true">GRANT AWARD</ix:nonNumeric></span></div><ix:continuation id="ia4cf214d671a4d8b9e8271ced7bcb1d8" continuedAt="ife35872b261c44f68c4992fe342a09bb"><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIH Grant Funding</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received notices of awards and grant funding from the National Institutes of Health, or the NIH to support the development of Ovaprene and DARE-FRT1. The NIH issues notices of awards to the Company for a specified amount, and the Company must incur and track expenses eligible for reimbursement under the award and submit a detailed accounting of such expenses to receive payment. If the Company receives payments under the award, the amounts of such payments are recognized in the statement of operations as a reduction to research and development activities as the related costs are incurred to meet those obligations over the period. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ife35872b261c44f68c4992fe342a09bb"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ovaprene</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2018, the Company has received approximately $<ix:nonFraction unitRef="usd" contextRef="i6cd38b5d0d18443eb25f5b075faaf8d0_D20180101-20200930" decimals="-5" format="ixt:numdotdecimal" name="dare:ProceedsFromAwardOfGrant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMTA5OTUxMTYzOTYwOA_8088d6c3-ccbf-4e77-802f-0abe021b879b">1.9</ix:nonFraction> million of grant funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, a division of the NIH, for clinical development efforts supporting Ovaprene. The most recent and final notice of award the Company received was for approximately $<ix:nonFraction unitRef="usd" contextRef="i07edbdfe23b14e1b882ecc8189596d12_D20200401-20200430" decimals="0" format="ixt:numdotdecimal" name="dare:ProceedsFromAwardOfGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfNTE4_97a157dd-97f8-47c8-89f4-983809e21262">731,000</ix:nonFraction> in April 2020, substantially all of which has been funded to date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded credits to research and development expense for costs related to the NIH award of approximately $<ix:nonFraction unitRef="usd" contextRef="iec804f8af9ee49218d67d6fd78a4180c_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMTA5OTUxMTYzMDQwOA_1108b73e-1493-4943-81ec-24036e54823f">124,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i160a0b42d86e4a8bbd0f05476b0f68e6_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMTA5OTUxMTYzMDQzOQ_286bb74c-f181-4d4c-95b3-c4c2024185df">302,000</ix:nonFraction> for the three months ended September&#160;30, 2020 and September&#160;30, 2019, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i07b04c713b994fddb69fb22f61dcce47_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMTA5OTUxMTYzMDI3OQ_28bebdcd-282b-4556-993e-a4769f615f6c">583,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iee4d04ac7d154b5da7eff0fa25f65c41_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMTA5OTUxMTYzMDQzNQ_091bba8b-1603-4c0e-bb38-9aa9f8d01086">920,000</ix:nonFraction> for the nine months ended&#160;September&#160;30, 2020 and September&#160;30, 2019, respectively. At September&#160;30, 2020, the Company recorded a receivable of approximately $<ix:nonFraction unitRef="usd" contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMTY0MA_64313b4f-c690-41f9-81eb-676c75708822">69,000</ix:nonFraction> for expenses incurred through such date that it believes are eligible for reimbursement under the final notice of award received in April 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DARE-FRT1</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company received a notice of award of a grant from the NIH to support the development of DARE-FRT1. The award in the amount of $<ix:nonFraction unitRef="usd" contextRef="ifa5514aaaa824b3aa79107f5c9c5d73d_D20200801-20200831" decimals="0" format="ixt:numdotdecimal" name="dare:ProceedsFromAwardOfGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMTA5OTUxMTYzOTYyNA_655fa0d3-623d-446a-abee-ba5e68efffa1">300,000</ix:nonFraction> was for what is referred to as the "Phase I" segment of the project outlined in the Company's grant application, which is to occur during the period of August 2020 through July 2021. Additional potential funding of up to approximately $<ix:nonFraction unitRef="usd" contextRef="ida0b6e85f82e4e608327c8ca8bc71f2d_I20200831" decimals="-5" format="ixt:numdotdecimal" name="dare:AdditionalPotentialFundingRelatedToGrantAward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMTA5OTUxMTY0MDU0Nw_7b482d6d-7081-4a03-977d-fd3c13e4efc8">2.0</ix:nonFraction> million for the "Phase II" segment of the project outlined in the grant application is contingent upon satisfying specified requirements, including, assessment of the results of the Phase I segment, determination that the Phase I goals were achieved, and availability of funds. There is no guarantee the Company will receive any Phase II award. The Company recorded credits to research and development expense for costs related to the NIH award of approximately $<ix:nonFraction unitRef="usd" contextRef="i61ac128034e543f09fa5c2ccee686dd9_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMTA5OTUxMTYzOTU2Mw_2bf92277-8cad-4cf3-9d59-dfd66074bdab">3,000</ix:nonFraction> during the three months ended September&#160;30, 2020. At September&#160;30, 2020, the Company recorded a receivable of approximately $<ix:nonFraction unitRef="usd" contextRef="ic6eebb50c9aa442eb1c1e54f219936db_I20200930" decimals="0" format="ixt:numdotdecimal" name="dare:ReceivableForExpensesEligibleForReimbursement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMTA5OTUxMTYzOTU3Mg_f3f955eb-e170-4ffa-92fa-6ea4fb03631b">3,000</ix:nonFraction> for expenses incurred through such date that it believes are eligible for reimbursement under the grant.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's wholly-owned subsidiary, Microchips, has a grant agreement with the Bill &amp; Melinda Gates Foundation, or the Foundation, relating to the development of the pre-clinical stage contraceptive candidate, DARE-LARC1. Expenses eligible for grant funding must be incurred, tracked and reported to the Foundation. Microchips received grant funding payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i1e9574645f90496484a14992487f17b9_D20190701-20190731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMjE5OA_e01ec3b3-e451-43b4-8d30-3b8d15925ed3">2.9</ix:nonFraction> million in July 2019, $<ix:nonFraction unitRef="usd" contextRef="i08cd90f2ba3140dbb283240c624fe12e_D20200601-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMTA5OTUxMTY0MTQ5NQ_5b3e6c34-5bcc-4f33-b9ba-75b4665ec23e">1.6</ix:nonFraction> million in June 2020 and $<ix:nonFraction unitRef="usd" contextRef="i9f10d1b26cc94a1fa3cb93ec8aedbb85_D20200901-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMjE5OTAyMzI1ODE3OQ_34086eb3-bcfc-4aae-bf4b-97c4fc6679bf">899,000</ix:nonFraction> in September 2020. At September&#160;30, 2020, grant funding payments associated with research and development expenses for DARE-LARC1 not yet incurred totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i811a18ee61a041bcb8b2a9a6d171b9a6_I20200930" decimals="-5" format="ixt:numdotdecimal" name="dare:DeferredGrantFundingCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMjM4NA_21ce0b16-a446-4643-af1a-fea70c455cdd">2.2</ix:nonFraction> million and are recorded as deferred grant funding liability in the Company's consolidated balance sheet.</span></div></ix:continuation><div id="i868f48d3ece34cfab595a46f6986b439_64"></div><div style="margin-top:18pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82NC9mcmFnOjExMTNjOWVlNTBhZDQ2ZWU5ZGUzYTBjZjI2NjBkYWIzL3RleHRyZWdpb246MTExM2M5ZWU1MGFkNDZlZTlkZTNhMGNmMjY2MGRhYjNfODUw_1bb8cb3c-1b71-41d7-ac32-0731562a4097" continuedAt="ib5f8aa82874b44328c6f477c595e0b10" escape="true">NET LOSS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="ib5f8aa82874b44328c6f477c595e0b10"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes basic net loss per share using the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares and potentially dilutive securities (common share equivalents) outstanding during the period. Common share equivalents outstanding, determined using the treasury stock method, are comprised of shares that may be issued under outstanding options and warrants to purchase shares of the Company&#8217;s common stock. Common share equivalents are excluded from the diluted net loss per share calculation if their effect is anti-dilutive.</span></div><ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82NC9mcmFnOjExMTNjOWVlNTBhZDQ2ZWU5ZGUzYTBjZjI2NjBkYWIzL3RleHRyZWdpb246MTExM2M5ZWU1MGFkNDZlZTlkZTNhMGNmMjY2MGRhYjNfODUy_1d5229f2-64ac-4aa9-b410-e38de250cdee" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive outstanding securities were excluded from diluted net loss per common share for the period indicated because of their anti-dilutive effect:</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:372.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Potentially dilutive securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f2fd361955c4af0b36cfc82bd1dd299_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82NC9mcmFnOjExMTNjOWVlNTBhZDQ2ZWU5ZGUzYTBjZjI2NjBkYWIzL3RhYmxlOmE3MWIyMGJlMDMwMjRkYzFhZWFjYjEwYTEwY2I3ZjFlL3RhYmxlcmFuZ2U6YTcxYjIwYmUwMzAyNGRjMWFlYWNiMTBhMTBjYjdmMWVfMi0yLTEtMS0w_b4aa305d-a89e-4733-be4b-af1d2ea2b92a">2,783,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c48e9816275492c80d5c9b5987290e9_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82NC9mcmFnOjExMTNjOWVlNTBhZDQ2ZWU5ZGUzYTBjZjI2NjBkYWIzL3RhYmxlOmE3MWIyMGJlMDMwMjRkYzFhZWFjYjEwYTEwY2I3ZjFlL3RhYmxlcmFuZ2U6YTcxYjIwYmUwMzAyNGRjMWFlYWNiMTBhMTBjYjdmMWVfMi00LTEtMS0w_8863a496-57f3-432f-aa92-9b5d315c28fb">1,824,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9fa32febc2e54647a6368e846d71b024_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82NC9mcmFnOjExMTNjOWVlNTBhZDQ2ZWU5ZGUzYTBjZjI2NjBkYWIzL3RhYmxlOmE3MWIyMGJlMDMwMjRkYzFhZWFjYjEwYTEwY2I3ZjFlL3RhYmxlcmFuZ2U6YTcxYjIwYmUwMzAyNGRjMWFlYWNiMTBhMTBjYjdmMWVfMy0yLTEtMS0w_a411a0ad-85b8-45e7-90d9-f524e82431bf">1,908,643</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd0fb129419e4ee29415f58d00c829e5_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82NC9mcmFnOjExMTNjOWVlNTBhZDQ2ZWU5ZGUzYTBjZjI2NjBkYWIzL3RhYmxlOmE3MWIyMGJlMDMwMjRkYzFhZWFjYjEwYTEwY2I3ZjFlL3RhYmxlcmFuZ2U6YTcxYjIwYmUwMzAyNGRjMWFlYWNiMTBhMTBjYjdmMWVfMy00LTEtMS0w_e0f62017-c0f6-4bba-8404-316d6ceb76d9">3,750,833</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82NC9mcmFnOjExMTNjOWVlNTBhZDQ2ZWU5ZGUzYTBjZjI2NjBkYWIzL3RhYmxlOmE3MWIyMGJlMDMwMjRkYzFhZWFjYjEwYTEwY2I3ZjFlL3RhYmxlcmFuZ2U6YTcxYjIwYmUwMzAyNGRjMWFlYWNiMTBhMTBjYjdmMWVfNC0yLTEtMS0w_1fd5f72a-08e4-4f0a-a9ff-b0c2bf523186">4,692,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82NC9mcmFnOjExMTNjOWVlNTBhZDQ2ZWU5ZGUzYTBjZjI2NjBkYWIzL3RhYmxlOmE3MWIyMGJlMDMwMjRkYzFhZWFjYjEwYTEwY2I3ZjFlL3RhYmxlcmFuZ2U6YTcxYjIwYmUwMzAyNGRjMWFlYWNiMTBhMTBjYjdmMWVfNC00LTEtMS0w_4c0bd267-f662-4316-b1fe-a757d403c7f7">5,575,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i868f48d3ece34cfab595a46f6986b439_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82Ny9mcmFnOjY1NTFjOWE1ZjYyYTQwNmM4YjFlMjgwMGNmMDlkMDlmL3RleHRyZWdpb246NjU1MWM5YTVmNjJhNDA2YzhiMWUyODAwY2YwOWQwOWZfMTEyNg_adc7701f-5b35-4b1f-bdfb-17244d6247e1" continuedAt="i48d384bb488d4699af621f3935fa4535" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i48d384bb488d4699af621f3935fa4535"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Sales</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between October 1, 2020 and November&#160;11, 2020, the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="ia980a0c4d8c2414ca34948ab72d9b74d_D20201001-20201111" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82Ny9mcmFnOjY1NTFjOWE1ZjYyYTQwNmM4YjFlMjgwMGNmMDlkMDlmL3RleHRyZWdpb246NjU1MWM5YTVmNjJhNDA2YzhiMWUyODAwY2YwOWQwOWZfNzky_08ef4d69-2eb5-4b41-a533-793a75c83c10">3,987,485</ix:nonFraction> shares of common stock in "at-the-market" equity offerings and received aggregate net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ia980a0c4d8c2414ca34948ab72d9b74d_D20201001-20201111" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82Ny9mcmFnOjY1NTFjOWE1ZjYyYTQwNmM4YjFlMjgwMGNmMDlkMDlmL3RleHRyZWdpb246NjU1MWM5YTVmNjJhNDA2YzhiMWUyODAwY2YwOWQwOWZfOTA3_664a2f56-7fe3-4cb5-81c1-4517f9d599bb">4.1</ix:nonFraction> million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Line</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between October 1, 2020 and November&#160;11, 2020 the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="ic93f45ca4cb841cf9744ed2f4001e2a4_D20201001-20201111" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82Ny9mcmFnOjY1NTFjOWE1ZjYyYTQwNmM4YjFlMjgwMGNmMDlkMDlmL3RleHRyZWdpb246NjU1MWM5YTVmNjJhNDA2YzhiMWUyODAwY2YwOWQwOWZfOTk5_77cf10b5-f8ab-46f4-8056-6da18538c706">400,000</ix:nonFraction> shares of common stock to Lincoln Park under the Purchase Agreement and received aggregate net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ic93f45ca4cb841cf9744ed2f4001e2a4_D20201001-20201111" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82Ny9mcmFnOjY1NTFjOWE1ZjYyYTQwNmM4YjFlMjgwMGNmMDlkMDlmL3RleHRyZWdpb246NjU1MWM5YTVmNjJhNDA2YzhiMWUyODAwY2YwOWQwOWZfMTEyMw_4593d5e2-917d-4b81-a7eb-fe095b15ac90">0.4</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i868f48d3ece34cfab595a46f6986b439_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of financial condition and results of operations should be read in conjunction with our interim consolidated financial statements and notes thereto included in this Quarterly Report on Form 10-Q and our audited financial statements and notes thereto for the year ended December&#160;31, 2019 included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, or our 2019 10-K, filed with the Securities and Exchange Commission, or SEC, on March 27, 2020. Past operating results are not necessarily indicative of results that may occur in future periods.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> The following discussion includes forward-looking statements.&#160;See &#8220;CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS,&#8221; above. Forward-looking statements are not guarantees of future performance and our actual results may differ materially from those currently anticipated and from historical results depending upon a variety of factors, including, but not limited to, those discussed in Part I, Item 1A. Risk Factors of our 2019 10-K, and in our subsequent filings with the SEC, including any discussed in Part II, Item 1A of this report under the heading &#8220;Risk Factors,&#8221; which are incorporated herein by reference.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this report, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Dar&#233;&#8221; or the &#8220;Company&#8221; refer collectively to Dar&#233; Bioscience, Inc. and its wholly owned subsidiaries, unless otherwise stated or the context otherwise requires. All information presented in this report is based on our fiscal year. Unless otherwise stated, references to particular years, quarters, months or periods refer to our fiscal years ending December 31 and the associated quarters, months and periods of those fiscal years.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dar&#233; Bioscience</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a registered trademark of Dar&#233; Bioscience, Inc. Ovaprene</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a registered trademark licensed to Dar&#233; Bioscience, Inc. All other trademarks, service marks or trade names appearing in this report are the property of their respective owners. Use or display by us of other parties&#8217; trademarks, service marks or trade names is not intended to and does not imply a relationship with, or endorsements or sponsorship of, us by the trademark, service mark or trade name owners.</span></div><div id="i868f48d3ece34cfab595a46f6986b439_73"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company committed to the acceleration of innovative products for women&#8217;s health. We are driven by a mission to identify, acquire and develop a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, fertility, and sexual and vaginal health. Our business strategy is to in-license or otherwise acquire the rights to differentiated product candidates in our areas of focus, some of which have existing clinical proof-of-concept data, to take those candidates through mid- to late-stage clinical development, and to establish and leverage strategic partnerships to achieve commercialization.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since July 2017, we have assembled a portfolio of clinical-stage and pre-clinical-stage candidates. While we will continue to assess opportunities to expand our portfolio, our current focus is on advancing our existing product candidates through mid- and late stages of clinical development or approval. Our portfolio includes three product candidates in advanced clinical development:</span></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-BV1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a novel thermosetting bioadhesive hydrogel formulated with clindamycin phosphate 2% to be administered in a single vaginally delivered application, as a first line treatment for bacterial vaginosis, or BV;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Ovaprene</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a hormone-free, monthly vaginal contraceptive; and</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Sildenafil Cream, 3.6%</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a proprietary cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder, or FSAD.</span></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Our portfolio also includes three product candidates in Phase 1 clinical development or that we believe are Phase 1-ready:</span></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-HRT1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a combination bio-identical estradiol and progesterone intravaginal ring for the treatment of menopausal symptoms, including vasomotor symptoms, as part of a hormone replacement therapy, or HRT, following menopause;</span></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-FRT1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-VVA1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy, or VVA, in patients with hormone-receptor positive breast cancer.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our portfolio includes these pre-clinical stage product candidates:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-LARC1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a combination product designed to provide long-acting, reversible contraception comprising an implantable, user-controlled wireless drug delivery system and levonorgestrel;</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">ORB-204 and ORB-214</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, injectable formulations of etonogestrel designed to provide contraception over 6-month and 12-month periods, respectively; and</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-RH1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a novel approach to non</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hormonal contraception for both men and women by targeting the CatSper ion channel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary operations have consisted of, and are expected to continue to consist of, product research and development and advancing our portfolio of product candidates through clinical development and regulatory approval. We expect that the majority of our development expenses for the remainder of 2020 and in 2021 will support the advancement of DARE-BV1, Ovaprene and Sildenafil Cream, 3.6%.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not obtained any regulatory approvals for any of our product candidates, commercialized any of our product candidates or generated any product revenue. We are subject to several risks common to clinical-stage biopharmaceutical companies, including dependence on key employees as well as third-party licensors, partners and service providers, competition from other companies, the need to develop commercially viable products in a timely and cost-effective manner, and the need to obtain adequate additional capital to fund the development of product candidates. We are also subject to several risks common to other companies in the industry, including rapid technology change, regulatory approval of products, uncertainty of market acceptance of products, competition from substitute products and larger companies, compliance with government regulations, protection of proprietary technology, dependence on third parties, and product liability.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the COVID-19 pandemic continues to rapidly evolve. Infectious disease experts have cautioned that the U.S. may experience a substantial surge in cases and hospitalizations during the cooler months, which may lead the federal government and/or state governments to impose or re-impose stay-at-home orders and shutdowns of non-essential businesses in efforts to reduce spread of the disease, such as those announced by the United Kingdom, Germany, France and other European countries in October 2020. We do not yet know the full extent of the pandemic's potential effects on our business, including the anticipated aggregate costs for development of our product candidates, on our anticipated timelines for the development of our product candidates, or on the supply chain for our clinical supplies. However, these effects could have a material adverse impact on our business and financial condition. See the risk factor titled, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The novel coronavirus (COVID-19) pandemic and efforts to reduce its spread could negatively impact our business, including by increasing the cost and timelines for our clinical development programs,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part II, Item 1A. Risk Factors of this report</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Stage Product Candidates</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">DARE-BV1</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we commenced a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of DARE-BV1 (clindamycin phosphate vaginal gel, 2%) for the treatment of BV, or the DARE-BVFREE (DARE-BV1-001) study.</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The study enrolled 307 postmenarchal women, ages 15 and above, at 32 sites in the United States. The primary efficacy endpoint of the study is clinical cure of BV at the evaluation visit to occur 21 to 30 days after enrollment in the study, or the Day 21-30 visit, with clinical cure defined as meeting three criteria (derived from the Amsel criteria): resolution of abnormal vaginal discharge associated with BV as confirmed by the investigator; a negative 10% potassium hydroxide (KOH) "whiff test"; and the presence of clue cells at less than 20% of total epithelial cells in a saline wet mount. We anticipate having topline data from this study by year-end 2020. If the DARE-BVFREE study is successful, we expect to be in a position to submit a new drug application, or NDA, to the FDA in the first half of 2021. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that the aggregate costs of the DARE-BV1 program through NDA filing, including the DARE-BV1FREE study, planned nonclinical studies, manufacturing activities for the program through filing of the NDA, and the NDA filing, including the credit eligible for first time filers, will be between approximately $10.0 to $12.0 million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Ovaprene</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the positive results of our postcoital test (PCT) clinical trial of Ovaprene, topline data from which was announced in November 2019, and with the support of Bayer under the commercial license agreement we executed in January 2020, we are conducting activities to support submission of an Investigational Device Exemption application, or IDE, to the FDA for a pivotal clinical study of Ovaprene. We are designing that study to evaluate the safety and efficacy of Ovaprene to prevent pregnancy when used over a period of 12 months by approximately 250 women and will seek to confirm alignment with the FDA on the study's design prior to commencement. We are conducting development activities prior to commencement of the planned pivotal study of Ovaprene that we believe will continue to advance this program and enable us to report topline data for the pivotal clinical study by year-end 2022. If successful, we expect the study's data to support a premarket approval, or PMA, submission to the FDA, as well as marketing approvals of Ovaprene in Europe and other countries worldwide.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Sildenafil Cream, 3.6%</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sildenafil Cream, 3.6% is in Phase 2b clinical development for FSAD. In December 2019, we announced that, we reached alignment with the FDA on the design of our Phase 2b clinical trial, including the patient reported outcome, or PRO, instruments to be used to screen eligible patients with FSAD and to measure achievement of the primary efficacy endpoints, namely improvement in localized genital sensations of arousal and reduction in the distress that women with FSAD experience. The Phase 2b trial is designed to evaluate Sildenafil Cream, 3.6% compared to placebo cream over 12 weeks of dosing following both a non-drug and placebo run-in period. In light of disruptions resulting from the COVID-19 pandemic, we are evaluating the optimal time to commence enrollment in the Phase 2b trial to support projected topline data for the Phase 2b trial by year-end 2021. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">DARE-HRT1</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2020, our wholly-owned Australian subsidiary commenced a Phase 1 open-label, three-arm, parallel group clinical study of DARE-HRT1 in Australia to evaluate the pharmacokinetics, or PK, and safety of DARE-HRT1 in approximately 30 healthy, post-menopausal women, at specialty women's health sites in Australia. The primary objective of the study is to describe the PK parameters of two different dose combinations (estradiol 80 &#181;g/progesterone 4 mg IVR and estradiol 160 &#181;g/progesterone 8 mg IVR) over 28 days. Secondary endpoints of the study include assessing the safety and tolerability of DARE-HRT1 and comparing the exposure of estradiol, estrone, and progesterone of DARE-HRT1 over 28 days against a daily combination of oral estrogen (Estrofem&#174;) and oral progesterone (Prometrium&#174;). If the study's rate of enrollment occurs as we currently expect, then we anticipate having topline data from this study in the first half of 2021. We anticipate that the aggregate costs of the DARE-HRT1 Phase 1 clinical study will be approximately $2.5 million. Currently, Australia's research and development tax incentive, or R&amp;DTI, gives 43.5% of every dollar spent by eligible companies on eligible R&amp;D activities back to those companies in a cash payment. Dar&#233;&#8217;s subsidiary intends to apply for the maximum refundable cash credit then available under the Australian R&amp;DTI program for eligible study costs incurred.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our currently anticipated timelines and aggregate costs for the development of our product candidates could be delayed and could increase as a result of the COVID-19 pandemic. See the risk factor titled, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The COVID-19 pandemic and efforts to reduce the spread of COVID-19 could negatively impact our business, including by increasing the cost and timelines for our clinical development programs, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Part II, Item 1A. Risk Factors of this report. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i868f48d3ece34cfab595a46f6986b439_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Events</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grant Funding for DARE-FRT1 Program</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we received a Notice of Award of a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a division of the National Institutes of Health (NIH). The grant funding will support the development of DARE-FRT1. The award in the amount of $0.3 million was for what is referred to as the &#8220;Phase I&#8221; segment of the project outlined in our grant application, which is to occur during the period of August 2020 through July 2021. Additional potential funding of up to approximately $2.0 million for the &#8220;Phase II&#8221; segment of the project outlined in the grant application is contingent upon satisfying specified requirements, including, assessment of the results of the Phase I segment, determination that the Phase I goals were achieved, and availability of funds. There is no guarantee we will receive any Phase II award. To receive payment under the Phase I award, we must first incur expenses eligible for reimbursement and submit a detailed accounting of such expenses to the NICHD. During the nine months ended September 30, 2020 we did not submit any requests for payment under the award.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">COVID-19 Update</span></div><div style="margin-bottom:3pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We closely monitor the COVID-19 pandemic and actions taken in the United States and other countries to contain and treat the disease and aid economic recovery, and we continue to assess the potential impact on our employees, operations, including our clinical trials, business strategy and financial condition and performance. In response to the spread of COVID-19, in March 2020, we implemented work-from-home and restricted travel policies. In May 2020, we modified our work-from-home policy such that some of our personnel returned to working in our facilities for a portion or all of their working time. We expect to continue to modify our work-from-home and restricted travel policies as the pandemic and state and local stay-at-home orders evolve. While we have systems and technologies in place to enable our employees to work from home, and we do not believe employee productivity has been materially adversely affected to date, we may experience material adverse impacts to productivity and challenges to our ability to effectively manage and operate our business in future periods. In addition, many of our consultants, partners and vendors on which we rely heavily are subject to similar work and travel restrictions that may adversely impact their ability to perform contracted services in a timely manner or at all. Infectious disease experts have cautioned that the U.S. may experience a substantial surge in cases and hospitalizations during the cooler months, which may lead the federal government and/or state governments to impose or re-impose stay-at-home orders and shutdowns of non-essential businesses in efforts to reduce spread of the disease, such as those announced by the United Kingdom, Germany, France, and other European countries in October 2020. The effect of the pandemic and its associated restrictions may increase the anticipated aggregate costs for the development of our product candidates and may adversely impact our anticipated timelines for the development of our product candidates by, among other things,&#160;causing disruptions in the supply chain for our clinical supplies, delays in commencement of planned clinical trials, as well as in the timing and pace of subject enrollment in our ongoing clinical trials and lower than anticipated subject enrollment and completion rates, delays in submission of any applications for marketing approval of our product candidates, delays in the review and approval of our regulatory submissions by the FDA and other agencies with respect to our product candidates, and other unforeseen disruptions. The economic impact of the pandemic and the uncertainty and volatility in the capital markets it has caused, and may continue to cause, may negatively impact investor sentiment and the availability and cost of capital, and may adversely impact our ability to raise capital when needed or on terms favorable to us and our stockholders to fund our development programs and our operations. The effect of the pandemic and efforts to reduce the spread of COVID-19 remain a rapidly evolving and uncertain risk to our business, operating results, financial condition and stock price. Given the high level of uncertainty regarding the duration and impact of the pandemic on the U.S. and global economies, workplace environments and capital markets, we are unable to assess the full extent of the effects of the pandemic on our business, clinical trial activities, ability to access capital or on healthcare systems or the global economy as a whole. However, these effects could have a material adverse impact on our business and financial condition. See the risk factor titled, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The novel coronavirus (COVID-19) and efforts to reduce its spread could negatively impact our business, including by increasing the cost and timelines for our clinical development programs,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part II, Item 1A. Risk Factors of this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i868f48d3ece34cfab595a46f6986b439_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred a loss of approximately $19.0&#160;million for the nine months ended September&#160;30, 2020. As of September&#160;30, 2020, we had an accumulated deficit of approximately $63.0 million and cash and cash equivalents of approximately $5.4 million. We also had negative cash flow from operations of approximately $16.0 million during the nine months ended September&#160;30, 2020. We will need to raise substantial additional capital to continue to fund our operations and to successfully execute our current operating plan, including the development of our current product candidates. The amount and timing of our capital needs will continue to depend highly on many factors, including the product development programs we choose to pursue and the pace and results of our clinical development efforts. If we do not raise capital as and when needed, we will not be able to continue development of our product candidates or we will be required to delay, scale back or eliminate some or all of our development programs or cease operations. For additional information regarding our ability to continue as a going concern, see Note 1 to our unaudited interim consolidated financial statements contained in this report and &#8220;Liquidity and Capital Resources and Financial Condition,&#8221; below.</span></div><div id="i868f48d3ece34cfab595a46f6986b439_82"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date we have not generated any revenue. In the future, and if we are successful in advancing our product candidates through late stages of clinical development, we may generate revenue from license fees, milestone payments, research and development payments in connection with strategic partnerships, as well as royalties and commercial milestones resulting from the sale of products. Our ability to generate such revenue will depend on the successful clinical development of our product candidates, the receipt of regulatory approvals to market such products and the eventual successful commercialization of product candidates. If we fail to complete the development of product candidates in a timely manner, or to receive regulatory approval for such product candidates, our ability to generate future revenue and our results of operations would be materially adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include research and development costs for our product candidates and transaction costs related to our acquisitions. We recognize all research and development expenses as they are incurred. Research and development expenses consist primarily of:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">expenses incurred under agreements with consultants and clinical trial sites that conduct research and development activities on our behalf;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">laboratory and vendor expenses related to the execution of nonclinical studies and clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:81pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">contract manufacturing expenses, primarily for the production of clinical supplies; </span></div><div style="margin-bottom:3pt;padding-left:81pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">transaction costs related to the acquisitions of companies, technologies and related intellectual property, and other assets; and</span></div><div style="margin-bottom:3pt;padding-left:81pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">internal costs that are associated with activities performed by our research and development organization and generally benefit multiple programs.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect research and development expenses to increase in the future as we continue to invest in the development of our clinical-stage product candidates and as any other potential product candidates we may develop are advanced into and through clinical trials in the pursuit of regulatory approvals. Such activities will require a significant increase in investment in regulatory support, clinical supplies, inventory build-up related costs, and the payment of success-based milestones to licensors. In addition, we continue to evaluate opportunities to acquire or in-license other product candidates and technologies, which may result in higher research and development expenses due to, among other factors, license fee and/or milestone payments.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We may not obtain regulatory approval for any product candidate on a timely and cost-effective basis or at all. The probability of success of our product candidates may be affected by numerous factors, including clinical results and data, competition, intellectual property rights, manufacturing capability and commercial viability. As a result, we cannot accurately determine the duration and completion costs of development projects or when and to what extent we will generate revenue from the commercialization of any of our product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist of personnel costs, facility expenses, expenses for outside professional services, including legal, audit and accounting services. Personnel costs consist of salaries, benefits and stock-based compensation. Facility expenses consist of rent and other related costs. </span></div><div id="i868f48d3ece34cfab595a46f6986b439_85"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s discussion and analysis of financial condition and results of operations is based on our interim consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Preparing these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses, and related disclosures. On an ongoing basis, we evaluate these estimates and judgments. We base our estimates on historical experience and on various assumptions we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. For a description of critical accounting policies that affect our significant judgments and estimates used in the preparation of our unaudited consolidated interim financial statements, refer to Item 7 in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, Note 1 to our financial statements contained in our 2019 10-K, and Note 2 to our unaudited interim consolidated financial statements contained in this report.</span></div><div id="i868f48d3ece34cfab595a46f6986b439_88"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Three Months Ended September&#160;30, 2020 and 2019 (Unaudited)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results for the periods indicated, together with the changes in those items in dollars:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:522.00pt"><tr><td style="width:1.0pt"></td><td style="width:306.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:69.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,203,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,966,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,237,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,333)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,581,822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,418,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,163,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,581,822)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,418,549)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,163,273)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(986)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,582,808)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,393,078)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,189,730)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend from trigger of down round provision feature</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,863)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,863)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss to common shareholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,589,671)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,393,078)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,196,593)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,378)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,588,999)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,408,456)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,180,543)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not recognize any revenues for either of the three months ended September&#160;30, 2020 or 2019.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and administrative expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $34,083 in general and administrative expenses&#160;for the three months ended September&#160;30, 2020 as compared to the three months ended September&#160;30, 2019 was primarily attributable to increases in (i) personnel costs of approximately $148,000, (ii) rent and facilities expenses of approximately $61,000, due to the addition of two leases when we acquired Microchips in November 2019, and (iii) stock-based compensation expense of approximately $26,000. These increases were partially offset by a decrease in expenses for professional services of approximately $190,000.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $4.2&#160;million in research and development expenses for the three months ended September&#160;30, 2020 as compared to the three months ended September&#160;30, 2019 was primarily attributable to increases in (i) costs related to development activities of approximately $3.2 million for DARE-BV1, (ii) costs related to development activities of approximately $856,000 for Ovaprene, offset by increased grant funding recorded as a reduction to research and development expenses of approximately $178,000 related to Ovaprene, (iii) costs related to pre-clinical development activities of approximately $665,000 for DARE-LARC1, which we acquired in November 2019, (iv) personnel costs of approximately $159,000, and (v) costs related to development activities of approximately $76,000 related to DARE-FRT1. These increases were partially offset by (a) an increase in grant funding recorded as a reduction to research and development expenses of approximately $665,000 related to preclinical expenses for DARE-LARC1, (b) a decrease in costs related to development activities of approximately $212,000 for DARE-HRT1, and (c) a decrease in costs related to development activities of approximately $72,000 for Sildenafil Cream, 3.6%.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License fees</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September&#160;30, 2020 we accrued $25,000 of the $100,000 annual license maintenance fee payable in the second quarter of 2021 under our license agreement related to DARE-HRT1.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September&#160;30, 2019 we accrued $133,333 of license expenses comprised of the $112,500 of deferred license fees due under our license agreement related to DARE-BV1 and the $20,833 of the annual license maintenance fee payable in the second quarter of 2020 under our license agreement related to DARE-HRT1. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further discussion of these license fees, see Note 3 to our unaudited interim consolidated financial statements contained in this report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease of $26,457 in other income for the three months ended September&#160;30, 2020 as compared to the three months ended September&#160;30, 2019 was primarily due to a decrease in interest earned on cash balances in the current period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Nine Months Ended September&#160;30, 2020 and 2019 (Unaudited)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results for the periods indicated, together with the changes in those items in dollars:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:522.00pt"><tr><td style="width:1.0pt"></td><td style="width:306.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:69.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,772,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,903,545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,131,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,172,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,958,815&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,961,722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,484,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,477,652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,961,722)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,484,070)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,477,652)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,249)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,959,268)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,397,367)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,561,901)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend from trigger of down round provision feature</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,863)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789,594)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss to common shareholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,966,131)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,186,961)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,779,170)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,182)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,674)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,976,313)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,202,635)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,773,678)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not recognize any revenues for either of the nine months ended September&#160;30, 2020 or 2019.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and administrative expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $868,837 in general and administrative expenses&#160;for the nine months ended September&#160;30, 2020 as compared to the nine months ended September&#160;30, 2019 was primarily attributable to increases in (i) personnel costs of approximately $397,000, (ii) rent and facilities expenses of approximately $175,000 due to the addition of two leases when we acquired Microchips in November 2019, (iii) expenses for professional services of approximately $118,000, (iv) stock-based compensation expense of approximately $110,000, and (v) insurance expense of approximately $42,000.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $8.0&#160;million in research and development expenses for the nine months ended September&#160;30, 2020 as compared to the nine months ended September&#160;30, 2019 was primarily attributable to increases in (i) costs related to development activities of approximately $5.6 million for DARE-BV1, (ii) costs related to development activities of approximately $2.7 million for Ovaprene, inclusive of decreased grant funding recorded as a reduction to research and development expenses of approximately $336,000 related to Ovaprene, (iii) costs related to pre-clinical development activities of approximately $2.3 million for DARE-LARC1, which we acquired in November 2019, (iv) personnel costs of approximately $407,000, and (v) stock-based compensation expense of approximately $88,000. Those increases were partially offset by (a) an increase in grant funding recorded as a reduction to research and development expenses of approximately $2.4 million related to preclinical expenses for DARE-LARC1, (b) a decrease in costs related to development activities of approximately $393,000 for Sildenafil Cream, 3.6%, (c) a decrease in costs related to development activities of approximately $486,000 for DARE-HRT1, and (d) a decrease in costs related to pre-clinical development activities of approximately $44,000.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License fees</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September&#160;30, 2020 we accrued $58,333 of the $100,000 license maintenance fee payable in the second quarter of 2021 under our license agreement related to DARE-HRT1.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September&#160;30, 2019 the $408,333 of license expenses comprised of the $337,500 of deferred license fees due under our license agreement related to DARE-BV1, the $50,000 annual license fee paid in the second quarter of 2019 under our license agreement related to DARE-HRT1, and the accrual of $20,833 of the $50,000 annual license maintenance fee due under our agreement related to DARE-HRT1 in the second quarter of 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further discussion of these license fees, see Note 3 to our unaudited interim consolidated financial statements contained in this report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease of $84,249 in other income for the nine months ended September&#160;30, 2020 as compared to the nine months ended September&#160;30, 2019 was primarily due to a decrease in interest earned on cash balances in the current period.</span></div><div id="i868f48d3ece34cfab595a46f6986b439_91"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources and Financial Condition</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plan of Operations and Future Funding Requirements</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared the accompanying consolidated financial statements on a going concern basis, which assumes that we will realize our assets and satisfy our liabilities in the normal course of business. In addition, we have a history of losses from operations, we expect negative cash flows from our operations to continue for the foreseeable future, and we expect that our net losses will continue for at least the next several years as we develop our existing product candidates and seek to acquire, license or develop additional product candidates. These circumstances raise substantial doubt about our ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and reclassification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty of our ability to remain a going concern.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, our accumulated deficit was approximately $63.0 million, our cash and cash equivalents were approximately $5.4 million, and our working capital deficit was approximately $1.0 million. We incurred a loss from operations of approximately $19.0 million, and had negative cash flow from operations of approximately $16.0 million during the nine months ended September&#160;30, 2020. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may raise additional capital to fund our operations through the sale and issuance of additional shares of our common stock from time to time under our equity line and in "at-the-market" equity offerings (as defined in Rule 415 promulgated under the Securities Act of 1933, as amended) under our common stock sales agreement, or our ATM sales agreement. While we control the initiation of sales of our common stock under both our equity line and ATM sales agreement, our ability to sell stock is subject to limitations and restrictions on the timing and amount of such sales under both our equity line and the ATM sales agreement, as well as under applicable securities laws and Nasdaq Stock Market rules. See the discussion of our equity line and ATM sales agreement in Note 6 to our unaudited interim consolidated financial statements contained in this report. See also the risk factor titled, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our ability to raise capital may be limited by laws and regulations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1A. Risk Factors of our 2019 10-K, and the risk factor titled, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The sale of our common stock through our ATM sales agreement or our Purchase Agreement may cause substantial dilution to our existing stockholders, and such sales, or the anticipation of such sales, may cause the price of our common stock to decline, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Part II, Item 1A. Risk Factors of this report. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, due to the economic uncertainty resulting from the impact of the COVID-19 pandemic on our operations and to support our ongoing operations and retain all employees, we applied for a loan under the Paycheck Protection Program, or the PPP, of the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, administered by the U.S. Small Business Administration, or the SBA. We received a loan of approximately $367,000. The loan matures in April 2022, bears interest at a rate of 1.00% per annum, is payable in equal monthly payments commencing in November 2020 through maturity and may be prepaid at any time prior to maturity with no prepayment penalties. Under the terms of the PPP, certain amounts of the loan, including accrued interest, may be forgiven. In September 2020, we submitted our forgiveness application and we requested that the entire amount of the loan, including accrued interest, be forgiven. There can be no assurance that the loan will be forgiven, in whole or in part. Under current SBA guidance, it may take up to 90 days from the date our loan forgiveness application is submitted to the SBA by our lender for the SBA to make a determination with respect to our loan forgiveness application. For further information regarding this loan, see the discussion in Note 8 to our unaudited interim consolidated financial statements contained in this report. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash used to fund our operations comes from a variety of sources. During the nine months ended September&#160;30, 2020, we received (1) approximately $10.4 million in net proceeds from sales of shares of our common stock under our ATM sales agreement; (2) approximately $4.1&#160;million in net proceeds from sales of shares of our common stock under our equity line; (3) approximately $2.5 million under an existing grant from the Bill &amp; Melinda Gates Foundation that funded a portion of research and development expenses for DARE-LARC1; (4) approximately $1.8 million upon the exercise of warrants to purchase 1.8 million shares of our common stock; (5) a $1.0 million upfront non-refundable license fee payment under our license agreement with Bayer HealthCare, LLC, (6) approximately $650,000 under an existing grant from the National Institutes of Health that funded a portion of the Ovaprene PCT clinical study costs; and (7) approximately $367,000 in loan proceeds under the PPP. Subsequent to September&#160;30, 2020 and through November&#160;11, 2020, we received (a) approximately $4.1 million in net proceeds from sales of shares of our common stock under our ATM sales agreement; and (b) approximately $398,000 in net proceeds from sales of shares of our common stock under our equity line.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of capital are, and we expect will continue to be, staff-related expenses, the cost of clinical trials and regulatory activities related to our product candidates, costs associated with contract manufacturing services and third-party clinical research and development services, payments due under license or merger agreements upon the successful achievement of milestones of our product candidates, legal expenses, other regulatory expenses and general overhead costs.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to expect our expenses, and in particular our research and development expenses, for the year ending 2020 to be significantly greater than they were for 2019 as we continue the development of our product candidates, with a focus on DARE-BV1, Sildenafil Cream, 3.6%, Ovaprene, and DARE-HRT1, as discussed above, and as we incur license expenses associated therewith and as milestones associated therewith are achieved. We currently anticipate that, during the first half of 2021, $1.0 million in milestone payments will become payable under the merger agreement pursuant to which we acquired Microchips in November 2019.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not obtained any regulatory approvals for any of our product candidates, commercialized any of our product candidates or generated any product revenue, and we cannot anticipate if, and when we will generate any revenue. We have devoted significant resources to acquiring our portfolio of product candidates and to research and development activities for our product candidates. We must obtain regulatory approvals to sell any of our products in the future. We will need to generate sufficient safety and efficacy data on our product candidates for them to be attractive assets for potential strategic partners to license or for pharmaceutical companies to acquire, and for us to generate cash and other license fees related to such product candidates.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan estimates, we will not have sufficient cash to satisfy our working capital needs and other liquidity requirements over at least the next 12 months from the date of issuance of the accompanying interim consolidated financial statements.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to raise substantial additional capital to continue to fund our operations and to successfully execute our current operating plan, including the development of our current product candidates. We will continue to seek to raise capital through the sale of shares of our common stock under our ATM sales agreement and our equity line, however, when we can effect such sales and the amount of shares we can sell under these agreements depends on a variety of factors to be determined by us from time to time, including, among others, market conditions, the trading price of our common stock and our determination as to the appropriate sources of funding for our operations. We are also currently evaluating a variety of capital raising options, including equity and debt financings, government or other grant funding, collaborations and strategic alliances or other similar types of arrangements to cover our operating expenses, including the development and, if approved, commercialization of our product candidates and future product candidates we may license or otherwise acquire. The amount and timing of our capital needs have been and will continue to depend highly on many factors, including the product development programs we choose to pursue and the pace and results of our clinical development efforts. If we raise capital through collaborations, strategic alliances or other similar types of arrangements, we may have to relinquish, on terms that are not favorable to us, rights to some of our technologies or product candidates we would otherwise seek to develop or commercialize. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that capital will be available when needed or that, if available, it will be obtained on terms favorable to us and our stockholders, and the uncertainty and volatility in the capital markets caused by the COVID-19 pandemic may negatively impact the availability and cost of capital and investor sentiment. In addition, equity or debt financings may have a dilutive effect on the holdings of our existing stockholders. If we cannot raise capital when needed, on favorable terms or at all, we will not be able to continue development of our product candidates, will need to reevaluate our planned operations and may need to delay, scale back or eliminate some or all of our development programs, reduce expenses, file for bankruptcy, reorganize, merge with another entity, or cease operations. If we become unable to continue as a going concern, we may have to liquidate our assets, and might realize significantly less than the values at which they are carried on our financial statements, and stockholders may lose all or part of their investment in our common stock. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for the periods indicated:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:520.50pt"><tr><td style="width:1.0pt"></td><td style="width:378.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,041,176)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,506,797)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,246)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,675,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,151,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,182)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,674)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609,307&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,370,769)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net cash used in operating activities</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities for the nine months ended September&#160;30, 2020 included the net loss of $19.0 million, decreased by non-cash stock-based compensation expense of approximately $543,000. Components providing operating cash were a $472,000 increase in accounts payable, a $1.0 million increase in deferred license revenue, a $342,000 decrease in other receivables, a $355,000 increase in accrued expenses, a $159,000 increase in deferred grant funding, a $118,000 decrease in other non-current assets, and a $18,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase in prepaid expenses.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities for the nine months ended September&#160;30, 2019 included the net loss of $10.4 million, decreased by non-cash stock-based compensation expense of $344,712. A $367,409 increase in prepaid expenses and a $107,463 decrease in accounts payable reduced operating cash in this period. A $905,236 increase in accrued expenses and a $138,719 increase in other non-current assets and deferred charges provided operating cash in this period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net cash provided by financing activities </span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities for the nine months ended September&#160;30, 2020 included approximately $10.4 million of net proceeds from the sales of an aggregate of 7,916,092 shares of our common stock in "at-the-market" offerings completed during the period, approximately $1.8 million received upon the exercise of warrants to purchase 1.8 million shares of our common stock, approximately $4.1&#160;million of net proceeds from the sales of an aggregate of 3,882,160 shares of common stock under our equity line, and approximately $367,000 in loan proceeds under the PPP.</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities for the nine months ended September&#160;30, 2019 consisted of proceeds from the underwritten public offering completed in April 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net cash used in investing activities</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities for the nine months ended September&#160;30, 2020 was $15,246. No cash was provided by or used in investing activities for the nine months ended September&#160;30, 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Royalty Agreements</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have to make various royalty and milestone payments under the product license and development agreements related to DARE-BV1, Ovaprene, and Sildenafil Cream, 3.6%, and under the other agreements related to our other clinical and preclinical candidates.&#160;For further discussion of these potential payments, see Note 3 to our unaudited interim consolidated financial statements contained in this report.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Contracts</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into contracts in the normal course of business with various third parties for research studies, clinical trials, testing and other services. These contracts generally provide for termination upon notice, and we do not believe that our non-cancelable obligations under these agreements are material.</span></div><div id="i868f48d3ece34cfab595a46f6986b439_94"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC rules.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i868f48d3ece34cfab595a46f6986b439_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under SEC rules and regulations, as a smaller reporting company we are not required to provide the information required by this item.</span></div><div id="i868f48d3ece34cfab595a46f6986b439_100"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the conclusion of the quarterly period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) were effective as of September&#160;30, 2020 at the reasonable assurance level.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the fiscal quarter to which this report relates that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i868f48d3ece34cfab595a46f6986b439_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i868f48d3ece34cfab595a46f6986b439_106"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-bottom:10pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in various claims and legal proceedings. Regardless of outcome, litigation and other legal and administrative proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. There are no material pending legal proceedings, other than ordinary routine litigation incidental to our business, to which we are a party or of which any of our property is in the subject.</span></div><div id="i868f48d3ece34cfab595a46f6986b439_109"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An investment in shares of our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described in our 2019 10-K, in addition to other information in this report, before investing in our common stock. The occurrence of any of these risks could have a material adverse effect on our business, financial condition, results of operations and growth prospects. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment. There have been no material changes from the risk factors disclosed in Part I, Item 1A. Risk Factors in our 2019 10-K other than as described below:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 pandemic and efforts to reduce the spread of COVID-19 could negatively impact our business, including by increasing the cost and timelines for our clinical development programs.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and efforts to reduce the spread of COVID-19 remain a rapidly evolving and uncertain risk to our business, operating results, financial condition and stock price. In large part, the extent to which the pandemic affects us will depend on future developments that are beyond our knowledge or control, including, but not limited to, the duration and severity of the pandemic, governmental and individual organization actions and policies implemented to reduce transmission of the disease, and the speed with which and degree to which normal economic and operating conditions resume.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The longer the pandemic persists, the greater the potential for significant adverse impact to our business operations and those of the contract research organizations (CROs), contract manufacturing organizations (CMOs) and other third-party consultants and vendors on which we depend to, among other things, conduct our clinical and nonclinical studies, supply our clinical trial materials, and assist with regulatory affairs necessary to advance our programs. Employee and family member illness, increased childcare and elder care responsibilities, and quarantines, travel restrictions, prohibitions on non-essential gatherings, shelter-in-place orders and other similar directives and policies intended to reduce the spread of the disease, may reduce our productivity and that of the third parties on which we rely and may disrupt and delay many aspects of our business, including research and development activities and production and supply of clinical trial materials. As a result of resource constraints, third parties on which we rely may not meet their contractual obligations to us or may allocate constrained resources to projects other than ours, any of which could significantly increase the cost and timelines for our development programs. In addition, the increase in personnel working remotely, both ours and those of the third parties on which we rely, could increase our cybersecurity risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could significantly adversely impact our business operations or significantly delay necessary interactions with the FDA and other regulatory agencies, our CROs and CMOs, clinical trial sites, current and potential collaborators, and other third parties. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pandemic could cause delays in current timelines for our planned clinical studies. As of the date of this report, we expect to report topline data for the Phase 3 study of DARE-BV1 by year-end 2020, and we expect to commence, or continue to conduct, clinical studies such that we can report topline data for the Phase 1 study of DARE-HRT1 and the Phase 2b study of Sildenafil Cream, 3.6% in 2021, and for the pivotal study of Ovaprene in 2022. However, the pandemic may adversely impact these expectations. For example, clinical site initiation and/or patient enrollment may be significantly delayed or suspended as a result of personnel and other resource constraints of healthcare providers, as well as adherence to governmental orders and internal policies intended to reduce the spread of COVID-19. In addition, we may experience lower than anticipated subject enrollment and completion rates, including because individuals may avoid medical settings, particularly for non-critical conditions, due to concerns of contracting COVID-19 or due to shelter-in-place and social distancing orders. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the pandemic has resulted in disruption and volatility in the global capital markets, and while the longer-term economic impact is difficult to assess and predict at this time, it could negatively impact our ability to access additional capital when needed or on terms favorable to us and our stockholders. We currently do not have adequate capital to complete all of our planned clinical studies on our current timelines. If we cannot raise capital when needed, on favorable terms or at all, we will not be able to continue development of our product candidates as currently planned or at all, will need to reevaluate our planned operations and may need to delay, scale back or eliminate some or all of our development programs, reduce expenses or cease operations, any of which could have a significant negative impact on our prospects and financial condition, as well as the trading price of our common stock.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, a key aspect of our business strategy is to seek collaborations with partners, such as large pharmaceutical companies, that are willing to conduct later-stage clinical trials and further develop and commercialize our product candidates. As a result of the pandemic, potential and current partners may experience operational disruptions and financial and other resource constraints and implement new strategic plans that delay or reduce their efforts in the women&#8217;s health in general or in our programs in particular, which could adversely affect our ability to enter into or maintain collaborations, strategic alliances or other similar types of arrangements and may result in or contribute to disruption and delays in later-stage clinical development and, if approved, commercial launch of our product candidates. We do not have, and do not currently plan to develop, the internal sales, marketing and distribution infrastructure necessary to independently market and sell our product candidates, if approved. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help mitigate the impact of the pandemic on our business, we developed a plan with our third-party service providers designed to address the challenges and risks presented by the pandemic on our ongoing clinical trials, and we developed a plan designed to protect the safety, health and well-being of our employees while maintaining employee productivity. However, there can be no assurance that such plans will be effective in mitigating the potential adverse effects of the pandemic on our ongoing clinical trials, on the productivity of our employees or on our business, financial condition and results of operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the pandemic and efforts to reduce its spread impacts our business, financial condition and results of operations is uncertain and cannot be predicted with reasonable accuracy at this time and will depend on future developments that are also uncertain and cannot be predicted with reasonable accuracy at this time, including new information that may emerge concerning the degree to which COVID-19 is contagious and virulent, the effect of actions taken in the United States and other countries to contain and treat COVID-19, and further actions implemented to contain and treat the disease and its impact, among others. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pandemic may also have the effect of heightening many of the other risks and uncertainties described the &#8220;Risk Factors&#8221; section of our 2019 10-K. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cyber-attacks, security breaches, loss of data and other disruptions to our information technology systems or those of our third-party service providers could compromise sensitive information related to our business, delay or prevent us from accessing critical information or expose us to liability, any of which could adversely affect our business and our reputation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize information technology systems and networks to process, transmit and store electronic information in connection with our business activities. As the use of digital technologies has increased, cyber incidents, including deliberate attacks, the deployment of harmful malware or ransomware, denial of service, and attempts to gain unauthorized access to computer systems and networks, have increased in frequency and sophistication. These threats pose a risk to the security of our systems and networks and those of our third-party service providers, and could compromise the confidentiality, availability and integrity of our data, confidential information, or other intellectual property, all of which are vital to our operations and business strategy. There can be no assurance we will succeed in preventing cyber-attacks or successfully mitigate their effects.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite implementing security measures, any of the internal computer systems belonging to us or our third-party service providers are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war, and telecommunication and electrical failure. Moreover, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches. Any system failure, accident, security breach or data breach that causes interruptions in our own or in third-party service vendors&#8217; operations could result in a material disruption of our product development programs. For example, losing clinical study data from future clinical studies could result in delays in our or our partners&#8217; regulatory approval efforts and significantly increase our costs in order to recover or reproduce the lost data. In addition, a security breach or privacy violation that leads to disclosure of personally identifiable information or protected health information could harm our reputation, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, require us to verify the correctness of database contents and subject us to litigation or other liability under laws and regulations that protect personal data. Further, our information technology and other internal infrastructure systems, including firewalls, servers, leased lines and connection to the Internet, face the risk of systemic failure, which could disrupt our operations. If any disruption or security breach results in a loss or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we may incur resulting liability, our product development programs and competitive position may be adversely affected, and the further development of our products may be delayed. Furthermore, we may incur additional costs to remedy the damage caused by these disruptions or security breaches.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Clinical Development, Manufacturing and Commercialization</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data, and others, including regulatory authorities, may not agree with our interpretation of study data.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose interim, preliminary or topline data from our clinical studies, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analysis of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. There can be no guarantee that a favorable futility analysis will result in a favorable final result at the completion of the clinical trial.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, others, including regulatory authorities, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of study data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, drug candidate or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition. For example, even if we report positive topline data for the DARE-BVFREE study, FDA may still require the conduct of additional efficacy or safety trials before it will accept a DARE-BV1 NDA for filing or approve the NDA.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The sale of our common stock through our ATM sales agreement or our Purchase Agreement may cause substantial dilution to our existing stockholders, and such sales, or the anticipation of such sales, may cause the price of our common stock to decline.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, we entered into the ATM sales agreement , under which, from time to time, we may offer and sell shares of our common stock. In April 2020, we entered into the Purchase Agreement with Lincoln Park. The purchase price for the shares we may sell under our Purchase Agreement will vary based the market price of our common stock at the time we initiate a sale. Although we have the right to control whether we sell any shares, if at all, under these agreements, and we generally have the right to control the timing and amount of any such sales, we are subject to certain restrictions, including those that limit the number of shares we may sell. For example, based on our current public float, during any 12-month period, we may not sell securities under our shelf registration statement pursuant to General Instruction I.B.6 to Form S-3 having an aggregate market value of more than one-third of our public float, which limits the amount of shares we can sell under the ATM sales agreement. In addition, with respect to the Purchase Agreement, we may not sell more than 4,941,089 shares to Lincoln Park, which we refer to as the Exchange Cap, unless we obtain stockholder approval to issue shares in excess of the Exchange Cap or the average price per share of all sales to Lincoln Park equals or exceeds $1.0117, and we may not sell shares to Lincoln Park if it would result in Lincoln Park beneficially owning more than 9.99% of our then outstanding shares of common stock. Accordingly, we may not be able to utilize the ATM sales agreement or the Purchase Agreement to raise additional capital when, or in the amounts, we desire. However, to the extent we do sell shares of our common stock under these agreements, such sales may result in substantial dilution to our existing stockholders, and such sales, or the anticipation of such sales, may cause the trading price of our common stock to decline.</span></div><div id="i868f48d3ece34cfab595a46f6986b439_112"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">None.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">None.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">None.</span></div><div id="i868f48d3ece34cfab595a46f6986b439_115"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i868f48d3ece34cfab595a46f6986b439_118"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i868f48d3ece34cfab595a46f6986b439_121"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;None.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i868f48d3ece34cfab595a46f6986b439_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.248%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.283%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Incorporated by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Exhibit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">File No.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit No.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Filed Herewith</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit31120200930-ngv.htm">Certification of principal executive officer pursuant to Rule&#160;13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit31220200930-ngv.htm">Certification of principal financial officer pursuant to Rule&#160;13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit32120200930-ngv.htm">Certification of principal executive officer pursuant to 18&#160;U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit32220200930-ngv.htm">Certification of principal financial officer pursuant to 18&#160;U.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit32220200930-ngv.htm">Certification of principal financial officer pursuant to 18&#160;U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Instance Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Label Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith. This certification is being furnished solely to accompany this report pursuant to U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated herein by reference into any filing of the registrant whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></td></tr></table></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i868f48d3ece34cfab595a46f6986b439_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:45.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.966%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dar&#233; Bioscience, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 12, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Sabrina Martucci Johnson</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sabrina Martucci Johnson</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 12, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Lisa Walters-Hoffert</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lisa Walters-Hoffert</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit31120200930-ngv.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i11526220c9ba4324857ef4dba4ca324e_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1 </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Sabrina Martucci Johnson, certify that&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Quarterly Report on Form 10-Q of Dar&#233; Bioscience, Inc.&#59;</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;  November&#160;12, 2020 </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:39.150%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sabrina Martucci Johnson</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sabrina Martucci Johnson</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal executive officer)</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit31220200930-ngv.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i982c26e2dbba4b13a751de4a85ed7841_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2 </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Lisa Walters-Hoffert, certify that&#58; </font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Quarterly Report on Form 10-Q of Dar&#233; Bioscience, Inc.&#59;</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.270%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;12, 2020 </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:39.150%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Lisa Walters-Hoffert</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lisa Walters-Hoffert</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial officer)</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit32120200930-ngv.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="if9327e4e8565414db7a662f780964fba_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Dar&#233; Bioscience, Inc. (the &#8220;Company&#8221;) for the fiscal quarter ended September&#160;30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Sabrina Martucci Johnson, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that, to her knowledge on the date hereof&#58; </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;12, 2020 </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:39.903%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sabrina Martucci Johnson</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sabrina Martucci Johnson</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal executive officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit32220200930-ngv.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i12a265765ea8476faa2345362ea77299_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Dar&#233; Bioscience, Inc. (the &#8220;Company&#8221;) for the fiscal quarter ended September&#160;30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Lisa Walters-Hoffert, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that, to her knowledge on the date hereof&#58; </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;12, 2020 </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:39.903%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Lisa Walters-Hoffert</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lisa Walters-Hoffert</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>dare-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:9ad61a15-e285-44cc-ad2a-44a040d7fb22,g:5f0dd9b0-b13f-4c69-b05c-880a09202ba6-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dare="http://darebioscience.com/20200930" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://darebioscience.com/20200930">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dare-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dare-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dare-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dare-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://darebioscience.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://darebioscience.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1004005 - Statement - Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://darebioscience.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionoftheBusiness" roleURI="http://darebioscience.com/role/OrganizationandDescriptionoftheBusiness">
        <link:definition>2101101 - Disclosure - Organization and Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionoftheBusinessAdditionalInformationDetails" roleURI="http://darebioscience.com/role/OrganizationandDescriptionoftheBusinessAdditionalInformationDetails">
        <link:definition>2402401 - Disclosure - Organization and Description of the Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://darebioscience.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails" roleURI="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Financial Assets and Liabilities Remeasured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreements" roleURI="http://darebioscience.com/role/LicenseandCollaborationAgreements">
        <link:definition>2108103 - Disclosure - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsAdditionalInformationDetails" roleURI="http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails">
        <link:definition>2409404 - Disclosure - License and Collaboration Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisition" roleURI="http://darebioscience.com/role/Acquisition">
        <link:definition>2110104 - Disclosure - Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionNarrativeDetails" roleURI="http://darebioscience.com/role/AcquisitionNarrativeDetails">
        <link:definition>2411405 - Disclosure - Acquisition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://darebioscience.com/role/StockBasedCompensation">
        <link:definition>2112105 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://darebioscience.com/role/StockBasedCompensationTables">
        <link:definition>2313302 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>2414406 - Disclosure - Stock Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails" roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails">
        <link:definition>2415407 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails" roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails">
        <link:definition>2416408 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails" roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails">
        <link:definition>2417409 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://darebioscience.com/role/StockholdersEquity">
        <link:definition>2118106 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://darebioscience.com/role/StockholdersEquityTables">
        <link:definition>2319303 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetails" roleURI="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails">
        <link:definition>2420410 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails" roleURI="http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails">
        <link:definition>2421411 - Disclosure - Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasedProperties" roleURI="http://darebioscience.com/role/LeasedProperties">
        <link:definition>2122107 - Disclosure - Leased Properties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasedPropertiesTables" roleURI="http://darebioscience.com/role/LeasedPropertiesTables">
        <link:definition>2323304 - Disclosure - Leased Properties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasedPropertiesAdditionalInformationDetails" roleURI="http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails">
        <link:definition>2424412 - Disclosure - Leased Properties - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasedPropertiesFutureMinimumLeasePaymentsDetails" roleURI="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails">
        <link:definition>2425413 - Disclosure - Leased Properties - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasedPropertiesFutureMinimumLeasePaymentsDetails_1" roleURI="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1">
        <link:definition>2425413 - Disclosure - Leased Properties - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://darebioscience.com/role/CommitmentsandContingencies">
        <link:definition>2126108 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://darebioscience.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2427414 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantAward" roleURI="http://darebioscience.com/role/GrantAward">
        <link:definition>2128109 - Disclosure - Grant Award</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantAwardNarrativeDetails" roleURI="http://darebioscience.com/role/GrantAwardNarrativeDetails">
        <link:definition>2429415 - Disclosure - Grant Award - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://darebioscience.com/role/NetLossPerShare">
        <link:definition>2130110 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://darebioscience.com/role/NetLossPerShareTables">
        <link:definition>2331305 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails" roleURI="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails">
        <link:definition>2432416 - Disclosure - Net Loss Per Share - Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://darebioscience.com/role/SubsequentEvents">
        <link:definition>2133111 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://darebioscience.com/role/SubsequentEventsDetails">
        <link:definition>2434417 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="dare_StockholdersEquityTable" abstract="true" name="StockholdersEquityTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" abstract="false" name="NetProceedsFromIssuanceOfCommonStockAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" abstract="false" name="PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="dare_NotesPayableCurrentPlusAccruedInterest" abstract="false" name="NotesPayableCurrentPlusAccruedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_HammockPharmaceuticalsInc.Member" abstract="true" name="HammockPharmaceuticalsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_RegularPurchaseCommonStockIssuableMaximumAmount" abstract="false" name="RegularPurchaseCommonStockIssuableMaximumAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure" abstract="false" name="LicenseAgreementTerminationPeriodDueToPerformanceFailure" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dare_AssetAcquisitionContingentConsiderationCurrent" abstract="false" name="AssetAcquisitionContingentConsiderationCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod" abstract="false" name="UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dare_UpfrontLicenseFeePaid" abstract="false" name="UpfrontLicenseFeePaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_NationalInstitutesOfHealthMember" abstract="true" name="NationalInstitutesOfHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares" abstract="false" name="StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_MaximumPotentialMilestonePayments" abstract="false" name="MaximumPotentialMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_PrivateDareMember" abstract="true" name="PrivateDareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_GrantOvapreneMember" abstract="true" name="GrantOvapreneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_IncreaseDecreaseInDeferredGrantFunding" abstract="false" name="IncreaseDecreaseInDeferredGrantFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_JuniperPharmaceuticalsInc.Member" abstract="true" name="JuniperPharmaceuticalsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_SalesMilestonesMember" abstract="true" name="SalesMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_AtTheMarketSalesAgreementMember" abstract="true" name="AtTheMarketSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" abstract="false" name="IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_CommencementPeriodForStageTwoUponAchievementOfStageOne" abstract="false" name="CommencementPeriodForStageTwoUponAchievementOfStageOne" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dare_WeightedAverageAmortizationPeriod" abstract="false" name="WeightedAverageAmortizationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dare_BusinessCombinationReverseMergerLineItems" abstract="true" name="BusinessCombinationReverseMergerLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dare_AdarePharmaceuticalsMember" abstract="true" name="AdarePharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_MilestonePaymentsContingentAmount" abstract="false" name="MilestonePaymentsContingentAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" abstract="false" name="PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_UnderwritersOptionToPurchaseAdditionalShares" abstract="false" name="UnderwritersOptionToPurchaseAdditionalShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember" abstract="true" name="UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_PercentageOfRoyaltyRate" abstract="false" name="PercentageOfRoyaltyRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="dare_TwoThousandAndFifteenStockIncentivePlanMember" abstract="true" name="TwoThousandAndFifteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_AssignmentAgreementMember" abstract="true" name="AssignmentAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember" abstract="true" name="UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_BillAndMelindaGatesFoundationMember" abstract="true" name="BillAndMelindaGatesFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_ReceivableForExpensesEligibleForReimbursement" abstract="false" name="ReceivableForExpensesEligibleForReimbursement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_LicenseAndCollaborationAgreementMember" abstract="true" name="LicenseAndCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_CommonStockExchangeCap" abstract="false" name="CommonStockExchangeCap" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dare_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" abstract="true" name="UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_GrantAwardTextBlock" abstract="false" name="GrantAwardTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandAndFourteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived" abstract="false" name="CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_LincolnParkMember" abstract="true" name="LincolnParkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_PeriodofInsufficientCashandLiquidityRequirements" abstract="false" name="PeriodofInsufficientCashandLiquidityRequirements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct" abstract="false" name="LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dare_AdditionalPotentialFundingRelatedToGrantAward" abstract="false" name="AdditionalPotentialFundingRelatedToGrantAward" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" abstract="true" name="WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_CommonStockExchangeCapPercentage" abstract="false" name="CommonStockExchangeCapPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="dare_LicenseFeeToBePaidUponContingency" abstract="false" name="LicenseFeeToBePaidUponContingency" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_UponSigningOfDevelopmentAndOptionAgreementMember" abstract="true" name="UponSigningOfDevelopmentAndOptionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_PercentageOfAggregateCommission" abstract="false" name="PercentageOfAggregateCommission" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="dare_ResearchAndDevelopmentMilestonePayment" abstract="false" name="ResearchAndDevelopmentMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_GrantDAREFRT1Member" abstract="true" name="GrantDAREFRT1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_UponAchievingCertainCommercialMilestonesMember" abstract="true" name="UponAchievingCertainCommercialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_EstimatedFairValueOfWarrantsRecordedInEquity" abstract="false" name="EstimatedFairValueOfWarrantsRecordedInEquity" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" abstract="true" name="WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_SaleofStockMaximumAmountRegistered" abstract="false" name="SaleofStockMaximumAmountRegistered" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dare_GrossProceedsFromOfferingOfCommonStockAndWarrants" abstract="false" name="GrossProceedsFromOfferingOfCommonStockAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dare_IssuanceCostOnEquityPaidInCommonStock" abstract="false" name="IssuanceCostOnEquityPaidInCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" abstract="true" name="StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_MilestonePayments" abstract="false" name="MilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_ClinicalAndRegulatoryMilestonesMember" abstract="true" name="ClinicalAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember" abstract="true" name="WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_ScheduleOfBusinessCombinationReverseMergerTable" abstract="true" name="ScheduleOfBusinessCombinationReverseMergerTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" abstract="false" name="BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_SignificantAccountingPoliciesLineItems" abstract="true" name="SignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="dare_LicenseAgreementNoticePeriodOfTermination" abstract="false" name="LicenseAgreementNoticePeriodOfTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dare_OfferingExpenses" abstract="false" name="OfferingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_ClassOfWarrantOrRightsWarrantsExpirationDate" abstract="false" name="ClassOfWarrantOrRightsWarrantsExpirationDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:dateItemType"/>
  <xs:element id="dare_DevelopmentAndOptionAgreementMember" abstract="true" name="DevelopmentAndOptionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_DeferredGrantFundingCurrent" abstract="false" name="DeferredGrantFundingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_AtTheMarketEquityOfferingsMember" abstract="true" name="AtTheMarketEquityOfferingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_ADVATecAgreementMember" abstract="true" name="ADVATecAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_MicrochipsBiotechInc.Member" abstract="true" name="MicrochipsBiotechInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_AssetAcquisitionContingentConsiderationNoncurrent" abstract="false" name="AssetAcquisitionContingentConsiderationNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_NumberOfCommonStockWarrantsExercised" abstract="false" name="NumberOfCommonStockWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember" abstract="true" name="AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_PublicStockOfferingMember" abstract="true" name="PublicStockOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" abstract="true" name="UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_PurchaseAgreementMember" abstract="true" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_UponReachingCertainWorldwideNetSalesMilestonesMember" abstract="true" name="UponReachingCertainWorldwideNetSalesMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_LicenseFee" abstract="false" name="LicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_UponAchievingCertainDevelopmentMilestonesMember" abstract="true" name="UponAchievingCertainDevelopmentMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_MilanaPharmMember" abstract="true" name="MilanaPharmMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_NonCashLeaseExpense" abstract="false" name="NonCashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_ProceedsFromAwardOfGrant" abstract="false" name="ProceedsFromAwardOfGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_ProceedsFromIssuanceOfCommonStockAndWarrants" abstract="false" name="ProceedsFromIssuanceOfCommonStockAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_DeferredOfferingCostsUnamortizedPortion" abstract="false" name="DeferredOfferingCostsUnamortizedPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dare_RegularRepurchaseCommonStockIssuable" abstract="false" name="RegularRepurchaseCommonStockIssuable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember" abstract="true" name="WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_StockholdersEquityLineItems" abstract="true" name="StockholdersEquityLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dare_BayerHealthcareLicenseAgreementMember" abstract="true" name="BayerHealthcareLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="dare_SignificantAccountingPoliciesTable" abstract="true" name="SignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dare_StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares" abstract="false" name="StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dare_RegularPurchaseCommonStockIssuableIncreaseAmount" abstract="false" name="RegularPurchaseCommonStockIssuableIncreaseAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" abstract="false" name="PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>dare-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:9ad61a15-e285-44cc-ad2a-44a040d7fb22,g:5f0dd9b0-b13f-4c69-b05c-880a09202ba6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://darebioscience.com/role/CoverPage" xlink:type="simple" xlink:href="dare-20200930.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="dare-20200930.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8d926af7-4bb9-4ede-9518-df954111b93f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a9790ec2-6804-4b8c-a6e6-0e0487d25e86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8d926af7-4bb9-4ede-9518-df954111b93f" xlink:to="loc_us-gaap_PreferredStockValue_a9790ec2-6804-4b8c-a6e6-0e0487d25e86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6f2d440d-3fa9-49c9-8dac-9a6c713dbe45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8d926af7-4bb9-4ede-9518-df954111b93f" xlink:to="loc_us-gaap_CommonStockValue_6f2d440d-3fa9-49c9-8dac-9a6c713dbe45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_397f4ca5-9b68-41fc-b7e9-2196cae359ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8d926af7-4bb9-4ede-9518-df954111b93f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_397f4ca5-9b68-41fc-b7e9-2196cae359ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_30c7741f-4376-4823-92db-af1156c0856b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8d926af7-4bb9-4ede-9518-df954111b93f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_30c7741f-4376-4823-92db-af1156c0856b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_58589fcd-4718-4511-8808-e5641fc17000" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8d926af7-4bb9-4ede-9518-df954111b93f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_58589fcd-4718-4511-8808-e5641fc17000" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_afce41ea-c717-4208-bb23-dd9d3145151d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2d2563f6-8684-4251-91f1-55b9812af946" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_afce41ea-c717-4208-bb23-dd9d3145151d" xlink:to="loc_us-gaap_AssetsCurrent_2d2563f6-8684-4251-91f1-55b9812af946" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1cbbab3f-8b85-4859-9f52-7931eebcb2b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_afce41ea-c717-4208-bb23-dd9d3145151d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1cbbab3f-8b85-4859-9f52-7931eebcb2b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_084bb2f1-40c5-47eb-862c-960d8ea7a702" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_afce41ea-c717-4208-bb23-dd9d3145151d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_084bb2f1-40c5-47eb-862c-960d8ea7a702" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8dd7edec-74c7-4c80-a5ed-ee7e4ddd07dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_e642f795-03f5-4ac0-9691-fc6387d37f0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8dd7edec-74c7-4c80-a5ed-ee7e4ddd07dc" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_e642f795-03f5-4ac0-9691-fc6387d37f0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_229972dd-bb64-4b0d-a196-9bff4130f435" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8dd7edec-74c7-4c80-a5ed-ee7e4ddd07dc" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_229972dd-bb64-4b0d-a196-9bff4130f435" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c36a64f0-0ffc-4eb1-9b2f-ff91f4a1e105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8dd7edec-74c7-4c80-a5ed-ee7e4ddd07dc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c36a64f0-0ffc-4eb1-9b2f-ff91f4a1e105" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f7b7157b-2e32-4d5a-a60f-0160c9b97ef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b1f14890-43b1-4d62-9171-fe2213ffb7f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f7b7157b-2e32-4d5a-a60f-0160c9b97ef2" xlink:to="loc_us-gaap_Liabilities_b1f14890-43b1-4d62-9171-fe2213ffb7f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_be051ee0-a24d-4555-a179-c9e9a9c8541a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f7b7157b-2e32-4d5a-a60f-0160c9b97ef2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_be051ee0-a24d-4555-a179-c9e9a9c8541a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_07accff3-224b-4eb0-bf13-0358d7482393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f7b7157b-2e32-4d5a-a60f-0160c9b97ef2" xlink:to="loc_us-gaap_StockholdersEquity_07accff3-224b-4eb0-bf13-0358d7482393" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ddfebc9a-55c3-4b55-9430-b73ed660ae98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4b616833-8ac2-4669-911a-3b8e78fe23aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ddfebc9a-55c3-4b55-9430-b73ed660ae98" xlink:to="loc_us-gaap_AccountsPayableCurrent_4b616833-8ac2-4669-911a-3b8e78fe23aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4db274e6-a4a6-4606-bd77-da0619e8f1ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ddfebc9a-55c3-4b55-9430-b73ed660ae98" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4db274e6-a4a6-4606-bd77-da0619e8f1ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeferredGrantFundingCurrent_e97cd7de-30ea-4a88-8b83-71bdcff77e13" xlink:href="dare-20200930.xsd#dare_DeferredGrantFundingCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ddfebc9a-55c3-4b55-9430-b73ed660ae98" xlink:to="loc_dare_DeferredGrantFundingCurrent_e97cd7de-30ea-4a88-8b83-71bdcff77e13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b4548ea9-b5a4-4d4e-991d-eb854def8ec8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ddfebc9a-55c3-4b55-9430-b73ed660ae98" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b4548ea9-b5a4-4d4e-991d-eb854def8ec8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_44bcdb55-9294-465d-93e9-3bc3ef4191e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ddfebc9a-55c3-4b55-9430-b73ed660ae98" xlink:to="loc_us-gaap_NotesPayableCurrent_44bcdb55-9294-465d-93e9-3bc3ef4191e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2c4791c3-91e3-4b34-aa60-6dc67e1f5698" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ddfebc9a-55c3-4b55-9430-b73ed660ae98" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2c4791c3-91e3-4b34-aa60-6dc67e1f5698" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_51a32ab9-1c0c-48f2-b62f-7b26598c5f8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5a6dbd79-8f92-4c86-9cae-af0e4cbe9497" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_51a32ab9-1c0c-48f2-b62f-7b26598c5f8b" xlink:to="loc_us-gaap_LiabilitiesCurrent_5a6dbd79-8f92-4c86-9cae-af0e4cbe9497" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_fa918b8d-61e2-4054-8af3-cff903850051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_51a32ab9-1c0c-48f2-b62f-7b26598c5f8b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_fa918b8d-61e2-4054-8af3-cff903850051" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_412c0419-b123-4302-9406-58dbb273a12d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_51a32ab9-1c0c-48f2-b62f-7b26598c5f8b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_412c0419-b123-4302-9406-58dbb273a12d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_637cd91d-c577-4c48-9768-5be47355ae23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_51a32ab9-1c0c-48f2-b62f-7b26598c5f8b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_637cd91d-c577-4c48-9768-5be47355ae23" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="dare-20200930.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="dare-20200930.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2b908e72-7f1f-4063-9a1b-3462b7471ebe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_43427572-7fc5-4b8e-80b7-7609d4c38e76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2b908e72-7f1f-4063-9a1b-3462b7471ebe" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_43427572-7fc5-4b8e-80b7-7609d4c38e76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f960f87f-cc9f-4d0d-8ee1-87fcc0652d03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2b908e72-7f1f-4063-9a1b-3462b7471ebe" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f960f87f-cc9f-4d0d-8ee1-87fcc0652d03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a253500d-e821-4bb8-a470-ad1283346ff0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_698cae8f-75f2-4dd1-b26b-63760cfe9dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a253500d-e821-4bb8-a470-ad1283346ff0" xlink:to="loc_us-gaap_OperatingIncomeLoss_698cae8f-75f2-4dd1-b26b-63760cfe9dc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ef441f49-b018-4686-911d-08389d9ca448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a253500d-e821-4bb8-a470-ad1283346ff0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ef441f49-b018-4686-911d-08389d9ca448" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_09d77682-6427-4c9a-a561-529c81dcfb44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_27177e38-5f76-4dd2-90c2-77086dc9a7dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_09d77682-6427-4c9a-a561-529c81dcfb44" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_27177e38-5f76-4dd2-90c2-77086dc9a7dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_92e5faa6-f0e8-446b-a992-fe2b9a397da3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_09d77682-6427-4c9a-a561-529c81dcfb44" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_92e5faa6-f0e8-446b-a992-fe2b9a397da3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseFee_c2daa3e2-111e-4cdd-a771-93204aaec19f" xlink:href="dare-20200930.xsd#dare_LicenseFee"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_09d77682-6427-4c9a-a561-529c81dcfb44" xlink:to="loc_dare_LicenseFee_c2daa3e2-111e-4cdd-a771-93204aaec19f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1853eae7-8404-48bd-8713-6f2d8229d441" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0ef9ca33-b862-4742-9714-5d2ad0bd5da0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1853eae7-8404-48bd-8713-6f2d8229d441" xlink:to="loc_us-gaap_OperatingExpenses_0ef9ca33-b862-4742-9714-5d2ad0bd5da0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7663afbc-d9e6-4e7c-b5e2-0b4291f098b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_93365b47-84f0-40b8-a592-037c4f277e00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7663afbc-d9e6-4e7c-b5e2-0b4291f098b9" xlink:to="loc_us-gaap_NetIncomeLoss_93365b47-84f0-40b8-a592-037c4f277e00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_b65dc941-7d72-49bf-ae08-acf116b9eec3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7663afbc-d9e6-4e7c-b5e2-0b4291f098b9" xlink:to="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_b65dc941-7d72-49bf-ae08-acf116b9eec3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="dare-20200930.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="dare-20200930.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d4467436-d2e0-466a-871e-039c192894bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_489d5527-5776-4193-8cd2-2d46e81fc0eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d4467436-d2e0-466a-871e-039c192894bc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_489d5527-5776-4193-8cd2-2d46e81fc0eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c1989795-bb85-4600-81e8-2ba19f235d11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d4467436-d2e0-466a-871e-039c192894bc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c1989795-bb85-4600-81e8-2ba19f235d11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_6fd4ba47-6886-495b-9998-a6e2dbe39862" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d4467436-d2e0-466a-871e-039c192894bc" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_6fd4ba47-6886-495b-9998-a6e2dbe39862" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_25024e36-eba2-4999-aac1-b9bfc77d8919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d4467436-d2e0-466a-871e-039c192894bc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_25024e36-eba2-4999-aac1-b9bfc77d8919" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7806c5d5-0cf1-40aa-85d8-a1af4a591d70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_00725285-f638-44ba-b19d-c7050c239152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7806c5d5-0cf1-40aa-85d8-a1af4a591d70" xlink:to="loc_us-gaap_ProfitLoss_00725285-f638-44ba-b19d-c7050c239152" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_cd339094-b467-4270-b9e3-b3c4dc395047" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7806c5d5-0cf1-40aa-85d8-a1af4a591d70" xlink:to="loc_us-gaap_Depreciation_cd339094-b467-4270-b9e3-b3c4dc395047" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bc40d73f-8aad-4f28-8da5-f2010d515a19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7806c5d5-0cf1-40aa-85d8-a1af4a591d70" xlink:to="loc_us-gaap_ShareBasedCompensation_bc40d73f-8aad-4f28-8da5-f2010d515a19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_11f1aea3-0349-4270-b70c-6f658bb15aab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7806c5d5-0cf1-40aa-85d8-a1af4a591d70" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_11f1aea3-0349-4270-b70c-6f658bb15aab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_be1d5ea7-ee04-4a6e-b247-5765326fcd8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7806c5d5-0cf1-40aa-85d8-a1af4a591d70" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_be1d5ea7-ee04-4a6e-b247-5765326fcd8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_5b0d5cbd-2252-428f-90d9-b0dfe803e9b9" xlink:href="dare-20200930.xsd#dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7806c5d5-0cf1-40aa-85d8-a1af4a591d70" xlink:to="loc_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_5b0d5cbd-2252-428f-90d9-b0dfe803e9b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_be1ddbbb-4623-4cc9-8ef9-d8e995c8022e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7806c5d5-0cf1-40aa-85d8-a1af4a591d70" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_be1ddbbb-4623-4cc9-8ef9-d8e995c8022e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1587faa5-5428-486b-8539-714b36119490" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7806c5d5-0cf1-40aa-85d8-a1af4a591d70" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1587faa5-5428-486b-8539-714b36119490" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0eeb78f6-df85-45d8-a373-e1ecf5a7affa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7806c5d5-0cf1-40aa-85d8-a1af4a591d70" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0eeb78f6-df85-45d8-a373-e1ecf5a7affa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NonCashLeaseExpense_629bc128-8ad5-44f2-b8c8-ebbde04c90dc" xlink:href="dare-20200930.xsd#dare_NonCashLeaseExpense"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7806c5d5-0cf1-40aa-85d8-a1af4a591d70" xlink:to="loc_dare_NonCashLeaseExpense_629bc128-8ad5-44f2-b8c8-ebbde04c90dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_IncreaseDecreaseInDeferredGrantFunding_7e646ad8-63e0-41e4-9d72-ad91cafbb909" xlink:href="dare-20200930.xsd#dare_IncreaseDecreaseInDeferredGrantFunding"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7806c5d5-0cf1-40aa-85d8-a1af4a591d70" xlink:to="loc_dare_IncreaseDecreaseInDeferredGrantFunding_7e646ad8-63e0-41e4-9d72-ad91cafbb909" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5f96120e-f72c-4873-8747-03f93bd403da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6e71a503-1285-4500-a353-21d74e575b28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5f96120e-f72c-4873-8747-03f93bd403da" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6e71a503-1285-4500-a353-21d74e575b28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_07057606-d236-42ec-b65a-97a64e2555ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_fb7f4452-f675-4f1e-8096-e4e69fdd2190" xlink:href="dare-20200930.xsd#dare_NetProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_07057606-d236-42ec-b65a-97a64e2555ae" xlink:to="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_fb7f4452-f675-4f1e-8096-e4e69fdd2190" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_b2ee9c14-98d3-417a-9597-d5f81445d8f2" xlink:href="dare-20200930.xsd#dare_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_07057606-d236-42ec-b65a-97a64e2555ae" xlink:to="loc_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_b2ee9c14-98d3-417a-9597-d5f81445d8f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_ec5fc85e-b849-46df-ab6c-d47d4d8d1b95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_07057606-d236-42ec-b65a-97a64e2555ae" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_ec5fc85e-b849-46df-ab6c-d47d4d8d1b95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_04ee00c3-fbae-4f7b-9b95-d04fce379ea8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_07057606-d236-42ec-b65a-97a64e2555ae" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_04ee00c3-fbae-4f7b-9b95-d04fce379ea8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/OrganizationandDescriptionoftheBusiness" xlink:type="simple" xlink:href="dare-20200930.xsd#OrganizationandDescriptionoftheBusiness"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/OrganizationandDescriptionoftheBusiness" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/OrganizationandDescriptionoftheBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#OrganizationandDescriptionoftheBusinessAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/OrganizationandDescriptionoftheBusinessAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="dare-20200930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="dare-20200930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="dare-20200930.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="dare-20200930.xsd#LicenseandCollaborationAgreements"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/LicenseandCollaborationAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/Acquisition" xlink:type="simple" xlink:href="dare-20200930.xsd#Acquisition"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/Acquisition" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/AcquisitionNarrativeDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#AcquisitionNarrativeDetails"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/AcquisitionNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="dare-20200930.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="dare-20200930.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquity" xlink:type="simple" xlink:href="dare-20200930.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="dare-20200930.xsd#StockholdersEquityTables"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedProperties" xlink:type="simple" xlink:href="dare-20200930.xsd#LeasedProperties"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/LeasedProperties" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesTables" xlink:type="simple" xlink:href="dare-20200930.xsd#LeasedPropertiesTables"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#LeasedPropertiesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#LeasedPropertiesFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6c04afb3-f0e3-47c1-abd5-4508f9abd082" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f1bb73ff-c58c-4561-9e06-a9b4416fda8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6c04afb3-f0e3-47c1-abd5-4508f9abd082" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f1bb73ff-c58c-4561-9e06-a9b4416fda8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_67a95037-ab98-439c-8c41-6d14367b4592" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6c04afb3-f0e3-47c1-abd5-4508f9abd082" xlink:to="loc_us-gaap_OperatingLeaseLiability_67a95037-ab98-439c-8c41-6d14367b4592" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="dare-20200930.xsd#LeasedPropertiesFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_68cd9d40-ff20-4512-9a0a-02f5b5c0410a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_07397074-dfa3-48d0-81ff-51f2c9ffc0d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_68cd9d40-ff20-4512-9a0a-02f5b5c0410a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_07397074-dfa3-48d0-81ff-51f2c9ffc0d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_14a863e6-648a-4adf-8400-e84f85815cac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_68cd9d40-ff20-4512-9a0a-02f5b5c0410a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_14a863e6-648a-4adf-8400-e84f85815cac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_51952a40-0fed-40d4-9737-4fadf859d176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_68cd9d40-ff20-4512-9a0a-02f5b5c0410a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_51952a40-0fed-40d4-9737-4fadf859d176" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="dare-20200930.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/GrantAward" xlink:type="simple" xlink:href="dare-20200930.xsd#GrantAward"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/GrantAward" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/GrantAwardNarrativeDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#GrantAwardNarrativeDetails"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/GrantAwardNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerShare" xlink:type="simple" xlink:href="dare-20200930.xsd#NetLossPerShare"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/NetLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="dare-20200930.xsd#NetLossPerShareTables"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/NetLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/SubsequentEvents" xlink:type="simple" xlink:href="dare-20200930.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/SubsequentEvents" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#SubsequentEventsDetails"/>
  <link:calculationLink xlink:role="http://darebioscience.com/role/SubsequentEventsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>dare-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:9ad61a15-e285-44cc-ad2a-44a040d7fb22,g:5f0dd9b0-b13f-4c69-b05c-880a09202ba6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://darebioscience.com/role/CoverPage" xlink:type="simple" xlink:href="dare-20200930.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/CoverPage" xlink:type="extended" id="i3f32eb0577574ac0ba0012d396321535_CoverPage"/>
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="dare-20200930.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="i255ed13958cd410e8ddff0357b5cdef9_ConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="dare-20200930.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="ic4ce3eb472e9414d8ec14b639e9c778a_ConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="dare-20200930.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="iebfc75e38ecf441d8f50c7a2926cf694_ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="dare-20200930.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="ie892956f503d40ae9d8f647de69c0250_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cc9dbfe4-49dd-4bee-bd55-11ae794f1519" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cc9dbfe4-49dd-4bee-bd55-11ae794f1519" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c8b32406-841c-41f7-9d97-073c63aa38ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_us-gaap_StockholdersEquity_c8b32406-841c-41f7-9d97-073c63aa38ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_5a334478-c7c8-4eb7-b3d0-0c6974406e0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_us-gaap_SharesOutstanding_5a334478-c7c8-4eb7-b3d0-0c6974406e0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9f47e2ad-233a-4b1a-92c0-1a1c2647b931" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9f47e2ad-233a-4b1a-92c0-1a1c2647b931" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_99845256-54a5-4f79-9639-767aa447d872" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_99845256-54a5-4f79-9639-767aa447d872" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_10faec07-af5e-4f22-970f-1564ce69ba3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_10faec07-af5e-4f22-970f-1564ce69ba3a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares_458bf55c-f1e2-4fe4-a4f3-a591db17effc" xlink:href="dare-20200930.xsd#dare_StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_dare_StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares_458bf55c-f1e2-4fe4-a4f3-a591db17effc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares_ea5d9687-991b-4d86-8bd9-74d3baf90b64" xlink:href="dare-20200930.xsd#dare_StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_dare_StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares_ea5d9687-991b-4d86-8bd9-74d3baf90b64" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_546f2b0a-d6bb-4600-921a-30544c047cbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_546f2b0a-d6bb-4600-921a-30544c047cbc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_3ddf0ee9-ef7c-47fe-8449-454b125eda81" xlink:href="dare-20200930.xsd#dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_3ddf0ee9-ef7c-47fe-8449-454b125eda81" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7b3a5c93-c8ae-468c-9377-688c252dc929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7b3a5c93-c8ae-468c-9377-688c252dc929" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b9528f66-617f-4632-ad88-6173b7caac36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b9528f66-617f-4632-ad88-6173b7caac36" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_e2270a6d-50f7-494f-ae0b-c387aba8b784" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_e2270a6d-50f7-494f-ae0b-c387aba8b784" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7c230d34-4ca0-45c9-bb6f-f07d8d5740cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_us-gaap_NetIncomeLoss_7c230d34-4ca0-45c9-bb6f-f07d8d5740cf" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4587424f-dbc1-448f-9fa2-85148fa286cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4587424f-dbc1-448f-9fa2-85148fa286cd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_69228f94-d369-4dbb-9710-81bbdde3012a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_5e5d9e89-97e6-4669-b953-4e6745fbb061" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d83ac518-6b10-4dcc-b407-a30592cdbd83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_cc9dbfe4-49dd-4bee-bd55-11ae794f1519" xlink:to="loc_us-gaap_StatementTable_d83ac518-6b10-4dcc-b407-a30592cdbd83" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_84d2e033-0254-49f9-8a1a-cf16ddebe3b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d83ac518-6b10-4dcc-b407-a30592cdbd83" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_84d2e033-0254-49f9-8a1a-cf16ddebe3b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_84d2e033-0254-49f9-8a1a-cf16ddebe3b5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_84d2e033-0254-49f9-8a1a-cf16ddebe3b5" xlink:to="loc_us-gaap_EquityComponentDomain_84d2e033-0254-49f9-8a1a-cf16ddebe3b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c63cea62-00a8-48e4-98cb-11b4f4076cee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_84d2e033-0254-49f9-8a1a-cf16ddebe3b5" xlink:to="loc_us-gaap_EquityComponentDomain_c63cea62-00a8-48e4-98cb-11b4f4076cee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e8df3af2-432e-4626-a06b-5c741a095c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c63cea62-00a8-48e4-98cb-11b4f4076cee" xlink:to="loc_us-gaap_CommonStockMember_e8df3af2-432e-4626-a06b-5c741a095c8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f70a95dc-a0e9-4b4b-96cd-3043140a5eab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c63cea62-00a8-48e4-98cb-11b4f4076cee" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f70a95dc-a0e9-4b4b-96cd-3043140a5eab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a7b74af3-1190-4732-b294-23322ef5fb39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c63cea62-00a8-48e4-98cb-11b4f4076cee" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a7b74af3-1190-4732-b294-23322ef5fb39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d32608a5-260b-40ce-92a1-e9dcda47c150" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c63cea62-00a8-48e4-98cb-11b4f4076cee" xlink:to="loc_us-gaap_RetainedEarningsMember_d32608a5-260b-40ce-92a1-e9dcda47c150" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="dare-20200930.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i7538357a36714a34bff01f0f9bee7b1a_ConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://darebioscience.com/role/OrganizationandDescriptionoftheBusiness" xlink:type="simple" xlink:href="dare-20200930.xsd#OrganizationandDescriptionoftheBusiness"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/OrganizationandDescriptionoftheBusiness" xlink:type="extended" id="ib52323e1519a4678a3547e3a63ec7959_OrganizationandDescriptionoftheBusiness"/>
  <link:roleRef roleURI="http://darebioscience.com/role/OrganizationandDescriptionoftheBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#OrganizationandDescriptionoftheBusinessAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/OrganizationandDescriptionoftheBusinessAdditionalInformationDetails" xlink:type="extended" id="i27c60ca305f545668e3ecbe03e001a40_OrganizationandDescriptionoftheBusinessAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_dare_SignificantAccountingPoliciesLineItems_2d50e80e-af67-4ebb-b0f7-73b1a295d9f4" xlink:href="dare-20200930.xsd#dare_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_fffd106e-a884-45f4-af50-26c58c80d3de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_2d50e80e-af67-4ebb-b0f7-73b1a295d9f4" xlink:to="loc_us-gaap_NumberOfOperatingSegments_fffd106e-a884-45f4-af50-26c58c80d3de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_568694f6-31ea-4ee8-ac23-e4c06c2ceeaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_2d50e80e-af67-4ebb-b0f7-73b1a295d9f4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_568694f6-31ea-4ee8-ac23-e4c06c2ceeaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_4cfa6952-a5cd-4445-88c7-cd98a050c37f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_2d50e80e-af67-4ebb-b0f7-73b1a295d9f4" xlink:to="loc_us-gaap_ConvertibleDebt_4cfa6952-a5cd-4445-88c7-cd98a050c37f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_c5395188-69cd-40ca-803e-bfbd664e27dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_2d50e80e-af67-4ebb-b0f7-73b1a295d9f4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_c5395188-69cd-40ca-803e-bfbd664e27dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PeriodofInsufficientCashandLiquidityRequirements_566bb33f-6ff5-43a6-9510-0e52a636036c" xlink:href="dare-20200930.xsd#dare_PeriodofInsufficientCashandLiquidityRequirements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_2d50e80e-af67-4ebb-b0f7-73b1a295d9f4" xlink:to="loc_dare_PeriodofInsufficientCashandLiquidityRequirements_566bb33f-6ff5-43a6-9510-0e52a636036c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SignificantAccountingPoliciesTable_3978f34e-0f7d-49ff-997d-8edf2c7d6795" xlink:href="dare-20200930.xsd#dare_SignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_2d50e80e-af67-4ebb-b0f7-73b1a295d9f4" xlink:to="loc_dare_SignificantAccountingPoliciesTable_3978f34e-0f7d-49ff-997d-8edf2c7d6795" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b6d19e3c-71b2-4ebe-8c30-401bd25ad046" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_SignificantAccountingPoliciesTable_3978f34e-0f7d-49ff-997d-8edf2c7d6795" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b6d19e3c-71b2-4ebe-8c30-401bd25ad046" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6d19e3c-71b2-4ebe-8c30-401bd25ad046_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b6d19e3c-71b2-4ebe-8c30-401bd25ad046" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6d19e3c-71b2-4ebe-8c30-401bd25ad046_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4521844b-0c82-4e57-b270-959b22e3e910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b6d19e3c-71b2-4ebe-8c30-401bd25ad046" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4521844b-0c82-4e57-b270-959b22e3e910" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cc2164d3-bdb7-4860-ae95-0eaf2ba047a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4521844b-0c82-4e57-b270-959b22e3e910" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cc2164d3-bdb7-4860-ae95-0eaf2ba047a7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="dare-20200930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="i585894e305334aa7ab6b0573564573b6_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="dare-20200930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i3e893bccd12941cbacf7ef62e125c839_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="dare-20200930.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="ic76b4d39c90146d18470e1a31dc332c3_SummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails" xlink:type="extended" id="i225e7983f30743829ece9444b5739850_SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff1645d1-cd45-4705-8095-78dc73b153c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ca6e366e-9213-4405-9ce0-5ee2dbf5cf08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff1645d1-cd45-4705-8095-78dc73b153c8" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ca6e366e-9213-4405-9ce0-5ee2dbf5cf08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsiderationCurrent_9ffe1ede-dce7-46c3-a649-13bedb035b4d" xlink:href="dare-20200930.xsd#dare_AssetAcquisitionContingentConsiderationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff1645d1-cd45-4705-8095-78dc73b153c8" xlink:to="loc_dare_AssetAcquisitionContingentConsiderationCurrent_9ffe1ede-dce7-46c3-a649-13bedb035b4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsiderationNoncurrent_a3e8d292-381b-427d-a834-50c6e9c0cfa9" xlink:href="dare-20200930.xsd#dare_AssetAcquisitionContingentConsiderationNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff1645d1-cd45-4705-8095-78dc73b153c8" xlink:to="loc_dare_AssetAcquisitionContingentConsiderationNoncurrent_a3e8d292-381b-427d-a834-50c6e9c0cfa9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_524f0ba2-44b3-4a35-9e12-a30298cb0548" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff1645d1-cd45-4705-8095-78dc73b153c8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_524f0ba2-44b3-4a35-9e12-a30298cb0548" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e5533c5a-f9cd-47de-aecc-48c80aa0c7ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_524f0ba2-44b3-4a35-9e12-a30298cb0548" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e5533c5a-f9cd-47de-aecc-48c80aa0c7ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e5533c5a-f9cd-47de-aecc-48c80aa0c7ce_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e5533c5a-f9cd-47de-aecc-48c80aa0c7ce" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e5533c5a-f9cd-47de-aecc-48c80aa0c7ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4985c1e4-1ee0-4481-bb17-ff0ec2d09bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e5533c5a-f9cd-47de-aecc-48c80aa0c7ce" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4985c1e4-1ee0-4481-bb17-ff0ec2d09bb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a63691a5-29d1-4fd7-9001-bbbccb07b183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4985c1e4-1ee0-4481-bb17-ff0ec2d09bb0" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a63691a5-29d1-4fd7-9001-bbbccb07b183" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_174f85da-4bb8-4f33-b67f-2b428c0aa7f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_524f0ba2-44b3-4a35-9e12-a30298cb0548" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_174f85da-4bb8-4f33-b67f-2b428c0aa7f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_174f85da-4bb8-4f33-b67f-2b428c0aa7f8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_174f85da-4bb8-4f33-b67f-2b428c0aa7f8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_174f85da-4bb8-4f33-b67f-2b428c0aa7f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_424cb732-fc81-4295-ba5c-af8d455f3650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_174f85da-4bb8-4f33-b67f-2b428c0aa7f8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_424cb732-fc81-4295-ba5c-af8d455f3650" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f8950e24-ad89-4d01-afbc-1362e444a2bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_424cb732-fc81-4295-ba5c-af8d455f3650" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f8950e24-ad89-4d01-afbc-1362e444a2bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0b60338e-2ae3-4d0f-841d-7e53483f1daf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_424cb732-fc81-4295-ba5c-af8d455f3650" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0b60338e-2ae3-4d0f-841d-7e53483f1daf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c7cea69a-f742-4877-8c0c-27a2ed0d9dcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_424cb732-fc81-4295-ba5c-af8d455f3650" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c7cea69a-f742-4877-8c0c-27a2ed0d9dcb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="i3bd7868f64064fa898047c79fa0a4ecd_SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_dare_SignificantAccountingPoliciesLineItems_d7551257-4c23-44c3-a70e-b4e6a059bf8c" xlink:href="dare-20200930.xsd#dare_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UpfrontLicenseFeePaid_be074d50-2b9b-4a5d-87c7-d9e3548afeda" xlink:href="dare-20200930.xsd#dare_UpfrontLicenseFeePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_d7551257-4c23-44c3-a70e-b4e6a059bf8c" xlink:to="loc_dare_UpfrontLicenseFeePaid_be074d50-2b9b-4a5d-87c7-d9e3548afeda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_212bfd64-f898-4612-8b2a-cb73826516c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_d7551257-4c23-44c3-a70e-b4e6a059bf8c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_212bfd64-f898-4612-8b2a-cb73826516c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmount_a0248f57-196e-4d5d-b5bd-7a82f7f93464" xlink:href="dare-20200930.xsd#dare_MilestonePaymentsContingentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_d7551257-4c23-44c3-a70e-b4e6a059bf8c" xlink:to="loc_dare_MilestonePaymentsContingentAmount_a0248f57-196e-4d5d-b5bd-7a82f7f93464" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SignificantAccountingPoliciesTable_8bd666de-79e0-4c38-ab75-25ee91b119e9" xlink:href="dare-20200930.xsd#dare_SignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_d7551257-4c23-44c3-a70e-b4e6a059bf8c" xlink:to="loc_dare_SignificantAccountingPoliciesTable_8bd666de-79e0-4c38-ab75-25ee91b119e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d93197f6-1bf0-417d-9544-2b52c0a7c978" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_SignificantAccountingPoliciesTable_8bd666de-79e0-4c38-ab75-25ee91b119e9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d93197f6-1bf0-417d-9544-2b52c0a7c978" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d93197f6-1bf0-417d-9544-2b52c0a7c978_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d93197f6-1bf0-417d-9544-2b52c0a7c978" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d93197f6-1bf0-417d-9544-2b52c0a7c978_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a74baf39-88fd-42c1-a885-b06be9e5dc4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d93197f6-1bf0-417d-9544-2b52c0a7c978" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a74baf39-88fd-42c1-a885-b06be9e5dc4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_BayerHealthcareLicenseAgreementMember_f3fed554-79db-46dc-a384-708c9c9ed6c8" xlink:href="dare-20200930.xsd#dare_BayerHealthcareLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a74baf39-88fd-42c1-a885-b06be9e5dc4a" xlink:to="loc_dare_BayerHealthcareLicenseAgreementMember_f3fed554-79db-46dc-a384-708c9c9ed6c8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="dare-20200930.xsd#LicenseandCollaborationAgreements"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/LicenseandCollaborationAgreements" xlink:type="extended" id="ic37fe248eafa4c09bdb314f40e5f2331_LicenseandCollaborationAgreements"/>
  <link:roleRef roleURI="http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="extended" id="i7a342263ae554939b01d61ef545ddb51_LicenseandCollaborationAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UpfrontLicenseFeePaid_5fbcdd47-6c3e-43f7-a61c-25f6c566cee3" xlink:href="dare-20200930.xsd#dare_UpfrontLicenseFeePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_UpfrontLicenseFeePaid_5fbcdd47-6c3e-43f7-a61c-25f6c566cee3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc3ae5dc-0f5d-45c5-81e0-5b2ad7350915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc3ae5dc-0f5d-45c5-81e0-5b2ad7350915" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmount_b444962a-ab34-4b3d-9dd5-d9472e03928c" xlink:href="dare-20200930.xsd#dare_MilestonePaymentsContingentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_MilestonePaymentsContingentAmount_b444962a-ab34-4b3d-9dd5-d9472e03928c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseFee_5185b89f-3f88-42f6-9974-d22515881149" xlink:href="dare-20200930.xsd#dare_LicenseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_LicenseFee_5185b89f-3f88-42f6-9974-d22515881149" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseFeeToBePaidUponContingency_30dbed4c-38bd-42d2-8c23-02387b0ade7d" xlink:href="dare-20200930.xsd#dare_LicenseFeeToBePaidUponContingency"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_LicenseFeeToBePaidUponContingency_30dbed4c-38bd-42d2-8c23-02387b0ade7d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct_2b3fa56b-a0fd-4129-91b3-5cba5d5a8643" xlink:href="dare-20200930.xsd#dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct_2b3fa56b-a0fd-4129-91b3-5cba5d5a8643" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_040cfd36-6d85-4c65-80ed-5b9f241639f2" xlink:href="dare-20200930.xsd#dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_040cfd36-6d85-4c65-80ed-5b9f241639f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAgreementNoticePeriodOfTermination_7eefdb67-286a-4629-8ef2-85e5035b6e71" xlink:href="dare-20200930.xsd#dare_LicenseAgreementNoticePeriodOfTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_LicenseAgreementNoticePeriodOfTermination_7eefdb67-286a-4629-8ef2-85e5035b6e71" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePayments_12a7ae67-e2a2-4032-9cbd-d4f771d03b6b" xlink:href="dare-20200930.xsd#dare_MilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_MilestonePayments_12a7ae67-e2a2-4032-9cbd-d4f771d03b6b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ResearchAndDevelopmentMilestonePayment_9fb1d619-cfe5-486b-8696-d8a7f82c08e8" xlink:href="dare-20200930.xsd#dare_ResearchAndDevelopmentMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_ResearchAndDevelopmentMilestonePayment_9fb1d619-cfe5-486b-8696-d8a7f82c08e8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PercentageOfRoyaltyRate_9cd10f49-08c1-4341-949e-f07c583af0a6" xlink:href="dare-20200930.xsd#dare_PercentageOfRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_PercentageOfRoyaltyRate_9cd10f49-08c1-4341-949e-f07c583af0a6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_1b4d1bab-c885-413b-866d-58b53a24961c" xlink:href="dare-20200930.xsd#dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_1b4d1bab-c885-413b-866d-58b53a24961c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_59b53ee1-11aa-4906-9f89-574c80fb261e" xlink:href="dare-20200930.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_59b53ee1-11aa-4906-9f89-574c80fb261e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_f069b531-7f24-412c-8495-ed891432e628" xlink:href="dare-20200930.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_f069b531-7f24-412c-8495-ed891432e628" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MaximumPotentialMilestonePayments_c9728124-503e-44c3-8296-45e504ba5008" xlink:href="dare-20200930.xsd#dare_MaximumPotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_MaximumPotentialMilestonePayments_c9728124-503e-44c3-8296-45e504ba5008" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_8abd766b-516b-4493-b0db-4cf1948a759c" xlink:href="dare-20200930.xsd#dare_CommencementPeriodForStageTwoUponAchievementOfStageOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_8abd766b-516b-4493-b0db-4cf1948a759c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c111f6e0-b1c0-4818-a75d-9f16cdc6a797" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c111f6e0-b1c0-4818-a75d-9f16cdc6a797" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsiderationCurrent_db802276-cfec-4d77-951c-22f47edd4701" xlink:href="dare-20200930.xsd#dare_AssetAcquisitionContingentConsiderationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_AssetAcquisitionContingentConsiderationCurrent_db802276-cfec-4d77-951c-22f47edd4701" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a5a9ba8-9584-4626-bb66-a55f00cd338e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a5a9ba8-9584-4626-bb66-a55f00cd338e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2b0b3e7a-a155-4bc5-a65f-5caf9d3043ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a5a9ba8-9584-4626-bb66-a55f00cd338e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2b0b3e7a-a155-4bc5-a65f-5caf9d3043ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2b0b3e7a-a155-4bc5-a65f-5caf9d3043ca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2b0b3e7a-a155-4bc5-a65f-5caf9d3043ca" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2b0b3e7a-a155-4bc5-a65f-5caf9d3043ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8fd9a48-f51a-4431-9797-daa6357b8832" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2b0b3e7a-a155-4bc5-a65f-5caf9d3043ca" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8fd9a48-f51a-4431-9797-daa6357b8832" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_BayerHealthcareLicenseAgreementMember_402edb4c-fe99-4949-ac4f-9531cc9d1d4c" xlink:href="dare-20200930.xsd#dare_BayerHealthcareLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8fd9a48-f51a-4431-9797-daa6357b8832" xlink:to="loc_dare_BayerHealthcareLicenseAgreementMember_402edb4c-fe99-4949-ac4f-9531cc9d1d4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_331778d0-ceba-440b-aa41-650ec467fac1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8fd9a48-f51a-4431-9797-daa6357b8832" xlink:to="loc_us-gaap_LicensingAgreementsMember_331778d0-ceba-440b-aa41-650ec467fac1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssignmentAgreementMember_8e559089-920a-45cd-b373-af933f468539" xlink:href="dare-20200930.xsd#dare_AssignmentAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8fd9a48-f51a-4431-9797-daa6357b8832" xlink:to="loc_dare_AssignmentAgreementMember_8e559089-920a-45cd-b373-af933f468539" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAndCollaborationAgreementMember_cfcc8ef1-52d0-4081-a206-93300914bec5" xlink:href="dare-20200930.xsd#dare_LicenseAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8fd9a48-f51a-4431-9797-daa6357b8832" xlink:to="loc_dare_LicenseAndCollaborationAgreementMember_cfcc8ef1-52d0-4081-a206-93300914bec5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_JuniperPharmaceuticalsInc.Member_488e7992-f462-4b92-a1b6-e5e453c099e3" xlink:href="dare-20200930.xsd#dare_JuniperPharmaceuticalsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8fd9a48-f51a-4431-9797-daa6357b8832" xlink:to="loc_dare_JuniperPharmaceuticalsInc.Member_488e7992-f462-4b92-a1b6-e5e453c099e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DevelopmentAndOptionAgreementMember_6ae7fd0e-f712-4399-9559-5031709c4705" xlink:href="dare-20200930.xsd#dare_DevelopmentAndOptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8fd9a48-f51a-4431-9797-daa6357b8832" xlink:to="loc_dare_DevelopmentAndOptionAgreementMember_6ae7fd0e-f712-4399-9559-5031709c4705" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_f29fdca4-28d3-47d8-9587-272966b64599" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a5a9ba8-9584-4626-bb66-a55f00cd338e" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_f29fdca4-28d3-47d8-9587-272966b64599" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_f29fdca4-28d3-47d8-9587-272966b64599_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_f29fdca4-28d3-47d8-9587-272966b64599" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_f29fdca4-28d3-47d8-9587-272966b64599_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0348bafb-0f31-4644-9b45-efed93c64ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_f29fdca4-28d3-47d8-9587-272966b64599" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0348bafb-0f31-4644-9b45-efed93c64ce4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainDevelopmentMilestonesMember_63b00562-4c5d-4fb9-8a94-79218dc2e310" xlink:href="dare-20200930.xsd#dare_UponAchievingCertainDevelopmentMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0348bafb-0f31-4644-9b45-efed93c64ce4" xlink:to="loc_dare_UponAchievingCertainDevelopmentMilestonesMember_63b00562-4c5d-4fb9-8a94-79218dc2e310" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainCommercialMilestonesMember_1c5c3456-b701-4e4c-b92a-7cbd8a976a58" xlink:href="dare-20200930.xsd#dare_UponAchievingCertainCommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0348bafb-0f31-4644-9b45-efed93c64ce4" xlink:to="loc_dare_UponAchievingCertainCommercialMilestonesMember_1c5c3456-b701-4e4c-b92a-7cbd8a976a58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_9dbef5d7-0d82-4b2b-b22f-69a96b6c1892" xlink:href="dare-20200930.xsd#dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0348bafb-0f31-4644-9b45-efed93c64ce4" xlink:to="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_9dbef5d7-0d82-4b2b-b22f-69a96b6c1892" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponSigningOfDevelopmentAndOptionAgreementMember_37663467-e4e9-46e8-98de-6e81dc298ff4" xlink:href="dare-20200930.xsd#dare_UponSigningOfDevelopmentAndOptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0348bafb-0f31-4644-9b45-efed93c64ce4" xlink:to="loc_dare_UponSigningOfDevelopmentAndOptionAgreementMember_37663467-e4e9-46e8-98de-6e81dc298ff4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_d050057d-297d-4782-b399-2df6987a9b9a" xlink:href="dare-20200930.xsd#dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0348bafb-0f31-4644-9b45-efed93c64ce4" xlink:to="loc_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_d050057d-297d-4782-b399-2df6987a9b9a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember_e44c1cc9-c1d8-40f2-990d-7d0b6e3e362c" xlink:href="dare-20200930.xsd#dare_UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0348bafb-0f31-4644-9b45-efed93c64ce4" xlink:to="loc_dare_UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember_e44c1cc9-c1d8-40f2-990d-7d0b6e3e362c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dc45d516-337c-4140-b20e-e77b9eeea4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a5a9ba8-9584-4626-bb66-a55f00cd338e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dc45d516-337c-4140-b20e-e77b9eeea4d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_dc45d516-337c-4140-b20e-e77b9eeea4d1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dc45d516-337c-4140-b20e-e77b9eeea4d1" xlink:to="loc_us-gaap_RelatedPartyDomain_dc45d516-337c-4140-b20e-e77b9eeea4d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_32305b03-541f-48ea-99ed-f91d92fc7f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dc45d516-337c-4140-b20e-e77b9eeea4d1" xlink:to="loc_us-gaap_RelatedPartyDomain_32305b03-541f-48ea-99ed-f91d92fc7f1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilanaPharmMember_250613c3-626c-4a70-93d3-89d360a5f8d1" xlink:href="dare-20200930.xsd#dare_MilanaPharmMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_32305b03-541f-48ea-99ed-f91d92fc7f1d" xlink:to="loc_dare_MilanaPharmMember_250613c3-626c-4a70-93d3-89d360a5f8d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_HammockPharmaceuticalsInc.Member_fa4d5b72-91f5-4949-819a-713ef0b7f16c" xlink:href="dare-20200930.xsd#dare_HammockPharmaceuticalsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_32305b03-541f-48ea-99ed-f91d92fc7f1d" xlink:to="loc_dare_HammockPharmaceuticalsInc.Member_fa4d5b72-91f5-4949-819a-713ef0b7f16c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_d410af75-b039-4eb0-9314-9a44ef69c0a6" xlink:href="dare-20200930.xsd#dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_32305b03-541f-48ea-99ed-f91d92fc7f1d" xlink:to="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_d410af75-b039-4eb0-9314-9a44ef69c0a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AdarePharmaceuticalsMember_a9b33ef4-4a57-483b-86f3-6c1113487f08" xlink:href="dare-20200930.xsd#dare_AdarePharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_32305b03-541f-48ea-99ed-f91d92fc7f1d" xlink:to="loc_dare_AdarePharmaceuticalsMember_a9b33ef4-4a57-483b-86f3-6c1113487f08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c7b9b3a8-3a1d-490d-9731-f155dcdcea9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a5a9ba8-9584-4626-bb66-a55f00cd338e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c7b9b3a8-3a1d-490d-9731-f155dcdcea9d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c7b9b3a8-3a1d-490d-9731-f155dcdcea9d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c7b9b3a8-3a1d-490d-9731-f155dcdcea9d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c7b9b3a8-3a1d-490d-9731-f155dcdcea9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_686baa84-855b-4005-a730-e6d4763e6761" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c7b9b3a8-3a1d-490d-9731-f155dcdcea9d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_686baa84-855b-4005-a730-e6d4763e6761" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ADVATecAgreementMember_6d4ca9fc-af64-464f-976e-7e19d49d4c19" xlink:href="dare-20200930.xsd#dare_ADVATecAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_686baa84-855b-4005-a730-e6d4763e6761" xlink:to="loc_dare_ADVATecAgreementMember_6d4ca9fc-af64-464f-976e-7e19d49d4c19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ClinicalAndRegulatoryMilestonesMember_1b6c2d25-4f69-4c09-a719-43eccfdb2fab" xlink:href="dare-20200930.xsd#dare_ClinicalAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_686baa84-855b-4005-a730-e6d4763e6761" xlink:to="loc_dare_ClinicalAndRegulatoryMilestonesMember_1b6c2d25-4f69-4c09-a719-43eccfdb2fab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SalesMilestonesMember_99e455f0-af28-48f0-97be-794e7dadce4d" xlink:href="dare-20200930.xsd#dare_SalesMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_686baa84-855b-4005-a730-e6d4763e6761" xlink:to="loc_dare_SalesMilestonesMember_99e455f0-af28-48f0-97be-794e7dadce4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_34050819-f311-4127-8edd-3e2bbc46ee23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a5a9ba8-9584-4626-bb66-a55f00cd338e" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_34050819-f311-4127-8edd-3e2bbc46ee23" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_34050819-f311-4127-8edd-3e2bbc46ee23_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_34050819-f311-4127-8edd-3e2bbc46ee23" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_34050819-f311-4127-8edd-3e2bbc46ee23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_ef13521b-678f-47e1-95b7-e0715f83dee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_34050819-f311-4127-8edd-3e2bbc46ee23" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_ef13521b-678f-47e1-95b7-e0715f83dee3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_a4aa68d3-ee12-4ab1-a3a7-5d1aa158d811" xlink:href="dare-20200930.xsd#dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_ef13521b-678f-47e1-95b7-e0715f83dee3" xlink:to="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_a4aa68d3-ee12-4ab1-a3a7-5d1aa158d811" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_5d7689d3-a4c0-46a6-865c-776fba06693f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a5a9ba8-9584-4626-bb66-a55f00cd338e" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_5d7689d3-a4c0-46a6-865c-776fba06693f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_5d7689d3-a4c0-46a6-865c-776fba06693f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_5d7689d3-a4c0-46a6-865c-776fba06693f" xlink:to="loc_us-gaap_ProjectMember_5d7689d3-a4c0-46a6-865c-776fba06693f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_41a63b37-a621-41e6-8225-2a634911dfe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_5d7689d3-a4c0-46a6-865c-776fba06693f" xlink:to="loc_us-gaap_ProjectMember_41a63b37-a621-41e6-8225-2a634911dfe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_fab676d7-9dfc-426f-ae4c-39eb8896302a" xlink:href="dare-20200930.xsd#dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_41a63b37-a621-41e6-8225-2a634911dfe3" xlink:to="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_fab676d7-9dfc-426f-ae4c-39eb8896302a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_6dfbe3bd-fa91-4d21-aa1b-0c5537f38e53" xlink:href="dare-20200930.xsd#dare_UponReachingCertainWorldwideNetSalesMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_41a63b37-a621-41e6-8225-2a634911dfe3" xlink:to="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_6dfbe3bd-fa91-4d21-aa1b-0c5537f38e53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_94047fbf-e176-4d4b-81fd-973b480fc53a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a5a9ba8-9584-4626-bb66-a55f00cd338e" xlink:to="loc_srt_RangeAxis_94047fbf-e176-4d4b-81fd-973b480fc53a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_94047fbf-e176-4d4b-81fd-973b480fc53a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_94047fbf-e176-4d4b-81fd-973b480fc53a" xlink:to="loc_srt_RangeMember_94047fbf-e176-4d4b-81fd-973b480fc53a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_75968d30-ba61-4ee5-9846-cb537e1b5a63" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_94047fbf-e176-4d4b-81fd-973b480fc53a" xlink:to="loc_srt_RangeMember_75968d30-ba61-4ee5-9846-cb537e1b5a63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4c76a2d2-3ba2-4769-9eac-4f4d47485772" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_75968d30-ba61-4ee5-9846-cb537e1b5a63" xlink:to="loc_srt_MaximumMember_4c76a2d2-3ba2-4769-9eac-4f4d47485772" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0db4b382-7878-433e-afd3-a4426f2e94a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_75968d30-ba61-4ee5-9846-cb537e1b5a63" xlink:to="loc_srt_MinimumMember_0db4b382-7878-433e-afd3-a4426f2e94a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8e91c145-697d-43f0-a74a-3d583796570c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a5a9ba8-9584-4626-bb66-a55f00cd338e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8e91c145-697d-43f0-a74a-3d583796570c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8e91c145-697d-43f0-a74a-3d583796570c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8e91c145-697d-43f0-a74a-3d583796570c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8e91c145-697d-43f0-a74a-3d583796570c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ed0fe6b5-e2f0-44f6-a5bb-3b80c9db79bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8e91c145-697d-43f0-a74a-3d583796570c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ed0fe6b5-e2f0-44f6-a5bb-3b80c9db79bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MicrochipsBiotechInc.Member_aa0f8294-8f46-4ad2-9832-4ba94b7c496d" xlink:href="dare-20200930.xsd#dare_MicrochipsBiotechInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ed0fe6b5-e2f0-44f6-a5bb-3b80c9db79bc" xlink:to="loc_dare_MicrochipsBiotechInc.Member_aa0f8294-8f46-4ad2-9832-4ba94b7c496d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ed43d38f-dc0a-4447-bc19-ec1b9cd544a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a5a9ba8-9584-4626-bb66-a55f00cd338e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ed43d38f-dc0a-4447-bc19-ec1b9cd544a1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ed43d38f-dc0a-4447-bc19-ec1b9cd544a1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ed43d38f-dc0a-4447-bc19-ec1b9cd544a1" xlink:to="loc_us-gaap_ClassOfStockDomain_ed43d38f-dc0a-4447-bc19-ec1b9cd544a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_46825bb0-592b-4120-bab4-73adf592c848" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ed43d38f-dc0a-4447-bc19-ec1b9cd544a1" xlink:to="loc_us-gaap_ClassOfStockDomain_46825bb0-592b-4120-bab4-73adf592c848" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_594b1138-0de7-495a-91c8-9bb17f7227a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_46825bb0-592b-4120-bab4-73adf592c848" xlink:to="loc_us-gaap_CommonStockMember_594b1138-0de7-495a-91c8-9bb17f7227a2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/Acquisition" xlink:type="simple" xlink:href="dare-20200930.xsd#Acquisition"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/Acquisition" xlink:type="extended" id="id30cf6f0401b479888bd5dd90841e216_Acquisition"/>
  <link:roleRef roleURI="http://darebioscience.com/role/AcquisitionNarrativeDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#AcquisitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/AcquisitionNarrativeDetails" xlink:type="extended" id="i29ca1a193e1f4e24ba7ef5c8b956e8bb_AcquisitionNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_dare_BusinessCombinationReverseMergerLineItems_e49dfe39-1d53-4076-892e-c8251ce40d4b" xlink:href="dare-20200930.xsd#dare_BusinessCombinationReverseMergerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_8d87622e-61c4-4ab7-a5c7-a0d4f4e9e7bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_e49dfe39-1d53-4076-892e-c8251ce40d4b" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_8d87622e-61c4-4ab7-a5c7-a0d4f4e9e7bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_55f1e61d-64c7-4a6a-94ac-82b4f76a2b85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_e49dfe39-1d53-4076-892e-c8251ce40d4b" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_55f1e61d-64c7-4a6a-94ac-82b4f76a2b85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_2c984439-79a0-44ff-9dec-66b76aa68d25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_e49dfe39-1d53-4076-892e-c8251ce40d4b" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_2c984439-79a0-44ff-9dec-66b76aa68d25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_23cdd511-fef4-4c9e-a820-af758df8db54" xlink:href="dare-20200930.xsd#dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_e49dfe39-1d53-4076-892e-c8251ce40d4b" xlink:to="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_23cdd511-fef4-4c9e-a820-af758df8db54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_156d4366-5e14-4fd0-b465-d7e0b51008a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_e49dfe39-1d53-4076-892e-c8251ce40d4b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_156d4366-5e14-4fd0-b465-d7e0b51008a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsiderationCurrent_8cc87e24-fe07-4f61-bbf5-b963042961e8" xlink:href="dare-20200930.xsd#dare_AssetAcquisitionContingentConsiderationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_e49dfe39-1d53-4076-892e-c8251ce40d4b" xlink:to="loc_dare_AssetAcquisitionContingentConsiderationCurrent_8cc87e24-fe07-4f61-bbf5-b963042961e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_c4f62070-e9d8-4c30-ae9c-60837b3e6ec6" xlink:href="dare-20200930.xsd#dare_ScheduleOfBusinessCombinationReverseMergerTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_e49dfe39-1d53-4076-892e-c8251ce40d4b" xlink:to="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_c4f62070-e9d8-4c30-ae9c-60837b3e6ec6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_65f12960-309b-47f6-b00d-6358ef5b45a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_c4f62070-e9d8-4c30-ae9c-60837b3e6ec6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_65f12960-309b-47f6-b00d-6358ef5b45a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_65f12960-309b-47f6-b00d-6358ef5b45a4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_65f12960-309b-47f6-b00d-6358ef5b45a4" xlink:to="loc_us-gaap_ClassOfStockDomain_65f12960-309b-47f6-b00d-6358ef5b45a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_149ed409-74ad-4d42-bd62-3058deca756a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_65f12960-309b-47f6-b00d-6358ef5b45a4" xlink:to="loc_us-gaap_ClassOfStockDomain_149ed409-74ad-4d42-bd62-3058deca756a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e543521d-722e-41b0-b8de-28a3697db14a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_149ed409-74ad-4d42-bd62-3058deca756a" xlink:to="loc_us-gaap_CommonStockMember_e543521d-722e-41b0-b8de-28a3697db14a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0253ccd5-96d7-4558-a16e-59d6a1ac4bca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_c4f62070-e9d8-4c30-ae9c-60837b3e6ec6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0253ccd5-96d7-4558-a16e-59d6a1ac4bca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0253ccd5-96d7-4558-a16e-59d6a1ac4bca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0253ccd5-96d7-4558-a16e-59d6a1ac4bca" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0253ccd5-96d7-4558-a16e-59d6a1ac4bca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0da5edf5-5696-4ee6-a21b-144ad031d224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0253ccd5-96d7-4558-a16e-59d6a1ac4bca" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0da5edf5-5696-4ee6-a21b-144ad031d224" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f02006b1-f8fa-4969-b2a9-f12807335589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0da5edf5-5696-4ee6-a21b-144ad031d224" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f02006b1-f8fa-4969-b2a9-f12807335589" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ceef5148-5772-4642-a2af-2d16c5f8782a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_c4f62070-e9d8-4c30-ae9c-60837b3e6ec6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ceef5148-5772-4642-a2af-2d16c5f8782a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ceef5148-5772-4642-a2af-2d16c5f8782a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ceef5148-5772-4642-a2af-2d16c5f8782a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ceef5148-5772-4642-a2af-2d16c5f8782a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07326e07-e80a-4d09-927f-2f0853744a7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ceef5148-5772-4642-a2af-2d16c5f8782a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07326e07-e80a-4d09-927f-2f0853744a7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MicrochipsBiotechInc.Member_13ecf327-90b8-424c-837a-e25652cff5ad" xlink:href="dare-20200930.xsd#dare_MicrochipsBiotechInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07326e07-e80a-4d09-927f-2f0853744a7b" xlink:to="loc_dare_MicrochipsBiotechInc.Member_13ecf327-90b8-424c-837a-e25652cff5ad" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="dare-20200930.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockBasedCompensation" xlink:type="extended" id="i6befa543fd3d43f68725be7282889baf_StockBasedCompensation"/>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="dare-20200930.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockBasedCompensationTables" xlink:type="extended" id="i8c1919bfa86944f2a0dc387001c64e65_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="i878870df637c4750a5e604839781c57c_StockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_daacb477-ffdd-4edf-8c21-9e777859e326" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_23915fa6-20db-4305-ab45-32eba9869960" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_daacb477-ffdd-4edf-8c21-9e777859e326" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_23915fa6-20db-4305-ab45-32eba9869960" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_92587804-6fcf-4156-8668-887aa87eb6d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_daacb477-ffdd-4edf-8c21-9e777859e326" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_92587804-6fcf-4156-8668-887aa87eb6d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bb3f8464-9bfe-4485-8d8d-c0d14239bc3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_daacb477-ffdd-4edf-8c21-9e777859e326" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bb3f8464-9bfe-4485-8d8d-c0d14239bc3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a6890056-1ae2-4f24-b56d-e4ba6b39654f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_daacb477-ffdd-4edf-8c21-9e777859e326" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a6890056-1ae2-4f24-b56d-e4ba6b39654f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_280a3fc1-cfc7-4527-94fe-fd4ef5df0d23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_daacb477-ffdd-4edf-8c21-9e777859e326" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_280a3fc1-cfc7-4527-94fe-fd4ef5df0d23" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_f78a20ad-e228-4463-8217-7b1b5f98ae57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_daacb477-ffdd-4edf-8c21-9e777859e326" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_f78a20ad-e228-4463-8217-7b1b5f98ae57" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_91c10794-941c-4ee0-869e-40e0ce14799e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_daacb477-ffdd-4edf-8c21-9e777859e326" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_91c10794-941c-4ee0-869e-40e0ce14799e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WeightedAverageAmortizationPeriod_3701bc03-7b1a-4c0b-b54a-0f07f1218d59" xlink:href="dare-20200930.xsd#dare_WeightedAverageAmortizationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_daacb477-ffdd-4edf-8c21-9e777859e326" xlink:to="loc_dare_WeightedAverageAmortizationPeriod_3701bc03-7b1a-4c0b-b54a-0f07f1218d59" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_444493f9-54d3-4f7d-8204-2fb73884e30d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_daacb477-ffdd-4edf-8c21-9e777859e326" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_444493f9-54d3-4f7d-8204-2fb73884e30d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_916b3578-cf47-4326-a858-d9a814bd5414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_daacb477-ffdd-4edf-8c21-9e777859e326" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_916b3578-cf47-4326-a858-d9a814bd5414" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_30350f8e-9821-4d12-a9ee-8b64fa845d7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_916b3578-cf47-4326-a858-d9a814bd5414" xlink:to="loc_us-gaap_PlanNameAxis_30350f8e-9821-4d12-a9ee-8b64fa845d7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_30350f8e-9821-4d12-a9ee-8b64fa845d7d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_30350f8e-9821-4d12-a9ee-8b64fa845d7d" xlink:to="loc_us-gaap_PlanNameDomain_30350f8e-9821-4d12-a9ee-8b64fa845d7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_67099bc2-e37c-497b-99c7-f8b4b20df8c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_30350f8e-9821-4d12-a9ee-8b64fa845d7d" xlink:to="loc_us-gaap_PlanNameDomain_67099bc2-e37c-497b-99c7-f8b4b20df8c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember_f7f55ee0-cd35-4889-9ed9-467d67d8e3bc" xlink:href="dare-20200930.xsd#dare_TwoThousandAndFifteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_67099bc2-e37c-497b-99c7-f8b4b20df8c1" xlink:to="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember_f7f55ee0-cd35-4889-9ed9-467d67d8e3bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_a518a930-822a-4858-8856-b125aad593ca" xlink:href="dare-20200930.xsd#dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_67099bc2-e37c-497b-99c7-f8b4b20df8c1" xlink:to="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_a518a930-822a-4858-8856-b125aad593ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_c94421c4-8444-4072-89ae-371c50fae742" xlink:href="dare-20200930.xsd#dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_67099bc2-e37c-497b-99c7-f8b4b20df8c1" xlink:to="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_c94421c4-8444-4072-89ae-371c50fae742" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_35ce6768-52b6-41df-bc1a-8f6e5a702cb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_916b3578-cf47-4326-a858-d9a814bd5414" xlink:to="loc_us-gaap_AwardTypeAxis_35ce6768-52b6-41df-bc1a-8f6e5a702cb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35ce6768-52b6-41df-bc1a-8f6e5a702cb1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_35ce6768-52b6-41df-bc1a-8f6e5a702cb1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35ce6768-52b6-41df-bc1a-8f6e5a702cb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6bde817-ff98-40b8-a251-1fb8d331bb6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_35ce6768-52b6-41df-bc1a-8f6e5a702cb1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6bde817-ff98-40b8-a251-1fb8d331bb6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_77dcc63f-4aae-415a-ad78-5957af9b19e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6bde817-ff98-40b8-a251-1fb8d331bb6a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_77dcc63f-4aae-415a-ad78-5957af9b19e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_56c21a54-4c5f-4e03-b65d-d775ec5d9c03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6bde817-ff98-40b8-a251-1fb8d331bb6a" xlink:to="loc_us-gaap_RestrictedStockMember_56c21a54-4c5f-4e03-b65d-d775ec5d9c03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1e5d0dc9-3af5-4a52-bc3c-9548db3e4749" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_916b3578-cf47-4326-a858-d9a814bd5414" xlink:to="loc_dei_LegalEntityAxis_1e5d0dc9-3af5-4a52-bc3c-9548db3e4749" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1e5d0dc9-3af5-4a52-bc3c-9548db3e4749_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1e5d0dc9-3af5-4a52-bc3c-9548db3e4749" xlink:to="loc_dei_EntityDomain_1e5d0dc9-3af5-4a52-bc3c-9548db3e4749_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0bbdba22-2a34-439a-a312-06aa6b41c186" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1e5d0dc9-3af5-4a52-bc3c-9548db3e4749" xlink:to="loc_dei_EntityDomain_0bbdba22-2a34-439a-a312-06aa6b41c186" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PrivateDareMember_67d2e7bc-037e-4ab8-bc1d-a95cb7285558" xlink:href="dare-20200930.xsd#dare_PrivateDareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0bbdba22-2a34-439a-a312-06aa6b41c186" xlink:to="loc_dare_PrivateDareMember_67d2e7bc-037e-4ab8-bc1d-a95cb7285558" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails" xlink:type="extended" id="id8ba7e6b02d844e2b789efd72ddc0820_StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_925fa347-9b5b-42ef-b498-eba64e6e3444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_32cd191e-856e-4fd7-b7e9-7a51abf1f0bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_925fa347-9b5b-42ef-b498-eba64e6e3444" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_32cd191e-856e-4fd7-b7e9-7a51abf1f0bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f8551d23-56f8-4fa9-b56c-3f4bd4093a91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_32cd191e-856e-4fd7-b7e9-7a51abf1f0bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f8551d23-56f8-4fa9-b56c-3f4bd4093a91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_51f5fcf7-1484-48e5-ac5b-e192fcc84c2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_32cd191e-856e-4fd7-b7e9-7a51abf1f0bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_51f5fcf7-1484-48e5-ac5b-e192fcc84c2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e6459a89-5d81-4f36-9e98-64074204fc47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_32cd191e-856e-4fd7-b7e9-7a51abf1f0bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e6459a89-5d81-4f36-9e98-64074204fc47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e5376170-52fb-4575-af9f-079d2fc0508f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_32cd191e-856e-4fd7-b7e9-7a51abf1f0bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e5376170-52fb-4575-af9f-079d2fc0508f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40d92493-1645-49f2-a071-fc8a81d4816e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_32cd191e-856e-4fd7-b7e9-7a51abf1f0bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40d92493-1645-49f2-a071-fc8a81d4816e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30545ca4-9e63-47f2-be6e-f10f4b6773f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6ed617c9-0b62-422c-b120-9fbfb1ca5f39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_925fa347-9b5b-42ef-b498-eba64e6e3444" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6ed617c9-0b62-422c-b120-9fbfb1ca5f39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bdaff452-47b5-41b6-9bbf-3a45bc1fb9de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_925fa347-9b5b-42ef-b498-eba64e6e3444" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bdaff452-47b5-41b6-9bbf-3a45bc1fb9de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e82f4a22-ea24-4ecc-b5ed-1de28fb71620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bdaff452-47b5-41b6-9bbf-3a45bc1fb9de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e82f4a22-ea24-4ecc-b5ed-1de28fb71620" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d14d3a82-b4ca-463b-895e-597a16e89579" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bdaff452-47b5-41b6-9bbf-3a45bc1fb9de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d14d3a82-b4ca-463b-895e-597a16e89579" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_fc0136c3-b1e6-4835-8751-a586d7749176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bdaff452-47b5-41b6-9bbf-3a45bc1fb9de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_fc0136c3-b1e6-4835-8751-a586d7749176" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_886e1ccc-0fb9-46b0-9626-a3a2028331ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bdaff452-47b5-41b6-9bbf-3a45bc1fb9de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_886e1ccc-0fb9-46b0-9626-a3a2028331ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d8a765ec-0794-4b13-8942-5cbe0d5ebc33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bdaff452-47b5-41b6-9bbf-3a45bc1fb9de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d8a765ec-0794-4b13-8942-5cbe0d5ebc33" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1dcf923c-0fef-454e-a848-92731d1fdef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a56c4604-7e37-40c2-b87b-75c9939bdea0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_925fa347-9b5b-42ef-b498-eba64e6e3444" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a56c4604-7e37-40c2-b87b-75c9939bdea0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bfe45e5-4f5e-4da1-b311-105c3c0d3e59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_925fa347-9b5b-42ef-b498-eba64e6e3444" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bfe45e5-4f5e-4da1-b311-105c3c0d3e59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7b87a4a3-d6db-4cc8-aee5-ffcb526beaa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bfe45e5-4f5e-4da1-b311-105c3c0d3e59" xlink:to="loc_us-gaap_PlanNameAxis_7b87a4a3-d6db-4cc8-aee5-ffcb526beaa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7b87a4a3-d6db-4cc8-aee5-ffcb526beaa9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_7b87a4a3-d6db-4cc8-aee5-ffcb526beaa9" xlink:to="loc_us-gaap_PlanNameDomain_7b87a4a3-d6db-4cc8-aee5-ffcb526beaa9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_08b76447-6f30-4dba-85a8-3ec750e71069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_7b87a4a3-d6db-4cc8-aee5-ffcb526beaa9" xlink:to="loc_us-gaap_PlanNameDomain_08b76447-6f30-4dba-85a8-3ec750e71069" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_17aed947-2e5c-4624-91d4-90ba3fad8e34" xlink:href="dare-20200930.xsd#dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_08b76447-6f30-4dba-85a8-3ec750e71069" xlink:to="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_17aed947-2e5c-4624-91d4-90ba3fad8e34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_916acabb-ff5c-4bab-841d-c22a2321d7a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bfe45e5-4f5e-4da1-b311-105c3c0d3e59" xlink:to="loc_us-gaap_AwardTypeAxis_916acabb-ff5c-4bab-841d-c22a2321d7a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_916acabb-ff5c-4bab-841d-c22a2321d7a6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_916acabb-ff5c-4bab-841d-c22a2321d7a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_916acabb-ff5c-4bab-841d-c22a2321d7a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9826f455-0638-49c0-a89d-472f784b4729" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_916acabb-ff5c-4bab-841d-c22a2321d7a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9826f455-0638-49c0-a89d-472f784b4729" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fd60d774-0e11-4854-8d51-1d0d6158dcb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9826f455-0638-49c0-a89d-472f784b4729" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fd60d774-0e11-4854-8d51-1d0d6158dcb1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails" xlink:type="extended" id="i04ecf8031f874c518a2ced32afe0be64_StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ba16dbd3-9c45-4932-8bb5-f9923c305a92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c036378d-55c4-4de7-a754-962461ba1d8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ba16dbd3-9c45-4932-8bb5-f9923c305a92" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c036378d-55c4-4de7-a754-962461ba1d8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0040dcd3-f0ac-4c16-b011-ef629e1615b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ba16dbd3-9c45-4932-8bb5-f9923c305a92" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0040dcd3-f0ac-4c16-b011-ef629e1615b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bc9e1e7c-6a3f-4ffe-bd71-94ee7f0b4a73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0040dcd3-f0ac-4c16-b011-ef629e1615b0" xlink:to="loc_us-gaap_AwardTypeAxis_bc9e1e7c-6a3f-4ffe-bd71-94ee7f0b4a73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc9e1e7c-6a3f-4ffe-bd71-94ee7f0b4a73_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bc9e1e7c-6a3f-4ffe-bd71-94ee7f0b4a73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc9e1e7c-6a3f-4ffe-bd71-94ee7f0b4a73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_805ea59f-a4d2-4684-8ae5-a45b8e4b2568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bc9e1e7c-6a3f-4ffe-bd71-94ee7f0b4a73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_805ea59f-a4d2-4684-8ae5-a45b8e4b2568" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_dbfd55c5-b829-4f1a-a90c-8829b53055ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_805ea59f-a4d2-4684-8ae5-a45b8e4b2568" xlink:to="loc_us-gaap_EmployeeStockOptionMember_dbfd55c5-b829-4f1a-a90c-8829b53055ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_44f5e7cc-b0ce-499b-bbe7-d6cc51f55ecc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0040dcd3-f0ac-4c16-b011-ef629e1615b0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_44f5e7cc-b0ce-499b-bbe7-d6cc51f55ecc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_44f5e7cc-b0ce-499b-bbe7-d6cc51f55ecc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_44f5e7cc-b0ce-499b-bbe7-d6cc51f55ecc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_44f5e7cc-b0ce-499b-bbe7-d6cc51f55ecc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a87ac120-8f92-40c9-9414-425e4b449643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_44f5e7cc-b0ce-499b-bbe7-d6cc51f55ecc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a87ac120-8f92-40c9-9414-425e4b449643" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b1ac6963-fa04-43dd-b1d6-c49b2caedf93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a87ac120-8f92-40c9-9414-425e4b449643" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b1ac6963-fa04-43dd-b1d6-c49b2caedf93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_555f73b3-d39e-4b3a-af9c-0cfe1ba4bac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a87ac120-8f92-40c9-9414-425e4b449643" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_555f73b3-d39e-4b3a-af9c-0cfe1ba4bac9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails" xlink:type="extended" id="i0af50430c8924def867f5ea579673dcc_StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails"/>
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquity" xlink:type="simple" xlink:href="dare-20200930.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockholdersEquity" xlink:type="extended" id="i2a876cb1ec7548949cd9d6a6186fc92f_StockholdersEquity"/>
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="dare-20200930.xsd#StockholdersEquityTables"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockholdersEquityTables" xlink:type="extended" id="i94528788e71a44a8a8dffc61d4ae485f_StockholdersEquityTables"/>
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended" id="ibc0664fa97244746aaeb9a1dd5aae99b_StockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:href="dare-20200930.xsd#dare_StockholdersEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PercentageOfAggregateCommission_8dfb95cd-8c0b-480a-a087-0f296688cbdc" xlink:href="dare-20200930.xsd#dare_PercentageOfAggregateCommission"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_PercentageOfAggregateCommission_8dfb95cd-8c0b-480a-a087-0f296688cbdc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a2e4cdb3-9a7e-416d-9f98-ae6f89c4657c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a2e4cdb3-9a7e-416d-9f98-ae6f89c4657c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_751c0e17-3c10-4fb4-ac4b-10b21ccf579f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_751c0e17-3c10-4fb4-ac4b-10b21ccf579f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_OfferingExpenses_7c8362d6-ee4d-4eea-8fc0-41aa2725efeb" xlink:href="dare-20200930.xsd#dare_OfferingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_OfferingExpenses_7c8362d6-ee4d-4eea-8fc0-41aa2725efeb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_fe143a36-6b7a-45b7-bd16-11256dba9d2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_fe143a36-6b7a-45b7-bd16-11256dba9d2a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_fac2e4ca-6b5b-4a50-b134-c09fb779556f" xlink:href="dare-20200930.xsd#dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_fac2e4ca-6b5b-4a50-b134-c09fb779556f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UnderwritersOptionToPurchaseAdditionalShares_a17ae12c-3880-43db-904d-2a7e4683c9f4" xlink:href="dare-20200930.xsd#dare_UnderwritersOptionToPurchaseAdditionalShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_UnderwritersOptionToPurchaseAdditionalShares_a17ae12c-3880-43db-904d-2a7e4683c9f4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_63c516b3-879c-4f02-b020-e016f3ee789e" xlink:href="dare-20200930.xsd#dare_GrossProceedsFromOfferingOfCommonStockAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_63c516b3-879c-4f02-b020-e016f3ee789e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_df410805-8447-4d29-9734-f811ddbd50a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_df410805-8447-4d29-9734-f811ddbd50a6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_1ee6b853-90b0-48fc-a373-2fe9af867fd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_PurchaseObligation_1ee6b853-90b0-48fc-a373-2fe9af867fd7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SaleofStockMaximumAmountRegistered_28c861fa-edd1-4343-a81b-7c53a816d013" xlink:href="dare-20200930.xsd#dare_SaleofStockMaximumAmountRegistered"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_SaleofStockMaximumAmountRegistered_28c861fa-edd1-4343-a81b-7c53a816d013" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_2fb2339e-1103-4cac-9339-595eaf1c8240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_DeferredOfferingCosts_2fb2339e-1103-4cac-9339-595eaf1c8240" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeferredOfferingCostsUnamortizedPortion_63581056-6b52-4d1e-9052-60a9b3defc2b" xlink:href="dare-20200930.xsd#dare_DeferredOfferingCostsUnamortizedPortion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_DeferredOfferingCostsUnamortizedPortion_63581056-6b52-4d1e-9052-60a9b3defc2b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_eb6214d8-b998-4e42-8a76-3f5ba46d6e3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_eb6214d8-b998-4e42-8a76-3f5ba46d6e3c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_61a9a15b-c2f4-4c97-9b84-907bea8c235d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_61a9a15b-c2f4-4c97-9b84-907bea8c235d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_RegularRepurchaseCommonStockIssuable_d6a1e881-af28-42f7-a2ae-809e9906e9a5" xlink:href="dare-20200930.xsd#dare_RegularRepurchaseCommonStockIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_RegularRepurchaseCommonStockIssuable_d6a1e881-af28-42f7-a2ae-809e9906e9a5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_RegularPurchaseCommonStockIssuableIncreaseAmount_dc3f992f-9377-4b92-a2f7-ae62319364af" xlink:href="dare-20200930.xsd#dare_RegularPurchaseCommonStockIssuableIncreaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_RegularPurchaseCommonStockIssuableIncreaseAmount_dc3f992f-9377-4b92-a2f7-ae62319364af" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_RegularPurchaseCommonStockIssuableMaximumAmount_18a517d4-d7cc-49fe-91ea-6c80693b5389" xlink:href="dare-20200930.xsd#dare_RegularPurchaseCommonStockIssuableMaximumAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_RegularPurchaseCommonStockIssuableMaximumAmount_18a517d4-d7cc-49fe-91ea-6c80693b5389" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommonStockExchangeCap_75a55067-52a4-4c87-897f-819b96487a1b" xlink:href="dare-20200930.xsd#dare_CommonStockExchangeCap"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_CommonStockExchangeCap_75a55067-52a4-4c87-897f-819b96487a1b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_161ae274-b178-4811-886c-329bb6fb97bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_SharePrice_161ae274-b178-4811-886c-329bb6fb97bc" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommonStockExchangeCapPercentage_f7fe1f17-341b-4782-924b-3d4f8dfe331e" xlink:href="dare-20200930.xsd#dare_CommonStockExchangeCapPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_CommonStockExchangeCapPercentage_f7fe1f17-341b-4782-924b-3d4f8dfe331e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_26dea4e7-ce99-439f-92fd-754ae0c520ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_26dea4e7-ce99-439f-92fd-754ae0c520ba" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity_44f5b1db-0a07-4815-ac14-e5dbab36dba9" xlink:href="dare-20200930.xsd#dare_EstimatedFairValueOfWarrantsRecordedInEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity_44f5b1db-0a07-4815-ac14-e5dbab36dba9" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantExercisePriceDecrease_aeabf3c1-7910-49a6-afaa-2eea5b7413ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_WarrantExercisePriceDecrease_aeabf3c1-7910-49a6-afaa-2eea5b7413ad" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_70adfa52-f048-4361-b804-bdd67b2ead59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_70adfa52-f048-4361-b804-bdd67b2ead59" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NumberOfCommonStockWarrantsExercised_4db89767-05a2-44b3-9533-5e27e38cc627" xlink:href="dare-20200930.xsd#dare_NumberOfCommonStockWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_NumberOfCommonStockWarrantsExercised_4db89767-05a2-44b3-9533-5e27e38cc627" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_4dd68f5f-6bfd-4b45-8616-59f4a37c692a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_4dd68f5f-6bfd-4b45-8616-59f4a37c692a" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StockholdersEquityTable_9a25d9bc-d7eb-4041-af52-21d3009fdc8c" xlink:href="dare-20200930.xsd#dare_StockholdersEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_StockholdersEquityTable_9a25d9bc-d7eb-4041-af52-21d3009fdc8c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_0b4f9cc8-8cdd-44fe-afbf-c256de0a6c3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_StockholdersEquityTable_9a25d9bc-d7eb-4041-af52-21d3009fdc8c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_0b4f9cc8-8cdd-44fe-afbf-c256de0a6c3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0b4f9cc8-8cdd-44fe-afbf-c256de0a6c3f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0b4f9cc8-8cdd-44fe-afbf-c256de0a6c3f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0b4f9cc8-8cdd-44fe-afbf-c256de0a6c3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe05a20b-9171-4e7b-9978-f040fe495c32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0b4f9cc8-8cdd-44fe-afbf-c256de0a6c3f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe05a20b-9171-4e7b-9978-f040fe495c32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AtTheMarketSalesAgreementMember_be2c8499-6a08-455e-99c5-caa264626f0b" xlink:href="dare-20200930.xsd#dare_AtTheMarketSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe05a20b-9171-4e7b-9978-f040fe495c32" xlink:to="loc_dare_AtTheMarketSalesAgreementMember_be2c8499-6a08-455e-99c5-caa264626f0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PublicStockOfferingMember_35acc52c-7df6-46eb-ad9c-5fbca625be22" xlink:href="dare-20200930.xsd#dare_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe05a20b-9171-4e7b-9978-f040fe495c32" xlink:to="loc_dare_PublicStockOfferingMember_35acc52c-7df6-46eb-ad9c-5fbca625be22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_f5d98186-4add-4414-a4a6-bf8a0e99d886" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe05a20b-9171-4e7b-9978-f040fe495c32" xlink:to="loc_us-gaap_OverAllotmentOptionMember_f5d98186-4add-4414-a4a6-bf8a0e99d886" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PurchaseAgreementMember_44f78104-e5e9-4b73-8dd4-8cec3ed85dd1" xlink:href="dare-20200930.xsd#dare_PurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe05a20b-9171-4e7b-9978-f040fe495c32" xlink:to="loc_dare_PurchaseAgreementMember_44f78104-e5e9-4b73-8dd4-8cec3ed85dd1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7a3c5c01-9469-45f4-a0d7-9f5cb41595d1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_StockholdersEquityTable_9a25d9bc-d7eb-4041-af52-21d3009fdc8c" xlink:to="loc_dei_LegalEntityAxis_7a3c5c01-9469-45f4-a0d7-9f5cb41595d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7a3c5c01-9469-45f4-a0d7-9f5cb41595d1_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_7a3c5c01-9469-45f4-a0d7-9f5cb41595d1" xlink:to="loc_dei_EntityDomain_7a3c5c01-9469-45f4-a0d7-9f5cb41595d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_318eee92-9142-4429-b984-e3142ae2e40f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_7a3c5c01-9469-45f4-a0d7-9f5cb41595d1" xlink:to="loc_dei_EntityDomain_318eee92-9142-4429-b984-e3142ae2e40f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LincolnParkMember_a11c153d-ff82-48d4-a140-e268b450ab46" xlink:href="dare-20200930.xsd#dare_LincolnParkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_318eee92-9142-4429-b984-e3142ae2e40f" xlink:to="loc_dare_LincolnParkMember_a11c153d-ff82-48d4-a140-e268b450ab46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_93c55e50-6393-4031-8977-789187959f90" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_StockholdersEquityTable_9a25d9bc-d7eb-4041-af52-21d3009fdc8c" xlink:to="loc_srt_CounterpartyNameAxis_93c55e50-6393-4031-8977-789187959f90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93c55e50-6393-4031-8977-789187959f90_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_93c55e50-6393-4031-8977-789187959f90" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93c55e50-6393-4031-8977-789187959f90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_684f2524-4814-4f7b-a4c1-46998aa6b2b4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_93c55e50-6393-4031-8977-789187959f90" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_684f2524-4814-4f7b-a4c1-46998aa6b2b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LincolnParkMember_e195139a-d9bf-4623-9ebb-65443ac5f5c5" xlink:href="dare-20200930.xsd#dare_LincolnParkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_684f2524-4814-4f7b-a4c1-46998aa6b2b4" xlink:to="loc_dare_LincolnParkMember_e195139a-d9bf-4623-9ebb-65443ac5f5c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_640d19df-a81a-4997-a148-bacd173da65d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_StockholdersEquityTable_9a25d9bc-d7eb-4041-af52-21d3009fdc8c" xlink:to="loc_srt_RangeAxis_640d19df-a81a-4997-a148-bacd173da65d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_640d19df-a81a-4997-a148-bacd173da65d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_640d19df-a81a-4997-a148-bacd173da65d" xlink:to="loc_srt_RangeMember_640d19df-a81a-4997-a148-bacd173da65d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a0a6ce6b-85ff-451e-a67e-738e40b790db" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_640d19df-a81a-4997-a148-bacd173da65d" xlink:to="loc_srt_RangeMember_a0a6ce6b-85ff-451e-a67e-738e40b790db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3ced223d-d0dc-41e9-b74f-19636851390d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a0a6ce6b-85ff-451e-a67e-738e40b790db" xlink:to="loc_srt_MinimumMember_3ced223d-d0dc-41e9-b74f-19636851390d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d5824e89-502e-4e7b-a0af-382833d6d1b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a0a6ce6b-85ff-451e-a67e-738e40b790db" xlink:to="loc_srt_MaximumMember_d5824e89-502e-4e7b-a0af-382833d6d1b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8a7872a4-2aa9-484b-8a2a-0a43f50cb213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_StockholdersEquityTable_9a25d9bc-d7eb-4041-af52-21d3009fdc8c" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8a7872a4-2aa9-484b-8a2a-0a43f50cb213" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_8a7872a4-2aa9-484b-8a2a-0a43f50cb213_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8a7872a4-2aa9-484b-8a2a-0a43f50cb213" xlink:to="loc_us-gaap_TypeOfAdoptionMember_8a7872a4-2aa9-484b-8a2a-0a43f50cb213_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_04a9b2c9-d2b6-431c-b6c2-2859cde97723" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8a7872a4-2aa9-484b-8a2a-0a43f50cb213" xlink:to="loc_us-gaap_TypeOfAdoptionMember_04a9b2c9-d2b6-431c-b6c2-2859cde97723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201711Member_ca4155ae-482c-4aaf-b44d-68dd49b323be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201711Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_04a9b2c9-d2b6-431c-b6c2-2859cde97723" xlink:to="loc_us-gaap_AccountingStandardsUpdate201711Member_ca4155ae-482c-4aaf-b44d-68dd49b323be" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails" xlink:type="extended" id="i5281e60076de42a7b2f030ee27c27c57_StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_d95ce360-42fa-4b69-b63b-a7ded13b996c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_639140a7-6e09-4e49-b9d8-e8e322d0d160" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d95ce360-42fa-4b69-b63b-a7ded13b996c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_639140a7-6e09-4e49-b9d8-e8e322d0d160" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e0b9a9fa-ccd1-4782-9079-265dd3247f9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d95ce360-42fa-4b69-b63b-a7ded13b996c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e0b9a9fa-ccd1-4782-9079-265dd3247f9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_c597de1c-5aa2-4787-84c2-b2bc0ed475ff" xlink:href="dare-20200930.xsd#dare_ClassOfWarrantOrRightsWarrantsExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d95ce360-42fa-4b69-b63b-a7ded13b996c" xlink:to="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_c597de1c-5aa2-4787-84c2-b2bc0ed475ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_e576c3a6-9823-4d92-aaac-923f82a85c28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d95ce360-42fa-4b69-b63b-a7ded13b996c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_e576c3a6-9823-4d92-aaac-923f82a85c28" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_c8174007-e364-4439-887b-44ec843e9014" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e576c3a6-9823-4d92-aaac-923f82a85c28" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_c8174007-e364-4439-887b-44ec843e9014" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_c8174007-e364-4439-887b-44ec843e9014_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_c8174007-e364-4439-887b-44ec843e9014" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_c8174007-e364-4439-887b-44ec843e9014_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_111895f8-b94c-4f4d-bf8b-7d6e1d382fe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_c8174007-e364-4439-887b-44ec843e9014" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_111895f8-b94c-4f4d-bf8b-7d6e1d382fe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_3a96cf95-2632-485e-9b8e-a67de1cce8a9" xlink:href="dare-20200930.xsd#dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_111895f8-b94c-4f4d-bf8b-7d6e1d382fe3" xlink:to="loc_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_3a96cf95-2632-485e-9b8e-a67de1cce8a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_5eeb9508-6554-4c62-9ab6-1f107d2db50e" xlink:href="dare-20200930.xsd#dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_111895f8-b94c-4f4d-bf8b-7d6e1d382fe3" xlink:to="loc_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_5eeb9508-6554-4c62-9ab6-1f107d2db50e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_55bc77dd-2201-4dd6-8026-3743ece7b197" xlink:href="dare-20200930.xsd#dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_111895f8-b94c-4f4d-bf8b-7d6e1d382fe3" xlink:to="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_55bc77dd-2201-4dd6-8026-3743ece7b197" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_722a76a9-ba2a-4082-bcee-8e16aeb4ace5" xlink:href="dare-20200930.xsd#dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_111895f8-b94c-4f4d-bf8b-7d6e1d382fe3" xlink:to="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_722a76a9-ba2a-4082-bcee-8e16aeb4ace5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedProperties" xlink:type="simple" xlink:href="dare-20200930.xsd#LeasedProperties"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/LeasedProperties" xlink:type="extended" id="i8224bbccd1e740e7ae69b0b88ecd7c96_LeasedProperties"/>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesTables" xlink:type="simple" xlink:href="dare-20200930.xsd#LeasedPropertiesTables"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/LeasedPropertiesTables" xlink:type="extended" id="i8847d6aa72b94c94b38fe34345419c03_LeasedPropertiesTables"/>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#LeasedPropertiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails" xlink:type="extended" id="ib7f4c86933f149f5956cd32d87cbafc5_LeasedPropertiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_7e9475a6-af12-4b06-bfa6-cdf0d8b27058" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetRentableArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:to="loc_us-gaap_NetRentableArea_7e9475a6-af12-4b06-bfa6-cdf0d8b27058" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d9c0b557-464b-44e4-a099-39f3ecda27eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d9c0b557-464b-44e4-a099-39f3ecda27eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_aad05e77-f5dc-45a1-bd90-2cde9d7c6c2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_aad05e77-f5dc-45a1-bd90-2cde9d7c6c2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_aca02b5d-c967-4f46-9f7a-f798cd3c13f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_aca02b5d-c967-4f46-9f7a-f798cd3c13f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_385c8226-4da2-453f-a81c-07ad05aa5ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_385c8226-4da2-453f-a81c-07ad05aa5ae3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_01918d53-ce6d-4019-8129-34e6473a582d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_01918d53-ce6d-4019-8129-34e6473a582d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_61dce36c-34f0-4eff-bee5-ff27d2a286d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_61dce36c-34f0-4eff-bee5-ff27d2a286d5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_90d0b192-acc4-45e4-a07d-2186c6d11fb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_90d0b192-acc4-45e4-a07d-2186c6d11fb6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_0e595258-49ef-47d1-87b1-3cc54ae15a9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_0e595258-49ef-47d1-87b1-3cc54ae15a9f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_889757ac-ca3a-49a3-91fa-ef3c9250b4a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:to="loc_us-gaap_OperatingLeaseCost_889757ac-ca3a-49a3-91fa-ef3c9250b4a7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_9fb254bf-ba8f-483c-9237-f6e4cdde68e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:to="loc_us-gaap_OperatingLeasePayments_9fb254bf-ba8f-483c-9237-f6e4cdde68e1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_80b8de05-c4d2-4a2a-9046-5c25e58dd062" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_80b8de05-c4d2-4a2a-9046-5c25e58dd062" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_a8c48a8d-dd56-4e9a-8905-28db2f5753ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_a8c48a8d-dd56-4e9a-8905-28db2f5753ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_44fe334a-bc1c-4aad-945a-6242b96dbde1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a8c48a8d-dd56-4e9a-8905-28db2f5753ab" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_44fe334a-bc1c-4aad-945a-6242b96dbde1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_44fe334a-bc1c-4aad-945a-6242b96dbde1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_44fe334a-bc1c-4aad-945a-6242b96dbde1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_44fe334a-bc1c-4aad-945a-6242b96dbde1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_666226b3-1e93-4eaf-939c-723e39bae2c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_44fe334a-bc1c-4aad-945a-6242b96dbde1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_666226b3-1e93-4eaf-939c-723e39bae2c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_f5c70245-b8e7-404a-b7e6-358d0e027338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_666226b3-1e93-4eaf-939c-723e39bae2c5" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_f5c70245-b8e7-404a-b7e6-358d0e027338" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#LeasedPropertiesFutureMinimumLeasePaymentsDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="extended" id="i1596a131588e4d23bdde7bfd1d6a665d_LeasedPropertiesFutureMinimumLeasePaymentsDetails"/>
  <link:roleRef roleURI="http://darebioscience.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="dare-20200930.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/CommitmentsandContingencies" xlink:type="extended" id="ifd727352197e41e8991aa70e287eb095_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://darebioscience.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="ida1ac695911c4c9ca885f59d1512d80f_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommitmentsAndContingenciesLineItems_8a21ec34-f00d-44f0-939a-8f3fa0ffd41d" xlink:href="dare-20200930.xsd#dare_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsiderationCurrent_ef5bb550-b850-435f-948f-9f782498c871" xlink:href="dare-20200930.xsd#dare_AssetAcquisitionContingentConsiderationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_8a21ec34-f00d-44f0-939a-8f3fa0ffd41d" xlink:to="loc_dare_AssetAcquisitionContingentConsiderationCurrent_ef5bb550-b850-435f-948f-9f782498c871" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived_777c4ea0-57af-444e-9503-476821be71f2" xlink:href="dare-20200930.xsd#dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_8a21ec34-f00d-44f0-939a-8f3fa0ffd41d" xlink:to="loc_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived_777c4ea0-57af-444e-9503-476821be71f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2a0d7b9d-2244-45c2-ac2b-1246f7c8a15f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_8a21ec34-f00d-44f0-939a-8f3fa0ffd41d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2a0d7b9d-2244-45c2-ac2b-1246f7c8a15f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NotesPayableCurrentPlusAccruedInterest_774c1b9c-5acb-4174-89eb-2f41d4a22a3f" xlink:href="dare-20200930.xsd#dare_NotesPayableCurrentPlusAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_8a21ec34-f00d-44f0-939a-8f3fa0ffd41d" xlink:to="loc_dare_NotesPayableCurrentPlusAccruedInterest_774c1b9c-5acb-4174-89eb-2f41d4a22a3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommitmentsAndContingenciesTable_e42ff2e5-b135-43b6-ba9c-a364d364f121" xlink:href="dare-20200930.xsd#dare_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_8a21ec34-f00d-44f0-939a-8f3fa0ffd41d" xlink:to="loc_dare_CommitmentsAndContingenciesTable_e42ff2e5-b135-43b6-ba9c-a364d364f121" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_abcb56ec-4183-47ba-8e35-339719e0d29a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_CommitmentsAndContingenciesTable_e42ff2e5-b135-43b6-ba9c-a364d364f121" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_abcb56ec-4183-47ba-8e35-339719e0d29a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_abcb56ec-4183-47ba-8e35-339719e0d29a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_abcb56ec-4183-47ba-8e35-339719e0d29a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_abcb56ec-4183-47ba-8e35-339719e0d29a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_05e43109-d856-4cac-980f-9586e3b65ab2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_abcb56ec-4183-47ba-8e35-339719e0d29a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_05e43109-d856-4cac-980f-9586e3b65ab2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MicrochipsBiotechInc.Member_577fc2bb-7f5b-4e8e-bce4-b4341e783601" xlink:href="dare-20200930.xsd#dare_MicrochipsBiotechInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_05e43109-d856-4cac-980f-9586e3b65ab2" xlink:to="loc_dare_MicrochipsBiotechInc.Member_577fc2bb-7f5b-4e8e-bce4-b4341e783601" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/GrantAward" xlink:type="simple" xlink:href="dare-20200930.xsd#GrantAward"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/GrantAward" xlink:type="extended" id="i3e3b9be445374420a8436688cdb7ac56_GrantAward"/>
  <link:roleRef roleURI="http://darebioscience.com/role/GrantAwardNarrativeDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#GrantAwardNarrativeDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/GrantAwardNarrativeDetails" xlink:type="extended" id="i2549309f8d074f7b9e782fac8b1e0fb3_GrantAwardNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ebf657dd-3f25-4b28-97a3-a9b216b3d675" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ProceedsFromAwardOfGrant_f095ecd8-1586-469a-b9d8-e0b8912d90c9" xlink:href="dare-20200930.xsd#dare_ProceedsFromAwardOfGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ebf657dd-3f25-4b28-97a3-a9b216b3d675" xlink:to="loc_dare_ProceedsFromAwardOfGrant_f095ecd8-1586-469a-b9d8-e0b8912d90c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_549255c7-8ba3-4981-9836-9f42167f717a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ebf657dd-3f25-4b28-97a3-a9b216b3d675" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_549255c7-8ba3-4981-9836-9f42167f717a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_ead3056b-dd62-4fb2-8680-89f11c3e76dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ebf657dd-3f25-4b28-97a3-a9b216b3d675" xlink:to="loc_us-gaap_GrantsReceivable_ead3056b-dd62-4fb2-8680-89f11c3e76dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AdditionalPotentialFundingRelatedToGrantAward_15bba840-0c68-4973-8e45-6a361bcf5fa2" xlink:href="dare-20200930.xsd#dare_AdditionalPotentialFundingRelatedToGrantAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ebf657dd-3f25-4b28-97a3-a9b216b3d675" xlink:to="loc_dare_AdditionalPotentialFundingRelatedToGrantAward_15bba840-0c68-4973-8e45-6a361bcf5fa2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ReceivableForExpensesEligibleForReimbursement_4177a944-1db4-4704-b09e-d56544852b9f" xlink:href="dare-20200930.xsd#dare_ReceivableForExpensesEligibleForReimbursement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ebf657dd-3f25-4b28-97a3-a9b216b3d675" xlink:to="loc_dare_ReceivableForExpensesEligibleForReimbursement_4177a944-1db4-4704-b09e-d56544852b9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ab85190e-c51a-47ea-b249-631dae687492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ebf657dd-3f25-4b28-97a3-a9b216b3d675" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ab85190e-c51a-47ea-b249-631dae687492" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeferredGrantFundingCurrent_c24bb75e-4717-4196-8fef-4878b99d2dec" xlink:href="dare-20200930.xsd#dare_DeferredGrantFundingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ebf657dd-3f25-4b28-97a3-a9b216b3d675" xlink:to="loc_dare_DeferredGrantFundingCurrent_c24bb75e-4717-4196-8fef-4878b99d2dec" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0e42c158-bddd-41f8-a385-65997e331b74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ebf657dd-3f25-4b28-97a3-a9b216b3d675" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0e42c158-bddd-41f8-a385-65997e331b74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7e702371-d7f5-4c82-815c-6f677995195b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0e42c158-bddd-41f8-a385-65997e331b74" xlink:to="loc_srt_ProductOrServiceAxis_7e702371-d7f5-4c82-815c-6f677995195b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7e702371-d7f5-4c82-815c-6f677995195b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7e702371-d7f5-4c82-815c-6f677995195b" xlink:to="loc_srt_ProductsAndServicesDomain_7e702371-d7f5-4c82-815c-6f677995195b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b55a4318-90c2-4e52-9fe4-f0c13eeee63f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7e702371-d7f5-4c82-815c-6f677995195b" xlink:to="loc_srt_ProductsAndServicesDomain_b55a4318-90c2-4e52-9fe4-f0c13eeee63f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrantOvapreneMember_1f47aff2-df49-494e-b221-17d7f53c0dfc" xlink:href="dare-20200930.xsd#dare_GrantOvapreneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b55a4318-90c2-4e52-9fe4-f0c13eeee63f" xlink:to="loc_dare_GrantOvapreneMember_1f47aff2-df49-494e-b221-17d7f53c0dfc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrantDAREFRT1Member_e23067dc-6aa6-41e2-94b4-d986babf87f8" xlink:href="dare-20200930.xsd#dare_GrantDAREFRT1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b55a4318-90c2-4e52-9fe4-f0c13eeee63f" xlink:to="loc_dare_GrantDAREFRT1Member_e23067dc-6aa6-41e2-94b4-d986babf87f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_df0ad762-7674-4018-a02d-73b5d91b2722" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b55a4318-90c2-4e52-9fe4-f0c13eeee63f" xlink:to="loc_us-gaap_GrantMember_df0ad762-7674-4018-a02d-73b5d91b2722" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareTrustFundAxis_5300bea8-67fa-40f1-b642-b98f4cbce0c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareTrustFundAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0e42c158-bddd-41f8-a385-65997e331b74" xlink:to="loc_us-gaap_HealthCareTrustFundAxis_5300bea8-67fa-40f1-b642-b98f4cbce0c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareTrustFundNameDomain_5300bea8-67fa-40f1-b642-b98f4cbce0c9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareTrustFundNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HealthCareTrustFundAxis_5300bea8-67fa-40f1-b642-b98f4cbce0c9" xlink:to="loc_us-gaap_HealthCareTrustFundNameDomain_5300bea8-67fa-40f1-b642-b98f4cbce0c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareTrustFundNameDomain_f1ca33b3-6b1d-4762-9954-5407bdbc5407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareTrustFundNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HealthCareTrustFundAxis_5300bea8-67fa-40f1-b642-b98f4cbce0c9" xlink:to="loc_us-gaap_HealthCareTrustFundNameDomain_f1ca33b3-6b1d-4762-9954-5407bdbc5407" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_BillAndMelindaGatesFoundationMember_4c201184-a1c6-40da-b3c6-f73e23897589" xlink:href="dare-20200930.xsd#dare_BillAndMelindaGatesFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareTrustFundNameDomain_f1ca33b3-6b1d-4762-9954-5407bdbc5407" xlink:to="loc_dare_BillAndMelindaGatesFoundationMember_4c201184-a1c6-40da-b3c6-f73e23897589" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e21df296-c905-4414-b3d5-c8214538f885" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0e42c158-bddd-41f8-a385-65997e331b74" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e21df296-c905-4414-b3d5-c8214538f885" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e21df296-c905-4414-b3d5-c8214538f885_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e21df296-c905-4414-b3d5-c8214538f885" xlink:to="loc_us-gaap_RelatedPartyDomain_e21df296-c905-4414-b3d5-c8214538f885_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ceb6abbb-3bf4-4660-a75b-404c866256f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e21df296-c905-4414-b3d5-c8214538f885" xlink:to="loc_us-gaap_RelatedPartyDomain_ceb6abbb-3bf4-4660-a75b-404c866256f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NationalInstitutesOfHealthMember_e398a0cf-8e01-4c08-87ae-9497809e0d9d" xlink:href="dare-20200930.xsd#dare_NationalInstitutesOfHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_ceb6abbb-3bf4-4660-a75b-404c866256f8" xlink:to="loc_dare_NationalInstitutesOfHealthMember_e398a0cf-8e01-4c08-87ae-9497809e0d9d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerShare" xlink:type="simple" xlink:href="dare-20200930.xsd#NetLossPerShare"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/NetLossPerShare" xlink:type="extended" id="ia9e1356e4e534bbdb9d2dce8674d277c_NetLossPerShare"/>
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="dare-20200930.xsd#NetLossPerShareTables"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/NetLossPerShareTables" xlink:type="extended" id="ia7387c1cb0404546b1307fa3ad6e1f2c_NetLossPerShareTables"/>
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails" xlink:type="extended" id="ic8dac7d8a4734148bb8d64934e07d92a_NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4da36cfd-89ea-4574-a819-62b25d1bf530" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0f0db650-f649-41eb-8ebd-059b247b41e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4da36cfd-89ea-4574-a819-62b25d1bf530" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0f0db650-f649-41eb-8ebd-059b247b41e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_07895570-dba3-4a59-ada1-dcb977706416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4da36cfd-89ea-4574-a819-62b25d1bf530" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_07895570-dba3-4a59-ada1-dcb977706416" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a1c3d03b-2e18-4df7-9d7a-d930de2710c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_07895570-dba3-4a59-ada1-dcb977706416" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a1c3d03b-2e18-4df7-9d7a-d930de2710c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a1c3d03b-2e18-4df7-9d7a-d930de2710c7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a1c3d03b-2e18-4df7-9d7a-d930de2710c7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a1c3d03b-2e18-4df7-9d7a-d930de2710c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f6201065-320c-4c3d-9b57-63e58298a68f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a1c3d03b-2e18-4df7-9d7a-d930de2710c7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f6201065-320c-4c3d-9b57-63e58298a68f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_19af4227-8cd0-4262-b02e-3b5882df1783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f6201065-320c-4c3d-9b57-63e58298a68f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_19af4227-8cd0-4262-b02e-3b5882df1783" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_26deb3a0-58ef-41c3-b44c-ea1e6d4954be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f6201065-320c-4c3d-9b57-63e58298a68f" xlink:to="loc_us-gaap_WarrantMember_26deb3a0-58ef-41c3-b44c-ea1e6d4954be" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://darebioscience.com/role/SubsequentEvents" xlink:type="simple" xlink:href="dare-20200930.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/SubsequentEvents" xlink:type="extended" id="ia4d6044d54dd42f7ac0f461075c16551_SubsequentEvents"/>
  <link:roleRef roleURI="http://darebioscience.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://darebioscience.com/role/SubsequentEventsDetails" xlink:type="extended" id="i64f8c1ed0fd847548637959be18ba323_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_4b851db8-4897-4718-93d6-21a744d52a25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_610afce4-ebb5-4f2e-b8aa-5d39b25ccf82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4b851db8-4897-4718-93d6-21a744d52a25" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_610afce4-ebb5-4f2e-b8aa-5d39b25ccf82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_444cf05c-ae20-420a-829d-8a0aa705c7cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4b851db8-4897-4718-93d6-21a744d52a25" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_444cf05c-ae20-420a-829d-8a0aa705c7cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_7160b8f4-2ce2-4136-bb8d-86711732f4f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_4b851db8-4897-4718-93d6-21a744d52a25" xlink:to="loc_us-gaap_SubsequentEventTable_7160b8f4-2ce2-4136-bb8d-86711732f4f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ad0b072a-5480-4e7e-9039-9037701685fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_7160b8f4-2ce2-4136-bb8d-86711732f4f4" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ad0b072a-5480-4e7e-9039-9037701685fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ad0b072a-5480-4e7e-9039-9037701685fd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ad0b072a-5480-4e7e-9039-9037701685fd" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ad0b072a-5480-4e7e-9039-9037701685fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f21bc27a-78f7-4cb1-82f0-61dc12382391" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ad0b072a-5480-4e7e-9039-9037701685fd" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f21bc27a-78f7-4cb1-82f0-61dc12382391" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_38d73a3f-b3a7-4b01-b06c-23fb76555c54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f21bc27a-78f7-4cb1-82f0-61dc12382391" xlink:to="loc_us-gaap_SubsequentEventMember_38d73a3f-b3a7-4b01-b06c-23fb76555c54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5b00f780-dddb-4a4f-8d70-f5c2ca6eecb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_7160b8f4-2ce2-4136-bb8d-86711732f4f4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5b00f780-dddb-4a4f-8d70-f5c2ca6eecb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5b00f780-dddb-4a4f-8d70-f5c2ca6eecb0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5b00f780-dddb-4a4f-8d70-f5c2ca6eecb0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5b00f780-dddb-4a4f-8d70-f5c2ca6eecb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0ce19570-dc07-48b2-9949-8aa485a8777e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5b00f780-dddb-4a4f-8d70-f5c2ca6eecb0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0ce19570-dc07-48b2-9949-8aa485a8777e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AtTheMarketEquityOfferingsMember_b027430c-071f-4845-8714-6096ddb1b132" xlink:href="dare-20200930.xsd#dare_AtTheMarketEquityOfferingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0ce19570-dc07-48b2-9949-8aa485a8777e" xlink:to="loc_dare_AtTheMarketEquityOfferingsMember_b027430c-071f-4845-8714-6096ddb1b132" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PurchaseAgreementMember_5f5eba86-3a86-4040-95ac-57b75e48c4d1" xlink:href="dare-20200930.xsd#dare_PurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0ce19570-dc07-48b2-9949-8aa485a8777e" xlink:to="loc_dare_PurchaseAgreementMember_5f5eba86-3a86-4040-95ac-57b75e48c4d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c8843499-4727-465e-a571-3ae8cbdbd7e4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_7160b8f4-2ce2-4136-bb8d-86711732f4f4" xlink:to="loc_srt_CounterpartyNameAxis_c8843499-4727-465e-a571-3ae8cbdbd7e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c8843499-4727-465e-a571-3ae8cbdbd7e4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c8843499-4727-465e-a571-3ae8cbdbd7e4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c8843499-4727-465e-a571-3ae8cbdbd7e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_661d9581-50d5-442e-bb52-8f11e22f724c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c8843499-4727-465e-a571-3ae8cbdbd7e4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_661d9581-50d5-442e-bb52-8f11e22f724c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LincolnParkMember_6fba2dae-dbc8-46f9-a2bd-29c292df176c" xlink:href="dare-20200930.xsd#dare_LincolnParkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_661d9581-50d5-442e-bb52-8f11e22f724c" xlink:to="loc_dare_LincolnParkMember_6fba2dae-dbc8-46f9-a2bd-29c292df176c" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>dare-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:9ad61a15-e285-44cc-ad2a-44a040d7fb22,g:5f0dd9b0-b13f-4c69-b05c-880a09202ba6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dare_BillAndMelindaGatesFoundationMember_211c5e49-0146-4834-85a0-f37b73f15609_terseLabel_en-US" xlink:label="lab_dare_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill And Melinda Gates Foundation</link:label>
    <link:label id="lab_dare_BillAndMelindaGatesFoundationMember_label_en-US" xlink:label="lab_dare_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:label id="lab_dare_BillAndMelindaGatesFoundationMember_documentation_en-US" xlink:label="lab_dare_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_BillAndMelindaGatesFoundationMember" xlink:href="dare-20200930.xsd#dare_BillAndMelindaGatesFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_BillAndMelindaGatesFoundationMember" xlink:to="lab_dare_BillAndMelindaGatesFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_13c30b72-ece2-4ebb-ac70-6ccb3d8fc6b9_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_56c468af-e87c-4b41-8c24-7c42e13cdadc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1a4a41cb-9a05-49fb-941e-7dafcd0ea4af_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c3534d6f-cbf8-4e93-b860-c6def42ca324_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_MicrochipsBiotechInc.Member_a9eda895-db25-4a38-ab03-48cb58660c98_terseLabel_en-US" xlink:label="lab_dare_MicrochipsBiotechInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Microchips Biotech, Inc.</link:label>
    <link:label id="lab_dare_MicrochipsBiotechInc.Member_label_en-US" xlink:label="lab_dare_MicrochipsBiotechInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Microchips Biotech, Inc. [Member]</link:label>
    <link:label id="lab_dare_MicrochipsBiotechInc.Member_documentation_en-US" xlink:label="lab_dare_MicrochipsBiotechInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Microchips Biotech, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MicrochipsBiotechInc.Member" xlink:href="dare-20200930.xsd#dare_MicrochipsBiotechInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MicrochipsBiotechInc.Member" xlink:to="lab_dare_MicrochipsBiotechInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_a88df5f1-9ee8-412c-a538-c9f08ed888df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_be93d403-56d2-4f30-a30c-54d0c99bac49_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_8342d10d-b9c5-4edd-a39d-8ffe9cd845b5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_57bbcc02-973d-4151-98d3-fcab2e3c2559_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Stock Warrants Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_3f4e9e73-ef07-4061-9765-86e72dc4c568_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercises, gross</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_056d1684-fcca-4084-ac1a-85d60e62f71d_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_34915362-fa9d-42e4-b551-5b7b91641613_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6669534e-cfa6-4eb3-9fb5-6c8d93c92804_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9b2feee-80cb-4b12-8012-2e42da78815d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_AdditionalPotentialFundingRelatedToGrantAward_c65b93be-8777-442c-be4a-de712f540e5e_terseLabel_en-US" xlink:label="lab_dare_AdditionalPotentialFundingRelatedToGrantAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional potential grant funding</link:label>
    <link:label id="lab_dare_AdditionalPotentialFundingRelatedToGrantAward_label_en-US" xlink:label="lab_dare_AdditionalPotentialFundingRelatedToGrantAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Potential Funding Related To Grant Award</link:label>
    <link:label id="lab_dare_AdditionalPotentialFundingRelatedToGrantAward_documentation_en-US" xlink:label="lab_dare_AdditionalPotentialFundingRelatedToGrantAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Potential Funding Related To Grant Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AdditionalPotentialFundingRelatedToGrantAward" xlink:href="dare-20200930.xsd#dare_AdditionalPotentialFundingRelatedToGrantAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AdditionalPotentialFundingRelatedToGrantAward" xlink:to="lab_dare_AdditionalPotentialFundingRelatedToGrantAward" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_NumberOfCommonStockWarrantsExercised_464dfb6a-039c-42e0-9b47-15d91d44161b_terseLabel_en-US" xlink:label="lab_dare_NumberOfCommonStockWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_dare_NumberOfCommonStockWarrantsExercised_label_en-US" xlink:label="lab_dare_NumberOfCommonStockWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Common Stock Warrants Exercised</link:label>
    <link:label id="lab_dare_NumberOfCommonStockWarrantsExercised_documentation_en-US" xlink:label="lab_dare_NumberOfCommonStockWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock warrants exercised.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NumberOfCommonStockWarrantsExercised" xlink:href="dare-20200930.xsd#dare_NumberOfCommonStockWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NumberOfCommonStockWarrantsExercised" xlink:to="lab_dare_NumberOfCommonStockWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_LicenseAndCollaborationAgreementMember_b585fab5-d0d3-4bcc-87e1-fc6dfe29f630_terseLabel_en-US" xlink:label="lab_dare_LicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreement</link:label>
    <link:label id="lab_dare_LicenseAndCollaborationAgreementMember_label_en-US" xlink:label="lab_dare_LicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreement [Member]</link:label>
    <link:label id="lab_dare_LicenseAndCollaborationAgreementMember_documentation_en-US" xlink:label="lab_dare_LicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAndCollaborationAgreementMember" xlink:href="dare-20200930.xsd#dare_LicenseAndCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAndCollaborationAgreementMember" xlink:to="lab_dare_LicenseAndCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_0201c1ac-9f31-470a-9f9e-56b6451ad6cf_terseLabel_en-US" xlink:label="lab_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated Two Thousand Fourteen Stock Incentive Plan</link:label>
    <link:label id="lab_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_label_en-US" xlink:label="lab_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember" xlink:href="dare-20200930.xsd#dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember" xlink:to="lab_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_MilestonePaymentsContingentAmount_2085aa5c-8200-48f7-8406-772bb5f1075f_terseLabel_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments, contingent amount</link:label>
    <link:label id="lab_dare_MilestonePaymentsContingentAmount_label_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Contingent Amount</link:label>
    <link:label id="lab_dare_MilestonePaymentsContingentAmount_documentation_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments, contingent amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmount" xlink:href="dare-20200930.xsd#dare_MilestonePaymentsContingentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MilestonePaymentsContingentAmount" xlink:to="lab_dare_MilestonePaymentsContingentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_7061f468-cd74-4fb8-baf9-a27a56804e84_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_68e2b7cf-0cdb-4064-8397-4bb6413f9649_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_NationalInstitutesOfHealthMember_b2423bbc-1ff1-4868-be0a-4f571b098fd1_terseLabel_en-US" xlink:label="lab_dare_NationalInstitutesOfHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">National Institutes of Health</link:label>
    <link:label id="lab_dare_NationalInstitutesOfHealthMember_label_en-US" xlink:label="lab_dare_NationalInstitutesOfHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">National Institutes Of Health [Member]</link:label>
    <link:label id="lab_dare_NationalInstitutesOfHealthMember_documentation_en-US" xlink:label="lab_dare_NationalInstitutesOfHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">National Institutes Of Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NationalInstitutesOfHealthMember" xlink:href="dare-20200930.xsd#dare_NationalInstitutesOfHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NationalInstitutesOfHealthMember" xlink:to="lab_dare_NationalInstitutesOfHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_HammockPharmaceuticalsInc.Member_646cb642-5fe7-49bc-b1ea-65fc29e31c12_terseLabel_en-US" xlink:label="lab_dare_HammockPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hammock Pharmaceuticals, Inc</link:label>
    <link:label id="lab_dare_HammockPharmaceuticalsInc.Member_label_en-US" xlink:label="lab_dare_HammockPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hammock Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_dare_HammockPharmaceuticalsInc.Member_documentation_en-US" xlink:label="lab_dare_HammockPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hammock Pharmaceuticals, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_HammockPharmaceuticalsInc.Member" xlink:href="dare-20200930.xsd#dare_HammockPharmaceuticalsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_HammockPharmaceuticalsInc.Member" xlink:to="lab_dare_HammockPharmaceuticalsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_297ced36-6738-4de3-a790-dfe2798b9837_negatedLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow from operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_2fab042b-7c2d-4daa-a5d0-6cc4a4d5732b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 8)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_04ff3736-3b95-49f4-874c-29ce04a5e46e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_d36d6201-5001-44e6-b2d4-eeff25e34bdc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_1ebeecd4-b2b9-44c7-8fdc-045ddca9f616_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_d2726887-31c4-4e24-9183-c72b958e7236_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for measurement of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_1d7342d1-3673-4d25-ab2d-2ecd1e8d3e6b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_21be55ee-5454-41e6-8975-e62f6ad68883_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_c32518c3-20e7-4977-abbf-031c14594f59_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_46e3dfcc-e9ee-4063-a2ef-afd6997f12d1_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_68d89b62-93c3-42a6-9fd8-37f0923830d3_terseLabel_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential annual license maintenance fee, payments in year one</link:label>
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_label_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Annual License Maintenance Fee, Payments In Year One</link:label>
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_documentation_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Annual License Maintenance Fee, Payments In Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" xlink:href="dare-20200930.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" xlink:to="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_15c8fc7a-2d5d-460c-a34a-cc5105b0f6ff_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a6186424-a663-4adb-8809-17c246258659_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_838b7292-5518-4cc9-af5c-8ea055045f11_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e6d2200e-d0ee-44d6-ae15-8dfd01d43390_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_39c78e6a-2d01-4fd4-9d40-48c4828c9881_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_2cdba685-4c92-4413-8d8d-88d2b22b4702_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_13453c78-78e9-4e85-b646-b11f0804a88d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_d41adf44-3170-41cf-9b7e-04b0e26c61b0_terseLabel_en-US" xlink:label="lab_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from offering of common stock and warrants</link:label>
    <link:label id="lab_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_label_en-US" xlink:label="lab_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Proceeds From Offering Of Common Stock And Warrants</link:label>
    <link:label id="lab_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_documentation_en-US" xlink:label="lab_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Proceeds From Offering Of Common Stock And Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants" xlink:href="dare-20200930.xsd#dare_GrossProceedsFromOfferingOfCommonStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants" xlink:to="lab_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareTrustFundAxis_d660b8d7-93e6-41af-b41c-060796ca362f_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareTrustFundAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Trust Fund</link:label>
    <link:label id="lab_us-gaap_HealthCareTrustFundAxis_label_en-US" xlink:label="lab_us-gaap_HealthCareTrustFundAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Trust Fund [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareTrustFundAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareTrustFundAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareTrustFundAxis" xlink:to="lab_us-gaap_HealthCareTrustFundAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_CommonStockExchangeCap_07d9a10b-8eeb-4902-ac26-e50705d70d24_terseLabel_en-US" xlink:label="lab_dare_CommonStockExchangeCap" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange cap (in shares)</link:label>
    <link:label id="lab_dare_CommonStockExchangeCap_label_en-US" xlink:label="lab_dare_CommonStockExchangeCap" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Exchange Cap</link:label>
    <link:label id="lab_dare_CommonStockExchangeCap_documentation_en-US" xlink:label="lab_dare_CommonStockExchangeCap" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Exchange Cap</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommonStockExchangeCap" xlink:href="dare-20200930.xsd#dare_CommonStockExchangeCap"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_CommonStockExchangeCap" xlink:to="lab_dare_CommonStockExchangeCap" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_9ed73675-7ad8-425b-9bdf-8c9736b1717a_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5eec9b2e-febb-4885-a335-24a09f2bf101_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4178a147-3b6e-48b0-a2c4-3942fd427f3f_terseLabel_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_documentation_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination reverse merger recognized identifiable assets acquired and liabilities assumed cash and equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="dare-20200930.xsd#dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_bf12a42c-ec0f-49b1-8ac0-62e4e89b7be9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantExercisePriceDecrease_19ebd2b1-9d49-45fb-aad2-868b3658b855_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantExercisePriceDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant, exercise price, decrease (in usd per share)</link:label>
    <link:label id="lab_us-gaap_WarrantExercisePriceDecrease_label_en-US" xlink:label="lab_us-gaap_WarrantExercisePriceDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant, Exercise Price, Decrease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantExercisePriceDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantExercisePriceDecrease" xlink:to="lab_us-gaap_WarrantExercisePriceDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b22e5b4c-9141-4f3e-a76d-0dcef5e95808_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_045b5567-09ad-4e90-bb75-d570badcc1c2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from grant for notice of award</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_RegularRepurchaseCommonStockIssuable_dca3d420-2c0b-4e74-be3f-259460fca5c3_terseLabel_en-US" xlink:label="lab_dare_RegularRepurchaseCommonStockIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regular purchase, common stock issuable (in shares) (up to)</link:label>
    <link:label id="lab_dare_RegularRepurchaseCommonStockIssuable_label_en-US" xlink:label="lab_dare_RegularRepurchaseCommonStockIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regular Repurchase, Common Stock Issuable</link:label>
    <link:label id="lab_dare_RegularRepurchaseCommonStockIssuable_documentation_en-US" xlink:label="lab_dare_RegularRepurchaseCommonStockIssuable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regular Repurchase, Common Stock Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_RegularRepurchaseCommonStockIssuable" xlink:href="dare-20200930.xsd#dare_RegularRepurchaseCommonStockIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_RegularRepurchaseCommonStockIssuable" xlink:to="lab_dare_RegularRepurchaseCommonStockIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_273c03ab-bdc0-4237-82c0-8bf6f8612e32_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_5a7681e3-51e3-4fba-8bea-871c6378e91e_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing price of the Company's common stock (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_PrivateDareMember_996a1b6d-19b5-45e3-b9fa-b0de52196025_terseLabel_en-US" xlink:label="lab_dare_PrivateDareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Dare</link:label>
    <link:label id="lab_dare_PrivateDareMember_label_en-US" xlink:label="lab_dare_PrivateDareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Dare [Member]</link:label>
    <link:label id="lab_dare_PrivateDareMember_documentation_en-US" xlink:label="lab_dare_PrivateDareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Dare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PrivateDareMember" xlink:href="dare-20200930.xsd#dare_PrivateDareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PrivateDareMember" xlink:to="lab_dare_PrivateDareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_a9285bb0-7197-4e74-aaf5-32dd76bf6c68_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f04d9929-d1a3-4dfe-9854-40f323259898_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_875ad634-25a7-473f-80b4-d3a0e85fcda1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_74ce7d17-c2e9-4571-b98f-5fd26b0f40fc_terseLabel_en-US" xlink:label="lab_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring on December 1, 2021</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_label_en-US" xlink:label="lab_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring On December One Two Thousand Twenty One [Member]</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_documentation_en-US" xlink:label="lab_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expiring on december one two thousand twenty one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember" xlink:href="dare-20200930.xsd#dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember" xlink:to="lab_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_f9522bdf-4756-405e-87b3-ccee436f577b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0a0ddafa-5faf-4c1f-9a57-d6e303736ce0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_db89a456-e863-4120-98bd-a51fdc3984f2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, net of current portion</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_e1c04c8d-753e-4e0c-9b7c-58a4282e4478_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_d643e9b7-b8cd-4f29-9097-595cf51440c4_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9b2ebf6d-9ac9-414a-8eb2-716642699ed1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_8ada1d38-c9c7-4f6b-aa82-ce201b83d6e3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_723ce545-82bd-47fc-a1c4-0518c6ffa431_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d3b3038f-5572-4789-b525-579c8df9b588_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_SalesMilestonesMember_93dae053-9045-4404-a687-0b621d1eac61_terseLabel_en-US" xlink:label="lab_dare_SalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones</link:label>
    <link:label id="lab_dare_SalesMilestonesMember_label_en-US" xlink:label="lab_dare_SalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones [Member]</link:label>
    <link:label id="lab_dare_SalesMilestonesMember_documentation_en-US" xlink:label="lab_dare_SalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SalesMilestonesMember" xlink:href="dare-20200930.xsd#dare_SalesMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_SalesMilestonesMember" xlink:to="lab_dare_SalesMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_0c8bf511-b34e-4d98-8ded-693c541eb8d1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_GrantDAREFRT1Member_f51577ec-9e2b-42e7-a70e-908d9f3f8a23_terseLabel_en-US" xlink:label="lab_dare_GrantDAREFRT1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant, DARE-FRT1</link:label>
    <link:label id="lab_dare_GrantDAREFRT1Member_label_en-US" xlink:label="lab_dare_GrantDAREFRT1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant, DARE-FRT1 [Member]</link:label>
    <link:label id="lab_dare_GrantDAREFRT1Member_documentation_en-US" xlink:label="lab_dare_GrantDAREFRT1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant, DARE-FRT1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrantDAREFRT1Member" xlink:href="dare-20200930.xsd#dare_GrantDAREFRT1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_GrantDAREFRT1Member" xlink:to="lab_dare_GrantDAREFRT1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_7e2f2612-0c5e-412c-a047-c077387bd323_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share - basic and diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_efcf40f6-3ba8-4c2a-abf2-fe44624e9f91_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1ca2f2b9-38e5-4206-ae62-e9308721aac2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_73ae5143-d623-4c5e-9f65-751a6393adf1_terseLabel_en-US" xlink:label="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
    <link:label id="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_label_en-US" xlink:label="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Proceeds From Issuance Of Common Stock And Warrants</link:label>
    <link:label id="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_documentation_en-US" xlink:label="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock and warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:href="dare-20200930.xsd#dare_NetProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7cb1f802-d08d-4cf5-9ee1-f0a822de8e97_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_9b553629-1634-4932-8ba2-4c3f560dd2ab_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_67e25124-2c11-4897-a201-855af38ef881_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate net proceeds on sales of shares of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_UponAchievingCertainCommercialMilestonesMember_48c77ae8-6f80-4a3e-a835-17f922997cd2_terseLabel_en-US" xlink:label="lab_dare_UponAchievingCertainCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Commercial Milestones</link:label>
    <link:label id="lab_dare_UponAchievingCertainCommercialMilestonesMember_label_en-US" xlink:label="lab_dare_UponAchievingCertainCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Commercial Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievingCertainCommercialMilestonesMember_documentation_en-US" xlink:label="lab_dare_UponAchievingCertainCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Commercial Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainCommercialMilestonesMember" xlink:href="dare-20200930.xsd#dare_UponAchievingCertainCommercialMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponAchievingCertainCommercialMilestonesMember" xlink:to="lab_dare_UponAchievingCertainCommercialMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d68f5a5c-e0ad-40c3-b55b-1656fb2ff3b2_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_54b7d9f3-f1c4-4392-86d4-226bcec459ff_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_ce2ab2bf-34a5-4a4b-bde5-741d5648d919_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_9dbf23d3-5ad3-43c0-b109-d9b01c52ba73_terseLabel_en-US" xlink:label="lab_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring on December 6, 2021</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_label_en-US" xlink:label="lab_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring On December Six Two Thousand Twenty One [Member]</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_documentation_en-US" xlink:label="lab_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expiring on december six two thousand twenty one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember" xlink:href="dare-20200930.xsd#dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember" xlink:to="lab_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_f2ecffa3-3074-4eac-a607-6709543652eb_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_53d654bb-6f6b-42bc-86eb-90ac1e7a7df2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition transaction value</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_aea5c1fe-6d1e-4076-8441-a15e1ed5bbf5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase number of outstanding shares of common stock</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_PercentageOfAggregateCommission_07252630-e091-4173-97d8-56da3f91c091_terseLabel_en-US" xlink:label="lab_dare_PercentageOfAggregateCommission" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate commission rate</link:label>
    <link:label id="lab_dare_PercentageOfAggregateCommission_label_en-US" xlink:label="lab_dare_PercentageOfAggregateCommission" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Aggregate Commission</link:label>
    <link:label id="lab_dare_PercentageOfAggregateCommission_documentation_en-US" xlink:label="lab_dare_PercentageOfAggregateCommission" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of aggregate commission.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PercentageOfAggregateCommission" xlink:href="dare-20200930.xsd#dare_PercentageOfAggregateCommission"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PercentageOfAggregateCommission" xlink:to="lab_dare_PercentageOfAggregateCommission" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_be41533d-ca90-4d7b-8948-7fee4cf0b7fa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Assets and Liabilities Remeasured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_5b4237d1-a232-4ef3-833d-3a17ba498a9a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7be15c3d-e75d-4a8f-83f7-476cb6379b33_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_938a5390-d2cf-47d8-90ff-8690c4f83655_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_9437a873-0961-4676-84bf-f73894601d18_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_45a7b5a4-a11f-42b7-a935-09707a76b690_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_BusinessCombinationReverseMergerLineItems_fdefdf08-7f19-4745-9f4f-57e6d5752940_terseLabel_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Reverse Merger [Line Items]</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerLineItems_label_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Reverse Merger [Line Items]</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerLineItems_documentation_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination reverse merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_BusinessCombinationReverseMergerLineItems" xlink:href="dare-20200930.xsd#dare_BusinessCombinationReverseMergerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems" xlink:to="lab_dare_BusinessCombinationReverseMergerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_388e2947-f99d-46d9-b3aa-f17502c4042a_terseLabel_en-US" xlink:label="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Clinical and Regulatory Development Milestones</link:label>
    <link:label id="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_label_en-US" xlink:label="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Clinical And Regulatory Development Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_documentation_en-US" xlink:label="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Clinical And Regulatory Development Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" xlink:href="dare-20200930.xsd#dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" xlink:to="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_ccfcfdbf-ca5a-42af-b716-d16116068d8f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_MilestonePayments_030b583f-e5ff-47ee-837e-948e88d5f787_terseLabel_en-US" xlink:label="lab_dare_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments</link:label>
    <link:label id="lab_dare_MilestonePayments_label_en-US" xlink:label="lab_dare_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments</link:label>
    <link:label id="lab_dare_MilestonePayments_documentation_en-US" xlink:label="lab_dare_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePayments" xlink:href="dare-20200930.xsd#dare_MilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MilestonePayments" xlink:to="lab_dare_MilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_0f7ec2d5-ab5c-4051-84ad-06c26f2efa28_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term of operating lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_09f3700f-606a-4015-8f86-88a3acb56ca7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_06331226-07c9-4a34-a43f-5aaf8fe03696_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_a83c63a0-f25c-4785-bf16-943022f7551a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_610a79c1-27d3-45cb-8dec-0f1fac081969_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_c9e05aaa-e48c-4a66-bc8a-edd3a47fc602_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_097fbb84-0940-499a-a405-4ee57294f44f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8d8538a5-2fb4-4c13-8fcb-c7d04863e05f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_AtTheMarketSalesAgreementMember_28b88a3b-2003-4607-881f-9472aafc1ec8_terseLabel_en-US" xlink:label="lab_dare_AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Sales Agreement</link:label>
    <link:label id="lab_dare_AtTheMarketSalesAgreementMember_label_en-US" xlink:label="lab_dare_AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Sales Agreement [Member]</link:label>
    <link:label id="lab_dare_AtTheMarketSalesAgreementMember_documentation_en-US" xlink:label="lab_dare_AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Sales Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AtTheMarketSalesAgreementMember" xlink:href="dare-20200930.xsd#dare_AtTheMarketSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AtTheMarketSalesAgreementMember" xlink:to="lab_dare_AtTheMarketSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_AssetAcquisitionContingentConsiderationNoncurrent_ca62223b-7843-4aad-bb4b-e1339dfb1596_terseLabel_en-US" xlink:label="lab_dare_AssetAcquisitionContingentConsiderationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, net of current portion</link:label>
    <link:label id="lab_dare_AssetAcquisitionContingentConsiderationNoncurrent_label_en-US" xlink:label="lab_dare_AssetAcquisitionContingentConsiderationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Noncurrent</link:label>
    <link:label id="lab_dare_AssetAcquisitionContingentConsiderationNoncurrent_documentation_en-US" xlink:label="lab_dare_AssetAcquisitionContingentConsiderationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsiderationNoncurrent" xlink:href="dare-20200930.xsd#dare_AssetAcquisitionContingentConsiderationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AssetAcquisitionContingentConsiderationNoncurrent" xlink:to="lab_dare_AssetAcquisitionContingentConsiderationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_BayerHealthcareLicenseAgreementMember_f9f958bc-daaa-48af-bf63-9d653ceaff39_terseLabel_en-US" xlink:label="lab_dare_BayerHealthcareLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer Healthcare License Agreement</link:label>
    <link:label id="lab_dare_BayerHealthcareLicenseAgreementMember_label_en-US" xlink:label="lab_dare_BayerHealthcareLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer Healthcare License Agreement [Member]</link:label>
    <link:label id="lab_dare_BayerHealthcareLicenseAgreementMember_documentation_en-US" xlink:label="lab_dare_BayerHealthcareLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer Healthcare License Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_BayerHealthcareLicenseAgreementMember" xlink:href="dare-20200930.xsd#dare_BayerHealthcareLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_BayerHealthcareLicenseAgreementMember" xlink:to="lab_dare_BayerHealthcareLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_eed9eafa-40de-4fc2-afb2-bbe8e02617de_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_7edb8dde-1b87-4c40-9c5f-04593cc45802_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_CommonStockExchangeCapPercentage_cce9d2b9-b6e0-4044-997b-853972e0c247_terseLabel_en-US" xlink:label="lab_dare_CommonStockExchangeCapPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange cap, percentage</link:label>
    <link:label id="lab_dare_CommonStockExchangeCapPercentage_label_en-US" xlink:label="lab_dare_CommonStockExchangeCapPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Exchange Cap, Percentage</link:label>
    <link:label id="lab_dare_CommonStockExchangeCapPercentage_documentation_en-US" xlink:label="lab_dare_CommonStockExchangeCapPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Exchange Cap, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommonStockExchangeCapPercentage" xlink:href="dare-20200930.xsd#dare_CommonStockExchangeCapPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_CommonStockExchangeCapPercentage" xlink:to="lab_dare_CommonStockExchangeCapPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_705f3b25-ee93-4744-957e-34d101828160_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fbe0c7c8-d6e4-45ea-aa7d-b5cb6ff9f7a1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_77aa3a3f-f33c-4ae1-8504-bcd26e52134b_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e2255fb1-8701-4f59-8c5d-7e28ff2fdeb6_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_90daed59-a9f1-47b1-8d28-e6bf8f72371a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value of options granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_1bd1d47c-0820-47de-be87-4b2703b9233f_terseLabel_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement termination period due to performance failure</link:label>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_label_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Termination Period Due To Performance Failure</link:label>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_documentation_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, termination period due to performance failure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure" xlink:href="dare-20200930.xsd#dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure" xlink:to="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_60aae106-4867-4f9a-a9b9-e6734de3d3f3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d76b52b1-654a-433b-b0aa-694352ae82d8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_c9649818-f833-4ebc-87d5-cf87ff6235cd_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_845527ed-6e92-4c3e-b06b-984097780ce9_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds received in public offering, net of underwriting discounts and offering expenses</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_b5fd1ad2-21d9-4c2f-b726-293282de2b64_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_53b3db00-82f5-469c-b752-a1628cd9cdfc_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_e3a20484-c172-4879-99ad-b85493b24818_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of note payable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_48c0f1bf-b340-487f-a292-c4de4e019767_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_81c52a82-7b15-45ea-96fc-94e7d935a175_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Difference between future minimum lease payments and discounted operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_dc8f34bc-fb4b-4892-9a1a-149e9fdd5f62_terseLabel_en-US" xlink:label="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring on April 4, 2026</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_label_en-US" xlink:label="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring On April Four Two Thousand Twenty Six [Member]</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_documentation_en-US" xlink:label="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expiring on april four two thousand twenty six.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" xlink:href="dare-20200930.xsd#dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" xlink:to="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_CommitmentsAndContingenciesTable_cdb7d491-f89d-4517-80c2-497ca3a2ea92_terseLabel_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_dare_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_dare_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommitmentsAndContingenciesTable" xlink:href="dare-20200930.xsd#dare_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_CommitmentsAndContingenciesTable" xlink:to="lab_dare_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_73787337-16bf-4acc-bae5-2ce65d00213d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_42d85e6f-fd07-4ffb-a2b1-9a9235da437d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_45bc5ffa-2f56-4bfd-aeb0-f7257bab221c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_62b2fc26-cf17-40cc-8b8c-997bed8550f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_9a9dfaed-0daa-489e-86f1-5e74e0cd5679_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal, accounting and other fees related to Purchase Agreement</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c35ad59c-ecf2-4ed9-95ae-03a888c46caa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_7cc27760-1f44-419f-992e-021970a1a62c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_CommitmentsAndContingenciesLineItems_358f587f-8595-4f53-a522-8a05940f6213_terseLabel_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_dare_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_dare_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommitmentsAndContingenciesLineItems" xlink:href="dare-20200930.xsd#dare_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems" xlink:to="lab_dare_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_fcfc8671-c49d-4e2f-856e-44e06586ec57_terseLabel_en-US" xlink:label="lab_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters overallotment option to purchase additional shares of common stock and warrants period</link:label>
    <link:label id="lab_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_label_en-US" xlink:label="lab_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters Option To Purchase Additional Shares Of Common Stock Period</link:label>
    <link:label id="lab_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_documentation_en-US" xlink:label="lab_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters option to purchase additional shares of common stock period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod" xlink:href="dare-20200930.xsd#dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod" xlink:to="lab_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_cb8d4964-7cbb-4976-8091-ceb689f9f993_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_fbfcaff0-8984-47ea-a8e6-fa683584bc95_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_290f91dd-5221-434c-b0d9-456afa6bb8bf_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_63566062-6159-40e1-8223-2992c2be3b34_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d21b241b-e8ca-465d-abdf-a4f598c3cd7d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash adjustments reconciling net loss to operating cash flows:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_OfferingExpenses_cf0dddb7-527f-452a-b525-8eba1470bf2a_terseLabel_en-US" xlink:label="lab_dare_OfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering expenses</link:label>
    <link:label id="lab_dare_OfferingExpenses_label_en-US" xlink:label="lab_dare_OfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Expenses</link:label>
    <link:label id="lab_dare_OfferingExpenses_documentation_en-US" xlink:label="lab_dare_OfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_OfferingExpenses" xlink:href="dare-20200930.xsd#dare_OfferingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_OfferingExpenses" xlink:to="lab_dare_OfferingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived_f2b11253-306d-4edc-b293-bb169d5fbacb_terseLabel_en-US" xlink:label="lab_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan under Paycheck Protection Program</link:label>
    <link:label id="lab_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived_label_en-US" xlink:label="lab_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</link:label>
    <link:label id="lab_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived_documentation_en-US" xlink:label="lab_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived" xlink:href="dare-20200930.xsd#dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived" xlink:to="lab_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_54f8eb87-80a3-4f46-b013-a07bdb6edcb4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_cc339f05-2c4c-4967-b041-0c7d15d994df_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_54b59e53-a91d-44b0-adbe-d44316638bbb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_9b1102a5-00d4-4db6-914f-6dd73312eeed_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2bdfe2a0-10e5-4e84-bbb5-d4a626820fe6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d796c703-0251-4df9-af0b-224f3e4ff31d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_2350b0d6-e627-4521-a1fb-cc1405566b89_terseLabel_en-US" xlink:label="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Fourteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand and fourteen employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:href="dare-20200930.xsd#dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:to="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_9a2c4d2d-11b3-4a1e-a260-06e908942049_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_01ed5448-bf1b-418a-81ad-0320a23cb00c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eaa04a19-5dd8-4fb3-bf8c-fd4b6c8bc3fe_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_WeightedAverageAmortizationPeriod_ed1512ec-34d5-4668-8f52-d0ac8c6b5c15_terseLabel_en-US" xlink:label="lab_dare_WeightedAverageAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Amortization Period</link:label>
    <link:label id="lab_dare_WeightedAverageAmortizationPeriod_label_en-US" xlink:label="lab_dare_WeightedAverageAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Amortization Period</link:label>
    <link:label id="lab_dare_WeightedAverageAmortizationPeriod_documentation_en-US" xlink:label="lab_dare_WeightedAverageAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WeightedAverageAmortizationPeriod" xlink:href="dare-20200930.xsd#dare_WeightedAverageAmortizationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_WeightedAverageAmortizationPeriod" xlink:to="lab_dare_WeightedAverageAmortizationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_9a986b2b-6167-4e15-855b-0ed0dd2d3b07_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6d9a95ce-ad26-483b-b9f8-f3f3d7313b83_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_94036ac4-86b6-4f90-9267-f39179f78b29_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend from trigger of down round provision feature</link:label>
    <link:label id="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_92dd3ca9-6066-413f-8b5b-cf86bf24fb71_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend from trigger of down round provision feature</link:label>
    <link:label id="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_5ef947f3-36c2-44fc-a181-26e2faa6c779_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend from trigger of down round provision</link:label>
    <link:label id="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_label_en-US" xlink:label="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant, Down Round Feature, (Increase) Decrease in Equity, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:to="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a4dbf1c7-91ca-4f2d-95cb-4ab75b7410e6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities long-term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_328d34b1-0b66-48ca-9363-ef857e73cdd4_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten Offering</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_bbb016af-e771-48dd-8fdc-fc21cfdd52ae_terseLabel_en-US" xlink:label="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company</link:label>
    <link:label id="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_label_en-US" xlink:label="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Science And Technologies D Limited Liability Company And Strategic Science Technologies Limited Liability Company [Member]</link:label>
    <link:label id="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_documentation_en-US" xlink:label="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" xlink:href="dare-20200930.xsd#dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" xlink:to="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_37692d4c-0bf7-4365-8267-f4a71af77261_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember_121086d9-c39b-47c5-8cfb-90fa46a5fbab_terseLabel_en-US" xlink:label="lab_dare_UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Delivery of Six Month Batch Development Not Later Than Eleven Months</link:label>
    <link:label id="lab_dare_UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember_label_en-US" xlink:label="lab_dare_UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Delivery Of Six Month Batch Development Not Later Than Eleven Months [Member]</link:label>
    <link:label id="lab_dare_UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember_documentation_en-US" xlink:label="lab_dare_UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Delivery Of Six Month Batch Development Not Later Than Eleven Months [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember" xlink:href="dare-20200930.xsd#dare_UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember" xlink:to="lab_dare_UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_ad1fa712-ee38-4fcd-976d-fbf01508ed7f_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c254821d-4f05-4af1-885c-2cd1ff306990_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2dd813df-fda0-4432-8334-c13190e1bc7f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ResearchAndDevelopmentMilestonePayment_29b92d36-9874-4c28-aaa1-a919759f2b7f_terseLabel_en-US" xlink:label="lab_dare_ResearchAndDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_dare_ResearchAndDevelopmentMilestonePayment_label_en-US" xlink:label="lab_dare_ResearchAndDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Milestone Payment</link:label>
    <link:label id="lab_dare_ResearchAndDevelopmentMilestonePayment_documentation_en-US" xlink:label="lab_dare_ResearchAndDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ResearchAndDevelopmentMilestonePayment" xlink:href="dare-20200930.xsd#dare_ResearchAndDevelopmentMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ResearchAndDevelopmentMilestonePayment" xlink:to="lab_dare_ResearchAndDevelopmentMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_GrantOvapreneMember_a6a3f2ba-7536-48f8-ace1-b70555b0db71_terseLabel_en-US" xlink:label="lab_dare_GrantOvapreneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant, Ovaprene</link:label>
    <link:label id="lab_dare_GrantOvapreneMember_label_en-US" xlink:label="lab_dare_GrantOvapreneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant, Ovaprene [Member]</link:label>
    <link:label id="lab_dare_GrantOvapreneMember_documentation_en-US" xlink:label="lab_dare_GrantOvapreneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant, Ovaprene</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrantOvapreneMember" xlink:href="dare-20200930.xsd#dare_GrantOvapreneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_GrantOvapreneMember" xlink:to="lab_dare_GrantOvapreneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_TwoThousandAndFifteenStockIncentivePlanMember_061d6a81-2e44-4e80-92eb-cc9abc9cdc10_terseLabel_en-US" xlink:label="lab_dare_TwoThousandAndFifteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Stock Incentive Plan</link:label>
    <link:label id="lab_dare_TwoThousandAndFifteenStockIncentivePlanMember_label_en-US" xlink:label="lab_dare_TwoThousandAndFifteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Fifteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_dare_TwoThousandAndFifteenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_dare_TwoThousandAndFifteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Fifteen Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember" xlink:href="dare-20200930.xsd#dare_TwoThousandAndFifteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember" xlink:to="lab_dare_TwoThousandAndFifteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_DeferredGrantFundingCurrent_c8c2ce09-3a65-45e2-b922-49e5c8758f43_terseLabel_en-US" xlink:label="lab_dare_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred grant funding</link:label>
    <link:label id="lab_dare_DeferredGrantFundingCurrent_label_en-US" xlink:label="lab_dare_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding Current</link:label>
    <link:label id="lab_dare_DeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_dare_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeferredGrantFundingCurrent" xlink:href="dare-20200930.xsd#dare_DeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_DeferredGrantFundingCurrent" xlink:to="lab_dare_DeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_f3e7615b-e878-4aff-a79e-7954313eb6e8_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_4daeb952-cda5-4a57-afb7-d2c762097759_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4e15fe03-fa34-453d-87cf-9065c9d22705_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a59ab137-4e33-4a3b-bc85-7bb54c9b3761_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_854a63f7-350e-4829-a38a-76f3bafb4f00_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_SignificantAccountingPoliciesLineItems_b453d50c-3f59-40e9-afae-e612cc3c9eb5_terseLabel_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_dare_SignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_dare_SignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SignificantAccountingPoliciesLineItems" xlink:href="dare-20200930.xsd#dare_SignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems" xlink:to="lab_dare_SignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_223c1503-7d1a-482e-9baa-ab9b9af70554_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_PeriodofInsufficientCashandLiquidityRequirements_70b461c3-3271-42be-9284-ae0688dbcdfb_terseLabel_en-US" xlink:label="lab_dare_PeriodofInsufficientCashandLiquidityRequirements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of insufficient cash and liquidity requirements</link:label>
    <link:label id="lab_dare_PeriodofInsufficientCashandLiquidityRequirements_label_en-US" xlink:label="lab_dare_PeriodofInsufficientCashandLiquidityRequirements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of Insufficient Cash and Liquidity Requirements</link:label>
    <link:label id="lab_dare_PeriodofInsufficientCashandLiquidityRequirements_documentation_en-US" xlink:label="lab_dare_PeriodofInsufficientCashandLiquidityRequirements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of Insufficient Cash and Liquidity Requirements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PeriodofInsufficientCashandLiquidityRequirements" xlink:href="dare-20200930.xsd#dare_PeriodofInsufficientCashandLiquidityRequirements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PeriodofInsufficientCashandLiquidityRequirements" xlink:to="lab_dare_PeriodofInsufficientCashandLiquidityRequirements" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares_eda3d536-f072-4a8d-9c63-ef8ef28f6950_terseLabel_en-US" xlink:label="lab_dare_StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance cost on equity line paid in common stock (in shares)</link:label>
    <link:label id="lab_dare_StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares_label_en-US" xlink:label="lab_dare_StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Consideration For Commitment To Purchase Shares</link:label>
    <link:label id="lab_dare_StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares_documentation_en-US" xlink:label="lab_dare_StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Consideration For Commitment To Purchase Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares" xlink:href="dare-20200930.xsd#dare_StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares" xlink:to="lab_dare_StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_cca6a0cd-770c-4f00-9d33-5196f216af4b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_868dddc4-6e6f-482c-b527-ceab023d7e16_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_75ed4a46-955a-4b7b-a219-525b846be8e9_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_bd6c2ed6-4bd1-4932-848f-d7cf39469548_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_AssignmentAgreementMember_84522e37-a74f-4569-950f-736e283c9c92_terseLabel_en-US" xlink:label="lab_dare_AssignmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement</link:label>
    <link:label id="lab_dare_AssignmentAgreementMember_label_en-US" xlink:label="lab_dare_AssignmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement [Member]</link:label>
    <link:label id="lab_dare_AssignmentAgreementMember_documentation_en-US" xlink:label="lab_dare_AssignmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assignment Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssignmentAgreementMember" xlink:href="dare-20200930.xsd#dare_AssignmentAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AssignmentAgreementMember" xlink:to="lab_dare_AssignmentAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_5d19f36d-25ef-4a0e-85f3-99f24153d784_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_74bea2f8-4f71-4cb5-8bd3-39fae67092b0_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_LicenseFee_b0483366-ac8e-472d-8c95-fabc453db555_terseLabel_en-US" xlink:label="lab_dare_LicenseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fees</link:label>
    <link:label id="lab_dare_LicenseFee_a9aa9a66-ea9d-4872-b4fc-d561f99b9e8a_verboseLabel_en-US" xlink:label="lab_dare_LicenseFee" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fee</link:label>
    <link:label id="lab_dare_LicenseFee_label_en-US" xlink:label="lab_dare_LicenseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fee</link:label>
    <link:label id="lab_dare_LicenseFee_documentation_en-US" xlink:label="lab_dare_LicenseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseFee" xlink:href="dare-20200930.xsd#dare_LicenseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseFee" xlink:to="lab_dare_LicenseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_SignificantAccountingPoliciesTable_68dc0015-89fe-47d6-a396-85e1468881cc_terseLabel_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_dare_SignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_dare_SignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SignificantAccountingPoliciesTable" xlink:href="dare-20200930.xsd#dare_SignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_SignificantAccountingPoliciesTable" xlink:to="lab_dare_SignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_DevelopmentAndOptionAgreementMember_a18a752c-789a-4004-b94a-8a66c1da01b5_terseLabel_en-US" xlink:label="lab_dare_DevelopmentAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Option Agreement</link:label>
    <link:label id="lab_dare_DevelopmentAndOptionAgreementMember_label_en-US" xlink:label="lab_dare_DevelopmentAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Option Agreement [Member]</link:label>
    <link:label id="lab_dare_DevelopmentAndOptionAgreementMember_documentation_en-US" xlink:label="lab_dare_DevelopmentAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Option Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DevelopmentAndOptionAgreementMember" xlink:href="dare-20200930.xsd#dare_DevelopmentAndOptionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_DevelopmentAndOptionAgreementMember" xlink:to="lab_dare_DevelopmentAndOptionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_UpfrontLicenseFeePaid_5cff08ab-ff96-4b78-80a7-378a4f53f7ad_terseLabel_en-US" xlink:label="lab_dare_UpfrontLicenseFeePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront license fee paid</link:label>
    <link:label id="lab_dare_UpfrontLicenseFeePaid_label_en-US" xlink:label="lab_dare_UpfrontLicenseFeePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront License Fee Paid</link:label>
    <link:label id="lab_dare_UpfrontLicenseFeePaid_documentation_en-US" xlink:label="lab_dare_UpfrontLicenseFeePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront License Fee Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UpfrontLicenseFeePaid" xlink:href="dare-20200930.xsd#dare_UpfrontLicenseFeePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UpfrontLicenseFeePaid" xlink:to="lab_dare_UpfrontLicenseFeePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ReceivableForExpensesEligibleForReimbursement_c5c83086-5773-463e-a4a0-d121ef454a2b_terseLabel_en-US" xlink:label="lab_dare_ReceivableForExpensesEligibleForReimbursement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable for expenses eligible for reimbursement</link:label>
    <link:label id="lab_dare_ReceivableForExpensesEligibleForReimbursement_label_en-US" xlink:label="lab_dare_ReceivableForExpensesEligibleForReimbursement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable For Expenses Eligible For Reimbursement</link:label>
    <link:label id="lab_dare_ReceivableForExpensesEligibleForReimbursement_documentation_en-US" xlink:label="lab_dare_ReceivableForExpensesEligibleForReimbursement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable For Expenses Eligible For Reimbursement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ReceivableForExpensesEligibleForReimbursement" xlink:href="dare-20200930.xsd#dare_ReceivableForExpensesEligibleForReimbursement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ReceivableForExpensesEligibleForReimbursement" xlink:to="lab_dare_ReceivableForExpensesEligibleForReimbursement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_a021b580-2ca6-4d2a-abba-8a83977843d8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_14ecf455-8fce-4215-92b5-fe04b3103d1d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred license revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_a0fb9bf2-886e-4ced-9305-3b595fedac8f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased Properties</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_ec5bd976-3856-43b3-9de1-c1d15d06cb9a_terseLabel_en-US" xlink:label="lab_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commencement period for stage two upon achievement of stage one</link:label>
    <link:label id="lab_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_label_en-US" xlink:label="lab_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commencement Period For Stage Two Upon Achievement Of Stage One</link:label>
    <link:label id="lab_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_documentation_en-US" xlink:label="lab_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commencement Period For Stage Two Upon Achievement Of Stage One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne" xlink:href="dare-20200930.xsd#dare_CommencementPeriodForStageTwoUponAchievementOfStageOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne" xlink:to="lab_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_277bce51-b32d-45e4-b2b1-1d09f6b8cf38_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_bcc501c1-dedd-4bf9-bd96-3497d33197cb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_9dc90df9-ef4c-4960-9664-8859145941fa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_1f348349-bf43-4514-a221-17ba916af17f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_94811a86-8459-43cd-bea2-77e65f7fd479_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_70b27008-b5f8-4d7e-ae18-4b17a5cedccd_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_2dfdf470-1abc-4d16-8990-aeeb3e15fd6f_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_db5b3a02-c09e-4350-9651-c695d9084937_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ClinicalAndRegulatoryMilestonesMember_c960cbd5-15bc-4998-988c-4447d09d8d98_terseLabel_en-US" xlink:label="lab_dare_ClinicalAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical and Regulatory Milestones</link:label>
    <link:label id="lab_dare_ClinicalAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_dare_ClinicalAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_dare_ClinicalAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_dare_ClinicalAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical And Regulatory Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ClinicalAndRegulatoryMilestonesMember" xlink:href="dare-20200930.xsd#dare_ClinicalAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ClinicalAndRegulatoryMilestonesMember" xlink:to="lab_dare_ClinicalAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_84670169-4fba-480e-905d-2f4e495c299c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_bc52eaae-a95a-46c2-93e1-e6f903c46b75_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_2387c2c0-a7fc-4652-aad3-29c9553e5c78_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e6b12cda-0bfc-4710-b9df-fc1cb6ac1ef1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetRentableArea_68624319-130e-4277-a0a5-1f1743636935_terseLabel_en-US" xlink:label="lab_us-gaap_NetRentableArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Square footage of office space</link:label>
    <link:label id="lab_us-gaap_NetRentableArea_label_en-US" xlink:label="lab_us-gaap_NetRentableArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Rentable Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetRentableArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetRentableArea" xlink:to="lab_us-gaap_NetRentableArea" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7af11ea6-487a-43e1-a5b7-8853417c724e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_47beae89-0d51-4eee-8c62-9ce46ac25cfd_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_3edd959f-e816-4335-bb68-ae0af8ff08b1_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligation to purchase common stock</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2c5f40db-9162-41f4-8101-4ec6911b7d5e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity for Amended 2014 Plan and Related Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_d8d1ae2f-422b-4142-89f5-841369a99591_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_9eeb1f7c-bc0d-4f80-b839-11b89f43323a_terseLabel_en-US" xlink:label="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Reaching Certain Worldwide Net Sales Milestones</link:label>
    <link:label id="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_label_en-US" xlink:label="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Reaching Certain Worldwide Net Sales Milestones [Member]</link:label>
    <link:label id="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_documentation_en-US" xlink:label="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon reaching certain worldwide net sales milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember" xlink:href="dare-20200930.xsd#dare_UponReachingCertainWorldwideNetSalesMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember" xlink:to="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8af70bc5-b7bc-4950-b9e6-8588fda9f887_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareTrustFundNameDomain_44f4ec3e-d02e-4952-92b2-e6f36833a72e_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareTrustFundNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Trust Fund, Name</link:label>
    <link:label id="lab_us-gaap_HealthCareTrustFundNameDomain_label_en-US" xlink:label="lab_us-gaap_HealthCareTrustFundNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Trust Fund, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareTrustFundNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareTrustFundNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareTrustFundNameDomain" xlink:to="lab_us-gaap_HealthCareTrustFundNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b5452def-cc2b-4f85-b2e4-7ba78eea4646_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_c2214078-e39f-4094-b88d-368518eb34e4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_61d345e6-f4fe-44a3-a133-0a1f54556eae_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_2dd4cdb5-b332-4265-b5b5-5ecae5bfb349_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_UponAchievingCertainDevelopmentMilestonesMember_bdc394de-b251-47f1-9d00-11e0a7b6ad48_terseLabel_en-US" xlink:label="lab_dare_UponAchievingCertainDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Development Milestones</link:label>
    <link:label id="lab_dare_UponAchievingCertainDevelopmentMilestonesMember_label_en-US" xlink:label="lab_dare_UponAchievingCertainDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Development Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievingCertainDevelopmentMilestonesMember_documentation_en-US" xlink:label="lab_dare_UponAchievingCertainDevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achieving Certain Development Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainDevelopmentMilestonesMember" xlink:href="dare-20200930.xsd#dare_UponAchievingCertainDevelopmentMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponAchievingCertainDevelopmentMilestonesMember" xlink:to="lab_dare_UponAchievingCertainDevelopmentMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_423a2376-1f53-4b63-aa27-eedd9bfcba75_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eb2e7fd1-99d5-4a62-9875-7c832ae88502_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_AdarePharmaceuticalsMember_463ab4a3-ffb6-4831-a21f-59a7820750e6_terseLabel_en-US" xlink:label="lab_dare_AdarePharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adare</link:label>
    <link:label id="lab_dare_AdarePharmaceuticalsMember_label_en-US" xlink:label="lab_dare_AdarePharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adare Pharmaceuticals [Member]</link:label>
    <link:label id="lab_dare_AdarePharmaceuticalsMember_documentation_en-US" xlink:label="lab_dare_AdarePharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adare Pharmaceuticals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AdarePharmaceuticalsMember" xlink:href="dare-20200930.xsd#dare_AdarePharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AdarePharmaceuticalsMember" xlink:to="lab_dare_AdarePharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_603ebed2-dd12-41ee-a433-3f920747c2b9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_MaximumPotentialMilestonePayments_eea5f166-0c6e-4fd7-bf47-9930c4321672_terseLabel_en-US" xlink:label="lab_dare_MaximumPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential milestone payments</link:label>
    <link:label id="lab_dare_MaximumPotentialMilestonePayments_label_en-US" xlink:label="lab_dare_MaximumPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Potential Milestone Payments</link:label>
    <link:label id="lab_dare_MaximumPotentialMilestonePayments_documentation_en-US" xlink:label="lab_dare_MaximumPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Potential Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MaximumPotentialMilestonePayments" xlink:href="dare-20200930.xsd#dare_MaximumPotentialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MaximumPotentialMilestonePayments" xlink:to="lab_dare_MaximumPotentialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_39975d53-ef83-41f9-9172-c86b388e1a4a_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_b86136e1-21cd-4b33-81d2-c16c4a364353_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_e3acfe08-c1a9-4ea4-b754-7b19dcc9f4db_terseLabel_en-US" xlink:label="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of common stock warrants</link:label>
    <link:label id="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_label_en-US" xlink:label="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Warrants</link:label>
    <link:label id="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_documentation_en-US" xlink:label="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock and warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:href="dare-20200930.xsd#dare_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_90bb36fe-c483-4693-8e0a-bc72c363132c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2cbb7b37-4c8a-4760-a3c3-81b98eb007c3_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_45e6e939-ebd7-408f-99d3-8845dc3055dc_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_cf40cf20-6d54-4120-bc4f-72d7847e7ca9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_b0d3120f-2125-4922-9bb6-daf6b64e8697_terseLabel_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential annual license maintenance fee payments, thereafter</link:label>
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_label_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Annual License Maintenance Fee Payments, Thereafter</link:label>
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_documentation_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Annual License Maintenance Fee Payments, Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" xlink:href="dare-20200930.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" xlink:to="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3b1cfa8a-5b58-4a82-b7f8-ffdc9005df01_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6ae905b5-8cd8-4159-bb6a-faa86bdd4ee4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_e90c316b-2a8c-492b-af81-20abf8cf952d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_15fb04e5-02e8-42ab-99e3-a6401c31e02f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb520db9-629a-4738-bd02-8c0948e41c8d_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_51780df3-a527-467e-abfd-6b9f0bcc1da5_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_12b1e972-3e05-46b3-b292-1a1af9987346_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares underlying outstanding warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_604dd217-6afa-40d3-96e4-410de4de7646_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_a37b0ec1-1f01-4b6f-801d-6e1b582d8701_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_bfb5ed6d-7216-4231-8a18-2445a20a5244_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_113e32c9-4725-4645-8d8e-4e7d22a8c4a6_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_64a4d177-b520-416e-9b4e-a83c93d88251_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_c3d0bfab-6ae6-403a-a64d-b016b48178b1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_779786ce-7eef-46f3-adc4-105c15e10b60_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_87069a29-ef24-4e91-bc17-13e647ed4904_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_3f00d65a-7142-488c-93df-d7e5afffc847_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual percentage increase in outstanding number of common stock</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_c1bb978a-e77d-4986-b52b-cbfd3b83700f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fe21e054-ebae-4b41-80ad-1934a02f6b36_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_LicenseAgreementNoticePeriodOfTermination_000289b6-4d90-468c-8265-082218f62884_terseLabel_en-US" xlink:label="lab_dare_LicenseAgreementNoticePeriodOfTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain clinical and regulatory development milestone payments</link:label>
    <link:label id="lab_dare_LicenseAgreementNoticePeriodOfTermination_label_en-US" xlink:label="lab_dare_LicenseAgreementNoticePeriodOfTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Notice Period Of Termination</link:label>
    <link:label id="lab_dare_LicenseAgreementNoticePeriodOfTermination_documentation_en-US" xlink:label="lab_dare_LicenseAgreementNoticePeriodOfTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Notice Period Of Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAgreementNoticePeriodOfTermination" xlink:href="dare-20200930.xsd#dare_LicenseAgreementNoticePeriodOfTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAgreementNoticePeriodOfTermination" xlink:to="lab_dare_LicenseAgreementNoticePeriodOfTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8b32d6aa-ff29-4fa4-97f1-e8651566e2d7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_920443f3-b25b-4f02-bb6b-cd9609d1dd83_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_319b3397-4656-4b33-9549-04908ca2cbf1_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_18aa1840-877a-4f98-a854-77695711e91a_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a6c74f1d-4184-485e-a241-db9f74552e21_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_8e4f016f-cffc-4530-bcf3-fbf5bbdba2f1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_16bca8d2-bbbe-4217-a61b-6ff644e4584a_terseLabel_en-US" xlink:label="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_label_en-US" xlink:label="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights Warrants Expiration Date</link:label>
    <link:label id="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_documentation_en-US" xlink:label="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or rights warrants expiration date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate" xlink:href="dare-20200930.xsd#dare_ClassOfWarrantOrRightsWarrantsExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate" xlink:to="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_c1e53b72-ae03-438a-b7c0-23d36652710f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_PercentageOfRoyaltyRate_7a3d3254-307b-40b3-a44a-6c95bec4c35f_terseLabel_en-US" xlink:label="lab_dare_PercentageOfRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalty rate</link:label>
    <link:label id="lab_dare_PercentageOfRoyaltyRate_label_en-US" xlink:label="lab_dare_PercentageOfRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Royalty Rate</link:label>
    <link:label id="lab_dare_PercentageOfRoyaltyRate_documentation_en-US" xlink:label="lab_dare_PercentageOfRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalty rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PercentageOfRoyaltyRate" xlink:href="dare-20200930.xsd#dare_PercentageOfRoyaltyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PercentageOfRoyaltyRate" xlink:to="lab_dare_PercentageOfRoyaltyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1931bec5-4186-4f84-8af4-fbca1aa52f57_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from the exercise of warrants</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_RegularPurchaseCommonStockIssuableIncreaseAmount_8426be37-5f78-4a52-806f-55efe8a34172_terseLabel_en-US" xlink:label="lab_dare_RegularPurchaseCommonStockIssuableIncreaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regular purchase, common stock issuable, increase amount (in shares)</link:label>
    <link:label id="lab_dare_RegularPurchaseCommonStockIssuableIncreaseAmount_label_en-US" xlink:label="lab_dare_RegularPurchaseCommonStockIssuableIncreaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regular Purchase, Common Stock Issuable, Increase Amount</link:label>
    <link:label id="lab_dare_RegularPurchaseCommonStockIssuableIncreaseAmount_documentation_en-US" xlink:label="lab_dare_RegularPurchaseCommonStockIssuableIncreaseAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regular Purchase, Common Stock Issuable, Increase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_RegularPurchaseCommonStockIssuableIncreaseAmount" xlink:href="dare-20200930.xsd#dare_RegularPurchaseCommonStockIssuableIncreaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_RegularPurchaseCommonStockIssuableIncreaseAmount" xlink:to="lab_dare_RegularPurchaseCommonStockIssuableIncreaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_8249c24c-299e-4964-8534-f85723fe57a2_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_85bc51f8-2237-49f3-bb36-a08163f5785b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in number of shares authorized</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_2a7b4900-2e68-4eaf-93a1-bf7e95ade278_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_JuniperPharmaceuticalsInc.Member_6448cabf-7278-46c7-851c-a255dd53c05f_terseLabel_en-US" xlink:label="lab_dare_JuniperPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juniper Pharmaceuticals, Inc</link:label>
    <link:label id="lab_dare_JuniperPharmaceuticalsInc.Member_label_en-US" xlink:label="lab_dare_JuniperPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juniper Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_dare_JuniperPharmaceuticalsInc.Member_documentation_en-US" xlink:label="lab_dare_JuniperPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juniper Pharmaceuticals, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_JuniperPharmaceuticalsInc.Member" xlink:href="dare-20200930.xsd#dare_JuniperPharmaceuticalsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_JuniperPharmaceuticalsInc.Member" xlink:to="lab_dare_JuniperPharmaceuticalsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_460d6be8-7273-451f-a74e-ffb2eddcf8f0_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_748e6339-c39d-4ff3-84c1-c51c278bea6c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 120,000,000 shares authorized; 33,602,516 and 19,683,401 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_f025d994-df75-425b-a752-af4ab8b9e613_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_2dccbf0d-9a35-4af8-baca-260d780f5564_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_DeferredOfferingCostsUnamortizedPortion_dd5c874f-3e61-4e79-9b22-c5143a1df846_terseLabel_en-US" xlink:label="lab_dare_DeferredOfferingCostsUnamortizedPortion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized costs related to legal, accounting, and other fees</link:label>
    <link:label id="lab_dare_DeferredOfferingCostsUnamortizedPortion_label_en-US" xlink:label="lab_dare_DeferredOfferingCostsUnamortizedPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs, Unamortized Portion</link:label>
    <link:label id="lab_dare_DeferredOfferingCostsUnamortizedPortion_documentation_en-US" xlink:label="lab_dare_DeferredOfferingCostsUnamortizedPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs, Unamortized Portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeferredOfferingCostsUnamortizedPortion" xlink:href="dare-20200930.xsd#dare_DeferredOfferingCostsUnamortizedPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_DeferredOfferingCostsUnamortizedPortion" xlink:to="lab_dare_DeferredOfferingCostsUnamortizedPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_IncreaseDecreaseInDeferredGrantFunding_ec101503-8c21-4d7c-bfee-3f6fb2a2c057_negatedTerseLabel_en-US" xlink:label="lab_dare_IncreaseDecreaseInDeferredGrantFunding" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred grant funding</link:label>
    <link:label id="lab_dare_IncreaseDecreaseInDeferredGrantFunding_label_en-US" xlink:label="lab_dare_IncreaseDecreaseInDeferredGrantFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Deferred Grant Funding</link:label>
    <link:label id="lab_dare_IncreaseDecreaseInDeferredGrantFunding_documentation_en-US" xlink:label="lab_dare_IncreaseDecreaseInDeferredGrantFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Deferred Grant Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_IncreaseDecreaseInDeferredGrantFunding" xlink:href="dare-20200930.xsd#dare_IncreaseDecreaseInDeferredGrantFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_IncreaseDecreaseInDeferredGrantFunding" xlink:to="lab_dare_IncreaseDecreaseInDeferredGrantFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_92d965c2-be89-49ec-9047-80f0563f39b3_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_3c1ca9ee-404c-4bd9-aaf0-98473c300a35_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock sale price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_a12ca4db-fa92-4e63-bce3-20388eef392f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_8e1ac875-47df-4264-9f35-78c942028be7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_88560b87-9caf-460a-8088-837728fceda7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination shares issued (in usd per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct_81a773b1-d322-462a-a504-868e69acee75_terseLabel_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement termination periodic discontinued sale of product</link:label>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct_label_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Termination Periodic Discontinued Sale Of Product</link:label>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct_documentation_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Termination Periodic Discontinued Sale Of Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct" xlink:href="dare-20200930.xsd#dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct" xlink:to="lab_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_AssetAcquisitionContingentConsiderationCurrent_b3dd71b2-bc33-43fe-b7b3-330d92697a9d_terseLabel_en-US" xlink:label="lab_dare_AssetAcquisitionContingentConsiderationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of contingent consideration</link:label>
    <link:label id="lab_dare_AssetAcquisitionContingentConsiderationCurrent_label_en-US" xlink:label="lab_dare_AssetAcquisitionContingentConsiderationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Current</link:label>
    <link:label id="lab_dare_AssetAcquisitionContingentConsiderationCurrent_documentation_en-US" xlink:label="lab_dare_AssetAcquisitionContingentConsiderationCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsiderationCurrent" xlink:href="dare-20200930.xsd#dare_AssetAcquisitionContingentConsiderationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AssetAcquisitionContingentConsiderationCurrent" xlink:to="lab_dare_AssetAcquisitionContingentConsiderationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_96ac550b-ef57-4456-b931-5ab722e9ba48_negatedLabel_en-US" xlink:label="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_label_en-US" xlink:label="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Other Non Current Assets And Deferred Charges</link:label>
    <link:label id="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_documentation_en-US" xlink:label="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in other non-current assets and deferred charges.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" xlink:href="dare-20200930.xsd#dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" xlink:to="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_eca904c7-942a-4985-8be2-f45ca6502baf_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_35be306d-26e6-4567-8401-18087f2ca8eb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e6838e97-fd30-4abd-bae5-a1fcb7da40ac_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_080a0e9e-ebbb-4875-9bef-53d154bee32e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_PurchaseAgreementMember_c395bb4b-7ecd-4860-bef8-ba63103d150a_terseLabel_en-US" xlink:label="lab_dare_PurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement</link:label>
    <link:label id="lab_dare_PurchaseAgreementMember_label_en-US" xlink:label="lab_dare_PurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement [Member]</link:label>
    <link:label id="lab_dare_PurchaseAgreementMember_documentation_en-US" xlink:label="lab_dare_PurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PurchaseAgreementMember" xlink:href="dare-20200930.xsd#dare_PurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PurchaseAgreementMember" xlink:to="lab_dare_PurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_UponSigningOfDevelopmentAndOptionAgreementMember_90a6d925-0966-482b-9310-c2d5ef3b623b_terseLabel_en-US" xlink:label="lab_dare_UponSigningOfDevelopmentAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Signing of Development and Option Agreement</link:label>
    <link:label id="lab_dare_UponSigningOfDevelopmentAndOptionAgreementMember_label_en-US" xlink:label="lab_dare_UponSigningOfDevelopmentAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Signing Of Development And Option Agreement [Member]</link:label>
    <link:label id="lab_dare_UponSigningOfDevelopmentAndOptionAgreementMember_documentation_en-US" xlink:label="lab_dare_UponSigningOfDevelopmentAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Signing Of Development And Option Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponSigningOfDevelopmentAndOptionAgreementMember" xlink:href="dare-20200930.xsd#dare_UponSigningOfDevelopmentAndOptionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponSigningOfDevelopmentAndOptionAgreementMember" xlink:to="lab_dare_UponSigningOfDevelopmentAndOptionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ScheduleOfBusinessCombinationReverseMergerTable_36459102-23f3-4412-97a6-3bbd8b41265e_terseLabel_en-US" xlink:label="lab_dare_ScheduleOfBusinessCombinationReverseMergerTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Business Combination Reverse Merger [Table]</link:label>
    <link:label id="lab_dare_ScheduleOfBusinessCombinationReverseMergerTable_label_en-US" xlink:label="lab_dare_ScheduleOfBusinessCombinationReverseMergerTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Business Combination Reverse Merger [Table]</link:label>
    <link:label id="lab_dare_ScheduleOfBusinessCombinationReverseMergerTable_documentation_en-US" xlink:label="lab_dare_ScheduleOfBusinessCombinationReverseMergerTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of business combination reverse merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable" xlink:href="dare-20200930.xsd#dare_ScheduleOfBusinessCombinationReverseMergerTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable" xlink:to="lab_dare_ScheduleOfBusinessCombinationReverseMergerTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_21b5bfad-140b-4d8a-874b-ee50c0fc8ff2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProjectMember_8f9e1374-78c2-4888-a81a-3cb31c57b8ca_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_label_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember" xlink:to="lab_us-gaap_ProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_16942dff-3335-46cf-a611-434ddf46e7d8_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_7cdd01d8-eac0-40e0-9d04-c06de5e7b126_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_81c2c0d6-8618-4a67-986a-34463b437cf3_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_a6d6d72a-efbf-4682-ab82-0bb8cd2fef95_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering expenses</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0667d695-a3b9-400a-ae9e-c985e544f6f3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_332c096c-6260-4f0e-9532-afaed5bbc65b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued to microchips capital stock holders (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ee3b2213-821d-4874-a886-0186d1f4e7e1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_37d8de08-5cdf-43a1-afed-1178a7e7c336_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_33f70b69-5e79-473e-bb69-a03411276f30_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantsReceivable_0595f7b9-dc8b-40c4-b2a0-6e13cea5e1fb_terseLabel_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants receivable</link:label>
    <link:label id="lab_us-gaap_GrantsReceivable_label_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivable" xlink:to="lab_us-gaap_GrantsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_c98795e5-bce2-44e2-a371-178c2fb73246_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expenses</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_3628bcd2-aa87-4aa4-bd1f-7f8eec82a7c1_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_cec2b997-7293-4c00-94b3-afdfcafa1eac_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_34e3b7e9-e256-46ee-a428-5936e3ecf0c9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_IssuanceCostOnEquityPaidInCommonStock_e213ea93-a334-4e50-9f54-81d70fd06243_terseLabel_en-US" xlink:label="lab_dare_IssuanceCostOnEquityPaidInCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance cost on equity paid in common stock</link:label>
    <link:label id="lab_dare_IssuanceCostOnEquityPaidInCommonStock_label_en-US" xlink:label="lab_dare_IssuanceCostOnEquityPaidInCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Cost On Equity Paid In Common Stock</link:label>
    <link:label id="lab_dare_IssuanceCostOnEquityPaidInCommonStock_documentation_en-US" xlink:label="lab_dare_IssuanceCostOnEquityPaidInCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Cost On Equity Paid In Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_IssuanceCostOnEquityPaidInCommonStock" xlink:href="dare-20200930.xsd#dare_IssuanceCostOnEquityPaidInCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_IssuanceCostOnEquityPaidInCommonStock" xlink:to="lab_dare_IssuanceCostOnEquityPaidInCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_NotesPayableCurrentPlusAccruedInterest_c88b1088-4414-4341-a655-a1f36cc93b7c_terseLabel_en-US" xlink:label="lab_dare_NotesPayableCurrentPlusAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable including accrued interest</link:label>
    <link:label id="lab_dare_NotesPayableCurrentPlusAccruedInterest_label_en-US" xlink:label="lab_dare_NotesPayableCurrentPlusAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current, Plus Accrued Interest</link:label>
    <link:label id="lab_dare_NotesPayableCurrentPlusAccruedInterest_documentation_en-US" xlink:label="lab_dare_NotesPayableCurrentPlusAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current, Plus Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NotesPayableCurrentPlusAccruedInterest" xlink:href="dare-20200930.xsd#dare_NotesPayableCurrentPlusAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NotesPayableCurrentPlusAccruedInterest" xlink:to="lab_dare_NotesPayableCurrentPlusAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_LicenseFeeToBePaidUponContingency_f49e1a05-3472-4457-85c0-5b8bb22bb1b4_terseLabel_en-US" xlink:label="lab_dare_LicenseFeeToBePaidUponContingency" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fee to be paid upon contingency</link:label>
    <link:label id="lab_dare_LicenseFeeToBePaidUponContingency_label_en-US" xlink:label="lab_dare_LicenseFeeToBePaidUponContingency" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fee, To Be Paid Upon Contingency</link:label>
    <link:label id="lab_dare_LicenseFeeToBePaidUponContingency_documentation_en-US" xlink:label="lab_dare_LicenseFeeToBePaidUponContingency" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fee, To Be Paid Upon Contingency</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseFeeToBePaidUponContingency" xlink:href="dare-20200930.xsd#dare_LicenseFeeToBePaidUponContingency"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseFeeToBePaidUponContingency" xlink:to="lab_dare_LicenseFeeToBePaidUponContingency" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_866d51af-b8df-4c23-85ec-1f9ce4ce2596_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_1404d84f-8732-4f3c-bfe1-200b2d9d1941_terseLabel_en-US" xlink:label="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of rights to inventions by employees under license agreement</link:label>
    <link:label id="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_label_en-US" xlink:label="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Rights To Inventions By Employees Under License Agreement</link:label>
    <link:label id="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_documentation_en-US" xlink:label="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of rights to inventions by employees under license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" xlink:href="dare-20200930.xsd#dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" xlink:to="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_StockholdersEquityLineItems_597937a2-1231-44c8-aa82-3209ddbd7863_terseLabel_en-US" xlink:label="lab_dare_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Line Items]</link:label>
    <link:label id="lab_dare_StockholdersEquityLineItems_label_en-US" xlink:label="lab_dare_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Line Items]</link:label>
    <link:label id="lab_dare_StockholdersEquityLineItems_documentation_en-US" xlink:label="lab_dare_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StockholdersEquityLineItems" xlink:href="dare-20200930.xsd#dare_StockholdersEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_StockholdersEquityLineItems" xlink:to="lab_dare_StockholdersEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f71728a0-8265-42cd-a890-50f28d1724df_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_45dcccd7-a365-4e22-91fc-2e51423f66b3_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_44ad0cbb-8bb0-47f0-840f-4dc4d476b7de_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_a5371594-09ff-4934-a502-bfeb80fc4150_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4f710a11-88ef-4b91-add0-dcf9bfdfd65c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_16ced38d-3324-43af-bf4b-33ca8e50eb78_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_d50a4c1e-d63e-48f1-9afb-3986bd8ddd2e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_9ad1c317-6ccc-4018-a61a-aebbd3fcb3f8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f4480bd6-d61d-45a8-9346-e2fabed6aa80_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c26943f3-599c-44e7-99c2-43def3e1f752_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_StockholdersEquityTable_7ca3dad6-f83a-47aa-8a75-51dcf7a8c1c2_terseLabel_en-US" xlink:label="lab_dare_StockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Table]</link:label>
    <link:label id="lab_dare_StockholdersEquityTable_label_en-US" xlink:label="lab_dare_StockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Table]</link:label>
    <link:label id="lab_dare_StockholdersEquityTable_documentation_en-US" xlink:label="lab_dare_StockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StockholdersEquityTable" xlink:href="dare-20200930.xsd#dare_StockholdersEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_StockholdersEquityTable" xlink:to="lab_dare_StockholdersEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_e49b03f4-ad46-4e82-98a7-9459eb1381fa_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f4b462f9-b47f-4db1-927f-986045985d7d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6659f9b3-9f66-4030-86fe-28084662d0fe_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_6ef07b93-dea9-46db-8abc-d8e620288277_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_d7083ada-9af5-4650-8a0f-65e51f42db65_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_SaleofStockMaximumAmountRegistered_6d7ab3e8-e912-4d22-b475-a073e68cbfb5_terseLabel_en-US" xlink:label="lab_dare_SaleofStockMaximumAmountRegistered" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock registered for resale (in shares)</link:label>
    <link:label id="lab_dare_SaleofStockMaximumAmountRegistered_label_en-US" xlink:label="lab_dare_SaleofStockMaximumAmountRegistered" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Maximum Amount Registered</link:label>
    <link:label id="lab_dare_SaleofStockMaximumAmountRegistered_documentation_en-US" xlink:label="lab_dare_SaleofStockMaximumAmountRegistered" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Maximum Amount Registered</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SaleofStockMaximumAmountRegistered" xlink:href="dare-20200930.xsd#dare_SaleofStockMaximumAmountRegistered"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_SaleofStockMaximumAmountRegistered" xlink:to="lab_dare_SaleofStockMaximumAmountRegistered" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_87e2c720-0a49-4292-b5dd-2c73aa2217ca_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_220bf79a-f9de-42a8-b8ec-ac5b132b9e6c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_MilanaPharmMember_80632bbc-59ce-4b1c-a49d-e586d52b11de_terseLabel_en-US" xlink:label="lab_dare_MilanaPharmMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MilanaPharm</link:label>
    <link:label id="lab_dare_MilanaPharmMember_label_en-US" xlink:label="lab_dare_MilanaPharmMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MilanaPharm [Member]</link:label>
    <link:label id="lab_dare_MilanaPharmMember_documentation_en-US" xlink:label="lab_dare_MilanaPharmMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MilanaPharm [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilanaPharmMember" xlink:href="dare-20200930.xsd#dare_MilanaPharmMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MilanaPharmMember" xlink:to="lab_dare_MilanaPharmMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_29988297-1636-4921-ad61-8f8fd6dde621_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_51c5fa60-1416-4624-96cf-ca57d2b2fc16_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_ab145d7c-aa67-4257-b183-34e7bff4c7f5_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_AtTheMarketEquityOfferingsMember_a60b2785-9387-4c15-96e0-85f8c57c4945_terseLabel_en-US" xlink:label="lab_dare_AtTheMarketEquityOfferingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-Market Equity Offerings</link:label>
    <link:label id="lab_dare_AtTheMarketEquityOfferingsMember_label_en-US" xlink:label="lab_dare_AtTheMarketEquityOfferingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-Market Equity Offerings [Member]</link:label>
    <link:label id="lab_dare_AtTheMarketEquityOfferingsMember_documentation_en-US" xlink:label="lab_dare_AtTheMarketEquityOfferingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-Market Equity Offerings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AtTheMarketEquityOfferingsMember" xlink:href="dare-20200930.xsd#dare_AtTheMarketEquityOfferingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AtTheMarketEquityOfferingsMember" xlink:to="lab_dare_AtTheMarketEquityOfferingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_625693f4-5098-42e0-92e3-1910d42f26e7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred license revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_1baa17e9-caf7-448b-a7b6-2a134d1cd074_terseLabel_en-US" xlink:label="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring on February 15, 2023</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_label_en-US" xlink:label="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member]</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_documentation_en-US" xlink:label="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" xlink:href="dare-20200930.xsd#dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" xlink:to="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_c597e071-8b18-4299-a1c1-db38c78eb0e7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_db0514a4-87cc-4564-a5d4-9bb46d635fa3_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash operating and financing activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_UnderwritersOptionToPurchaseAdditionalShares_37240269-8f59-48dc-977a-069c7197ce6a_terseLabel_en-US" xlink:label="lab_dare_UnderwritersOptionToPurchaseAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters option to purchase additional shares</link:label>
    <link:label id="lab_dare_UnderwritersOptionToPurchaseAdditionalShares_label_en-US" xlink:label="lab_dare_UnderwritersOptionToPurchaseAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters Option To Purchase Additional Shares</link:label>
    <link:label id="lab_dare_UnderwritersOptionToPurchaseAdditionalShares_documentation_en-US" xlink:label="lab_dare_UnderwritersOptionToPurchaseAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters option to purchase additional shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UnderwritersOptionToPurchaseAdditionalShares" xlink:href="dare-20200930.xsd#dare_UnderwritersOptionToPurchaseAdditionalShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UnderwritersOptionToPurchaseAdditionalShares" xlink:to="lab_dare_UnderwritersOptionToPurchaseAdditionalShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1e52870d-3482-4eb5-be53-ffef1c45f73a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_bf9c0fb7-f6ff-4e4b-8566-02991c6ac5dc_terseLabel_en-US" xlink:label="lab_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Completion of Fifty Percent Development Not Later Than Six Months</link:label>
    <link:label id="lab_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_label_en-US" xlink:label="lab_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Completion Of Fifty Percent Development Not Later Than Six Months [Member]</link:label>
    <link:label id="lab_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_documentation_en-US" xlink:label="lab_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Completion Of Fifty Percent Development Not Later Than Six Months [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember" xlink:href="dare-20200930.xsd#dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember" xlink:to="lab_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_bc9d6158-928f-41ae-9821-15a333de7926_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8bdaf772-e45b-40ca-934c-211817bdf818_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_195b3786-c313-4af6-a8bc-d30643d4b212_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_8987a2b6-6e08-4bed-b3cd-557ecf8e5db5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_ba17a87a-6265-4e26-a4f1-93ef8b976408_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_96823bd6-86eb-4943-a4a5-fbef29c48016_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental borrowing rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ca353385-f88b-40d1-a35d-f3fa490ca2bd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_63ce28fd-db66-4eb9-8732-2335fa297414_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued and sold</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_GrantAwardTextBlock_23314c5a-7652-4a42-9c61-51586c782e45_terseLabel_en-US" xlink:label="lab_dare_GrantAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Award</link:label>
    <link:label id="lab_dare_GrantAwardTextBlock_label_en-US" xlink:label="lab_dare_GrantAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Award [Text Block]</link:label>
    <link:label id="lab_dare_GrantAwardTextBlock_documentation_en-US" xlink:label="lab_dare_GrantAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Award [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrantAwardTextBlock" xlink:href="dare-20200930.xsd#dare_GrantAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_GrantAwardTextBlock" xlink:to="lab_dare_GrantAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1922f900-6ec5-430e-b84d-3cd98c96c051_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note annual interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_376b7be9-0760-4988-a86b-3151033de3fc_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f22c913a-fdc3-4f42-97e3-83caf40f7bba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d475a2c4-572f-4787-90e0-495662ec92c2_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_cec934cf-efc3-4aa9-a195-23cc902fab23_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_43ad19ef-4aad-40d8-97dd-5c4f40daaa12_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_b57ef5c4-30ec-49d3-b6fa-42f29a62fd3d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_7f62d3a0-e00e-43ff-b447-44c326db1713_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6b51869c-01a7-4a91-bdf8-bb60c6dd0d44_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201711Member_85710da8-cb0a-48ae-8d1d-2ac603e3eafd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201711Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2017-11</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201711Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201711Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2017-11 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201711Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201711Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201711Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201711Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_be68c16c-5c15-44c0-ac0d-8352c4837a80_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_cc42344e-f8ec-4cbe-ac66-b80c39103ff4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c93f95d3-94c7-45c4-bd25-3d625e7ba326_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled/forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_9ff7b5c4-a3bc-4aa4-a435-9de3291929f9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_22821ea7-54e9-45d5-9cd0-6f7ad1fe8cf1_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_e37beb4a-32cc-4475-a6b7-ab893986e55a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_e948a4e0-3a8f-4fd4-bbb1-6beda506695c_terseLabel_en-US" xlink:label="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achievement of Specified Development and Regulatory Milestones</link:label>
    <link:label id="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Achievement Of Specified Development And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon achievement of specified development and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" xlink:href="dare-20200930.xsd#dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" xlink:to="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_cb3fd50d-a511-4308-a112-8f136200f0c8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_ffe5e47f-c95a-4225-bab6-b2970a0b3591_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Description of the Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_8e05bfca-4e0e-4adf-974e-0337e660405e_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_6d9a011a-93b9-405a-88c7-e5e80df9554e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0fa68dc0-af52-4012-a17a-6a88f2590098_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_93c2374e-5b83-4cca-ace4-18e7a3cf1823_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_5592b769-73c5-4b1c-babf-b1cc806564f7_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_fb5f1a09-3383-46bc-9944-99bd7fcf51dc_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity_b5f6d39e-95ea-44c6-98ac-102a07aaf54f_terseLabel_en-US" xlink:label="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of warrants recorded in equity</link:label>
    <link:label id="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity_label_en-US" xlink:label="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value Of Warrants Recorded In Equity</link:label>
    <link:label id="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity_documentation_en-US" xlink:label="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value Of Warrants Recorded In Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity" xlink:href="dare-20200930.xsd#dare_EstimatedFairValueOfWarrantsRecordedInEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity" xlink:to="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_3296742a-8831-4ce6-9dc1-1ef2fa5ff98f_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_LincolnParkMember_98d22b6d-ac0b-42b7-a86e-818aab0c9ee4_terseLabel_en-US" xlink:label="lab_dare_LincolnParkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Park</link:label>
    <link:label id="lab_dare_LincolnParkMember_label_en-US" xlink:label="lab_dare_LincolnParkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Park [Member]</link:label>
    <link:label id="lab_dare_LincolnParkMember_documentation_en-US" xlink:label="lab_dare_LincolnParkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Park</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LincolnParkMember" xlink:href="dare-20200930.xsd#dare_LincolnParkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LincolnParkMember" xlink:to="lab_dare_LincolnParkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_NonCashLeaseExpense_09561102-f6d4-4bab-93ee-187f6881aaf2_terseLabel_en-US" xlink:label="lab_dare_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating lease cost</link:label>
    <link:label id="lab_dare_NonCashLeaseExpense_label_en-US" xlink:label="lab_dare_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:label id="lab_dare_NonCashLeaseExpense_documentation_en-US" xlink:label="lab_dare_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NonCashLeaseExpense" xlink:href="dare-20200930.xsd#dare_NonCashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NonCashLeaseExpense" xlink:to="lab_dare_NonCashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_82630307-62b3-4a91-b46b-9f1821bd06e8_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3ebacd16-53ba-4cd3-9aed-369835939074_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_ca0aba96-8380-4f53-abe9-84371e4445df_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7ff829b0-53cd-46e1-b9e3-ba9e5ec73310_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_dba19ef7-dc5d-4245-8828-99b28264dbc6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e5c2925c-2d13-4856-8840-85d95d76faaa_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_79ba08d8-7a4c-4d0a-9785-ca10e7bbb190_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_886332b6-d6e5-42a6-be52-bb34613e2dda_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_3bfb01a6-ec3f-40ae-bdc6-1d8b6f34f513_terseLabel_en-US" xlink:label="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeiture rate</link:label>
    <link:label id="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_label_en-US" xlink:label="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate</link:label>
    <link:label id="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_documentation_en-US" xlink:label="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by Share-based payment award fair value assumptions forfeiture rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:href="dare-20200930.xsd#dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:to="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_1b5f5300-5c32-40b7-8bb1-8d439b51e065_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_5968284c-e5b8-4217-98c0-b37dc10f24ea_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f2c6bb0a-fe55-4301-b053-34e263923200_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares_debf0054-c5a6-4958-a71d-7851f768cd5b_terseLabel_en-US" xlink:label="lab_dare_StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance cost on equity line paid in common stock</link:label>
    <link:label id="lab_dare_StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares_label_en-US" xlink:label="lab_dare_StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Consideration For Commitment To Purchase Shares</link:label>
    <link:label id="lab_dare_StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares_documentation_en-US" xlink:label="lab_dare_StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Consideration For Commitment To Purchase Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares" xlink:href="dare-20200930.xsd#dare_StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares" xlink:to="lab_dare_StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_b4c19c98-1f2c-4891-90a4-4c50f4155457_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_PublicStockOfferingMember_f6bd2832-303a-44a9-93f7-ff5ec0cb4b6e_terseLabel_en-US" xlink:label="lab_dare_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:label id="lab_dare_PublicStockOfferingMember_label_en-US" xlink:label="lab_dare_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:label id="lab_dare_PublicStockOfferingMember_documentation_en-US" xlink:label="lab_dare_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PublicStockOfferingMember" xlink:href="dare-20200930.xsd#dare_PublicStockOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PublicStockOfferingMember" xlink:to="lab_dare_PublicStockOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e71f6cbf-fa74-4f44-a18e-589a3b3df811_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_6d3ab4c8-8e4a-418b-84f1-732b26f23c07_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_f327f552-af67-41fc-9d2f-b053dba73b87_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f831e45-90c2-4bf0-86a7-988565dcf4f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bddc988-6e97-41a2-9f9d-ba7e7107b230_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ADVATecAgreementMember_85beb297-ae2c-42d5-88c0-e16519a83728_terseLabel_en-US" xlink:label="lab_dare_ADVATecAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVA Tec Agreement</link:label>
    <link:label id="lab_dare_ADVATecAgreementMember_label_en-US" xlink:label="lab_dare_ADVATecAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A D V A Tec Agreement [Member]</link:label>
    <link:label id="lab_dare_ADVATecAgreementMember_documentation_en-US" xlink:label="lab_dare_ADVATecAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVA Tec agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ADVATecAgreementMember" xlink:href="dare-20200930.xsd#dare_ADVATecAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ADVATecAgreementMember" xlink:to="lab_dare_ADVATecAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_8c540dda-5eca-4222-a565-d92300fe87f2_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_bf143c2c-a3fd-4330-a489-96a72f5d5c5b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_6b1651a6-b11b-4726-ae86-3767f6ae8198_terseLabel_en-US" xlink:label="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from the exercise of warrants (in shares)</link:label>
    <link:label id="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_label_en-US" xlink:label="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares</link:label>
    <link:label id="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_documentation_en-US" xlink:label="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" xlink:href="dare-20200930.xsd#dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" xlink:to="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_47666898-df00-46ba-a82a-b34c949097f9_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_5a2f429a-f348-4687-9e2d-d2e7ff8c2412_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_53dca50e-ba10-43d3-903b-3a1bde4f3005_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits recorded to research and development expense for costs related to award</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9edaa100-9b57-46bc-97d5-951fd163852d_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_02dfaf49-5f94-4434-b6b4-9d5ffc22e1fa_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_a3c034ab-f616-4aea-b9d5-8da956483e39_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_ProceedsFromAwardOfGrant_4189fd64-dcf5-4d65-88f3-69df982e4109_terseLabel_en-US" xlink:label="lab_dare_ProceedsFromAwardOfGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount awarded for grant</link:label>
    <link:label id="lab_dare_ProceedsFromAwardOfGrant_label_en-US" xlink:label="lab_dare_ProceedsFromAwardOfGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Award Of Grant</link:label>
    <link:label id="lab_dare_ProceedsFromAwardOfGrant_documentation_en-US" xlink:label="lab_dare_ProceedsFromAwardOfGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Award Of Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ProceedsFromAwardOfGrant" xlink:href="dare-20200930.xsd#dare_ProceedsFromAwardOfGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ProceedsFromAwardOfGrant" xlink:to="lab_dare_ProceedsFromAwardOfGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_2c69186d-fcd7-48fb-87d7-805d37464544_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_f5fbcfa9-2509-40c5-9d37-aefc2f60d31f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_5fe8707a-d55d-45ac-8f4b-6354c606bc57_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dare_RegularPurchaseCommonStockIssuableMaximumAmount_2d49acc3-33dc-4c9d-9b4a-610f86105f4f_terseLabel_en-US" xlink:label="lab_dare_RegularPurchaseCommonStockIssuableMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regular purchase, common stock issuable, maximum amount (in shares)</link:label>
    <link:label id="lab_dare_RegularPurchaseCommonStockIssuableMaximumAmount_label_en-US" xlink:label="lab_dare_RegularPurchaseCommonStockIssuableMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regular Purchase, Common Stock Issuable, Maximum Amount</link:label>
    <link:label id="lab_dare_RegularPurchaseCommonStockIssuableMaximumAmount_documentation_en-US" xlink:label="lab_dare_RegularPurchaseCommonStockIssuableMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regular Purchase, Common Stock Issuable, Maximum Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dare_RegularPurchaseCommonStockIssuableMaximumAmount" xlink:href="dare-20200930.xsd#dare_RegularPurchaseCommonStockIssuableMaximumAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_RegularPurchaseCommonStockIssuableMaximumAmount" xlink:to="lab_dare_RegularPurchaseCommonStockIssuableMaximumAmount" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>dare-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:9ad61a15-e285-44cc-ad2a-44a040d7fb22,g:5f0dd9b0-b13f-4c69-b05c-880a09202ba6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://darebioscience.com/role/CoverPage" xlink:type="simple" xlink:href="dare-20200930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_285097ab-9685-4a25-943f-353fb161b850" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_DocumentType_285097ab-9685-4a25-943f-353fb161b850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_5f98635b-1dfd-49bf-9932-9299416e62b7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_DocumentQuarterlyReport_5f98635b-1dfd-49bf-9932-9299416e62b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_708346ab-4186-4a7f-a391-cb3c0eb14d25" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_DocumentPeriodEndDate_708346ab-4186-4a7f-a391-cb3c0eb14d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_ffa2a364-3da2-4045-9c25-0b93ebff7c55" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_DocumentTransitionReport_ffa2a364-3da2-4045-9c25-0b93ebff7c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e3232381-af61-48db-8eb5-b1e7ea8cba5a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_EntityRegistrantName_e3232381-af61-48db-8eb5-b1e7ea8cba5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e2ae7c88-4771-4766-ab43-834e230f72f3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_AmendmentFlag_e2ae7c88-4771-4766-ab43-834e230f72f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_91955f4e-57f0-4b92-8f8d-d26f274d5423" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_DocumentFiscalYearFocus_91955f4e-57f0-4b92-8f8d-d26f274d5423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_77bcba79-f653-4dc9-a2f9-6577a71fcbcd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_DocumentFiscalPeriodFocus_77bcba79-f653-4dc9-a2f9-6577a71fcbcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_89b500e2-12e5-4248-acf6-3fcefdd725cd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_EntityCentralIndexKey_89b500e2-12e5-4248-acf6-3fcefdd725cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_4851f6d2-0480-4941-9914-541aeb021700" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_CurrentFiscalYearEndDate_4851f6d2-0480-4941-9914-541aeb021700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c87d89f7-f66a-4ba0-939f-94ab6950d2c2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c87d89f7-f66a-4ba0-939f-94ab6950d2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2b067e5c-8781-4996-9c05-b5952475d84b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_EntityFileNumber_2b067e5c-8781-4996-9c05-b5952475d84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_5e2c5242-0b59-4280-9caf-c98a76dbdc64" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_EntityTaxIdentificationNumber_5e2c5242-0b59-4280-9caf-c98a76dbdc64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c43cad9c-6d37-4767-b445-fd96c811ce27" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_EntityAddressAddressLine1_c43cad9c-6d37-4767-b445-fd96c811ce27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_c61b38d4-c2f9-4506-b84f-81ce656649a3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_EntityAddressAddressLine2_c61b38d4-c2f9-4506-b84f-81ce656649a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b6dcf59b-87bd-44fd-aa26-e5163a738ffd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_EntityAddressCityOrTown_b6dcf59b-87bd-44fd-aa26-e5163a738ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a76909f2-8d11-4c6e-bfe7-7df931b1af11" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_EntityAddressStateOrProvince_a76909f2-8d11-4c6e-bfe7-7df931b1af11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9650b1f1-bdc8-445f-9b1c-32d3a71bbc6d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_CityAreaCode_9650b1f1-bdc8-445f-9b1c-32d3a71bbc6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ba9b2ed1-f1e6-4db0-8b92-f12f2af39444" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_LocalPhoneNumber_ba9b2ed1-f1e6-4db0-8b92-f12f2af39444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_10b3d840-eb43-403f-b3e9-1d22a14de580" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_EntityAddressPostalZipCode_10b3d840-eb43-403f-b3e9-1d22a14de580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_87838879-1ba7-45ae-bb71-8719c3aaf3eb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_Security12bTitle_87838879-1ba7-45ae-bb71-8719c3aaf3eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_bfebb47d-8de8-4253-88d2-34b45d6e8310" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_TradingSymbol_bfebb47d-8de8-4253-88d2-34b45d6e8310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c1cc1cfc-9e15-49c5-9558-8179dcd1c994" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_EntityCurrentReportingStatus_c1cc1cfc-9e15-49c5-9558-8179dcd1c994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_fa3c21a6-2d0b-49b8-aa27-d9adfadb7e38" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_EntityInteractiveDataCurrent_fa3c21a6-2d0b-49b8-aa27-d9adfadb7e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_4cb81842-d297-460e-a1f0-7e73016b30ee" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_EntityFilerCategory_4cb81842-d297-460e-a1f0-7e73016b30ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_16938a19-b25a-4de6-b943-b96fc5d0999f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_EntitySmallBusiness_16938a19-b25a-4de6-b943-b96fc5d0999f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f87b2719-ad85-457f-8dbf-e6720b806cb6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_EntityEmergingGrowthCompany_f87b2719-ad85-457f-8dbf-e6720b806cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_9cd87dfd-8f32-4256-85a7-cf4f89339276" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_EntityShellCompany_9cd87dfd-8f32-4256-85a7-cf4f89339276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_da033a74-de4a-4f45-8a5a-118d067ae875" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a7841826-7af2-43b9-ba40-b1f8b6a6769d" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_da033a74-de4a-4f45-8a5a-118d067ae875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="dare-20200930.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d986e6b7-47f7-4219-a321-51732ce457af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_35542593-d87a-4d7e-a56e-fe19a492c3cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d986e6b7-47f7-4219-a321-51732ce457af" xlink:to="loc_us-gaap_AssetsAbstract_35542593-d87a-4d7e-a56e-fe19a492c3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_83a0854e-e099-4b2d-88fa-2fd2fbf96f9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_35542593-d87a-4d7e-a56e-fe19a492c3cd" xlink:to="loc_us-gaap_AssetsCurrentAbstract_83a0854e-e099-4b2d-88fa-2fd2fbf96f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_231d381c-fc4c-4717-9d24-9179a1858563" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_83a0854e-e099-4b2d-88fa-2fd2fbf96f9a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_231d381c-fc4c-4717-9d24-9179a1858563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_0fb81157-cedc-4968-b0ea-f124bd811b03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_83a0854e-e099-4b2d-88fa-2fd2fbf96f9a" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_0fb81157-cedc-4968-b0ea-f124bd811b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1a57139b-de1c-4be1-87a7-b9939bf87d96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_83a0854e-e099-4b2d-88fa-2fd2fbf96f9a" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_1a57139b-de1c-4be1-87a7-b9939bf87d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_07a3a55c-139c-4455-90b3-6a16bada06de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_83a0854e-e099-4b2d-88fa-2fd2fbf96f9a" xlink:to="loc_us-gaap_AssetsCurrent_07a3a55c-139c-4455-90b3-6a16bada06de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3a073f78-0e37-4f25-ae43-ea4835a479dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_35542593-d87a-4d7e-a56e-fe19a492c3cd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3a073f78-0e37-4f25-ae43-ea4835a479dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4243e186-28c6-4ead-9878-5251922e1f31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_35542593-d87a-4d7e-a56e-fe19a492c3cd" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4243e186-28c6-4ead-9878-5251922e1f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_590c45bf-9807-4fa3-989c-02a82b7c8d66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_35542593-d87a-4d7e-a56e-fe19a492c3cd" xlink:to="loc_us-gaap_Assets_590c45bf-9807-4fa3-989c-02a82b7c8d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15fd7879-10af-49f2-9d4b-ad435064e2e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d986e6b7-47f7-4219-a321-51732ce457af" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15fd7879-10af-49f2-9d4b-ad435064e2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_80fa4e42-03c4-4bf0-b92c-06290af0ebcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15fd7879-10af-49f2-9d4b-ad435064e2e0" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_80fa4e42-03c4-4bf0-b92c-06290af0ebcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_15b51f6d-4638-48b2-bba1-93c5394a0520" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_80fa4e42-03c4-4bf0-b92c-06290af0ebcd" xlink:to="loc_us-gaap_AccountsPayableCurrent_15b51f6d-4638-48b2-bba1-93c5394a0520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_964d9b00-a887-4773-aa34-88b744aa1e97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_80fa4e42-03c4-4bf0-b92c-06290af0ebcd" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_964d9b00-a887-4773-aa34-88b744aa1e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeferredGrantFundingCurrent_b05138dd-ab3b-4972-b7fa-af9f25552d92" xlink:href="dare-20200930.xsd#dare_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_80fa4e42-03c4-4bf0-b92c-06290af0ebcd" xlink:to="loc_dare_DeferredGrantFundingCurrent_b05138dd-ab3b-4972-b7fa-af9f25552d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_6fed1c6e-9c85-462b-b001-113d8b7db831" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_80fa4e42-03c4-4bf0-b92c-06290af0ebcd" xlink:to="loc_us-gaap_NotesPayableCurrent_6fed1c6e-9c85-462b-b001-113d8b7db831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_b59c0f7d-e9c6-4fdc-a247-ece4e0546d06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_80fa4e42-03c4-4bf0-b92c-06290af0ebcd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_b59c0f7d-e9c6-4fdc-a247-ece4e0546d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ec2c7252-6d11-4c3a-8531-94ec75fcb414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_80fa4e42-03c4-4bf0-b92c-06290af0ebcd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ec2c7252-6d11-4c3a-8531-94ec75fcb414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_821eb59c-3ecf-46a4-a963-70bf388fc239" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_80fa4e42-03c4-4bf0-b92c-06290af0ebcd" xlink:to="loc_us-gaap_LiabilitiesCurrent_821eb59c-3ecf-46a4-a963-70bf388fc239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_86709df9-e015-4a48-bff7-0ba75f4da7e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15fd7879-10af-49f2-9d4b-ad435064e2e0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_86709df9-e015-4a48-bff7-0ba75f4da7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_df953b54-0e9c-4f28-8b74-bea8d5e8c0c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15fd7879-10af-49f2-9d4b-ad435064e2e0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_df953b54-0e9c-4f28-8b74-bea8d5e8c0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a8e69c31-3a6b-488a-9e89-ef9da055a86d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15fd7879-10af-49f2-9d4b-ad435064e2e0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a8e69c31-3a6b-488a-9e89-ef9da055a86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7ce5dd34-d7a0-44a6-80cc-f7c6b07b6419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15fd7879-10af-49f2-9d4b-ad435064e2e0" xlink:to="loc_us-gaap_Liabilities_7ce5dd34-d7a0-44a6-80cc-f7c6b07b6419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5de659ec-6393-4023-aeb6-8c6286de72d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15fd7879-10af-49f2-9d4b-ad435064e2e0" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5de659ec-6393-4023-aeb6-8c6286de72d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_d93a93ba-e0da-499f-bc53-88e364328bc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15fd7879-10af-49f2-9d4b-ad435064e2e0" xlink:to="loc_us-gaap_StockholdersEquityAbstract_d93a93ba-e0da-499f-bc53-88e364328bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a4446c31-ef03-426f-be2d-95c2b3456185" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d93a93ba-e0da-499f-bc53-88e364328bc2" xlink:to="loc_us-gaap_PreferredStockValue_a4446c31-ef03-426f-be2d-95c2b3456185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_57ac0470-2569-44a8-846a-065510b537d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d93a93ba-e0da-499f-bc53-88e364328bc2" xlink:to="loc_us-gaap_CommonStockValue_57ac0470-2569-44a8-846a-065510b537d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0d004fa1-3278-4487-bcca-a3ee1ba0f44f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d93a93ba-e0da-499f-bc53-88e364328bc2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0d004fa1-3278-4487-bcca-a3ee1ba0f44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ae23c749-b24c-4b8b-9605-7ab560a3cf0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d93a93ba-e0da-499f-bc53-88e364328bc2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ae23c749-b24c-4b8b-9605-7ab560a3cf0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a5e394c0-64ec-4c3d-b1c6-0a2eebae0d58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d93a93ba-e0da-499f-bc53-88e364328bc2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a5e394c0-64ec-4c3d-b1c6-0a2eebae0d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4b6170f0-e889-4a15-9f2e-28a2e97ac76f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d93a93ba-e0da-499f-bc53-88e364328bc2" xlink:to="loc_us-gaap_StockholdersEquity_4b6170f0-e889-4a15-9f2e-28a2e97ac76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_47ee38c7-d4db-45a9-965a-b4e75c1d1c39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15fd7879-10af-49f2-9d4b-ad435064e2e0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_47ee38c7-d4db-45a9-965a-b4e75c1d1c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="dare-20200930.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_13e5d846-7ffc-4721-ad4f-7b56d3771fde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_fe150a9d-04f7-4d04-b5f3-4b09d68c8b05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_13e5d846-7ffc-4721-ad4f-7b56d3771fde" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_fe150a9d-04f7-4d04-b5f3-4b09d68c8b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3b2fa2c4-7293-438b-b0d0-997ba95262ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_13e5d846-7ffc-4721-ad4f-7b56d3771fde" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3b2fa2c4-7293-438b-b0d0-997ba95262ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_18e22a20-2701-4bc1-8ef4-55bcb7f4d8ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_13e5d846-7ffc-4721-ad4f-7b56d3771fde" xlink:to="loc_us-gaap_PreferredStockSharesIssued_18e22a20-2701-4bc1-8ef4-55bcb7f4d8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d99b44b7-d1d4-4314-a85b-d74e20280460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_13e5d846-7ffc-4721-ad4f-7b56d3771fde" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d99b44b7-d1d4-4314-a85b-d74e20280460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5b537061-5f88-42eb-8749-338b2f38251e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_13e5d846-7ffc-4721-ad4f-7b56d3771fde" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5b537061-5f88-42eb-8749-338b2f38251e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9282e410-f446-4887-be58-cdc59c67ef53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_13e5d846-7ffc-4721-ad4f-7b56d3771fde" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9282e410-f446-4887-be58-cdc59c67ef53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2d2290a7-2c9b-4c1d-8871-5e7f0ed8df54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_13e5d846-7ffc-4721-ad4f-7b56d3771fde" xlink:to="loc_us-gaap_CommonStockSharesIssued_2d2290a7-2c9b-4c1d-8871-5e7f0ed8df54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e2c8ba32-2674-4976-a6f1-197aad58c9e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_13e5d846-7ffc-4721-ad4f-7b56d3771fde" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e2c8ba32-2674-4976-a6f1-197aad58c9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="dare-20200930.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_165c85eb-7790-4f6b-ac0f-6153bac0b5f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_44c4ea3f-0659-4ad4-a1fe-034b16fd9d4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_165c85eb-7790-4f6b-ac0f-6153bac0b5f9" xlink:to="loc_us-gaap_OperatingExpensesAbstract_44c4ea3f-0659-4ad4-a1fe-034b16fd9d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3aae8edb-d2fa-40a7-b3e9-b07b6db2bc62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_44c4ea3f-0659-4ad4-a1fe-034b16fd9d4c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3aae8edb-d2fa-40a7-b3e9-b07b6db2bc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a6932fae-7cce-434c-9b73-f5be7e58e217" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_44c4ea3f-0659-4ad4-a1fe-034b16fd9d4c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a6932fae-7cce-434c-9b73-f5be7e58e217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseFee_f5d15402-3a0d-475d-8611-efa510d717cf" xlink:href="dare-20200930.xsd#dare_LicenseFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_44c4ea3f-0659-4ad4-a1fe-034b16fd9d4c" xlink:to="loc_dare_LicenseFee_f5d15402-3a0d-475d-8611-efa510d717cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ad1b1cd9-cb16-4add-bd7c-8a6261e41ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_44c4ea3f-0659-4ad4-a1fe-034b16fd9d4c" xlink:to="loc_us-gaap_OperatingExpenses_ad1b1cd9-cb16-4add-bd7c-8a6261e41ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fc95d017-f325-47d0-a99d-6226e2d01fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_165c85eb-7790-4f6b-ac0f-6153bac0b5f9" xlink:to="loc_us-gaap_OperatingIncomeLoss_fc95d017-f325-47d0-a99d-6226e2d01fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_71807052-bb20-4d59-b51a-26a62a43a12e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_165c85eb-7790-4f6b-ac0f-6153bac0b5f9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_71807052-bb20-4d59-b51a-26a62a43a12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5e595f78-99ea-4f8f-b3ce-885edb8aabd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_165c85eb-7790-4f6b-ac0f-6153bac0b5f9" xlink:to="loc_us-gaap_NetIncomeLoss_5e595f78-99ea-4f8f-b3ce-885edb8aabd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_b5c33cc3-57d7-4500-b541-4837d8a209df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_165c85eb-7790-4f6b-ac0f-6153bac0b5f9" xlink:to="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_b5c33cc3-57d7-4500-b541-4837d8a209df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4262f52b-1fd3-4434-af20-9dd0bc681c96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_165c85eb-7790-4f6b-ac0f-6153bac0b5f9" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4262f52b-1fd3-4434-af20-9dd0bc681c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_61e08728-67d6-44f7-b15e-4caba4274fbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_165c85eb-7790-4f6b-ac0f-6153bac0b5f9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_61e08728-67d6-44f7-b15e-4caba4274fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_52871a47-ccbf-4164-b38b-ca44c9496e1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_165c85eb-7790-4f6b-ac0f-6153bac0b5f9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_52871a47-ccbf-4164-b38b-ca44c9496e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_318a7bf3-202c-49a7-8340-36a28f78004f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_165c85eb-7790-4f6b-ac0f-6153bac0b5f9" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_318a7bf3-202c-49a7-8340-36a28f78004f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_89c35235-c340-49fe-bbbe-cd18c3d42dcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_165c85eb-7790-4f6b-ac0f-6153bac0b5f9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_89c35235-c340-49fe-bbbe-cd18c3d42dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9c21adec-b51f-408a-ad58-d480b9331ddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_89c35235-c340-49fe-bbbe-cd18c3d42dcb" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9c21adec-b51f-408a-ad58-d480b9331ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="dare-20200930.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_04c9b988-93db-43f7-a810-08356e0de731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d83ac518-6b10-4dcc-b407-a30592cdbd83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_04c9b988-93db-43f7-a810-08356e0de731" xlink:to="loc_us-gaap_StatementTable_d83ac518-6b10-4dcc-b407-a30592cdbd83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_84d2e033-0254-49f9-8a1a-cf16ddebe3b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d83ac518-6b10-4dcc-b407-a30592cdbd83" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_84d2e033-0254-49f9-8a1a-cf16ddebe3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c63cea62-00a8-48e4-98cb-11b4f4076cee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_84d2e033-0254-49f9-8a1a-cf16ddebe3b5" xlink:to="loc_us-gaap_EquityComponentDomain_c63cea62-00a8-48e4-98cb-11b4f4076cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e8df3af2-432e-4626-a06b-5c741a095c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c63cea62-00a8-48e4-98cb-11b4f4076cee" xlink:to="loc_us-gaap_CommonStockMember_e8df3af2-432e-4626-a06b-5c741a095c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f70a95dc-a0e9-4b4b-96cd-3043140a5eab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c63cea62-00a8-48e4-98cb-11b4f4076cee" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f70a95dc-a0e9-4b4b-96cd-3043140a5eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a7b74af3-1190-4732-b294-23322ef5fb39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c63cea62-00a8-48e4-98cb-11b4f4076cee" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a7b74af3-1190-4732-b294-23322ef5fb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d32608a5-260b-40ce-92a1-e9dcda47c150" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c63cea62-00a8-48e4-98cb-11b4f4076cee" xlink:to="loc_us-gaap_RetainedEarningsMember_d32608a5-260b-40ce-92a1-e9dcda47c150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cc9dbfe4-49dd-4bee-bd55-11ae794f1519" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d83ac518-6b10-4dcc-b407-a30592cdbd83" xlink:to="loc_us-gaap_StatementLineItems_cc9dbfe4-49dd-4bee-bd55-11ae794f1519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cc9dbfe4-49dd-4bee-bd55-11ae794f1519" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c8b32406-841c-41f7-9d97-073c63aa38ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_us-gaap_StockholdersEquity_c8b32406-841c-41f7-9d97-073c63aa38ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_5a334478-c7c8-4eb7-b3d0-0c6974406e0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_us-gaap_SharesOutstanding_5a334478-c7c8-4eb7-b3d0-0c6974406e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9f47e2ad-233a-4b1a-92c0-1a1c2647b931" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9f47e2ad-233a-4b1a-92c0-1a1c2647b931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_99845256-54a5-4f79-9639-767aa447d872" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_99845256-54a5-4f79-9639-767aa447d872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_10faec07-af5e-4f22-970f-1564ce69ba3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_10faec07-af5e-4f22-970f-1564ce69ba3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares_458bf55c-f1e2-4fe4-a4f3-a591db17effc" xlink:href="dare-20200930.xsd#dare_StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_dare_StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares_458bf55c-f1e2-4fe4-a4f3-a591db17effc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares_ea5d9687-991b-4d86-8bd9-74d3baf90b64" xlink:href="dare-20200930.xsd#dare_StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_dare_StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares_ea5d9687-991b-4d86-8bd9-74d3baf90b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_546f2b0a-d6bb-4600-921a-30544c047cbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_546f2b0a-d6bb-4600-921a-30544c047cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_3ddf0ee9-ef7c-47fe-8449-454b125eda81" xlink:href="dare-20200930.xsd#dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_3ddf0ee9-ef7c-47fe-8449-454b125eda81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7b3a5c93-c8ae-468c-9377-688c252dc929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7b3a5c93-c8ae-468c-9377-688c252dc929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b9528f66-617f-4632-ad88-6173b7caac36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b9528f66-617f-4632-ad88-6173b7caac36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_e2270a6d-50f7-494f-ae0b-c387aba8b784" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_e2270a6d-50f7-494f-ae0b-c387aba8b784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7c230d34-4ca0-45c9-bb6f-f07d8d5740cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_us-gaap_NetIncomeLoss_7c230d34-4ca0-45c9-bb6f-f07d8d5740cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4587424f-dbc1-448f-9fa2-85148fa286cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4587424f-dbc1-448f-9fa2-85148fa286cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_69228f94-d369-4dbb-9710-81bbdde3012a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_us-gaap_StockholdersEquity_69228f94-d369-4dbb-9710-81bbdde3012a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_5e5d9e89-97e6-4669-b953-4e6745fbb061" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bf7abd5-46d1-432a-bb1e-274440dfab72" xlink:to="loc_us-gaap_SharesOutstanding_5e5d9e89-97e6-4669-b953-4e6745fbb061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="dare-20200930.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f1146cb2-08ab-4d64-baef-4ff1489658c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d3396130-cf12-4dfb-bf53-289864dad832" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f1146cb2-08ab-4d64-baef-4ff1489658c2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d3396130-cf12-4dfb-bf53-289864dad832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e025b3fe-d265-40cc-a493-2e940ac836bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d3396130-cf12-4dfb-bf53-289864dad832" xlink:to="loc_us-gaap_ProfitLoss_e025b3fe-d265-40cc-a493-2e940ac836bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cbd5e927-0b34-4601-ae0e-f6b5b72d19c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d3396130-cf12-4dfb-bf53-289864dad832" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cbd5e927-0b34-4601-ae0e-f6b5b72d19c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_39e9f26a-339c-4e0f-b40d-199d79fd135e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cbd5e927-0b34-4601-ae0e-f6b5b72d19c4" xlink:to="loc_us-gaap_Depreciation_39e9f26a-339c-4e0f-b40d-199d79fd135e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_810b1181-8fed-4ec6-a39d-170832dc49c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cbd5e927-0b34-4601-ae0e-f6b5b72d19c4" xlink:to="loc_us-gaap_ShareBasedCompensation_810b1181-8fed-4ec6-a39d-170832dc49c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NonCashLeaseExpense_87097aea-1464-428c-889f-20e92764e0b9" xlink:href="dare-20200930.xsd#dare_NonCashLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cbd5e927-0b34-4601-ae0e-f6b5b72d19c4" xlink:to="loc_dare_NonCashLeaseExpense_87097aea-1464-428c-889f-20e92764e0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7544de3d-9c80-4b2e-924e-9a811d6e7e8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cbd5e927-0b34-4601-ae0e-f6b5b72d19c4" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7544de3d-9c80-4b2e-924e-9a811d6e7e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_288a3c79-40a9-462c-8618-ac93d932ca76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7544de3d-9c80-4b2e-924e-9a811d6e7e8a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_288a3c79-40a9-462c-8618-ac93d932ca76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_ae9e7202-b42d-4d22-b706-547159cc56d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7544de3d-9c80-4b2e-924e-9a811d6e7e8a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_ae9e7202-b42d-4d22-b706-547159cc56d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_e570ceb8-c683-46f0-ac7f-1f254ec99aba" xlink:href="dare-20200930.xsd#dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7544de3d-9c80-4b2e-924e-9a811d6e7e8a" xlink:to="loc_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_e570ceb8-c683-46f0-ac7f-1f254ec99aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0622b842-9dab-4884-9278-4ab15cf24258" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7544de3d-9c80-4b2e-924e-9a811d6e7e8a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0622b842-9dab-4884-9278-4ab15cf24258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_18c1bed5-3755-43df-b5de-6f4e78680019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7544de3d-9c80-4b2e-924e-9a811d6e7e8a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_18c1bed5-3755-43df-b5de-6f4e78680019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_IncreaseDecreaseInDeferredGrantFunding_38c55db0-dde2-4f6a-9cd5-1b5c48aa2350" xlink:href="dare-20200930.xsd#dare_IncreaseDecreaseInDeferredGrantFunding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7544de3d-9c80-4b2e-924e-9a811d6e7e8a" xlink:to="loc_dare_IncreaseDecreaseInDeferredGrantFunding_38c55db0-dde2-4f6a-9cd5-1b5c48aa2350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fed9dc64-d939-4a9a-bc92-ac5b797b955d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7544de3d-9c80-4b2e-924e-9a811d6e7e8a" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fed9dc64-d939-4a9a-bc92-ac5b797b955d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab2d64dc-99da-4e91-af4b-fedcf753be7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d3396130-cf12-4dfb-bf53-289864dad832" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab2d64dc-99da-4e91-af4b-fedcf753be7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d58c7f12-4f36-41e5-996b-b4db3079d05a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f1146cb2-08ab-4d64-baef-4ff1489658c2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d58c7f12-4f36-41e5-996b-b4db3079d05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_55befe17-fb3d-40fb-918d-881cfe07e1ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d58c7f12-4f36-41e5-996b-b4db3079d05a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_55befe17-fb3d-40fb-918d-881cfe07e1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_57f1e722-0738-425c-846b-c14412e1be55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d58c7f12-4f36-41e5-996b-b4db3079d05a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_57f1e722-0738-425c-846b-c14412e1be55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_52b3bb5b-4255-488f-bb1c-77282e17546d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f1146cb2-08ab-4d64-baef-4ff1489658c2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_52b3bb5b-4255-488f-bb1c-77282e17546d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_107714ae-e1af-471b-be39-5b8f006ac811" xlink:href="dare-20200930.xsd#dare_NetProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_52b3bb5b-4255-488f-bb1c-77282e17546d" xlink:to="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_107714ae-e1af-471b-be39-5b8f006ac811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_74d943d6-6fe9-4cb8-9633-911e101c0243" xlink:href="dare-20200930.xsd#dare_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_52b3bb5b-4255-488f-bb1c-77282e17546d" xlink:to="loc_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_74d943d6-6fe9-4cb8-9633-911e101c0243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_21c95571-c35b-456c-ac07-df49b68dd5b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_52b3bb5b-4255-488f-bb1c-77282e17546d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_21c95571-c35b-456c-ac07-df49b68dd5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_af8e425e-8e9a-49f5-bbfd-16ac6e83fcb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_52b3bb5b-4255-488f-bb1c-77282e17546d" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_af8e425e-8e9a-49f5-bbfd-16ac6e83fcb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a931c221-ca7d-47f9-b10e-f1993c230af7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_52b3bb5b-4255-488f-bb1c-77282e17546d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a931c221-ca7d-47f9-b10e-f1993c230af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_645716f3-e245-4205-babc-39a3e8c0b559" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f1146cb2-08ab-4d64-baef-4ff1489658c2" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_645716f3-e245-4205-babc-39a3e8c0b559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d58cebb2-43e1-4894-b0f4-7b9487de0d1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f1146cb2-08ab-4d64-baef-4ff1489658c2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d58cebb2-43e1-4894-b0f4-7b9487de0d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ad0e6a88-6d74-4317-af78-019787f6e247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f1146cb2-08ab-4d64-baef-4ff1489658c2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ad0e6a88-6d74-4317-af78-019787f6e247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1b78d830-893d-4797-974c-33c7f4294e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f1146cb2-08ab-4d64-baef-4ff1489658c2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1b78d830-893d-4797-974c-33c7f4294e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_0ad1debe-fea0-4f9a-9ec5-fb8be534dc59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f1146cb2-08ab-4d64-baef-4ff1489658c2" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_0ad1debe-fea0-4f9a-9ec5-fb8be534dc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3e966f5f-be42-4d17-955b-823f71e0a6f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0ad1debe-fea0-4f9a-9ec5-fb8be534dc59" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3e966f5f-be42-4d17-955b-823f71e0a6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_IssuanceCostOnEquityPaidInCommonStock_6971ab7c-c8bd-4779-b7cb-8bce64ea9f7d" xlink:href="dare-20200930.xsd#dare_IssuanceCostOnEquityPaidInCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0ad1debe-fea0-4f9a-9ec5-fb8be534dc59" xlink:to="loc_dare_IssuanceCostOnEquityPaidInCommonStock_6971ab7c-c8bd-4779-b7cb-8bce64ea9f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_41f3bc82-d054-4abf-ae93-cf4474a17d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0ad1debe-fea0-4f9a-9ec5-fb8be534dc59" xlink:to="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_41f3bc82-d054-4abf-ae93-cf4474a17d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/OrganizationandDescriptionoftheBusiness" xlink:type="simple" xlink:href="dare-20200930.xsd#OrganizationandDescriptionoftheBusiness"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/OrganizationandDescriptionoftheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1fe8ecaf-9457-4397-ae38-3a68295e7681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7a97c043-2a7d-438e-947b-c59e16666bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1fe8ecaf-9457-4397-ae38-3a68295e7681" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7a97c043-2a7d-438e-947b-c59e16666bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/OrganizationandDescriptionoftheBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#OrganizationandDescriptionoftheBusinessAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/OrganizationandDescriptionoftheBusinessAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_71400d6c-b197-4df2-8085-e4f7acda0078" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SignificantAccountingPoliciesTable_3978f34e-0f7d-49ff-997d-8edf2c7d6795" xlink:href="dare-20200930.xsd#dare_SignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_71400d6c-b197-4df2-8085-e4f7acda0078" xlink:to="loc_dare_SignificantAccountingPoliciesTable_3978f34e-0f7d-49ff-997d-8edf2c7d6795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b6d19e3c-71b2-4ebe-8c30-401bd25ad046" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesTable_3978f34e-0f7d-49ff-997d-8edf2c7d6795" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b6d19e3c-71b2-4ebe-8c30-401bd25ad046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4521844b-0c82-4e57-b270-959b22e3e910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b6d19e3c-71b2-4ebe-8c30-401bd25ad046" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4521844b-0c82-4e57-b270-959b22e3e910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cc2164d3-bdb7-4860-ae95-0eaf2ba047a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4521844b-0c82-4e57-b270-959b22e3e910" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cc2164d3-bdb7-4860-ae95-0eaf2ba047a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SignificantAccountingPoliciesLineItems_2d50e80e-af67-4ebb-b0f7-73b1a295d9f4" xlink:href="dare-20200930.xsd#dare_SignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesTable_3978f34e-0f7d-49ff-997d-8edf2c7d6795" xlink:to="loc_dare_SignificantAccountingPoliciesLineItems_2d50e80e-af67-4ebb-b0f7-73b1a295d9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_fffd106e-a884-45f4-af50-26c58c80d3de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_2d50e80e-af67-4ebb-b0f7-73b1a295d9f4" xlink:to="loc_us-gaap_NumberOfOperatingSegments_fffd106e-a884-45f4-af50-26c58c80d3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_568694f6-31ea-4ee8-ac23-e4c06c2ceeaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_2d50e80e-af67-4ebb-b0f7-73b1a295d9f4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_568694f6-31ea-4ee8-ac23-e4c06c2ceeaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_4cfa6952-a5cd-4445-88c7-cd98a050c37f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_2d50e80e-af67-4ebb-b0f7-73b1a295d9f4" xlink:to="loc_us-gaap_ConvertibleDebt_4cfa6952-a5cd-4445-88c7-cd98a050c37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_c5395188-69cd-40ca-803e-bfbd664e27dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_2d50e80e-af67-4ebb-b0f7-73b1a295d9f4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_c5395188-69cd-40ca-803e-bfbd664e27dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PeriodofInsufficientCashandLiquidityRequirements_566bb33f-6ff5-43a6-9510-0e52a636036c" xlink:href="dare-20200930.xsd#dare_PeriodofInsufficientCashandLiquidityRequirements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_2d50e80e-af67-4ebb-b0f7-73b1a295d9f4" xlink:to="loc_dare_PeriodofInsufficientCashandLiquidityRequirements_566bb33f-6ff5-43a6-9510-0e52a636036c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="dare-20200930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_51c80fbc-620e-4c14-8a01-67a2905ecb34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_58829f1b-f0de-4f7a-834e-a7b0776f55f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51c80fbc-620e-4c14-8a01-67a2905ecb34" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_58829f1b-f0de-4f7a-834e-a7b0776f55f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="dare-20200930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6882543b-d303-4ca4-8ee6-d92c746d42ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4b2cc041-93c6-4f6f-b3bd-4b9d7f1df900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6882543b-d303-4ca4-8ee6-d92c746d42ab" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4b2cc041-93c6-4f6f-b3bd-4b9d7f1df900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_aa58ee23-f02f-4952-a150-04ef81857c3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6882543b-d303-4ca4-8ee6-d92c746d42ab" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_aa58ee23-f02f-4952-a150-04ef81857c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_243a1bb7-6767-4db3-a8ac-bfd57e87d073" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6882543b-d303-4ca4-8ee6-d92c746d42ab" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_243a1bb7-6767-4db3-a8ac-bfd57e87d073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5a04cfa6-3f3e-4f3c-b2c2-c7b3ab768971" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6882543b-d303-4ca4-8ee6-d92c746d42ab" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5a04cfa6-3f3e-4f3c-b2c2-c7b3ab768971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="dare-20200930.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fb40c9e1-d308-4f7a-a8a1-b9e980a40d42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_0f5caf98-90e6-4ebf-b43b-5030c3a29443" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fb40c9e1-d308-4f7a-a8a1-b9e980a40d42" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_0f5caf98-90e6-4ebf-b43b-5030c3a29443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_89089bf1-523d-4430-aee5-77d788199e1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_524f0ba2-44b3-4a35-9e12-a30298cb0548" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_89089bf1-523d-4430-aee5-77d788199e1f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_524f0ba2-44b3-4a35-9e12-a30298cb0548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e5533c5a-f9cd-47de-aecc-48c80aa0c7ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_524f0ba2-44b3-4a35-9e12-a30298cb0548" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e5533c5a-f9cd-47de-aecc-48c80aa0c7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4985c1e4-1ee0-4481-bb17-ff0ec2d09bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e5533c5a-f9cd-47de-aecc-48c80aa0c7ce" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4985c1e4-1ee0-4481-bb17-ff0ec2d09bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a63691a5-29d1-4fd7-9001-bbbccb07b183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4985c1e4-1ee0-4481-bb17-ff0ec2d09bb0" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a63691a5-29d1-4fd7-9001-bbbccb07b183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_174f85da-4bb8-4f33-b67f-2b428c0aa7f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_524f0ba2-44b3-4a35-9e12-a30298cb0548" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_174f85da-4bb8-4f33-b67f-2b428c0aa7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_424cb732-fc81-4295-ba5c-af8d455f3650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_174f85da-4bb8-4f33-b67f-2b428c0aa7f8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_424cb732-fc81-4295-ba5c-af8d455f3650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f8950e24-ad89-4d01-afbc-1362e444a2bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_424cb732-fc81-4295-ba5c-af8d455f3650" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f8950e24-ad89-4d01-afbc-1362e444a2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0b60338e-2ae3-4d0f-841d-7e53483f1daf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_424cb732-fc81-4295-ba5c-af8d455f3650" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0b60338e-2ae3-4d0f-841d-7e53483f1daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c7cea69a-f742-4877-8c0c-27a2ed0d9dcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_424cb732-fc81-4295-ba5c-af8d455f3650" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c7cea69a-f742-4877-8c0c-27a2ed0d9dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff1645d1-cd45-4705-8095-78dc73b153c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_524f0ba2-44b3-4a35-9e12-a30298cb0548" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff1645d1-cd45-4705-8095-78dc73b153c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ca6e366e-9213-4405-9ce0-5ee2dbf5cf08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff1645d1-cd45-4705-8095-78dc73b153c8" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ca6e366e-9213-4405-9ce0-5ee2dbf5cf08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsiderationCurrent_9ffe1ede-dce7-46c3-a649-13bedb035b4d" xlink:href="dare-20200930.xsd#dare_AssetAcquisitionContingentConsiderationCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff1645d1-cd45-4705-8095-78dc73b153c8" xlink:to="loc_dare_AssetAcquisitionContingentConsiderationCurrent_9ffe1ede-dce7-46c3-a649-13bedb035b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsiderationNoncurrent_a3e8d292-381b-427d-a834-50c6e9c0cfa9" xlink:href="dare-20200930.xsd#dare_AssetAcquisitionContingentConsiderationNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff1645d1-cd45-4705-8095-78dc73b153c8" xlink:to="loc_dare_AssetAcquisitionContingentConsiderationNoncurrent_a3e8d292-381b-427d-a834-50c6e9c0cfa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_dbc4d484-8e11-43ba-ba8f-4c44ee3cb9da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SignificantAccountingPoliciesTable_8bd666de-79e0-4c38-ab75-25ee91b119e9" xlink:href="dare-20200930.xsd#dare_SignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dbc4d484-8e11-43ba-ba8f-4c44ee3cb9da" xlink:to="loc_dare_SignificantAccountingPoliciesTable_8bd666de-79e0-4c38-ab75-25ee91b119e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d93197f6-1bf0-417d-9544-2b52c0a7c978" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesTable_8bd666de-79e0-4c38-ab75-25ee91b119e9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d93197f6-1bf0-417d-9544-2b52c0a7c978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a74baf39-88fd-42c1-a885-b06be9e5dc4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d93197f6-1bf0-417d-9544-2b52c0a7c978" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a74baf39-88fd-42c1-a885-b06be9e5dc4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_BayerHealthcareLicenseAgreementMember_f3fed554-79db-46dc-a384-708c9c9ed6c8" xlink:href="dare-20200930.xsd#dare_BayerHealthcareLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a74baf39-88fd-42c1-a885-b06be9e5dc4a" xlink:to="loc_dare_BayerHealthcareLicenseAgreementMember_f3fed554-79db-46dc-a384-708c9c9ed6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SignificantAccountingPoliciesLineItems_d7551257-4c23-44c3-a70e-b4e6a059bf8c" xlink:href="dare-20200930.xsd#dare_SignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesTable_8bd666de-79e0-4c38-ab75-25ee91b119e9" xlink:to="loc_dare_SignificantAccountingPoliciesLineItems_d7551257-4c23-44c3-a70e-b4e6a059bf8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UpfrontLicenseFeePaid_be074d50-2b9b-4a5d-87c7-d9e3548afeda" xlink:href="dare-20200930.xsd#dare_UpfrontLicenseFeePaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_d7551257-4c23-44c3-a70e-b4e6a059bf8c" xlink:to="loc_dare_UpfrontLicenseFeePaid_be074d50-2b9b-4a5d-87c7-d9e3548afeda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_212bfd64-f898-4612-8b2a-cb73826516c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_d7551257-4c23-44c3-a70e-b4e6a059bf8c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_212bfd64-f898-4612-8b2a-cb73826516c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmount_a0248f57-196e-4d5d-b5bd-7a82f7f93464" xlink:href="dare-20200930.xsd#dare_MilestonePaymentsContingentAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_d7551257-4c23-44c3-a70e-b4e6a059bf8c" xlink:to="loc_dare_MilestonePaymentsContingentAmount_a0248f57-196e-4d5d-b5bd-7a82f7f93464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="dare-20200930.xsd#LicenseandCollaborationAgreements"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/LicenseandCollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ac06e254-2f63-4bac-8932-d36156210190" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e2af0558-f7d7-4a67-8ca3-4e1bdd1cb45b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ac06e254-2f63-4bac-8932-d36156210190" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e2af0558-f7d7-4a67-8ca3-4e1bdd1cb45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14c61c53-ceab-47ce-8ff6-4939e9b48147" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a5a9ba8-9584-4626-bb66-a55f00cd338e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14c61c53-ceab-47ce-8ff6-4939e9b48147" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a5a9ba8-9584-4626-bb66-a55f00cd338e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2b0b3e7a-a155-4bc5-a65f-5caf9d3043ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a5a9ba8-9584-4626-bb66-a55f00cd338e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2b0b3e7a-a155-4bc5-a65f-5caf9d3043ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8fd9a48-f51a-4431-9797-daa6357b8832" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2b0b3e7a-a155-4bc5-a65f-5caf9d3043ca" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8fd9a48-f51a-4431-9797-daa6357b8832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_BayerHealthcareLicenseAgreementMember_402edb4c-fe99-4949-ac4f-9531cc9d1d4c" xlink:href="dare-20200930.xsd#dare_BayerHealthcareLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8fd9a48-f51a-4431-9797-daa6357b8832" xlink:to="loc_dare_BayerHealthcareLicenseAgreementMember_402edb4c-fe99-4949-ac4f-9531cc9d1d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_331778d0-ceba-440b-aa41-650ec467fac1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8fd9a48-f51a-4431-9797-daa6357b8832" xlink:to="loc_us-gaap_LicensingAgreementsMember_331778d0-ceba-440b-aa41-650ec467fac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssignmentAgreementMember_8e559089-920a-45cd-b373-af933f468539" xlink:href="dare-20200930.xsd#dare_AssignmentAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8fd9a48-f51a-4431-9797-daa6357b8832" xlink:to="loc_dare_AssignmentAgreementMember_8e559089-920a-45cd-b373-af933f468539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAndCollaborationAgreementMember_cfcc8ef1-52d0-4081-a206-93300914bec5" xlink:href="dare-20200930.xsd#dare_LicenseAndCollaborationAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8fd9a48-f51a-4431-9797-daa6357b8832" xlink:to="loc_dare_LicenseAndCollaborationAgreementMember_cfcc8ef1-52d0-4081-a206-93300914bec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_JuniperPharmaceuticalsInc.Member_488e7992-f462-4b92-a1b6-e5e453c099e3" xlink:href="dare-20200930.xsd#dare_JuniperPharmaceuticalsInc.Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8fd9a48-f51a-4431-9797-daa6357b8832" xlink:to="loc_dare_JuniperPharmaceuticalsInc.Member_488e7992-f462-4b92-a1b6-e5e453c099e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DevelopmentAndOptionAgreementMember_6ae7fd0e-f712-4399-9559-5031709c4705" xlink:href="dare-20200930.xsd#dare_DevelopmentAndOptionAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8fd9a48-f51a-4431-9797-daa6357b8832" xlink:to="loc_dare_DevelopmentAndOptionAgreementMember_6ae7fd0e-f712-4399-9559-5031709c4705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_f29fdca4-28d3-47d8-9587-272966b64599" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a5a9ba8-9584-4626-bb66-a55f00cd338e" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_f29fdca4-28d3-47d8-9587-272966b64599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0348bafb-0f31-4644-9b45-efed93c64ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_f29fdca4-28d3-47d8-9587-272966b64599" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0348bafb-0f31-4644-9b45-efed93c64ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainDevelopmentMilestonesMember_63b00562-4c5d-4fb9-8a94-79218dc2e310" xlink:href="dare-20200930.xsd#dare_UponAchievingCertainDevelopmentMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0348bafb-0f31-4644-9b45-efed93c64ce4" xlink:to="loc_dare_UponAchievingCertainDevelopmentMilestonesMember_63b00562-4c5d-4fb9-8a94-79218dc2e310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainCommercialMilestonesMember_1c5c3456-b701-4e4c-b92a-7cbd8a976a58" xlink:href="dare-20200930.xsd#dare_UponAchievingCertainCommercialMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0348bafb-0f31-4644-9b45-efed93c64ce4" xlink:to="loc_dare_UponAchievingCertainCommercialMilestonesMember_1c5c3456-b701-4e4c-b92a-7cbd8a976a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_9dbef5d7-0d82-4b2b-b22f-69a96b6c1892" xlink:href="dare-20200930.xsd#dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0348bafb-0f31-4644-9b45-efed93c64ce4" xlink:to="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_9dbef5d7-0d82-4b2b-b22f-69a96b6c1892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponSigningOfDevelopmentAndOptionAgreementMember_37663467-e4e9-46e8-98de-6e81dc298ff4" xlink:href="dare-20200930.xsd#dare_UponSigningOfDevelopmentAndOptionAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0348bafb-0f31-4644-9b45-efed93c64ce4" xlink:to="loc_dare_UponSigningOfDevelopmentAndOptionAgreementMember_37663467-e4e9-46e8-98de-6e81dc298ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_d050057d-297d-4782-b399-2df6987a9b9a" xlink:href="dare-20200930.xsd#dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0348bafb-0f31-4644-9b45-efed93c64ce4" xlink:to="loc_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_d050057d-297d-4782-b399-2df6987a9b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember_e44c1cc9-c1d8-40f2-990d-7d0b6e3e362c" xlink:href="dare-20200930.xsd#dare_UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0348bafb-0f31-4644-9b45-efed93c64ce4" xlink:to="loc_dare_UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember_e44c1cc9-c1d8-40f2-990d-7d0b6e3e362c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dc45d516-337c-4140-b20e-e77b9eeea4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a5a9ba8-9584-4626-bb66-a55f00cd338e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dc45d516-337c-4140-b20e-e77b9eeea4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_32305b03-541f-48ea-99ed-f91d92fc7f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dc45d516-337c-4140-b20e-e77b9eeea4d1" xlink:to="loc_us-gaap_RelatedPartyDomain_32305b03-541f-48ea-99ed-f91d92fc7f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilanaPharmMember_250613c3-626c-4a70-93d3-89d360a5f8d1" xlink:href="dare-20200930.xsd#dare_MilanaPharmMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_32305b03-541f-48ea-99ed-f91d92fc7f1d" xlink:to="loc_dare_MilanaPharmMember_250613c3-626c-4a70-93d3-89d360a5f8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_HammockPharmaceuticalsInc.Member_fa4d5b72-91f5-4949-819a-713ef0b7f16c" xlink:href="dare-20200930.xsd#dare_HammockPharmaceuticalsInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_32305b03-541f-48ea-99ed-f91d92fc7f1d" xlink:to="loc_dare_HammockPharmaceuticalsInc.Member_fa4d5b72-91f5-4949-819a-713ef0b7f16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_d410af75-b039-4eb0-9314-9a44ef69c0a6" xlink:href="dare-20200930.xsd#dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_32305b03-541f-48ea-99ed-f91d92fc7f1d" xlink:to="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_d410af75-b039-4eb0-9314-9a44ef69c0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AdarePharmaceuticalsMember_a9b33ef4-4a57-483b-86f3-6c1113487f08" xlink:href="dare-20200930.xsd#dare_AdarePharmaceuticalsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_32305b03-541f-48ea-99ed-f91d92fc7f1d" xlink:to="loc_dare_AdarePharmaceuticalsMember_a9b33ef4-4a57-483b-86f3-6c1113487f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c7b9b3a8-3a1d-490d-9731-f155dcdcea9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a5a9ba8-9584-4626-bb66-a55f00cd338e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c7b9b3a8-3a1d-490d-9731-f155dcdcea9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_686baa84-855b-4005-a730-e6d4763e6761" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c7b9b3a8-3a1d-490d-9731-f155dcdcea9d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_686baa84-855b-4005-a730-e6d4763e6761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ADVATecAgreementMember_6d4ca9fc-af64-464f-976e-7e19d49d4c19" xlink:href="dare-20200930.xsd#dare_ADVATecAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_686baa84-855b-4005-a730-e6d4763e6761" xlink:to="loc_dare_ADVATecAgreementMember_6d4ca9fc-af64-464f-976e-7e19d49d4c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ClinicalAndRegulatoryMilestonesMember_1b6c2d25-4f69-4c09-a719-43eccfdb2fab" xlink:href="dare-20200930.xsd#dare_ClinicalAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_686baa84-855b-4005-a730-e6d4763e6761" xlink:to="loc_dare_ClinicalAndRegulatoryMilestonesMember_1b6c2d25-4f69-4c09-a719-43eccfdb2fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SalesMilestonesMember_99e455f0-af28-48f0-97be-794e7dadce4d" xlink:href="dare-20200930.xsd#dare_SalesMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_686baa84-855b-4005-a730-e6d4763e6761" xlink:to="loc_dare_SalesMilestonesMember_99e455f0-af28-48f0-97be-794e7dadce4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_34050819-f311-4127-8edd-3e2bbc46ee23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a5a9ba8-9584-4626-bb66-a55f00cd338e" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_34050819-f311-4127-8edd-3e2bbc46ee23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_ef13521b-678f-47e1-95b7-e0715f83dee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_34050819-f311-4127-8edd-3e2bbc46ee23" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_ef13521b-678f-47e1-95b7-e0715f83dee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_a4aa68d3-ee12-4ab1-a3a7-5d1aa158d811" xlink:href="dare-20200930.xsd#dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_ef13521b-678f-47e1-95b7-e0715f83dee3" xlink:to="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_a4aa68d3-ee12-4ab1-a3a7-5d1aa158d811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_5d7689d3-a4c0-46a6-865c-776fba06693f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a5a9ba8-9584-4626-bb66-a55f00cd338e" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_5d7689d3-a4c0-46a6-865c-776fba06693f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_41a63b37-a621-41e6-8225-2a634911dfe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_5d7689d3-a4c0-46a6-865c-776fba06693f" xlink:to="loc_us-gaap_ProjectMember_41a63b37-a621-41e6-8225-2a634911dfe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_fab676d7-9dfc-426f-ae4c-39eb8896302a" xlink:href="dare-20200930.xsd#dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_41a63b37-a621-41e6-8225-2a634911dfe3" xlink:to="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_fab676d7-9dfc-426f-ae4c-39eb8896302a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_6dfbe3bd-fa91-4d21-aa1b-0c5537f38e53" xlink:href="dare-20200930.xsd#dare_UponReachingCertainWorldwideNetSalesMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_41a63b37-a621-41e6-8225-2a634911dfe3" xlink:to="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_6dfbe3bd-fa91-4d21-aa1b-0c5537f38e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_94047fbf-e176-4d4b-81fd-973b480fc53a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a5a9ba8-9584-4626-bb66-a55f00cd338e" xlink:to="loc_srt_RangeAxis_94047fbf-e176-4d4b-81fd-973b480fc53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_75968d30-ba61-4ee5-9846-cb537e1b5a63" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_94047fbf-e176-4d4b-81fd-973b480fc53a" xlink:to="loc_srt_RangeMember_75968d30-ba61-4ee5-9846-cb537e1b5a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4c76a2d2-3ba2-4769-9eac-4f4d47485772" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_75968d30-ba61-4ee5-9846-cb537e1b5a63" xlink:to="loc_srt_MaximumMember_4c76a2d2-3ba2-4769-9eac-4f4d47485772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0db4b382-7878-433e-afd3-a4426f2e94a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_75968d30-ba61-4ee5-9846-cb537e1b5a63" xlink:to="loc_srt_MinimumMember_0db4b382-7878-433e-afd3-a4426f2e94a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8e91c145-697d-43f0-a74a-3d583796570c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a5a9ba8-9584-4626-bb66-a55f00cd338e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8e91c145-697d-43f0-a74a-3d583796570c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ed0fe6b5-e2f0-44f6-a5bb-3b80c9db79bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8e91c145-697d-43f0-a74a-3d583796570c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ed0fe6b5-e2f0-44f6-a5bb-3b80c9db79bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MicrochipsBiotechInc.Member_aa0f8294-8f46-4ad2-9832-4ba94b7c496d" xlink:href="dare-20200930.xsd#dare_MicrochipsBiotechInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ed0fe6b5-e2f0-44f6-a5bb-3b80c9db79bc" xlink:to="loc_dare_MicrochipsBiotechInc.Member_aa0f8294-8f46-4ad2-9832-4ba94b7c496d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ed43d38f-dc0a-4447-bc19-ec1b9cd544a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a5a9ba8-9584-4626-bb66-a55f00cd338e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ed43d38f-dc0a-4447-bc19-ec1b9cd544a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_46825bb0-592b-4120-bab4-73adf592c848" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ed43d38f-dc0a-4447-bc19-ec1b9cd544a1" xlink:to="loc_us-gaap_ClassOfStockDomain_46825bb0-592b-4120-bab4-73adf592c848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_594b1138-0de7-495a-91c8-9bb17f7227a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_46825bb0-592b-4120-bab4-73adf592c848" xlink:to="loc_us-gaap_CommonStockMember_594b1138-0de7-495a-91c8-9bb17f7227a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a5a9ba8-9584-4626-bb66-a55f00cd338e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UpfrontLicenseFeePaid_5fbcdd47-6c3e-43f7-a61c-25f6c566cee3" xlink:href="dare-20200930.xsd#dare_UpfrontLicenseFeePaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_UpfrontLicenseFeePaid_5fbcdd47-6c3e-43f7-a61c-25f6c566cee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc3ae5dc-0f5d-45c5-81e0-5b2ad7350915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc3ae5dc-0f5d-45c5-81e0-5b2ad7350915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePaymentsContingentAmount_b444962a-ab34-4b3d-9dd5-d9472e03928c" xlink:href="dare-20200930.xsd#dare_MilestonePaymentsContingentAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_MilestonePaymentsContingentAmount_b444962a-ab34-4b3d-9dd5-d9472e03928c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseFee_5185b89f-3f88-42f6-9974-d22515881149" xlink:href="dare-20200930.xsd#dare_LicenseFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_LicenseFee_5185b89f-3f88-42f6-9974-d22515881149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseFeeToBePaidUponContingency_30dbed4c-38bd-42d2-8c23-02387b0ade7d" xlink:href="dare-20200930.xsd#dare_LicenseFeeToBePaidUponContingency"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_LicenseFeeToBePaidUponContingency_30dbed4c-38bd-42d2-8c23-02387b0ade7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct_2b3fa56b-a0fd-4129-91b3-5cba5d5a8643" xlink:href="dare-20200930.xsd#dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct_2b3fa56b-a0fd-4129-91b3-5cba5d5a8643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_040cfd36-6d85-4c65-80ed-5b9f241639f2" xlink:href="dare-20200930.xsd#dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_040cfd36-6d85-4c65-80ed-5b9f241639f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LicenseAgreementNoticePeriodOfTermination_7eefdb67-286a-4629-8ef2-85e5035b6e71" xlink:href="dare-20200930.xsd#dare_LicenseAgreementNoticePeriodOfTermination"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_LicenseAgreementNoticePeriodOfTermination_7eefdb67-286a-4629-8ef2-85e5035b6e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MilestonePayments_12a7ae67-e2a2-4032-9cbd-d4f771d03b6b" xlink:href="dare-20200930.xsd#dare_MilestonePayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_MilestonePayments_12a7ae67-e2a2-4032-9cbd-d4f771d03b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ResearchAndDevelopmentMilestonePayment_9fb1d619-cfe5-486b-8696-d8a7f82c08e8" xlink:href="dare-20200930.xsd#dare_ResearchAndDevelopmentMilestonePayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_ResearchAndDevelopmentMilestonePayment_9fb1d619-cfe5-486b-8696-d8a7f82c08e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PercentageOfRoyaltyRate_9cd10f49-08c1-4341-949e-f07c583af0a6" xlink:href="dare-20200930.xsd#dare_PercentageOfRoyaltyRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_PercentageOfRoyaltyRate_9cd10f49-08c1-4341-949e-f07c583af0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_1b4d1bab-c885-413b-866d-58b53a24961c" xlink:href="dare-20200930.xsd#dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_1b4d1bab-c885-413b-866d-58b53a24961c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_59b53ee1-11aa-4906-9f89-574c80fb261e" xlink:href="dare-20200930.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_59b53ee1-11aa-4906-9f89-574c80fb261e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_f069b531-7f24-412c-8495-ed891432e628" xlink:href="dare-20200930.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_f069b531-7f24-412c-8495-ed891432e628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MaximumPotentialMilestonePayments_c9728124-503e-44c3-8296-45e504ba5008" xlink:href="dare-20200930.xsd#dare_MaximumPotentialMilestonePayments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_MaximumPotentialMilestonePayments_c9728124-503e-44c3-8296-45e504ba5008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_8abd766b-516b-4493-b0db-4cf1948a759c" xlink:href="dare-20200930.xsd#dare_CommencementPeriodForStageTwoUponAchievementOfStageOne"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_8abd766b-516b-4493-b0db-4cf1948a759c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c111f6e0-b1c0-4818-a75d-9f16cdc6a797" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c111f6e0-b1c0-4818-a75d-9f16cdc6a797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsiderationCurrent_db802276-cfec-4d77-951c-22f47edd4701" xlink:href="dare-20200930.xsd#dare_AssetAcquisitionContingentConsiderationCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba93b21c-5f12-498f-8c0e-cec73895693b" xlink:to="loc_dare_AssetAcquisitionContingentConsiderationCurrent_db802276-cfec-4d77-951c-22f47edd4701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/Acquisition" xlink:type="simple" xlink:href="dare-20200930.xsd#Acquisition"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/Acquisition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_1db15a11-d5ee-4125-9899-0f52652b97a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_3688dc31-3b3a-409c-8e2d-e1c2e1741b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_1db15a11-d5ee-4125-9899-0f52652b97a5" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_3688dc31-3b3a-409c-8e2d-e1c2e1741b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/AcquisitionNarrativeDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#AcquisitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/AcquisitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_56933f95-ce8e-49df-b245-70912b57a71c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_c4f62070-e9d8-4c30-ae9c-60837b3e6ec6" xlink:href="dare-20200930.xsd#dare_ScheduleOfBusinessCombinationReverseMergerTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_56933f95-ce8e-49df-b245-70912b57a71c" xlink:to="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_c4f62070-e9d8-4c30-ae9c-60837b3e6ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_65f12960-309b-47f6-b00d-6358ef5b45a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_c4f62070-e9d8-4c30-ae9c-60837b3e6ec6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_65f12960-309b-47f6-b00d-6358ef5b45a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_149ed409-74ad-4d42-bd62-3058deca756a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_65f12960-309b-47f6-b00d-6358ef5b45a4" xlink:to="loc_us-gaap_ClassOfStockDomain_149ed409-74ad-4d42-bd62-3058deca756a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e543521d-722e-41b0-b8de-28a3697db14a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_149ed409-74ad-4d42-bd62-3058deca756a" xlink:to="loc_us-gaap_CommonStockMember_e543521d-722e-41b0-b8de-28a3697db14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0253ccd5-96d7-4558-a16e-59d6a1ac4bca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_c4f62070-e9d8-4c30-ae9c-60837b3e6ec6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0253ccd5-96d7-4558-a16e-59d6a1ac4bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0da5edf5-5696-4ee6-a21b-144ad031d224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0253ccd5-96d7-4558-a16e-59d6a1ac4bca" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0da5edf5-5696-4ee6-a21b-144ad031d224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f02006b1-f8fa-4969-b2a9-f12807335589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0da5edf5-5696-4ee6-a21b-144ad031d224" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f02006b1-f8fa-4969-b2a9-f12807335589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ceef5148-5772-4642-a2af-2d16c5f8782a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_c4f62070-e9d8-4c30-ae9c-60837b3e6ec6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ceef5148-5772-4642-a2af-2d16c5f8782a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07326e07-e80a-4d09-927f-2f0853744a7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ceef5148-5772-4642-a2af-2d16c5f8782a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07326e07-e80a-4d09-927f-2f0853744a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MicrochipsBiotechInc.Member_13ecf327-90b8-424c-837a-e25652cff5ad" xlink:href="dare-20200930.xsd#dare_MicrochipsBiotechInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07326e07-e80a-4d09-927f-2f0853744a7b" xlink:to="loc_dare_MicrochipsBiotechInc.Member_13ecf327-90b8-424c-837a-e25652cff5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_BusinessCombinationReverseMergerLineItems_e49dfe39-1d53-4076-892e-c8251ce40d4b" xlink:href="dare-20200930.xsd#dare_BusinessCombinationReverseMergerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_c4f62070-e9d8-4c30-ae9c-60837b3e6ec6" xlink:to="loc_dare_BusinessCombinationReverseMergerLineItems_e49dfe39-1d53-4076-892e-c8251ce40d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_8d87622e-61c4-4ab7-a5c7-a0d4f4e9e7bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_e49dfe39-1d53-4076-892e-c8251ce40d4b" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_8d87622e-61c4-4ab7-a5c7-a0d4f4e9e7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_55f1e61d-64c7-4a6a-94ac-82b4f76a2b85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_e49dfe39-1d53-4076-892e-c8251ce40d4b" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_55f1e61d-64c7-4a6a-94ac-82b4f76a2b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_2c984439-79a0-44ff-9dec-66b76aa68d25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_e49dfe39-1d53-4076-892e-c8251ce40d4b" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_2c984439-79a0-44ff-9dec-66b76aa68d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_23cdd511-fef4-4c9e-a820-af758df8db54" xlink:href="dare-20200930.xsd#dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_e49dfe39-1d53-4076-892e-c8251ce40d4b" xlink:to="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_23cdd511-fef4-4c9e-a820-af758df8db54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_156d4366-5e14-4fd0-b465-d7e0b51008a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_e49dfe39-1d53-4076-892e-c8251ce40d4b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_156d4366-5e14-4fd0-b465-d7e0b51008a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsiderationCurrent_8cc87e24-fe07-4f61-bbf5-b963042961e8" xlink:href="dare-20200930.xsd#dare_AssetAcquisitionContingentConsiderationCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_e49dfe39-1d53-4076-892e-c8251ce40d4b" xlink:to="loc_dare_AssetAcquisitionContingentConsiderationCurrent_8cc87e24-fe07-4f61-bbf5-b963042961e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="dare-20200930.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_75362754-87b2-446e-876c-e8759e80c0ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e9d75780-921e-487c-9371-5952e94d9dd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_75362754-87b2-446e-876c-e8759e80c0ef" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e9d75780-921e-487c-9371-5952e94d9dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="dare-20200930.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d3d301b5-ed13-4bac-ad58-5d33244b0dc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8b07e8ef-3005-41cb-ad3a-64a3b45d271b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d3d301b5-ed13-4bac-ad58-5d33244b0dc0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8b07e8ef-3005-41cb-ad3a-64a3b45d271b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_55af6b52-0c6a-4e0e-9501-b017059987aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d3d301b5-ed13-4bac-ad58-5d33244b0dc0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_55af6b52-0c6a-4e0e-9501-b017059987aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a8a916b3-c61e-4ff8-bc6c-0b1c4e8ded7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d3d301b5-ed13-4bac-ad58-5d33244b0dc0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a8a916b3-c61e-4ff8-bc6c-0b1c4e8ded7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3bd49012-9d50-4b6b-be4e-eda2971f5326" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_916b3578-cf47-4326-a858-d9a814bd5414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3bd49012-9d50-4b6b-be4e-eda2971f5326" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_916b3578-cf47-4326-a858-d9a814bd5414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_30350f8e-9821-4d12-a9ee-8b64fa845d7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_916b3578-cf47-4326-a858-d9a814bd5414" xlink:to="loc_us-gaap_PlanNameAxis_30350f8e-9821-4d12-a9ee-8b64fa845d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_67099bc2-e37c-497b-99c7-f8b4b20df8c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_30350f8e-9821-4d12-a9ee-8b64fa845d7d" xlink:to="loc_us-gaap_PlanNameDomain_67099bc2-e37c-497b-99c7-f8b4b20df8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember_f7f55ee0-cd35-4889-9ed9-467d67d8e3bc" xlink:href="dare-20200930.xsd#dare_TwoThousandAndFifteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_67099bc2-e37c-497b-99c7-f8b4b20df8c1" xlink:to="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember_f7f55ee0-cd35-4889-9ed9-467d67d8e3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_a518a930-822a-4858-8856-b125aad593ca" xlink:href="dare-20200930.xsd#dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_67099bc2-e37c-497b-99c7-f8b4b20df8c1" xlink:to="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_a518a930-822a-4858-8856-b125aad593ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_c94421c4-8444-4072-89ae-371c50fae742" xlink:href="dare-20200930.xsd#dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_67099bc2-e37c-497b-99c7-f8b4b20df8c1" xlink:to="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_c94421c4-8444-4072-89ae-371c50fae742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_35ce6768-52b6-41df-bc1a-8f6e5a702cb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_916b3578-cf47-4326-a858-d9a814bd5414" xlink:to="loc_us-gaap_AwardTypeAxis_35ce6768-52b6-41df-bc1a-8f6e5a702cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6bde817-ff98-40b8-a251-1fb8d331bb6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_35ce6768-52b6-41df-bc1a-8f6e5a702cb1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6bde817-ff98-40b8-a251-1fb8d331bb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_77dcc63f-4aae-415a-ad78-5957af9b19e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6bde817-ff98-40b8-a251-1fb8d331bb6a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_77dcc63f-4aae-415a-ad78-5957af9b19e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_56c21a54-4c5f-4e03-b65d-d775ec5d9c03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6bde817-ff98-40b8-a251-1fb8d331bb6a" xlink:to="loc_us-gaap_RestrictedStockMember_56c21a54-4c5f-4e03-b65d-d775ec5d9c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1e5d0dc9-3af5-4a52-bc3c-9548db3e4749" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_916b3578-cf47-4326-a858-d9a814bd5414" xlink:to="loc_dei_LegalEntityAxis_1e5d0dc9-3af5-4a52-bc3c-9548db3e4749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0bbdba22-2a34-439a-a312-06aa6b41c186" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1e5d0dc9-3af5-4a52-bc3c-9548db3e4749" xlink:to="loc_dei_EntityDomain_0bbdba22-2a34-439a-a312-06aa6b41c186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PrivateDareMember_67d2e7bc-037e-4ab8-bc1d-a95cb7285558" xlink:href="dare-20200930.xsd#dare_PrivateDareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0bbdba22-2a34-439a-a312-06aa6b41c186" xlink:to="loc_dare_PrivateDareMember_67d2e7bc-037e-4ab8-bc1d-a95cb7285558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_daacb477-ffdd-4edf-8c21-9e777859e326" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_916b3578-cf47-4326-a858-d9a814bd5414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_daacb477-ffdd-4edf-8c21-9e777859e326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_23915fa6-20db-4305-ab45-32eba9869960" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_daacb477-ffdd-4edf-8c21-9e777859e326" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_23915fa6-20db-4305-ab45-32eba9869960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_92587804-6fcf-4156-8668-887aa87eb6d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_daacb477-ffdd-4edf-8c21-9e777859e326" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_92587804-6fcf-4156-8668-887aa87eb6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bb3f8464-9bfe-4485-8d8d-c0d14239bc3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_daacb477-ffdd-4edf-8c21-9e777859e326" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bb3f8464-9bfe-4485-8d8d-c0d14239bc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a6890056-1ae2-4f24-b56d-e4ba6b39654f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_daacb477-ffdd-4edf-8c21-9e777859e326" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a6890056-1ae2-4f24-b56d-e4ba6b39654f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_280a3fc1-cfc7-4527-94fe-fd4ef5df0d23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_daacb477-ffdd-4edf-8c21-9e777859e326" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_280a3fc1-cfc7-4527-94fe-fd4ef5df0d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_f78a20ad-e228-4463-8217-7b1b5f98ae57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_daacb477-ffdd-4edf-8c21-9e777859e326" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_f78a20ad-e228-4463-8217-7b1b5f98ae57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_91c10794-941c-4ee0-869e-40e0ce14799e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_daacb477-ffdd-4edf-8c21-9e777859e326" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_91c10794-941c-4ee0-869e-40e0ce14799e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WeightedAverageAmortizationPeriod_3701bc03-7b1a-4c0b-b54a-0f07f1218d59" xlink:href="dare-20200930.xsd#dare_WeightedAverageAmortizationPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_daacb477-ffdd-4edf-8c21-9e777859e326" xlink:to="loc_dare_WeightedAverageAmortizationPeriod_3701bc03-7b1a-4c0b-b54a-0f07f1218d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_444493f9-54d3-4f7d-8204-2fb73884e30d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_daacb477-ffdd-4edf-8c21-9e777859e326" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_444493f9-54d3-4f7d-8204-2fb73884e30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab0d9ce1-027e-4ebd-bec6-6dd3989b97c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bfe45e5-4f5e-4da1-b311-105c3c0d3e59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab0d9ce1-027e-4ebd-bec6-6dd3989b97c5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bfe45e5-4f5e-4da1-b311-105c3c0d3e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7b87a4a3-d6db-4cc8-aee5-ffcb526beaa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bfe45e5-4f5e-4da1-b311-105c3c0d3e59" xlink:to="loc_us-gaap_PlanNameAxis_7b87a4a3-d6db-4cc8-aee5-ffcb526beaa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_08b76447-6f30-4dba-85a8-3ec750e71069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_7b87a4a3-d6db-4cc8-aee5-ffcb526beaa9" xlink:to="loc_us-gaap_PlanNameDomain_08b76447-6f30-4dba-85a8-3ec750e71069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_17aed947-2e5c-4624-91d4-90ba3fad8e34" xlink:href="dare-20200930.xsd#dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_08b76447-6f30-4dba-85a8-3ec750e71069" xlink:to="loc_dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember_17aed947-2e5c-4624-91d4-90ba3fad8e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_916acabb-ff5c-4bab-841d-c22a2321d7a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bfe45e5-4f5e-4da1-b311-105c3c0d3e59" xlink:to="loc_us-gaap_AwardTypeAxis_916acabb-ff5c-4bab-841d-c22a2321d7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9826f455-0638-49c0-a89d-472f784b4729" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_916acabb-ff5c-4bab-841d-c22a2321d7a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9826f455-0638-49c0-a89d-472f784b4729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fd60d774-0e11-4854-8d51-1d0d6158dcb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9826f455-0638-49c0-a89d-472f784b4729" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fd60d774-0e11-4854-8d51-1d0d6158dcb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_925fa347-9b5b-42ef-b498-eba64e6e3444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bfe45e5-4f5e-4da1-b311-105c3c0d3e59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_925fa347-9b5b-42ef-b498-eba64e6e3444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_32cd191e-856e-4fd7-b7e9-7a51abf1f0bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_925fa347-9b5b-42ef-b498-eba64e6e3444" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_32cd191e-856e-4fd7-b7e9-7a51abf1f0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f8551d23-56f8-4fa9-b56c-3f4bd4093a91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_32cd191e-856e-4fd7-b7e9-7a51abf1f0bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f8551d23-56f8-4fa9-b56c-3f4bd4093a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_51f5fcf7-1484-48e5-ac5b-e192fcc84c2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_32cd191e-856e-4fd7-b7e9-7a51abf1f0bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_51f5fcf7-1484-48e5-ac5b-e192fcc84c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e6459a89-5d81-4f36-9e98-64074204fc47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_32cd191e-856e-4fd7-b7e9-7a51abf1f0bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e6459a89-5d81-4f36-9e98-64074204fc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e5376170-52fb-4575-af9f-079d2fc0508f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_32cd191e-856e-4fd7-b7e9-7a51abf1f0bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e5376170-52fb-4575-af9f-079d2fc0508f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40d92493-1645-49f2-a071-fc8a81d4816e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_32cd191e-856e-4fd7-b7e9-7a51abf1f0bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40d92493-1645-49f2-a071-fc8a81d4816e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30545ca4-9e63-47f2-be6e-f10f4b6773f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_32cd191e-856e-4fd7-b7e9-7a51abf1f0bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30545ca4-9e63-47f2-be6e-f10f4b6773f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6ed617c9-0b62-422c-b120-9fbfb1ca5f39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_925fa347-9b5b-42ef-b498-eba64e6e3444" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6ed617c9-0b62-422c-b120-9fbfb1ca5f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bdaff452-47b5-41b6-9bbf-3a45bc1fb9de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_925fa347-9b5b-42ef-b498-eba64e6e3444" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bdaff452-47b5-41b6-9bbf-3a45bc1fb9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e82f4a22-ea24-4ecc-b5ed-1de28fb71620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bdaff452-47b5-41b6-9bbf-3a45bc1fb9de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e82f4a22-ea24-4ecc-b5ed-1de28fb71620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d14d3a82-b4ca-463b-895e-597a16e89579" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bdaff452-47b5-41b6-9bbf-3a45bc1fb9de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d14d3a82-b4ca-463b-895e-597a16e89579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_fc0136c3-b1e6-4835-8751-a586d7749176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bdaff452-47b5-41b6-9bbf-3a45bc1fb9de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_fc0136c3-b1e6-4835-8751-a586d7749176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_886e1ccc-0fb9-46b0-9626-a3a2028331ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bdaff452-47b5-41b6-9bbf-3a45bc1fb9de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_886e1ccc-0fb9-46b0-9626-a3a2028331ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d8a765ec-0794-4b13-8942-5cbe0d5ebc33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bdaff452-47b5-41b6-9bbf-3a45bc1fb9de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d8a765ec-0794-4b13-8942-5cbe0d5ebc33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1dcf923c-0fef-454e-a848-92731d1fdef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bdaff452-47b5-41b6-9bbf-3a45bc1fb9de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1dcf923c-0fef-454e-a848-92731d1fdef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a56c4604-7e37-40c2-b87b-75c9939bdea0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_925fa347-9b5b-42ef-b498-eba64e6e3444" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a56c4604-7e37-40c2-b87b-75c9939bdea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_febce060-dfef-4769-8c88-f7e09ea201ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0040dcd3-f0ac-4c16-b011-ef629e1615b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_febce060-dfef-4769-8c88-f7e09ea201ee" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0040dcd3-f0ac-4c16-b011-ef629e1615b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bc9e1e7c-6a3f-4ffe-bd71-94ee7f0b4a73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0040dcd3-f0ac-4c16-b011-ef629e1615b0" xlink:to="loc_us-gaap_AwardTypeAxis_bc9e1e7c-6a3f-4ffe-bd71-94ee7f0b4a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_805ea59f-a4d2-4684-8ae5-a45b8e4b2568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bc9e1e7c-6a3f-4ffe-bd71-94ee7f0b4a73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_805ea59f-a4d2-4684-8ae5-a45b8e4b2568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_dbfd55c5-b829-4f1a-a90c-8829b53055ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_805ea59f-a4d2-4684-8ae5-a45b8e4b2568" xlink:to="loc_us-gaap_EmployeeStockOptionMember_dbfd55c5-b829-4f1a-a90c-8829b53055ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_44f5e7cc-b0ce-499b-bbe7-d6cc51f55ecc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0040dcd3-f0ac-4c16-b011-ef629e1615b0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_44f5e7cc-b0ce-499b-bbe7-d6cc51f55ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a87ac120-8f92-40c9-9414-425e4b449643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_44f5e7cc-b0ce-499b-bbe7-d6cc51f55ecc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a87ac120-8f92-40c9-9414-425e4b449643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b1ac6963-fa04-43dd-b1d6-c49b2caedf93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a87ac120-8f92-40c9-9414-425e4b449643" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b1ac6963-fa04-43dd-b1d6-c49b2caedf93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_555f73b3-d39e-4b3a-af9c-0cfe1ba4bac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a87ac120-8f92-40c9-9414-425e4b449643" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_555f73b3-d39e-4b3a-af9c-0cfe1ba4bac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ba16dbd3-9c45-4932-8bb5-f9923c305a92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0040dcd3-f0ac-4c16-b011-ef629e1615b0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ba16dbd3-9c45-4932-8bb5-f9923c305a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c036378d-55c4-4de7-a754-962461ba1d8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ba16dbd3-9c45-4932-8bb5-f9923c305a92" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c036378d-55c4-4de7-a754-962461ba1d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e7d2580e-a1c5-496e-ba24-34fc378e7c2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_47d3b2bc-15e9-490e-a8c2-4965a58af2e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e7d2580e-a1c5-496e-ba24-34fc378e7c2b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_47d3b2bc-15e9-490e-a8c2-4965a58af2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fe137106-8b8e-4c5b-974b-846d34b61171" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e7d2580e-a1c5-496e-ba24-34fc378e7c2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fe137106-8b8e-4c5b-974b-846d34b61171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_34c874a0-f97c-458c-85a0-8d4a5ace72e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e7d2580e-a1c5-496e-ba24-34fc378e7c2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_34c874a0-f97c-458c-85a0-8d4a5ace72e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_a25c6443-4b94-45d6-9a5f-c70af05e19c2" xlink:href="dare-20200930.xsd#dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e7d2580e-a1c5-496e-ba24-34fc378e7c2b" xlink:to="loc_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_a25c6443-4b94-45d6-9a5f-c70af05e19c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7c4a3635-2680-46d4-9b5f-f09ca0e3c9ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e7d2580e-a1c5-496e-ba24-34fc378e7c2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7c4a3635-2680-46d4-9b5f-f09ca0e3c9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_af34f58b-1853-467c-8c4e-c74e51b6b900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e7d2580e-a1c5-496e-ba24-34fc378e7c2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_af34f58b-1853-467c-8c4e-c74e51b6b900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquity" xlink:type="simple" xlink:href="dare-20200930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_82c9b185-22d9-4a37-b90a-85cc9285dd6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_929b562b-5a70-4ecd-addd-0fcf93bb3b8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_82c9b185-22d9-4a37-b90a-85cc9285dd6d" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_929b562b-5a70-4ecd-addd-0fcf93bb3b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="dare-20200930.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_60d21ab9-0a80-4294-9ba7-cd9a91f94a51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_c21868f0-60c2-4e28-8e7b-fb88d822890e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_60d21ab9-0a80-4294-9ba7-cd9a91f94a51" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_c21868f0-60c2-4e28-8e7b-fb88d822890e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6ee525af-bb9c-4843-8934-463d9d25b0ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StockholdersEquityTable_9a25d9bc-d7eb-4041-af52-21d3009fdc8c" xlink:href="dare-20200930.xsd#dare_StockholdersEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6ee525af-bb9c-4843-8934-463d9d25b0ae" xlink:to="loc_dare_StockholdersEquityTable_9a25d9bc-d7eb-4041-af52-21d3009fdc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_0b4f9cc8-8cdd-44fe-afbf-c256de0a6c3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityTable_9a25d9bc-d7eb-4041-af52-21d3009fdc8c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_0b4f9cc8-8cdd-44fe-afbf-c256de0a6c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe05a20b-9171-4e7b-9978-f040fe495c32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0b4f9cc8-8cdd-44fe-afbf-c256de0a6c3f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe05a20b-9171-4e7b-9978-f040fe495c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AtTheMarketSalesAgreementMember_be2c8499-6a08-455e-99c5-caa264626f0b" xlink:href="dare-20200930.xsd#dare_AtTheMarketSalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe05a20b-9171-4e7b-9978-f040fe495c32" xlink:to="loc_dare_AtTheMarketSalesAgreementMember_be2c8499-6a08-455e-99c5-caa264626f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PublicStockOfferingMember_35acc52c-7df6-46eb-ad9c-5fbca625be22" xlink:href="dare-20200930.xsd#dare_PublicStockOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe05a20b-9171-4e7b-9978-f040fe495c32" xlink:to="loc_dare_PublicStockOfferingMember_35acc52c-7df6-46eb-ad9c-5fbca625be22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_f5d98186-4add-4414-a4a6-bf8a0e99d886" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe05a20b-9171-4e7b-9978-f040fe495c32" xlink:to="loc_us-gaap_OverAllotmentOptionMember_f5d98186-4add-4414-a4a6-bf8a0e99d886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PurchaseAgreementMember_44f78104-e5e9-4b73-8dd4-8cec3ed85dd1" xlink:href="dare-20200930.xsd#dare_PurchaseAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe05a20b-9171-4e7b-9978-f040fe495c32" xlink:to="loc_dare_PurchaseAgreementMember_44f78104-e5e9-4b73-8dd4-8cec3ed85dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7a3c5c01-9469-45f4-a0d7-9f5cb41595d1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityTable_9a25d9bc-d7eb-4041-af52-21d3009fdc8c" xlink:to="loc_dei_LegalEntityAxis_7a3c5c01-9469-45f4-a0d7-9f5cb41595d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_318eee92-9142-4429-b984-e3142ae2e40f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_7a3c5c01-9469-45f4-a0d7-9f5cb41595d1" xlink:to="loc_dei_EntityDomain_318eee92-9142-4429-b984-e3142ae2e40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LincolnParkMember_a11c153d-ff82-48d4-a140-e268b450ab46" xlink:href="dare-20200930.xsd#dare_LincolnParkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_318eee92-9142-4429-b984-e3142ae2e40f" xlink:to="loc_dare_LincolnParkMember_a11c153d-ff82-48d4-a140-e268b450ab46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_93c55e50-6393-4031-8977-789187959f90" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityTable_9a25d9bc-d7eb-4041-af52-21d3009fdc8c" xlink:to="loc_srt_CounterpartyNameAxis_93c55e50-6393-4031-8977-789187959f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_684f2524-4814-4f7b-a4c1-46998aa6b2b4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_93c55e50-6393-4031-8977-789187959f90" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_684f2524-4814-4f7b-a4c1-46998aa6b2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LincolnParkMember_e195139a-d9bf-4623-9ebb-65443ac5f5c5" xlink:href="dare-20200930.xsd#dare_LincolnParkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_684f2524-4814-4f7b-a4c1-46998aa6b2b4" xlink:to="loc_dare_LincolnParkMember_e195139a-d9bf-4623-9ebb-65443ac5f5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_640d19df-a81a-4997-a148-bacd173da65d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityTable_9a25d9bc-d7eb-4041-af52-21d3009fdc8c" xlink:to="loc_srt_RangeAxis_640d19df-a81a-4997-a148-bacd173da65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a0a6ce6b-85ff-451e-a67e-738e40b790db" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_640d19df-a81a-4997-a148-bacd173da65d" xlink:to="loc_srt_RangeMember_a0a6ce6b-85ff-451e-a67e-738e40b790db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3ced223d-d0dc-41e9-b74f-19636851390d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a0a6ce6b-85ff-451e-a67e-738e40b790db" xlink:to="loc_srt_MinimumMember_3ced223d-d0dc-41e9-b74f-19636851390d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d5824e89-502e-4e7b-a0af-382833d6d1b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a0a6ce6b-85ff-451e-a67e-738e40b790db" xlink:to="loc_srt_MaximumMember_d5824e89-502e-4e7b-a0af-382833d6d1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8a7872a4-2aa9-484b-8a2a-0a43f50cb213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityTable_9a25d9bc-d7eb-4041-af52-21d3009fdc8c" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8a7872a4-2aa9-484b-8a2a-0a43f50cb213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_04a9b2c9-d2b6-431c-b6c2-2859cde97723" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8a7872a4-2aa9-484b-8a2a-0a43f50cb213" xlink:to="loc_us-gaap_TypeOfAdoptionMember_04a9b2c9-d2b6-431c-b6c2-2859cde97723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201711Member_ca4155ae-482c-4aaf-b44d-68dd49b323be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201711Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_04a9b2c9-d2b6-431c-b6c2-2859cde97723" xlink:to="loc_us-gaap_AccountingStandardsUpdate201711Member_ca4155ae-482c-4aaf-b44d-68dd49b323be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:href="dare-20200930.xsd#dare_StockholdersEquityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityTable_9a25d9bc-d7eb-4041-af52-21d3009fdc8c" xlink:to="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PercentageOfAggregateCommission_8dfb95cd-8c0b-480a-a087-0f296688cbdc" xlink:href="dare-20200930.xsd#dare_PercentageOfAggregateCommission"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_PercentageOfAggregateCommission_8dfb95cd-8c0b-480a-a087-0f296688cbdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a2e4cdb3-9a7e-416d-9f98-ae6f89c4657c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a2e4cdb3-9a7e-416d-9f98-ae6f89c4657c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_751c0e17-3c10-4fb4-ac4b-10b21ccf579f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_751c0e17-3c10-4fb4-ac4b-10b21ccf579f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_OfferingExpenses_7c8362d6-ee4d-4eea-8fc0-41aa2725efeb" xlink:href="dare-20200930.xsd#dare_OfferingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_OfferingExpenses_7c8362d6-ee4d-4eea-8fc0-41aa2725efeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_fe143a36-6b7a-45b7-bd16-11256dba9d2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_fe143a36-6b7a-45b7-bd16-11256dba9d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_fac2e4ca-6b5b-4a50-b134-c09fb779556f" xlink:href="dare-20200930.xsd#dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_fac2e4ca-6b5b-4a50-b134-c09fb779556f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_UnderwritersOptionToPurchaseAdditionalShares_a17ae12c-3880-43db-904d-2a7e4683c9f4" xlink:href="dare-20200930.xsd#dare_UnderwritersOptionToPurchaseAdditionalShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_UnderwritersOptionToPurchaseAdditionalShares_a17ae12c-3880-43db-904d-2a7e4683c9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_63c516b3-879c-4f02-b020-e016f3ee789e" xlink:href="dare-20200930.xsd#dare_GrossProceedsFromOfferingOfCommonStockAndWarrants"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_63c516b3-879c-4f02-b020-e016f3ee789e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_df410805-8447-4d29-9734-f811ddbd50a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_df410805-8447-4d29-9734-f811ddbd50a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_1ee6b853-90b0-48fc-a373-2fe9af867fd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_PurchaseObligation_1ee6b853-90b0-48fc-a373-2fe9af867fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_SaleofStockMaximumAmountRegistered_28c861fa-edd1-4343-a81b-7c53a816d013" xlink:href="dare-20200930.xsd#dare_SaleofStockMaximumAmountRegistered"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_SaleofStockMaximumAmountRegistered_28c861fa-edd1-4343-a81b-7c53a816d013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_2fb2339e-1103-4cac-9339-595eaf1c8240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_DeferredOfferingCosts_2fb2339e-1103-4cac-9339-595eaf1c8240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeferredOfferingCostsUnamortizedPortion_63581056-6b52-4d1e-9052-60a9b3defc2b" xlink:href="dare-20200930.xsd#dare_DeferredOfferingCostsUnamortizedPortion"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_DeferredOfferingCostsUnamortizedPortion_63581056-6b52-4d1e-9052-60a9b3defc2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_eb6214d8-b998-4e42-8a76-3f5ba46d6e3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_eb6214d8-b998-4e42-8a76-3f5ba46d6e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_61a9a15b-c2f4-4c97-9b84-907bea8c235d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_61a9a15b-c2f4-4c97-9b84-907bea8c235d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_RegularRepurchaseCommonStockIssuable_d6a1e881-af28-42f7-a2ae-809e9906e9a5" xlink:href="dare-20200930.xsd#dare_RegularRepurchaseCommonStockIssuable"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_RegularRepurchaseCommonStockIssuable_d6a1e881-af28-42f7-a2ae-809e9906e9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_RegularPurchaseCommonStockIssuableIncreaseAmount_dc3f992f-9377-4b92-a2f7-ae62319364af" xlink:href="dare-20200930.xsd#dare_RegularPurchaseCommonStockIssuableIncreaseAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_RegularPurchaseCommonStockIssuableIncreaseAmount_dc3f992f-9377-4b92-a2f7-ae62319364af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_RegularPurchaseCommonStockIssuableMaximumAmount_18a517d4-d7cc-49fe-91ea-6c80693b5389" xlink:href="dare-20200930.xsd#dare_RegularPurchaseCommonStockIssuableMaximumAmount"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_RegularPurchaseCommonStockIssuableMaximumAmount_18a517d4-d7cc-49fe-91ea-6c80693b5389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommonStockExchangeCap_75a55067-52a4-4c87-897f-819b96487a1b" xlink:href="dare-20200930.xsd#dare_CommonStockExchangeCap"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_CommonStockExchangeCap_75a55067-52a4-4c87-897f-819b96487a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_161ae274-b178-4811-886c-329bb6fb97bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_SharePrice_161ae274-b178-4811-886c-329bb6fb97bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommonStockExchangeCapPercentage_f7fe1f17-341b-4782-924b-3d4f8dfe331e" xlink:href="dare-20200930.xsd#dare_CommonStockExchangeCapPercentage"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_CommonStockExchangeCapPercentage_f7fe1f17-341b-4782-924b-3d4f8dfe331e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_26dea4e7-ce99-439f-92fd-754ae0c520ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_26dea4e7-ce99-439f-92fd-754ae0c520ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity_44f5b1db-0a07-4815-ac14-e5dbab36dba9" xlink:href="dare-20200930.xsd#dare_EstimatedFairValueOfWarrantsRecordedInEquity"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity_44f5b1db-0a07-4815-ac14-e5dbab36dba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantExercisePriceDecrease_aeabf3c1-7910-49a6-afaa-2eea5b7413ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_WarrantExercisePriceDecrease_aeabf3c1-7910-49a6-afaa-2eea5b7413ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_70adfa52-f048-4361-b804-bdd67b2ead59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_70adfa52-f048-4361-b804-bdd67b2ead59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NumberOfCommonStockWarrantsExercised_4db89767-05a2-44b3-9533-5e27e38cc627" xlink:href="dare-20200930.xsd#dare_NumberOfCommonStockWarrantsExercised"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_dare_NumberOfCommonStockWarrantsExercised_4db89767-05a2-44b3-9533-5e27e38cc627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_4dd68f5f-6bfd-4b45-8616-59f4a37c692a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_80841a89-dd67-4e07-8590-de5d4d5a1f74" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_4dd68f5f-6bfd-4b45-8616-59f4a37c692a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_08634985-1bb1-43fb-a458-338795fde494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_e576c3a6-9823-4d92-aaac-923f82a85c28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_08634985-1bb1-43fb-a458-338795fde494" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_e576c3a6-9823-4d92-aaac-923f82a85c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_c8174007-e364-4439-887b-44ec843e9014" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e576c3a6-9823-4d92-aaac-923f82a85c28" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_c8174007-e364-4439-887b-44ec843e9014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_111895f8-b94c-4f4d-bf8b-7d6e1d382fe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_c8174007-e364-4439-887b-44ec843e9014" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_111895f8-b94c-4f4d-bf8b-7d6e1d382fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_3a96cf95-2632-485e-9b8e-a67de1cce8a9" xlink:href="dare-20200930.xsd#dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_111895f8-b94c-4f4d-bf8b-7d6e1d382fe3" xlink:to="loc_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_3a96cf95-2632-485e-9b8e-a67de1cce8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_5eeb9508-6554-4c62-9ab6-1f107d2db50e" xlink:href="dare-20200930.xsd#dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_111895f8-b94c-4f4d-bf8b-7d6e1d382fe3" xlink:to="loc_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_5eeb9508-6554-4c62-9ab6-1f107d2db50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_55bc77dd-2201-4dd6-8026-3743ece7b197" xlink:href="dare-20200930.xsd#dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_111895f8-b94c-4f4d-bf8b-7d6e1d382fe3" xlink:to="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_55bc77dd-2201-4dd6-8026-3743ece7b197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_722a76a9-ba2a-4082-bcee-8e16aeb4ace5" xlink:href="dare-20200930.xsd#dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_111895f8-b94c-4f4d-bf8b-7d6e1d382fe3" xlink:to="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_722a76a9-ba2a-4082-bcee-8e16aeb4ace5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_d95ce360-42fa-4b69-b63b-a7ded13b996c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e576c3a6-9823-4d92-aaac-923f82a85c28" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_d95ce360-42fa-4b69-b63b-a7ded13b996c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_639140a7-6e09-4e49-b9d8-e8e322d0d160" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d95ce360-42fa-4b69-b63b-a7ded13b996c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_639140a7-6e09-4e49-b9d8-e8e322d0d160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e0b9a9fa-ccd1-4782-9079-265dd3247f9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d95ce360-42fa-4b69-b63b-a7ded13b996c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e0b9a9fa-ccd1-4782-9079-265dd3247f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_c597de1c-5aa2-4787-84c2-b2bc0ed475ff" xlink:href="dare-20200930.xsd#dare_ClassOfWarrantOrRightsWarrantsExpirationDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d95ce360-42fa-4b69-b63b-a7ded13b996c" xlink:to="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_c597de1c-5aa2-4787-84c2-b2bc0ed475ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedProperties" xlink:type="simple" xlink:href="dare-20200930.xsd#LeasedProperties"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/LeasedProperties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_995b9940-9609-408e-b0bd-ed97d90503b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1156c9f1-ddc4-4cb7-bc02-28b954383099" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_995b9940-9609-408e-b0bd-ed97d90503b8" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_1156c9f1-ddc4-4cb7-bc02-28b954383099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesTables" xlink:type="simple" xlink:href="dare-20200930.xsd#LeasedPropertiesTables"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_40102222-5dd6-4e26-8716-855352e00536" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_bd1a8b59-d092-42f2-8290-38d411f2feb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_40102222-5dd6-4e26-8716-855352e00536" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_bd1a8b59-d092-42f2-8290-38d411f2feb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#LeasedPropertiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_82c09462-0039-44d1-af72-859b974ea536" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_a8c48a8d-dd56-4e9a-8905-28db2f5753ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_82c09462-0039-44d1-af72-859b974ea536" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_a8c48a8d-dd56-4e9a-8905-28db2f5753ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_44fe334a-bc1c-4aad-945a-6242b96dbde1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a8c48a8d-dd56-4e9a-8905-28db2f5753ab" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_44fe334a-bc1c-4aad-945a-6242b96dbde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_666226b3-1e93-4eaf-939c-723e39bae2c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_44fe334a-bc1c-4aad-945a-6242b96dbde1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_666226b3-1e93-4eaf-939c-723e39bae2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_f5c70245-b8e7-404a-b7e6-358d0e027338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_666226b3-1e93-4eaf-939c-723e39bae2c5" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_f5c70245-b8e7-404a-b7e6-358d0e027338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a8c48a8d-dd56-4e9a-8905-28db2f5753ab" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_7e9475a6-af12-4b06-bfa6-cdf0d8b27058" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetRentableArea"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:to="loc_us-gaap_NetRentableArea_7e9475a6-af12-4b06-bfa6-cdf0d8b27058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d9c0b557-464b-44e4-a099-39f3ecda27eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d9c0b557-464b-44e4-a099-39f3ecda27eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_aad05e77-f5dc-45a1-bd90-2cde9d7c6c2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_aad05e77-f5dc-45a1-bd90-2cde9d7c6c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_aca02b5d-c967-4f46-9f7a-f798cd3c13f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_aca02b5d-c967-4f46-9f7a-f798cd3c13f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_385c8226-4da2-453f-a81c-07ad05aa5ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_385c8226-4da2-453f-a81c-07ad05aa5ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_01918d53-ce6d-4019-8129-34e6473a582d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_01918d53-ce6d-4019-8129-34e6473a582d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_61dce36c-34f0-4eff-bee5-ff27d2a286d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_61dce36c-34f0-4eff-bee5-ff27d2a286d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_90d0b192-acc4-45e4-a07d-2186c6d11fb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_90d0b192-acc4-45e4-a07d-2186c6d11fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_0e595258-49ef-47d1-87b1-3cc54ae15a9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_0e595258-49ef-47d1-87b1-3cc54ae15a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_889757ac-ca3a-49a3-91fa-ef3c9250b4a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:to="loc_us-gaap_OperatingLeaseCost_889757ac-ca3a-49a3-91fa-ef3c9250b4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_9fb254bf-ba8f-483c-9237-f6e4cdde68e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:to="loc_us-gaap_OperatingLeasePayments_9fb254bf-ba8f-483c-9237-f6e4cdde68e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_80b8de05-c4d2-4a2a-9046-5c25e58dd062" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9c73f5ec-785f-4fc3-89bc-7939c178cc7f" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_80b8de05-c4d2-4a2a-9046-5c25e58dd062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#LeasedPropertiesFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_761d4df4-d018-478e-b69e-b6c6319cfc63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_378f4421-1bfd-4752-a2da-c4e7a52d5344" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_761d4df4-d018-478e-b69e-b6c6319cfc63" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_378f4421-1bfd-4752-a2da-c4e7a52d5344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b8dce785-3bf0-4feb-9a50-a51f899339df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_761d4df4-d018-478e-b69e-b6c6319cfc63" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b8dce785-3bf0-4feb-9a50-a51f899339df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8d5d5335-dad1-4e13-897d-20d2304b16a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_761d4df4-d018-478e-b69e-b6c6319cfc63" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8d5d5335-dad1-4e13-897d-20d2304b16a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d41b68c5-c179-4eb4-b212-ffba518fb6dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_761d4df4-d018-478e-b69e-b6c6319cfc63" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d41b68c5-c179-4eb4-b212-ffba518fb6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_fd78852b-3541-4087-b3cf-d9f442a9a509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_761d4df4-d018-478e-b69e-b6c6319cfc63" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_fd78852b-3541-4087-b3cf-d9f442a9a509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2a6ec79a-f636-44eb-bb72-fdb15af606ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_761d4df4-d018-478e-b69e-b6c6319cfc63" xlink:to="loc_us-gaap_OperatingLeaseLiability_2a6ec79a-f636-44eb-bb72-fdb15af606ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="dare-20200930.xsd#LeasedPropertiesFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://darebioscience.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="dare-20200930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_92ac8581-39a1-4a89-b1aa-b63e947c72f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_91453479-615d-4d54-bf61-58dd297cacdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_92ac8581-39a1-4a89-b1aa-b63e947c72f0" xlink:to="loc_us-gaap_CommitmentsDisclosureTextBlock_91453479-615d-4d54-bf61-58dd297cacdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c2d23578-c5dd-4657-b24f-03f627c33b41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommitmentsAndContingenciesTable_e42ff2e5-b135-43b6-ba9c-a364d364f121" xlink:href="dare-20200930.xsd#dare_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c2d23578-c5dd-4657-b24f-03f627c33b41" xlink:to="loc_dare_CommitmentsAndContingenciesTable_e42ff2e5-b135-43b6-ba9c-a364d364f121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_abcb56ec-4183-47ba-8e35-339719e0d29a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesTable_e42ff2e5-b135-43b6-ba9c-a364d364f121" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_abcb56ec-4183-47ba-8e35-339719e0d29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_05e43109-d856-4cac-980f-9586e3b65ab2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_abcb56ec-4183-47ba-8e35-339719e0d29a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_05e43109-d856-4cac-980f-9586e3b65ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_MicrochipsBiotechInc.Member_577fc2bb-7f5b-4e8e-bce4-b4341e783601" xlink:href="dare-20200930.xsd#dare_MicrochipsBiotechInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_05e43109-d856-4cac-980f-9586e3b65ab2" xlink:to="loc_dare_MicrochipsBiotechInc.Member_577fc2bb-7f5b-4e8e-bce4-b4341e783601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CommitmentsAndContingenciesLineItems_8a21ec34-f00d-44f0-939a-8f3fa0ffd41d" xlink:href="dare-20200930.xsd#dare_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesTable_e42ff2e5-b135-43b6-ba9c-a364d364f121" xlink:to="loc_dare_CommitmentsAndContingenciesLineItems_8a21ec34-f00d-44f0-939a-8f3fa0ffd41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AssetAcquisitionContingentConsiderationCurrent_ef5bb550-b850-435f-948f-9f782498c871" xlink:href="dare-20200930.xsd#dare_AssetAcquisitionContingentConsiderationCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_8a21ec34-f00d-44f0-939a-8f3fa0ffd41d" xlink:to="loc_dare_AssetAcquisitionContingentConsiderationCurrent_ef5bb550-b850-435f-948f-9f782498c871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived_777c4ea0-57af-444e-9503-476821be71f2" xlink:href="dare-20200930.xsd#dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_8a21ec34-f00d-44f0-939a-8f3fa0ffd41d" xlink:to="loc_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived_777c4ea0-57af-444e-9503-476821be71f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2a0d7b9d-2244-45c2-ac2b-1246f7c8a15f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_8a21ec34-f00d-44f0-939a-8f3fa0ffd41d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2a0d7b9d-2244-45c2-ac2b-1246f7c8a15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NotesPayableCurrentPlusAccruedInterest_774c1b9c-5acb-4174-89eb-2f41d4a22a3f" xlink:href="dare-20200930.xsd#dare_NotesPayableCurrentPlusAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_8a21ec34-f00d-44f0-939a-8f3fa0ffd41d" xlink:to="loc_dare_NotesPayableCurrentPlusAccruedInterest_774c1b9c-5acb-4174-89eb-2f41d4a22a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/GrantAward" xlink:type="simple" xlink:href="dare-20200930.xsd#GrantAward"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/GrantAward" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_842a8837-cb19-4cf3-9f16-108330531c63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrantAwardTextBlock_84d5adeb-9171-479a-b955-93acc6f6ab52" xlink:href="dare-20200930.xsd#dare_GrantAwardTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_842a8837-cb19-4cf3-9f16-108330531c63" xlink:to="loc_dare_GrantAwardTextBlock_84d5adeb-9171-479a-b955-93acc6f6ab52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/GrantAwardNarrativeDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#GrantAwardNarrativeDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/GrantAwardNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_25b97845-bfb2-4554-8b99-d5f56b3be193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0e42c158-bddd-41f8-a385-65997e331b74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_25b97845-bfb2-4554-8b99-d5f56b3be193" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0e42c158-bddd-41f8-a385-65997e331b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7e702371-d7f5-4c82-815c-6f677995195b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0e42c158-bddd-41f8-a385-65997e331b74" xlink:to="loc_srt_ProductOrServiceAxis_7e702371-d7f5-4c82-815c-6f677995195b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b55a4318-90c2-4e52-9fe4-f0c13eeee63f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7e702371-d7f5-4c82-815c-6f677995195b" xlink:to="loc_srt_ProductsAndServicesDomain_b55a4318-90c2-4e52-9fe4-f0c13eeee63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrantOvapreneMember_1f47aff2-df49-494e-b221-17d7f53c0dfc" xlink:href="dare-20200930.xsd#dare_GrantOvapreneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b55a4318-90c2-4e52-9fe4-f0c13eeee63f" xlink:to="loc_dare_GrantOvapreneMember_1f47aff2-df49-494e-b221-17d7f53c0dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_GrantDAREFRT1Member_e23067dc-6aa6-41e2-94b4-d986babf87f8" xlink:href="dare-20200930.xsd#dare_GrantDAREFRT1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b55a4318-90c2-4e52-9fe4-f0c13eeee63f" xlink:to="loc_dare_GrantDAREFRT1Member_e23067dc-6aa6-41e2-94b4-d986babf87f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_df0ad762-7674-4018-a02d-73b5d91b2722" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b55a4318-90c2-4e52-9fe4-f0c13eeee63f" xlink:to="loc_us-gaap_GrantMember_df0ad762-7674-4018-a02d-73b5d91b2722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareTrustFundAxis_5300bea8-67fa-40f1-b642-b98f4cbce0c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareTrustFundAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0e42c158-bddd-41f8-a385-65997e331b74" xlink:to="loc_us-gaap_HealthCareTrustFundAxis_5300bea8-67fa-40f1-b642-b98f4cbce0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareTrustFundNameDomain_f1ca33b3-6b1d-4762-9954-5407bdbc5407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareTrustFundNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareTrustFundAxis_5300bea8-67fa-40f1-b642-b98f4cbce0c9" xlink:to="loc_us-gaap_HealthCareTrustFundNameDomain_f1ca33b3-6b1d-4762-9954-5407bdbc5407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_BillAndMelindaGatesFoundationMember_4c201184-a1c6-40da-b3c6-f73e23897589" xlink:href="dare-20200930.xsd#dare_BillAndMelindaGatesFoundationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareTrustFundNameDomain_f1ca33b3-6b1d-4762-9954-5407bdbc5407" xlink:to="loc_dare_BillAndMelindaGatesFoundationMember_4c201184-a1c6-40da-b3c6-f73e23897589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e21df296-c905-4414-b3d5-c8214538f885" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0e42c158-bddd-41f8-a385-65997e331b74" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e21df296-c905-4414-b3d5-c8214538f885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ceb6abbb-3bf4-4660-a75b-404c866256f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e21df296-c905-4414-b3d5-c8214538f885" xlink:to="loc_us-gaap_RelatedPartyDomain_ceb6abbb-3bf4-4660-a75b-404c866256f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_NationalInstitutesOfHealthMember_e398a0cf-8e01-4c08-87ae-9497809e0d9d" xlink:href="dare-20200930.xsd#dare_NationalInstitutesOfHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_ceb6abbb-3bf4-4660-a75b-404c866256f8" xlink:to="loc_dare_NationalInstitutesOfHealthMember_e398a0cf-8e01-4c08-87ae-9497809e0d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ebf657dd-3f25-4b28-97a3-a9b216b3d675" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0e42c158-bddd-41f8-a385-65997e331b74" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ebf657dd-3f25-4b28-97a3-a9b216b3d675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ProceedsFromAwardOfGrant_f095ecd8-1586-469a-b9d8-e0b8912d90c9" xlink:href="dare-20200930.xsd#dare_ProceedsFromAwardOfGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ebf657dd-3f25-4b28-97a3-a9b216b3d675" xlink:to="loc_dare_ProceedsFromAwardOfGrant_f095ecd8-1586-469a-b9d8-e0b8912d90c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_549255c7-8ba3-4981-9836-9f42167f717a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ebf657dd-3f25-4b28-97a3-a9b216b3d675" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_549255c7-8ba3-4981-9836-9f42167f717a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_ead3056b-dd62-4fb2-8680-89f11c3e76dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ebf657dd-3f25-4b28-97a3-a9b216b3d675" xlink:to="loc_us-gaap_GrantsReceivable_ead3056b-dd62-4fb2-8680-89f11c3e76dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AdditionalPotentialFundingRelatedToGrantAward_15bba840-0c68-4973-8e45-6a361bcf5fa2" xlink:href="dare-20200930.xsd#dare_AdditionalPotentialFundingRelatedToGrantAward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ebf657dd-3f25-4b28-97a3-a9b216b3d675" xlink:to="loc_dare_AdditionalPotentialFundingRelatedToGrantAward_15bba840-0c68-4973-8e45-6a361bcf5fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_ReceivableForExpensesEligibleForReimbursement_4177a944-1db4-4704-b09e-d56544852b9f" xlink:href="dare-20200930.xsd#dare_ReceivableForExpensesEligibleForReimbursement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ebf657dd-3f25-4b28-97a3-a9b216b3d675" xlink:to="loc_dare_ReceivableForExpensesEligibleForReimbursement_4177a944-1db4-4704-b09e-d56544852b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ab85190e-c51a-47ea-b249-631dae687492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ebf657dd-3f25-4b28-97a3-a9b216b3d675" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ab85190e-c51a-47ea-b249-631dae687492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_DeferredGrantFundingCurrent_c24bb75e-4717-4196-8fef-4878b99d2dec" xlink:href="dare-20200930.xsd#dare_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ebf657dd-3f25-4b28-97a3-a9b216b3d675" xlink:to="loc_dare_DeferredGrantFundingCurrent_c24bb75e-4717-4196-8fef-4878b99d2dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerShare" xlink:type="simple" xlink:href="dare-20200930.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3aefd895-99ee-48c7-85bf-f3d6c3e92581" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_24a92fe2-384f-4c52-aa5f-fb3f864f0175" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3aefd895-99ee-48c7-85bf-f3d6c3e92581" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_24a92fe2-384f-4c52-aa5f-fb3f864f0175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="dare-20200930.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_84fcfe29-fe79-463c-be0b-fffec9adc78e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d42182f9-b145-4bd1-b089-63df056e05a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84fcfe29-fe79-463c-be0b-fffec9adc78e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d42182f9-b145-4bd1-b089-63df056e05a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3e20b181-3ebe-4400-940f-d57e28ba75e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_07895570-dba3-4a59-ada1-dcb977706416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3e20b181-3ebe-4400-940f-d57e28ba75e6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_07895570-dba3-4a59-ada1-dcb977706416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a1c3d03b-2e18-4df7-9d7a-d930de2710c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_07895570-dba3-4a59-ada1-dcb977706416" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a1c3d03b-2e18-4df7-9d7a-d930de2710c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f6201065-320c-4c3d-9b57-63e58298a68f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a1c3d03b-2e18-4df7-9d7a-d930de2710c7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f6201065-320c-4c3d-9b57-63e58298a68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_19af4227-8cd0-4262-b02e-3b5882df1783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f6201065-320c-4c3d-9b57-63e58298a68f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_19af4227-8cd0-4262-b02e-3b5882df1783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_26deb3a0-58ef-41c3-b44c-ea1e6d4954be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f6201065-320c-4c3d-9b57-63e58298a68f" xlink:to="loc_us-gaap_WarrantMember_26deb3a0-58ef-41c3-b44c-ea1e6d4954be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4da36cfd-89ea-4574-a819-62b25d1bf530" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_07895570-dba3-4a59-ada1-dcb977706416" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4da36cfd-89ea-4574-a819-62b25d1bf530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0f0db650-f649-41eb-8ebd-059b247b41e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4da36cfd-89ea-4574-a819-62b25d1bf530" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0f0db650-f649-41eb-8ebd-059b247b41e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/SubsequentEvents" xlink:type="simple" xlink:href="dare-20200930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_45cfe2e3-2cbd-411f-a546-3975534f019e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1311bced-abc7-4043-9ffb-adda35e093ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_45cfe2e3-2cbd-411f-a546-3975534f019e" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1311bced-abc7-4043-9ffb-adda35e093ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://darebioscience.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="dare-20200930.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://darebioscience.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_66f7b6fd-9d5d-4471-a571-7a4d7275f0b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_7160b8f4-2ce2-4136-bb8d-86711732f4f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_66f7b6fd-9d5d-4471-a571-7a4d7275f0b6" xlink:to="loc_us-gaap_SubsequentEventTable_7160b8f4-2ce2-4136-bb8d-86711732f4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ad0b072a-5480-4e7e-9039-9037701685fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_7160b8f4-2ce2-4136-bb8d-86711732f4f4" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ad0b072a-5480-4e7e-9039-9037701685fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f21bc27a-78f7-4cb1-82f0-61dc12382391" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ad0b072a-5480-4e7e-9039-9037701685fd" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f21bc27a-78f7-4cb1-82f0-61dc12382391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_38d73a3f-b3a7-4b01-b06c-23fb76555c54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f21bc27a-78f7-4cb1-82f0-61dc12382391" xlink:to="loc_us-gaap_SubsequentEventMember_38d73a3f-b3a7-4b01-b06c-23fb76555c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5b00f780-dddb-4a4f-8d70-f5c2ca6eecb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_7160b8f4-2ce2-4136-bb8d-86711732f4f4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5b00f780-dddb-4a4f-8d70-f5c2ca6eecb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0ce19570-dc07-48b2-9949-8aa485a8777e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5b00f780-dddb-4a4f-8d70-f5c2ca6eecb0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0ce19570-dc07-48b2-9949-8aa485a8777e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_AtTheMarketEquityOfferingsMember_b027430c-071f-4845-8714-6096ddb1b132" xlink:href="dare-20200930.xsd#dare_AtTheMarketEquityOfferingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0ce19570-dc07-48b2-9949-8aa485a8777e" xlink:to="loc_dare_AtTheMarketEquityOfferingsMember_b027430c-071f-4845-8714-6096ddb1b132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_PurchaseAgreementMember_5f5eba86-3a86-4040-95ac-57b75e48c4d1" xlink:href="dare-20200930.xsd#dare_PurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0ce19570-dc07-48b2-9949-8aa485a8777e" xlink:to="loc_dare_PurchaseAgreementMember_5f5eba86-3a86-4040-95ac-57b75e48c4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c8843499-4727-465e-a571-3ae8cbdbd7e4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_7160b8f4-2ce2-4136-bb8d-86711732f4f4" xlink:to="loc_srt_CounterpartyNameAxis_c8843499-4727-465e-a571-3ae8cbdbd7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_661d9581-50d5-442e-bb52-8f11e22f724c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c8843499-4727-465e-a571-3ae8cbdbd7e4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_661d9581-50d5-442e-bb52-8f11e22f724c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dare_LincolnParkMember_6fba2dae-dbc8-46f9-a2bd-29c292df176c" xlink:href="dare-20200930.xsd#dare_LincolnParkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_661d9581-50d5-442e-bb52-8f11e22f724c" xlink:to="loc_dare_LincolnParkMember_6fba2dae-dbc8-46f9-a2bd-29c292df176c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_4b851db8-4897-4718-93d6-21a744d52a25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_7160b8f4-2ce2-4136-bb8d-86711732f4f4" xlink:to="loc_us-gaap_SubsequentEventLineItems_4b851db8-4897-4718-93d6-21a744d52a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_610afce4-ebb5-4f2e-b8aa-5d39b25ccf82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4b851db8-4897-4718-93d6-21a744d52a25" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_610afce4-ebb5-4f2e-b8aa-5d39b25ccf82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_444cf05c-ae20-420a-829d-8a0aa705c7cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4b851db8-4897-4718-93d6-21a744d52a25" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_444cf05c-ae20-420a-829d-8a0aa705c7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>dare-20200930_g1.jpg
<TEXT>
begin 644 dare-20200930_g1.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M4D="                  #VU@ !     -,M2% @(
M                                            $6-P<G0   %0
M,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M    %&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0
M  +$    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE
M87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (
M#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE
M='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V
M+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                                  !865H@
M    \U$  0    $6S%A96B                      6%E:(        &^B
M   X]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0
M +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M   6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                 &1E<V,         +DE%0R V,3DV
M-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M    +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@
M<U)'0@                            !D97-C         "Q2969E<F5N
M8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M   L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N
M,0                                  =FEE=P      $Z3^ !1?+@ 0
MSQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M      $                        "CP    )S:6<@     $-25"!C=7)V
M        !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0
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MBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW____N  Y!9&]B90!DP
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M&?_:  P# 0 "$0,1 #\ W\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_?SS7_K7_LUG_LX_VP_(W^T3_P"D=%_ZL#^[_2/_ ,)_UM;^,']_/-?^M?\
MLUG_ +.7.Z)DKN9T?3<QDIOK.1RNJ:[DK]CVXH?K%V]B*=JU-[->.*"+W9Y7
M.[6-:QO7HB(G1"O&9T:=OF5Q;T5A1IUZD8K:\%&;26+Q;P2Z7B7_ --7=QF&
MG,OO[N7'=U[*A4G+!+BG.E&4GA%)+%MO!))="2/5GPGM@
M
M
M
M                                           BIYQ?A+YV^X]K]=HD
M3<]?LBS_ .02]*)-GAQ^W+37TE'T)F1HQ^-U   #8IRS^&S<_P"%5O[ :;U:
M ^<,H]U;_@B?S+<Z/JGJ7Y->?EE#9;<RP   -$_&'[M.//N-J7V!CRI>=?/%
MW\IJ^G(U4T=]4,J^C;;X&![D\PZ0
M
M
M
M                          $5/.+\)?.WW'M?KM$B;GK]D6?_ ""7I1)L
M\./VY::^DH^A,R-&/QNH   ;%.6?PV;G_"JW]@--ZM ?.&4>ZM_P1/YEN='U
M3U+\FO/RRALMN98   &B?C#]VG'GW&U+[ QY4O.OGB[^4U?3D:J:.^J&5?1M
MM\# ]R>8=(
M
M
M
M        "*GG%^$OG;[CVOUVB1-SU^R+/_D$O2B39X<?MRTU])1]"9D:,?C=
M0   V*<L_ALW/^%5O[ :;U: ^<,H]U;_ ((G\RW.CZIZE^37GY90V6W,L
M#1/QA^[3CS[C:E]@8\J7G7SQ=_*:OIR-5-'?5#*OHVV^!@>Y/,.D
M
M
M
M                                                  !%3SB_"7SM
M]Q[7Z[1(FYZ_9%G_ ,@EZ42;/#C]N6FOI*/H3,C1C\;J   &Q3EG\-FY_P *
MK?V TWJT!\X91[JW_!$_F6YT?5/4OR:\_+*&RVYE@   :)^,/W:<>?<;4OL#
M'E2\Z^>+OY35].1JIH[ZH95]&VWP,#W)YAT@
M
M
M
M                                  (J><7X2^=ON/:_7:)$W/7[(L_^
M02]*)-GAQ^W+37TE'T)F1HQ^-U   #8IRS^&S<_X56_L!IO5H#YPRCW5O^")
M_,MSH^J>I?DUY^64-EMS+    T3\8?NTX\^XVI?8&/*EYU\\7?RFKZ<C531W
MU0RKZ-MO@8'N3S#I
M
M
M
M               14\XOPE\[?<>U^NT2)N>OV19_\@EZ42;/#C]N6FOI*/H3
M,C1C\;J   &Q3EG\-FY_PJM_8#3>K0'SAE'NK?\ !$_F6YT?5/4OR:\_+*&R
MVYE@   :)^,/W:<>?<;4OL#'E2\Z^>+OY35].1JIH[ZH95]&VWP,#W)YAT@
M
M
M
M                                                         (J>
M<7X2^=ON/:_7:)$W/7[(L_\ D$O2B39X<?MRTU])1]"9D:,?C=0   V*<L_A
MLW/^%5O[ :;U: ^<,H]U;_@B?S+<Z/JGJ7Y->?EE#9;<RP   -$_&'[M.//N
M-J7V!CRI>=?/%W\IJ^G(U4T=]4,J^C;;X&![D\PZ0
M
M
M
M                                       $5/.+\)?.WW'M?KM$B;GK
M]D6?_()>E$FSPX_;EIKZ2CZ$S(T8_&Z@  !L4Y9_#9N?\*K?V TWJT!\X91[
MJW_!$_F6YT?5/4OR:\_+*&RVYE@   :)^,/W:<>?<;4OL#'E2\Z^>+OY35].
M1JIH[ZH95]&VWP,#W)YAT@
M
M
M
M                    (J><7X2^=ON/:_7:)$W/7[(L_P#D$O2B39X<?MRT
MU])1]"9D:,?C=0   V*<L_ALW/\ A5;^P&F]6@/G#*/=6_X(G\RW.CZIZE^3
M7GY90V6W,L   #1/QA^[3CS[C:E]@8\J7G7SQ=_*:OIR-5-'?5#*OHVV^!@>
MY/,.D
M
M
M
M   !%3SB_"7SM]Q[7Z[1(FYZ_9%G_P @EZ42;/#C]N6FOI*/H3,C1C\;J
M&Q3EG\-FY_PJM_8#3>K0'SAE'NK?\$3^9;G1]4]2_)KS\LH;+;F6   !HGXP
M_=IQY]QM2^P,>5+SKYXN_E-7TY&JFCOJAE7T;;? P/<GF'2
M
M
M
M                                              BIYQ?A+YV^X]K]
M=HD3<]?LBS_Y!+THDV>''[<M-?24?0F9&C'XW4   -BG+/X;-S_A5;^P&F]6
M@/G#*/=6_P"")_,MSH^J>I?DUY^64-EMS+    T3\8?NTX\^XVI?8&/*EYU\
M\7?RFKZ<C531WU0RKZ-MO@8'N3S#I
M
M
M
M                            14\XOPE\[?<>U^NT2)N>OV19_P#()>E$
MFSPX_;EIKZ2CZ$S(T8_&Z@  !L4Y9_#9N?\ "JW]@--ZM ?.&4>ZM_P1/YEN
M='U3U+\FO/RRALMN98   &B?C#]VG'GW&U+[ QY4O.OGB[^4U?3D:J:.^J&5
M?1MM\# ]R>8=(
M
M
M
M           "*GG%^$OG;[CVOUVB1-SU^R+/_D$O2B39X<?MRTU])1]"9D:,
M?C=0   V*<L_ALW/^%5O[ :;U: ^<,H]U;_@B?S+<Z/JGJ7Y->?EE#9;<RP
M  -$_&'[M.//N-J7V!CRI>=?/%W\IJ^G(U4T=]4,J^C;;X&![D\PZ0
M
M
M
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M;Y=94<OM$XVM"E"G!-MX0A%1BL7M>"2VO:^D^@?J/J
M
M
M
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MN83IUEOC).+7E3P:)GL[ZRS&WC>9?6I5[2:QC.G.,X279*+<7ZC/H'ZCZ@
M
M
M
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MTEQ13PJ0QZ*E.6$X=G%%)]#:/>'F'2@
M
M
M
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M6E._RZK3KV56/%"<)*49)]*DL4_U-Q](_2?6
M
M
M
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M_ALW/^%5O[ :;U: ^<,H]U;_ ((G\RW.CZIZE^37GY90V6W,L
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M0GC!=I.=)!
M
M
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MX*/::6O.+\)?.WW'M?KM$TYYZ_9%G_R"7I1,@_#C]N6FOI*/H3,C1C\;J
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MN$-L-T*ZBMM2ECN>]RI8N44G*+E%/AEH<(3>
M
M
M
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M[\F^;]#6UI'(\]G&&K:47MP48W,5[."6"51+\Y326YU(+AXHTYBD?D]
M
M
M
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M'.@
M    J]YY^:1Q3Q#OEW1-3U2[RO+A4=7V#/878Z.)P-++L?VRXC'7'8W+)F9J
M:(J6)8T9#'+^C:Y[FO1E6-?^*O2>CL_GD&46D\WG0V5:M*M&G2C4QVTX2X*G
M>./LY+",9>:G)J7#<OEEX,-;:[TS3U+G=]3R2G<>=0HUJ$ZM:=)K95G!5*7=
M*>^G&6,Y1\YJ*<>+BO\ OE=:_L$SG_>!0_ZJ'#_XT\L_L_7_ -;A_LY(?_\
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MYPD,
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MIOV-6-D.3?V4Z>^B;;X-&#//G[:-4?3=W\+(D<241*
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M,O/7GWJ7G1G?O[G:Z/MJK=I9I[([.%5J[6RI7E'';MC24I0I['.4YADS$"
M       &>OFG]\?+/\3-\_K3E2UVG?J_8?(Z'P<3+;F#]?<\^F+S^D5"X_Q2
M_#[QK_DS)_UAS!7W7'UKO/=Q^#@7VY*?9=E'[S4^'JDA3DR4P
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M5-QE3J)8X<7!449..[SHIQ3:3:;P.J'AG:
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M;B>'KD_:\GM T<KK1@]47O#7OZBVXUFO-HQETT[>+X(]#FZE18=XT1#(>)V
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M   &Q3EG\-FY_P *K?V TWJT!\X91[JW_!$_F6YT?5/4OR:\_+*&RVYE@
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MT=J-91F-3#3N83C">+\VE6?FTZW4D]D*KV+A:E)X4TBZ4KJ:"@
M                   &1KS@_%GSM]^;?ZG2,?N>OVNY_P#+Y>C$W4\./V&Z
M:^C8^G,BH1,38; O$#\+? /\*=-^QJQLAR;^RG3WT3;?!HP9Y\_;1JCZ;N_A
M9$CB2B)0
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MNHOTOGLNYRNCC&UM(2;HV\'Y<..K/!.K6:4IM))0IQA3C)4DXB$
M &>OFG]\?+/\3-\_K3E2UVG?J_8?(Z'P<3+;F#]?<\^F+S^D5"X_Q2_#[QK_
M ),R?]8<P5]UQ]:[SW<?@X%]N2GV791^\U/AZI(4Y,E,
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MT*Y%:\>L-)JPOI\6>9;PTJC;\Z=/!]S5?6VDX2>UN<')^N1+$X4FX
M                     &1KS@_%GSM]^;?ZG2,?N>OVNY_\OEZ,3=3PX_8;
MIKZ-CZ<R*A$Q-AL"\0/PM\ _PITW[&K&R')O[*=/?1-M\&C!GGS]M&J/IN[^
M%D2.)*(E
M   !\39-DP&GX'*[/M.8Q^ U[!TY<AE\SE;,5.ACZ<"=9)[%B9S6,;U5$:G\
MISE1K45RHB_#F69Y?DUA5S3-:U.WRZA!SJ5*DE&$(K>VWL7X6\$L6ST<IRC,
M\^S.ADV2T*MUFMS44*5*G%RG.;W*,5M?6^A)-O!)LS5^;OGML'D1?MZ#Q[-D
MM:X7HSNCDKO5U3*\@V*UELD&5S\;>DE7#120,DIXY5]'=)K'=+[<=?,GGGS_
M ,QYCW$]/Z=E5M=$TY8->MJ7;C+%5*JWQIII.G1Z'Y]3&?#&GKSX<_#)E?*F
MUIZGU5&C><PJD<5)>=3L8RC@Z5![I56FXU:ZWKWNEA#BE5K>*TEMB1?C7XR\
MB>3F\PZIIM1]'"TGP3;=NURI--@=2QDCG?IK3V.A;=RMML;TIT&2,FM/:J]8
MXF2S121RRY7ZCYHY]'*<E@Z=C!IW%S*+=*W@^F3V<526#[NDFI5&GMC",YQB
M?F[SATIR=TW+.]05%4S&HFK6TA)*M<U%T13Q<*<6TZM9Q<:::V2G*%.>I;@/
MQ_X[\<]$I:/Q_BXX42."78-BLQ0KG]LRT;'I)E<Y=C8U\[^^5Z00ITAJQN]N
M)K6]>NK/+[EYIOEMD$,BT]245@G5K22[VXJ+?4JR2VO:^&/K:<7PP21B[S/Y
MHZKYLZEJ:CU16<GBU0H1;[BVI-K"G1@W@E@EQS]?4DN*;;W=O.Y(Y
M     ,]?-/[X^6?XF;Y_6G*EKM._5^P^1T/@XF6W,'Z^YY],7G](J%Q_BE^'
MWC7_ "9D_P"L.8*^ZX^M=Y[N/P<"^W)3[+LH_>:GP]4D*<F2F
M                >/W/0-,Y#QD>(W77<;L5"&;ZQ7BOQ.]VK/T[5FIVX7Q6
MZ<KV?1<Z*1BN;Z+U3T/0R[-<QRFL[C+JTZ-5K!N+WKJ:>*:\J9X6H-,9!JJS
M5CJ&TI75K&7%%36V+ZX234H-K8W%K%;'L/PZ/Q=Q]QM%;BT?5<7KWU]6K=GJ
M,EENVFL7K'%/?N2V;TD$;O5L:R>VU5541%53]F99WFN<2C+,J\ZO#N3P27:H
MI)8];PQ9\VG-&Z7TE"<-.65&U[WU[BFYRPW)SDY3:71'BP70CWQY9TP
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MS2UG=ZQSV35:O+AI4DVX6]"+?=4(8X>;!/:TEQU)3J-<4Y'9#M#@
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M.:Y$<US516N:J=45%3T5%0J^UAL>\TO336*VIG_0?Z
M         9&O.#\6?.WWYM_J=(Q^YZ_:[G_R^7HQ-U/#C]ANFOHV/IS(J$3$
MV&P+Q _"WP#_  ITW[&K&R')O[*=/?1-M\&C!GGS]M&J/IN[^%D2.)*(E
M                                                    !X_=^/\
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M?9=E'[S4^'JDA3DR4P
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M\:RL]4].U+$J)\>J_ A[,?&E>2FXY1D%.$$]DJUU*;:[8PHPX?)QR\I.V5>
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M; O$#\+? /\ "G3?L:L;(<F_LIT]]$VWP:,&>?/VT:H^F[OX61(XDHB4
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M6MKI73UU=W=.KEM.YJ2KNFY1G4K5Z:@N[A!)<-)2VK'SEMPW3,)J*_
M'_%5&HKG*B-1%555>B(B>JJJKZ(B(&TEB]Q_J3;P6\B'RQYV>,/#\UK'[!R5
MC\]GZCG1RZYHT4FW92.>-5;+5LV,6K\)C+<3DZ.BN7*[T7\A#NKN??*W1LYV
MV8YG3N,PAL=&U3N)IK?&3A[U"2Z8U*D'V$[:(\-7.37M.%WE>45;;*YK%5[Q
MJUIM/=*,:F%:I%]$J5*:?604V_YR.JUYI8M"X1V#,5^Y4@O[?MN.UN9&HJ*C
MY<3AL5M3'.<G5.U+J=%]>Y?@L"9QXT,IIS<-/Y%<5J?1.XN(47ZM.G3KKU%4
MV=;+*Y#X LZJTXSU/J.UMZN&V%K;5+A>15:M2V?JNEMZEO.*W?G$\PR3(['<
M4<:U:_9T6*[:VB_,K^YZJY)X,KC6(SL5J=OM]>J*O7UZ)Q%?QF:RE/&VRC+(
M4\-TI5YO'RJI!;L-F';CMP4AV_@'T%&GA=YWF\ZN.^$;>"PP71*G4>...WBW
M8+#9B_V8OYQG*4+T7-\/Z!D(_<55;B\OL6'>L79T1B/MR9Q$D23U5W:J*WT[
M47U/W6GC.U7!_P NR;+ZD<?W.I6I[,.N3J[<>G#=LPZ3]%[X!=%U(_\ =V?9
MI2EA^Z4J%58X[\(JCLPZ,=^W'H)!Z1\X7BO*20P\@<5[KI[I9$C?:UW*8C=*
M,"+T3WYUM1ZC?2)/BY(H)GHGP1RDBY%XR])W4HPU#E-]9MO!RHU*=S%=KXE;
MSPZ^&,GU)D5ZC\!.M;*,JFE\[RZ_26*C7IU;2<NR/"[J&/5Q3BNMHL%XF\H^
M N;_ &8>-^3=<S66FC]Q-:M3R8/:F]K%?,C=;SD6/S%AE;HJ22PQ2PI\4>J*
MU5L1I#FKR^UUPPTUFEM7O)+'N9-TJ_;[S54*DN'IE&,H^V::;JUKGDQS/Y<\
M535V3W=O8Q>'QB,56MM^"_E%%SI1<O8QG*,_:III=^)!(P            ,]
M?-/[X^6?XF;Y_6G*EKM._5^P^1T/@XF6W,'Z^YY],7G](J%Q_BE^'WC7_)F3
M_K#F"ONN/K7>>[C\' OMR4^R[*/WFI\/5)"G)DI@ _!D\KC,+1L9/,Y*AB<;
M48LEK(9.Y7H4:T:?&2Q;M2100L3\[G(A^VC0K7-14;>$JE:6Z,4Y-^1+%L^:
M\O;/+[>5Y?U:5"T@L93J2C"$5URE)J*7E9%'=?-GA;5GS5<1<R^[WX^K>W7:
M/MXULJ?S9,ME9*$$D2I_RE9MEOY/S].YR[EQJ*^2G<1IVU)_YR7G8>YCQ/'L
MEPD)ZA\0W+[)92HV-2OF-RMGO$,*>/;4J.":[::J(CCF_F%['*]R:WQQA*$:
M*J-?F\U?R[WIU]'.CH5L(V-53^;W.Z?G4ZZVY46<5_++RI-^TA&'I.?X$1/F
M/BES:<FLIRFWI0ZZU6=5OU(1HX>3%^4\%8\]N:IG-='BN/JB(WHK*^#S3FN7
MJJ][EM[+:?W=%Z>BHGI\#U(<K].16#G=R\LX?J4T<U5\3',&HTX4,KIK#=&C
M5^[YUQ)_?/IX_P _^5X71IDM6T&_"UK4?]7I;!0LRJBIW/=,NP7*[7.;U^$*
M(BKUZ=/0_35Y69%)/N:]U&7:X27W.[3^^?7:^)[6U.25W9995II;>&%:$GZO
M?RC]R'ZQV'5_F$:Y9?%%N/'V8Q**J,DNZ]E:F;C]>GZ5:-^#"20QM5?5J32N
M1$ZIU5>AS][RIO()RR^[IU.RI%P]3&+GC]Q'>9/XH\IJR4,^RNO06YSH5(UE
MY>":HM+L4I/JQW$NN/\ G/BOD[VXM0W#&7,C(U5_8EQS\7G45K5=(C,5D65K
M=EL2(O<^%LL:?'NZ'!9KIG/,FQE?V\XT5[->=#]M'%+'J>#["<]+\Q]%ZPPA
MD5_1J7;7YF>-.MLWX4YJ,I8=+@I1[3K1X1W
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M3=.K%QJ1>#3333ZFGM1,U"XH75&-Q:SA4MYK&,HM2C)/I4DVFNU,_2?@?N
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MWA=_QIHW_<WRA_LKIO\ W99?Q!<?\I;D_DKDC_7_ /ZP^0]YWW]C?ZJOV/\
MTTVW/[3^ROVC_K(_:'[-_;F0O?4?KWU&#WO:[?=]EG=U[&]+H>$/5.I]2_\
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M.NQWH^>5S(6*O17=RM:ONY%IW,]07'<6$/>UZZ<MD(>5]?5%8M]6&+.)UMS
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M,L   #1/QA^[3CS[C:E]@8\J7G7SQ=_*:OIR-5-'?5#*OHVV^!@>Y/,.D
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MG)MK$S:YE:NCKW7N;:QITYT:.87M2K"G)IRA!O"$9..";C!13:Z4=8.N.'
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MGL79%;HKLBDBXN0Z;R+3%BLNR"UHVMHL,5".#DULXIRVRG+VTW*7:>K/A/;
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M&6O>:F>:H4N*UKWTX47C_P"[T,*%#L6-*G"3PV<3;V[SOY(1%P
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MD^3%+*J5'6&K*2EFLTIV]O-;*">ZI4BUMK-;8Q:PI+:_?,.[L((H+1@
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MGX?^74-3YW+4V;4U+),OFN",ML:MS@I1BUTQI)JI)/8Y.FFI1<D7#$ %\0
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MO>"Q[<"I_C1SEY7R,NK-2P>8YA:6^]+'";NFMKQ>RV>*6+PQQ6&)IY-23&\
M            $5/.+\)?.WW'M?KM$B;GK]D6?_()>E$FSPX_;EIKZ2CZ$S(T
M8_&Z@  !L4Y9_#9N?\*K?V TWJT!\X91[JW_  1/YEN='U3U+\FO/RRALMN9
M8   &B?C#]VG'GW&U+[ QY4O.OGB[^4U?3D:J:.^J&5?1MM\# ]R>8=(
M         "A3R:PR8'GGDZBC48D^QOS/1.GJNQTZFPN=]'TZO=E.[\_KZ^I:
M'1MQ\:TO95.JCP?P;=/\DS/YOY>LMYEYQ;I8<5VZO\/"-?'U>\Q.%'3$;@
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MR3.ZY#Z1AJG75*XNX\66Y='XS-/=*<6E1@_+4:FT]DHTY)[R[<K@:'@
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M0>EJ&C=)V>GZ27>T:2=62]G6GYU67;C-M1VO"*BMR1TP\8Z\
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M=U2^[Y#-#Q^Z?A3S/3NJJ<?/K4+FTJ/#HI3IUJ*Q[>^KO#L>'278EX3.X
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MW$\'[:1IQX!-/0I9!J#5<HXU*]Y0M(O#<J%-UJB3W><[BFY+VL>M%+A28T(
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M_@PTQ_75_P#P5+]<?X^]7_V?RW^&K?K#_<Y<:_VR[Q_F# ?X0?X,-,?UU?\
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M4*C_  X$?^&2V577EU<26*I974P?5*5:A%?Y/$BWT@(O8
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MIL)YKIG,<KIQ4ZES87%)1>U2=2E."323>#;P>Q^0VQ&X1_.X
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MRZA+RNIWGJ>;47X3&WQH6=2UYZWE>?K;FPLZD?(J2I>KYU*75U=!8F6/*H@
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M<.4O,.3$+Z*VV.<6U9OI49PKV[6Y['*O'%8K:D\=F#TLFG)D&
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MIXUU&:OCZTE5C?9#KNC%NA.E4L*LL-D90E*XMXX]<U.Y:71W;ZR[<O(9T@
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M^C:D_P#)4EZI5?DOG4,CYE99<59<-"M5E;RZO?X2IPQ[%4E!^H7N%8S28
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MV)56WV(ASQ!Z=EJGDMJ/*8+BK++9UX+>W.T<;J,5OVRE145VOH->1L081
M           BIYQ?A+YV^X]K]=HD3<]?LBS_ .02]*)-GAQ^W+37TE'T)F1H
MQ^-U   #8IRS^&S<_P"%5O[ :;U: ^<,H]U;_@B?S+<Z/JGJ7Y->?EE#9;<R
MP   -$_&'[M.//N-J7V!CRI>=?/%W\IJ^G(U4T=]4,J^C;;X&![D\PZ0
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M*N9VB."2/OQVB8FZLL$-E.OO0R;)GZ;&Q*WT?!1LL=Z/3K3[Q;\PZ63Z9I:
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MK4E-^63;P\BQP1JMDV5V^1Y1:Y-:?S:UMZ=*/1BJ<5%-]KPQ?6VS[Q\IZ0
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M)4=OJ=*+H>!K4:ROFU<Y%5:5+-,JJPBNNM0G"O'[E*-?9OZ=R9FY,T#7
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M\@EZ42;/#C]N6FOI*/H3,C1C\;J   &Q3EG\-FY_PJM_8#3>K0'SAE'NK?\
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MS&7LL%>+D9RREHO)GG6<0PU+?06*:VT*.R4:76IR>$ZN[!J$&L:;;F&1^3R
M                    9#?,KBMW#ODIRII\4#H,1-L4^SZW]!60KKVVM;L&
M.@K*O_&Q8OZ^^DKORR5G)\4,=^=.DWHSF;FV30CPV<KEUZ.S!=S<>_04>M4^
M-TL>N#-W/#_K5:^Y19)GTY*5_&T5O<;<7W]M[Q.4NIU.!5DOQ:D2,)%I,@
M!,#P8YS;P)Y%:?L62M?5M1V=S]&W5SG(R&'!;#/69!DYG.7MCBP6<KU+LKNB
MN]B"1C?5Y,G(?7BY?\R+/,KJ?#D]UC:W/4J59QPF^I4JJIU9/?P0DEO(&\27
M+:7,[E1?Y39PX\]LTKRTP6+=:@I-TUTMUJ,JM&*V+CG"3]::T#78PX
M      (J><7X2^=ON/:_7:)$W/7[(L_^02]*)-GAQ^W+37TE'T)F1HQ^-U
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MG3QR[*\WJU>JHK>DONQKUG_DGT9?X">9-2KAFN<9'1HX[Z4KJM+#W,[:@O\
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MQ<,7U-,OIX<M*O)=&3SVXCPWF:5>-8K!]Q2QA26W\:3J33Z8SB^IDUB.2P@
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MCVFC^C]=Z/U]EBS?1V86U_8X+B=*:<Z;DL5&K3>%2C/#V%6$)+J.<G-G6
M   'K=+T/=.1L[5UC0]6SFW9^XY$@Q> QMG)6NU51'3S-KQO;5J1?&2:5611
MM17.<B(JGKY)D&=ZEOX97D%I7O,PGNITH2G+RO!/ABNF4L(Q6UM(\/4.IM/:
M2RR><ZFO;:QRNFMM2M4C3CCU+B:XI/=&$<92>R*;V%S_ (P_*B6&;';CY+W8
M9?;6.U7XJU^_[K%>U[7,CV_9J$J1R,^BO?4QLCFN16JMO^7$MV.5OA*<)T\Z
MYGSB\,)*PHSQ6/5<5X/!]M.BVGL;K;X&?'.3QN*I3JY!R?IRCCC&695X8/##
M:[6WFL4]V%6XBFMJ5#ULR[+#X?$:]BL?@\#B\?A<+B:D-#%XG%4Z^/QN.I5F
M)'7J4:-2.*M5K0QM1&L8UK6I\$+Q65E9Y=:4[#+Z5.A8T8*$*=.*A"$4L%&,
M8I1C%+<DDD9VW^87V:WM7,LSK5;C,*\W.I5JSE.I4G)XRE.<FY2DWM;;;9](
M^D^0          $<_(CQ;XE\F->;B>0<*L>:H0OCUW=</[-/:]>>Y7O]NI??
M%*RYC)))%66E99-5>J]Z,;*C)&QMS'Y4Z0YGY<K/45#"^IQ:HW-/"->CO>$9
MX-2@VVY4IJ4'CC@II24L<J>=&N>3^:N^TM<8Y=5DG7M*N,K:NMBQE!-.%1))
M1K4W&HDN%R<'*$L^'D1\O#GC@J:]E\5B9N4>/X%EFBVK3J%FSD*%.-O>LFRZ
MO']9RF(6*-KG231+;I,8G5T[57M3.WF/X<M?Z"G4O+2C+-=/1Q:KVT)2G"*V
MXUJ"XIT\%BW*/>4DEBZB>Q:F\J?%7RSYE4Z=C>UXY+JB6"=M=3C&$YO9A;W#
MX:=7%X*,)=U6;>"I-+%P*( +-@       FWX\^ W/7/\U#*18*7C_0++F22[
MUN-2>E7L5'?26;7<%(M?+;(Z1J+[<D38Z3GIVOLQJ3ERY\/O,#F%.G=PMWEV
MGI8-W5S%Q3CUT:3PJ5L?8N*5)O8ZL2NO-7Q.\LN5].K93N8YIJB":5G:RC.4
M9=5>LN*E;X>RC)RK)/&-&2-"OC;XC\2>,6%=6TO%NRFV7ZS(-@W[.1PV-ERZ
M=6R25:\K6>UA<,LK45M.JC(W=C'3+-(WW%T4Y9\G](<K;%T\DI=[F]2.%:[J
MI.M4Z7%/=2IXX84X8)X1<W.2XC*[F[STUUSCS%5=0UE1R.E-NA946XV]+H4I
M+'&M5PQ3JU,6L9*FJ<'P$>?FHX3,Y_QEH4<%B,GFKJ<H:K.M/$T+>2M)!'B-
MH;),M>G%-,D3'2-17=.B*Y.OQ(Z\5]C>YAROIT+"C5KU_P!*T'PTX2G+!4Z^
M+PBF\%BMN[:2KX*LQR_*^<-6YS.O1M[?]#7,>.K.-..+JV^"XIM+%X/!8X[&
M9SO]6/)7]GN\?]$\_P#Z/,V_^%M3_P!77_\ J]7_ )AK%_QEI#^M<M_UFC_S
MRT#Y3.G;=KWD9NEW/ZKL>#IR\*;'5CMYC!Y/&5I++]ZXXE979/=JP1/G?% ]
MR,1>Y6L<O3HBEI_"+DN<9=S)OJ^86ES0HO(ZT5*I2G"+D[JS:2<HI8X)O#?@
MF^@IKXXL_P BS7E/E]OE=[:7-Q'45"3C2K4ZDE%6=^G)QA)M13:6.&&+2Z4:
M%S18RM    !41\W77=@V+CKB&'7\%F<[-6W7.RV(L-B[N3D@C?@HV,DFCI03
MNB8YR=$5R(BJ4\\866YCF6F\GAEUO6N)QOJK:IPE-I=TMK44\%Y2]G@4S;*L
MIU9GU3-;FWMJ<\NHJ+JU(4U)JLVTG-I-X="*'_\ 5CR5_9[O'_1//_Z/*"_\
M+:G_ *NO_P#5ZO\ S#3#_C+2']:Y;_K-'_GEU?R?-8V77/\ :(_I#KV<P/US
M_5)]3_;6)OXOZW]7_P!9OUCZM]>KP>_['OL[^WKV][>O3JA=_P &V59GEG_$
M?Z2MJ]OQ_H_A[RG.GQ8?'<>'B2QPQ6.&[%8[S/'QZYSD^;_\*?HJ[MKKN_TG
MQ=U5A4X>+]'\/%P2?#Q<+PQPQP>&YEUA=XSQ             !#[R?\ "KB3
MR>HNO9RJ_5>0ZM7V,3R'@:U=,KVQ1.95H[#4>D<.R8>%_:J12NCL1-16P3PH
MY_=#7-/DAI#FE0=>_B[34<(84[RDEWFQ>;&M%X*M37XLFIQ6RG4AB\9ZY->(
M;7/)NY5MELU>Z5G/BJV-:4N[VO&4Z$EB[>JUCYT5*$F\:E.HU'#/=Y!^$///
MCO+=R&PZU)L^C5GO=%R!J,<^5P#*R+U;+FH61_M+67HU6HY;L4<"R+VQ2R_$
MSLYB<B]?\N)SN<QM7=9#%O"[MTZE)1ZZJ2XZ'1CWL8PQV1G/>:G<K/$9RRYK
M0IVN57BL]232QL;IJG6<NJBV^[N%O:[F4I\*QG3AN(@D.D\      '](HI9Y
M8X88Y)III&1111,=)+++(Y&1QQQL17/D>Y41$1%554_*$)5)*$$W-O!);6V]
MR2Z6S\9SA3@ZE1J-.*;;;P22VMMO8DEO98OXY?+5YNYEFHYW>J=GB'0'R0RR
MW]EHRQ[?F*BKWO;@=4G]FY![L:)VV<A]5A[9&R1-L(BL+(\MO#)KG6DZ=_GT
M)9/IYM-SK1:N*D>GNK=X26*W3K<$<&I053!HJ=S9\7G+KE_3J9;IJI#/M4)-
M*%O-.UI2W)UKE8PE@]].AWD\8N,W2;4C01P9X]<6>.VJ,U3C37HL<V9L+LUG
M[GMV]FV:W"UR-N9[,>U'-:<QTCUBA8D=6OWN2&*-JJBZ':#Y=:4Y<92LITQ;
M*FI8=[5EA*O7DO95:F"<M[X8K"$,6H0BFT9;\R>:FM.:V=O.]874JLHMJC0A
MC&WMXOV%&EBU''!<4VY5*F"=2<VDSMIW)'0             (<\Z^'^H\GR6
M]CU*6MIF[3+)-8E9 [^CV>L.17*[+4J[5DI6Y9.G=;KM5R]7.DBF<J*D@Z9U
M_?Y*HV=^G<9:MB6/OD%[5O>E^++L2E%$"<R.1&1ZQG/-LCE#+]0RQ<FE[Q6E
M_I81VPDWOJP3>]RA4>#55G(?$G(7%E_ZCNVMWL4R21T=3*-:EO"Y#IU5%HY:
MLLE*=ZL3N6/N29B+]-C5]";LIS[*L[I=YEM:,VEMCNG'W47M7EPP?0V4NU5H
M?5.C+GXOJ&TJ48MX1J>NI3]Q5CC!O#;PXJ:7KHH^QQ_SURQQDR.MJ>XY&MBX
MU],)D/:R^%1JKU<V''9..S!25ZI])U?V7K_?'Z,UTOD6<MSO[>#K/V<<83]6
M4<&_)+%=A]^F.9>M]'Q5')+^K"S7[C/"K2]2G44E#'I<.%]I*W7/F$;;5CCC
MVSC_  &:>G1K[&"RM_7GJU.B>XZ"[!L4;Y>GJJ-=&UR_#M3X<-><J;";;L;N
MK375.,:GWTZ?ZOJDUY3XH\\HQ4<[RNUN)=,J-2=!^7":KIOKP<4WNP1T:+YA
M6I+&U9N.=BCE5/ILBS&,EC:[\S9'P0N>G_"K&_W#R'RHO\?-NZ+C[B2_5?X3
MJX>*7(W%.IE-VI]*56FUZC:6/W$?/R7S#<.R)W['XPR5F96*C5R6S5:,3)%[
MD17-JXC(.E8WT7IU8KO5.J?$_=1Y3W#E_*+V"C[6FV_OSCA]\^6\\4]A&'\@
MR>M.IA^Z7$8)/]C2GBO56.[9O.&;?YT<Q[!'+6U^+7M*K2(]K9L70=D\JC'^
MBHZ[F9+E1'(ST1\56)Z*JJBHO3ITMARST_:M3NG5N9KHE+AC]R&#]1R:(XSW
MQ'Z]S2,J.5QM<OHO';3AWE3!^WJN4=W3&G%K>GCAA$S.;!L>WY5^3V',9?8L
MQ;<V-;>3N6LE=E5SU]N"-\[Y9$C1[^C(V=&MZ]&HGP.[MK2TL*'<VE.G1MX]
M$4HI=NS#U6_5(0S'-,USV]=YFE>O=W\WAQ5)RJ3>W8DY-O#%[(K8MR1*OA[P
MSY#W^2KEMQCGT#57+%*YV1KK_27)0*O<K,=AI>U]%)&)T]ZY[:-[FN9%,G5#
MA]0<P\IRI2H9>U=7VU>:_>XOVTUO\D,>IRB35H/D#JK4\X7N?*669*\'C4C_
M "BHNJ%)[88KV=7APQ3C"HL46N<=<9Z9Q7@(M=TO#Q8VFBLDN67+[^3RUIK5
M:MW*WWI[URR[JO3KTCB:O;&UC$1J0;FV<YCG=T[O,:CG4Z%NC%=48[DOOO>V
MWM+KZ5TAD&B\L65:?H1HT-\I;ZE27X]2;VREU>QBO-@HQ22]Z>6=,
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M9PS.]:OM2)8JK*/F4G_H(/'!]'>2QF_8\";B2M.&)K
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MC4YN/^3)2],A#./"U9SFYY#FU2G#HA<4E4?\)3E3^"9R2_X"<OUU<M'8./\
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M:F6"$5%H0
M
M
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MDHQ2Z$DDD?L/UG[P
M
M
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MU>J*GHJ%YHRC.*G!IQ:Q36U-/I1G1*,H2<)IJ:>#3V--;TUT-'^S_3\0
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M3"DFXQZ&W*>"X\#OQRQ)P
M
M
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M#^34I+;1IR6#JR36*JU$\(K?"FWCYTVH6 $5EGP
M
M
M
M    ?PM5:UZM8I7:\%RG<@FJVZEJ&.Q6M5K$;HIZ]B"5KXIX)XGJU['(K7-5
M45%13]=6E2KTI4*\8SHSBXRC))QE%K!II[&FMC3V-;&?MHUJUM6A<6\Y4[BG
M)2C*+<91E%XQE&2P:DFDTT\4]J,VWGUX*7^#,OD.5>+L9-<X9S%QDE_&54FL
MV>-LE<>QGU*XKG2S2:K>MOZ4K2JOU=[VU9E1WLR6,S_$%R%N-!WE35FE:4IZ
M*K3QG".,I64Y;.&6]NA*3]ZJ>P;5*>W@E4UQ\,/B5M>9%A2T3K.M&GS H4VH
M5)81C?TXIOCCN2N817OM->O2=:GL[R%*K\JR7*      /?\ &W*?(?$&RUMN
MXUVW,:CGZRL1;>*L]D-R!CTD^I97'S-EQV8QSWM17UK44T#U1%5BJB'0Z9U7
MJ/1V9QSC3-Y6L\PC[*F]DECCPU(/&%2#Z85(RB^E'+ZNT5I77F43R+5]C;W^
M63Q\VI'%P;6''3FL*E*HENJ4Y1FNB1=CX]?-IUO+,H:WY$Z^_6<ETCKKR'JE
M6Q?UZR[T;]9SNLQ)/E\0O:G5\E%;S'O=Z00L3TO#RZ\7F67D:>6\Q[=VMSL7
MQRWBYT9=M6@L:E/M=+O4V]D(1,[N:G@:S>QE5S;E1=*\M-LOB-S*,*\?:T;A
M\-*KV1K=RTEMJ5)%N6D[_I/)."@V;0=KP.WX&SVI'D]?R=7)5F2K&R5:UE:T
MCWT[L;)$]R"9&31JO1S47T+@9'J'(]36$<TT_=V]YE\MTZ,XSBGACPRX6^&2
MQVQEA);FDRBNHM+ZBTCF4LGU/8W5AF<-].O3E3DUBUQ1XDE*#:?#.+<9;XMH
M]<>P>$14\XOPE\[?<>U^NT2)N>OV19_\@EZ42;/#C]N6FOI*/H3,C1C\;J
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M&M5BU^;6^G!K&H\)OWO!5+2"%"Y8
M
M
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MF-%K&3P=1*/FSL^1$1$1$1$1.B(GHB(GP1$_(B$+EQ4DE@MQ_P!
M
M
M
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MR(L=+NEGVJU3NM0QPE"ELE1MWT/;LJU8[^/UD)>L3<54<XR-2QH
M
M
M
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M)*/\JDDJE>>$JU3W4L%A'':H048+?ACBWUP\$[D
M
M
M
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M#_0
M
M
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ME"X[JMY?,V=.\C^J*U5:Y%1R*J*BIT5%3T5%1?5%12/&FG@]Y**::Q6X_P"
M   &Q3EG\-FY_P *K?V TWJT!\X91[JW_!$_F6YT?5/4OR:\_+*&RVYE@
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M18/2W*+06DG&ME]C"M?QW5KCWZICUQXEP0?;3A!G>CER2P
M
M
M
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MK"1IU]6*WK^3H7$R6O+)*]M7MTIRM7#AXMSX,,,<,-^&W# H3JK+J6K<MO\
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M><I>DV=]EN09%DT>')[*TM8_Z&C3I^A%;^D](?&>L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
)        ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>dare-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dare="http://darebioscience.com/20200930"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="dare-20200930.xsd" xlink:type="simple"/>
    <context id="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i49663014624147daaf0460b147931a88_I20201111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2020-11-11</instant>
        </period>
    </context>
    <context id="i541d1593a6734f80a2264c14bc99a339_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i44cca179a4a34f1e858332eb7fcba586_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id8c96646bea247b9938b381dd4090324_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib4aae1fde8a24498b3bc6e50aff2d4e1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8afa8464781b49a39b4681faf83f4671_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0073ec1a844c45b1b12b82e642dd6a0d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i84723044896e4ab9937bf3130967d6a7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i88d2ffda43594518bae4aac3bbe0861d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i433a6eab314144b584233fa1098fc8b0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ibed628a16b5f4ca89e9d282060d3f6a9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3d54ca496ab242d283acce737c73d143_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i468d0e095ca5490b9de2575fd7a58a4e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i778d6dd4e63740179791957d7305f2d7_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i9582df1f48a942c1843feec52a079e1b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ib17d45f7c7314d7e8b1fcddab7ac50b4_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ideedcc5e7e244a87ad925fd33a419342_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i9f7e83b86b284e20a0d23c9d195bdac6_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i9145a313e1704334b699d500b0ae36f5_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i151cfac574024088b63a3767d69922af_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib72039df45d24401a53a53bc832e4837_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib1cc1b354afd4948a85810f1bd926e05_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i64f2c60cd7e34b7a8f98d5f6c6890113_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4a5c11ea74534c2794d2172e3aa03449_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i76559cf393ca49de9e7e135807775d99_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ibcd5510991654ecd9e8099e2226b8f7d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8703c6e447584c3a98ba5761b1da8b14_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i57949e2187364d4a9adfe732ba2936e0_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if86e95ff8cf340409d913ec4b47d61aa_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib52fe01a8be246969cc36b76ea728405_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9c6459561ac24633955667a0e138a61d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic5b514c768bf44b98354f79ace769b2b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idb45eeeb928743849e7b50bfe4b365b2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2787ea775c17482bae9bb54124be9c7a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9b807e058c5c42409d7dfd94b4bd478f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iaebd7d8309614a7e99f2a6f1bb3dafb1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i230e979e152146c681167c318df557ef_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i688bebc3cdcd4ca48392c35cf27fb782_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7a5ba66df1e847c9a79436490357853b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i78009fb2296d46f394545d697435837a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i25c35de4c46a4497b5ac99d104d6962c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id0a3948de04b49feb4074444bfe4c48a_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ic7acea1d9dc949cdb1eba8efb4698c44_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i8280d4d773d546688557038d3b275d97_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i49b5674e31f74d72ba13e82dac7e8633_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ida47f40a6fe841c087027031cad177ba_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ib92f3eb9ef0b48db84cc7350557622d2_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i7c547f1fe1484bc6a952437a3d10d9dd_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i449930a975d04b9ea1c18df54bf78b4b_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i353a8bedc0db4bee96fe2d31985e5160_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="id22f3847410f44a987757fc5805190ca_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i42ad961aed164f408dfab70f502a4e98_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia38cd88862524a25953e1e12fcbed8da_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i20c1dd4c92ea492d812ea60776150735_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i368ed0b181144e64a2f66800be6d6815_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i99271232f7ab4dc9b246dc5b7b11dcad_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ib4ff10b061754f5888a60896993775e5_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="id40cf5fc96ed4ccdabbc1a27d10c3f5b_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="iaf2e4de4cdd14243bd2e981a38608f20_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i0c0eb362b20e46349b240d667ece7a11_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ia9e90787a50b48e68e5848b83240c00e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifaf82bec24924dfa8554c21c40d52902_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1138443634a2487caabd35c4a968772e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0593b34027c74956b65c17141dc3c7fe_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i6a4b2196c78848c28cbb2f6c038213dd_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i102d49b207054edeacf51fa8bd1a45a3_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i7a33072e23e94e97a50599beb8d9e67a_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ie3d4d54b0f7c4a229b25cbe2d9ad07e1_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i17feaef906b24653ac55862eb815e6dc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i61802997b9674fab8ffd3af8bfb3c702_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic5ea3391305d40f1a09bb8baa7e4411b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9564923853734eb58d6d4aa1c93e63f2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibf36c001049f4946aa8e0ca7818e0e67_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i237f1cb504f84950b23fc22b495fd451_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i95e67fe471b24b518cb739618ce1fa5b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6d74cf524f4149c68caa93d927c1dd50_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i073719e46a364115ad47c32863916d2b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i28e27dfd8d1744fd931fe1123a4379d6_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:BayerHealthcareLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="ib620eb86663f4b8eb249d3ca45e8961f_D20200110-20200110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:BayerHealthcareLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-10</startDate>
            <endDate>2020-01-10</endDate>
        </period>
    </context>
    <context id="i675ccdafc7724770bc5f9d69ad53a137_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i663f6a3e47204c84a850cfb01668fd90_D20191205-20191205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-05</startDate>
            <endDate>2019-12-05</endDate>
        </period>
    </context>
    <context id="i13d5e927223840e1ae39274dbb5609d3_D20200131-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-31</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="ic44f91cd00fb46e9b948e5acc2a670e9_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2508e3e579a94cdea63398846fa669b5_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9480befabfcf46ad88721e52ff929278_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib18fb0a15d48447fa6a79f7ea2a55a0f_D20191205-20191205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:HammockPharmaceuticalsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:AssignmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-05</startDate>
            <endDate>2019-12-05</endDate>
        </period>
    </context>
    <context id="ib69e2f5dfaaa4c50b61ce358dfe41490_D20200131-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:HammockPharmaceuticalsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:AssignmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-31</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i9d27e115aa2d4aa195fb48879883d1a1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:HammockPharmaceuticalsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:AssignmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i389b47dad95042fe93f5c460e656a37d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:HammockPharmaceuticalsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:AssignmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i84c418494d874dde87ff86a8ad8133ad_D20170301-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="i27a820732a994084bea4346080486a18_D20170301-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dare:UponReachingCertainWorldwideNetSalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="i8f872d8e39ed4734a655cc6daabe747c_D20170301-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="ifc98d29e798c45f386168a17588148ad_D20170301-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="i88ef2e92e2db432987e74cad75d700a3_D20180201-20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="if910f6abc722476083f07bcc96a49f22_D20180201-20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="i1ef6eb9665eb4b70a2eaa329f9ee2427_D20180201-20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="i75219243251d4cfb879a00b8d9c29575_D20180201-20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="if58b7340a7a6466bb0aae7cb62f4cf97_D20180201-20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="i49b990efd5e94bda8624d4a3746d6795_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i35e21a41a4f34efb9124460b6ace1b6e_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ie5cb9f4c567542a0a0afd091500582b8_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:SalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ibb3910bfa3544d7bb4cb75487de595bc_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:AdarePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:DevelopmentAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="ic8e3c00cd33e4af2a7e1c65065c3b12b_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponSigningOfDevelopmentAndOptionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:AdarePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:DevelopmentAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="id9aa0a2281ea41fc9868218205b55f9c_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:AdarePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:DevelopmentAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i5d6c1e846f824bddaf958f3525ddafea_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:AdarePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:DevelopmentAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i240f37dfb7c84e948e9a4cfed130cbc1_D20191130-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-30</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i86cbc311d1df479cb96f4a597e179fe5_D20191120-20191120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-20</startDate>
            <endDate>2019-11-20</endDate>
        </period>
    </context>
    <context id="i19e761cec8174fb4bcb03e95810a4853_I20191120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-20</instant>
        </period>
    </context>
    <context id="i1ad6893defad461fa065876a751e3690_I20191120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-20</instant>
        </period>
    </context>
    <context id="ibec4b74376bf439b97a248a65f5b0eae_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i934a565bb58b4ec5acca2c91b69403b1_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:MicrochipsBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i2a4aaadc8c3b47a6a160697edf8e4341_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6272459e3f90454cbd5e25ce85446ee8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">dare:PrivateDareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3ab49a29689548b9833e3f0ae8c799b5_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2928b74a51bf456b8caf39b2a4cfa467_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4e27560f58324d76aa01f67cbf138dc4_I20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="i91e3f089ee85463896dc24cc0479b252_I20180710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-10</instant>
        </period>
    </context>
    <context id="i48b5c358a2b64cbf929fdc1e1a69614a_D20180710-20180710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-10</startDate>
            <endDate>2018-07-10</endDate>
        </period>
    </context>
    <context id="id0e7f22b525c449280e635ae64efe397_D20200101-20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="ia09f304e0bb247cd9fb0ea915995673a_I20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="ie6fbf357b1224eeb9a1eed68e2f55aff_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id3721c96df454703ab043d1b9396afec_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i748cf08e328d4f8e88ce6250028b6f5c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaedce4b2446d4390afdde0c8b65ed211_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id30e47d05e2d4a89bd634aed60cdde96_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib435822bc7804f31be11690ccf5f9859_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3b128d3f8bbe4c5482cb6f55c962c6aa_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie9f7aa24af72476481534c2c2f333aba_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9d8b23a6ddc647dd8a654ce4e72821b1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i164eef1d163e46c2afb6bc319807e895_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i55a9907b8e8649348aa6657478dfe2cc_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3caed64836884e1cb8f9c5b521f55da0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iea59aafe0f1745f7a971f2eaffe8481c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i452d4b20caeb47d2985cd2793d9a7eac_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic57e6d999ba14991863c6606b7f50384_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i56d13a7ae7894e27975f5d3dc7ebf378_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="ic2c303c2ae4943dd8fbcfc1e44714b26_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i416122ab3120493b993ec3ad05b96111_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7a6ac70780144725885adc47194a94b4_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i868ac446cd6e4c439961eab65e3c6861_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="i60d87dbf215545a1b5c48615b58b820f_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="ia456760e828443768946d965d3e5d697_D20190412-20190412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-12</startDate>
            <endDate>2019-04-12</endDate>
        </period>
    </context>
    <context id="i9f7b9efd7dda44b2bec435609ae73e40_I20200422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">dare:LincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-22</instant>
        </period>
    </context>
    <context id="i8bfaf2e8371745b2b5e46ebc3e913e82_D20200422-20200422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-22</startDate>
            <endDate>2020-04-22</endDate>
        </period>
    </context>
    <context id="icd932424f77b4acfbcb47c05aacbb08a_D20200501-20200501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-01</endDate>
        </period>
    </context>
    <context id="i01002baf920d410fac2c775eac9c140e_I20200422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-22</instant>
        </period>
    </context>
    <context id="ib32b7d0c93d34cbe804300d040f5b315_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic5c15ea8e6c24d4b9e6b1c403108842f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie264785d23cd421d928dd14372cfabf0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i08898414c3aa4894b7ad663dd58d2ddc_D20200422-20200422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-22</startDate>
            <endDate>2020-04-22</endDate>
        </period>
    </context>
    <context id="i0955c43f6b5843e3b4a7d1e24a09a0ae_D20200422-20200422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-22</startDate>
            <endDate>2020-04-22</endDate>
        </period>
    </context>
    <context id="ia927dba53c23411a8034d4380544fcb1_D20200422-20200422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-22</startDate>
            <endDate>2020-04-22</endDate>
        </period>
    </context>
    <context id="ic533380ee2c447de91cd03aa8a73d217_I20200422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-22</instant>
        </period>
    </context>
    <context id="i61a90f906d204892bcb7fb20f2f34ff8_I20200422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-22</instant>
        </period>
    </context>
    <context id="ie54a63cb8870455387d630bcd302c82e_I20200421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-21</instant>
        </period>
    </context>
    <context id="i648dfc2b093f4a32a88926256f87782e_I20200422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-22</instant>
        </period>
    </context>
    <context id="ic75ab5f711a541808c1cac6b1d2728cc_I20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="ib0a8869e72f444d7a1483b278b655bd2_I20180215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201711Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-15</instant>
        </period>
    </context>
    <context id="i8656d31612a94a26a509031e31dde229_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="ia1285bc78ac34b519323112460b394f5_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i2508825fce204dd18b05c1f2654f691a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic02e362243bc4544af3beee1e4271766_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icd48642e50f1470c986bf4baf9540666_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i194102b3e8904dd394f4b80afaad69ba_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i856b85e65eba4389af62e53fcb4ddb88_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnAprilFourTwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if2f84c97f44e4cb286f9274ce4c5ce72_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnAprilFourTwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ife8c2ec7d4b44a57b608f2c92187d0d9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i637dd6b17c604a2b8aa23ef3d1d38219_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8ad78d95daba4838b75da7b4df9b8b00_I20180701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2018-07-01</instant>
        </period>
    </context>
    <context id="ic5600cf051b646c18541fb6d7163c31b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i07edbdfe23b14e1b882ecc8189596d12_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i5eedf8fd854e4e299d621b34d7105036_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i6cd38b5d0d18443eb25f5b075faaf8d0_D20180101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iec804f8af9ee49218d67d6fd78a4180c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantOvapreneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i160a0b42d86e4a8bbd0f05476b0f68e6_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantOvapreneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i07b04c713b994fddb69fb22f61dcce47_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantOvapreneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iee4d04ac7d154b5da7eff0fa25f65c41_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantOvapreneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifa5514aaaa824b3aa79107f5c9c5d73d_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREFRT1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="ida0b6e85f82e4e608327c8ca8bc71f2d_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREFRT1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i61ac128034e543f09fa5c2ccee686dd9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREFRT1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic6eebb50c9aa442eb1c1e54f219936db_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:GrantDAREFRT1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1e9574645f90496484a14992487f17b9_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareTrustFundAxis">dare:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i08cd90f2ba3140dbb283240c624fe12e_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareTrustFundAxis">dare:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9f10d1b26cc94a1fa3cb93ec8aedbb85_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareTrustFundAxis">dare:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i811a18ee61a041bcb8b2a9a6d171b9a6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0f2fd361955c4af0b36cfc82bd1dd299_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9c48e9816275492c80d5c9b5987290e9_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9fa32febc2e54647a6368e846d71b024_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icd0fb129419e4ee29415f58d00c829e5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia980a0c4d8c2414ca34948ab72d9b74d_D20201001-20201111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:AtTheMarketEquityOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-11-11</endDate>
        </period>
    </context>
    <context id="ic93f45ca4cb841cf9744ed2f4001e2a4_D20201001-20201111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401914</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dare:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-11-11</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>dare:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80L2ZyYWc6ZjI5OGViOWI0OTNhNGI0MmE2ODkxNWQzNDE4MjI1MDEvdGFibGU6MGUxMTU2OTU3MGI4NDY0M2EyODE0OTcxYjgxMWRmZmMvdGFibGVyYW5nZTowZTExNTY5NTcwYjg0NjQzYTI4MTQ5NzFiODExZGZmY18yLTEtMS0xLTA_1e086ec7-780d-40e4-a6dd-3c37bc13b5c4">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80L2ZyYWc6ZjI5OGViOWI0OTNhNGI0MmE2ODkxNWQzNDE4MjI1MDEvdGFibGU6MGUxMTU2OTU3MGI4NDY0M2EyODE0OTcxYjgxMWRmZmMvdGFibGVyYW5nZTowZTExNTY5NTcwYjg0NjQzYTI4MTQ5NzFiODExZGZmY180LTEtMS0xLTA_7d037d88-8186-44d8-b196-107b52cfc9fd">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80L2ZyYWc6ZjI5OGViOWI0OTNhNGI0MmE2ODkxNWQzNDE4MjI1MDEvdGFibGU6MGUxMTU2OTU3MGI4NDY0M2EyODE0OTcxYjgxMWRmZmMvdGFibGVyYW5nZTowZTExNTY5NTcwYjg0NjQzYTI4MTQ5NzFiODExZGZmY181LTEtMS0xLTA_8e4eafeb-c4fd-446c-b432-6ce124003295">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80L2ZyYWc6ZjI5OGViOWI0OTNhNGI0MmE2ODkxNWQzNDE4MjI1MDEvdGFibGU6MGUxMTU2OTU3MGI4NDY0M2EyODE0OTcxYjgxMWRmZmMvdGFibGVyYW5nZTowZTExNTY5NTcwYjg0NjQzYTI4MTQ5NzFiODExZGZmY183LTEtMS0xLTA_7c8e6b50-3c93-41f9-8362-a1204438413b">0001401914</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80L2ZyYWc6ZjI5OGViOWI0OTNhNGI0MmE2ODkxNWQzNDE4MjI1MDEvdGFibGU6MGUxMTU2OTU3MGI4NDY0M2EyODE0OTcxYjgxMWRmZmMvdGFibGVyYW5nZTowZTExNTY5NTcwYjg0NjQzYTI4MTQ5NzFiODExZGZmY184LTEtMS0xLTA_c33cabd1-85cf-4804-b8fe-e978964f7a69">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81NS9mcmFnOjRhOTdjNWI4Y2ZjYzQ0ZDI5ZWUyYTA3NGZlYTcwNjgzL3RhYmxlOjA4MmJmMjk3ODYxNTRiYTk4ZjdkNmMyMDdjMGY1OTAzL3RhYmxlcmFuZ2U6MDgyYmYyOTc4NjE1NGJhOThmN2Q2YzIwN2MwZjU5MDNfMS0xLTEtMS0w_cbaf9acf-1f46-4f5d-a9e2-e57f2655c64a">us-gaap:OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81NS9mcmFnOjRhOTdjNWI4Y2ZjYzQ0ZDI5ZWUyYTA3NGZlYTcwNjgzL3RhYmxlOjA4MmJmMjk3ODYxNTRiYTk4ZjdkNmMyMDdjMGY1OTAzL3RhYmxlcmFuZ2U6MDgyYmYyOTc4NjE1NGJhOThmN2Q2YzIwN2MwZjU5MDNfMi0xLTEtMS0w_e450dd45-6e1c-4ce6-a80b-54086aadb951">us-gaap:OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81NS9mcmFnOjRhOTdjNWI4Y2ZjYzQ0ZDI5ZWUyYTA3NGZlYTcwNjgzL3RhYmxlOjA4MmJmMjk3ODYxNTRiYTk4ZjdkNmMyMDdjMGY1OTAzL3RhYmxlcmFuZ2U6MDgyYmYyOTc4NjE1NGJhOThmN2Q2YzIwN2MwZjU5MDNfMy0xLTEtMS0w_69a33745-9a1c-4e9e-971d-3fab9230fb83">us-gaap:OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGV4dHJlZ2lvbjpjYmI3NzIwZDNkZGE0ZmRjYWQwYzkwNDg2YzA0MDRkMF8xNzQ5_9e17a434-88f5-425a-a0ba-6bd51770ed16">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6ZmE3YzY0YjlhNWRmNGQ2Zjk1YjZhYzRkMjI3NjUyZDkvdGFibGVyYW5nZTpmYTdjNjRiOWE1ZGY0ZDZmOTViNmFjNGQyMjc2NTJkOV8wLTAtMS0xLTA_b8e9ca27-6e51-450e-9859-7e31cd4adab1">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGV4dHJlZ2lvbjpjYmI3NzIwZDNkZGE0ZmRjYWQwYzkwNDg2YzA0MDRkMF8zMjk4NTM0ODg1MDk3_8c32770a-8174-4658-82ba-427dc52a8667">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6ZDI2NTBkMDk1ZmQ3NGNhOWJhN2MxOGIzN2QzOTIzODIvdGFibGVyYW5nZTpkMjY1MGQwOTVmZDc0Y2E5YmE3YzE4YjM3ZDM5MjM4Ml8wLTAtMS0xLTA_973efafb-afcd-4dc6-b272-e1d7aa91b66e">false</dei:DocumentTransitionReport>
    <dei:EntityRegistrantName
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF8wLTEtMS0xLTAvdGV4dHJlZ2lvbjozNTIzYzI1ZDA4NzM0OTkyOTZjNTgxYjNkZDg2NDFiNF81_c28aed9a-9cb2-48f5-b9d5-7d4780cbade6">DAR&#xc9; BIOSCIENCE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF8xLTAtMS0xLTAvdGV4dHJlZ2lvbjozMjAyZDQ5ZDU0MGY0NTFkOTE1YmQ2MGZkYjJlMDYyNV81_d64c901f-e8cb-41db-96de-1d6fa995ebe2">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF8xLTEtMS0xLTAvdGV4dHJlZ2lvbjpkODU1MjJjOTljMDM0MThjYjc2Y2MyNzE5ZmE3ZDllOV8yNA_4f544cfc-c5be-4158-bdd1-f94e7387a233">001-36395</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF8xLTItMS0xLTAvdGV4dHJlZ2lvbjphMzY1ZGM0YTQ5OTg0N2Q1OWNlMmVlODVmZTVjZGVmNl81_1b3e9f89-860b-4a21-8c5c-79ee4ee916ff">20-4139823</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpmNDY0YWYyZTEzMTQ0YTUxOWI0ZjdlZGNmZTg1NTIyM181_e62c6400-582d-41b9-8626-fc80f195693f">3655 Nobel Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpmNDY0YWYyZTEzMTQ0YTUxOWI0ZjdlZGNmZTg1NTIyM185_083db6e2-0cd7-479a-8bb0-1588a3a68a0b">Suite 260</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpmNDY0YWYyZTEzMTQ0YTUxOWI0ZjdlZGNmZTg1NTIyM18xMg_e66b2dd6-fcbc-498e-878f-d65107b49fbe">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjpmNDY0YWYyZTEzMTQ0YTUxOWI0ZjdlZGNmZTg1NTIyM18xNg_92a0e067-8449-48e1-9db0-f271ba8506be">CA</dei:EntityAddressStateOrProvince>
    <dei:CityAreaCode
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF8zLTEtMS0xLTAvdGV4dHJlZ2lvbjo1YjEzNmIyZGY5YmY0MGNmODU2Nzk3ZDU2N2FlODExNV82_c4e563c4-ebb3-4a22-809d-11663132e256">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF8zLTEtMS0xLTAvdGV4dHJlZ2lvbjo1YjEzNmIyZGY5YmY0MGNmODU2Nzk3ZDU2N2FlODExNV8xMA_3d73e358-ee00-4b8e-afc2-9e80e6f8cbc4">926-7655</dei:LocalPhoneNumber>
    <dei:EntityAddressPostalZipCode
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF8zLTItMS0xLTAvdGV4dHJlZ2lvbjplODI0NWNlZGViNDM0YjAyYjM1MWQzMGM3MjE1Zjc3NF81_8c88d8df-f0d7-4b95-befe-9ed11b0f08f2">92122</dei:EntityAddressPostalZipCode>
    <dei:Security12bTitle
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF84LTAtMS0xLTA_87ede753-553a-4670-b0ce-dd8405f10a09">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjRkMzdjYjM0NjA5NGNkNTg2YWY3NTYwMzA5OTE2YTgvdGFibGVyYW5nZTo2NGQzN2NiMzQ2MDk0Y2Q1ODZhZjc1NjAzMDk5MTZhOF84LTEtMS0xLTA_d5b62427-d99f-4f30-9514-7fe8f2ae4caf">DARE</dei:TradingSymbol>
    <dei:EntityCurrentReportingStatus
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGV4dHJlZ2lvbjpjYmI3NzIwZDNkZGE0ZmRjYWQwYzkwNDg2YzA0MDRkMF8xNzQ2_08ddf95d-c9d5-4651-a352-9db6119168fd">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGV4dHJlZ2lvbjpjYmI3NzIwZDNkZGE0ZmRjYWQwYzkwNDg2YzA0MDRkMF8xNzQ3_b9addc52-4e8c-4c12-bebb-eb94d0aa31f2">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjQxYTQyNmVlMzhlNGNlODkyMWUxNzM4MTFkMTczZjcvdGFibGVyYW5nZTo2NDFhNDI2ZWUzOGU0Y2U4OTIxZTE3MzgxMWQxNzNmN18xLTAtMS0xLTA_a7a70b78-8624-4a2d-8e2d-52723ca69e4d">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjQxYTQyNmVlMzhlNGNlODkyMWUxNzM4MTFkMTczZjcvdGFibGVyYW5nZTo2NDFhNDI2ZWUzOGU0Y2U4OTIxZTE3MzgxMWQxNzNmN18xLTUtMS0xLTA_8ac95871-c8d9-4b98-8a19-ab65c5507b4f">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGFibGU6NjQxYTQyNmVlMzhlNGNlODkyMWUxNzM4MTFkMTczZjcvdGFibGVyYW5nZTo2NDFhNDI2ZWUzOGU0Y2U4OTIxZTE3MzgxMWQxNzNmN18yLTItMS0xLTA_8b7a8a8a-3f66-41a7-a8b7-63cb72ec686c">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGV4dHJlZ2lvbjpjYmI3NzIwZDNkZGE0ZmRjYWQwYzkwNDg2YzA0MDRkMF8xNzQ4_058826d5-b056-434b-9a5f-4e651af314a4">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i49663014624147daaf0460b147931a88_I20201111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xL2ZyYWc6Y2JiNzcyMGQzZGRhNGZkY2FkMGM5MDQ4NmMwNDA0ZDAvdGV4dHJlZ2lvbjpjYmI3NzIwZDNkZGE0ZmRjYWQwYzkwNDg2YzA0MDRkMF8xNjUy_f041bbd4-e12e-4c28-8bc7-49d853947d21"
      unitRef="shares">37990001</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfNC0xLTEtMS0w_b993d7e6-f240-413a-9141-8c227fc044a3"
      unitRef="usd">5389414</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfNC0zLTEtMS0w_9d94c6e5-2392-4e65-a4f1-4bc25d6c97b9"
      unitRef="usd">4780107</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfNS0xLTEtMS0w_008f138d-13b4-4959-84cb-38914649f86a"
      unitRef="usd">213560</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfNS0zLTEtMS0w_bc9368d7-654d-4695-982c-86a1c7d038cd"
      unitRef="usd">555210</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfNi0xLTEtMS0w_d5bd65ee-ff59-434b-9e94-f7bf43858848"
      unitRef="usd">1381462</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfNi0zLTEtMS0w_fd9da235-a639-418e-94e5-4debbdc3afdd"
      unitRef="usd">1108615</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfOC0xLTEtMS0w_52a4ab8c-3489-4716-8426-d43370d6f9ab"
      unitRef="usd">6984436</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfOC0zLTEtMS0w_8860ded9-275f-461c-a004-ea29b1514587"
      unitRef="usd">6443932</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfOS0xLTEtMS0w_524079a4-9206-4613-b72f-d3ae56964638"
      unitRef="usd">42349</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfOS0zLTEtMS0w_d8d937df-dde2-49c0-9f0c-3d10bb6e866f"
      unitRef="usd">63531</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTEtMS0xLTEtMA_d84c91b4-c24a-4b34-a3a5-89d520f2555d"
      unitRef="usd">634957</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTEtMy0xLTEtMA_ab3a5661-2ef6-4705-9307-af54a3b000ed"
      unitRef="usd">935325</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTItMS0xLTEtMA_e4c0e180-f3ac-4926-872d-34bcfc0c31d6"
      unitRef="usd">7661742</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTItMy0xLTEtMA_abeb7b38-b859-425d-a086-b588f0e17f72"
      unitRef="usd">7442788</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTUtMS0xLTEtMA_c6e11362-6dae-4b66-913e-1bc6e8c47bfe"
      unitRef="usd">1555307</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTUtMy0xLTEtMA_3212e352-eb9b-4f52-9e7f-d85974130215"
      unitRef="usd">1083183</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTYtMS0xLTEtMA_3a117f44-fa24-4e42-8053-241b250943b9"
      unitRef="usd">2454048</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTYtMy0xLTEtMA_1fa77bd8-e56b-478f-9f01-49bd234fb952"
      unitRef="usd">2098653</us-gaap:AccruedLiabilitiesCurrent>
    <dare:DeferredGrantFundingCurrent
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTctMS0xLTEtMA_4af3ae84-4b60-4aab-9d52-aeadf993044c"
      unitRef="usd">2178379</dare:DeferredGrantFundingCurrent>
    <dare:DeferredGrantFundingCurrent
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTctMy0xLTEtMA_51d926db-160b-46ee-930c-4994cd125ef7"
      unitRef="usd">2019674</dare:DeferredGrantFundingCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTgtMS0xLTEtMA_300c2030-fb38-43d2-b741-96bdc3b4f6a3"
      unitRef="usd">367285</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTgtMy0xLTEtMA_7e1d3bf4-879c-4d4b-a304-a65e9c54e999"
      unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTktMS0xLTEtNjc2_4b8b772c-0272-492e-95d6-bab494ecaf82"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTktMy0xLTEtNjc2_f055295d-7abe-4d81-bb74-68a49550c75b"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTktMS0xLTEtMA_39ab7436-11f0-4128-8b9e-6061fc71d64c"
      unitRef="usd">409647</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMTktMy0xLTEtMA_94ba8db5-8285-4ed6-8bd1-d24cd8f73ed9"
      unitRef="usd">410896</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjAtMS0xLTEtMA_52704cc0-3e75-407b-9fa5-01abab7043d8"
      unitRef="usd">7964666</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjAtMy0xLTEtMA_56f99614-bfe3-44c5-91e4-77c720205d3a"
      unitRef="usd">5612406</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjEtMS0xLTEtMA_5d160c17-3fa4-41aa-9348-8a35daf4af90"
      unitRef="usd">1000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjEtMy0xLTEtMA_f21278ff-e1c9-4167-9581-11316862c3fa"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjItMS0xLTEtMA_bf20fd75-fa9b-4822-bbf3-c45e272d8f11"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjItMy0xLTEtMA_66de9d80-70a2-4a61-84a0-250dbbd295a7"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjMtMS0xLTEtMA_4bbea6df-2002-4932-81a7-eb9f3d08ed93"
      unitRef="usd">82964</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjMtMy0xLTEtMA_e0498a04-7929-4ab4-9764-e5b27a0bc717"
      unitRef="usd">389556</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjQtMS0xLTEtMA_5dd6d0c9-bacd-4e31-b1ca-55eedcade9fa"
      unitRef="usd">9047630</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjQtMy0xLTEtMA_713ef7eb-8a2b-4802-b597-f8cecdc2df78"
      unitRef="usd">7001962</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjUtMS0xLTEtMA_18397f76-16d7-4eda-9a36-ed18ac8dd553"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjUtMy0xLTEtMA_d5c21737-3c28-4353-a410-abd3899f6c4f"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdiN2U4NGQwYWQ1NzQxMGFiYmRlNzcwYTQ1M2Q1NmUwXzIx_a25d9738-8dcf-49ed-8334-2f08d3e57ad8"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdiN2U4NGQwYWQ1NzQxMGFiYmRlNzcwYTQ1M2Q1NmUwXzIx_a4a63956-6cdf-4c89-9b08-639b1b8470d7"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdiN2U4NGQwYWQ1NzQxMGFiYmRlNzcwYTQ1M2Q1NmUwXzM1_cc32efbf-fe5f-41a2-8bcc-de1083b26a70"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdiN2U4NGQwYWQ1NzQxMGFiYmRlNzcwYTQ1M2Q1NmUwXzM1_ecb8e5e2-3fc8-49b9-adfd-d870510866fd"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdiN2U4NGQwYWQ1NzQxMGFiYmRlNzcwYTQ1M2Q1NmUwXzU3_52c0b1d1-1033-49e9-8dae-0fc2dad5a3ca"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdiN2U4NGQwYWQ1NzQxMGFiYmRlNzcwYTQ1M2Q1NmUwXzU3_b298ac56-751c-4981-8d7a-a9c6403d1e59"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdiN2U4NGQwYWQ1NzQxMGFiYmRlNzcwYTQ1M2Q1NmUwXzU3_b623bd62-269d-4035-9fa9-553341385b5d"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjdiN2U4NGQwYWQ1NzQxMGFiYmRlNzcwYTQ1M2Q1NmUwXzU3_ef4560c7-b3ec-47e4-a689-7972d0616479"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjctMS0xLTEtMA_7ba69eb7-6e17-4f70-8dd6-9f90e17edf80"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjctMy0xLTEtMA_51aa3092-9c07-4c2f-b1e4-de45f73db3a8"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjJlMmVjOGM3ZGUwNzRlY2ViM2M3ZjhhNmY0YTU5MTE5XzE4_0ac7299e-a94c-404a-9656-d24c3cefde8c"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjJlMmVjOGM3ZGUwNzRlY2ViM2M3ZjhhNmY0YTU5MTE5XzE4_e1cd2e7b-7fb5-4df5-a4e6-86e319eaaf55"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjJlMmVjOGM3ZGUwNzRlY2ViM2M3ZjhhNmY0YTU5MTE5XzMy_448ee0de-0838-4dc5-bc1c-d1cdb8bb62ae"
      unitRef="shares">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjJlMmVjOGM3ZGUwNzRlY2ViM2M3ZjhhNmY0YTU5MTE5XzMy_4f542939-5f5a-4e95-96d5-ffb999f72874"
      unitRef="shares">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjJlMmVjOGM3ZGUwNzRlY2ViM2M3ZjhhNmY0YTU5MTE5XzU0_34b58967-b7ba-4361-86dd-73b7569b793e"
      unitRef="shares">33602516</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjJlMmVjOGM3ZGUwNzRlY2ViM2M3ZjhhNmY0YTU5MTE5XzU0_6efb2c24-8872-4f6d-841e-11590d33bbc5"
      unitRef="shares">33602516</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjJlMmVjOGM3ZGUwNzRlY2ViM2M3ZjhhNmY0YTU5MTE5XzYx_503cf01f-e341-4444-be29-30dd8a4f53fb"
      unitRef="shares">19683401</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjJlMmVjOGM3ZGUwNzRlY2ViM2M3ZjhhNmY0YTU5MTE5XzYx_acb4f585-ae7c-4a76-9859-66f19ce4a8b3"
      unitRef="shares">19683401</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjgtMS0xLTEtMA_7b41c73f-f6d0-4bd4-a8ca-b3e8cd197974"
      unitRef="usd">3360</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjgtMy0xLTEtMA_057e8bc8-5627-4edb-abb7-5adda41ecba2"
      unitRef="usd">1968</us-gaap:CommonStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjktMS0xLTEtMA_a8a090b7-e38d-4214-ae73-724397405e08"
      unitRef="usd">-112807</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMjktMy0xLTEtMA_b342c8ea-650e-4697-a90e-cb24a6c4eed0"
      unitRef="usd">-102625</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMzAtMS0xLTEtMA_291455ff-b150-41c9-b381-6a559cf0889b"
      unitRef="usd">61712882</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMzAtMy0xLTEtMA_98764828-2f91-428b-8a1d-956aceb86bd5"
      unitRef="usd">44564674</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMzEtMS0xLTEtMA_c322a0cc-c040-4ab6-9341-cdfd60e2d075"
      unitRef="usd">-62989323</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMzEtMy0xLTEtMA_338fbe93-810b-4b4c-8fd3-25ceb100da54"
      unitRef="usd">-44023191</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMzItMS0xLTEtMA_ef0b8539-a07b-412e-afd8-f0b73456484f"
      unitRef="usd">-1385888</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMzItMy0xLTEtMA_b9e7980d-e2e2-497e-8820-16a69d30ef0e"
      unitRef="usd">440826</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMzMtMS0xLTEtMA_98fcd469-cef3-45fb-8868-0377e32c1d3b"
      unitRef="usd">7661742</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8xOS9mcmFnOmY1NzY5OWRlOTI4NjRjY2ViYjRlOWI0ZWI0NDU5ZDFjL3RhYmxlOjNhOGM0MjQ2NzcxNTQ2ZDU4MDFkZTI0OTM5YTZmOWMxL3RhYmxlcmFuZ2U6M2E4YzQyNDY3NzE1NDZkNTgwMWRlMjQ5MzlhNmY5YzFfMzMtMy0xLTEtMA_8b5b515d-1a86-4ee4-8996-4ba79e0eaa5e"
      unitRef="usd">7442788</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMy0xLTEtMS0w_bbbfb1b2-6b2b-4c06-8b4a-6edbc58df7cc"
      unitRef="usd">1353069</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMy0zLTEtMS0w_e1fcd698-0c31-40fb-b174-129bb325740a"
      unitRef="usd">1318986</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMy01LTEtMS0w_93e5a820-425b-4a41-9722-69b549194ffc"
      unitRef="usd">4772382</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMy03LTEtMS0w_9694e157-54b4-4f25-a60e-6b62c9dc5cf4"
      unitRef="usd">3903545</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNC0xLTEtMS0w_811014ca-e113-4423-9ab7-ba6b2b1ac508"
      unitRef="usd">6203753</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNC0zLTEtMS0w_9d221d38-6b13-48c5-a597-ba43844299af"
      unitRef="usd">1966230</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNC01LTEtMS0w_2d0f8c03-9eee-4678-b31d-b0154f5b00d6"
      unitRef="usd">14131007</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNC03LTEtMS0w_73925c7e-c415-47db-8464-db1bcb2713d7"
      unitRef="usd">6172192</us-gaap:ResearchAndDevelopmentExpense>
    <dare:LicenseFee
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNS0xLTEtMS0w_8c29bfd9-93bc-45cf-8760-eebb09ead498"
      unitRef="usd">25000</dare:LicenseFee>
    <dare:LicenseFee
      contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNS0zLTEtMS0w_cc3bdf58-3feb-4e1e-a139-7e785c5ea688"
      unitRef="usd">133333</dare:LicenseFee>
    <dare:LicenseFee
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNS01LTEtMS0w_b33530af-6897-40c8-a907-feeeaeff27f7"
      unitRef="usd">58333</dare:LicenseFee>
    <dare:LicenseFee
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNS03LTEtMS0w_8c39a3f9-45ec-453c-bda3-8fff57386568"
      unitRef="usd">408333</dare:LicenseFee>
    <us-gaap:OperatingExpenses
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNi0xLTEtMS0w_87eb8a7b-2ba6-47b2-9a03-6eea72fe2140"
      unitRef="usd">7581822</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNi0zLTEtMS0w_78b95280-113c-4e0a-a07f-9e898e7f7963"
      unitRef="usd">3418549</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNi01LTEtMS0w_0ba2b777-78ca-4e0d-a190-9087e64358ff"
      unitRef="usd">18961722</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNi03LTEtMS0w_70d32862-c558-4f2e-af4f-d0b8ee6b22f4"
      unitRef="usd">10484070</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNy0xLTEtMS0w_3d4f48ea-f152-4716-a86b-5125de0dc7c0"
      unitRef="usd">-7581822</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNy0zLTEtMS0w_588d10bb-960a-4467-bf4a-90d596c62dad"
      unitRef="usd">-3418549</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNy01LTEtMS0w_be6b8eb2-f774-460a-9b15-a8d5c62fed3f"
      unitRef="usd">-18961722</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfNy03LTEtMS0w_e266980a-fb82-47bf-a3ed-665c3b00c940"
      unitRef="usd">-10484070</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfOC0xLTEtMS0w_1332b832-e987-4d2f-8956-c381ec9ff568"
      unitRef="usd">-986</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfOC0zLTEtMS0w_c8c4bb0f-2c41-4d3a-b342-7236fb68cdbd"
      unitRef="usd">25471</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfOC01LTEtMS0w_50c1bd6d-d123-4bd2-bb46-2809de83f3f9"
      unitRef="usd">2454</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfOC03LTEtMS0w_568074ec-58f5-4eef-8589-87c29965429f"
      unitRef="usd">86703</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfOS0xLTEtMS0w_8f41b3f3-bef1-4aa2-a438-5f447130fc47"
      unitRef="usd">-7582808</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfOS0zLTEtMS0w_20f5e685-95e3-4d45-869f-216852afaa84"
      unitRef="usd">-3393078</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfOS01LTEtMS0w_74a62076-f47d-43f9-a47d-1fb6c9035d5e"
      unitRef="usd">-18959268</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfOS03LTEtMS0w_4b3b7bad-35bc-41a9-b596-9406fa4f7144"
      unitRef="usd">-10397367</us-gaap:NetIncomeLoss>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTAtMS0xLTEtMA_3290649f-0feb-4f3f-a327-466b666a8e0c"
      unitRef="usd">6863</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
      contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTAtMy0xLTEtMA_7316918c-f545-4df1-a083-704b1150deb8"
      unitRef="usd">0</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTAtNS0xLTEtMA_c6185c78-9828-4d61-8a0b-429be93c9dd7"
      unitRef="usd">6863</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTAtNy0xLTEtMA_d0cae931-d974-48af-8943-44d23d21f928"
      unitRef="usd">789594</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTEtMS0xLTEtMA_0bd4bdec-8154-49b7-bcbe-2c489a2c05a9"
      unitRef="usd">-7589671</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTEtMy0xLTEtMA_abe0178b-4c31-44e9-81b0-1eafa069a4ec"
      unitRef="usd">-3393078</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTEtNS0xLTEtMA_b8e6811b-1747-44c6-802b-92b7c0d2e39c"
      unitRef="usd">-18966131</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTEtNy0xLTEtMA_964f1878-a7a8-4857-b263-1702bde22dfd"
      unitRef="usd">-11186961</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTItMS0xLTEtMA_3c8db855-aae7-4d6a-87b9-d1fbbb625770"
      unitRef="usd">672</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTItMy0xLTEtMA_b991754f-2137-4938-876b-2b00fb86c904"
      unitRef="usd">-15378</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTItNS0xLTEtMA_34f8c993-bf7d-4f75-9cab-5c8f91acc1b1"
      unitRef="usd">-10182</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTItNy0xLTEtMA_6ddceee5-9225-4378-83f9-985e7d738db1"
      unitRef="usd">-15674</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTMtMS0xLTEtMA_a4c04c7e-6570-46d8-a08e-4c38d8b9796b"
      unitRef="usd">-7588999</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTMtMy0xLTEtMA_bcfd4f48-47a1-48cf-8199-a1da1f3ab7d1"
      unitRef="usd">-3408456</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTMtNS0xLTEtMA_94744f7b-13f4-4c0a-9ca9-c731acbc8998"
      unitRef="usd">-18976313</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTMtNy0xLTEtMA_dc49fe28-d46a-4e20-b18b-7142cd6a5b23"
      unitRef="usd">-11202635</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTQtMS0xLTEtMA_53cbfccd-7b97-4fb9-a00d-b2a52f0b30f5"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTQtMy0xLTEtMA_abc8cd83-f4bf-4c72-898c-0778ad7db2fe"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTQtNS0xLTEtMA_96836c11-63ac-4535-aba7-5994454ee7d9"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTQtNy0xLTEtMA_ccbf204e-7156-4dc6-922c-d4f4fcdbebaa"
      unitRef="usdPerShare">-0.76</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTYtMS0xLTEtMA_7d7ae933-d989-45e9-85c8-7190740448fd"
      unitRef="shares">31588152</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTYtMy0xLTEtMA_04851193-fbe3-4b04-a775-c0c6b74b9ae8"
      unitRef="shares">16683411</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTYtNS0xLTEtMA_18e0537a-eb27-4c94-b439-53104f2cc9b2"
      unitRef="shares">27381508</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yMi9mcmFnOjc2ZjhhYzlkMDA2MTRhNjA4YTE3YzI0MDkyY2E4ZGY5L3RhYmxlOjUwOTc1MjYxNzY5MTQ1NTA4YmVjZTkzMGY1ZmQ3MmFiL3RhYmxlcmFuZ2U6NTA5NzUyNjE3NjkxNDU1MDhiZWNlOTMwZjVmZDcyYWJfMTYtNy0xLTEtMA_d0cb703f-fa2e-41b6-ab76-7273407748a1"
      unitRef="shares">14756213</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="ib4aae1fde8a24498b3bc6e50aff2d4e1_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMy0xLTEtMS0w_868540ef-af52-4445-8fbb-f70a22d1900e"
      unitRef="shares">19683401</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib4aae1fde8a24498b3bc6e50aff2d4e1_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMy0zLTEtMS0w_15005a43-87a6-4a45-8868-ae70f6cefec3"
      unitRef="usd">1968</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8afa8464781b49a39b4681faf83f4671_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMy01LTEtMS0w_1fb0c6c9-7fef-49a4-974b-4a0412b99e76"
      unitRef="usd">44564674</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0073ec1a844c45b1b12b82e642dd6a0d_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMy03LTEtMS0w_f0b7c26b-2a29-4511-a582-2142c33cb1ed"
      unitRef="usd">-102625</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i84723044896e4ab9937bf3130967d6a7_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMy05LTEtMS0w_d92342c2-2a0d-4656-85b4-93d48b8fb393"
      unitRef="usd">-44023191</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMy0xMS0xLTEtMA_8242d08a-a805-418b-a634-8fb32da19aac"
      unitRef="usd">440826</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i88d2ffda43594518bae4aac3bbe0861d_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNC01LTEtMS0w_278f1ff8-f666-4768-800c-3e86fb5b96fa"
      unitRef="usd">160841</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i433a6eab314144b584233fa1098fc8b0_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNC0xMS0xLTEtMA_f784bcad-c578-4e53-8300-2f48f536eed0"
      unitRef="usd">160841</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ibed628a16b5f4ca89e9d282060d3f6a9_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNS0xLTEtMS0w_430cf6a4-fc99-4d05-bbf8-ffc36dbabd86"
      unitRef="shares">3308003</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibed628a16b5f4ca89e9d282060d3f6a9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNS0zLTEtMS0w_bae013fa-6dea-46e5-858e-7c91e9b317b1"
      unitRef="usd">331</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i88d2ffda43594518bae4aac3bbe0861d_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNS01LTEtMS0w_eacf3e65-d8ce-4088-a755-3a14ae238653"
      unitRef="usd">5222356</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i433a6eab314144b584233fa1098fc8b0_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNS0xMS0xLTEtMA_d1975014-385f-484f-9b35-c93fe9f471f4"
      unitRef="usd">5222687</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares
      contextRef="ibed628a16b5f4ca89e9d282060d3f6a9_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNi0xLTEtMS0w_21bc16cf-d57b-471c-8287-d0c8ac7c22ac"
      unitRef="shares">1699000</dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ibed628a16b5f4ca89e9d282060d3f6a9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNi0zLTEtMS0w_132e5d95-7107-43f8-9d8b-1af3f11bfbf0"
      unitRef="usd">170</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i88d2ffda43594518bae4aac3bbe0861d_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNi01LTEtMS0w_f884d57c-3a89-428e-9218-b8c719489cc4"
      unitRef="usd">1664850</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i433a6eab314144b584233fa1098fc8b0_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNi0xMS0xLTEtMA_b185ece5-faee-42c5-8eea-65624c5cbe21"
      unitRef="usd">1665020</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ibed628a16b5f4ca89e9d282060d3f6a9_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNy0xLTEtMS0w_59489566-6183-4907-bcdb-71fefc27b6c1"
      unitRef="shares">10149</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibed628a16b5f4ca89e9d282060d3f6a9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNy0zLTEtMS0w_b413afff-304a-41e8-9e89-064f9a9a7a72"
      unitRef="usd">1</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i433a6eab314144b584233fa1098fc8b0_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfNy0xMS0xLTEtMA_93fc1acf-3370-4a9e-afb1-b9b87bff212f"
      unitRef="usd">1</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="i3d54ca496ab242d283acce737c73d143_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfOC05LTEtMS0w_5af13f8b-bcd4-4065-b2a6-d929e2142963"
      unitRef="usd">-4252248</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i433a6eab314144b584233fa1098fc8b0_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfOC0xMS0xLTEtMA_253fe2c5-8c93-45b7-a958-ce069f6e157d"
      unitRef="usd">-4252248</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i468d0e095ca5490b9de2575fd7a58a4e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfOS03LTEtMS0w_aa62e0d5-f5e0-4bfa-aab1-cf2836c409ce"
      unitRef="usd">-22944</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i433a6eab314144b584233fa1098fc8b0_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfOS0xMS0xLTEtMA_d9d82c7c-8cbb-4a87-ba19-e749f5bb53c7"
      unitRef="usd">-22944</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i778d6dd4e63740179791957d7305f2d7_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTAtMS0xLTEtMA_4d63f2b9-0c8e-4184-bcb2-03055443f97e"
      unitRef="shares">24700553</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i778d6dd4e63740179791957d7305f2d7_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTAtMy0xLTEtMA_e552882d-cc0c-4093-9647-9aa1794f4e34"
      unitRef="usd">2470</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9582df1f48a942c1843feec52a079e1b_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTAtNS0xLTEtMA_3d41db21-ce6e-4913-9dbb-edccd4ce1c3b"
      unitRef="usd">51612721</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib17d45f7c7314d7e8b1fcddab7ac50b4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTAtNy0xLTEtMA_319a29eb-bdc7-4b92-84bc-4955d28bd88e"
      unitRef="usd">-125569</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ideedcc5e7e244a87ad925fd33a419342_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTAtOS0xLTEtMA_a220c439-f31e-42fc-b319-b6eafcc5f155"
      unitRef="usd">-48275439</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9f7e83b86b284e20a0d23c9d195bdac6_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTAtMTEtMS0xLTA_a388eade-bfa2-4461-b1ad-3bd8f821b16b"
      unitRef="usd">3214183</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9145a313e1704334b699d500b0ae36f5_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTEtNS0xLTEtMA_547beef5-8ff2-47ef-b37c-d60cfdfdb649"
      unitRef="usd">186859</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i151cfac574024088b63a3767d69922af_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTEtMTEtMS0xLTA_d730005b-fd2e-4845-a409-1f82a6c8c673"
      unitRef="usd">186859</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib72039df45d24401a53a53bc832e4837_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTItMS0xLTEtMA_58b118ef-9980-4159-917c-4381bd45f619"
      unitRef="shares">3823451</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib72039df45d24401a53a53bc832e4837_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTItMy0xLTEtMA_d6f121f1-145b-4c76-ac34-f1a43308bcdb"
      unitRef="usd">382</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9145a313e1704334b699d500b0ae36f5_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTItNS0xLTEtMA_2ef5dca1-4721-4aaf-9e44-ab3560720617"
      unitRef="usd">4021954</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i151cfac574024088b63a3767d69922af_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTItMTEtMS0xLTA_d1d1d577-f6aa-4c60-b282-2c5122808414"
      unitRef="usd">4022336</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="ib1cc1b354afd4948a85810f1bd926e05_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTMtOS0xLTEtMA_0fa040f3-dbc3-42c3-8c2e-3517a2129ee7"
      unitRef="usd">-7124213</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i151cfac574024088b63a3767d69922af_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTMtMTEtMS0xLTA_424a5fc2-d445-422f-9256-b9752a3938e7"
      unitRef="usd">-7124213</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i64f2c60cd7e34b7a8f98d5f6c6890113_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTQtNy0xLTEtMA_d62eda36-760c-4950-ac72-ef9539a3b32f"
      unitRef="usd">12090</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i151cfac574024088b63a3767d69922af_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTQtMTEtMS0xLTA_b2f57858-fe20-4575-99a5-3a79a6ab97e9"
      unitRef="usd">12090</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i4a5c11ea74534c2794d2172e3aa03449_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTUtMS0xLTEtMA_5f7aad44-99f9-43a8-ab60-70443ef0c1a5"
      unitRef="shares">28524004</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4a5c11ea74534c2794d2172e3aa03449_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTUtMy0xLTEtMA_e2d74b2c-c0ce-4eb1-b19f-dd62dec0010c"
      unitRef="usd">2852</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i76559cf393ca49de9e7e135807775d99_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTUtNS0xLTEtMA_d170cc65-e301-4e93-9fae-999716d52875"
      unitRef="usd">55821534</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibcd5510991654ecd9e8099e2226b8f7d_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTUtNy0xLTEtMA_0cb83553-2c4e-4898-86ee-e2806e7ced37"
      unitRef="usd">-113479</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8703c6e447584c3a98ba5761b1da8b14_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTUtOS0xLTEtMA_79f81884-1ab5-4b45-9950-a4b97a65ce00"
      unitRef="usd">-55399652</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i57949e2187364d4a9adfe732ba2936e0_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTUtMTEtMS0xLTA_e9f0c8e0-0927-47d3-bc83-4e32f7b61e02"
      unitRef="usd">311255</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if86e95ff8cf340409d913ec4b47d61aa_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTYtNS0xLTEtOTAw_1043ee62-ffa9-40ba-a76f-1a4159b339b3"
      unitRef="usd">194882</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTYtMTEtMS0xLTM2Nw_7c07fbbf-1217-4f36-ad19-2d06ee591832"
      unitRef="usd">194882</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib52fe01a8be246969cc36b76ea728405_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTctMS0xLTEtMzY3_bd0f4835-0ea5-4aa2-95ba-cc24b87ce66a"
      unitRef="shares">4666798</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib52fe01a8be246969cc36b76ea728405_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTctMy0xLTEtMzY3_b5d55a05-28f0-4872-948a-d66eadbbbd0e"
      unitRef="usd">466</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if86e95ff8cf340409d913ec4b47d61aa_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTctNS0xLTEtOTAw_568ca286-5b11-424c-bf88-5f3660754e17"
      unitRef="usd">5277156</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTctMTEtMS0xLTM2Nw_c4d98b17-19cd-4018-9c3d-b7479ba95209"
      unitRef="usd">5277622</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <dare:StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares
      contextRef="ib52fe01a8be246969cc36b76ea728405_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTgtMS0xLTEtMjI3MA_d81df52a-7833-41dd-84fc-30394fbb3568"
      unitRef="shares">285714</dare:StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares>
    <dare:StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares
      contextRef="ib52fe01a8be246969cc36b76ea728405_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTgtMy0xLTEtMjI3MA_17485947-cc7f-4db1-a948-ca582dc41269"
      unitRef="usd">29</dare:StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares>
    <dare:StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares
      contextRef="if86e95ff8cf340409d913ec4b47d61aa_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTgtNS0xLTEtMjI3MA_84ca7e8f-8f91-4336-b21f-5669d47bcbb5"
      unitRef="usd">291500</dare:StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares>
    <dare:StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTgtMTEtMS0xLTIyNzA_914b0f3e-1cba-4fdb-9982-33b71782165c"
      unitRef="usd">291529</dare:StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares>
    <dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares
      contextRef="ib52fe01a8be246969cc36b76ea728405_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTgtMS0xLTEtODY0_1739acc5-d04a-48ff-a752-b607fa8e5a83"
      unitRef="shares">126000</dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ib52fe01a8be246969cc36b76ea728405_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTgtMy0xLTEtODY0_c0880108-85e8-416f-9b7f-b133e0c44941"
      unitRef="usd">13</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="if86e95ff8cf340409d913ec4b47d61aa_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTgtNS0xLTEtOTAw_ba6a567a-cbf1-4285-a2bb-7f909defacaf"
      unitRef="usd">120947</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTgtMTEtMS0xLTkwOA_6da591bb-b6bb-4629-93b3-6ad46699b39c"
      unitRef="usd">120960</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
      contextRef="if86e95ff8cf340409d913ec4b47d61aa_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTgtNS0xLTEtMzY3_28ee78e1-7862-4496-86c7-1b21c7344abe"
      unitRef="usd">-6863</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
      contextRef="i9c6459561ac24633955667a0e138a61d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTgtOS0xLTEtMzY3_cc0fa563-e864-46c0-8755-abc6fb3015b8"
      unitRef="usd">6863</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
    <us-gaap:NetIncomeLoss
      contextRef="i9c6459561ac24633955667a0e138a61d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTktOS0xLTEtMzY3_886cf810-c8af-47d0-8572-1e8d1d0e2f0b"
      unitRef="usd">-7582808</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMTktMTEtMS0xLTM2Nw_e0037ff1-5348-45da-a434-057d1ab1cb87"
      unitRef="usd">-7582808</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ic5b514c768bf44b98354f79ace769b2b_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMjAtNy0xLTEtNTcx_0091236c-a832-45a6-8663-8b2e80b4ceaa"
      unitRef="usd">672</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMjAtMTEtMS0xLTM2Nw_74a7b6fb-bf32-41a0-aa8f-a8dfbdf3ca66"
      unitRef="usd">672</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="idb45eeeb928743849e7b50bfe4b365b2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMjEtMS0xLTEtMzY3_21391857-0049-4531-aa7a-35ea91d0ed3a"
      unitRef="shares">33602516</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idb45eeeb928743849e7b50bfe4b365b2_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMjEtMy0xLTEtMzY3_b28a358d-6a74-45da-ab60-705fa6101f8b"
      unitRef="usd">3360</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2787ea775c17482bae9bb54124be9c7a_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMjEtNS0xLTEtMzY3_560fc365-5abb-462f-bda4-9e4a3eb07319"
      unitRef="usd">61712882</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9b807e058c5c42409d7dfd94b4bd478f_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMjEtNy0xLTEtMzY3_762c02f5-b4f1-4b29-856b-d482b8a407d1"
      unitRef="usd">-112807</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaebd7d8309614a7e99f2a6f1bb3dafb1_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMjEtOS0xLTEtMzY3_abb8065e-d9a8-409b-9133-2b7761113003"
      unitRef="usd">-62989323</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOjVlMWY4YWU3Mzg3MDQ2ZjJiNDYwNDJiZGY3YmQ2MjNmL3RhYmxlcmFuZ2U6NWUxZjhhZTczODcwNDZmMmI0NjA0MmJkZjdiZDYyM2ZfMjEtMTEtMS0xLTM2Nw_2c5775ec-6ef0-47df-930e-650c4e3bdf46"
      unitRef="usd">-1385888</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i230e979e152146c681167c318df557ef_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMy0xLTEtMS00Mzk_83a01394-5242-4f71-8d5f-60efbb947aa6"
      unitRef="shares">11422161</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i230e979e152146c681167c318df557ef_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMy0zLTEtMS00Mzk_59e2d4a7-32e9-487f-a24a-72771a7e961d"
      unitRef="usd">1143</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i688bebc3cdcd4ca48392c35cf27fb782_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMy01LTEtMS00Mzk_80c2fd69-c3d7-43b0-b076-cdd75e2b8541"
      unitRef="usd">35791972</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7a5ba66df1e847c9a79436490357853b_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMy03LTEtMS00Mzk_6c2a5a0f-7ec1-4149-8238-53b203540ba3"
      unitRef="usd">-96728</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i78009fb2296d46f394545d697435837a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMy05LTEtMS00Mzk_e8ca86fc-f36e-4cd0-b690-6bfebc607607"
      unitRef="usd">-28969767</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i25c35de4c46a4497b5ac99d104d6962c_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMy0xMS0xLTEtNDM5_0156c829-612d-49c5-aa5c-18996b3d2718"
      unitRef="usd">6726620</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id0a3948de04b49feb4074444bfe4c48a_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfNC01LTEtMS00Mzk_84f885d4-dddb-422a-9989-4c1ad69e8858"
      unitRef="usd">97968</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic7acea1d9dc949cdb1eba8efb4698c44_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfNC0xMS0xLTEtNDM5_0ee4091d-998c-4233-8127-ac4b822e41d6"
      unitRef="usd">97968</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i8280d4d773d546688557038d3b275d97_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfNS05LTEtMS00Mzk_4bb35c9f-a876-4a3d-ba93-4f8e09542842"
      unitRef="usd">-3051840</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic7acea1d9dc949cdb1eba8efb4698c44_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfNS0xMS0xLTEtNDM5_a815fe83-76d8-4177-9bd1-09a6a9ae5731"
      unitRef="usd">-3051840</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i49b5674e31f74d72ba13e82dac7e8633_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfNi03LTEtMS00Mzk_68c1e5bc-5bb3-4f7b-a4fc-acc1436ac2c6"
      unitRef="usd">7621</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ic7acea1d9dc949cdb1eba8efb4698c44_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfNi0xMS0xLTEtNDM5_79cabfc6-24e4-4cf7-9e71-572f52e4d720"
      unitRef="usd">7621</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="ida47f40a6fe841c087027031cad177ba_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfNy0xLTEtMS00Mzk_b67e87dc-02d6-4204-bbe8-3a381bc45509"
      unitRef="shares">11422161</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ida47f40a6fe841c087027031cad177ba_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfNy0zLTEtMS00Mzk_a454ebd2-32f7-4897-b232-89a4765f3183"
      unitRef="usd">1143</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib92f3eb9ef0b48db84cc7350557622d2_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfNy01LTEtMS00Mzk_c1b77104-b108-40ad-af8c-3ea925a69848"
      unitRef="usd">35889940</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7c547f1fe1484bc6a952437a3d10d9dd_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfNy03LTEtMS00Mzk_6aeefa21-e49b-489b-89a3-132c8f92c844"
      unitRef="usd">-89107</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i449930a975d04b9ea1c18df54bf78b4b_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfNy05LTEtMS00Mzk_a7c79e30-8ae1-4c5b-94a1-52698ec58449"
      unitRef="usd">-32021607</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i353a8bedc0db4bee96fe2d31985e5160_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfNy0xMS0xLTEtNDM5_30fb088a-0313-4c3e-aed0-5256833d0d81"
      unitRef="usd">3780369</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id22f3847410f44a987757fc5805190ca_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfOC01LTEtMS00Mzk_112864eb-9751-4d65-9c4d-04af1e307bda"
      unitRef="usd">111351</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i42ad961aed164f408dfab70f502a4e98_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfOC0xMS0xLTEtNDM5_8007144c-ba50-4b33-80ca-60610473cefc"
      unitRef="usd">111351</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia38cd88862524a25953e1e12fcbed8da_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfOS0xLTEtMS00Mzk_ca33953d-f3ed-4a84-b55d-337bb6f14fd4"
      unitRef="shares">5261250</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia38cd88862524a25953e1e12fcbed8da_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfOS0zLTEtMS00Mzk_a62d2815-3772-4b5f-83f0-ece82065bafe"
      unitRef="usd">525</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id22f3847410f44a987757fc5805190ca_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfOS01LTEtMS00Mzk_edc2d01e-32f4-4602-b536-a3395540569f"
      unitRef="usd">5151177</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i42ad961aed164f408dfab70f502a4e98_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfOS0xMS0xLTEtNDM5_514b4691-709a-4bcb-a599-0820aae5006f"
      unitRef="usd">5151702</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
      contextRef="id22f3847410f44a987757fc5805190ca_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTAtNS0xLTEtNDM5_2111d659-4216-438e-83a9-07daa9b55751"
      unitRef="usd">-789594</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
      contextRef="i20c1dd4c92ea492d812ea60776150735_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTAtOS0xLTEtNDM5_dbe974f4-af25-4659-9442-fee0340503f3"
      unitRef="usd">789594</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
    <us-gaap:NetIncomeLoss
      contextRef="i20c1dd4c92ea492d812ea60776150735_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTEtOS0xLTEtNDM5_69e6fcf0-9e6d-4b01-b424-40c9cce4d0a1"
      unitRef="usd">-3952450</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i42ad961aed164f408dfab70f502a4e98_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTEtMTEtMS0xLTQzOQ_a7c79edb-eceb-404a-adaa-6a7d23a121bc"
      unitRef="usd">-3952450</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i368ed0b181144e64a2f66800be6d6815_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTItNy0xLTEtNDM5_a6183701-b7f5-43c6-8920-40107e4415f6"
      unitRef="usd">-7917</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i42ad961aed164f408dfab70f502a4e98_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTItMTEtMS0xLTQzOQ_436c0d20-25b9-41a1-b4d6-5d6f6c6a72ad"
      unitRef="usd">-7917</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i99271232f7ab4dc9b246dc5b7b11dcad_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTMtMS0xLTEtNDM5_40bff04c-fcb5-4c7e-b72a-5abba40796e8"
      unitRef="shares">16683411</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i99271232f7ab4dc9b246dc5b7b11dcad_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTMtMy0xLTEtNDM5_6f58102c-69ae-4532-b2a5-9213c6d6d9af"
      unitRef="usd">1668</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib4ff10b061754f5888a60896993775e5_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTMtNS0xLTEtNDM5_f2d6cb1d-0208-4b39-b05b-2f6d27ac8ccb"
      unitRef="usd">41942062</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id40cf5fc96ed4ccdabbc1a27d10c3f5b_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTMtNy0xLTEtNDM5_480200c2-e9a8-4f9f-b44c-f4dc3fdf99a0"
      unitRef="usd">-97024</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaf2e4de4cdd14243bd2e981a38608f20_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTMtOS0xLTEtNDM5_2a962a44-4cf5-4b1e-aa28-3517fe018666"
      unitRef="usd">-36763651</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0c0eb362b20e46349b240d667ece7a11_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTMtMTEtMS0xLTQzOQ_98eaf2a4-6edf-4811-bff8-1e00d041cc76"
      unitRef="usd">5083055</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia9e90787a50b48e68e5848b83240c00e_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTQtNS0xLTEtNDM5_0983cae1-727e-4a4c-a586-b8ef7bb82224"
      unitRef="usd">135393</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTQtMTEtMS0xLTQzOQ_faf55608-897d-421b-bb62-7cf3e441143f"
      unitRef="usd">135393</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ifaf82bec24924dfa8554c21c40d52902_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTUtOS0xLTEtNDM5_b4797dca-7b9b-461f-b9f0-67009f792068"
      unitRef="usd">-3393078</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTUtMTEtMS0xLTQzOQ_9ad5a4c5-546d-42f1-ab18-20011c1bd815"
      unitRef="usd">-3393078</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i1138443634a2487caabd35c4a968772e_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTYtNy0xLTEtNDM5_be3ddf79-b76a-471c-934b-93eac6409b84"
      unitRef="usd">-15378</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTYtMTEtMS0xLTQzOQ_de2f3428-f6d3-44db-a231-0bba5429113b"
      unitRef="usd">-15378</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i0593b34027c74956b65c17141dc3c7fe_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTctMS0xLTEtNDM5_02a5eb5b-456e-40af-ac8e-326a50093638"
      unitRef="shares">16683411</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0593b34027c74956b65c17141dc3c7fe_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTctMy0xLTEtNDM5_87f037e9-d9c7-4f1c-b8fa-05dc8ef73753"
      unitRef="usd">1668</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6a4b2196c78848c28cbb2f6c038213dd_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTctNS0xLTEtNDM5_dfde0a4c-2af5-40a0-a8a7-fddcc221ba82"
      unitRef="usd">42077455</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i102d49b207054edeacf51fa8bd1a45a3_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTctNy0xLTEtNDM5_88d4b07e-689b-438f-bf8a-1e644919f04d"
      unitRef="usd">-112402</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7a33072e23e94e97a50599beb8d9e67a_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTctOS0xLTEtNDM5_ef155dc6-2313-405e-8010-61279e926b12"
      unitRef="usd">-40156729</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie3d4d54b0f7c4a229b25cbe2d9ad07e1_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yNS9mcmFnOmNhNWE4MWFkMjUxNjQ3OTY4ZWM2NmM5ZGVlNTM0OGExL3RhYmxlOmNiZGRiNDhmYjNiODQzM2FiNzcxOTNjMWJkZjI1NjJjL3RhYmxlcmFuZ2U6Y2JkZGI0OGZiM2I4NDMzYWI3NzE5M2MxYmRmMjU2MmNfMTctMTEtMS0xLTQzOQ_b1e85418-c69c-46b9-a1f8-f3b63bc540af"
      unitRef="usd">1809992</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMy0xLTEtMS0w_e41d0b6f-a805-4322-b941-7ce173cc9b37"
      unitRef="usd">-18959268</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMy0zLTEtMS0w_cff9819b-b3c2-4109-898f-45fc9ded27fd"
      unitRef="usd">-10397367</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfNS0xLTEtMS0w_961047f2-49e9-434b-a2d0-a5ae077d0744"
      unitRef="usd">36428</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfNS0zLTEtMS0w_2fb3f002-96c1-48e0-8e57-023b61cb41e8"
      unitRef="usd">3491</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfNi0xLTEtMS0w_35b3fb44-0202-4de4-8b9b-8f9511283fec"
      unitRef="usd">542582</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfNi0zLTEtMS0w_830189bb-31cf-42b7-91f3-2795b89c5623"
      unitRef="usd">344712</us-gaap:ShareBasedCompensation>
    <dare:NonCashLeaseExpense
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfNy0xLTEtMS0w_aa51bb00-145b-43e5-9138-ab912790b9a6"
      unitRef="usd">-125517</dare:NonCashLeaseExpense>
    <dare:NonCashLeaseExpense
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfNy0zLTEtMS0w_4c0107cc-6b5b-4944-bd32-a378547e0f9e"
      unitRef="usd">-19914</dare:NonCashLeaseExpense>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTAtMS0xLTEtMA_f03f205e-fce5-4a2c-ac6f-cc37d76226ba"
      unitRef="usd">-341650</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTAtMy0xLTEtMA_2a771e7c-daf3-4967-b0c9-d56f146790c1"
      unitRef="usd">6802</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTEtMS0xLTEtMA_871821e4-0068-4108-bb2d-f65b15d40cca"
      unitRef="usd">-18682</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTEtMy0xLTEtMA_17eccf65-e735-4046-b1af-1a1c6e19b12b"
      unitRef="usd">367409</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <dare:IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTMtMS0xLTEtMA_1ff777a8-f2a8-4ffb-839d-ebc0e92b5230"
      unitRef="usd">-118044</dare:IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges>
    <dare:IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTMtMy0xLTEtMA_15c92083-2f88-4033-b5f8-6e9d09b16bad"
      unitRef="usd">-138719</dare:IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTQtMS0xLTEtMA_1082d0e6-2489-413c-a2fa-68e8e68abe20"
      unitRef="usd">472124</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTQtMy0xLTEtMA_81cac436-dbd9-4d8e-a94a-9c7fb5e53ee9"
      unitRef="usd">-107463</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTYtMS0xLTEtMA_2a1a105d-62d8-4a1f-a09b-67df8a1d1e69"
      unitRef="usd">355395</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTYtMy0xLTEtMA_9291f2a1-60ae-466c-8d30-f24d42e4070d"
      unitRef="usd">905236</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <dare:IncreaseDecreaseInDeferredGrantFunding
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTctMS0xLTEtMA_e675f48e-89cc-48a8-be9d-67242afbcb16"
      unitRef="usd">-158704</dare:IncreaseDecreaseInDeferredGrantFunding>
    <dare:IncreaseDecreaseInDeferredGrantFunding
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTctMy0xLTEtMA_e348085d-c69e-4cdc-87f4-5305c7186e16"
      unitRef="usd">0</dare:IncreaseDecreaseInDeferredGrantFunding>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTgtMS0xLTEtMA_46c1af84-5cc2-4776-9f4f-87f3996ebd98"
      unitRef="usd">1000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTgtMy0xLTEtMA_9c5549e9-cf78-4035-8231-fab69b8e1651"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTktMS0xLTEtMA_02bce1e4-4206-49db-a319-93638aacda2d"
      unitRef="usd">-16041176</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMTktMy0xLTEtMA_57458e7f-d6d3-4a62-b88b-977358e08466"
      unitRef="usd">-9506797</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjEtMS0xLTEtMA_4e32469a-176b-4d3b-bb8d-20924b2c8cf9"
      unitRef="usd">15246</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjEtMy0xLTEtMA_57205cf6-6988-4035-9f43-7c3984f7eddc"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjItMS0xLTEtMA_9f95e08e-4a07-48d3-8ea8-3c6c32a7ecfe"
      unitRef="usd">-15246</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjItMy0xLTEtMA_ab6c1113-c860-48b3-9706-443b0f501622"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <dare:NetProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjQtMS0xLTEtMA_5615422d-5ce4-40e2-b933-59e3940d58be"
      unitRef="usd">14522645</dare:NetProceedsFromIssuanceOfCommonStockAndWarrants>
    <dare:NetProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjQtMy0xLTEtMA_612d33a9-314b-46ff-beb2-625a9b4ebb18"
      unitRef="usd">5151702</dare:NetProceedsFromIssuanceOfCommonStockAndWarrants>
    <dare:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjYtMS0xLTEtMA_f9ec4ce5-5cfb-4746-8155-24dbb9397374"
      unitRef="usd">1785980</dare:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <dare:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjYtMy0xLTEtMA_36252562-389c-4dce-ab35-01bbb3577baf"
      unitRef="usd">0</dare:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjctMS0xLTEtMA_11fec863-48ae-4fb0-999f-f076dc6955eb"
      unitRef="usd">1</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjctMy0xLTEtMA_620018f1-22be-45b0-b258-1ed9899d100c"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjgtMS0xLTEtMA_4b8e645d-d361-48b0-9053-a4ee1c444cda"
      unitRef="usd">367285</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjgtMy0xLTEtMA_ffaa488d-74c3-4334-8257-52915f56fb4e"
      unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjktMS0xLTEtMA_8df18b91-62ef-4abf-8353-8de9a686eee0"
      unitRef="usd">16675911</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMjktMy0xLTEtMA_dd26b1f9-0af5-42f1-8fc3-4e6e5ed74a94"
      unitRef="usd">5151702</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzAtMS0xLTEtMA_f577f8e4-b9bf-431a-9def-fdae759d2b87"
      unitRef="usd">-10182</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzAtMy0xLTEtMA_9715e172-dbcb-4763-b92a-8a5c661e7085"
      unitRef="usd">-15674</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzEtMS0xLTEtMA_e7adb5f7-3e2f-4a7f-9955-d8e9cdfd53be"
      unitRef="usd">609307</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzEtMy0xLTEtMA_09cf9855-c99e-43b6-970c-2d3ca5d7366f"
      unitRef="usd">-4370769</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i44cca179a4a34f1e858332eb7fcba586_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzItMS0xLTEtMA_858aca3e-7022-4f7f-8aad-70dca6f3f7d6"
      unitRef="usd">4780107</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i25c35de4c46a4497b5ac99d104d6962c_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzItMy0xLTEtMA_a61534ec-46a2-4117-8fe4-28a70e3ae7ba"
      unitRef="usd">6805889</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzMtMS0xLTEtMA_7015cc58-3a11-4ec1-b735-e8fd0aa76032"
      unitRef="usd">5389414</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie3d4d54b0f7c4a229b25cbe2d9ad07e1_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzMtMy0xLTEtMA_4e16921c-c978-4902-ae0e-cf1f39aa5fb4"
      unitRef="usd">2435120</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzUtMS0xLTEtMA_58b3b055-166c-41d5-9d10-622bedeab871"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzUtMy0xLTEtMA_93572da9-5bd2-443d-b9dd-921294ec0f41"
      unitRef="usd">231698</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <dare:IssuanceCostOnEquityPaidInCommonStock
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzYtMS0xLTEtMTg5MQ_a52d07fb-e1e7-4dc7-bf1f-60a74305e59e"
      unitRef="usd">291428</dare:IssuanceCostOnEquityPaidInCommonStock>
    <dare:IssuanceCostOnEquityPaidInCommonStock
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzYtMy0xLTEtMTg5MQ_daee0f0d-f760-4adb-afa0-b09b3c8374e9"
      unitRef="usd">0</dare:IssuanceCostOnEquityPaidInCommonStock>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzYtMS0xLTEtMA_ca6d778a-5237-4cb0-8bf7-d0242d6942c2"
      unitRef="usd">6863</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8yOC9mcmFnOjVkYjk1Y2RjMjU2ZTQyOWViOTZjZDdmNDE0NmEwNGQ4L3RhYmxlOjA0YjQwN2M4MmEwZjRlNjhhYmQ4ODkyOTkzOGJjZGVhL3RhYmxlcmFuZ2U6MDRiNDA3YzgyYTBmNGU2OGFiZDg4OTI5OTM4YmNkZWFfMzYtMy0xLTEtMA_b44de645-6a51-4390-b3f4-4cbfd92dffb1"
      unitRef="usd">789594</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNC9mcmFnOjYzNWQ2OTNhNDc1MjRkMGI4ZmM0N2RjOTBkYjQ1MjExL3RleHRyZWdpb246NjM1ZDY5M2E0NzUyNGQwYjhmYzQ3ZGM5MGRiNDUyMTFfMTE2OTM_72d39c16-509e-4aa5-b71a-3c21307126c0">ORGANIZATION AND DESCRIPTION OF THE BUSINESS&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dar&#xe9; Bioscience, Inc. is a clinical-stage biopharmaceutical company committed to the acceleration of innovative products for women&#x2019;s health. Dar&#xe9; Bioscience, Inc. and its wholly owned subsidiaries operate in one segment. In this report, the &#x201c;Company&#x201d; refers collectively to Dar&#xe9; Bioscience, Inc. and its wholly owned subsidiaries, unless otherwise stated or the context otherwise requires.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is driven by a mission to identify, acquire and develop a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, fertility, and sexual and vaginal health. The Company's business strategy is to in-license or otherwise acquire the rights to differentiated product candidates in the Company's areas of focus, some of which have existing clinical proof-of-concept data, to take those candidates through mid- to late-stage clinical development, and to establish and leverage strategic partnerships to achieve commercialization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since July 2017, the Company has assembled a portfolio of clinical-stage and pre-clinical-stage candidates. While the Company will continue to assess opportunities to expand its portfolio, its current focus is on advancing its existing product candidates through mid- and late-stages of clinical development or approval. The Company's portfolio includes three product candidates in advanced clinical development:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;DARE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;BV1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; a novel thermosetting bioadhesive hydrogel formulated with clindamycin phosphate 2% to be administered in a single vaginally delivered application&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as a first line treatment for bacterial vaginosis;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;Ovaprene&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, a hormone-free, monthly vaginal contraceptive; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;Sildenafil Cream&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; a proprietary cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's portfolio also includes three product candidates in Phase 1 clinical development or that the Company believes are Phase 1-ready:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;DARE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;HRT1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; a combination bio-identical estradiol and progesterone intravaginal ring for the treatment of menopausal symptoms, including vasomotor symptoms, as part of a hormone replacement therapy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or HRT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; following menopause;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;DARE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;FRT1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;DARE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;VVA1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or VVA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in patients with hormone-receptor positive breast cancer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's portfolio also includes these pre-clinical stage product candidates:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;DARE-LARC1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, a combination product designed to provide long-acting, reversible contraception comprising an implantable, user-controlled wireless drug delivery system and levonorgestrel;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;ORB-204 and ORB-214&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, injectable formulations of etonogestrel designed to provide contraception over 6-month and 12-month periods, respectively; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;DARE-RH1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, a novel approach to non&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hormonal contraception for both men and women by targeting the CatSper ion channel&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s primary operations have consisted of, and are expected to continue to consist of, product research and development and advancing its portfolio of product candidates through clinical development and regulatory approval. The Company expects that the majority of its development expenses for the remainder of 2020 and in 2021 will support the advancement of DARE-BV1, Ovaprene, and Sildenafil Cream, 3.6%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has not obtained any regulatory approvals for any of its product candidates, commercialized any of its product candidates or generated any product revenue. The Company is subject to several risks common to clinical-stage biopharmaceutical companies, including dependence on key employees as well as third-party licensors, partners and service providers, competition from other companies, the need to develop commercially viable products in a timely and cost-effective manner, and the need to obtain adequate additional capital to fund the development of product candidates. The Company is also subject to several risks common to other companies in the industry, including rapid technology change, regulatory approval of products, uncertainty of market acceptance of products, competition from substitute products and larger companies, compliance with government regulations, protection of proprietary technology, dependence on third parties, and product liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has prepared its interim consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. The Company has a history of losses from operations, expects negative cash flows from operations will continue for the foreseeable future, and expects that its net losses will continue for at least the next several years as it develops its existing product candidates and seeks to acquire, license or develop additional product candidates. These circumstances raise substantial doubt about the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty of the Company's ability to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the Company had an accumulated deficit of approximately $63.0 million and cash and cash equivalents of approximately $5.4 million. The Company also had negative cash flow from operations of approximately $16.0 million during the nine months ended September&#160;30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is focused primarily on the development and commercialization of innovative products in women&#x2019;s health. The Company will continue to incur significant research and development and other expenses related to these activities. If the clinical trials for any of the Company&#x2019;s product candidates fail to produce successful results such that those product candidates do not advance in clinical development, then the Company&#x2019;s business and prospects may suffer. Even if the product candidates advance in clinical development, they may fail to gain regulatory approval. Even if the product candidates are approved, they may fail to achieve market acceptance, and the Company may never become profitable. Even if the Company becomes profitable, it may not sustain profitability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Company's current operating plan estimates, the Company does not have sufficient cash to satisfy its working capital needs and other liquidity requirements over at least the next 12 months from the date of issuance of the accompanying consolidated financial statements. The Company needs to raise substantial additional capital to continue to fund its operations and to successfully execute its current operating plan, including to continue the planned development of DARE-BV1, Ovaprene, and Sildenafil Cream, 3.6%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is currently evaluating a variety of capital raising options, including equity and debt financings, government or other grant funding, collaborations and strategic alliances or other similar types of arrangements to cover its operating expenses, including the development of its product candidates and any future product candidates it may license or otherwise acquire. The amount and timing of the Company's capital needs have been and will continue to depend highly on many factors, including the product development programs the Company chooses to pursue and the pace and results of its clinical development efforts. If the Company raises capital through collaborations, strategic alliances or other similar types of arrangements, it may have to relinquish, on terms that are not favorable to the Company, rights to some of its technologies or product candidates it would otherwise seek to develop or commercialize. There can be no assurances that capital will be available when needed or that, if available, it will be obtained on terms favorable to the Company and its stockholders. Additionally, equity or debt financings may have a dilutive effect on the holdings of the Company's existing stockholders. If the Company cannot raise capital when needed, on favorable terms or at all, the Company will not be able to continue development of its product candidates, will need to reevaluate its planned operations and may need to delay, scale back or eliminate some or all of its development programs, reduce expenses, file for bankruptcy, reorganize, merge with another entity, or cease operations. If the Company becomes unable to continue as a going concern, the Company may have to liquidate its assets, and might realize significantly less than the values at which they are carried on its consolidated financial statements, and stockholders may lose all or part of their investment in the Company's common stock. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. &lt;/span&gt;&lt;/div&gt;The effect of the COVID-19 pandemic and efforts to reduce the spread of COVID-19 remain a rapidly evolving and uncertain risk to the Company's business, operating results, financial condition and stock price. In large part, the extent to which the pandemic affects the Company will depend on future developments that are beyond its knowledge or control, including, but not limited to, the duration and severity of the pandemic, governmental and individual organization actions and policies implemented to reduce transmission of the disease or facilitate development of or access to therapies to treat or vaccinations to protect against the disease, governmental actions and policies to assist economic recovery, and the speed with which and degree to which normal economic and operating conditions resume. Infectious disease experts have cautioned that the U.S. may experience a substantial surge in cases and hospitalizations during the cooler months, which may lead the federal government and/or state governments to impose or re-impose stay-at-home orders and shutdowns of non-essential businesses in efforts to reduce the spread of the disease, such as those announced by the United Kingdom, Germany, France and other European countries in October 2020. The pandemic may increase the anticipated aggregate costs for the development of the Company's product candidates and may adversely impact the anticipated timelines for the development of the Company's product candidates by, among other things,&#160;causing disruptions in the supply chain for clinical supplies, delays in the commencement of clinical trials, delays in the timing and pace of subject enrollment in any ongoing clinical trials and lower than anticipated subject enrollment and completion rates, delays in the review and approval of the Company's regulatory submissions by regulatory agencies with respect to the Company's product candidates, and other unforeseen disruptions. The economic impact of the pandemic and the uncertainty and volatility in the capital markets it has caused, and may continue to cause, may negatively impact investor sentiment and the availability and cost of capital, and may adversely impact the Company's ability to raise capital when needed or on terms favorable to the Company and its stockholders to fund its development programs and operations.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNC9mcmFnOjYzNWQ2OTNhNDc1MjRkMGI4ZmM0N2RjOTBkYjQ1MjExL3RleHRyZWdpb246NjM1ZDY5M2E0NzUyNGQwYjhmYzQ3ZGM5MGRiNDUyMTFfMjYx_1264d0cf-46e5-4c1e-8bec-2a5ff1dff1d4"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNC9mcmFnOjYzNWQ2OTNhNDc1MjRkMGI4ZmM0N2RjOTBkYjQ1MjExL3RleHRyZWdpb246NjM1ZDY5M2E0NzUyNGQwYjhmYzQ3ZGM5MGRiNDUyMTFfNjAyNw_0f7a0b63-44c5-40f1-a87f-4735dd0cf634"
      unitRef="usd">-63000000.0</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ConvertibleDebt
      contextRef="i17feaef906b24653ac55862eb815e6dc_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNC9mcmFnOjYzNWQ2OTNhNDc1MjRkMGI4ZmM0N2RjOTBkYjQ1MjExL3RleHRyZWdpb246NjM1ZDY5M2E0NzUyNGQwYjhmYzQ3ZGM5MGRiNDUyMTFfNjA3Nw_7742a6f6-b81e-4b90-a2ba-3edf8a6ed160"
      unitRef="usd">5400000</us-gaap:ConvertibleDebt>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNC9mcmFnOjYzNWQ2OTNhNDc1MjRkMGI4ZmM0N2RjOTBkYjQ1MjExL3RleHRyZWdpb246NjM1ZDY5M2E0NzUyNGQwYjhmYzQ3ZGM5MGRiNDUyMTFfNjE1NA_b0558bd5-f8c2-4b69-90f1-61b0c1a18c32"
      unitRef="usd">16000000.0</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <dare:PeriodofInsufficientCashandLiquidityRequirements
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNC9mcmFnOjYzNWQ2OTNhNDc1MjRkMGI4ZmM0N2RjOTBkYjQ1MjExL3RleHRyZWdpb246NjM1ZDY5M2E0NzUyNGQwYjhmYzQ3ZGM5MGRiNDUyMTFfNzE2Mw_3df2d038-0abb-4b5f-925e-ee374c895ea6">P12M</dare:PeriodofInsufficientCashandLiquidityRequirements>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfOTk5OQ_23a68426-14b5-46a6-a201-e5840afefe11">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant accounting policies are described in Note 1 to the consolidated financial statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed with the Securities and Exchange Commission, or SEC on March 27, 2020. Since the date of those consolidated financial statements, there have been no material changes to the Company&#x2019;s significant accounting policies, except for the accounting policies related to revenue recognition as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X.&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#x2019;s opinion, the accompanying interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying interim consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use, or ROU, lease assets, current portion of lease obligations, and long-term lease obligations on the Company's consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU lease assets represent the Company's right to use an underlying asset for the lease term and lease obligations represent the Company's obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. If the lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset also includes any lease payments made and excludes lease incentives. The Company's lease terms may include options to extend or terminate the lease and the related payments are only included in the lease liability when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. (See Note 7, Leased Properties.)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The&lt;/span&gt;&lt;span style="color:#191c1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; following tables present the classification within the fair value hierarchy of financial assets and liabilities that are remeasured on a recurring basis as of September&#160;30, 2020 and December&#160;31, 2019. There were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 2) as of September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:477.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:208.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:7.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:7.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:7.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,389,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,389,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,780,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,780,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other non-current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:26pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue is accordance with Accounting Standards Codification, or ASC, Topic 606,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In a contract with multiple performance obligations, the Company develops estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Fees. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license&#160;to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from non-refundable, upfront fees allocated to the&#160;license when the&#160;license&#160;is transferred to the customer and the customer is able to use and benefit from the&#160;license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. To date, the Company has not recognized any license fee revenue resulting from any of its collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bayer License. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the Company entered into a license agreement with Bayer HealthCare LLC, or Bayer, regarding the further development and commercialization of Ovaprene in the U.S. Upon execution of the agreement, the Company received a $1.0 million upfront non-refundable license fee payment from Bayer. Bayer, in its sole discretion, has the right to make the license effective by paying the Company an additional $20.0 million. The Company concluded that there was one significant performance obligation related to the $1.0 million upfront payment: a distinct license to commercialize Ovaprene effective upon the receipt of the $20.0 million fee. The $1.0 million upfront payment will be recorded as license revenue at the earlier of (1) the point in time the&#160;Company receives the $20.0 million fee, the license&#160;is transferred to Bayer and Bayer is able to use and benefit from the&#160;license and (2) the termination of the agreement. As of September&#160;30, 2020, neither of the foregoing had occurred. The $1.0 million payment is recorded as long term deferred revenue in the Company's consolidated balance sheet at September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will also be entitled to receive (a) milestone payments totaling up to $310.0 million related to the commercial sales of Ovaprene, if all such milestones are achieved, and (b) tiered royalties starting in the low double digits based on annual net sales of Ovaprene during a calendar year, subject to customary royalty reductions and offsets, and (c) a percentage of sublicense revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potential future payments for variable consideration, such as commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur. (See Note 3, License and Collaboration Agreements.)&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfMTAwMDU_34151567-dbad-4a35-a2c6-d445aa60185b">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X.&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#x2019;s opinion, the accompanying interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying interim consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfMTAwMDI_a29d2647-592f-45d0-b7e3-6b63635b9c96">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use, or ROU, lease assets, current portion of lease obligations, and long-term lease obligations on the Company's consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;ROU lease assets represent the Company's right to use an underlying asset for the lease term and lease obligations represent the Company's obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. If the lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset also includes any lease payments made and excludes lease incentives. The Company's lease terms may include options to extend or terminate the lease and the related payments are only included in the lease liability when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfMTAwMDM_c2ae36cf-00df-43c0-a1b6-89b88d6e265e">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfOTk5Nw_d9aced9b-70d5-453b-870d-b27469f0397d">&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The&lt;/span&gt;&lt;span style="color:#191c1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; following tables present the classification within the fair value hierarchy of financial assets and liabilities that are remeasured on a recurring basis as of September&#160;30, 2020 and December&#160;31, 2019. There were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 2) as of September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:477.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:208.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:7.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:7.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:7.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,389,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,389,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,780,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,780,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other non-current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:26pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i61802997b9674fab8ffd3af8bfb3c702_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfNC0xLTEtMS0w_67ca1a40-51c8-40a7-b31e-815bcf518967"
      unitRef="usd">5389414</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic5ea3391305d40f1a09bb8baa7e4411b_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfNC0zLTEtMS0w_c98feb58-1a66-485d-b897-e55cdc8ecf1e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9564923853734eb58d6d4aa1c93e63f2_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfNC01LTEtMS0w_14e80330-9280-42c6-9e0b-3f620b127885"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibf36c001049f4946aa8e0ca7818e0e67_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfNC03LTEtMS0w_ec950bb0-a28c-47cb-88ff-6c9eeff9b3c8"
      unitRef="usd">5389414</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <dare:AssetAcquisitionContingentConsiderationCurrent
      contextRef="i61802997b9674fab8ffd3af8bfb3c702_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfNi0xLTEtMS0w_42832e19-e4b0-47f1-a04c-cb0b3adb55f1"
      unitRef="usd">0</dare:AssetAcquisitionContingentConsiderationCurrent>
    <dare:AssetAcquisitionContingentConsiderationCurrent
      contextRef="ic5ea3391305d40f1a09bb8baa7e4411b_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfNi0zLTEtMS0w_3d7d588b-03bc-438d-b524-963473f781fa"
      unitRef="usd">0</dare:AssetAcquisitionContingentConsiderationCurrent>
    <dare:AssetAcquisitionContingentConsiderationCurrent
      contextRef="i9564923853734eb58d6d4aa1c93e63f2_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfNi01LTEtMS0w_97a8be8c-f579-40b9-98d6-22c3c83262fe"
      unitRef="usd">1000000</dare:AssetAcquisitionContingentConsiderationCurrent>
    <dare:AssetAcquisitionContingentConsiderationCurrent
      contextRef="ibf36c001049f4946aa8e0ca7818e0e67_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfNi03LTEtMS0w_0c3fd969-0b1a-4434-8d89-6d57e40aa758"
      unitRef="usd">1000000</dare:AssetAcquisitionContingentConsiderationCurrent>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i237f1cb504f84950b23fc22b495fd451_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfOS0xLTEtMS0w_69f20bf5-06df-4a5d-9476-02894f4ddc0a"
      unitRef="usd">4780107</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i95e67fe471b24b518cb739618ce1fa5b_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfOS0zLTEtMS0w_789e13ed-ea7d-4e4c-9660-3f85c5abafd4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6d74cf524f4149c68caa93d927c1dd50_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfOS01LTEtMS0w_41ad0423-5fd1-4637-ae06-256dff2ee9f4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i073719e46a364115ad47c32863916d2b_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfOS03LTEtMS0w_6d4ea617-a28b-4b06-afee-5146c6660aa3"
      unitRef="usd">4780107</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <dare:AssetAcquisitionContingentConsiderationNoncurrent
      contextRef="i237f1cb504f84950b23fc22b495fd451_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfMTEtMS0xLTEtMA_770a2f4b-06dd-44fa-ad23-782d8bdfa697"
      unitRef="usd">0</dare:AssetAcquisitionContingentConsiderationNoncurrent>
    <dare:AssetAcquisitionContingentConsiderationNoncurrent
      contextRef="i95e67fe471b24b518cb739618ce1fa5b_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfMTEtMy0xLTEtMA_a9a3224f-f4c7-457d-9e1c-d26a0ab3375b"
      unitRef="usd">0</dare:AssetAcquisitionContingentConsiderationNoncurrent>
    <dare:AssetAcquisitionContingentConsiderationNoncurrent
      contextRef="i6d74cf524f4149c68caa93d927c1dd50_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfMTEtNS0xLTEtMA_1c6c29c4-3e17-4db9-89a5-e1d967516574"
      unitRef="usd">1000000</dare:AssetAcquisitionContingentConsiderationNoncurrent>
    <dare:AssetAcquisitionContingentConsiderationNoncurrent
      contextRef="i073719e46a364115ad47c32863916d2b_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RhYmxlOjg1NjNmOWNhMDE2MDRhZGE5OTgyNzY2NGZkMzAzMTc2L3RhYmxlcmFuZ2U6ODU2M2Y5Y2EwMTYwNGFkYTk5ODI3NjY0ZmQzMDMxNzZfMTEtNy0xLTEtMA_cbc2a48a-acf0-4394-a1e2-ae81dd00895d"
      unitRef="usd">1000000</dare:AssetAcquisitionContingentConsiderationNoncurrent>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfMjc0ODc3OTA3OTU1NA_658b467c-3008-458a-8559-db0655fcc595">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue is accordance with Accounting Standards Codification, or ASC, Topic 606,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In a contract with multiple performance obligations, the Company develops estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Fees. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license&#160;to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from non-refundable, upfront fees allocated to the&#160;license when the&#160;license&#160;is transferred to the customer and the customer is able to use and benefit from the&#160;license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. To date, the Company has not recognized any license fee revenue resulting from any of its collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <dare:UpfrontLicenseFeePaid
      contextRef="i28e27dfd8d1744fd931fe1123a4379d6_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfODQ5OQ_aa0153e2-3a8c-4ac2-ac29-1733eca43a43"
      unitRef="usd">1000000.0</dare:UpfrontLicenseFeePaid>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28e27dfd8d1744fd931fe1123a4379d6_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfODY2OA_b7a7c133-097a-4500-bab0-5137aa58e4f4"
      unitRef="usd">20000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dare:UpfrontLicenseFeePaid
      contextRef="i28e27dfd8d1744fd931fe1123a4379d6_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfODc2Mw_aa0153e2-3a8c-4ac2-ac29-1733eca43a43"
      unitRef="usd">1000000.0</dare:UpfrontLicenseFeePaid>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28e27dfd8d1744fd931fe1123a4379d6_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfODg2Mg_b7a7c133-097a-4500-bab0-5137aa58e4f4"
      unitRef="usd">20000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dare:UpfrontLicenseFeePaid
      contextRef="i28e27dfd8d1744fd931fe1123a4379d6_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfODg3NA_aa0153e2-3a8c-4ac2-ac29-1733eca43a43"
      unitRef="usd">1000000.0</dare:UpfrontLicenseFeePaid>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28e27dfd8d1744fd931fe1123a4379d6_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfODk5NA_b7a7c133-097a-4500-bab0-5137aa58e4f4"
      unitRef="usd">20000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dare:UpfrontLicenseFeePaid
      contextRef="i28e27dfd8d1744fd931fe1123a4379d6_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfOTE4Nw_aa0153e2-3a8c-4ac2-ac29-1733eca43a43"
      unitRef="usd">1000000.0</dare:UpfrontLicenseFeePaid>
    <dare:MilestonePaymentsContingentAmount
      contextRef="ib620eb86663f4b8eb249d3ca45e8961f_D20200110-20200110"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV8zNy9mcmFnOjUyOTEzZWM1MWE2YjQ5YWNhNTc1ZjY4Mzg5MDg3NWYyL3RleHRyZWdpb246NTI5MTNlYzUxYTZiNDlhY2E1NzVmNjgzODkwODc1ZjJfOTM2NA_96641c70-c39e-41d1-bcfa-a05270c33af2"
      unitRef="usd">310000000.0</dare:MilestonePaymentsContingentAmount>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTg2NTQ_7846afc3-3826-4bb9-bf3e-2ae997d7be3b">LICENSE AND COLLABORATION AGREEMENTS&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%"&gt;Out-License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%"&gt;Bayer HealthCare License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 10, 2020, the Company entered into a license agreement with Bayer, regarding the further development and commercialization of Ovaprene in the U.S. Under the agreement, the Company received a $1.0 million upfront non-refundable license fee payment from Bayer. If Bayer pays an additional $20.0 million to the Company after Bayer receives and reviews the results of the pivotal clinical trial of Ovaprene, which payment Bayer may elect to make in its sole discretion, the license grant to Bayer to develop and commercialize Ovaprene for human contraception in the U.S. becomes effective. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone &amp;amp; Royalty Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company will be entitled to receive (a) a milestone payment in the low double-digit millions upon the first commercial sale of Ovaprene in the U.S. and escalating milestone payments based on annual net sales of Ovaprene during a calendar year, totaling up to $310.0 million if all such milestones, including the first commercial sale, are achieved, (b) tiered royalties starting in the low double digits based on annual net sales of Ovaprene during a calendar year, subject to customary royalty reductions and offsets, and (c) a percentage of sublicense revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Efforts.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company is responsible for the pivotal trial for Ovaprene and for its development and regulatory activities and has product supply obligations. Bayer is supporting the Company in development and regulatory activities by providing up to two full-time equivalents with expertise in clinical, regulatory, preclinical, commercial, CMC and product supply matters in an advisory capacity. After payment of the $20.0 million fee, Bayer will be responsible for the commercialization of Ovaprene for human contraception in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Term. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial term of the agreement, which is subject to automatic renewal terms, continues until the later of (a) the expiration of any valid claim covering the manufacture, use, sale or import of Ovaprene in the U.S.; or (b) 15 years from the first commercial sale of Ovaprene in the U.S. In addition to customary termination rights for both parties, Bayer may terminate the agreement at any time on 90 days' notice and the agreement will automatically terminate if the Company does not receive the $20.0 million fee if and when due.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%"&gt;In-License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%"&gt;Hammock/MilanaPharm Assignment and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, the Company entered into (a) an Assignment Agreement with Hammock Pharmaceuticals, Inc., or the Assignment Agreement, and (b) a First Amendment to License Agreement with TriLogic Pharma, LLC and MilanaPharm LLC, or the License Amendment. Both agreements relate to the exclusive license agreement among Hammock, TriLogic and MilanaPharm dated as of January 9, 2017, or the MilanaPharm License Agreement. Under the Assignment Agreement and the MilanaPharm License Agreement, as amended by the License Amendment, the Company acquired an exclusive, worldwide license to develop and commercialize products for the diagnosis, treatment and prevention of human diseases or conditions in or through any intravaginal or urological applications. The licensed intellectual property relates to the hydrogel drug delivery platform of TriLogic and MilanaPharm known as TRI-726. In DARE-BV1, this proprietary technology is formulated with clindamycin, an antibiotic with FDA approval to treat certain bacterial infections, including bacterial vaginosis. In December 2019, the Company entered into amendments to each of the License Amendment and Assignment Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of other terms of the License Amendment, as amended:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Fees.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company paid MilanaPharm: (1) $25,000 in connection with the execution of the License Amendment; (2) $100,000 on December 5, 2019; and (3) $110,000 on January 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company will pay to MilanaPharm (1) up to $300,000 in the aggregate upon achievement of certain clinical and regulatory development milestones, $50,000 of which was paid during the second quarter of 2020, and (2) up to $1.75 million in the aggregate upon achieving certain commercial sales milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Sublicense Income.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company will pay MilanaPharm a low double-digit percentage of all income received by the Company or its affiliates in connection with any sublicense granted to a third party for use outside of the United States, subject to certain exclusions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; After the commercial launch of licensed products and processes and during the royalty term, the Company will pay MilanaPharm high single-digit to low double-digit royalties based on annual worldwide net sales of licensed products and processes in accordance with the agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Efforts. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company must use commercially reasonable efforts and resources to (1) develop and commercialize at least one licensed product or process in the United States and at least one licensed product or process in Canada, the United Kingdom, France, Germany, Italy or Spain, and (2) continue to commercialize that product or process following the first commercial sale of a licensed product or process in the applicable jurisdiction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Term.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Unless earlier terminated, the license term continues until (1) on a licensed product-by-product (or process-by-process basis) and country-by-country basis, the date of expiration of the royalty term with respect to such licensed product (or process) in such country, and (2) the expiration of all applicable royalty terms under the MilanaPharm License Agreement with respect to all licensed products and processes in all countries. Upon expiration of the term with respect to any licensed product or process in a country (but not upon earlier termination of the MilanaPharm License Agreement), the licenses granted to the Company under the MilanaPharm License Agreement will convert automatically to an exclusive, fully paid-up, royalty-free, perpetual, non-terminable and irrevocable right and license under the licensed intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to customary termination rights in favor of all parties, MilanaPharm may terminate the license solely with respect to a licensed product or process in a country if, after having launched such product or process in such country, the Company or its affiliates or sublicensees, (1) discontinue the sale of such product or process in such country and MilanaPharm notifies the Company of such termination within 60 days of having first been notified by the Company of such discontinuation, or (2) (A) discontinue all commercially reasonable marketing efforts to sell, and discontinue all sales of, such product or process in such country for nine months or more, (B) fail to resume such commercially reasonable marketing efforts within 120 days of having been notified of such failure by MilanaPharm, (C) fail to reasonably demonstrate a strategic justification for the discontinuation and failure to resume to MilanaPharm, and (D) MilanaPharm gives 90 days&#x2019; notice to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of other terms of the Assignment Agreement, as amended:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assignment; Technology Transfer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Hammock assigned and transferred to the Company all of its right, title and interest in and to the MilanaPharm License Agreement and agreed to cooperate to transfer to the Company all of the data, materials and the licensed technology in its possession pursuant to a technology transfer plan to be agreed upon by the parties, with a goal for the Company to independently practice the licensed intellectual property as soon as commercially practical in order to develop and commercialize the licensed products and processes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fees&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company paid Hammock: (1) $250,000 in connection with the execution of the Assignment Agreement; (2) $125,000 on December 5, 2019; and (3) $137,500 on January 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company will pay Hammock up to $1.1 million in the aggregate upon achievement of certain clinical and regulatory development milestones, $100,000 of which was paid during the third quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Term.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Assignment Agreement will terminate upon the later of (1) completion of the parties' technology transfer plan, and (2) payment to Hammock of the last of the milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ADVA-Tec License Agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, the Company entered into a license agreement with ADVA-Tec, Inc., under which the Company was granted the exclusive right to develop and commercialize Ovaprene for human contraceptive use worldwide. The Company must use commercially reasonable efforts to develop and commercialize Ovaprene.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company will pay ADVA-Tec: (1) up to $14.6 million in the aggregate based on the achievement of specified development and regulatory milestones; and (2) up to $20.0 million in the aggregate based on the achievement of certain worldwide net sales milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  After the commercial launch of Ovaprene, the Company will pay ADVA-Tec royalties based on aggregate annual net sales of Ovaprene in specified regions, at a royalty rate that will vary between 1% and 10% and will increase based on various net sales thresholds. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Unless earlier terminated, the license continues on a country-by-country basis until the later of the life of the licensed patents or final commercial sale of Ovaprene. In addition to customary termination rights for both parties: (A) the Company may terminate the agreement with or without cause in whole or on a country-by-country basis upon 60 days prior written notice; and (B) ADVA-Tec may terminate the agreement if (1) the Company develops or commercializes any non-hormonal ring-based vaginal contraceptive device competitive to Ovaprene or (2) if the Company fails to meet agreed upon efforts to commercialize Ovaprene.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%"&gt;SST License and Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, the Company entered into a license and collaboration agreement with Strategic Science &amp;amp;&#160;Technologies-D,&#160;LLC and Strategic Science &amp;amp; Technologies, LLC, referred to collectively as SST, under which the Company received an exclusive, royalty-bearing, sublicensable license to develop and commercialize the Licensed Product (as defined below), in all countries and geographic territories of the world, for all indications for women related to female sexual dysfunction and/or female reproductive health, or the Field of Use. The Licensed Product, is defined as SST&#x2019;s proprietary topical formulation of sildenafil cream as it existed as of the effective date of the agreement, or any other topically applied pharmaceutical product containing sildenafil or a salt thereof as a pharmaceutically active ingredient, alone or with other active ingredients, but specifically excluding any product containing ibuprofen or any salt derivative of ibuprofen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of other terms of this license and collaboration agreement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Invention Ownership.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company retains rights to inventions made by its employees, SST retains rights to inventions made by its employees, and each party will own a 50% undivided interest in all joint inventions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Joint Development Committee.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The parties will collaborate through a joint development committee that will determine the strategic objectives for, and generally oversee, the development efforts of both parties under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Development.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company must use commercially reasonable efforts to develop the Licensed Products in the Field of Use in accordance with a development plan in the agreement, and to commercialize the Licensed Products in the Field of Use. The Company is responsible for all reasonable internal and external costs and expenses incurred by SST in its performance of the development activities it must perform under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; SST will be eligible to receive tiered royalties based on percentages of annual net sales of Licensed Products in the single digits to the mid double digits, subject to customary royalty reductions and offsets, and a percentage of sublicense revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; SST will be eligible to receive payments (1) ranging from $0.5 million to $18.0 million in the aggregate upon achieving certain clinical and regulatory milestones in the U.S. and worldwide, and (2) between $10.0 million to $100.0 million in the aggregate upon achieving certain commercial sales milestones. If the Company enters into strategic development or distribution partnerships related to the Licensed Products, additional milestone payments would be due to SST.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Catalent JNP License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018,&#160;the Company entered into an exclusive license agreement with Catalent JNP, Inc. (formerly known as Juniper Pharmaceuticals, Inc., and which the Company refers to as Catalent), under which Catalent granted the Company (a) an exclusive, royalty-bearing worldwide license under certain patent rights, either owned by or exclusively licensed to Catalent, to make, have made, use, have used, sell, have sold, import and have imported products and processes; and (b) a non-exclusive, royalty-bearing worldwide license to use certain technological information owned by Catalent to make, have made, use, have used, sell, have sold, import and have imported products and processes. The Company is entitled to sublicense the rights granted to it under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Upfront Fee.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company paid a $250,000 non-creditable upfront license fee to Catalent in connection with the execution of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Annual Maintenance Fee.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company will pay an annual license maintenance fee to Catalent on each anniversary of the date of the agreement, the amount of which was $50,000 for each of the first two years and will be $100,000 thereafter, and which will be creditable against royalties and other payments due to Catalent in the same calendar year but may not be carried forward to any other year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company must make potential future development and sales milestone payments of (1) up to $13.5 million in the aggregate upon achieving certain clinical and regulatory milestones, and (2) up to $30.3 million in the aggregate upon achieving certain commercial sales milestones for each product or process covered by the licenses granted under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. During the royalty term, the Company will pay Catalent mid-single-digit to low double-digit royalties based on worldwide net sales of products and processes covered by the licenses granted under the agreement. In lieu of such royalty payments, the Company will pay Catalent a low double-digit percentage of all sublicense income the Company receives for the sublicense of rights under the agreement to a third party. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adare Development and Option Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2018, the Company entered into an exclusive development and option agreement with Adare Pharmaceuticals (formerly known as Orbis Biosciences, and which the Company refers to as Adare), for the development of long-acting injectable etonogestrel contraceptive with 6- and 12-month durations (ORB-204 and ORB-214, respectively). Under this agreement, the Company paid Adare $300,000 to conduct the first stage of development work as follows: $150,000 upon signing the agreement; $75,000 at the 50% completion point, not later than 6 months following the date the agreement was signed (which the Company paid in September 2018); and $75,000 upon delivery by Adare of the 6-month batch, not later than 11 months following the date the agreement was signed (which the Company paid in January 2019). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon Adare successfully completing the first stage of development work and achieving the predetermined target milestones for that stage, the Company will have 90 days to instruct Adare whether to commence the second stage of development work. Should the Company execute its option to proceed with the second stage, it will have to provide additional funding to Adare for such activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-clinical studies for the 6- and 12-month formulations have been completed, including establishing pharmacokinetics and pharmacodynamics profiles. The collaboration with Adare will continue to advance the program through formulation optimization with the goal of achieving sustained release over the target time period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement provides the Company with an option to enter into a license agreement for ORB-204 and ORB-214 should development efforts be successful.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%"&gt;Acquired Products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Microchips Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As further discussed in Note 4. Acquisition below, in November 2019, the Company completed its acquisition of Microchips (as defined below). The Company acquired Microchips to secure the rights to develop an implantable, user-controlled, long-acting reversible contraception method, now known as DARE-LARC1. The Company agreed to use commercially reasonable efforts to achieve specified development and regulatory objectives relating to the implantable contraceptive product in development by Microchips.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company issued an aggregate of 2,999,990 shares of its common stock to the holders of shares of Microchips' capital stock outstanding immediately prior to the effective time of the merger. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also agreed to pay the following contingent consideration to the former Microchips stockholders: (a) up to $46.5 million contingent upon the achievement of specified funding, product development and regulatory milestones; (b) up to $55.0 million contingent upon the achievement of specified amounts of aggregate net sales of products incorporating the intellectual property acquired by the Company in the merger; (c) tiered royalty payments ranging from low single-digit to low double-digit percentages of annual net sales of such products, subject to customary provisions permitting royalty reductions and offset; and (d)&#160;a percentage of sublicense revenue related to such products. The Company agreed to use commercially reasonable efforts to achieve specified development and regulatory objectives relating to DARE-LARC1. The Company recorded $1.0 million in contingent consideration associated with milestone payments it expects to become payable in the first half of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pear Tree Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, the Company completed its acquisition of Pear Tree Pharmaceuticals, Inc., or Pear Tree. The Company acquired Pear Tree to secure the rights to develop a proprietary vaginal formulation of tamoxifen, now known as DARE-VVA1, as a potential treatment for vulvar and vaginal atrophy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company must make contingent payments to the Pear Tree former stockholders and their representatives, or the Holders, that are based on achieving certain clinical, regulatory and commercial milestones, which may be paid, in the Company&#x2019;s sole discretion, in cash or shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;Royalty Payments. The Holders will be eligible to receive, subject to certain offsets, tiered royalties, including customary provisions permitting royalty reductions and offset, based on percentages of annual net sales of certain products subject to license agreements the Company assumed and a percentage of sublicense revenue.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <dare:UpfrontLicenseFeePaid
      contextRef="i28e27dfd8d1744fd931fe1123a4379d6_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMzMx_aa0153e2-3a8c-4ac2-ac29-1733eca43a43"
      unitRef="usd">1000000.0</dare:UpfrontLicenseFeePaid>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28e27dfd8d1744fd931fe1123a4379d6_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfNDE3_b7a7c133-097a-4500-bab0-5137aa58e4f4"
      unitRef="usd">20000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dare:MilestonePaymentsContingentAmount
      contextRef="ib620eb86663f4b8eb249d3ca45e8961f_D20200110-20200110"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTAwNQ_96641c70-c39e-41d1-bcfa-a05270c33af2"
      unitRef="usd">310000000.0</dare:MilestonePaymentsContingentAmount>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28e27dfd8d1744fd931fe1123a4379d6_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTcxOA_b7a7c133-097a-4500-bab0-5137aa58e4f4"
      unitRef="usd">20000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28e27dfd8d1744fd931fe1123a4379d6_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMjMzMQ_b7a7c133-097a-4500-bab0-5137aa58e4f4"
      unitRef="usd">20000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dare:LicenseFee
      contextRef="i675ccdafc7724770bc5f9d69ad53a137_D20191201-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMzcyOA_c70b481c-f081-42fa-a7d5-c32c1e24e2de"
      unitRef="usd">25000</dare:LicenseFee>
    <dare:LicenseFeeToBePaidUponContingency
      contextRef="i663f6a3e47204c84a850cfb01668fd90_D20191205-20191205"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMzc5NA_edfaec97-f454-4c5a-92d7-43ecf64fcae7"
      unitRef="usd">100000</dare:LicenseFeeToBePaidUponContingency>
    <dare:LicenseFeeToBePaidUponContingency
      contextRef="i13d5e927223840e1ae39274dbb5609d3_D20200131-20200131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMzgyNg_9e1d2b1d-5d18-46af-bc10-6904a4795aeb"
      unitRef="usd">110000</dare:LicenseFeeToBePaidUponContingency>
    <dare:MilestonePaymentsContingentAmount
      contextRef="ic44f91cd00fb46e9b948e5acc2a670e9_D20191201-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMzkxNg_fcbbcb58-39a2-4e67-a454-f6a274bef9ab"
      unitRef="usd">300000</dare:MilestonePaymentsContingentAmount>
    <dare:MilestonePaymentsContingentAmount
      contextRef="i2508e3e579a94cdea63398846fa669b5_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfNDAxMg_652db27b-bab7-40a8-af3c-2b894bc2457f"
      unitRef="usd">50000</dare:MilestonePaymentsContingentAmount>
    <dare:MilestonePaymentsContingentAmount
      contextRef="i9480befabfcf46ad88721e52ff929278_D20200401-20200630"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfNDA4Mg_1339835d-bc74-4401-85ed-6ea647edfb52"
      unitRef="usd">1750000</dare:MilestonePaymentsContingentAmount>
    <dare:LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct
      contextRef="i663f6a3e47204c84a850cfb01668fd90_D20191205-20191205"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfNjQzNg_48eec022-654e-4a40-9e6c-cb2d65e14b17">P60D</dare:LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct>
    <dare:LicenseAgreementTerminationPeriodDueToPerformanceFailure
      contextRef="i663f6a3e47204c84a850cfb01668fd90_D20191205-20191205"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfNjc1NQ_4a1b27df-5403-40c5-9bff-b5592aa077d4">P120D</dare:LicenseAgreementTerminationPeriodDueToPerformanceFailure>
    <dare:LicenseAgreementNoticePeriodOfTermination
      contextRef="i663f6a3e47204c84a850cfb01668fd90_D20191205-20191205"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfNjk2Mw_62c91511-809d-4636-974e-886579480f49">P90D</dare:LicenseAgreementNoticePeriodOfTermination>
    <dare:LicenseFee
      contextRef="ib18fb0a15d48447fa6a79f7ea2a55a0f_D20191205-20191205"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfNzY2Nw_1cf44b58-9014-4072-a567-60afe611308b"
      unitRef="usd">250000</dare:LicenseFee>
    <dare:LicenseFeeToBePaidUponContingency
      contextRef="ib18fb0a15d48447fa6a79f7ea2a55a0f_D20191205-20191205"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfNzczNg_6ab75424-6843-426a-a159-225a162b11e9"
      unitRef="usd">125000</dare:LicenseFeeToBePaidUponContingency>
    <dare:LicenseFeeToBePaidUponContingency
      contextRef="ib69e2f5dfaaa4c50b61ce358dfe41490_D20200131-20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfNzc2OA_78556fd3-1da9-4458-990b-aac04d49c56a"
      unitRef="usd">137500</dare:LicenseFeeToBePaidUponContingency>
    <dare:MilestonePaymentsContingentAmount
      contextRef="i9d27e115aa2d4aa195fb48879883d1a1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfNzg0OA_80f3d4f0-f965-48a2-aec0-90146e492a86"
      unitRef="usd">1100000</dare:MilestonePaymentsContingentAmount>
    <dare:MilestonePayments
      contextRef="i389b47dad95042fe93f5c460e656a37d_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMzI5ODUzNDkwMjQ3OA_969bd998-33c9-4b58-9e95-3351df042b0f"
      unitRef="usd">100000</dare:MilestonePayments>
    <dare:ResearchAndDevelopmentMilestonePayment
      contextRef="i84c418494d874dde87ff86a8ad8133ad_D20170301-20170331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfODUyOQ_0ab03e77-fab3-4f58-8f0b-e9734a724b29"
      unitRef="usd">14600000</dare:ResearchAndDevelopmentMilestonePayment>
    <dare:ResearchAndDevelopmentMilestonePayment
      contextRef="i27a820732a994084bea4346080486a18_D20170301-20170331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfODY0MA_4120a090-2b7a-4ccc-8e13-59a22d0ee8be"
      unitRef="usd">20000000.0</dare:ResearchAndDevelopmentMilestonePayment>
    <dare:PercentageOfRoyaltyRate
      contextRef="i8f872d8e39ed4734a655cc6daabe747c_D20170301-20170331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfODk0Mg_0322846c-53f5-4213-8c0a-4ec344fb684e"
      unitRef="number">0.01</dare:PercentageOfRoyaltyRate>
    <dare:PercentageOfRoyaltyRate
      contextRef="ifc98d29e798c45f386168a17588148ad_D20170301-20170331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfODk0OQ_017bb3df-9e6d-478d-b592-c56979435409"
      unitRef="number">0.10</dare:PercentageOfRoyaltyRate>
    <dare:PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement
      contextRef="i88ef2e92e2db432987e74cad75d700a3_D20180201-20180228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTA4NDY_a30d8210-d2e7-48b0-9098-d6a543b3787b"
      unitRef="number">0.50</dare:PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement>
    <dare:MilestonePaymentsContingentAmount
      contextRef="if910f6abc722476083f07bcc96a49f22_D20180201-20180228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTE4OTg_dda4d2b4-bd29-4087-bdd2-c863cad5e52e"
      unitRef="usd">500000</dare:MilestonePaymentsContingentAmount>
    <dare:MilestonePaymentsContingentAmount
      contextRef="i1ef6eb9665eb4b70a2eaa329f9ee2427_D20180201-20180228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTE5MDQ_a6dd61cd-6ea3-4435-a605-c1ecabe5dfc9"
      unitRef="usd">18000000.0</dare:MilestonePaymentsContingentAmount>
    <dare:MilestonePaymentsContingentAmount
      contextRef="i75219243251d4cfb879a00b8d9c29575_D20180201-20180228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTIwMjM_2603c508-ed11-4228-a244-79cf89c6db95"
      unitRef="usd">10000000.0</dare:MilestonePaymentsContingentAmount>
    <dare:MilestonePaymentsContingentAmount
      contextRef="if58b7340a7a6466bb0aae7cb62f4cf97_D20180201-20180228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTIwMjk_e00aab80-d38e-4ba1-b358-282728e676a5"
      unitRef="usd">100000000.0</dare:MilestonePaymentsContingentAmount>
    <dare:UpfrontLicenseFeePaid
      contextRef="i49b990efd5e94bda8624d4a3746d6795_D20180401-20180430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTMxMDA_0b633ba0-3e42-4848-8c78-2fe117fd381c"
      unitRef="usd">250000</dare:UpfrontLicenseFeePaid>
    <dare:PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne
      contextRef="i49b990efd5e94bda8624d4a3746d6795_D20180401-20180430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTMzNzA_a1de5eef-eb5d-4280-a335-95fd08ea68df"
      unitRef="usd">50000</dare:PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne>
    <dare:PotentialAnnualLicenseMaintenanceFeePaymentsThereafter
      contextRef="i49b990efd5e94bda8624d4a3746d6795_D20180401-20180430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTM0MDE_b095340b-7337-4231-9fc4-4c50329174cb"
      unitRef="usd">100000</dare:PotentialAnnualLicenseMaintenanceFeePaymentsThereafter>
    <dare:MaximumPotentialMilestonePayments
      contextRef="i35e21a41a4f34efb9124460b6ace1b6e_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTM2ODc_abafb97c-94f3-4763-a0b3-fdca7b2e92f5"
      unitRef="usd">13500000</dare:MaximumPotentialMilestonePayments>
    <dare:MaximumPotentialMilestonePayments
      contextRef="ie5cb9f4c567542a0a0afd091500582b8_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTM3ODA_acd0ee01-33b8-4841-b4a9-943b9685ceff"
      unitRef="usd">30300000</dare:MaximumPotentialMilestonePayments>
    <dare:ResearchAndDevelopmentMilestonePayment
      contextRef="ibb3910bfa3544d7bb4cb75487de595bc_D20180301-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTQ3MTM_6e33af1c-684b-4a39-9805-0b3fac47b8f7"
      unitRef="usd">300000</dare:ResearchAndDevelopmentMilestonePayment>
    <dare:ResearchAndDevelopmentMilestonePayment
      contextRef="ic8e3c00cd33e4af2a7e1c65065c3b12b_D20180301-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTQ3NzU_2c8ae335-34ea-4d6a-a27b-613fac10f0f9"
      unitRef="usd">150000</dare:ResearchAndDevelopmentMilestonePayment>
    <dare:ResearchAndDevelopmentMilestonePayment
      contextRef="id9aa0a2281ea41fc9868218205b55f9c_D20180301-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTQ4MDY_07dc1a75-35e0-4984-859b-68155799fb04"
      unitRef="usd">75000</dare:ResearchAndDevelopmentMilestonePayment>
    <dare:PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement
      contextRef="id9aa0a2281ea41fc9868218205b55f9c_D20180301-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTQ4MTY_f38578ba-3f88-4397-9d1b-027d7424dc15"
      unitRef="number">0.50</dare:PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement>
    <dare:ResearchAndDevelopmentMilestonePayment
      contextRef="i5d6c1e846f824bddaf958f3525ddafea_D20180301-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTQ5NTM_aba76411-63e0-4b65-a899-a9f1fcf89762"
      unitRef="usd">75000</dare:ResearchAndDevelopmentMilestonePayment>
    <dare:CommencementPeriodForStageTwoUponAchievementOfStageOne
      contextRef="ibb3910bfa3544d7bb4cb75487de595bc_D20180301-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTUyNzI_768cede2-54e4-4f73-b4ce-043c8eb5952b">P90D</dare:CommencementPeriodForStageTwoUponAchievementOfStageOne>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i240f37dfb7c84e948e9a4cfed130cbc1_D20191130-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTY2MDQ_e62d8789-2f34-4ce5-93ba-ff2ff72d77ba"
      unitRef="shares">2999990</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <dare:ResearchAndDevelopmentMilestonePayment
      contextRef="i86cbc311d1df479cb96f4a597e179fe5_D20191120-20191120"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTY4NzU_1c67599a-f50d-4f19-8f84-ddd57167f4a3"
      unitRef="usd">46500000</dare:ResearchAndDevelopmentMilestonePayment>
    <dare:AssetAcquisitionContingentConsiderationCurrent
      contextRef="i19e761cec8174fb4bcb03e95810a4853_I20191120"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTY5ODk_7d2dacef-9a43-4d59-9736-2bc71a024e55"
      unitRef="usd">55000000.0</dare:AssetAcquisitionContingentConsiderationCurrent>
    <dare:AssetAcquisitionContingentConsiderationCurrent
      contextRef="i1ad6893defad461fa065876a751e3690_I20191120"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80MC9mcmFnOjkwZjZkMmRiNzgwMDRhMTRhNDgwYmJkMGRkMTFlN2Q0L3RleHRyZWdpb246OTBmNmQyZGI3ODAwNGExNGE0ODBiYmQwZGQxMWU3ZDRfMTc2MDY_ea42d155-60f3-4692-a3dd-4f0205031aad"
      unitRef="usd">1000000.0</dare:AssetAcquisitionContingentConsiderationCurrent>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80My9mcmFnOjM5NzgxY2JjZmU1YzQ2YjdhYWFjNzAwYTVmNjIxYjNjL3RleHRyZWdpb246Mzk3ODFjYmNmZTVjNDZiN2FhYWM3MDBhNWY2MjFiM2NfMjI5OA_ecef9f8b-7f62-4956-974c-a6d106f1658a">ACQUISITION&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, the Company acquired Microchips Biotech, Inc., or Microchips, via a merger transaction in which a wholly owned subsidiary of the Company, formed for purposes of this transaction, merged with and into Microchips&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Microchips survived as the Company&#x2019;s wholly owned subsidiary. Microchips is developing a proprietary, implantable drug delivery system designed to store and precisely deliver numerous therapeutic doses over months and years on a schedule determined by the user and controlled via wireless remote. Microchips&#x2019; lead product candidate is a pre-clinical stage contraceptive application of that technology that utilizes levonorgestrel, now known as DARE-LARC1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company issued an aggregate of 2,999,990 shares of its common stock to the holders of shares of Microchips' capital stock outstanding immediately prior to the effective time of the merger. The transaction was valued at $2.4 million, based on the fair value of the 2,999,990 shares issued of $0.79 per share, which was the closing price per share of the Company's common stock on the date of closing. The shares were issued in exchange for Microchips&#x2019; cash and cash equivalents of $6.1 million, less net liabilities of $3.5 million and transaction costs of $202,000, which was allocated based on the relative fair value of the assets acquired and liabilities assumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also agreed to pay certain contingent consideration payments, tiered royalty payments and a percentage of sublicense revenue as discussed in Note 3, Acquired Products&#x2014;Microchips Acquisition, above.&lt;/span&gt;&lt;/div&gt;The Company determined the transaction was accounted for as an asset acquisition as there were no outputs or substantive processes in existence as of the acquisition date. Transaction costs of approximately $202,000 associated with the merger were included in the Company&#x2019;s research and development expense in the fourth quarter of 2019.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i240f37dfb7c84e948e9a4cfed130cbc1_D20191130-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80My9mcmFnOjM5NzgxY2JjZmU1YzQ2YjdhYWFjNzAwYTVmNjIxYjNjL3RleHRyZWdpb246Mzk3ODFjYmNmZTVjNDZiN2FhYWM3MDBhNWY2MjFiM2NfNzQ1_e62d8789-2f34-4ce5-93ba-ff2ff72d77ba"
      unitRef="shares">2999990</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
      contextRef="ibec4b74376bf439b97a248a65f5b0eae_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80My9mcmFnOjM5NzgxY2JjZmU1YzQ2YjdhYWFjNzAwYTVmNjIxYjNjL3RleHRyZWdpb246Mzk3ODFjYmNmZTVjNDZiN2FhYWM3MDBhNWY2MjFiM2NfOTI2_9d9f126c-f6a4-4663-a906-b02fbe60ae78"
      unitRef="usd">2400000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i240f37dfb7c84e948e9a4cfed130cbc1_D20191130-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80My9mcmFnOjM5NzgxY2JjZmU1YzQ2YjdhYWFjNzAwYTVmNjIxYjNjL3RleHRyZWdpb246Mzk3ODFjYmNmZTVjNDZiN2FhYWM3MDBhNWY2MjFiM2NfOTYx_e62d8789-2f34-4ce5-93ba-ff2ff72d77ba"
      unitRef="shares">2999990</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="ibec4b74376bf439b97a248a65f5b0eae_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80My9mcmFnOjM5NzgxY2JjZmU1YzQ2YjdhYWFjNzAwYTVmNjIxYjNjL3RleHRyZWdpb246Mzk3ODFjYmNmZTVjNDZiN2FhYWM3MDBhNWY2MjFiM2NfOTgx_c1168f79-37c6-4fb8-8c25-3d0d9412a526"
      unitRef="usdPerShare">0.79</us-gaap:BusinessAcquisitionSharePrice>
    <dare:BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="ibec4b74376bf439b97a248a65f5b0eae_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80My9mcmFnOjM5NzgxY2JjZmU1YzQ2YjdhYWFjNzAwYTVmNjIxYjNjL3RleHRyZWdpb246Mzk3ODFjYmNmZTVjNDZiN2FhYWM3MDBhNWY2MjFiM2NfMTE2Nw_30c1f115-379e-4112-bebc-28234f6e59ea"
      unitRef="usd">6100000</dare:BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ibec4b74376bf439b97a248a65f5b0eae_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80My9mcmFnOjM5NzgxY2JjZmU1YzQ2YjdhYWFjNzAwYTVmNjIxYjNjL3RleHRyZWdpb246Mzk3ODFjYmNmZTVjNDZiN2FhYWM3MDBhNWY2MjFiM2NfMTE5NQ_0e6d5db4-e7e3-4f82-8531-029ac2126bff"
      unitRef="usd">3500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
      contextRef="i934a565bb58b4ec5acca2c91b69403b1_I20191130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80My9mcmFnOjM5NzgxY2JjZmU1YzQ2YjdhYWFjNzAwYTVmNjIxYjNjL3RleHRyZWdpb246Mzk3ODFjYmNmZTVjNDZiN2FhYWM3MDBhNWY2MjFiM2NfMTIyMw_32ed8da9-6252-41d6-aa31-4e39848fcfc8"
      unitRef="usd">202000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
      contextRef="i934a565bb58b4ec5acca2c91b69403b1_I20191130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80My9mcmFnOjM5NzgxY2JjZmU1YzQ2YjdhYWFjNzAwYTVmNjIxYjNjL3RleHRyZWdpb246Mzk3ODFjYmNmZTVjNDZiN2FhYWM3MDBhNWY2MjFiM2NfMjE3NA_32ed8da9-6252-41d6-aa31-4e39848fcfc8"
      unitRef="usd">202000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMzM1MA_c45c2ccf-175c-44db-a52b-8617549995e4">STOCK-BASED COMPENSATION&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;The 2015 Employee, Director and Consultant Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the business combination transaction in July 2017 between the Company and Dar&#xe9; Bioscience Operations, Inc., a privately held Delaware corporation, or Private Dar&#xe9;, the Company assumed the Private Dar&#xe9; 2015 Employee, Director and Consultant Equity Incentive Plan, or the 2015 Private Dar&#xe9; Plan and each then outstanding award granted thereunder, which consisted of options and restricted stock. Based on the exchange ratio for the business combination transaction and after giving effect to the reverse stock split effected in connection with the closing of that transaction, the outstanding options and restricted stock awards granted under the 2015 Private Dar&#xe9; Plan were replaced with options to purchase 10,149 shares of the Company&#x2019;s common stock with a correspondingly adjusted exercise price and 223,295 shares of the Company&#x2019;s common stock. All of the options that were assumed were exercised as of September&#160;30, 2020. No awards may be granted under the 2015 Private Dar&#xe9; Plan following the closing of the business combination transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2014 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s 2014 Employee Stock Purchase Plan, or the ESPP, became effective in April 2014, but no offering period has been initiated thereunder since January 2017 and there was no stock-based compensation related to the ESPP for the nine months ended September&#160;30, 2020 or September&#160;30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amended and Restated 2014 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains the Amended and Restated 2014 Plan, or the Amended 2014 Plan, which provides for the grant of options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards to employees, officers and directors, and consultants and advisors. There were 2,046,885 shares of common stock authorized for issuance under the Amended 2014 Plan when it was approved by the Company's stockholders in July 2018. The number of authorized shares increases annually on the first day of each fiscal year until, and including, the fiscal year ending December 31, 2024 by the least of (i) 2,000,000, (ii) 4% of the number of outstanding shares of common stock on such date, or (iii) an amount determined by the Company&#x2019;s board of directors. On January 1, 2020, the number of authorized shares increased by 787,336 to 1,411,481, which increase represented 4% of the number of outstanding shares of common stock on such date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes stock option activity under the Amended 2014 Plan, and related information for the nine months ended September&#160;30, 2020. The exercise price of all options granted during the nine months ended September&#160;30, 2020 was equal to the market value of the Company&#x2019;s common stock on the date of grant. As of September&#160;30, 2020, unamortized stock-based compensation expense of $1,493,686 will be amortized over a weighted average period of 2.37 years. At September&#160;30, 2020, 507,516 shares of common stock were reserved for future awards granted under the Amended 2014 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:376.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,889,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,783,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense related to stock options granted to employees and directors recognized in the consolidated statement of operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:238.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used in the Black-Scholes option-pricing model for stock options granted to employees and to directors in respect of board services during the three and nine months ended September&#160;30, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:373.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:36pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.82%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value of options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2a4aaadc8c3b47a6a160697edf8e4341_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfODI0_037d6a71-0ea4-4f55-ac59-232336463436"
      unitRef="shares">10149</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6272459e3f90454cbd5e25ce85446ee8_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfOTE1_7a350a18-1402-49d0-9f3c-05c5d484c88f"
      unitRef="shares">223295</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3ab49a29689548b9833e3f0ae8c799b5_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMTM1Mw_901bd7b5-243d-40f4-b7b4-5b42b27d6938"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2928b74a51bf456b8caf39b2a4cfa467_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMTM1Mw_c128eb01-df28-41a6-b70f-616220bed5f5"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i4e27560f58324d76aa01f67cbf138dc4_I20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMTc4Mw_88e62325-14a5-400f-bce5-2b534808411c"
      unitRef="shares">2046885</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i91e3f089ee85463896dc24cc0479b252_I20180710"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMjA5Nw_19987938-fee5-406c-9071-082a8fb7865b"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="i48b5c358a2b64cbf929fdc1e1a69614a_D20180710-20180710"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMjEwNg_ef61eb04-b2bd-4760-af7b-b7a141547b7e"
      unitRef="number">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease
      contextRef="id0e7f22b525c449280e635ae64efe397_D20200101-20200101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMjMwNQ_c00393a5-a333-4857-b7c5-fda8e2e69694"
      unitRef="shares">787336</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ia09f304e0bb247cd9fb0ea915995673a_I20200101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMjMxMQ_d442fadb-1a39-41f9-8375-d98f8ff9cfc3"
      unitRef="shares">1411481</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="id0e7f22b525c449280e635ae64efe397_D20200101-20200101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMjM0Mg_34056eeb-b636-4d3e-a5f6-cb55b814068b"
      unitRef="number">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMzM1MQ_c34488c8-753b-401d-ac62-e6ff613d8fdd">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes stock option activity under the Amended 2014 Plan, and related information for the nine months ended September&#160;30, 2020. The exercise price of all options granted during the nine months ended September&#160;30, 2020 was equal to the market value of the Company&#x2019;s common stock on the date of grant. As of September&#160;30, 2020, unamortized stock-based compensation expense of $1,493,686 will be amortized over a weighted average period of 2.37 years. At September&#160;30, 2020, 507,516 shares of common stock were reserved for future awards granted under the Amended 2014 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:376.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,889,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,783,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMjc4Ng_f1ef6bf6-239f-4811-8944-a21b3c27cbe5"
      unitRef="usd">1493686</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <dare:WeightedAverageAmortizationPeriod
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMjg0MQ_d5eee951-593a-4a2f-abc4-5b603bfe5e4b">P2Y4M13D</dare:WeightedAverageAmortizationPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ie6fbf357b1224eeb9a1eed68e2f55aff_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMjg1Mg_8c3cc6fd-cb52-4b01-876c-71fa091dff2c"
      unitRef="shares">507516</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id3721c96df454703ab043d1b9396afec_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfMS0xLTEtMS0w_6dbbf3db-8e82-4b6f-b765-dc52996e89fc"
      unitRef="shares">1889775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id3721c96df454703ab043d1b9396afec_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfMS0zLTEtMS0w_c40d4dd1-0670-4cfd-9b37-21fedbe73be1"
      unitRef="usdPerShare">1.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i748cf08e328d4f8e88ce6250028b6f5c_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfMi0xLTEtMS0w_f0adfa26-3461-4ee6-bb20-bd518bdcdfdb"
      unitRef="shares">903965</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i748cf08e328d4f8e88ce6250028b6f5c_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfMi0zLTEtMS0w_e06574ca-c91b-4c34-bc0b-5afc1c00f60c"
      unitRef="usdPerShare">1.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i748cf08e328d4f8e88ce6250028b6f5c_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfMy0xLTEtMS0w_c5aa8f10-fdb6-448e-b8a3-307f0e77d582"
      unitRef="shares">10149</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i748cf08e328d4f8e88ce6250028b6f5c_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfMy0zLTEtMS0w_79ac2bd7-651e-42cd-9ad5-eb0f7e9506ee"
      unitRef="usdPerShare">0.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i748cf08e328d4f8e88ce6250028b6f5c_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfNC0xLTEtMS0w_777618bb-df34-4caf-a037-27a1b8d81cd8"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i748cf08e328d4f8e88ce6250028b6f5c_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfNC0zLTEtMS0w_cf8c0f0b-dcf7-4926-958f-0e78611f2363"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i748cf08e328d4f8e88ce6250028b6f5c_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfNS0xLTEtMS0w_149064ec-5dd5-4d15-b129-5c36ca42e28b"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i748cf08e328d4f8e88ce6250028b6f5c_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfNS0zLTEtMS0w_4bf3b03e-87b9-4c33-8d01-e32f06b7bdca"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie6fbf357b1224eeb9a1eed68e2f55aff_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfNi0xLTEtMS0w_f2f65486-47b8-4d66-92f5-b2dd1872af38"
      unitRef="shares">2783591</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie6fbf357b1224eeb9a1eed68e2f55aff_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfNi0zLTEtMS0w_deb0ca98-4d82-476e-8aba-dae4c8e645da"
      unitRef="usdPerShare">1.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ie6fbf357b1224eeb9a1eed68e2f55aff_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfNy0xLTEtMS0w_002d9bed-d1f9-4bbe-8a76-77cb766c01d2"
      unitRef="shares">1038659</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ie6fbf357b1224eeb9a1eed68e2f55aff_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjMwMWFmZTRhNWRjODQ1ZGI4YTUxOGNlMDkyOTRkZmI0L3RhYmxlcmFuZ2U6MzAxYWZlNGE1ZGM4NDVkYjhhNTE4Y2UwOTI5NGRmYjRfNy0zLTEtMS0w_425fab91-3990-42e2-82e1-63f9d1790fd4"
      unitRef="usdPerShare">1.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMzM1Mw_df365ec6-1a7a-4a07-a3c0-1def97db7a21">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense related to stock options granted to employees and directors recognized in the consolidated statement of operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:238.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaedce4b2446d4390afdde0c8b65ed211_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjEwNGRkNjU4YzU5MjQ1MWNiMjgwMmNjZjZiZmQ0ZTQzL3RhYmxlcmFuZ2U6MTA0ZGQ2NThjNTkyNDUxY2IyODAyY2NmNmJmZDRlNDNfMi0xLTEtMS0w_226ad03a-8e0b-4c79-9858-c97f81cf92df"
      unitRef="usd">60546</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id30e47d05e2d4a89bd634aed60cdde96_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjEwNGRkNjU4YzU5MjQ1MWNiMjgwMmNjZjZiZmQ0ZTQzL3RhYmxlcmFuZ2U6MTA0ZGQ2NThjNTkyNDUxY2IyODAyY2NmNmJmZDRlNDNfMi0zLTEtMS0w_98fa66ca-5f4d-4c4b-8cb7-79ba6feccb3e"
      unitRef="usd">27081</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib435822bc7804f31be11690ccf5f9859_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjEwNGRkNjU4YzU5MjQ1MWNiMjgwMmNjZjZiZmQ0ZTQzL3RhYmxlcmFuZ2U6MTA0ZGQ2NThjNTkyNDUxY2IyODAyY2NmNmJmZDRlNDNfMi01LTEtMS0w_c3957cf3-62f0-4926-9cce-5237b0f24443"
      unitRef="usd">166639</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3b128d3f8bbe4c5482cb6f55c962c6aa_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjEwNGRkNjU4YzU5MjQ1MWNiMjgwMmNjZjZiZmQ0ZTQzL3RhYmxlcmFuZ2U6MTA0ZGQ2NThjNTkyNDUxY2IyODAyY2NmNmJmZDRlNDNfMi03LTEtMS0w_c4ba89fd-6c5f-4d8c-ba37-8b2d94e4b747"
      unitRef="usd">78780</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie9f7aa24af72476481534c2c2f333aba_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjEwNGRkNjU4YzU5MjQ1MWNiMjgwMmNjZjZiZmQ0ZTQzL3RhYmxlcmFuZ2U6MTA0ZGQ2NThjNTkyNDUxY2IyODAyY2NmNmJmZDRlNDNfMy0xLTEtMS0w_ad610be3-1ca9-4ba4-b156-729f80aeb0ea"
      unitRef="usd">134336</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9d8b23a6ddc647dd8a654ce4e72821b1_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjEwNGRkNjU4YzU5MjQ1MWNiMjgwMmNjZjZiZmQ0ZTQzL3RhYmxlcmFuZ2U6MTA0ZGQ2NThjNTkyNDUxY2IyODAyY2NmNmJmZDRlNDNfMy0zLTEtMS0w_d82e5d5d-86ce-468a-baa5-149f14f089c5"
      unitRef="usd">108312</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i164eef1d163e46c2afb6bc319807e895_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjEwNGRkNjU4YzU5MjQ1MWNiMjgwMmNjZjZiZmQ0ZTQzL3RhYmxlcmFuZ2U6MTA0ZGQ2NThjNTkyNDUxY2IyODAyY2NmNmJmZDRlNDNfMy01LTEtMS0w_b25775ab-78bd-4e8f-a3ad-9cbd42b583d8"
      unitRef="usd">375943</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i55a9907b8e8649348aa6657478dfe2cc_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjEwNGRkNjU4YzU5MjQ1MWNiMjgwMmNjZjZiZmQ0ZTQzL3RhYmxlcmFuZ2U6MTA0ZGQ2NThjNTkyNDUxY2IyODAyY2NmNmJmZDRlNDNfMy03LTEtMS0w_9602d9af-4105-4f81-9842-74021000fc89"
      unitRef="usd">265932</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3caed64836884e1cb8f9c5b521f55da0_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjEwNGRkNjU4YzU5MjQ1MWNiMjgwMmNjZjZiZmQ0ZTQzL3RhYmxlcmFuZ2U6MTA0ZGQ2NThjNTkyNDUxY2IyODAyY2NmNmJmZDRlNDNfNC0xLTEtMS0w_7d121887-0c8b-41e6-9d3d-78fbf2bf4ed2"
      unitRef="usd">194882</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iea59aafe0f1745f7a971f2eaffe8481c_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjEwNGRkNjU4YzU5MjQ1MWNiMjgwMmNjZjZiZmQ0ZTQzL3RhYmxlcmFuZ2U6MTA0ZGQ2NThjNTkyNDUxY2IyODAyY2NmNmJmZDRlNDNfNC0zLTEtMS0w_6e31885c-aef6-4c6f-b91d-a7980fb9bad1"
      unitRef="usd">135393</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i452d4b20caeb47d2985cd2793d9a7eac_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjEwNGRkNjU4YzU5MjQ1MWNiMjgwMmNjZjZiZmQ0ZTQzL3RhYmxlcmFuZ2U6MTA0ZGQ2NThjNTkyNDUxY2IyODAyY2NmNmJmZDRlNDNfNC01LTEtMS0w_0c9806d0-3cfa-4106-8544-64d35962afd5"
      unitRef="usd">542582</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic57e6d999ba14991863c6606b7f50384_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjEwNGRkNjU4YzU5MjQ1MWNiMjgwMmNjZjZiZmQ0ZTQzL3RhYmxlcmFuZ2U6MTA0ZGQ2NThjNTkyNDUxY2IyODAyY2NmNmJmZDRlNDNfNC03LTEtMS0w_2f245b6e-3e7c-4424-89f8-d6e0164fdb05"
      unitRef="usd">344712</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RleHRyZWdpb246ZWU2MjE4M2VkNmM3NDljYTlmZmMyZDMyZDhhNDdkNjRfMzM1NA_3a922b11-6654-4559-9c83-32772540a27a">&lt;div style="margin-top:12pt;text-align:center;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used in the Black-Scholes option-pricing model for stock options granted to employees and to directors in respect of board services during the three and nine months ended September&#160;30, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:373.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:36pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.82%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value of options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjYyZmZhOGZkNGQ5NDQ4YzZhMzBlZjk1MGU4ZWE0NWUwL3RhYmxlcmFuZ2U6NjJmZmE4ZmQ0ZDk0NDhjNmEzMGVmOTUwZThlYTQ1ZTBfMS0yLTEtMS0w_2beda1ea-b107-4cfe-9786-a8cb1c5f2af5">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjYyZmZhOGZkNGQ5NDQ4YzZhMzBlZjk1MGU4ZWE0NWUwL3RhYmxlcmFuZ2U6NjJmZmE4ZmQ0ZDk0NDhjNmEzMGVmOTUwZThlYTQ1ZTBfMS00LTEtMS0w_6bb7d3bd-15d7-4ca7-b5f1-b2d57fb22ff3">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjYyZmZhOGZkNGQ5NDQ4YzZhMzBlZjk1MGU4ZWE0NWUwL3RhYmxlcmFuZ2U6NjJmZmE4ZmQ0ZDk0NDhjNmEzMGVmOTUwZThlYTQ1ZTBfMi0yLTEtMS0w_8fd7cf50-cd87-455a-a2ed-bcc4aca76f44"
      unitRef="number">0.0071</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjYyZmZhOGZkNGQ5NDQ4YzZhMzBlZjk1MGU4ZWE0NWUwL3RhYmxlcmFuZ2U6NjJmZmE4ZmQ0ZDk0NDhjNmEzMGVmOTUwZThlYTQ1ZTBfMi00LTEtMS0w_4fe2947e-4803-43f8-92e9-d5787743cc77"
      unitRef="number">0.0082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjYyZmZhOGZkNGQ5NDQ4YzZhMzBlZjk1MGU4ZWE0NWUwL3RhYmxlcmFuZ2U6NjJmZmE4ZmQ0ZDk0NDhjNmEzMGVmOTUwZThlYTQ1ZTBfMy0yLTEtMS0w_cb63681b-225b-430b-a377-213e6d1db42e"
      unitRef="number">1.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjYyZmZhOGZkNGQ5NDQ4YzZhMzBlZjk1MGU4ZWE0NWUwL3RhYmxlcmFuZ2U6NjJmZmE4ZmQ0ZDk0NDhjNmEzMGVmOTUwZThlYTQ1ZTBfMy00LTEtMS0w_79b5b00e-02f5-421d-a4e3-694fc7741fe6"
      unitRef="number">1.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <dare:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjYyZmZhOGZkNGQ5NDQ4YzZhMzBlZjk1MGU4ZWE0NWUwL3RhYmxlcmFuZ2U6NjJmZmE4ZmQ0ZDk0NDhjNmEzMGVmOTUwZThlYTQ1ZTBfNC0yLTEtMS0w_2eb3ae49-4e0d-496d-a35b-5264147eef60"
      unitRef="number">0.000</dare:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate>
    <dare:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjYyZmZhOGZkNGQ5NDQ4YzZhMzBlZjk1MGU4ZWE0NWUwL3RhYmxlcmFuZ2U6NjJmZmE4ZmQ0ZDk0NDhjNmEzMGVmOTUwZThlYTQ1ZTBfNC00LTEtMS0w_162c2c5e-b62d-40af-9697-f95588b19626"
      unitRef="number">0.000</dare:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjYyZmZhOGZkNGQ5NDQ4YzZhMzBlZjk1MGU4ZWE0NWUwL3RhYmxlcmFuZ2U6NjJmZmE4ZmQ0ZDk0NDhjNmEzMGVmOTUwZThlYTQ1ZTBfNS0yLTEtMS0w_0c2df28b-0aa3-4903-b8a4-2e5e756d09c3"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjYyZmZhOGZkNGQ5NDQ4YzZhMzBlZjk1MGU4ZWE0NWUwL3RhYmxlcmFuZ2U6NjJmZmE4ZmQ0ZDk0NDhjNmEzMGVmOTUwZThlYTQ1ZTBfNS00LTEtMS0w_03ece4d9-107b-432d-8adc-bde1d834e543"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjYyZmZhOGZkNGQ5NDQ4YzZhMzBlZjk1MGU4ZWE0NWUwL3RhYmxlcmFuZ2U6NjJmZmE4ZmQ0ZDk0NDhjNmEzMGVmOTUwZThlYTQ1ZTBfNi0yLTEtMS0w_93373611-6762-4753-93c9-570712354ae3"
      unitRef="usdPerShare">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80Ni9mcmFnOmVlNjIxODNlZDZjNzQ5Y2E5ZmZjMmQzMmQ4YTQ3ZDY0L3RhYmxlOjYyZmZhOGZkNGQ5NDQ4YzZhMzBlZjk1MGU4ZWE0NWUwL3RhYmxlcmFuZ2U6NjJmZmE4ZmQ0ZDk0NDhjNmEzMGVmOTUwZThlYTQ1ZTBfNi00LTEtMS0w_3c7f18d2-091d-4ac0-890b-07886179c568"
      unitRef="usdPerShare">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfNTQzOQ_40eeb308-bfc0-400d-8092-37f4b306e00b">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ATM Sales Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2018, the Company entered into a common stock sales agreement under which the Company may sell shares of its common stock from time to time in &#x201c;at-the-market&#x201d; equity offerings (as defined in Rule 415 promulgated under the Securities Act of 1933, as amended). The Company will pay a commission of up to 3% of the gross proceeds of any common stock sold under this agreement plus certain legal expenses. The common stock sales agreement was amended in August 2018 to refer to the Company&#x2019;s shelf registration statement on Form S-3 (File No. 333-227019) that was filed to replace the Company&#x2019;s shelf registration statement on Form S-3 (File No. 333-206396) that expired on August 28, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September&#160;30, 2020, the Company sold 1,952,512 shares under the common stock sales agreement for gross proceeds of approximately $2.4 million and incurred offering expenses of approximately $82,000. During the nine months ended September&#160;30, 2020, the Company sold 7,916,092 shares under the common stock sales agreement for gross proceeds of approximately $10.8 million and incurred offering expenses of approximately $420,000. The Company did not sell any shares under this agreement during the three or nine months ended September&#160;30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;April 2019 Underwritten Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2019, the Company closed an underwritten public offering of 4,575,000 shares of its common stock at a public offering price of $1.10 per share. The Company granted the underwriters a 30-day over-allotment option to purchase up to an additional 686,250 shares which was exercised in full on April 12, 2019. Including the over-allotment shares, the Company issued a total of 5,261,250 shares in the underwritten public offering and received gross proceeds of approximately $5.8 million and net proceeds of approximately $5.2 million after deducting underwriting discounts and offering expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Line&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 22, 2020, the Company entered into a purchase agreement, or the Purchase Agreement, and a registration rights agreement with Lincoln Park Capital Fund, LLC, or Lincoln Park. Under the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to&#160;$15.0 million&#160;of the Company&#x2019;s common stock. Such sales of common stock by the Company may occur from time to time, at the Company&#x2019;s sole discretion, subject to certain limitations, until May 19, 2023. On April 22, 2020, in accordance with the Purchase Agreement, the Company issued 285,714 shares of its common stock, or the Commitment Shares, to Lincoln Park in consideration for its commitment to purchase shares under the Purchase Agreement. The Company filed a registration statement on Form S-1 (File No. 333-237954) to register the resale by Lincoln Park of up to 7.5 million shares of the Company's common stock issued or issuable to Lincoln Park under the Purchase Agreement, including the Commitment Shares, and such registration statement was declared effective by the SEC on May 12, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred legal, accounting, and other fees related to the Purchase Agreement of approximately $374,000. These costs are amortized and expensed as shares are sold under the Purchase Agreement and as of September&#160;30, 2020 there was approximately $269,000 of unamortized costs. During the three months ended September&#160;30, 2020, the Company sold, and Lincoln Park purchased, 3.0 million shares under the Purchase Agreement for gross proceeds of approximately $3.3 million and incurred offering expenses of approximately $83,000. During the nine months ended September&#160;30, 2020, the Company sold, and Lincoln Park purchased, 3,882,160 shares under the Purchase Agreement for gross proceeds of approximately $4.2 million and incurred offering expenses of approximately $105,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Purchase Agreement, on any business day until May 19, 2023, the Company may direct Lincoln Park to purchase up to 200,000 shares of common stock, each, a Regular Purchase. The Company may increase the share amount it directs Lincoln Park to purchase under a Regular Purchase to up to 250,000 shares or up to 300,000 shares if the closing sale price of the Company's common stock is not below $1.50 or $3.00, respectively, on the business day on which the Company initiates the purchase, subject to adjustment for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction as provided in the Purchase Agreement. However, Lincoln Park&#x2019;s maximum commitment in any single Regular Purchase may not exceed $1.0&#160;million. The purchase price per share for each Regular Purchase will be the lower of (i) the lowest sale price of the Company's common stock on the business day on which the Company initiates the purchase and (ii) the average of the three lowest closing sale prices of the Company's common stock during the 10-business day period immediately preceding the business day on which the Company initiates the purchase. In addition to Regular Purchases, the Company may also direct Lincoln Park to purchase other amounts of common stock as accelerated purchases and as additional accelerated purchases, subject to limits specified in the Purchase Agreement, at a purchase price per share calculated as specified in the Purchase Agreement, but in no case lower than the minimum price per share the Company stipulates in its notice to Lincoln Park initiating these purchases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, under applicable Nasdaq rules, the Company may not issue or sell to Lincoln Park under the Purchase Agreement more than 4,941,089 shares of its common stock, or the Exchange Cap, unless (i) the Company obtains stockholder approval to issue shares in excess of the Exchange Cap or (ii) the average price of all applicable sales of the Company's common stock to Lincoln Park under the Purchase Agreement equals or exceeds $1.0117 (which represents the closing sale price per share of the Company's common stock on the day before the Company entered into the Purchase Agreement, plus an incremental amount). In addition, the Company may not sell shares to Lincoln Park under the Purchase Agreement if such sale would result in Lincoln Park beneficially owning more than 9.99% of the Company's then outstanding shares of common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, the Company closed an underwritten public offering in connection with which the Company issued to the investors in that offering warrants that initially had an exercise price of $3.00 per share and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;are exercisable through February 2023.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The warrants include a price-based anti-dilution provision, which provides that, subject to certain limited exceptions, the exercise price of the warrants will be reduced each time the Company issues or sells (or is deemed to issue or sell) securities for a net consideration per share less than the exercise price of those warrants in effect immediately prior to such issuance or sale. In addition, subject to certain exceptions, if the Company issues, sells or enters into any agreement to issue or sell securities at a price which varies or may vary with the market price of the shares of the Company&#x2019;s common stock, the warrant holders have the right to substitute such variable price for the exercise price of the warrant then in effect. These warrants are exercisable only for cash, unless a registration statement covering the shares issued upon exercise of the warrants is not effective, in which case the warrants may be exercised on a cashless basis. A registration statement covering the shares issued upon exercise of the warrants is currently effective. The Company estimated the fair value of the warrants as of February 15, 2018 to be approximately $3.0 million which has been recorded in equity as of the grant date. The Company early adopted ASU 2017-11 as of January 1, 2018 and recorded the fair value of the warrants as equity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2019 and July 2020, in accordance with the price-based anti-dilution provision discussed above, the exercise price of these warrants was automatically reduced to $0.98 per share and to $0.96 per share, respectively, and as a result of the triggering of the anti-dilution provision, $0.8 million and $6,863, respectively, was recorded to additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September&#160;30, 2020, warrants to purchase an aggregate of 126,000 shares of common stock were exercised for gross proceeds of approximately $121,000. During the nine months ended September&#160;30, 2020, warrants to purchase an aggregate of 1,825,000 shares of common stock were exercised for gross proceeds of approximately $1.8 million. No warrants were exercised during the three or nine months ended September&#160;30, 2019. As of September&#160;30, 2020, the Company had the following warrants outstanding:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:169.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:19.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:18.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:118.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:18.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:157.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying&lt;br/&gt;Outstanding Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,906&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021-12-01&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,737&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021-12-06&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026-04-04&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,895,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023-02-15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,908,643&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <dare:PercentageOfAggregateCommission
      contextRef="i56d13a7ae7894e27975f5d3dc7ebf378_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMzYy_205ce347-01b4-446d-8845-6c9eba74e933"
      unitRef="number">0.03</dare:PercentageOfAggregateCommission>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic2c303c2ae4943dd8fbcfc1e44714b26_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTA5OTUxMTY1NjExMw_09934b43-1723-4053-9ecf-45a0f74f03a3"
      unitRef="shares">1952512</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic2c303c2ae4943dd8fbcfc1e44714b26_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTA5OTUxMTY1NjEyOA_faeac2df-e34f-4d8e-a1bc-507ea3632bd4"
      unitRef="usd">2400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <dare:OfferingExpenses
      contextRef="ic2c303c2ae4943dd8fbcfc1e44714b26_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTA5OTUxMTY1NjE0Mg_288ecdbe-9984-4e97-86d5-99b901cca8a8"
      unitRef="usd">82000</dare:OfferingExpenses>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i416122ab3120493b993ec3ad05b96111_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfNzk1_2dc82996-f23c-4ba0-afa1-4cf1891511a0"
      unitRef="shares">7916092</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i416122ab3120493b993ec3ad05b96111_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfODgw_4c5ef638-607d-492b-ae73-6d743136baf8"
      unitRef="usd">10800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <dare:OfferingExpenses
      contextRef="i416122ab3120493b993ec3ad05b96111_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfOTMx_4197cdb6-2acd-479a-aee7-ed4b5f243e7c"
      unitRef="usd">420000</dare:OfferingExpenses>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7a6ac70780144725885adc47194a94b4_D20190401-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTEzMw_f995d03b-9b60-4aac-8ceb-cc7f74153c6b"
      unitRef="shares">4575000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i868ac446cd6e4c439961eab65e3c6861_I20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTE5Mw_99a38c56-271c-4c8c-8133-0aa893d1885b"
      unitRef="usdPerShare">1.10</us-gaap:SaleOfStockPricePerShare>
    <dare:UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod
      contextRef="i60d87dbf215545a1b5c48615b58b820f_D20190401-20190430"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfNTQzNg_6c62d11c-8f7c-43af-bab1-bfc5851caf76">P30D</dare:UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod>
    <dare:UnderwritersOptionToPurchaseAdditionalShares
      contextRef="ia456760e828443768946d965d3e5d697_D20190412-20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTMwNw_7dc0c2a9-0814-4a78-90ab-13b51eb9621d"
      unitRef="shares">686250</dare:UnderwritersOptionToPurchaseAdditionalShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i60d87dbf215545a1b5c48615b58b820f_D20190401-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTQzMQ_24e91c9a-256d-4387-8dcd-6917fec9f09f"
      unitRef="shares">5261250</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <dare:GrossProceedsFromOfferingOfCommonStockAndWarrants
      contextRef="i60d87dbf215545a1b5c48615b58b820f_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTUyMg_2a20219b-ba2f-4b46-baa4-c2e2e6270833"
      unitRef="usd">5800000</dare:GrossProceedsFromOfferingOfCommonStockAndWarrants>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i60d87dbf215545a1b5c48615b58b820f_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTU1OQ_6b75a96a-a357-4a6f-849b-cb2fff3bceda"
      unitRef="usd">5200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PurchaseObligation
      contextRef="i9f7b9efd7dda44b2bec435609ae73e40_I20200422"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjAxNw_e523b7cd-9e48-4967-8384-62b726b98132"
      unitRef="usd">15000000.0</us-gaap:PurchaseObligation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8bfaf2e8371745b2b5e46ebc3e913e82_D20200422-20200422"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjI4OQ_34512f7d-5723-4a5d-a439-882866a21a38"
      unitRef="shares">285714</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <dare:SaleofStockMaximumAmountRegistered
      contextRef="icd932424f77b4acfbcb47c05aacbb08a_D20200501-20200501"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjU3Mg_a5e52ec9-cdc2-4b04-bc6c-f59dc9e8b560"
      unitRef="shares">7500000</dare:SaleofStockMaximumAmountRegistered>
    <us-gaap:DeferredOfferingCosts
      contextRef="i01002baf920d410fac2c775eac9c140e_I20200422"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjg5OQ_953a15a3-c649-4c26-9431-89f2d4d4e67d"
      unitRef="usd">374000</us-gaap:DeferredOfferingCosts>
    <dare:DeferredOfferingCostsUnamortizedPortion
      contextRef="ib32b7d0c93d34cbe804300d040f5b315_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMzAxMw_38f1e838-90d9-49fa-a910-e55d5f992782"
      unitRef="usd">269000</dare:DeferredOfferingCostsUnamortizedPortion>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic5c15ea8e6c24d4b9e6b1c403108842f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTA5OTUxMTY1NjIyNg_92e88827-d562-492d-a016-e4d0aa429b30"
      unitRef="shares">3000000.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic5c15ea8e6c24d4b9e6b1c403108842f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTA5OTUxMTY1NjIzNw_6f5f4cd0-64e9-4dbb-a57e-574de6b08cd3"
      unitRef="usd">3300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ic5c15ea8e6c24d4b9e6b1c403108842f_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTA5OTUxMTY1NjI0Nw_d5ce60b6-acfd-4890-9a62-12576eb6bf41"
      unitRef="usd">83000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ie264785d23cd421d928dd14372cfabf0_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMzExNQ_d54ec964-7922-4823-83c0-51450391e802"
      unitRef="shares">3882160</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie264785d23cd421d928dd14372cfabf0_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMzE5MA_7ab7240d-6252-44de-ae6a-bd136b931b3b"
      unitRef="usd">4200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ie264785d23cd421d928dd14372cfabf0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMzI0MQ_ea7c5860-f265-4915-8cf3-8f96c6823112"
      unitRef="usd">105000</us-gaap:PaymentsOfStockIssuanceCosts>
    <dare:RegularRepurchaseCommonStockIssuable
      contextRef="i08898414c3aa4894b7ad663dd58d2ddc_D20200422-20200422"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjc0ODc3OTA5ODQ2OQ_e4fcac14-854d-476d-90d6-a346b945a92b"
      unitRef="shares">200000</dare:RegularRepurchaseCommonStockIssuable>
    <dare:RegularPurchaseCommonStockIssuableIncreaseAmount
      contextRef="i0955c43f6b5843e3b4a7d1e24a09a0ae_D20200422-20200422"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjc0ODc3OTA5ODQ3OA_12a8d756-165a-4ffb-a534-548f39533853"
      unitRef="shares">250000</dare:RegularPurchaseCommonStockIssuableIncreaseAmount>
    <dare:RegularPurchaseCommonStockIssuableIncreaseAmount
      contextRef="ia927dba53c23411a8034d4380544fcb1_D20200422-20200422"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjc0ODc3OTA5ODQ4Nw_91cbed45-4fb7-4b4a-bf98-cbaeaa78401c"
      unitRef="shares">300000</dare:RegularPurchaseCommonStockIssuableIncreaseAmount>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ic533380ee2c447de91cd03aa8a73d217_I20200422"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjc0ODc3OTA5ODQ5Ng_9f57ad0f-1dee-4ff6-9c75-369bc7cd2bab"
      unitRef="usdPerShare">1.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i61a90f906d204892bcb7fb20f2f34ff8_I20200422"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjc0ODc3OTA5ODUwMw_061e128b-6671-4e00-a4ef-41cd4d5fb113"
      unitRef="usdPerShare">3.00</us-gaap:SaleOfStockPricePerShare>
    <dare:RegularPurchaseCommonStockIssuableMaximumAmount
      contextRef="i08898414c3aa4894b7ad663dd58d2ddc_D20200422-20200422"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjc0ODc3OTA5ODUxMA_c0eeba46-2bab-4642-8e39-5cab00db5bc8"
      unitRef="shares">1000000.0</dare:RegularPurchaseCommonStockIssuableMaximumAmount>
    <dare:CommonStockExchangeCap
      contextRef="i08898414c3aa4894b7ad663dd58d2ddc_D20200422-20200422"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjc0ODc3OTA5ODU5Nw_b3c3879e-1264-42bb-b08e-d8b93e1d2c33"
      unitRef="shares">4941089</dare:CommonStockExchangeCap>
    <us-gaap:SharePrice
      contextRef="ie54a63cb8870455387d630bcd302c82e_I20200421"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjc0ODc3OTA5ODYwOA_18cd0579-29eb-4bfa-8a6a-cfa47888a929"
      unitRef="usdPerShare">1.0117</us-gaap:SharePrice>
    <dare:CommonStockExchangeCapPercentage
      contextRef="i648dfc2b093f4a32a88926256f87782e_I20200422"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMjc0ODc3OTA5ODYxNw_b3ca39c1-44a4-4f18-a046-3cdc7128b540"
      unitRef="number">0.0999</dare:CommonStockExchangeCapPercentage>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ic75ab5f711a541808c1cac6b1d2728cc_I20180228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMzQ2Mw_2e26200c-189e-43b2-9349-926812515465"
      unitRef="usdPerShare">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <dare:EstimatedFairValueOfWarrantsRecordedInEquity
      contextRef="ib0a8869e72f444d7a1483b278b655bd2_I20180215"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfNDY4Mw_79981409-6354-4af4-b264-003cb5da8a0a"
      unitRef="usd">3000000.0</dare:EstimatedFairValueOfWarrantsRecordedInEquity>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="i8656d31612a94a26a509031e31dde229_D20190401-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfNTA5MA_52ea8c80-4d40-4b7a-bf01-adeb6b792e02"
      unitRef="usdPerShare">0.98</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="ia1285bc78ac34b519323112460b394f5_D20200701-20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTA5OTUxMTYzNDg2Ng_2e005bf0-97aa-4c23-9979-7875040d886e"
      unitRef="usdPerShare">0.96</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
      contextRef="i8656d31612a94a26a509031e31dde229_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfNTEwNw_a6840a46-19f7-4a06-901a-0107d79c496e"
      unitRef="usd">800000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
      contextRef="ia1285bc78ac34b519323112460b394f5_D20200701-20200731"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTA5OTUxMTY1Njc5Nw_dced395f-4fea-400c-8c11-278e81c5ba6f"
      unitRef="usd">6863</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
    <dare:NumberOfCommonStockWarrantsExercised
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTY0OTI2NzQ3MDYzNA_670e63f3-d15a-4f9d-9d9e-c19b71cee947"
      unitRef="shares">126000</dare:NumberOfCommonStockWarrantsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTY0OTI2NzQ3MDY0NQ_51ad5ef9-c070-4a75-8bee-7b6134cb25f8"
      unitRef="usd">121000</us-gaap:ProceedsFromWarrantExercises>
    <dare:NumberOfCommonStockWarrantsExercised
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTA5OTUxMTYzNTQ0NA_22ec207b-6693-4fe0-b720-96ba17bb59c9"
      unitRef="shares">1825000</dare:NumberOfCommonStockWarrantsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfMTA5OTUxMTYzNTQ4Mw_f49d2ab3-419f-49f4-a527-8b8f14fb9de6"
      unitRef="usd">1800000</us-gaap:ProceedsFromWarrantExercises>
    <dare:NumberOfCommonStockWarrantsExercised
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfNTMxMw_c7674514-7910-4f2b-a9bc-6c04bbe74e0a"
      unitRef="shares">0</dare:NumberOfCommonStockWarrantsExercised>
    <dare:NumberOfCommonStockWarrantsExercised
      contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfNTMxMw_fd761b2f-1fe0-4110-a83a-bb0b0a113746"
      unitRef="shares">0</dare:NumberOfCommonStockWarrantsExercised>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RleHRyZWdpb246MmI1OTBlODI2ODc2NDA5ZDgzYzRjZTVjNDA5ZmUwNTdfNTQzNw_db3df617-5835-4fde-9adf-6c925e8b49f0">As of September&#160;30, 2020, the Company had the following warrants outstanding:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:169.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:19.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:18.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:118.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:18.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:157.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying&lt;br/&gt;Outstanding Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,906&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021-12-01&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,737&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021-12-06&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026-04-04&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,895,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023-02-15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,908,643&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i2508825fce204dd18b05c1f2654f691a_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfMS0wLTEtMS0w_9746a47a-e587-4c38-a4b1-0cebf634d1d8"
      unitRef="shares">2906</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i2508825fce204dd18b05c1f2654f691a_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfMS0zLTEtMS0w_56f38af8-1bc4-4f80-bed0-db75cd5fb5f5"
      unitRef="usdPerShare">120.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <dare:ClassOfWarrantOrRightsWarrantsExpirationDate
      contextRef="ic02e362243bc4544af3beee1e4271766_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfMS01LTEtMS0w_25bd655b-d72a-481b-af36-ded462f8f8ab">2021-12-01</dare:ClassOfWarrantOrRightsWarrantsExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="icd48642e50f1470c986bf4baf9540666_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfMi0wLTEtMS0w_49e63525-a0e7-499f-93d7-98dc23db604a"
      unitRef="shares">3737</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="icd48642e50f1470c986bf4baf9540666_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfMi0zLTEtMS0w_2dcdca71-4a53-4b51-8599-7abb7eef1555"
      unitRef="usdPerShare">120.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <dare:ClassOfWarrantOrRightsWarrantsExpirationDate
      contextRef="i194102b3e8904dd394f4b80afaad69ba_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfMi01LTEtMS0w_2f4cfd1f-d8b2-45bc-aa78-19631188a99e">2021-12-06</dare:ClassOfWarrantOrRightsWarrantsExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i856b85e65eba4389af62e53fcb4ddb88_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfMy0wLTEtMS0w_5758e304-66e8-44e6-8bab-7c2b3e59dad8"
      unitRef="shares">6500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i856b85e65eba4389af62e53fcb4ddb88_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfMy0zLTEtMS0w_d1227db3-1774-4088-b858-0f87246c9df1"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <dare:ClassOfWarrantOrRightsWarrantsExpirationDate
      contextRef="if2f84c97f44e4cb286f9274ce4c5ce72_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfMy01LTEtMS0w_42e64e4f-deea-477d-ad19-1446a251c235">2026-04-04</dare:ClassOfWarrantOrRightsWarrantsExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ife8c2ec7d4b44a57b608f2c92187d0d9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfNC0wLTEtMS0w_548556a0-9633-4e4c-9035-a4c8145817f3"
      unitRef="shares">1895500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ife8c2ec7d4b44a57b608f2c92187d0d9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfNC0zLTEtMS0w_3dd2b49b-729a-4a2d-97bb-d4e7af19d1b4"
      unitRef="usdPerShare">0.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <dare:ClassOfWarrantOrRightsWarrantsExpirationDate
      contextRef="i637dd6b17c604a2b8aa23ef3d1d38219_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfNC01LTEtMS0w_10b01c1f-e934-485b-9503-8db9b18b518a">2023-02-15</dare:ClassOfWarrantOrRightsWarrantsExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV80OS9mcmFnOjJiNTkwZTgyNjg3NjQwOWQ4M2M0Y2U1YzQwOWZlMDU3L3RhYmxlOmI0NzhjMTA2Y2Q0NzQwNjI4NGE1YWU5MWUwM2U0YWVhL3RhYmxlcmFuZ2U6YjQ3OGMxMDZjZDQ3NDA2Mjg0YTVhZTkxZTAzZTRhZWFfNS0wLTEtMS0w_2c5eb580-6570-4a44-8019-b8d1152426b5"
      unitRef="shares">1908643</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMjkwOA_a45ff46d-98ac-4e32-b564-cf4f8d8ef9ad">LEASED PROPERTIES&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's lease for its corporate headquarters (3,169 square feet of office space) commenced on July 1, 2018 and terminates on July 31, 2021. The Company has the option to extend the term of the lease for one year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Microchips, which the Company acquired in November 2019, leases general office space in Lexington, Massachusetts and warehouse space in Billerica, Massachusetts. The Lexington lease commenced on July 1, 2013 and terminates on September 30, 2021. The Billerica lease commenced on October 1, 2016 and terminates on March 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under&lt;/span&gt;&lt;span style="color:#191c1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the terms of each lease, the lessee pays base annual rent (subject to an annual fixed percentage increase), plus property taxes, and other normal and necessary expenses, such as utilities, repairs, and maintenance. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. The leases do not require material variable lease payments, residual value guarantees or restrictive covenants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The leases do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment. The Company uses an incremental borrowing rate of 7% for operating leases that commenced prior to January 2019. The depreciable lives of operating leases and leasehold improvements are limited by the expected lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2020, the Company reported operating lease ROU assets of approximately $306,000 in other non-current assets, and $410,000 and $83,000, respectively, in current and non-current other liabilities on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total operating lease costs were approximately&#160;$76,000 and $27,000 for the three months ended&#160;September&#160;30, 2020 and September&#160;30, 2019, respectively, and $228,000 and $81,000 for the nine months ended&#160;September&#160;30, 2020 and September&#160;30, 2019, respectively. Operating lease costs consist of monthly lease payments expense, common area maintenance and other repair and maintenance costs and are included in general and administrative expenses in the consolidated statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities were approximately $111,000 and $28,000&#160;for the three months ended&#160;September&#160;30, 2020 and September&#160;30, 2019, respectively, and $349,000 and $81,000 for the nine months ended&#160;September&#160;30, 2020 and September&#160;30, 2019, respectively. These amounts are included in operating activities in the consolidated statements of cash flows. Further, at September&#160;30, 2020, operating leases had a weighted average remaining lease term of 1.14 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, future minimum payments under the Company's operating leases are approximately:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:445.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Difference between future minimum lease payments and discounted operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:NetRentableArea
      contextRef="i8ad78d95daba4838b75da7b4df9b8b00_I20180701"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfNzk_311e0a92-ee1d-4b8d-8568-42aa17ee4282"
      unitRef="sqft">3169</us-gaap:NetRentableArea>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i8ad78d95daba4838b75da7b4df9b8b00_I20180701"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMjMz_fc6ea49f-1698-45e4-ba95-a7c2e80c293b">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="i25c35de4c46a4497b5ac99d104d6962c_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMTYyNQ_38f4bace-83ba-41cc-890a-60fd3c19db38"
      unitRef="number">0.07</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic5600cf051b646c18541fb6d7163c31b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMTg2OA_f279365c-1bdb-4de1-b125-bbcce7fd2701"
      unitRef="usd">306000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMTkwNA_90a3cf7d-ec2f-4c33-911d-b5d8bc8ee546"
      unitRef="usd">410000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMTkxMQ_23ca4cde-bb68-4734-93cb-6173964e5857"
      unitRef="usd">83000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseCost
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMjA1Ng_ec0e6fd9-a8fb-487e-a16f-fe4bc8ed72d3"
      unitRef="usd">76000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMjA2Mw_797d4bc5-384a-440c-8867-c547e26e6dd5"
      unitRef="usd">27000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMjEyMg_548fa047-0f8f-4c99-abd1-48f2d2817cc6"
      unitRef="usd">228000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMjEyOQ_87af783e-4d9c-480d-b1e5-377a395ad570"
      unitRef="usd">81000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMjUxMQ_81d49a2b-5bb8-46b3-9c4d-9f22eff804a6"
      unitRef="usd">111000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMjUxOA_6180b78b-f4db-41cf-8953-75b7e50ad32e"
      unitRef="usd">28000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMjU3Mw_5e8cdf35-632e-476b-af80-2cca319470e4"
      unitRef="usd">349000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="id9c164e66ac242ccb6e2aad750db3c9b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMjU4MA_0c873478-fe7c-4283-b417-347bda757f82"
      unitRef="usd">81000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMjgxMA_3e434a9b-e922-46f9-8d84-876eb3ee4ef6">P1Y1M20D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RleHRyZWdpb246OGFiMGFmMDdmMjdlNDI2ZGFiNzdkM2EwZDllNDQ4YTBfMjkwNg_ea46b2e6-41bc-4876-837f-6ec170660201">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, future minimum payments under the Company's operating leases are approximately:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:445.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Difference between future minimum lease payments and discounted operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RhYmxlOjU5OWY1ZGQxOTAyZDRhNGZiMTE4MTAwZDJhZGVhNjJhL3RhYmxlcmFuZ2U6NTk5ZjVkZDE5MDJkNGE0ZmIxMTgxMDBkMmFkZWE2MmFfMS0xLTEtMS0w_059310f8-17e8-4802-b83f-e731d43ffba1"
      unitRef="usd">112000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RhYmxlOjU5OWY1ZGQxOTAyZDRhNGZiMTE4MTAwZDJhZGVhNjJhL3RhYmxlcmFuZ2U6NTk5ZjVkZDE5MDJkNGE0ZmIxMTgxMDBkMmFkZWE2MmFfMi0xLTEtMS0w_3d630451-efd1-4b86-8f80-772788689258"
      unitRef="usd">363000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RhYmxlOjU5OWY1ZGQxOTAyZDRhNGZiMTE4MTAwZDJhZGVhNjJhL3RhYmxlcmFuZ2U6NTk5ZjVkZDE5MDJkNGE0ZmIxMTgxMDBkMmFkZWE2MmFfMy0xLTEtMS0w_0c20c4f9-ed7f-4429-a2a8-17e0834c7ee8"
      unitRef="usd">42000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RhYmxlOjU5OWY1ZGQxOTAyZDRhNGZiMTE4MTAwZDJhZGVhNjJhL3RhYmxlcmFuZ2U6NTk5ZjVkZDE5MDJkNGE0ZmIxMTgxMDBkMmFkZWE2MmFfNC0xLTEtMS0w_cdc846b9-c54e-4463-b475-18f9271b9249"
      unitRef="usd">517000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RhYmxlOjU5OWY1ZGQxOTAyZDRhNGZiMTE4MTAwZDJhZGVhNjJhL3RhYmxlcmFuZ2U6NTk5ZjVkZDE5MDJkNGE0ZmIxMTgxMDBkMmFkZWE2MmFfNS0xLTEtMS0w_b3d562ec-d79b-4d49-9572-07de6d72cfed"
      unitRef="usd">24000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81Mi9mcmFnOjhhYjBhZjA3ZjI3ZTQyNmRhYjc3ZDNhMGQ5ZTQ0OGEwL3RhYmxlOjU5OWY1ZGQxOTAyZDRhNGZiMTE4MTAwZDJhZGVhNjJhL3RhYmxlcmFuZ2U6NTk5ZjVkZDE5MDJkNGE0ZmIxMTgxMDBkMmFkZWE2MmFfNi0xLTEtMS0w_05733e16-c30e-4a6f-9a70-d6d627a33df1"
      unitRef="usd">493000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsDisclosureTextBlock
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81OC9mcmFnOjIxZjFjMzljOWFiNjQ3MDJhYjM0OGQ0ZjMwMGM5ZTgxL3RleHRyZWdpb246MjFmMWMzOWM5YWI2NDcwMmFiMzQ4ZDRmMzAwYzllODFfMTYzMw_3f0dd4d9-555d-467a-bf6a-44e1a0e78e4d">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Microchips, the Company agreed to pay contingent consideration based upon the achievement of specified funding, product development and regulatory milestones. The Company recorded $1.0 million in contingent consideration liability associated with milestone payments expected to become payable in the first half of 2021 in its consolidated balance sheet at September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Note&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; Payable&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, due to the economic uncertainty resulting from the impact of the COVID-19 pandemic on the Company's operations and to support its ongoing operations and retain all employees, the Company applied for a loan under the Paycheck Protection Program, or the PPP, of the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, administered by the U.S. Small Business Administration, or the SBA. The Company received a loan of approximately $367,000. The loan matures in April 2022, bears interest at a rate of 1.00% per annum, is payable in equal monthly payments commencing in November 2020 through maturity and may be prepaid at any time prior to maturity with no prepayment penalties. Under the terms of the PPP, the loan proceeds could be used for "qualifying expenses" and, subject to specified limitations in the CARES Act and under the terms of the PPP, certain amounts of the loan, including accrued interest, may be forgiven if used for qualifying expenses. Qualifying expenses include payroll costs, costs used to continue group health care benefits, mortgage interest payments, rent payments, utility payments, and interest payments on other debt obligations incurred before February 15, 2020. In September 2020, the Company submitted its forgiveness application. The Company used the entire amount of the loan for payroll and rent costs, which the Company believes are expenses that constitute qualifying expenses, and the Company requested that the entire amount of the loan, including accrued interest, be forgiven. There can be no assurance that the loan will be forgiven, in whole or in part. Under current SBA guidance, it may take up to 90 days from the date the Company's loan forgiveness application is submitted to the SBA by the Company's lender for the SBA to make a determination with respect to the Company's loan forgiveness application . The Company recorded a note payable plus accrued interest for the loan in the amount of approximately $369,000 in its consolidated balance sheet at September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <dare:AssetAcquisitionContingentConsiderationCurrent
      contextRef="ibec4b74376bf439b97a248a65f5b0eae_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81OC9mcmFnOjIxZjFjMzljOWFiNjQ3MDJhYjM0OGQ0ZjMwMGM5ZTgxL3RleHRyZWdpb246MjFmMWMzOWM5YWI2NDcwMmFiMzQ4ZDRmMzAwYzllODFfMjgx_119806c8-d2a5-484e-9e34-bab3a4045537"
      unitRef="usd">1000000.0</dare:AssetAcquisitionContingentConsiderationCurrent>
    <dare:CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived
      contextRef="i07edbdfe23b14e1b882ecc8189596d12_D20200401-20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81OC9mcmFnOjIxZjFjMzljOWFiNjQ3MDJhYjM0OGQ0ZjMwMGM5ZTgxL3RleHRyZWdpb246MjFmMWMzOWM5YWI2NDcwMmFiMzQ4ZDRmMzAwYzllODFfODk5_fe7de3d6-836c-4a11-9a06-b62e4a8bbe13"
      unitRef="usd">367000</dare:CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5eedf8fd854e4e299d621b34d7105036_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81OC9mcmFnOjIxZjFjMzljOWFiNjQ3MDJhYjM0OGQ0ZjMwMGM5ZTgxL3RleHRyZWdpb246MjFmMWMzOWM5YWI2NDcwMmFiMzQ4ZDRmMzAwYzllODFfOTYz_03accac3-df63-422c-b8f3-7cb8b481bbac"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <dare:NotesPayableCurrentPlusAccruedInterest
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV81OC9mcmFnOjIxZjFjMzljOWFiNjQ3MDJhYjM0OGQ0ZjMwMGM5ZTgxL3RleHRyZWdpb246MjFmMWMzOWM5YWI2NDcwMmFiMzQ4ZDRmMzAwYzllODFfMTU5MQ_66366178-8519-4970-8cb5-f744072154ea"
      unitRef="usd">369000</dare:NotesPayableCurrentPlusAccruedInterest>
    <dare:GrantAwardTextBlock
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMjQ4NA_5f9a72ec-575c-4a4c-8fa5-970e3019262c">GRANT AWARD&lt;div style="margin-top:18pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NIH Grant Funding&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has received notices of awards and grant funding from the National Institutes of Health, or the NIH to support the development of Ovaprene and DARE-FRT1. The NIH issues notices of awards to the Company for a specified amount, and the Company must incur and track expenses eligible for reimbursement under the award and submit a detailed accounting of such expenses to receive payment. If the Company receives payments under the award, the amounts of such payments are recognized in the statement of operations as a reduction to research and development activities as the related costs are incurred to meet those obligations over the period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ovaprene&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since 2018, the Company has received approximately $1.9 million of grant funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, a division of the NIH, for clinical development efforts supporting Ovaprene. The most recent and final notice of award the Company received was for approximately $731,000 in April 2020, substantially all of which has been funded to date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded credits to research and development expense for costs related to the NIH award of approximately $124,000 and $302,000 for the three months ended September&#160;30, 2020 and September&#160;30, 2019, respectively, and $583,000 and $920,000 for the nine months ended&#160;September&#160;30, 2020 and September&#160;30, 2019, respectively. At September&#160;30, 2020, the Company recorded a receivable of approximately $69,000 for expenses incurred through such date that it believes are eligible for reimbursement under the final notice of award received in April 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;DARE-FRT1&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company received a notice of award of a grant from the NIH to support the development of DARE-FRT1. The award in the amount of $300,000 was for what is referred to as the "Phase I" segment of the project outlined in the Company's grant application, which is to occur during the period of August 2020 through July 2021. Additional potential funding of up to approximately $2.0 million for the "Phase II" segment of the project outlined in the grant application is contingent upon satisfying specified requirements, including, assessment of the results of the Phase I segment, determination that the Phase I goals were achieved, and availability of funds. There is no guarantee the Company will receive any Phase II award. The Company recorded credits to research and development expense for costs related to the NIH award of approximately $3,000 during the three months ended September&#160;30, 2020. At September&#160;30, 2020, the Company recorded a receivable of approximately $3,000 for expenses incurred through such date that it believes are eligible for reimbursement under the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bill &amp;amp; Melinda Gates Foundation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's wholly-owned subsidiary, Microchips, has a grant agreement with the Bill &amp;amp; Melinda Gates Foundation, or the Foundation, relating to the development of the pre-clinical stage contraceptive candidate, DARE-LARC1. Expenses eligible for grant funding must be incurred, tracked and reported to the Foundation. Microchips received grant funding payments of approximately $2.9 million in July 2019, $1.6 million in June 2020 and $899,000 in September 2020. At September&#160;30, 2020, grant funding payments associated with research and development expenses for DARE-LARC1 not yet incurred totaled approximately $2.2 million and are recorded as deferred grant funding liability in the Company's consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;</dare:GrantAwardTextBlock>
    <dare:ProceedsFromAwardOfGrant
      contextRef="i6cd38b5d0d18443eb25f5b075faaf8d0_D20180101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMTA5OTUxMTYzOTYwOA_8088d6c3-ccbf-4e77-802f-0abe021b879b"
      unitRef="usd">1900000</dare:ProceedsFromAwardOfGrant>
    <dare:ProceedsFromAwardOfGrant
      contextRef="i07edbdfe23b14e1b882ecc8189596d12_D20200401-20200430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfNTE4_97a157dd-97f8-47c8-89f4-983809e21262"
      unitRef="usd">731000</dare:ProceedsFromAwardOfGrant>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
      contextRef="iec804f8af9ee49218d67d6fd78a4180c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMTA5OTUxMTYzMDQwOA_1108b73e-1493-4943-81ec-24036e54823f"
      unitRef="usd">124000</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
      contextRef="i160a0b42d86e4a8bbd0f05476b0f68e6_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMTA5OTUxMTYzMDQzOQ_286bb74c-f181-4d4c-95b3-c4c2024185df"
      unitRef="usd">302000</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
      contextRef="i07b04c713b994fddb69fb22f61dcce47_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMTA5OTUxMTYzMDI3OQ_28bebdcd-282b-4556-993e-a4769f615f6c"
      unitRef="usd">583000</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
      contextRef="iee4d04ac7d154b5da7eff0fa25f65c41_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMTA5OTUxMTYzMDQzNQ_091bba8b-1603-4c0e-bb38-9aa9f8d01086"
      unitRef="usd">920000</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
    <us-gaap:GrantsReceivable
      contextRef="i541d1593a6734f80a2264c14bc99a339_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMTY0MA_64313b4f-c690-41f9-81eb-676c75708822"
      unitRef="usd">69000</us-gaap:GrantsReceivable>
    <dare:ProceedsFromAwardOfGrant
      contextRef="ifa5514aaaa824b3aa79107f5c9c5d73d_D20200801-20200831"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMTA5OTUxMTYzOTYyNA_655fa0d3-623d-446a-abee-ba5e68efffa1"
      unitRef="usd">300000</dare:ProceedsFromAwardOfGrant>
    <dare:AdditionalPotentialFundingRelatedToGrantAward
      contextRef="ida0b6e85f82e4e608327c8ca8bc71f2d_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMTA5OTUxMTY0MDU0Nw_7b482d6d-7081-4a03-977d-fd3c13e4efc8"
      unitRef="usd">2000000.0</dare:AdditionalPotentialFundingRelatedToGrantAward>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
      contextRef="i61ac128034e543f09fa5c2ccee686dd9_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMTA5OTUxMTYzOTU2Mw_2bf92277-8cad-4cf3-9d59-dfd66074bdab"
      unitRef="usd">3000</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
    <dare:ReceivableForExpensesEligibleForReimbursement
      contextRef="ic6eebb50c9aa442eb1c1e54f219936db_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMTA5OTUxMTYzOTU3Mg_f3f955eb-e170-4ffa-92fa-6ea4fb03631b"
      unitRef="usd">3000</dare:ReceivableForExpensesEligibleForReimbursement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e9574645f90496484a14992487f17b9_D20190701-20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMjE5OA_e01ec3b3-e451-43b4-8d30-3b8d15925ed3"
      unitRef="usd">2900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08cd90f2ba3140dbb283240c624fe12e_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMTA5OTUxMTY0MTQ5NQ_5b3e6c34-5bcc-4f33-b9ba-75b4665ec23e"
      unitRef="usd">1600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f10d1b26cc94a1fa3cb93ec8aedbb85_D20200901-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMjE5OTAyMzI1ODE3OQ_34086eb3-bcfc-4aae-bf4b-97c4fc6679bf"
      unitRef="usd">899000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dare:DeferredGrantFundingCurrent
      contextRef="i811a18ee61a041bcb8b2a9a6d171b9a6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82MS9mcmFnOmE5ZTVjODRjNjk1MzQ5YTM5MWZjMDhkNWY0MjFlYjg1L3RleHRyZWdpb246YTllNWM4NGM2OTUzNDlhMzkxZmMwOGQ1ZjQyMWViODVfMjM4NA_21ce0b16-a446-4643-af1a-fea70c455cdd"
      unitRef="usd">2200000</dare:DeferredGrantFundingCurrent>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82NC9mcmFnOjExMTNjOWVlNTBhZDQ2ZWU5ZGUzYTBjZjI2NjBkYWIzL3RleHRyZWdpb246MTExM2M5ZWU1MGFkNDZlZTlkZTNhMGNmMjY2MGRhYjNfODUw_1bb8cb3c-1b71-41d7-ac32-0731562a4097">NET LOSS PER SHARE&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company computes basic net loss per share using the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares and potentially dilutive securities (common share equivalents) outstanding during the period. Common share equivalents outstanding, determined using the treasury stock method, are comprised of shares that may be issued under outstanding options and warrants to purchase shares of the Company&#x2019;s common stock. Common share equivalents are excluded from the diluted net loss per share calculation if their effect is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive outstanding securities were excluded from diluted net loss per common share for the period indicated because of their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:372.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,783,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,824,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,908,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,750,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,692,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,575,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82NC9mcmFnOjExMTNjOWVlNTBhZDQ2ZWU5ZGUzYTBjZjI2NjBkYWIzL3RleHRyZWdpb246MTExM2M5ZWU1MGFkNDZlZTlkZTNhMGNmMjY2MGRhYjNfODUy_1d5229f2-64ac-4aa9-b410-e38de250cdee">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive outstanding securities were excluded from diluted net loss per common share for the period indicated because of their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:372.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,783,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,824,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,908,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,750,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,692,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,575,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0f2fd361955c4af0b36cfc82bd1dd299_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82NC9mcmFnOjExMTNjOWVlNTBhZDQ2ZWU5ZGUzYTBjZjI2NjBkYWIzL3RhYmxlOmE3MWIyMGJlMDMwMjRkYzFhZWFjYjEwYTEwY2I3ZjFlL3RhYmxlcmFuZ2U6YTcxYjIwYmUwMzAyNGRjMWFlYWNiMTBhMTBjYjdmMWVfMi0yLTEtMS0w_b4aa305d-a89e-4733-be4b-af1d2ea2b92a"
      unitRef="shares">2783591</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9c48e9816275492c80d5c9b5987290e9_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82NC9mcmFnOjExMTNjOWVlNTBhZDQ2ZWU5ZGUzYTBjZjI2NjBkYWIzL3RhYmxlOmE3MWIyMGJlMDMwMjRkYzFhZWFjYjEwYTEwY2I3ZjFlL3RhYmxlcmFuZ2U6YTcxYjIwYmUwMzAyNGRjMWFlYWNiMTBhMTBjYjdmMWVfMi00LTEtMS0w_8863a496-57f3-432f-aa92-9b5d315c28fb"
      unitRef="shares">1824975</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9fa32febc2e54647a6368e846d71b024_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82NC9mcmFnOjExMTNjOWVlNTBhZDQ2ZWU5ZGUzYTBjZjI2NjBkYWIzL3RhYmxlOmE3MWIyMGJlMDMwMjRkYzFhZWFjYjEwYTEwY2I3ZjFlL3RhYmxlcmFuZ2U6YTcxYjIwYmUwMzAyNGRjMWFlYWNiMTBhMTBjYjdmMWVfMy0yLTEtMS0w_a411a0ad-85b8-45e7-90d9-f524e82431bf"
      unitRef="shares">1908643</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icd0fb129419e4ee29415f58d00c829e5_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82NC9mcmFnOjExMTNjOWVlNTBhZDQ2ZWU5ZGUzYTBjZjI2NjBkYWIzL3RhYmxlOmE3MWIyMGJlMDMwMjRkYzFhZWFjYjEwYTEwY2I3ZjFlL3RhYmxlcmFuZ2U6YTcxYjIwYmUwMzAyNGRjMWFlYWNiMTBhMTBjYjdmMWVfMy00LTEtMS0w_e0f62017-c0f6-4bba-8404-316d6ceb76d9"
      unitRef="shares">3750833</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id8c96646bea247b9938b381dd4090324_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82NC9mcmFnOjExMTNjOWVlNTBhZDQ2ZWU5ZGUzYTBjZjI2NjBkYWIzL3RhYmxlOmE3MWIyMGJlMDMwMjRkYzFhZWFjYjEwYTEwY2I3ZjFlL3RhYmxlcmFuZ2U6YTcxYjIwYmUwMzAyNGRjMWFlYWNiMTBhMTBjYjdmMWVfNC0yLTEtMS0w_1fd5f72a-08e4-4f0a-a9ff-b0c2bf523186"
      unitRef="shares">4692234</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5dd0684b117e4bf182f787c30f27f3b5_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82NC9mcmFnOjExMTNjOWVlNTBhZDQ2ZWU5ZGUzYTBjZjI2NjBkYWIzL3RhYmxlOmE3MWIyMGJlMDMwMjRkYzFhZWFjYjEwYTEwY2I3ZjFlL3RhYmxlcmFuZ2U6YTcxYjIwYmUwMzAyNGRjMWFlYWNiMTBhMTBjYjdmMWVfNC00LTEtMS0w_4c0bd267-f662-4316-b1fe-a757d403c7f7"
      unitRef="shares">5575808</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82Ny9mcmFnOjY1NTFjOWE1ZjYyYTQwNmM4YjFlMjgwMGNmMDlkMDlmL3RleHRyZWdpb246NjU1MWM5YTVmNjJhNDA2YzhiMWUyODAwY2YwOWQwOWZfMTEyNg_adc7701f-5b35-4b1f-bdfb-17244d6247e1">SUBSEQUENT EVENTS&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ATM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between October 1, 2020 and November&#160;11, 2020, the Company sold an aggregate of 3,987,485 shares of common stock in "at-the-market" equity offerings and received aggregate net proceeds of approximately $4.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Line&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between October 1, 2020 and November&#160;11, 2020 the Company sold an aggregate of 400,000 shares of common stock to Lincoln Park under the Purchase Agreement and received aggregate net proceeds of approximately $0.4&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia980a0c4d8c2414ca34948ab72d9b74d_D20201001-20201111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82Ny9mcmFnOjY1NTFjOWE1ZjYyYTQwNmM4YjFlMjgwMGNmMDlkMDlmL3RleHRyZWdpb246NjU1MWM5YTVmNjJhNDA2YzhiMWUyODAwY2YwOWQwOWZfNzky_08ef4d69-2eb5-4b41-a533-793a75c83c10"
      unitRef="shares">3987485</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ia980a0c4d8c2414ca34948ab72d9b74d_D20201001-20201111"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82Ny9mcmFnOjY1NTFjOWE1ZjYyYTQwNmM4YjFlMjgwMGNmMDlkMDlmL3RleHRyZWdpb246NjU1MWM5YTVmNjJhNDA2YzhiMWUyODAwY2YwOWQwOWZfOTA3_664a2f56-7fe3-4cb5-81c1-4517f9d599bb"
      unitRef="usd">4100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic93f45ca4cb841cf9744ed2f4001e2a4_D20201001-20201111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82Ny9mcmFnOjY1NTFjOWE1ZjYyYTQwNmM4YjFlMjgwMGNmMDlkMDlmL3RleHRyZWdpb246NjU1MWM5YTVmNjJhNDA2YzhiMWUyODAwY2YwOWQwOWZfOTk5_77cf10b5-f8ab-46f4-8056-6da18538c706"
      unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic93f45ca4cb841cf9744ed2f4001e2a4_D20201001-20201111"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2OGY0OGQzZWNlMzRjZmFiNTk1YTQ2ZjY5ODZiNDM5L3NlYzo4NjhmNDhkM2VjZTM0Y2ZhYjU5NWE0NmY2OTg2YjQzOV82Ny9mcmFnOjY1NTFjOWE1ZjYyYTQwNmM4YjFlMjgwMGNmMDlkMDlmL3RleHRyZWdpb246NjU1MWM5YTVmNjJhNDA2YzhiMWUyODAwY2YwOWQwOWZfMTEyMw_4593d5e2-917d-4b81-a7eb-fe095b15ac90"
      unitRef="usd">400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701184309752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Nov. 11, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">DAR&#201; BIOSCIENCE, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001401914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-4139823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3655 Nobel Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">926-7655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DARE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,990,001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701184013960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,389,414<span></span>
</td>
<td class="nump">$ 4,780,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">213,560<span></span>
</td>
<td class="nump">555,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">1,381,462<span></span>
</td>
<td class="nump">1,108,615<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">6,984,436<span></span>
</td>
<td class="nump">6,443,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">42,349<span></span>
</td>
<td class="nump">63,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">634,957<span></span>
</td>
<td class="nump">935,325<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">7,661,742<span></span>
</td>
<td class="nump">7,442,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,555,307<span></span>
</td>
<td class="nump">1,083,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,454,048<span></span>
</td>
<td class="nump">2,098,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_DeferredGrantFundingCurrent', window );">Deferred grant funding</a></td>
<td class="nump">2,178,379<span></span>
</td>
<td class="nump">2,019,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable</a></td>
<td class="nump">367,285<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="nump">409,647<span></span>
</td>
<td class="nump">410,896<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,964,666<span></span>
</td>
<td class="nump">5,612,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred license revenue</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities long-term</a></td>
<td class="nump">82,964<span></span>
</td>
<td class="nump">389,556<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,047,630<span></span>
</td>
<td class="nump">7,001,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 120,000,000 shares authorized; 33,602,516 and 19,683,401 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">3,360<span></span>
</td>
<td class="nump">1,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(112,807)<span></span>
</td>
<td class="num">(102,625)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">61,712,882<span></span>
</td>
<td class="nump">44,564,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(62,989,323)<span></span>
</td>
<td class="num">(44,023,191)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="num">(1,385,888)<span></span>
</td>
<td class="nump">440,826<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (deficit)</a></td>
<td class="nump">$ 7,661,742<span></span>
</td>
<td class="nump">$ 7,442,788<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701258070872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">33,602,516<span></span>
</td>
<td class="nump">19,683,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">33,602,516<span></span>
</td>
<td class="nump">19,683,401<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701258657672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 1,353,069<span></span>
</td>
<td class="nump">$ 1,318,986<span></span>
</td>
<td class="nump">$ 4,772,382<span></span>
</td>
<td class="nump">$ 3,903,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">6,203,753<span></span>
</td>
<td class="nump">1,966,230<span></span>
</td>
<td class="nump">14,131,007<span></span>
</td>
<td class="nump">6,172,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseFee', window );">License fees</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">133,333<span></span>
</td>
<td class="nump">58,333<span></span>
</td>
<td class="nump">408,333<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">7,581,822<span></span>
</td>
<td class="nump">3,418,549<span></span>
</td>
<td class="nump">18,961,722<span></span>
</td>
<td class="nump">10,484,070<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(7,581,822)<span></span>
</td>
<td class="num">(3,418,549)<span></span>
</td>
<td class="num">(18,961,722)<span></span>
</td>
<td class="num">(10,484,070)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="num">(986)<span></span>
</td>
<td class="nump">25,471<span></span>
</td>
<td class="nump">2,454<span></span>
</td>
<td class="nump">86,703<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,582,808)<span></span>
</td>
<td class="num">(3,393,078)<span></span>
</td>
<td class="num">(18,959,268)<span></span>
</td>
<td class="num">(10,397,367)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount', window );">Deemed dividend from trigger of down round provision feature</a></td>
<td class="num">(6,863)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,863)<span></span>
</td>
<td class="num">(789,594)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss to common shareholders</a></td>
<td class="num">(7,589,671)<span></span>
</td>
<td class="num">(3,393,078)<span></span>
</td>
<td class="num">(18,966,131)<span></span>
</td>
<td class="num">(11,186,961)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">672<span></span>
</td>
<td class="num">(15,378)<span></span>
</td>
<td class="num">(10,182)<span></span>
</td>
<td class="num">(15,674)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (7,588,999)<span></span>
</td>
<td class="num">$ (3,408,456)<span></span>
</td>
<td class="num">$ (18,976,313)<span></span>
</td>
<td class="num">$ (11,202,635)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per common share - basic and diluted (in usd per share)</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (0.76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted (in shares)</a></td>
<td class="nump">31,588,152<span></span>
</td>
<td class="nump">16,683,411<span></span>
</td>
<td class="nump">27,381,508<span></span>
</td>
<td class="nump">14,756,213<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease in equity for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=SL109261905-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12B<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL109261756-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701183066568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Accumulated deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 6,726,620<span></span>
</td>
<td class="nump">$ 1,143<span></span>
</td>
<td class="nump">$ 35,791,972<span></span>
</td>
<td class="num">$ (96,728)<span></span>
</td>
<td class="num">$ (28,969,767)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,422,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">97,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,051,840)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,051,840)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">7,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="nump">3,780,369<span></span>
</td>
<td class="nump">$ 1,143<span></span>
</td>
<td class="nump">35,889,940<span></span>
</td>
<td class="num">(89,107)<span></span>
</td>
<td class="num">(32,021,607)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,422,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">6,726,620<span></span>
</td>
<td class="nump">$ 1,143<span></span>
</td>
<td class="nump">35,791,972<span></span>
</td>
<td class="num">(96,728)<span></span>
</td>
<td class="num">(28,969,767)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,422,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount', window );">Deemed dividend from trigger of down round provision feature</a></td>
<td class="num">(789,594)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(10,397,367)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(15,674)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">1,809,992<span></span>
</td>
<td class="nump">$ 1,668<span></span>
</td>
<td class="nump">42,077,455<span></span>
</td>
<td class="num">(112,402)<span></span>
</td>
<td class="num">(40,156,729)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,683,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="nump">3,780,369<span></span>
</td>
<td class="nump">$ 1,143<span></span>
</td>
<td class="nump">35,889,940<span></span>
</td>
<td class="num">(89,107)<span></span>
</td>
<td class="num">(32,021,607)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,422,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">111,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">5,151,702<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
<td class="nump">5,151,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,261,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount', window );">Deemed dividend from trigger of down round provision feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">789,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(789,594)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,952,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,952,450)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(7,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">5,083,055<span></span>
</td>
<td class="nump">$ 1,668<span></span>
</td>
<td class="nump">41,942,062<span></span>
</td>
<td class="num">(97,024)<span></span>
</td>
<td class="num">(36,763,651)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,683,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">135,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount', window );">Deemed dividend from trigger of down round provision feature</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,393,078)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,393,078)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(15,378)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,378)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">1,809,992<span></span>
</td>
<td class="nump">$ 1,668<span></span>
</td>
<td class="nump">42,077,455<span></span>
</td>
<td class="num">(112,402)<span></span>
</td>
<td class="num">(40,156,729)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,683,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">440,826<span></span>
</td>
<td class="nump">$ 1,968<span></span>
</td>
<td class="nump">44,564,674<span></span>
</td>
<td class="num">(102,625)<span></span>
</td>
<td class="num">(44,023,191)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,683,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">160,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">5,222,687<span></span>
</td>
<td class="nump">$ 331<span></span>
</td>
<td class="nump">5,222,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,308,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock from the exercise of warrants</a></td>
<td class="nump">1,665,020<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">1,664,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares', window );">Issuance of common stock from the exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,699,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,252,248)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,252,248)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(22,944)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,944)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">3,214,183<span></span>
</td>
<td class="nump">$ 2,470<span></span>
</td>
<td class="nump">51,612,721<span></span>
</td>
<td class="num">(125,569)<span></span>
</td>
<td class="num">(48,275,439)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,700,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">440,826<span></span>
</td>
<td class="nump">$ 1,968<span></span>
</td>
<td class="nump">44,564,674<span></span>
</td>
<td class="num">(102,625)<span></span>
</td>
<td class="num">(44,023,191)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,683,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount', window );">Deemed dividend from trigger of down round provision feature</a></td>
<td class="num">(6,863)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(18,959,268)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(10,182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="num">(1,385,888)<span></span>
</td>
<td class="nump">$ 3,360<span></span>
</td>
<td class="nump">61,712,882<span></span>
</td>
<td class="num">(112,807)<span></span>
</td>
<td class="num">(62,989,323)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,602,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">3,214,183<span></span>
</td>
<td class="nump">$ 2,470<span></span>
</td>
<td class="nump">51,612,721<span></span>
</td>
<td class="num">(125,569)<span></span>
</td>
<td class="num">(48,275,439)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,700,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">186,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">4,022,336<span></span>
</td>
<td class="nump">$ 382<span></span>
</td>
<td class="nump">4,021,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,823,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,124,213)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,124,213)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">12,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">311,255<span></span>
</td>
<td class="nump">$ 2,852<span></span>
</td>
<td class="nump">55,821,534<span></span>
</td>
<td class="num">(113,479)<span></span>
</td>
<td class="num">(55,399,652)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,524,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">194,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">5,277,622<span></span>
</td>
<td class="nump">$ 466<span></span>
</td>
<td class="nump">5,277,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,666,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares', window );">Issuance cost on equity line paid in common stock</a></td>
<td class="nump">291,529<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">291,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares', window );">Issuance cost on equity line paid in common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock from the exercise of warrants</a></td>
<td class="nump">120,960<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">120,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares', window );">Issuance of common stock from the exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount', window );">Deemed dividend from trigger of down round provision feature</a></td>
<td class="num">(6,863)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,863)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,582,808)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,582,808)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="num">$ (1,385,888)<span></span>
</td>
<td class="nump">$ 3,360<span></span>
</td>
<td class="nump">$ 61,712,882<span></span>
</td>
<td class="num">$ (112,807)<span></span>
</td>
<td class="num">$ (62,989,323)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,602,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Consideration For Commitment To Purchase Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Consideration For Commitment To Purchase Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease in equity for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=SL109261905-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12B<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL109261756-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701184114328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (18,959,268)<span></span>
</td>
<td class="num">$ (10,397,367)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Non-cash adjustments reconciling net loss to operating cash flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">36,428<span></span>
</td>
<td class="nump">3,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">542,582<span></span>
</td>
<td class="nump">344,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NonCashLeaseExpense', window );">Non-cash operating lease cost</a></td>
<td class="num">(125,517)<span></span>
</td>
<td class="num">(19,914)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="nump">341,650<span></span>
</td>
<td class="num">(6,802)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">18,682<span></span>
</td>
<td class="num">(367,409)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges', window );">Other non-current assets</a></td>
<td class="nump">118,044<span></span>
</td>
<td class="nump">138,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">472,124<span></span>
</td>
<td class="num">(107,463)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">355,395<span></span>
</td>
<td class="nump">905,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_IncreaseDecreaseInDeferredGrantFunding', window );">Deferred grant funding</a></td>
<td class="nump">158,704<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred license revenue</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(16,041,176)<span></span>
</td>
<td class="num">(9,506,797)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(15,246)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(15,246)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">14,522,645<span></span>
</td>
<td class="nump">5,151,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Proceeds from the exercise of common stock warrants</a></td>
<td class="nump">1,785,980<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of note payable</a></td>
<td class="nump">367,285<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">16,675,911<span></span>
</td>
<td class="nump">5,151,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(10,182)<span></span>
</td>
<td class="num">(15,674)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">609,307<span></span>
</td>
<td class="num">(4,370,769)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">4,780,107<span></span>
</td>
<td class="nump">6,805,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">5,389,414<span></span>
</td>
<td class="nump">2,435,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash operating and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">231,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_IssuanceCostOnEquityPaidInCommonStock', window );">Issuance cost on equity paid in common stock</a></td>
<td class="nump">291,428<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount', window );">Deemed dividend from trigger of down round provision feature</a></td>
<td class="nump">$ 6,863<span></span>
</td>
<td class="nump">$ 789,594<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_IncreaseDecreaseInDeferredGrantFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Deferred Grant Funding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_IncreaseDecreaseInDeferredGrantFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in other non-current assets and deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_IssuanceCostOnEquityPaidInCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance Cost On Equity Paid In Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_IssuanceCostOnEquityPaidInCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NetProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease in equity for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=SL109261905-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12B<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL109261756-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701178059096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of the Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of the Business</a></td>
<td class="text">ORGANIZATION AND DESCRIPTION OF THE BUSINESS<div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dar&#233; Bioscience, Inc. is a clinical-stage biopharmaceutical company committed to the acceleration of innovative products for women&#8217;s health. Dar&#233; Bioscience, Inc. and its wholly owned subsidiaries operate in one segment. In this report, the &#8220;Company&#8221; refers collectively to Dar&#233; Bioscience, Inc. and its wholly owned subsidiaries, unless otherwise stated or the context otherwise requires.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is driven by a mission to identify, acquire and develop a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, fertility, and sexual and vaginal health. The Company's business strategy is to in-license or otherwise acquire the rights to differentiated product candidates in the Company's areas of focus, some of which have existing clinical proof-of-concept data, to take those candidates through mid- to late-stage clinical development, and to establish and leverage strategic partnerships to achieve commercialization.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since July 2017, the Company has assembled a portfolio of clinical-stage and pre-clinical-stage candidates. While the Company will continue to assess opportunities to expand its portfolio, its current focus is on advancing its existing product candidates through mid- and late-stages of clinical development or approval. The Company's portfolio includes three product candidates in advanced clinical development:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BV1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a novel thermosetting bioadhesive hydrogel formulated with clindamycin phosphate 2% to be administered in a single vaginally delivered application</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a first line treatment for bacterial vaginosis;</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Ovaprene&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a hormone-free, monthly vaginal contraceptive; and</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Sildenafil Cream</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a proprietary cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's portfolio also includes three product candidates in Phase 1 clinical development or that the Company believes are Phase 1-ready:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HRT1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a combination bio-identical estradiol and progesterone intravaginal ring for the treatment of menopausal symptoms, including vasomotor symptoms, as part of a hormone replacement therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or HRT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following menopause;</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FRT1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan; and</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VVA1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or VVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with hormone-receptor positive breast cancer.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's portfolio also includes these pre-clinical stage product candidates:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-LARC1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a combination product designed to provide long-acting, reversible contraception comprising an implantable, user-controlled wireless drug delivery system and levonorgestrel;</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">ORB-204 and ORB-214</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, injectable formulations of etonogestrel designed to provide contraception over 6-month and 12-month periods, respectively; and</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DARE-RH1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a novel approach to non</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hormonal contraception for both men and women by targeting the CatSper ion channel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary operations have consisted of, and are expected to continue to consist of, product research and development and advancing its portfolio of product candidates through clinical development and regulatory approval. The Company expects that the majority of its development expenses for the remainder of 2020 and in 2021 will support the advancement of DARE-BV1, Ovaprene, and Sildenafil Cream, 3.6%.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not obtained any regulatory approvals for any of its product candidates, commercialized any of its product candidates or generated any product revenue. The Company is subject to several risks common to clinical-stage biopharmaceutical companies, including dependence on key employees as well as third-party licensors, partners and service providers, competition from other companies, the need to develop commercially viable products in a timely and cost-effective manner, and the need to obtain adequate additional capital to fund the development of product candidates. The Company is also subject to several risks common to other companies in the industry, including rapid technology change, regulatory approval of products, uncertainty of market acceptance of products, competition from substitute products and larger companies, compliance with government regulations, protection of proprietary technology, dependence on third parties, and product liability.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has prepared its interim consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. The Company has a history of losses from operations, expects negative cash flows from operations will continue for the foreseeable future, and expects that its net losses will continue for at least the next several years as it develops its existing product candidates and seeks to acquire, license or develop additional product candidates. These circumstances raise substantial doubt about the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty of the Company's ability to continue as a going concern.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company had an accumulated deficit of approximately $63.0 million and cash and cash equivalents of approximately $5.4 million. The Company also had negative cash flow from operations of approximately $16.0 million during the nine months ended September&#160;30, 2020. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is focused primarily on the development and commercialization of innovative products in women&#8217;s health. The Company will continue to incur significant research and development and other expenses related to these activities. If the clinical trials for any of the Company&#8217;s product candidates fail to produce successful results such that those product candidates do not advance in clinical development, then the Company&#8217;s business and prospects may suffer. Even if the product candidates advance in clinical development, they may fail to gain regulatory approval. Even if the product candidates are approved, they may fail to achieve market acceptance, and the Company may never become profitable. Even if the Company becomes profitable, it may not sustain profitability.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company's current operating plan estimates, the Company does not have sufficient cash to satisfy its working capital needs and other liquidity requirements over at least the next 12 months from the date of issuance of the accompanying consolidated financial statements. The Company needs to raise substantial additional capital to continue to fund its operations and to successfully execute its current operating plan, including to continue the planned development of DARE-BV1, Ovaprene, and Sildenafil Cream, 3.6%.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently evaluating a variety of capital raising options, including equity and debt financings, government or other grant funding, collaborations and strategic alliances or other similar types of arrangements to cover its operating expenses, including the development of its product candidates and any future product candidates it may license or otherwise acquire. The amount and timing of the Company's capital needs have been and will continue to depend highly on many factors, including the product development programs the Company chooses to pursue and the pace and results of its clinical development efforts. If the Company raises capital through collaborations, strategic alliances or other similar types of arrangements, it may have to relinquish, on terms that are not favorable to the Company, rights to some of its technologies or product candidates it would otherwise seek to develop or commercialize. There can be no assurances that capital will be available when needed or that, if available, it will be obtained on terms favorable to the Company and its stockholders. Additionally, equity or debt financings may have a dilutive effect on the holdings of the Company's existing stockholders. If the Company cannot raise capital when needed, on favorable terms or at all, the Company will not be able to continue development of its product candidates, will need to reevaluate its planned operations and may need to delay, scale back or eliminate some or all of its development programs, reduce expenses, file for bankruptcy, reorganize, merge with another entity, or cease operations. If the Company becomes unable to continue as a going concern, the Company may have to liquidate its assets, and might realize significantly less than the values at which they are carried on its consolidated financial statements, and stockholders may lose all or part of their investment in the Company's common stock. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </span></div>The effect of the COVID-19 pandemic and efforts to reduce the spread of COVID-19 remain a rapidly evolving and uncertain risk to the Company's business, operating results, financial condition and stock price. In large part, the extent to which the pandemic affects the Company will depend on future developments that are beyond its knowledge or control, including, but not limited to, the duration and severity of the pandemic, governmental and individual organization actions and policies implemented to reduce transmission of the disease or facilitate development of or access to therapies to treat or vaccinations to protect against the disease, governmental actions and policies to assist economic recovery, and the speed with which and degree to which normal economic and operating conditions resume. Infectious disease experts have cautioned that the U.S. may experience a substantial surge in cases and hospitalizations during the cooler months, which may lead the federal government and/or state governments to impose or re-impose stay-at-home orders and shutdowns of non-essential businesses in efforts to reduce the spread of the disease, such as those announced by the United Kingdom, Germany, France and other European countries in October 2020. The pandemic may increase the anticipated aggregate costs for the development of the Company's product candidates and may adversely impact the anticipated timelines for the development of the Company's product candidates by, among other things,&#160;causing disruptions in the supply chain for clinical supplies, delays in the commencement of clinical trials, delays in the timing and pace of subject enrollment in any ongoing clinical trials and lower than anticipated subject enrollment and completion rates, delays in the review and approval of the Company's regulatory submissions by regulatory agencies with respect to the Company's product candidates, and other unforeseen disruptions. The economic impact of the pandemic and the uncertainty and volatility in the capital markets it has caused, and may continue to cause, may negatively impact investor sentiment and the availability and cost of capital, and may adversely impact the Company's ability to raise capital when needed or on terms favorable to the Company and its stockholders to fund its development programs and operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701178233704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are described in Note 1 to the consolidated financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed with the Securities and Exchange Commission, or SEC on March 27, 2020. Since the date of those consolidated financial statements, there have been no material changes to the Company&#8217;s significant accounting policies, except for the accounting policies related to revenue recognition as described below.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X.&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#8217;s opinion, the accompanying interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying interim consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use, or ROU, lease assets, current portion of lease obligations, and long-term lease obligations on the Company's consolidated balance sheets.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU lease assets represent the Company's right to use an underlying asset for the lease term and lease obligations represent the Company's obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. If the lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset also includes any lease payments made and excludes lease incentives. The Company's lease terms may include options to extend or terminate the lease and the related payments are only included in the lease liability when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. (See Note 7, Leased Properties.)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#191c1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following tables present the classification within the fair value hierarchy of financial assets and liabilities that are remeasured on a recurring basis as of September&#160;30, 2020 and December&#160;31, 2019. There were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 2) as of September&#160;30, 2020.</span></div><div style="margin-bottom:5pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:477.75pt"><tr><td style="width:1.0pt"/><td style="width:208.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:7.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:7.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:7.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,389,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,389,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,780,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,780,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other non-current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:26pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue is accordance with Accounting Standards Codification, or ASC, Topic 606,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a contract with multiple performance obligations, the Company develops estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license&#160;to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from non-refundable, upfront fees allocated to the&#160;license when the&#160;license&#160;is transferred to the customer and the customer is able to use and benefit from the&#160;license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. To date, the Company has not recognized any license fee revenue resulting from any of its collaborative arrangements.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bayer License. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Company entered into a license agreement with Bayer HealthCare LLC, or Bayer, regarding the further development and commercialization of Ovaprene in the U.S. Upon execution of the agreement, the Company received a $1.0 million upfront non-refundable license fee payment from Bayer. Bayer, in its sole discretion, has the right to make the license effective by paying the Company an additional $20.0 million. The Company concluded that there was one significant performance obligation related to the $1.0 million upfront payment: a distinct license to commercialize Ovaprene effective upon the receipt of the $20.0 million fee. The $1.0 million upfront payment will be recorded as license revenue at the earlier of (1) the point in time the&#160;Company receives the $20.0 million fee, the license&#160;is transferred to Bayer and Bayer is able to use and benefit from the&#160;license and (2) the termination of the agreement. As of September&#160;30, 2020, neither of the foregoing had occurred. The $1.0 million payment is recorded as long term deferred revenue in the Company's consolidated balance sheet at September&#160;30, 2020.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will also be entitled to receive (a) milestone payments totaling up to $310.0 million related to the commercial sales of Ovaprene, if all such milestones are achieved, and (b) tiered royalties starting in the low double digits based on annual net sales of Ovaprene during a calendar year, subject to customary royalty reductions and offsets, and (c) a percentage of sublicense revenue.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential future payments for variable consideration, such as commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur. (See Note 3, License and Collaboration Agreements.)</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701179581160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text">LICENSE AND COLLABORATION AGREEMENTS<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Out-License Agreements</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Bayer HealthCare License Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 10, 2020, the Company entered into a license agreement with Bayer, regarding the further development and commercialization of Ovaprene in the U.S. Under the agreement, the Company received a $1.0 million upfront non-refundable license fee payment from Bayer. If Bayer pays an additional $20.0 million to the Company after Bayer receives and reviews the results of the pivotal clinical trial of Ovaprene, which payment Bayer may elect to make in its sole discretion, the license grant to Bayer to develop and commercialize Ovaprene for human contraception in the U.S. becomes effective. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone &amp; Royalty Payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company will be entitled to receive (a) a milestone payment in the low double-digit millions upon the first commercial sale of Ovaprene in the U.S. and escalating milestone payments based on annual net sales of Ovaprene during a calendar year, totaling up to $310.0 million if all such milestones, including the first commercial sale, are achieved, (b) tiered royalties starting in the low double digits based on annual net sales of Ovaprene during a calendar year, subject to customary royalty reductions and offsets, and (c) a percentage of sublicense revenue.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Efforts.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company is responsible for the pivotal trial for Ovaprene and for its development and regulatory activities and has product supply obligations. Bayer is supporting the Company in development and regulatory activities by providing up to two full-time equivalents with expertise in clinical, regulatory, preclinical, commercial, CMC and product supply matters in an advisory capacity. After payment of the $20.0 million fee, Bayer will be responsible for the commercialization of Ovaprene for human contraception in the U.S.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial term of the agreement, which is subject to automatic renewal terms, continues until the later of (a) the expiration of any valid claim covering the manufacture, use, sale or import of Ovaprene in the U.S.; or (b) 15 years from the first commercial sale of Ovaprene in the U.S. In addition to customary termination rights for both parties, Bayer may terminate the agreement at any time on 90 days' notice and the agreement will automatically terminate if the Company does not receive the $20.0 million fee if and when due.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">In-License Agreements</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Hammock/MilanaPharm Assignment and License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the Company entered into (a) an Assignment Agreement with Hammock Pharmaceuticals, Inc., or the Assignment Agreement, and (b) a First Amendment to License Agreement with TriLogic Pharma, LLC and MilanaPharm LLC, or the License Amendment. Both agreements relate to the exclusive license agreement among Hammock, TriLogic and MilanaPharm dated as of January 9, 2017, or the MilanaPharm License Agreement. Under the Assignment Agreement and the MilanaPharm License Agreement, as amended by the License Amendment, the Company acquired an exclusive, worldwide license to develop and commercialize products for the diagnosis, treatment and prevention of human diseases or conditions in or through any intravaginal or urological applications. The licensed intellectual property relates to the hydrogel drug delivery platform of TriLogic and MilanaPharm known as TRI-726. In DARE-BV1, this proprietary technology is formulated with clindamycin, an antibiotic with FDA approval to treat certain bacterial infections, including bacterial vaginosis. In December 2019, the Company entered into amendments to each of the License Amendment and Assignment Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of other terms of the License Amendment, as amended:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company paid MilanaPharm: (1) $25,000 in connection with the execution of the License Amendment; (2) $100,000 on December 5, 2019; and (3) $110,000 on January 31, 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will pay to MilanaPharm (1) up to $300,000 in the aggregate upon achievement of certain clinical and regulatory development milestones, $50,000 of which was paid during the second quarter of 2020, and (2) up to $1.75 million in the aggregate upon achieving certain commercial sales milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Sublicense Income.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will pay MilanaPharm a low double-digit percentage of all income received by the Company or its affiliates in connection with any sublicense granted to a third party for use outside of the United States, subject to certain exclusions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> After the commercial launch of licensed products and processes and during the royalty term, the Company will pay MilanaPharm high single-digit to low double-digit royalties based on annual worldwide net sales of licensed products and processes in accordance with the agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Efforts. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company must use commercially reasonable efforts and resources to (1) develop and commercialize at least one licensed product or process in the United States and at least one licensed product or process in Canada, the United Kingdom, France, Germany, Italy or Spain, and (2) continue to commercialize that product or process following the first commercial sale of a licensed product or process in the applicable jurisdiction.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unless earlier terminated, the license term continues until (1) on a licensed product-by-product (or process-by-process basis) and country-by-country basis, the date of expiration of the royalty term with respect to such licensed product (or process) in such country, and (2) the expiration of all applicable royalty terms under the MilanaPharm License Agreement with respect to all licensed products and processes in all countries. Upon expiration of the term with respect to any licensed product or process in a country (but not upon earlier termination of the MilanaPharm License Agreement), the licenses granted to the Company under the MilanaPharm License Agreement will convert automatically to an exclusive, fully paid-up, royalty-free, perpetual, non-terminable and irrevocable right and license under the licensed intellectual property.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to customary termination rights in favor of all parties, MilanaPharm may terminate the license solely with respect to a licensed product or process in a country if, after having launched such product or process in such country, the Company or its affiliates or sublicensees, (1) discontinue the sale of such product or process in such country and MilanaPharm notifies the Company of such termination within 60 days of having first been notified by the Company of such discontinuation, or (2) (A) discontinue all commercially reasonable marketing efforts to sell, and discontinue all sales of, such product or process in such country for nine months or more, (B) fail to resume such commercially reasonable marketing efforts within 120 days of having been notified of such failure by MilanaPharm, (C) fail to reasonably demonstrate a strategic justification for the discontinuation and failure to resume to MilanaPharm, and (D) MilanaPharm gives 90 days&#8217; notice to the Company.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of other terms of the Assignment Agreement, as amended:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assignment; Technology Transfer</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Hammock assigned and transferred to the Company all of its right, title and interest in and to the MilanaPharm License Agreement and agreed to cooperate to transfer to the Company all of the data, materials and the licensed technology in its possession pursuant to a technology transfer plan to be agreed upon by the parties, with a goal for the Company to independently practice the licensed intellectual property as soon as commercially practical in order to develop and commercialize the licensed products and processes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fees</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company paid Hammock: (1) $250,000 in connection with the execution of the Assignment Agreement; (2) $125,000 on December 5, 2019; and (3) $137,500 on January 31, 2020. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company will pay Hammock up to $1.1 million in the aggregate upon achievement of certain clinical and regulatory development milestones, $100,000 of which was paid during the third quarter of 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Assignment Agreement will terminate upon the later of (1) completion of the parties' technology transfer plan, and (2) payment to Hammock of the last of the milestone payments.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ADVA-Tec License Agreement </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company entered into a license agreement with ADVA-Tec, Inc., under which the Company was granted the exclusive right to develop and commercialize Ovaprene for human contraceptive use worldwide. The Company must use commercially reasonable efforts to develop and commercialize Ovaprene.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will pay ADVA-Tec: (1) up to $14.6 million in the aggregate based on the achievement of specified development and regulatory milestones; and (2) up to $20.0 million in the aggregate based on the achievement of certain worldwide net sales milestones.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  After the commercial launch of Ovaprene, the Company will pay ADVA-Tec royalties based on aggregate annual net sales of Ovaprene in specified regions, at a royalty rate that will vary between 1% and 10% and will increase based on various net sales thresholds. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Unless earlier terminated, the license continues on a country-by-country basis until the later of the life of the licensed patents or final commercial sale of Ovaprene. In addition to customary termination rights for both parties: (A) the Company may terminate the agreement with or without cause in whole or on a country-by-country basis upon 60 days prior written notice; and (B) ADVA-Tec may terminate the agreement if (1) the Company develops or commercializes any non-hormonal ring-based vaginal contraceptive device competitive to Ovaprene or (2) if the Company fails to meet agreed upon efforts to commercialize Ovaprene.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">SST License and Collaboration Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into a license and collaboration agreement with Strategic Science &amp;&#160;Technologies-D,&#160;LLC and Strategic Science &amp; Technologies, LLC, referred to collectively as SST, under which the Company received an exclusive, royalty-bearing, sublicensable license to develop and commercialize the Licensed Product (as defined below), in all countries and geographic territories of the world, for all indications for women related to female sexual dysfunction and/or female reproductive health, or the Field of Use. The Licensed Product, is defined as SST&#8217;s proprietary topical formulation of sildenafil cream as it existed as of the effective date of the agreement, or any other topically applied pharmaceutical product containing sildenafil or a salt thereof as a pharmaceutically active ingredient, alone or with other active ingredients, but specifically excluding any product containing ibuprofen or any salt derivative of ibuprofen.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of other terms of this license and collaboration agreement:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invention Ownership.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company retains rights to inventions made by its employees, SST retains rights to inventions made by its employees, and each party will own a 50% undivided interest in all joint inventions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Development Committee.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The parties will collaborate through a joint development committee that will determine the strategic objectives for, and generally oversee, the development efforts of both parties under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company must use commercially reasonable efforts to develop the Licensed Products in the Field of Use in accordance with a development plan in the agreement, and to commercialize the Licensed Products in the Field of Use. The Company is responsible for all reasonable internal and external costs and expenses incurred by SST in its performance of the development activities it must perform under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SST will be eligible to receive tiered royalties based on percentages of annual net sales of Licensed Products in the single digits to the mid double digits, subject to customary royalty reductions and offsets, and a percentage of sublicense revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SST will be eligible to receive payments (1) ranging from $0.5 million to $18.0 million in the aggregate upon achieving certain clinical and regulatory milestones in the U.S. and worldwide, and (2) between $10.0 million to $100.0 million in the aggregate upon achieving certain commercial sales milestones. If the Company enters into strategic development or distribution partnerships related to the Licensed Products, additional milestone payments would be due to SST.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Catalent JNP License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018,&#160;the Company entered into an exclusive license agreement with Catalent JNP, Inc. (formerly known as Juniper Pharmaceuticals, Inc., and which the Company refers to as Catalent), under which Catalent granted the Company (a) an exclusive, royalty-bearing worldwide license under certain patent rights, either owned by or exclusively licensed to Catalent, to make, have made, use, have used, sell, have sold, import and have imported products and processes; and (b) a non-exclusive, royalty-bearing worldwide license to use certain technological information owned by Catalent to make, have made, use, have used, sell, have sold, import and have imported products and processes. The Company is entitled to sublicense the rights granted to it under this agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Upfront Fee.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company paid a $250,000 non-creditable upfront license fee to Catalent in connection with the execution of the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annual Maintenance Fee.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will pay an annual license maintenance fee to Catalent on each anniversary of the date of the agreement, the amount of which was $50,000 for each of the first two years and will be $100,000 thereafter, and which will be creditable against royalties and other payments due to Catalent in the same calendar year but may not be carried forward to any other year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company must make potential future development and sales milestone payments of (1) up to $13.5 million in the aggregate upon achieving certain clinical and regulatory milestones, and (2) up to $30.3 million in the aggregate upon achieving certain commercial sales milestones for each product or process covered by the licenses granted under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the royalty term, the Company will pay Catalent mid-single-digit to low double-digit royalties based on worldwide net sales of products and processes covered by the licenses granted under the agreement. In lieu of such royalty payments, the Company will pay Catalent a low double-digit percentage of all sublicense income the Company receives for the sublicense of rights under the agreement to a third party. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adare Development and Option Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, the Company entered into an exclusive development and option agreement with Adare Pharmaceuticals (formerly known as Orbis Biosciences, and which the Company refers to as Adare), for the development of long-acting injectable etonogestrel contraceptive with 6- and 12-month durations (ORB-204 and ORB-214, respectively). Under this agreement, the Company paid Adare $300,000 to conduct the first stage of development work as follows: $150,000 upon signing the agreement; $75,000 at the 50% completion point, not later than 6 months following the date the agreement was signed (which the Company paid in September 2018); and $75,000 upon delivery by Adare of the 6-month batch, not later than 11 months following the date the agreement was signed (which the Company paid in January 2019). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon Adare successfully completing the first stage of development work and achieving the predetermined target milestones for that stage, the Company will have 90 days to instruct Adare whether to commence the second stage of development work. Should the Company execute its option to proceed with the second stage, it will have to provide additional funding to Adare for such activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-clinical studies for the 6- and 12-month formulations have been completed, including establishing pharmacokinetics and pharmacodynamics profiles. The collaboration with Adare will continue to advance the program through formulation optimization with the goal of achieving sustained release over the target time period.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement provides the Company with an option to enter into a license agreement for ORB-204 and ORB-214 should development efforts be successful.</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Acquired Products</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Microchips Acquisition</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As further discussed in Note 4. Acquisition below, in November 2019, the Company completed its acquisition of Microchips (as defined below). The Company acquired Microchips to secure the rights to develop an implantable, user-controlled, long-acting reversible contraception method, now known as DARE-LARC1. The Company agreed to use commercially reasonable efforts to achieve specified development and regulatory objectives relating to the implantable contraceptive product in development by Microchips.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issued an aggregate of 2,999,990 shares of its common stock to the holders of shares of Microchips' capital stock outstanding immediately prior to the effective time of the merger. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also agreed to pay the following contingent consideration to the former Microchips stockholders: (a) up to $46.5 million contingent upon the achievement of specified funding, product development and regulatory milestones; (b) up to $55.0 million contingent upon the achievement of specified amounts of aggregate net sales of products incorporating the intellectual property acquired by the Company in the merger; (c) tiered royalty payments ranging from low single-digit to low double-digit percentages of annual net sales of such products, subject to customary provisions permitting royalty reductions and offset; and (d)&#160;a percentage of sublicense revenue related to such products. The Company agreed to use commercially reasonable efforts to achieve specified development and regulatory objectives relating to DARE-LARC1. The Company recorded $1.0 million in contingent consideration associated with milestone payments it expects to become payable in the first half of 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pear Tree Acquisition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company completed its acquisition of Pear Tree Pharmaceuticals, Inc., or Pear Tree. The Company acquired Pear Tree to secure the rights to develop a proprietary vaginal formulation of tamoxifen, now known as DARE-VVA1, as a potential treatment for vulvar and vaginal atrophy.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company must make contingent payments to the Pear Tree former stockholders and their representatives, or the Holders, that are based on achieving certain clinical, regulatory and commercial milestones, which may be paid, in the Company&#8217;s sole discretion, in cash or shares of the Company&#8217;s common stock.</span></div>Royalty Payments. The Holders will be eligible to receive, subject to certain offsets, tiered royalties, including customary provisions permitting royalty reductions and offset, based on percentages of annual net sales of certain products subject to license agreements the Company assumed and a percentage of sublicense revenue.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701180112856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisition</a></td>
<td class="text">ACQUISITION<div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company acquired Microchips Biotech, Inc., or Microchips, via a merger transaction in which a wholly owned subsidiary of the Company, formed for purposes of this transaction, merged with and into Microchips</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Microchips survived as the Company&#8217;s wholly owned subsidiary. Microchips is developing a proprietary, implantable drug delivery system designed to store and precisely deliver numerous therapeutic doses over months and years on a schedule determined by the user and controlled via wireless remote. Microchips&#8217; lead product candidate is a pre-clinical stage contraceptive application of that technology that utilizes levonorgestrel, now known as DARE-LARC1.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issued an aggregate of 2,999,990 shares of its common stock to the holders of shares of Microchips' capital stock outstanding immediately prior to the effective time of the merger. The transaction was valued at $2.4 million, based on the fair value of the 2,999,990 shares issued of $0.79 per share, which was the closing price per share of the Company's common stock on the date of closing. The shares were issued in exchange for Microchips&#8217; cash and cash equivalents of $6.1 million, less net liabilities of $3.5 million and transaction costs of $202,000, which was allocated based on the relative fair value of the assets acquired and liabilities assumed.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also agreed to pay certain contingent consideration payments, tiered royalty payments and a percentage of sublicense revenue as discussed in Note 3, Acquired Products&#8212;Microchips Acquisition, above.</span></div>The Company determined the transaction was accounted for as an asset acquisition as there were no outputs or substantive processes in existence as of the acquisition date. Transaction costs of approximately $202,000 associated with the merger were included in the Company&#8217;s research and development expense in the fourth quarter of 2019.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701180019544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The 2015 Employee, Director and Consultant Equity Incentive Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the business combination transaction in July 2017 between the Company and Dar&#233; Bioscience Operations, Inc., a privately held Delaware corporation, or Private Dar&#233;, the Company assumed the Private Dar&#233; 2015 Employee, Director and Consultant Equity Incentive Plan, or the 2015 Private Dar&#233; Plan and each then outstanding award granted thereunder, which consisted of options and restricted stock. Based on the exchange ratio for the business combination transaction and after giving effect to the reverse stock split effected in connection with the closing of that transaction, the outstanding options and restricted stock awards granted under the 2015 Private Dar&#233; Plan were replaced with options to purchase 10,149 shares of the Company&#8217;s common stock with a correspondingly adjusted exercise price and 223,295 shares of the Company&#8217;s common stock. All of the options that were assumed were exercised as of September&#160;30, 2020. No awards may be granted under the 2015 Private Dar&#233; Plan following the closing of the business combination transaction.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2014 Employee Stock Purchase Plan, or the ESPP, became effective in April 2014, but no offering period has been initiated thereunder since January 2017 and there was no stock-based compensation related to the ESPP for the nine months ended September&#160;30, 2020 or September&#160;30, 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated 2014 Stock Incentive Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains the Amended and Restated 2014 Plan, or the Amended 2014 Plan, which provides for the grant of options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards to employees, officers and directors, and consultants and advisors. There were 2,046,885 shares of common stock authorized for issuance under the Amended 2014 Plan when it was approved by the Company's stockholders in July 2018. The number of authorized shares increases annually on the first day of each fiscal year until, and including, the fiscal year ending December 31, 2024 by the least of (i) 2,000,000, (ii) 4% of the number of outstanding shares of common stock on such date, or (iii) an amount determined by the Company&#8217;s board of directors. On January 1, 2020, the number of authorized shares increased by 787,336 to 1,411,481, which increase represented 4% of the number of outstanding shares of common stock on such date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Stock Option Activity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes stock option activity under the Amended 2014 Plan, and related information for the nine months ended September&#160;30, 2020. The exercise price of all options granted during the nine months ended September&#160;30, 2020 was equal to the market value of the Company&#8217;s common stock on the date of grant. As of September&#160;30, 2020, unamortized stock-based compensation expense of $1,493,686 will be amortized over a weighted average period of 2.37 years. At September&#160;30, 2020, 507,516 shares of common stock were reserved for future awards granted under the Amended 2014 Plan.</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:376.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,889,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,783,591&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038,659&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense related to stock options granted to employees and directors recognized in the consolidated statement of operations is as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:238.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,546&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,882&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,393&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,582&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,712&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in the Black-Scholes option-pricing model for stock options granted to employees and to directors in respect of board services during the three and nine months ended September&#160;30, 2020 are as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:373.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/></tr><tr style="height:36pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of options granted</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.10</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.00</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701178206760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATM Sales Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company entered into a common stock sales agreement under which the Company may sell shares of its common stock from time to time in &#8220;at-the-market&#8221; equity offerings (as defined in Rule 415 promulgated under the Securities Act of 1933, as amended). The Company will pay a commission of up to 3% of the gross proceeds of any common stock sold under this agreement plus certain legal expenses. The common stock sales agreement was amended in August 2018 to refer to the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-227019) that was filed to replace the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-206396) that expired on August 28, 2018.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2020, the Company sold 1,952,512 shares under the common stock sales agreement for gross proceeds of approximately $2.4 million and incurred offering expenses of approximately $82,000. During the nine months ended September&#160;30, 2020, the Company sold 7,916,092 shares under the common stock sales agreement for gross proceeds of approximately $10.8 million and incurred offering expenses of approximately $420,000. The Company did not sell any shares under this agreement during the three or nine months ended September&#160;30, 2019.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">April 2019 Underwritten Public Offering</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, the Company closed an underwritten public offering of 4,575,000 shares of its common stock at a public offering price of $1.10 per share. The Company granted the underwriters a 30-day over-allotment option to purchase up to an additional 686,250 shares which was exercised in full on April 12, 2019. Including the over-allotment shares, the Company issued a total of 5,261,250 shares in the underwritten public offering and received gross proceeds of approximately $5.8 million and net proceeds of approximately $5.2 million after deducting underwriting discounts and offering expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Line</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 22, 2020, the Company entered into a purchase agreement, or the Purchase Agreement, and a registration rights agreement with Lincoln Park Capital Fund, LLC, or Lincoln Park. Under the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to&#160;$15.0 million&#160;of the Company&#8217;s common stock. Such sales of common stock by the Company may occur from time to time, at the Company&#8217;s sole discretion, subject to certain limitations, until May 19, 2023. On April 22, 2020, in accordance with the Purchase Agreement, the Company issued 285,714 shares of its common stock, or the Commitment Shares, to Lincoln Park in consideration for its commitment to purchase shares under the Purchase Agreement. The Company filed a registration statement on Form S-1 (File No. 333-237954) to register the resale by Lincoln Park of up to 7.5 million shares of the Company's common stock issued or issuable to Lincoln Park under the Purchase Agreement, including the Commitment Shares, and such registration statement was declared effective by the SEC on May 12, 2020.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred legal, accounting, and other fees related to the Purchase Agreement of approximately $374,000. These costs are amortized and expensed as shares are sold under the Purchase Agreement and as of September&#160;30, 2020 there was approximately $269,000 of unamortized costs. During the three months ended September&#160;30, 2020, the Company sold, and Lincoln Park purchased, 3.0 million shares under the Purchase Agreement for gross proceeds of approximately $3.3 million and incurred offering expenses of approximately $83,000. During the nine months ended September&#160;30, 2020, the Company sold, and Lincoln Park purchased, 3,882,160 shares under the Purchase Agreement for gross proceeds of approximately $4.2 million and incurred offering expenses of approximately $105,000.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Purchase Agreement, on any business day until May 19, 2023, the Company may direct Lincoln Park to purchase up to 200,000 shares of common stock, each, a Regular Purchase. The Company may increase the share amount it directs Lincoln Park to purchase under a Regular Purchase to up to 250,000 shares or up to 300,000 shares if the closing sale price of the Company's common stock is not below $1.50 or $3.00, respectively, on the business day on which the Company initiates the purchase, subject to adjustment for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction as provided in the Purchase Agreement. However, Lincoln Park&#8217;s maximum commitment in any single Regular Purchase may not exceed $1.0&#160;million. The purchase price per share for each Regular Purchase will be the lower of (i) the lowest sale price of the Company's common stock on the business day on which the Company initiates the purchase and (ii) the average of the three lowest closing sale prices of the Company's common stock during the 10-business day period immediately preceding the business day on which the Company initiates the purchase. In addition to Regular Purchases, the Company may also direct Lincoln Park to purchase other amounts of common stock as accelerated purchases and as additional accelerated purchases, subject to limits specified in the Purchase Agreement, at a purchase price per share calculated as specified in the Purchase Agreement, but in no case lower than the minimum price per share the Company stipulates in its notice to Lincoln Park initiating these purchases.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under applicable Nasdaq rules, the Company may not issue or sell to Lincoln Park under the Purchase Agreement more than 4,941,089 shares of its common stock, or the Exchange Cap, unless (i) the Company obtains stockholder approval to issue shares in excess of the Exchange Cap or (ii) the average price of all applicable sales of the Company's common stock to Lincoln Park under the Purchase Agreement equals or exceeds $1.0117 (which represents the closing sale price per share of the Company's common stock on the day before the Company entered into the Purchase Agreement, plus an incremental amount). In addition, the Company may not sell shares to Lincoln Park under the Purchase Agreement if such sale would result in Lincoln Park beneficially owning more than 9.99% of the Company's then outstanding shares of common stock. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company closed an underwritten public offering in connection with which the Company issued to the investors in that offering warrants that initially had an exercise price of $3.00 per share and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are exercisable through February 2023.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrants include a price-based anti-dilution provision, which provides that, subject to certain limited exceptions, the exercise price of the warrants will be reduced each time the Company issues or sells (or is deemed to issue or sell) securities for a net consideration per share less than the exercise price of those warrants in effect immediately prior to such issuance or sale. In addition, subject to certain exceptions, if the Company issues, sells or enters into any agreement to issue or sell securities at a price which varies or may vary with the market price of the shares of the Company&#8217;s common stock, the warrant holders have the right to substitute such variable price for the exercise price of the warrant then in effect. These warrants are exercisable only for cash, unless a registration statement covering the shares issued upon exercise of the warrants is not effective, in which case the warrants may be exercised on a cashless basis. A registration statement covering the shares issued upon exercise of the warrants is currently effective. The Company estimated the fair value of the warrants as of February 15, 2018 to be approximately $3.0 million which has been recorded in equity as of the grant date. The Company early adopted ASU 2017-11 as of January 1, 2018 and recorded the fair value of the warrants as equity. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019 and July 2020, in accordance with the price-based anti-dilution provision discussed above, the exercise price of these warrants was automatically reduced to $0.98 per share and to $0.96 per share, respectively, and as a result of the triggering of the anti-dilution provision, $0.8 million and $6,863, respectively, was recorded to additional paid-in capital.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2020, warrants to purchase an aggregate of 126,000 shares of common stock were exercised for gross proceeds of approximately $121,000. During the nine months ended September&#160;30, 2020, warrants to purchase an aggregate of 1,825,000 shares of common stock were exercised for gross proceeds of approximately $1.8 million. No warrants were exercised during the three or nine months ended September&#160;30, 2019. As of September&#160;30, 2020, the Company had the following warrants outstanding:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:169.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:19.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:18.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:118.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:18.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:157.00pt"/><td style="width:1.0pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying<br/>Outstanding Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,906</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.40</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021-12-01</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,737</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.40</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021-12-06</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,500</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026-04-04</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,895,500</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023-02-15</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908,643</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701179548536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leased Properties<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leased Properties</a></td>
<td class="text">LEASED PROPERTIES<div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease for its corporate headquarters (3,169 square feet of office space) commenced on July 1, 2018 and terminates on July 31, 2021. The Company has the option to extend the term of the lease for one year. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Microchips, which the Company acquired in November 2019, leases general office space in Lexington, Massachusetts and warehouse space in Billerica, Massachusetts. The Lexington lease commenced on July 1, 2013 and terminates on September 30, 2021. The Billerica lease commenced on October 1, 2016 and terminates on March 31, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under</span><span style="color:#191c1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the terms of each lease, the lessee pays base annual rent (subject to an annual fixed percentage increase), plus property taxes, and other normal and necessary expenses, such as utilities, repairs, and maintenance. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. The leases do not require material variable lease payments, residual value guarantees or restrictive covenants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The leases do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment. The Company uses an incremental borrowing rate of 7% for operating leases that commenced prior to January 2019. The depreciable lives of operating leases and leasehold improvements are limited by the expected lease term.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, the Company reported operating lease ROU assets of approximately $306,000 in other non-current assets, and $410,000 and $83,000, respectively, in current and non-current other liabilities on the consolidated balance sheet.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease costs were approximately&#160;$76,000 and $27,000 for the three months ended&#160;September&#160;30, 2020 and September&#160;30, 2019, respectively, and $228,000 and $81,000 for the nine months ended&#160;September&#160;30, 2020 and September&#160;30, 2019, respectively. Operating lease costs consist of monthly lease payments expense, common area maintenance and other repair and maintenance costs and are included in general and administrative expenses in the consolidated statement of operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities were approximately $111,000 and $28,000&#160;for the three months ended&#160;September&#160;30, 2020 and September&#160;30, 2019, respectively, and $349,000 and $81,000 for the nine months ended&#160;September&#160;30, 2020 and September&#160;30, 2019, respectively. These amounts are included in operating activities in the consolidated statements of cash flows. Further, at September&#160;30, 2020, operating leases had a weighted average remaining lease term of 1.14 years. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, future minimum payments under the Company's operating leases are approximately:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:445.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Difference between future minimum lease payments and discounted operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701180097960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Microchips, the Company agreed to pay contingent consideration based upon the achievement of specified funding, product development and regulatory milestones. The Company recorded $1.0 million in contingent consideration liability associated with milestone payments expected to become payable in the first half of 2021 in its consolidated balance sheet at September&#160;30, 2020.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Payable</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, due to the economic uncertainty resulting from the impact of the COVID-19 pandemic on the Company's operations and to support its ongoing operations and retain all employees, the Company applied for a loan under the Paycheck Protection Program, or the PPP, of the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, administered by the U.S. Small Business Administration, or the SBA. The Company received a loan of approximately $367,000. The loan matures in April 2022, bears interest at a rate of 1.00% per annum, is payable in equal monthly payments commencing in November 2020 through maturity and may be prepaid at any time prior to maturity with no prepayment penalties. Under the terms of the PPP, the loan proceeds could be used for "qualifying expenses" and, subject to specified limitations in the CARES Act and under the terms of the PPP, certain amounts of the loan, including accrued interest, may be forgiven if used for qualifying expenses. Qualifying expenses include payroll costs, costs used to continue group health care benefits, mortgage interest payments, rent payments, utility payments, and interest payments on other debt obligations incurred before February 15, 2020. In September 2020, the Company submitted its forgiveness application. The Company used the entire amount of the loan for payroll and rent costs, which the Company believes are expenses that constitute qualifying expenses, and the Company requested that the entire amount of the loan, including accrued interest, be forgiven. There can be no assurance that the loan will be forgiven, in whole or in part. Under current SBA guidance, it may take up to 90 days from the date the Company's loan forgiveness application is submitted to the SBA by the Company's lender for the SBA to make a determination with respect to the Company's loan forgiveness application . The Company recorded a note payable plus accrued interest for the loan in the amount of approximately $369,000 in its consolidated balance sheet at September&#160;30, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701179548536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Award<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_GrantAwardTextBlock', window );">Grant Award</a></td>
<td class="text">GRANT AWARD<div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIH Grant Funding</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received notices of awards and grant funding from the National Institutes of Health, or the NIH to support the development of Ovaprene and DARE-FRT1. The NIH issues notices of awards to the Company for a specified amount, and the Company must incur and track expenses eligible for reimbursement under the award and submit a detailed accounting of such expenses to receive payment. If the Company receives payments under the award, the amounts of such payments are recognized in the statement of operations as a reduction to research and development activities as the related costs are incurred to meet those obligations over the period. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ovaprene</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2018, the Company has received approximately $1.9 million of grant funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, a division of the NIH, for clinical development efforts supporting Ovaprene. The most recent and final notice of award the Company received was for approximately $731,000 in April 2020, substantially all of which has been funded to date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded credits to research and development expense for costs related to the NIH award of approximately $124,000 and $302,000 for the three months ended September&#160;30, 2020 and September&#160;30, 2019, respectively, and $583,000 and $920,000 for the nine months ended&#160;September&#160;30, 2020 and September&#160;30, 2019, respectively. At September&#160;30, 2020, the Company recorded a receivable of approximately $69,000 for expenses incurred through such date that it believes are eligible for reimbursement under the final notice of award received in April 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DARE-FRT1</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company received a notice of award of a grant from the NIH to support the development of DARE-FRT1. The award in the amount of $300,000 was for what is referred to as the "Phase I" segment of the project outlined in the Company's grant application, which is to occur during the period of August 2020 through July 2021. Additional potential funding of up to approximately $2.0 million for the "Phase II" segment of the project outlined in the grant application is contingent upon satisfying specified requirements, including, assessment of the results of the Phase I segment, determination that the Phase I goals were achieved, and availability of funds. There is no guarantee the Company will receive any Phase II award. The Company recorded credits to research and development expense for costs related to the NIH award of approximately $3,000 during the three months ended September&#160;30, 2020. At September&#160;30, 2020, the Company recorded a receivable of approximately $3,000 for expenses incurred through such date that it believes are eligible for reimbursement under the grant.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's wholly-owned subsidiary, Microchips, has a grant agreement with the Bill &amp; Melinda Gates Foundation, or the Foundation, relating to the development of the pre-clinical stage contraceptive candidate, DARE-LARC1. Expenses eligible for grant funding must be incurred, tracked and reported to the Foundation. Microchips received grant funding payments of approximately $2.9 million in July 2019, $1.6 million in June 2020 and $899,000 in September 2020. At September&#160;30, 2020, grant funding payments associated with research and development expenses for DARE-LARC1 not yet incurred totaled approximately $2.2 million and are recorded as deferred grant funding liability in the Company's consolidated balance sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_GrantAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Award [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_GrantAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701180112856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">NET LOSS PER SHARE<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes basic net loss per share using the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares and potentially dilutive securities (common share equivalents) outstanding during the period. Common share equivalents outstanding, determined using the treasury stock method, are comprised of shares that may be issued under outstanding options and warrants to purchase shares of the Company&#8217;s common stock. Common share equivalents are excluded from the diluted net loss per share calculation if their effect is anti-dilutive.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive outstanding securities were excluded from diluted net loss per common share for the period indicated because of their anti-dilutive effect:</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:372.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Potentially dilutive securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,783,591&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,824,975&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908,643&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750,833&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,692,234&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,575,808&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701179548536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">SUBSEQUENT EVENTS<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Sales</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between October 1, 2020 and November&#160;11, 2020, the Company sold an aggregate of 3,987,485 shares of common stock in "at-the-market" equity offerings and received aggregate net proceeds of approximately $4.1 million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Line</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between October 1, 2020 and November&#160;11, 2020 the Company sold an aggregate of 400,000 shares of common stock to Lincoln Park under the Purchase Agreement and received aggregate net proceeds of approximately $0.4&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701179623992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X.&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#8217;s opinion, the accompanying interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying interim consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use, or ROU, lease assets, current portion of lease obligations, and long-term lease obligations on the Company's consolidated balance sheets.</span></div>ROU lease assets represent the Company's right to use an underlying asset for the lease term and lease obligations represent the Company's obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. If the lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset also includes any lease payments made and excludes lease incentives. The Company's lease terms may include options to extend or terminate the lease and the related payments are only included in the lease liability when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue is accordance with Accounting Standards Codification, or ASC, Topic 606,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a contract with multiple performance obligations, the Company develops estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license&#160;to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from non-refundable, upfront fees allocated to the&#160;license when the&#160;license&#160;is transferred to the customer and the customer is able to use and benefit from the&#160;license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. To date, the Company has not recognized any license fee revenue resulting from any of its collaborative arrangements.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701178116920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Financial Assets and Liabilities Remeasured on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#191c1f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following tables present the classification within the fair value hierarchy of financial assets and liabilities that are remeasured on a recurring basis as of September&#160;30, 2020 and December&#160;31, 2019. There were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 2) as of September&#160;30, 2020.</span></div><div style="margin-bottom:5pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:477.75pt"><tr><td style="width:1.0pt"/><td style="width:208.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:7.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:7.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:7.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,389,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,389,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,780,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,780,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other non-current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:26pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701180148552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity for Amended 2014 Plan and Related Information</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes stock option activity under the Amended 2014 Plan, and related information for the nine months ended September&#160;30, 2020. The exercise price of all options granted during the nine months ended September&#160;30, 2020 was equal to the market value of the Company&#8217;s common stock on the date of grant. As of September&#160;30, 2020, unamortized stock-based compensation expense of $1,493,686 will be amortized over a weighted average period of 2.37 years. At September&#160;30, 2020, 507,516 shares of common stock were reserved for future awards granted under the Amended 2014 Plan.</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:376.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,889,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,783,591&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038,659&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense related to stock options granted to employees and directors recognized in the consolidated statement of operations is as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:238.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,546&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,882&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,393&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,582&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,712&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors</a></td>
<td class="text"><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in the Black-Scholes option-pricing model for stock options granted to employees and to directors in respect of board services during the three and nine months ended September&#160;30, 2020 are as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:373.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/></tr><tr style="height:36pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of options granted</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.10</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.00</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701178116920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Common Stock Warrants Outstanding</a></td>
<td class="text">As of September&#160;30, 2020, the Company had the following warrants outstanding:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:169.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:19.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:18.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:118.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:18.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:157.00pt"/><td style="width:1.0pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying<br/>Outstanding Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,906</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.40</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021-12-01</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,737</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.40</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021-12-06</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,500</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026-04-04</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,895,500</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023-02-15</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908,643</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701180157464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leased Properties (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Lease Payments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, future minimum payments under the Company's operating leases are approximately:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:445.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Difference between future minimum lease payments and discounted operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701177880680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive outstanding securities were excluded from diluted net loss per common share for the period indicated because of their anti-dilutive effect:</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:372.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Potentially dilutive securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,783,591&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,824,975&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908,643&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750,833&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,692,234&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,575,808&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701258138312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of the Business - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 62,989,323<span></span>
</td>
<td class="nump">$ 44,023,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Cash flow from operations</a></td>
<td class="num">$ (16,000,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PeriodofInsufficientCashandLiquidityRequirements', window );">Period of insufficient cash and liquidity requirements</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PeriodofInsufficientCashandLiquidityRequirements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of Insufficient Cash and Liquidity Requirements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PeriodofInsufficientCashandLiquidityRequirements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701183840056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Financial Assets and Liabilities Remeasured on a Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,389,414<span></span>
</td>
<td class="nump">$ 4,780,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AssetAcquisitionContingentConsiderationCurrent', window );">Current portion of contingent consideration</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AssetAcquisitionContingentConsiderationNoncurrent', window );">Contingent consideration, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">5,389,414<span></span>
</td>
<td class="nump">4,780,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AssetAcquisitionContingentConsiderationCurrent', window );">Current portion of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AssetAcquisitionContingentConsiderationNoncurrent', window );">Contingent consideration, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AssetAcquisitionContingentConsiderationCurrent', window );">Current portion of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AssetAcquisitionContingentConsiderationNoncurrent', window );">Contingent consideration, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AssetAcquisitionContingentConsiderationCurrent', window );">Current portion of contingent consideration</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AssetAcquisitionContingentConsiderationNoncurrent', window );">Contingent consideration, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_AssetAcquisitionContingentConsiderationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Contingent Consideration, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_AssetAcquisitionContingentConsiderationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_AssetAcquisitionContingentConsiderationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Contingent Consideration, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_AssetAcquisitionContingentConsiderationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701183158104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - Bayer Healthcare License Agreement - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 10, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_UpfrontLicenseFeePaid', window );">Upfront license fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from grant for notice of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="nump">$ 310.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_MilestonePaymentsContingentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments, contingent amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_MilestonePaymentsContingentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_UpfrontLicenseFeePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront License Fee Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_UpfrontLicenseFeePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_BayerHealthcareLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_BayerHealthcareLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701167851304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Jan. 10, 2020</div></th>
<th class="th"><div>Dec. 05, 2019</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Nov. 20, 2019</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseFee', window );">License fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,333<span></span>
</td>
<td class="nump">$ 58,333<span></span>
</td>
<td class="nump">$ 408,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member', window );">Microchips Biotech, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AssetAcquisitionContingentConsiderationCurrent', window );">Current portion of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member', window );">Microchips Biotech, Inc. | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Common stock issued to microchips capital stock holders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,999,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember', window );">Upon Achievement of Specified Development and Regulatory Milestones | Microchips Biotech, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AssetAcquisitionContingentConsiderationCurrent', window );">Current portion of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ADVATecAgreementMember', window );">ADVA Tec Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PercentageOfRoyaltyRate', window );">Percentage of royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ADVATecAgreementMember', window );">ADVA Tec Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PercentageOfRoyaltyRate', window );">Percentage of royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ADVATecAgreementMember', window );">ADVA Tec Agreement | Upon Achievement of Specified Development and Regulatory Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_BayerHealthcareLicenseAgreementMember', window );">Bayer Healthcare License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_UpfrontLicenseFeePaid', window );">Upfront license fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from grant for notice of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | ADVA Tec Agreement | Upon Reaching Certain Worldwide Net Sales Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | MilanaPharm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseFee', window );">License fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseFeeToBePaidUponContingency', window );">License fee to be paid upon contingency</a></td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct', window );">License agreement termination periodic discontinued sale of product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure', window );">License agreement termination period due to performance failure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementNoticePeriodOfTermination', window );">Certain clinical and regulatory development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | Upon Achieving Certain Development Milestones | MilanaPharm | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | Upon Achieving Certain Commercial Milestones | MilanaPharm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | Upon Achieving Certain Commercial Milestones | MilanaPharm | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_AssignmentAgreementMember', window );">Assignment Agreement | Hammock Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseFee', window );">License fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseFeeToBePaidUponContingency', window );">License fee to be paid upon contingency</a></td>
<td class="nump">$ 137,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_AssignmentAgreementMember', window );">Assignment Agreement | Upon Achieving Certain Clinical and Regulatory Development Milestones | Hammock Pharmaceuticals, Inc | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePayments', window );">Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement', window );">Percentage of rights to inventions by employees under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement | Upon Achieving Certain Commercial Milestones | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement | Upon Achieving Certain Commercial Milestones | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member', window );">Juniper Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_UpfrontLicenseFeePaid', window );">Upfront license fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne', window );">Potential annual license maintenance fee, payments in year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter', window );">Potential annual license maintenance fee payments, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member', window );">Juniper Pharmaceuticals, Inc | Clinical and Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MaximumPotentialMilestonePayments', window );">Maximum potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member', window );">Juniper Pharmaceuticals, Inc | Sales Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MaximumPotentialMilestonePayments', window );">Maximum potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_DevelopmentAndOptionAgreementMember', window );">Development and Option Agreement | Adare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne', window );">Commencement period for stage two upon achievement of stage one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_DevelopmentAndOptionAgreementMember', window );">Development and Option Agreement | Upon Signing of Development and Option Agreement | Adare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_DevelopmentAndOptionAgreementMember', window );">Development and Option Agreement | Upon Completion of Fifty Percent Development Not Later Than Six Months | Adare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement', window );">Percentage of rights to inventions by employees under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_DevelopmentAndOptionAgreementMember', window );">Development and Option Agreement | Upon Delivery of Six Month Batch Development Not Later Than Eleven Months | Adare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_AssetAcquisitionContingentConsiderationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Contingent Consideration, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_AssetAcquisitionContingentConsiderationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commencement Period For Stage Two Upon Achievement Of Stage One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_CommencementPeriodForStageTwoUponAchievementOfStageOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseAgreementNoticePeriodOfTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Notice Period Of Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseAgreementNoticePeriodOfTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement, termination period due to performance failure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Termination Periodic Discontinued Sale Of Product</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseFeeToBePaidUponContingency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Fee, To Be Paid Upon Contingency</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseFeeToBePaidUponContingency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_MaximumPotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Potential Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_MaximumPotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_MilestonePaymentsContingentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments, contingent amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_MilestonePaymentsContingentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of rights to inventions by employees under license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PercentageOfRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PercentageOfRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Annual License Maintenance Fee, Payments In Year One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Annual License Maintenance Fee Payments, Thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ResearchAndDevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ResearchAndDevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_UpfrontLicenseFeePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront License Fee Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_UpfrontLicenseFeePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ADVATecAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ADVATecAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_BayerHealthcareLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_BayerHealthcareLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponReachingCertainWorldwideNetSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponReachingCertainWorldwideNetSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_MilanaPharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_MilanaPharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_AssignmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_AssignmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_HammockPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_HammockPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ClinicalAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ClinicalAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_SalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_SalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_DevelopmentAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_DevelopmentAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_AdarePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_AdarePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dare_UponSigningOfDevelopmentAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dare_UponSigningOfDevelopmentAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dare_UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dare_UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701183440056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisition - Narrative (Details) - Microchips Biotech, Inc. - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Nov. 20, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerLineItems', window );"><strong>Business Combination Reverse Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Business acquisition transaction value</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business combination shares issued (in usd per share)</a></td>
<td class="nump">$ 0.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, liability</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AssetAcquisitionContingentConsiderationCurrent', window );">Current portion of contingent consideration</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerLineItems', window );"><strong>Business Combination Reverse Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Business acquisition transaction value</a></td>
<td class="nump">$ 202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerLineItems', window );"><strong>Business Combination Reverse Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Common stock issued to microchips capital stock holders (in shares)</a></td>
<td class="nump">2,999,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_AssetAcquisitionContingentConsiderationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Contingent Consideration, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_AssetAcquisitionContingentConsiderationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_BusinessCombinationReverseMergerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination reverse merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_BusinessCombinationReverseMergerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination reverse merger recognized identifiable assets acquired and liabilities assumed cash and equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701184988760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>Jul. 10, 2018</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,602,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,602,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,683,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Unamortized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,493,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,493,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_WeightedAverageAmortizationPeriod', window );">Weighted Average Amortization Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 194,882<span></span>
</td>
<td class="nump">$ 135,393<span></span>
</td>
<td class="nump">$ 542,582<span></span>
</td>
<td class="nump">$ 344,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Options to purchase number of outstanding shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,046,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Annual percentage increase in outstanding number of common stock</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease', window );">Increase in number of shares authorized</a></td>
<td class="nump">787,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">1,411,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dare_TwoThousandAndFifteenStockIncentivePlanMember', window );">2015 Stock Incentive Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dare_TwoThousandAndFifteenStockIncentivePlanMember', window );">2015 Stock Incentive Plan | Restricted Stock | Private Dare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember', window );">Amended and Restated Two Thousand Fourteen Stock Incentive Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,783,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,783,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,889,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">507,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">507,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_WeightedAverageAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Amortization Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_WeightedAverageAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of increase (decrease) of non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dare_TwoThousandAndFifteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dare_TwoThousandAndFifteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=dare_PrivateDareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=dare_PrivateDareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701183499864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Details) - Amended and Restated Two Thousand Fourteen Stock Incentive Plan - Employee Stock Option<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding beginning balance (in shares) | shares</a></td>
<td class="nump">1,889,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">903,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(10,149)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled/forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding ending balance (in shares) | shares</a></td>
<td class="nump">2,783,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares) | shares</a></td>
<td class="nump">1,038,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 1.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">1.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled/forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">1.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in usd per share) | $ / shares</a></td>
<td class="nump">$ 1.48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701258064168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details) - Employee Stock Option - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 194,882<span></span>
</td>
<td class="nump">$ 135,393<span></span>
</td>
<td class="nump">$ 542,582<span></span>
</td>
<td class="nump">$ 344,712<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">60,546<span></span>
</td>
<td class="nump">27,081<span></span>
</td>
<td class="nump">166,639<span></span>
</td>
<td class="nump">78,780<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 134,336<span></span>
</td>
<td class="nump">$ 108,312<span></span>
</td>
<td class="nump">$ 375,943<span></span>
</td>
<td class="nump">$ 265,932<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701178221352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.71%<span></span>
</td>
<td class="nump">0.82%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">119.00%<span></span>
</td>
<td class="nump">120.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate', window );">Forfeiture rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options granted (in usd per share)</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by Share-based payment award fair value assumptions forfeiture rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701172920408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 01, 2020</div></th>
<th class="th"><div>Apr. 22, 2020</div></th>
<th class="th"><div>Apr. 12, 2019</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Apr. 21, 2020</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Feb. 15, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PercentageOfAggregateCommission', window );">Aggregate commission rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_SaleofStockMaximumAmountRegistered', window );">Stock registered for resale (in shares)</a></td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,277,622<span></span>
</td>
<td class="nump">$ 4,022,336<span></span>
</td>
<td class="nump">$ 5,222,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,151,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Warrant, exercise price, decrease (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount', window );">Deemed dividend from trigger of down round provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,863<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,863<span></span>
</td>
<td class="nump">$ 789,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NumberOfCommonStockWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,825,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Warrant exercises, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201711Member', window );">Accounting Standards Update 2017-11</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_EstimatedFairValueOfWarrantsRecordedInEquity', window );">Estimated fair value of warrants recorded in equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=dare_LincolnParkMember', window );">Lincoln Park</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Obligation to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dare_AtTheMarketSalesAgreementMember', window );">ATM Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,916,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate net proceeds on sales of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_OfferingExpenses', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dare_PublicStockOfferingMember', window );">Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock sale price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwritten Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,261,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod', window );">Underwriters overallotment option to purchase additional shares of common stock and warrants period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_UnderwritersOptionToPurchaseAdditionalShares', window );">Underwriters option to purchase additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">686,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants', window );">Gross proceeds from offering of common stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds received in public offering, net of underwriting discounts and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dare_PurchaseAgreementMember', window );">Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,882,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Legal, accounting and other fees related to Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 374,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_DeferredOfferingCostsUnamortizedPortion', window );">Unamortized costs related to legal, accounting, and other fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 269,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 269,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dare_PurchaseAgreementMember', window );">Purchase Agreement | Lincoln Park</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate net proceeds on sales of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_RegularRepurchaseCommonStockIssuable', window );">Regular purchase, common stock issuable (in shares) (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_RegularPurchaseCommonStockIssuableMaximumAmount', window );">Regular purchase, common stock issuable, maximum amount (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommonStockExchangeCap', window );">Exchange cap (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,941,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing price of the Company's common stock (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommonStockExchangeCapPercentage', window );">Exchange cap, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dare_PurchaseAgreementMember', window );">Purchase Agreement | Lincoln Park | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock sale price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_RegularPurchaseCommonStockIssuableIncreaseAmount', window );">Regular purchase, common stock issuable, increase amount (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dare_PurchaseAgreementMember', window );">Purchase Agreement | Lincoln Park | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock sale price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_RegularPurchaseCommonStockIssuableIncreaseAmount', window );">Regular purchase, common stock issuable, increase amount (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_CommonStockExchangeCap">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Exchange Cap</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_CommonStockExchangeCap</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_CommonStockExchangeCapPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Exchange Cap, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_CommonStockExchangeCapPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_DeferredOfferingCostsUnamortizedPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs, Unamortized Portion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_DeferredOfferingCostsUnamortizedPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_EstimatedFairValueOfWarrantsRecordedInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Fair Value Of Warrants Recorded In Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_EstimatedFairValueOfWarrantsRecordedInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Offering Of Common Stock And Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_GrossProceedsFromOfferingOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NumberOfCommonStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NumberOfCommonStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_OfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_OfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PercentageOfAggregateCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of aggregate commission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PercentageOfAggregateCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_RegularPurchaseCommonStockIssuableIncreaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regular Purchase, Common Stock Issuable, Increase Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_RegularPurchaseCommonStockIssuableIncreaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_RegularPurchaseCommonStockIssuableMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regular Purchase, Common Stock Issuable, Maximum Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_RegularPurchaseCommonStockIssuableMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_RegularRepurchaseCommonStockIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regular Repurchase, Common Stock Issuable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_RegularRepurchaseCommonStockIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_SaleofStockMaximumAmountRegistered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Maximum Amount Registered</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_SaleofStockMaximumAmountRegistered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_StockholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_StockholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_UnderwritersOptionToPurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriters option to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_UnderwritersOptionToPurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriters option to purchase additional shares of common stock period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease in equity for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=SL109261905-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12B<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL109261756-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201711Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201711Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=dare_LincolnParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=dare_LincolnParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dare_AtTheMarketSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dare_AtTheMarketSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dare_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dare_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dare_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dare_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dare_LincolnParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dare_LincolnParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701183936568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares underlying outstanding warrants (in shares)</a></td>
<td class="nump">1,908,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember', window );">Warrants Expiring on December 1, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares underlying outstanding warrants (in shares)</a></td>
<td class="nump">2,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="nump">$ 120.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ClassOfWarrantOrRightsWarrantsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Dec.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember', window );">Warrants Expiring on December 6, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares underlying outstanding warrants (in shares)</a></td>
<td class="nump">3,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="nump">$ 120.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ClassOfWarrantOrRightsWarrantsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Dec.  06,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember', window );">Warrants Expiring on April 4, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares underlying outstanding warrants (in shares)</a></td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ClassOfWarrantOrRightsWarrantsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Apr.  04,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember', window );">Warrants Expiring on February 15, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares underlying outstanding warrants (in shares)</a></td>
<td class="nump">1,895,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ClassOfWarrantOrRightsWarrantsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Feb. 15,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ClassOfWarrantOrRightsWarrantsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights warrants expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ClassOfWarrantOrRightsWarrantsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701262520328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leased Properties - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th">
<div>Jul. 01, 2018 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Square footage of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term of operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:OtherAssetsNoncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:OtherAssetsNoncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="nump">$ 409,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 409,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 410,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:OtherLiabilitiesCurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:OtherLiabilitiesCurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities long-term</a></td>
<td class="nump">$ 82,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 389,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:OtherLiabilitiesNoncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:OtherLiabilitiesNoncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Non-cash lease expenses</a></td>
<td class="nump">$ 76,000<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="nump">$ 228,000<span></span>
</td>
<td class="nump">$ 81,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for measurement of operating lease liabilities</a></td>
<td class="nump">$ 111,000<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="nump">$ 349,000<span></span>
</td>
<td class="nump">$ 81,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease weighted average remaining lease term</a></td>
<td class="text">1 year 1 month 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 1 month 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">$ 306,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 306,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701178012616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leased Properties - Future Minimum Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2020</a></td>
<td class="nump">$ 112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Difference between future minimum lease payments and discounted operating lease liabilities</a></td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 493<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701258154728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Nov. 20, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived', window );">Loan under Paycheck Protection Program</a></td>
<td class="nump">$ 367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Note annual interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NotesPayableCurrentPlusAccruedInterest', window );">Notes payable including accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member', window );">Microchips Biotech, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AssetAcquisitionContingentConsiderationCurrent', window );">Current portion of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_AssetAcquisitionContingentConsiderationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Contingent Consideration, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_AssetAcquisitionContingentConsiderationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NotesPayableCurrentPlusAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Current, Plus Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NotesPayableCurrentPlusAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701262513768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Award - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">33 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ProceedsFromAwardOfGrant', window );">Amount awarded for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 731,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants receivable</a></td>
<td class="nump">$ 69,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_DeferredGrantFundingCurrent', window );">Deferred grant funding</a></td>
<td class="nump">2,178,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,178,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,178,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,178,379<span></span>
</td>
<td class="nump">$ 2,019,674<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dare_GrantOvapreneMember', window );">Grant, Ovaprene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred', window );">Credits recorded to research and development expense for costs related to award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,000<span></span>
</td>
<td class="nump">$ 302,000<span></span>
</td>
<td class="nump">583,000<span></span>
</td>
<td class="nump">$ 920,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dare_GrantDAREFRT1Member', window );">Grant, DARE-FRT1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ProceedsFromAwardOfGrant', window );">Amount awarded for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred', window );">Credits recorded to research and development expense for costs related to award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AdditionalPotentialFundingRelatedToGrantAward', window );">Additional potential grant funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ReceivableForExpensesEligibleForReimbursement', window );">Receivable for expenses eligible for reimbursement</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant | National Institutes of Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_DeferredGrantFundingCurrent', window );">Deferred grant funding</a></td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant | Bill And Melinda Gates Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from grant for notice of award</a></td>
<td class="nump">$ 899,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_AdditionalPotentialFundingRelatedToGrantAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Potential Funding Related To Grant Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_AdditionalPotentialFundingRelatedToGrantAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ProceedsFromAwardOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Award Of Grant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ProceedsFromAwardOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ReceivableForExpensesEligibleForReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable For Expenses Eligible For Reimbursement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ReceivableForExpensesEligibleForReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of customer funding recorded as an offset to costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dare_GrantOvapreneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dare_GrantOvapreneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dare_GrantDAREFRT1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dare_GrantDAREFRT1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_NationalInstitutesOfHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_NationalInstitutesOfHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareTrustFundAxis=dare_BillAndMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareTrustFundAxis=dare_BillAndMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701184183720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (shares)</a></td>
<td class="nump">4,692,234<span></span>
</td>
<td class="nump">5,575,808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (shares)</a></td>
<td class="nump">2,783,591<span></span>
</td>
<td class="nump">1,824,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (shares)</a></td>
<td class="nump">1,908,643<span></span>
</td>
<td class="nump">3,750,833<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140701184039848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 22, 2020</div></th>
<th class="th"><div>Nov. 11, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dare_PurchaseAgreementMember', window );">Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">285,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,882,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dare_PurchaseAgreementMember', window );">Purchase Agreement | Lincoln Park</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate net proceeds on sales of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | At-the-Market Equity Offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,987,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate net proceeds on sales of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Purchase Agreement | Lincoln Park</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate net proceeds on sales of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dare_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dare_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dare_LincolnParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dare_LincolnParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dare_AtTheMarketEquityOfferingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dare_AtTheMarketEquityOfferingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>53
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MI]<R,_L&7>5.X:[:*A+AS_0(S)_D7^=IB<%BF\=P(#7!.37!JRJ"&$5@&%1
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MM<$['ITAX'A5Q#%"/GOWCE?#..\V;51NVHU:[VQ;@E, 8-QV/@!PCX6&G^R
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M"^YT67*LZ+I5+"ENH[1JZ*JVUIZ#UZ30I:3LA)CQVZRUY-K@* H/PN9\2Z4
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MZ;$5V &27JH.[1!ICCRLG;&YL@^'CBS=5\;/)V2H$J</ABG#_C#A5O ?EC#
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M2;=2:5RS7VI"%P&*O"E"N:M84)0,[EG'VO;3MUYK&IY:6;E1RF>%,2X\]&G
MT%O5 1@]&X\3DU DHM4.3E; SHSU?=5*QW.:]8IVTYE1),S^1!ATV,C68PX)
M^> &5\P8#I6M(I\C3"=P6\LM;B9J&1\M1&%G@V>8Z0$D*=RU<CI(=3@H[DQ;
MYL,'U"#SP^[?V/$LA8/$\A,[>AA4\\.XU@;=6=YD-(X$>EZT1?5AN>^HQE+0
MI"?@$L4/9:1;P59)^[HY4&>.ARS0/8E'%Y;=%J:D<0<(:H>,)8P408!;DA$&
M]&Z@Q^5ER_PJT/94F.A(7CI)A:XW&E^]%TXP%GDP@'=GG]X:[/*!=JQM:-8@
M_+C8L7GH-#)MM$67;U^%%K-X1IS%6!6A-2!_PO&]8A'X0)H,E1(6=1D]MUK)
M[)9D1?Q6-$17,0@MB7YH]ICRF08G3.QZZ%OK,+G&H?6M;1N?470K$WY10P_Y
ME-W$V8:L(RN%ZO2+ 0I418](>L$G?D@<I:TGEIMV.+,)'TJY&BA",ECHUD)5
MJR@3NXG#@%\#^GC0CY@/(44F)^#V<8;!7$UR8EG4-HYZAJTO$87X6XE!^ 6@
M)S[,'K#=DR+<H5%WZJT*S>OT!PUQ,,:GA7+PY_MC[DFC71[I2K4;MJ4+<>B7
M6,>#G\EQ*-"/ 4EJ5*SPB[GNT^[WAA?A9W;]\O!CQ9^DW6C$=JG6V'JR>/;]
M4<#1],:;AG]TMS+>FXI?HK6"?6D!OE\;X],;NJ#[%>:K_P)02P,$%     @
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MD24P33206XHG6H"D,DH$4&G6%O;DFK:Q<\(XW2E,'DH-*B:+)]F%%"$-#HN
M.P8LA(=A.@N&+*/- '5@=* ##O.Q;9(=ZX!Z-!+-]]!/H\[(;U=MU> L>9?
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MLI@@%L,&,VE=R6*(]:B7),)0MNB-H\)-CBWT)D#(+Z5/1JFE0M5>]H:GYS%
M_7A_Z'W5P^S-8-#5@MY_1LU!-\XO":>GZ17K<WZSN%O.[V>_DVZA#0YTY[!U
M,G[ZPQ[7F/BEL36]9SRS#;@*?5PJ:)@=+H#?\:6V^ 4/2"^>O_H?4$L#!!0
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M6:Z>BD_F%B)X*SZZ<U@Q$I\3XJU!4X A4=-- 68".4]$<2Q/P-LR @RD\!C
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M'''1.M39,&D]U2CP$&J?%F$P?AEFV:HH%&SH4D;B1#!Z>JY -*VD 2!,UNQ
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MJO5%83+^T&MA"L #_UPK"871 CQ?&E/4%W1 \^7?L_\#4$L#!!0    ( )&
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M=#Q3C@;@^]3:T#Z0@>4O,.=_ U!+ P04    " "1@&Q1U0"GLA(&  !2#@
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M*!/!BEJNV5$?)'T4A$<D$TV-R]9YJ>B>.'5V[FM*5:ZP(V],!@=C43N;-6G
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MUE<*9S\9?X75=M/M/^)2<FW,-K(*?09OVF4!9W(*W$VXC6*!"&TQ(D91\J)
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M1"XAY)A:1V#T>L1+Y-R!*(V'/3/HMG2!Q^,#_;W73EK6S."EXE_+S!:38!1
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MIUNT 9"\TN[(<X.ZE+GQFVM,D2HJ.\)+ZB*55BEBYKFLHME32<6#? =ODOZ
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MBP#TWN8F(1L*?W(R#\BIKY5!-W.KR['$5NIKFZ0<U2/3NTE3!N*W(*?RX.5
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M5VUSVS8,_BLX+]FM=XJM=]MIDCOGI5T_M,TE[?IAMP^T!-N\2*)*TG&\7S^
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M)5DN<$:B% /J>+JYX3<3JVIWJYXJ2W=T-US03Q%JWD#?9TK9S80-=+]9%_\
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M+>R HK"#:=0PC?['+0F#U[<P^'?1;5Y=@FU&=YBV9;3F.JYZOW>JYO[1Z\Q
MYJYI*>3BJ1[J9K5IC#/7#OQ7\ZJKWF&9FY. *&0&&EQ>F>,OJT953;38NK=^
M([3I'&Y8F.8.TAJ8_4P(?9A8!\W?A>EO4$L#!!0    ( )& ;%'_C NT5 ,
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M#[X%4&#)-L+>J]TU]OEX@KD2QG]AU]M& >0;8U73@XE!PV7W9\^]#GN >'H
MD/2 Y+. 20^8^$0[9CZM*V99EFJU ^VLR9M;>&T\FK+ATE5Q;37=<L+9;-U5
M#U0):UY)7O*<20N+/%<;:;FL8*4$SSD:^ *+HN!.?";@1G8=Y$IQ?(66<6%.
MR.22O:"&:V3"UCG3"+<\IYHC+"J-2.6W9/2POH+CHQ,X B[AC@M!7DP:6LK'
ML0KSGOMEQSTYP/T'DV<01Z>01$DT E]^ CZ)Q^ AJ3A(F0Q2)M[?Y)"4_]'O
M]RT!X,9B8_Y\$&XRA)OX<-,#X1[:4BL*)7J!2T1H&2_&A.@\G7M/;JZW69R&
MVY'@TR'X],/@][A%N:&@6C50:9<R]0-(98F-:R:V8WJ4RO0=%2?^&)?9P&7V
M(1=J(*0YD2[]%]=AYA1RY<5W[<8:5XFQ[IJ]HS*)_^42[HV6>];NF*ZX-""P
M)%1T]I6<Z.ZIZ#96M7[:'I6EV?7+FEY7U,Z [DNE[-O&#?#P7F>O4$L#!!0
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M!5G'\C-_NJ#EA#S57\3CO/B-GLJVUA&*UKGD22D,&B0LW?XEW\N%J E@MT/
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MZH[5I7^(5]K2L^Z;.7UY@7$+:'ZMZ7%M.NYM;[_E%O\!4$L#!!0    ( )&
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MG&-]6^D&:=>-7Z7Q8W(H$+;A'+[VGK;+(^GM?,?2GUK_I&(10AXB-@>@T77
M@\B_7N8WBJ^R3ULSKA2/L\LEHP$3V@!^GW.NGF_TU[+R&_+P?U!+ P04
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M^U6]^M9_O\'_/WFZ!F%K<LWEH'(YL"X'#2Z_Y4I7@,64;=$:MI0Q>T5THB-
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M[JF@\I(GP1.T7\\!F6HL:CM/+SB+G/\/\D3,52WFJI7J@>M-)U%HA1BDC].
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MY$E<R$'^5+ES^O8P:7>PK-V)?'/=A'UL73 #/FZE&\FP;3[4*I&U4O/-E2A
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " "1@&Q1F5R<(Q &  "<)P  $P
M            @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M )& ;%&+FW1G'P4  %85   8              " @0T(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " "1@&Q1;)E,B $&   L%P  &
M            @(%B#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ D8!L43S\L2_9 @  LPD  !@              ("!F1,  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( )& ;%&X_=?4-P4  $D3
M   8              " @:@6  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    " "1@&Q1B8+RQCL*  "2/P  &               @($5'
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ D8!L403,SZ1Y
M!@  #1D  !@              ("!AB8  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( )& ;%&9T4F@, \  )$I   8              "
M@34M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "1@&Q1
MRR$L<<T/  "$+@  &               @(&;/   >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ D8!L4:F ,R1P%P  "4X  !@
M     ("!GDP  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M )& ;%&@(#$4W@0  'X*   9              " @41D  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ D8!L423=\\I-"   714  !D
M             ("!66D  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    " "1@&Q1JL>8%9T,   %*   &0              @('=<0  >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( )& ;%%1/SH'PP8
M (T1   9              " @;%^  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ D8!L4=4 I[(2!@  4@X  !D              ("!
MJX4  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "1@&Q1
MD_<SLIX&  #[$0  &0              @('TBP  >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( )& ;%%FVGTRE ,  #D(   9
M      " @<F2  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ D8!L437F?JFI @  ' 8  !D              ("!E)8  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "1@&Q11U2T- X+   B'P
M&0              @(%TF0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( )& ;%'#-I:^:P,  "D(   9              " @;FD  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ D8!L4>YOW@=T
M!0  <@T  !D              ("!6Z@  'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    " "1@&Q1ZR5H:ID"  !C!0  &0
M@($&K@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( )&
M;%%L:3!@E@(  +X%   9              " @=:P  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ D8!L42#O3,+, @  [ 4  !D
M         ("!H[,  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M    " "1@&Q1^T;$"P@#   Z"   &0              @(&FM@  >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( )& ;%'_C NT5 ,  )(.
M   9              " @>6Y  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M4$L! A0#%     @ D8!L4=9Y9=QT @  NP4  !D              ("!<+T
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "1@&Q1==?Z
M\?\)  #*00  &0              @($;P   >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;%!+ 0(4 Q0    ( )& ;%%*13XA0P,  -<)   9
M  " @5'*  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
MD8!L44'SOS,3!0  3Q8  !D              ("!R\T  'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    " "1@&Q1_MN[]J(#  #P#   &0
M            @($5TP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    ( )& ;%&VW^$E70,  "X+   9              " @>[6  !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ D8!L480WW:,W P
MM D  !D              ("!@MH  'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"% ,4    " "1@&Q1'?4L%4\(  #=*0  &0              @('P
MW0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( )& ;%$R
MQY%&O0,  .4/   9              " @7;F  !X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL4$L! A0#%     @ D8!L43RG$!FZ!   VA(  !D
M     ("!:NH  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )& ;%&ENG[H(P,  +P+   9              "
M@7[]  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ D8!L
M4<N"(OLW @  @@H   T              ( !V  ! 'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " "1@&Q1EXJ[',     3 @  "P              @ $Z P$
M7W)E;',O+G)E;'-02P$"% ,4    " "1@&Q1N91=)+H#   0&P  #P
M        @ $C! $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ D8!L43QA
M]1J- 0  3Q@  !H              ( !"@@! 'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ D8!L49C$(26B 0  IA@  !,
M     ( !SPD! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #  ,  '#0
&H@L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>194</ContextCount>
  <ElementCount>300</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>63</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/OrganizationandDescriptionoftheBusiness</Role>
      <ShortName>Organization and Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/LicenseandCollaborationAgreements</Role>
      <ShortName>License and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/Acquisition</Role>
      <ShortName>Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112105 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2118106 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - Leased Properties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/LeasedProperties</Role>
      <ShortName>Leased Properties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2128109 - Disclosure - Grant Award</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/GrantAward</Role>
      <ShortName>Grant Award</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2130110 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2133111 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://darebioscience.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://darebioscience.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2313302 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://darebioscience.com/role/StockBasedCompensation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2319303 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://darebioscience.com/role/StockholdersEquity</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2323304 - Disclosure - Leased Properties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/LeasedPropertiesTables</Role>
      <ShortName>Leased Properties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://darebioscience.com/role/LeasedProperties</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2331305 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://darebioscience.com/role/NetLossPerShare</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization and Description of the Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/OrganizationandDescriptionoftheBusinessAdditionalInformationDetails</Role>
      <ShortName>Organization and Description of the Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Financial Assets and Liabilities Remeasured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Financial Assets and Liabilities Remeasured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - License and Collaboration Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails</Role>
      <ShortName>License and Collaboration Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Acquisition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/AcquisitionNarrativeDetails</Role>
      <ShortName>Acquisition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Stock Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Leased Properties - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails</Role>
      <ShortName>Leased Properties - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Leased Properties - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leased Properties - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Grant Award - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/GrantAwardNarrativeDetails</Role>
      <ShortName>Grant Award - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2432416 - Disclosure - Net Loss Per Share - Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails</Role>
      <ShortName>Net Loss Per Share - Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="dare-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://darebioscience.com/role/SubsequentEvents</ParentRole>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="dare-20200930.htm">dare-20200930.htm</File>
    <File>dare-20200930.xsd</File>
    <File>dare-20200930_cal.xml</File>
    <File>dare-20200930_def.xml</File>
    <File>dare-20200930_lab.xml</File>
    <File>dare-20200930_pre.xml</File>
    <File>exhibit31120200930-ngv.htm</File>
    <File>exhibit31220200930-ngv.htm</File>
    <File>exhibit32120200930-ngv.htm</File>
    <File>exhibit32220200930-ngv.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>dare-20200930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "dare-20200930.htm": {
   "axisCustom": 0,
   "axisStandard": 25,
   "contextCount": 194,
   "dts": {
    "calculationLink": {
     "local": [
      "dare-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "dare-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "dare-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "dare-20200930_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dare-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "dare-20200930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 402,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 3,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 8
   },
   "keyCustom": 52,
   "keyStandard": 248,
   "memberCustom": 38,
   "memberStandard": 21,
   "nsprefix": "dare",
   "nsuri": "http://darebioscience.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://darebioscience.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - Acquisition",
     "role": "http://darebioscience.com/role/Acquisition",
     "shortName": "Acquisition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112105 - Disclosure - Stock-Based Compensation",
     "role": "http://darebioscience.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118106 - Disclosure - Stockholders' Equity",
     "role": "http://darebioscience.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - Leased Properties",
     "role": "http://darebioscience.com/role/LeasedProperties",
     "shortName": "Leased Properties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Commitments and Contingencies",
     "role": "http://darebioscience.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dare:GrantAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128109 - Disclosure - Grant Award",
     "role": "http://darebioscience.com/role/GrantAward",
     "shortName": "Grant Award",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dare:GrantAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130110 - Disclosure - Net Loss Per Share",
     "role": "http://darebioscience.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133111 - Disclosure - Subsequent Events",
     "role": "http://darebioscience.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i541d1593a6734f80a2264c14bc99a339_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://darebioscience.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i541d1593a6734f80a2264c14bc99a339_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313302 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://darebioscience.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319303 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://darebioscience.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323304 - Disclosure - Leased Properties (Tables)",
     "role": "http://darebioscience.com/role/LeasedPropertiesTables",
     "shortName": "Leased Properties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331305 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://darebioscience.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization and Description of the Business - Additional Information (Details)",
     "role": "http://darebioscience.com/role/OrganizationandDescriptionoftheBusinessAdditionalInformationDetails",
     "shortName": "Organization and Description of the Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "ibf36c001049f4946aa8e0ca7818e0e67_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Financial Assets and Liabilities Remeasured on a Recurring Basis (Details)",
     "role": "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails",
     "shortName": "Summary of Significant Accounting Policies - Financial Assets and Liabilities Remeasured on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "ibf36c001049f4946aa8e0ca7818e0e67_I20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i28e27dfd8d1744fd931fe1123a4379d6_D20200101-20200131",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "dare:UpfrontLicenseFeePaid",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "id8c96646bea247b9938b381dd4090324_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "dare:LicenseFee",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - License and Collaboration Agreements - Additional Information (Details)",
     "role": "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
     "shortName": "License and Collaboration Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i86cbc311d1df479cb96f4a597e179fe5_D20191120-20191120",
      "decimals": "-5",
      "lang": "en-US",
      "name": "dare:ResearchAndDevelopmentMilestonePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "ibec4b74376bf439b97a248a65f5b0eae_I20191130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Acquisition - Narrative (Details)",
     "role": "http://darebioscience.com/role/AcquisitionNarrativeDetails",
     "shortName": "Acquisition - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "ibec4b74376bf439b97a248a65f5b0eae_I20191130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i541d1593a6734f80a2264c14bc99a339_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Stock Based Compensation - Additional Information (Details)",
     "role": "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "lang": "en-US",
      "name": "dare:WeightedAverageAmortizationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i541d1593a6734f80a2264c14bc99a339_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i541d1593a6734f80a2264c14bc99a339_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "id3721c96df454703ab043d1b9396afec_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Details)",
     "role": "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i748cf08e328d4f8e88ce6250028b6f5c_D20200101-20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i3caed64836884e1cb8f9c5b521f55da0_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details)",
     "role": "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails",
     "shortName": "Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "iaedce4b2446d4390afdde0c8b65ed211_D20200701-20200930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "id8c96646bea247b9938b381dd4090324_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors (Details)",
     "role": "http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails",
     "shortName": "Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "id8c96646bea247b9938b381dd4090324_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i56d13a7ae7894e27975f5d3dc7ebf378_D20180101-20180131",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "dare:PercentageOfAggregateCommission",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "role": "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i56d13a7ae7894e27975f5d3dc7ebf378_D20180101-20180131",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "dare:PercentageOfAggregateCommission",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i541d1593a6734f80a2264c14bc99a339_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details)",
     "role": "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails",
     "shortName": "Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i541d1593a6734f80a2264c14bc99a339_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i8ad78d95daba4838b75da7b4df9b8b00_I20180701",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetRentableArea",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Leased Properties - Additional Information (Details)",
     "role": "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails",
     "shortName": "Leased Properties - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i8ad78d95daba4838b75da7b4df9b8b00_I20180701",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetRentableArea",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i541d1593a6734f80a2264c14bc99a339_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Leased Properties - Future Minimum Lease Payments (Details)",
     "role": "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails",
     "shortName": "Leased Properties - Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i541d1593a6734f80a2264c14bc99a339_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i07edbdfe23b14e1b882ecc8189596d12_D20200401-20200430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "dare:CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://darebioscience.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i07edbdfe23b14e1b882ecc8189596d12_D20200401-20200430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "dare:CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i07edbdfe23b14e1b882ecc8189596d12_D20200401-20200430",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "dare:ProceedsFromAwardOfGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Grant Award - Narrative (Details)",
     "role": "http://darebioscience.com/role/GrantAwardNarrativeDetails",
     "shortName": "Grant Award - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i07edbdfe23b14e1b882ecc8189596d12_D20200401-20200430",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "dare:ProceedsFromAwardOfGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "id8c96646bea247b9938b381dd4090324_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432416 - Disclosure - Net Loss Per Share - Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share (Details)",
     "role": "http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails",
     "shortName": "Net Loss Per Share - Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "id8c96646bea247b9938b381dd4090324_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "id8c96646bea247b9938b381dd4090324_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "id8c96646bea247b9938b381dd4090324_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i8bfaf2e8371745b2b5e46ebc3e913e82_D20200422-20200422",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Subsequent Events (Details)",
     "role": "http://darebioscience.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "ia980a0c4d8c2414ca34948ab72d9b74d_D20201001-20201111",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i25c35de4c46a4497b5ac99d104d6962c_I20181231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Stockholders\u2019 Equity",
     "role": "http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "ic7acea1d9dc949cdb1eba8efb4698c44_D20190101-20190331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Description of the Business",
     "role": "http://darebioscience.com/role/OrganizationandDescriptionoftheBusiness",
     "shortName": "Organization and Description of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://darebioscience.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - License and Collaboration Agreements",
     "role": "http://darebioscience.com/role/LicenseandCollaborationAgreements",
     "shortName": "License and Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dare-20200930.htm",
      "contextRef": "i92305c8a0b8344f593f21438a9c09fdd_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 63,
   "tag": {
    "dare_ADVATecAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ADVA Tec agreement.",
        "label": "A D V A Tec Agreement [Member]",
        "terseLabel": "ADVA Tec Agreement"
       }
      }
     },
     "localname": "ADVATecAgreementMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_AdarePharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adare Pharmaceuticals [Member]",
        "label": "Adare Pharmaceuticals [Member]",
        "terseLabel": "Adare"
       }
      }
     },
     "localname": "AdarePharmaceuticalsMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_AdditionalPotentialFundingRelatedToGrantAward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional Potential Funding Related To Grant Award",
        "label": "Additional Potential Funding Related To Grant Award",
        "terseLabel": "Additional potential grant funding"
       }
      }
     },
     "localname": "AdditionalPotentialFundingRelatedToGrantAward",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares",
        "label": "Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares",
        "terseLabel": "Issuance of common stock from the exercise of warrants (in shares)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "dare_AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member]",
        "label": "Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member]",
        "terseLabel": "Amended and Restated Two Thousand Fourteen Stock Incentive Plan"
       }
      }
     },
     "localname": "AmendedAndRestatedTwoThousandFourteenStockIncentivePlanMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_AssetAcquisitionContingentConsiderationCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition, Contingent Consideration, Current",
        "label": "Asset Acquisition, Contingent Consideration, Current",
        "terseLabel": "Current portion of contingent consideration"
       }
      }
     },
     "localname": "AssetAcquisitionContingentConsiderationCurrent",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/AcquisitionNarrativeDetails",
      "http://darebioscience.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_AssetAcquisitionContingentConsiderationNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition, Contingent Consideration, Noncurrent",
        "label": "Asset Acquisition, Contingent Consideration, Noncurrent",
        "terseLabel": "Contingent consideration, net of current portion"
       }
      }
     },
     "localname": "AssetAcquisitionContingentConsiderationNoncurrent",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_AssignmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assignment Agreement [Member]",
        "label": "Assignment Agreement [Member]",
        "terseLabel": "Assignment Agreement"
       }
      }
     },
     "localname": "AssignmentAgreementMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_AtTheMarketEquityOfferingsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "At-the-Market Equity Offerings",
        "label": "At-the-Market Equity Offerings [Member]",
        "terseLabel": "At-the-Market Equity Offerings"
       }
      }
     },
     "localname": "AtTheMarketEquityOfferingsMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_AtTheMarketSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "At The Market Sales Agreement [Member]",
        "label": "At The Market Sales Agreement [Member]",
        "terseLabel": "ATM Sales Agreement"
       }
      }
     },
     "localname": "AtTheMarketSalesAgreementMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_BayerHealthcareLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bayer Healthcare License Agreement [Member]",
        "label": "Bayer Healthcare License Agreement [Member]",
        "terseLabel": "Bayer Healthcare License Agreement"
       }
      }
     },
     "localname": "BayerHealthcareLicenseAgreementMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_BillAndMelindaGatesFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bill And Melinda Gates Foundation [Member]",
        "label": "Bill And Melinda Gates Foundation [Member]",
        "terseLabel": "Bill And Melinda Gates Foundation"
       }
      }
     },
     "localname": "BillAndMelindaGatesFoundationMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_BusinessCombinationReverseMergerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business combination reverse merger.",
        "label": "Business Combination Reverse Merger [Line Items]",
        "terseLabel": "Business Combination Reverse Merger [Line Items]"
       }
      }
     },
     "localname": "BusinessCombinationReverseMergerLineItems",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/AcquisitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business combination reverse merger recognized identifiable assets acquired and liabilities assumed cash and equivalents.",
        "label": "Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/AcquisitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_ClassOfWarrantOrRightsWarrantsExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of warrant or rights warrants expiration date.",
        "label": "Class Of Warrant Or Rights Warrants Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsWarrantsExpirationDate",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "dare_ClinicalAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clinical And Regulatory Milestones [Member]",
        "label": "Clinical And Regulatory Milestones [Member]",
        "terseLabel": "Clinical and Regulatory Milestones"
       }
      }
     },
     "localname": "ClinicalAndRegulatoryMilestonesMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_CommencementPeriodForStageTwoUponAchievementOfStageOne": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commencement Period For Stage Two Upon Achievement Of Stage One",
        "label": "Commencement Period For Stage Two Upon Achievement Of Stage One",
        "terseLabel": "Commencement period for stage two upon achievement of stage one"
       }
      }
     },
     "localname": "CommencementPeriodForStageTwoUponAchievementOfStageOne",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dare_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dare_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dare_CommonStockExchangeCap": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock, Exchange Cap",
        "label": "Common Stock, Exchange Cap",
        "terseLabel": "Exchange cap (in shares)"
       }
      }
     },
     "localname": "CommonStockExchangeCap",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "dare_CommonStockExchangeCapPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock, Exchange Cap, Percentage",
        "label": "Common Stock, Exchange Cap, Percentage",
        "terseLabel": "Exchange cap, percentage"
       }
      }
     },
     "localname": "CommonStockExchangeCapPercentage",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received",
        "label": "Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received",
        "terseLabel": "Loan under Paycheck Protection Program"
       }
      }
     },
     "localname": "CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_DeferredGrantFundingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Grant Funding Current",
        "label": "Deferred Grant Funding Current",
        "terseLabel": "Deferred grant funding"
       }
      }
     },
     "localname": "DeferredGrantFundingCurrent",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets",
      "http://darebioscience.com/role/GrantAwardNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_DeferredOfferingCostsUnamortizedPortion": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Offering Costs, Unamortized Portion",
        "label": "Deferred Offering Costs, Unamortized Portion",
        "terseLabel": "Unamortized costs related to legal, accounting, and other fees"
       }
      }
     },
     "localname": "DeferredOfferingCostsUnamortizedPortion",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_DevelopmentAndOptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development And Option Agreement [Member]",
        "label": "Development And Option Agreement [Member]",
        "terseLabel": "Development and Option Agreement"
       }
      }
     },
     "localname": "DevelopmentAndOptionAgreementMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_EstimatedFairValueOfWarrantsRecordedInEquity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated Fair Value Of Warrants Recorded In Equity",
        "label": "Estimated Fair Value Of Warrants Recorded In Equity",
        "terseLabel": "Estimated fair value of warrants recorded in equity"
       }
      }
     },
     "localname": "EstimatedFairValueOfWarrantsRecordedInEquity",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_GrantAwardTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Grant Award [Text Block]",
        "label": "Grant Award [Text Block]",
        "terseLabel": "Grant Award"
       }
      }
     },
     "localname": "GrantAwardTextBlock",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/GrantAward"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dare_GrantDAREFRT1Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Grant, DARE-FRT1",
        "label": "Grant, DARE-FRT1 [Member]",
        "terseLabel": "Grant, DARE-FRT1"
       }
      }
     },
     "localname": "GrantDAREFRT1Member",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_GrantOvapreneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Grant, Ovaprene",
        "label": "Grant, Ovaprene [Member]",
        "terseLabel": "Grant, Ovaprene"
       }
      }
     },
     "localname": "GrantOvapreneMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_GrossProceedsFromOfferingOfCommonStockAndWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross Proceeds From Offering Of Common Stock And Warrants",
        "label": "Gross Proceeds From Offering Of Common Stock And Warrants",
        "terseLabel": "Gross proceeds from offering of common stock and warrants"
       }
      }
     },
     "localname": "GrossProceedsFromOfferingOfCommonStockAndWarrants",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_HammockPharmaceuticalsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hammock Pharmaceuticals, Inc. [Member]",
        "label": "Hammock Pharmaceuticals, Inc. [Member]",
        "terseLabel": "Hammock Pharmaceuticals, Inc"
       }
      }
     },
     "localname": "HammockPharmaceuticalsInc.Member",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_IncreaseDecreaseInDeferredGrantFunding": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Deferred Grant Funding",
        "label": "Increase (Decrease) In Deferred Grant Funding",
        "negatedTerseLabel": "Deferred grant funding"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredGrantFunding",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase decrease in other non-current assets and deferred charges.",
        "label": "Increase Decrease In Other Non Current Assets And Deferred Charges",
        "negatedLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_IssuanceCostOnEquityPaidInCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Issuance Cost On Equity Paid In Common Stock",
        "label": "Issuance Cost On Equity Paid In Common Stock",
        "terseLabel": "Issuance cost on equity paid in common stock"
       }
      }
     },
     "localname": "IssuanceCostOnEquityPaidInCommonStock",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_JuniperPharmaceuticalsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Juniper Pharmaceuticals, Inc. [Member]",
        "label": "Juniper Pharmaceuticals, Inc. [Member]",
        "terseLabel": "Juniper Pharmaceuticals, Inc"
       }
      }
     },
     "localname": "JuniperPharmaceuticalsInc.Member",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_LicenseAgreementNoticePeriodOfTermination": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreement Notice Period Of Termination",
        "label": "License Agreement Notice Period Of Termination",
        "terseLabel": "Certain clinical and regulatory development milestone payments"
       }
      }
     },
     "localname": "LicenseAgreementNoticePeriodOfTermination",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License agreement, termination period due to performance failure.",
        "label": "License Agreement Termination Period Due To Performance Failure",
        "terseLabel": "License agreement termination period due to performance failure"
       }
      }
     },
     "localname": "LicenseAgreementTerminationPeriodDueToPerformanceFailure",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreement Termination Periodic Discontinued Sale Of Product",
        "label": "License Agreement Termination Periodic Discontinued Sale Of Product",
        "terseLabel": "License agreement termination periodic discontinued sale of product"
       }
      }
     },
     "localname": "LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dare_LicenseAndCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License And Collaboration Agreement [Member]",
        "label": "License And Collaboration Agreement [Member]",
        "terseLabel": "License and Collaboration Agreement"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_LicenseFee": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Fee",
        "label": "License Fee",
        "terseLabel": "License fees",
        "verboseLabel": "License fee"
       }
      }
     },
     "localname": "LicenseFee",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_LicenseFeeToBePaidUponContingency": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Fee, To Be Paid Upon Contingency",
        "label": "License Fee, To Be Paid Upon Contingency",
        "terseLabel": "License fee to be paid upon contingency"
       }
      }
     },
     "localname": "LicenseFeeToBePaidUponContingency",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_LincolnParkMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lincoln Park",
        "label": "Lincoln Park [Member]",
        "terseLabel": "Lincoln Park"
       }
      }
     },
     "localname": "LincolnParkMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_MaximumPotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum Potential Milestone Payments",
        "label": "Maximum Potential Milestone Payments",
        "terseLabel": "Maximum potential milestone payments"
       }
      }
     },
     "localname": "MaximumPotentialMilestonePayments",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_MicrochipsBiotechInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Microchips Biotech, Inc. [Member]",
        "label": "Microchips Biotech, Inc. [Member]",
        "terseLabel": "Microchips Biotech, Inc."
       }
      }
     },
     "localname": "MicrochipsBiotechInc.Member",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/AcquisitionNarrativeDetails",
      "http://darebioscience.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_MilanaPharmMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "MilanaPharm [Member]",
        "label": "MilanaPharm [Member]",
        "terseLabel": "MilanaPharm"
       }
      }
     },
     "localname": "MilanaPharmMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_MilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Payments",
        "label": "Milestone Payments",
        "terseLabel": "Milestone Payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_MilestonePaymentsContingentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone payments, contingent amount.",
        "label": "Milestone Payments Contingent Amount",
        "terseLabel": "Milestone payments, contingent amount"
       }
      }
     },
     "localname": "MilestonePaymentsContingentAmount",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_NationalInstitutesOfHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "National Institutes Of Health [Member]",
        "label": "National Institutes Of Health [Member]",
        "terseLabel": "National Institutes of Health"
       }
      }
     },
     "localname": "NationalInstitutesOfHealthMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_NetProceedsFromIssuanceOfCommonStockAndWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net proceeds from issuance of common stock and warrants.",
        "label": "Net Proceeds From Issuance Of Common Stock And Warrants",
        "terseLabel": "Net proceeds from issuance of common stock"
       }
      }
     },
     "localname": "NetProceedsFromIssuanceOfCommonStockAndWarrants",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_NonCashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-Cash Lease Expense",
        "label": "Non-Cash Lease Expense",
        "terseLabel": "Non-cash operating lease cost"
       }
      }
     },
     "localname": "NonCashLeaseExpense",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_NotesPayableCurrentPlusAccruedInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Notes Payable, Current, Plus Accrued Interest",
        "label": "Notes Payable, Current, Plus Accrued Interest",
        "terseLabel": "Notes payable including accrued interest"
       }
      }
     },
     "localname": "NotesPayableCurrentPlusAccruedInterest",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_NumberOfCommonStockWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of common stock warrants exercised.",
        "label": "Number Of Common Stock Warrants Exercised",
        "terseLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "NumberOfCommonStockWarrantsExercised",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "dare_OfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Offering Expenses",
        "label": "Offering Expenses",
        "terseLabel": "Offering expenses"
       }
      }
     },
     "localname": "OfferingExpenses",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_PercentageOfAggregateCommission": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of aggregate commission.",
        "label": "Percentage Of Aggregate Commission",
        "terseLabel": "Aggregate commission rate"
       }
      }
     },
     "localname": "PercentageOfAggregateCommission",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of rights to inventions by employees under license agreement.",
        "label": "Percentage Of Rights To Inventions By Employees Under License Agreement",
        "terseLabel": "Percentage of rights to inventions by employees under license agreement"
       }
      }
     },
     "localname": "PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dare_PercentageOfRoyaltyRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of royalty rate.",
        "label": "Percentage Of Royalty Rate",
        "terseLabel": "Percentage of royalty rate"
       }
      }
     },
     "localname": "PercentageOfRoyaltyRate",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dare_PeriodofInsufficientCashandLiquidityRequirements": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of Insufficient Cash and Liquidity Requirements",
        "label": "Period of Insufficient Cash and Liquidity Requirements",
        "terseLabel": "Period of insufficient cash and liquidity requirements"
       }
      }
     },
     "localname": "PeriodofInsufficientCashandLiquidityRequirements",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/OrganizationandDescriptionoftheBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential Annual License Maintenance Fee, Payments In Year One",
        "label": "Potential Annual License Maintenance Fee, Payments In Year One",
        "terseLabel": "Potential annual license maintenance fee, payments in year one"
       }
      }
     },
     "localname": "PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential Annual License Maintenance Fee Payments, Thereafter",
        "label": "Potential Annual License Maintenance Fee Payments, Thereafter",
        "terseLabel": "Potential annual license maintenance fee payments, thereafter"
       }
      }
     },
     "localname": "PotentialAnnualLicenseMaintenanceFeePaymentsThereafter",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_PrivateDareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Private Dare.",
        "label": "Private Dare [Member]",
        "terseLabel": "Private Dare"
       }
      }
     },
     "localname": "PrivateDareMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_ProceedsFromAwardOfGrant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds From Award Of Grant",
        "label": "Proceeds From Award Of Grant",
        "terseLabel": "Amount awarded for grant"
       }
      }
     },
     "localname": "ProceedsFromAwardOfGrant",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_ProceedsFromIssuanceOfCommonStockAndWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds from issuance of common stock and warrants.",
        "label": "Proceeds From Issuance Of Common Stock And Warrants",
        "terseLabel": "Proceeds from the exercise of common stock warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_PublicStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Public Stock Offering [Member]",
        "label": "Public Stock Offering [Member]",
        "terseLabel": "Public Stock Offering"
       }
      }
     },
     "localname": "PublicStockOfferingMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_PurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase Agreement",
        "label": "Purchase Agreement [Member]",
        "terseLabel": "Purchase Agreement"
       }
      }
     },
     "localname": "PurchaseAgreementMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_ReceivableForExpensesEligibleForReimbursement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Receivable For Expenses Eligible For Reimbursement",
        "label": "Receivable For Expenses Eligible For Reimbursement",
        "terseLabel": "Receivable for expenses eligible for reimbursement"
       }
      }
     },
     "localname": "ReceivableForExpensesEligibleForReimbursement",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_RegularPurchaseCommonStockIssuableIncreaseAmount": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regular Purchase, Common Stock Issuable, Increase Amount",
        "label": "Regular Purchase, Common Stock Issuable, Increase Amount",
        "terseLabel": "Regular purchase, common stock issuable, increase amount (in shares)"
       }
      }
     },
     "localname": "RegularPurchaseCommonStockIssuableIncreaseAmount",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "dare_RegularPurchaseCommonStockIssuableMaximumAmount": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regular Purchase, Common Stock Issuable, Maximum Amount",
        "label": "Regular Purchase, Common Stock Issuable, Maximum Amount",
        "terseLabel": "Regular purchase, common stock issuable, maximum amount (in shares)"
       }
      }
     },
     "localname": "RegularPurchaseCommonStockIssuableMaximumAmount",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "dare_RegularRepurchaseCommonStockIssuable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regular Repurchase, Common Stock Issuable",
        "label": "Regular Repurchase, Common Stock Issuable",
        "terseLabel": "Regular purchase, common stock issuable (in shares) (up to)"
       }
      }
     },
     "localname": "RegularRepurchaseCommonStockIssuable",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "dare_ResearchAndDevelopmentMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and development milestone payment.",
        "label": "Research And Development Milestone Payment",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "ResearchAndDevelopmentMilestonePayment",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_SaleofStockMaximumAmountRegistered": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of Stock, Maximum Amount Registered",
        "label": "Sale of Stock, Maximum Amount Registered",
        "terseLabel": "Stock registered for resale (in shares)"
       }
      }
     },
     "localname": "SaleofStockMaximumAmountRegistered",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "dare_SalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales Milestones [Member]",
        "label": "Sales Milestones [Member]",
        "terseLabel": "Sales Milestones"
       }
      }
     },
     "localname": "SalesMilestonesMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_ScheduleOfBusinessCombinationReverseMergerTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of business combination reverse merger.",
        "label": "Schedule Of Business Combination Reverse Merger [Table]",
        "terseLabel": "Schedule Of Business Combination Reverse Merger [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessCombinationReverseMergerTable",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/AcquisitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based compensation arrangement by Share-based payment award fair value assumptions forfeiture rate.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate",
        "terseLabel": "Forfeiture rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dare_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/OrganizationandDescriptionoftheBusinessAdditionalInformationDetails",
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dare_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/OrganizationandDescriptionoftheBusinessAdditionalInformationDetails",
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dare_StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Consideration For Commitment To Purchase Shares",
        "label": "Stock Issued During Period, Shares, Consideration For Commitment To Purchase Shares",
        "terseLabel": "Issuance cost on equity line paid in common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConsiderationForCommitmentToPurchaseShares",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "dare_StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Consideration For Commitment To Purchase Shares",
        "label": "Stock Issued During Period, Value, Consideration For Commitment To Purchase Shares",
        "terseLabel": "Issuance cost on equity line paid in common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_StockholdersEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stockholders' equity.",
        "label": "Stockholders Equity [Line Items]",
        "terseLabel": "Stockholders Equity [Line Items]"
       }
      }
     },
     "localname": "StockholdersEquityLineItems",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dare_StockholdersEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stockholders' equity.",
        "label": "Stockholders Equity [Table]",
        "terseLabel": "Stockholders Equity [Table]"
       }
      }
     },
     "localname": "StockholdersEquityTable",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC.",
        "label": "Strategic Science And Technologies D Limited Liability Company And Strategic Science Technologies Limited Liability Company [Member]",
        "terseLabel": "Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company"
       }
      }
     },
     "localname": "StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_TwoThousandAndFifteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two Thousand And Fifteen Stock Incentive Plan [Member]",
        "label": "Two Thousand And Fifteen Stock Incentive Plan [Member]",
        "terseLabel": "2015 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandAndFifteenStockIncentivePlanMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two thousand and fourteen employee stock purchase plan.",
        "label": "Two Thousand And Fourteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2014 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandAndFourteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_UnderwritersOptionToPurchaseAdditionalShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Underwriters option to purchase additional shares.",
        "label": "Underwriters Option To Purchase Additional Shares",
        "terseLabel": "Underwriters option to purchase additional shares"
       }
      }
     },
     "localname": "UnderwritersOptionToPurchaseAdditionalShares",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Underwriters option to purchase additional shares of common stock period.",
        "label": "Underwriters Option To Purchase Additional Shares Of Common Stock Period",
        "terseLabel": "Underwriters overallotment option to purchase additional shares of common stock and warrants period"
       }
      }
     },
     "localname": "UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dare_UpfrontLicenseFeePaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upfront License Fee Paid",
        "label": "Upfront License Fee Paid",
        "terseLabel": "Upfront license fee paid"
       }
      }
     },
     "localname": "UpfrontLicenseFeePaid",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upon achievement of specified development and regulatory milestones.",
        "label": "Upon Achievement Of Specified Development And Regulatory Milestones [Member]",
        "terseLabel": "Upon Achievement of Specified Development and Regulatory Milestones"
       }
      }
     },
     "localname": "UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upon Achieving Certain Clinical And Regulatory Development Milestones [Member]",
        "label": "Upon Achieving Certain Clinical And Regulatory Development Milestones [Member]",
        "terseLabel": "Upon Achieving Certain Clinical and Regulatory Development Milestones"
       }
      }
     },
     "localname": "UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_UponAchievingCertainCommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upon Achieving Certain Commercial Milestones [Member]",
        "label": "Upon Achieving Certain Commercial Milestones [Member]",
        "terseLabel": "Upon Achieving Certain Commercial Milestones"
       }
      }
     },
     "localname": "UponAchievingCertainCommercialMilestonesMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_UponAchievingCertainDevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upon Achieving Certain Development Milestones [Member]",
        "label": "Upon Achieving Certain Development Milestones [Member]",
        "terseLabel": "Upon Achieving Certain Development Milestones"
       }
      }
     },
     "localname": "UponAchievingCertainDevelopmentMilestonesMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upon Completion Of Fifty Percent Development Not Later Than Six Months [Member]",
        "label": "Upon Completion Of Fifty Percent Development Not Later Than Six Months [Member]",
        "terseLabel": "Upon Completion of Fifty Percent Development Not Later Than Six Months"
       }
      }
     },
     "localname": "UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upon Delivery Of Six Month Batch Development Not Later Than Eleven Months [Member]",
        "label": "Upon Delivery Of Six Month Batch Development Not Later Than Eleven Months [Member]",
        "terseLabel": "Upon Delivery of Six Month Batch Development Not Later Than Eleven Months"
       }
      }
     },
     "localname": "UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_UponReachingCertainWorldwideNetSalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upon reaching certain worldwide net sales milestones.",
        "label": "Upon Reaching Certain Worldwide Net Sales Milestones [Member]",
        "terseLabel": "Upon Reaching Certain Worldwide Net Sales Milestones"
       }
      }
     },
     "localname": "UponReachingCertainWorldwideNetSalesMilestonesMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_UponSigningOfDevelopmentAndOptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upon Signing Of Development And Option Agreement [Member]",
        "label": "Upon Signing Of Development And Option Agreement [Member]",
        "terseLabel": "Upon Signing of Development and Option Agreement"
       }
      }
     },
     "localname": "UponSigningOfDevelopmentAndOptionAgreementMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants expiring on april four two thousand twenty six.",
        "label": "Warrants Expiring On April Four Two Thousand Twenty Six [Member]",
        "terseLabel": "Warrants Expiring on April 4, 2026"
       }
      }
     },
     "localname": "WarrantsExpiringOnAprilFourTwoThousandTwentySixMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants expiring on december one two thousand twenty one.",
        "label": "Warrants Expiring On December One Two Thousand Twenty One [Member]",
        "terseLabel": "Warrants Expiring on December 1, 2021"
       }
      }
     },
     "localname": "WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants expiring on december six two thousand twenty one.",
        "label": "Warrants Expiring On December Six Two Thousand Twenty One [Member]",
        "terseLabel": "Warrants Expiring on December 6, 2021"
       }
      }
     },
     "localname": "WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member]",
        "label": "Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member]",
        "terseLabel": "Warrants Expiring on February 15, 2023"
       }
      }
     },
     "localname": "WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dare_WeightedAverageAmortizationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted Average Amortization Period",
        "label": "Weighted Average Amortization Period",
        "terseLabel": "Weighted Average Amortization Period"
       }
      }
     },
     "localname": "WeightedAverageAmortizationPeriod",
     "nsuri": "http://darebioscience.com/20200930",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r33",
      "r66"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r168",
      "r170",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r329",
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r168",
      "r170",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r329",
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r116",
      "r153",
      "r155",
      "r292",
      "r328",
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r116",
      "r153",
      "r155",
      "r292",
      "r328",
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r157",
      "r168",
      "r170",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r329",
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r157",
      "r168",
      "r170",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r329",
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201711Member": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2017-11 Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception.",
        "label": "Accounting Standards Update 2017-11 [Member]",
        "terseLabel": "Accounting Standards Update 2017-11"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201711Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r15",
      "r36",
      "r37",
      "r38",
      "r321",
      "r339",
      "r343"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r35",
      "r38",
      "r39",
      "r68",
      "r69",
      "r70",
      "r234",
      "r334",
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r68",
      "r69",
      "r70",
      "r200",
      "r201",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r74",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r212",
      "r213",
      "r214",
      "r215",
      "r293",
      "r294",
      "r295",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r171",
      "r173",
      "r206",
      "r207"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r135",
      "r136",
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of common stock from the exercise of warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Non-cash adjustments reconciling net loss to operating cash flows:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r173",
      "r194",
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r65",
      "r105",
      "r108",
      "r114",
      "r120",
      "r230",
      "r235",
      "r251",
      "r312",
      "r319"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r32",
      "r65",
      "r120",
      "r230",
      "r235",
      "r251"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r174",
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r240",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r167",
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/AcquisitionNarrativeDetails",
      "http://darebioscience.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r167",
      "r169",
      "r216",
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/AcquisitionNarrativeDetails",
      "http://darebioscience.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": {
     "auth_ref": [
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned",
        "terseLabel": "Business acquisition transaction value"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/AcquisitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Common stock issued to microchips capital stock holders (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/AcquisitionNarrativeDetails",
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Business combination shares issued (in usd per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/AcquisitionNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r219",
      "r220",
      "r223"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration, liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/AcquisitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r219",
      "r221"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Current portion of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r219",
      "r221"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration, net of current portion"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisition"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/Acquisition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r296",
      "r297",
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]",
        "terseLabel": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r19",
      "r60"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r55",
      "r60",
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r55",
      "r252"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r63",
      "r65",
      "r85",
      "r86",
      "r87",
      "r90",
      "r92",
      "r99",
      "r100",
      "r101",
      "r120",
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/AcquisitionNarrativeDetails",
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r140",
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise price (in usd per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Shares underlying outstanding warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r140",
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityScheduleofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r225",
      "r226",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r27",
      "r134",
      "r315",
      "r325"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r68",
      "r69"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/AcquisitionNarrativeDetails",
      "http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r12",
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "verboseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 120,000,000 shares authorized; 33,602,516 and 19,683,401 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r41",
      "r43",
      "r44",
      "r46",
      "r317",
      "r327"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r142",
      "r143",
      "r154"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred license revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r9",
      "r313",
      "r320"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/OrganizationandDescriptionoftheBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Note annual interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent",
        "terseLabel": "Unamortized stock-based compensation expense"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r31",
      "r129"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Legal, accounting and other fees related to Purchase Agreement"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r58",
      "r130"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Loss per common share - basic and diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r252"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails",
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r68",
      "r69",
      "r70",
      "r72",
      "r79",
      "r81",
      "r98",
      "r124",
      "r136",
      "r139",
      "r200",
      "r201",
      "r202",
      "r214",
      "r215",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r243",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities Remeasured on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r166",
      "r244",
      "r281",
      "r282",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/OrganizationandDescriptionoftheBusinessAdditionalInformationDetails",
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r243",
      "r244",
      "r246",
      "r247",
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r158",
      "r159",
      "r164",
      "r166",
      "r244",
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/OrganizationandDescriptionoftheBusinessAdditionalInformationDetails",
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r158",
      "r159",
      "r164",
      "r166",
      "r244",
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r166",
      "r244",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r166",
      "r281",
      "r282",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/OrganizationandDescriptionoftheBusinessAdditionalInformationDetails",
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r248",
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesFinancialAssetsandLiabilitiesRemeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "terseLabel": "Grants receivable"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HealthCareTrustFundAxis": {
     "auth_ref": [
      "r344",
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of health care organization trust fund.",
        "label": "Health Care Trust Fund [Axis]",
        "terseLabel": "Health Care Trust Fund"
       }
      }
     },
     "localname": "HealthCareTrustFundAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareTrustFundNameDomain": {
     "auth_ref": [
      "r344",
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the health care trust fund.",
        "label": "Health Care Trust Fund, Name [Domain]",
        "terseLabel": "Health Care Trust Fund, Name"
       }
      }
     },
     "localname": "HealthCareTrustFundNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/AcquisitionNarrativeDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/AcquisitionNarrativeDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred license revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Incremental borrowing rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Future Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Difference between future minimum lease payments and discounted operating lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term of operating lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leased Properties"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedProperties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r23",
      "r65",
      "r109",
      "r120",
      "r231",
      "r235",
      "r236",
      "r251"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r18",
      "r65",
      "r120",
      "r251",
      "r314",
      "r323"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r25",
      "r65",
      "r120",
      "r231",
      "r235",
      "r236",
      "r251"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r55",
      "r56",
      "r59"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r55",
      "r56",
      "r59"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "negatedLabel": "Cash flow from operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/OrganizationandDescriptionoftheBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r40",
      "r42",
      "r45",
      "r59",
      "r65",
      "r71",
      "r75",
      "r76",
      "r77",
      "r78",
      "r80",
      "r81",
      "r88",
      "r105",
      "r107",
      "r110",
      "r113",
      "r115",
      "r120",
      "r251",
      "r316",
      "r326"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r75",
      "r76",
      "r77",
      "r78",
      "r82",
      "r83",
      "r89",
      "r92",
      "r105",
      "r107",
      "r110",
      "r113",
      "r115"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetRentableArea": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net rentable area for properties owned.",
        "label": "Net Rentable Area",
        "terseLabel": "Square footage of office space"
       }
      }
     },
     "localname": "NetRentableArea",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Note payable"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/OrganizationandDescriptionoftheBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r105",
      "r107",
      "r110",
      "r113",
      "r115"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r268",
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Non-cash lease expenses"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r261"
     ],
     "calculation": {
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r261"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets",
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r261"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities long-term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets",
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r263",
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for measurement of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Right of use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r271",
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Description of the Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/OrganizationandDescriptionoftheBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments",
        "verboseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r240",
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LeasedPropertiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwritten Offering"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Offering expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r174",
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r3",
      "r5",
      "r127",
      "r128"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Aggregate net proceeds on sales of shares of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Proceeds from issuance of note payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Warrant exercises, gross"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r40",
      "r42",
      "r54",
      "r65",
      "r71",
      "r80",
      "r81",
      "r105",
      "r107",
      "r110",
      "r113",
      "r115",
      "r120",
      "r229",
      "r232",
      "r233",
      "r237",
      "r238",
      "r251",
      "r318"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Domain]",
        "terseLabel": "Project [Domain]"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r7",
      "r8",
      "r131",
      "r324"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Obligation to purchase common stock"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Receivables [Abstract]",
        "terseLabel": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r165",
      "r275",
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardNarrativeDetails",
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r165",
      "r275",
      "r276",
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r165",
      "r275",
      "r277",
      "r299",
      "r300",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardNarrativeDetails",
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r210",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r210",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of customer funding recorded as an offset to costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.",
        "label": "Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred",
        "terseLabel": "Credits recorded to research and development expense for costs related to award"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r209",
      "r346"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/AcquisitionNarrativeDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r14",
      "r139",
      "r203",
      "r322",
      "r338",
      "r343"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets",
      "http://darebioscience.com/role/OrganizationandDescriptionoftheBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r68",
      "r69",
      "r70",
      "r72",
      "r79",
      "r81",
      "r124",
      "r200",
      "r201",
      "r202",
      "r214",
      "r215",
      "r334",
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r103",
      "r104",
      "r106",
      "r111",
      "r112",
      "r116",
      "r117",
      "r118",
      "r152",
      "r153",
      "r292"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue from grant for notice of award"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardNarrativeDetails",
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r62",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r270",
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating right-of-use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "verboseLabel": "Proceeds received in public offering, net of underwriting discounts and offering expenses"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "verboseLabel": "Stock sale price (in usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/GrantAwardNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r173",
      "r193",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r173",
      "r193",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r174",
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r177",
      "r184",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity for Amended 2014 Plan and Related Information"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r140",
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Common Stock Warrants Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Options to purchase number of outstanding shares of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Canceled/forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value of options granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r179",
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding ending balance (in shares)",
        "periodStartLabel": "Outstanding beginning balance (in shares)",
        "terseLabel": "Stock options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding ending balance (in usd per share)",
        "periodStartLabel": "Outstanding beginning balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Annual percentage increase in outstanding number of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r172",
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseRelatedtoStockOptionsGrantedtoEmployeesandDirectorsDetails",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled/forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "verboseLabel": "Closing price of the Company's common stock (in usd per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r188",
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationSummaryofAssumptionsUsedinBlackScholesOptionPricingModelforStockOptionsGrantedtoEmployeesandDirectorsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of increase (decrease) of non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares, Period Increase (Decrease)",
        "terseLabel": "Increase in number of shares authorized"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r63",
      "r65",
      "r85",
      "r86",
      "r87",
      "r90",
      "r92",
      "r99",
      "r100",
      "r101",
      "r120",
      "r136",
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/AcquisitionNarrativeDetails",
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r29",
      "r68",
      "r69",
      "r70",
      "r72",
      "r79",
      "r81",
      "r98",
      "r124",
      "r136",
      "r139",
      "r200",
      "r201",
      "r202",
      "r214",
      "r215",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r68",
      "r69",
      "r70",
      "r98",
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r11",
      "r12",
      "r136",
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock (in shares)",
        "verboseLabel": "Common stock, shares issued and sold"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r11",
      "r12",
      "r136",
      "r139",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "verboseLabel": "Stock options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://darebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityforAmended2014PlanandRelatedInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r11",
      "r12",
      "r136",
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r29",
      "r136",
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r12",
      "r16",
      "r17",
      "r65",
      "r119",
      "r120",
      "r251"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets",
      "http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r64",
      "r139",
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r259",
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r259",
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r259",
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r259",
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r278",
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://darebioscience.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash operating and financing activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r74",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r212",
      "r213",
      "r214",
      "r215",
      "r293",
      "r294",
      "r295",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://darebioscience.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount": {
     "auth_ref": [
      "r84",
      "r92",
      "r138"
     ],
     "calculation": {
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of (increase) decrease in equity for down round feature triggered for warrant classified as equity.",
        "label": "Warrant, Down Round Feature, (Increase) Decrease in Equity, Amount",
        "negatedTerseLabel": "Deemed dividend from trigger of down round provision feature",
        "terseLabel": "Deemed dividend from trigger of down round provision",
        "verboseLabel": "Deemed dividend from trigger of down round provision feature"
       }
      }
     },
     "localname": "WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofCashFlows",
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://darebioscience.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.",
        "label": "Warrant, Exercise Price, Decrease",
        "terseLabel": "Warrant, exercise price, decrease (in usd per share)"
       }
      }
     },
     "localname": "WarrantExercisePriceDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average number of common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://darebioscience.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=27011391&loc=d3e105025-122735"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=SL109261905-112644"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6806780-109447"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "810",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=99406501&loc=d3e10314-115658"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "810",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6923141&loc=d3e10459-115659"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r347": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r348": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r349": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r350": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r351": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL109261756-109256"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109261464&loc=SL109261606-128450"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001401914-20-000118-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001401914-20-000118-xbrl.zip
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M@U[6.\J7A3[*DQB]891KQK&R!LAD'+4V+7GC+X(!=.D)-3,5^!,1"SI!W)]
M'(R".QR,I9AAQBQ7C% :#49:1:<LF@-QEV+>;/""*(.%Y9$YHW30GBB"!/(T
M"J.?GE \*F2;/T&IYT!'IH6QX+( +:EQ+D@JG:0>,_KT"/KXYFC^5 6,[E%
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M866+NT;^-6']SZB7P:Q\_W+X%(CZT!-/BENGD_C  \&&P7^1LA"MQH0Q@:R
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MF)?#5^_3'*"#DXT+Z ]N?'A["7VGC9-M#&W2(FU&.:6\\K$>47([K>9U&V(
MJ?886Q33:7))JG$ZV'XI1!J8J+9YCXC>O8E??&43_P]DQ_WHK7=&.O6/1W&O
M8IVSF_N=_@!XHQ#R]2(3!KZ8"BV;GA__%+,<NEE+&[) N\::.S:]H^!K>7+-
M:AV3#VN#8D/#[]\.!3]H@AX:"I[(6M73VG/TL*F[KNT$0T\V*0Q@0DY'@WR4
MLKN&_1K<4:S48/*;_3WY'BE1?<,-7\Q@V6;VK-3.AITBQ2T8=UQSZ6C!QUCI
MF,/ !J: $OL77=OO_);__C2&-<Y(+,@5SDN)K@&[?C[.X)=KGI[2XL[LQSUS
M@%2IA M,;"$-*UCT+5C$)G=W*1E\D)S6.:>FSH1$=8M<J'NO&.(1(X-TF78%
M7%I4M)KN%J]?@$,K75:JLA5[/H ]K[SQCYY;01B1=:]UK+-(45USS.HR!H#<
M)C!G8I&OOOTTV;)I<F_^KFV:TPP\OUI9^/#']@WJN_=63NXBQVIF<*[8L[;;
M\RFS)M3L!:#;X#[5NJG,S>?C4*3A)N@VN,[=_PW_7CLV.>#B#H ^T^E4\#=A
MP;]'64*"  !MJ&Z -J_ ($VYO>76S H23B#)[;$=!IB8+J>MF34_2D4EBUM/
M!\&% HU@4BO*).2UWZ ]@.FU? 1F.S_NIPT$XTV0PV,SO-WWS^9F+U,7RX>K
M,?R^7D#_WT@Y1AL"D&!D3V $Z?[B5G@H]:)J)VUMSHM.%)U,[H!&-6\N\F?W
M[HU[[#A%=?ANN<\ZZ;RA&8[RI=1Y/U5^BGQ$RONHN:^[M+V&"8[KAG*25G0$
MQAH+%?W:RX.0W]9;/[&+]*=K"A5">3[%7:0/>^-][-KLSWTR^@\IS\&67;,F
MC0/*IIL-AZ">0@>4SJ#?2X:O<U$+8 0O:KO)'J8S'\Y";<L,39E^?TOQ7K<Q
MZ9+OC>!. )/55JQ1I\REW*^W:[\ETLH_""7/JAN&QUF>(AVG:4?68VOALK]7
MRC7DOS][S"W4W\?],Q?#1[<.$SR46*@R%K^>=: ?K0;HZ< <L*!<G3E,ZC98
M6P]6,X^,H3C%DU?6864=%L Z@$(VM0X,*-2,<V =!NF\GT)A#A)JO?/7&C!M
M_8L+"8:;6MX%PP)?!F.8"+JF"V._6$_7 =BFN3NJ'0WZGX?'XVO/ +*'HFL^
MQ*Q7E!TIDDO2DB2!4=[3P>(R_F-\VS=ON+]SXQL33J]NOJ>OXSNS7FG\,+%U
M,O8\)MV-9]]BH*6NH$7H,RY_K*C#UZZ19T+HZ9>*>"8EG7JK5#W31$V_LS\^
ML]^:@X>5/)MCY=2?C\*_+E3%QH0F2&!V\',1HY\>U\-VB#QLA-/8]+(@)6[[
M*[(LFOQLW+:A3Y#1EEK!/7JYCO(LD(+V"4<>]0<7=Q7M*-3J9G7#4OIYXY6/
MM^?0AXMF]SWTZ[C3?-7LM+8^730^O -_KL$:;7B^[2X/3]R7*Q];.\?-K5UR
M^.'=9>O5.^CC.]9J[YX?MK=IX_+HO/'A+;31[#;QC2(='XTT$EFITCXHEI)+
M?5T%^(L32:@S0@?FUUXV[T+9TUT*66G0Q]$WYRNR+)K>W+_/]WL2##>/PP)*
M.U#,ZU^C'+J4+^=JT*SMP+OK! WC-%<2UYWR.J6>@D4P6->-%=QQGK:/Q4*9
M?$7G/][N\!D*Y_;=L9;O#/P]HM9[E!SW^0]KI?*^L^YXJ?/&[/JJX-;-DEE7
MNN];NN]B(F?_H[+2*/A?G48AZ@P;63?P6UU09R4)3BCA"L=MA7=7 YK^V0;X
MIZJQ/"0G2XT'-J^%H)C6;^Y9Q4A;NNY<)\KB70D$1=H N*"]?K'J/\K+U1H8
M77F"S1W5XON#XEV=B_3RSQF\&EY;ZP%=^@F$GV5YX=+V3,_!2-/B3JKYF6[.
MAZ;GS<#G=R?_T]_,[W>NMTQIL7U*RX</.OSE::P?YL>ATQES5NTWX)=B&:^L
MPOOE(AG0ZO=[B740\KG3;H[(8C]-Y3(#BI]*GF ?$5>*",_K%G% !939NC8\
MUED0')M(,3/LFP>2K-(7P&E<5OVS42S\-_MGQ=E:Y0QB7!ZP=54L9:=(-0)K
M,.IEI6#FQV80\K6;PLJT$!1A)@C#3'IC(F("6?BL*39*?=R].N$<5);+NB"4
M_UK;;>[<%-G>J.O[P^J&.Q)CBPT4Q?Z)_:(7K=&PL&% 1( \@&/@=O2K2?/)
MNXN/,-W86L_J 9-09XZHNK).UIGVBE,-)"%X[265ZUJC=92.%;])WI>UDJQC
MRW''7O7)W2OKM5,SJ)V9SBC4_D^1V0!\\SD, IBI?)3RRGN^UK\FS@]F:-Q*
MME_4#(VE.]E[\E3VTWX))U\,0DHI/0M?G--^W9.B"^CZ$6/S?F<TO/^16144
MN%O!X;M.E?_>H^WEVOB9X\&U5W44ZG80S*>ZB3"J%Z;SV5SDZ;B:2=8&+J[Z
MPQ)CWYZD<BI>_FD'SV]765Z8PFK%/&YNO$MG<VWL'=2:K?9V;6_[U<;>UF[S
M56VGM?<!/M9?MUK_D[X7Q[,WMIOM^X]HGSRL!WW;*%(Q_?,8BW9>I*U F7L
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M]&Z6%]EA!=?'K%Q1JO9JC>% TGWF-(R2MYS.X_J:WUY+.0[0S0ZHP^&-'5>
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MX/CPHDB?29DSIRES?KW6"\-5+&7VL922&&\ZIC?<Z/GM,3V:8:6-ODL;[=_
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M'[V8X"2&/_'@.,X^O6KC"W">G^P].>&\)Y:^_K]WU!_^.<"_[/'S]Z&_S_^
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MX*2Q2A.G7=Z)HA174"$0+9R6RCIMQ<*T=B<;J?JK.[";5$R.>P[$F-(=*:E
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M6/;ZA:86F_)&4><E_8ENQ)NURM1Z:7.N!CT/&ASWQ%,?"417BDS91$*VM[,
M2B<I7VK0&WGQ;DEES,J8E3&7[MJAI+0^"2L\@@W11AV9D(9JK66PE3&[P)AS
MEW@"T]1[)4D4E&7&+%T[$L:L=UK-5)#<Z*QH2MD8SII\"%;:K+19:?,6*L[[
M("6CUC(E(?I@H\G_B)QSY4S2X4K>K!6:[X) 9RHG]<X(*07A'DHI%&N(43&2
MR U54?L8A-[994PTH)<ISUQIK-)8]VG,:"J\B@!:&O "K7$HM6*.!32.0:6Q
M+M'87)JOMLDP8X P=)* @Q+W*%%I<%:CDCY2VNJ!PMI&76(^5R:K3-9U)EN
MR*2VD-4O9K10$  MAA2UX ZY%2K2:L=V@+_F [?1IM*XEQ)JN2:@@R"E!% V
M:05/VBD6*=_9%8PU7,IJQ=ZSW.N5EI;O;O++Y;1WDIG4^3U><Z%JHMI]%\X"
M*DHR*EJ9DO%)  5J@V4B^JR[ZZ 8XDFBFCY-5+.U&.^6:#ZOOGKPG[]\_/$-
MHR!B5)RDA)8 =4A0JY1-N5(-TPF1_[^SRRPTIM;4VQ >J"1=A5.%<\LG:##>
M*@7*1>2@G;7".&%8"/DPI8)#/4&W]P2=^0[R>#Z^T9[JY%P^-#G3!))0! .S
MA >J8I26&<&[>(9N0^+W&BK:;UJ1A@4KVDN>(F5H7.2@K++>"^6TBJBY@:\%
M5J[BL5K1_L[YR,^2O[^\$F]<H F,D(1&E*6T+B=69K7>>P[.:!^5PE)24"G5
M:&LZU&&C5EY9B6:R)*)K3?OU8/;S/&9ED!*I)-PD2L#HC%DP2(+*4@O.94S'
MC%FU= '0BM:NH76-GK@*Y-L \AEWFE3&(S>*2,<8 0Z>N&0,D=DH4%1+B*6N
MO6RXU@V3%<Z; >=:3;(*IPIG>QQJ]2"\%8WVK%?,0[#&,4V8]8$ 9898+P)Q
M&K1U:"6G]O0H5'QIOU@M([B(7\P/QY->QF-LD\=ZY2][1]@/O?Z@MH#L@,,L
MY _^MK?LR7 P[H<X:OW\/P]+*9C#?ALD>#G\]7CDW^$XOC@9?R6R!8CL[<R=
M]OZ9*-?<\B&4)$>BC1 $\HE$#"1/!!46DBL=JTRIIR ;S6JGJ@V'_.VYT[X%
MZ5;SJ(B^/41_/H-HIL%("YIXKQ.!X!A!"X9XE(8'#XRKK)KPI;M/5S!W#<QK
M\+95G-\=SO?/GMP&/.IH$C'),@)"*.(X2T0J94.V,;USI1*298VD7:K(MFJP
MUV=4\EN/AZ62WQTJ.5_]+\\^[W]Y_,8R<#2)2)AW2" %5]K<<R*$TTP;SI3T
M)^S7*57G_J4E]=)H>-B;O(N]^"F.?'_<_L5''(WPICT=ML91?,<^F.OD7CYI
M1=FRWN-!^.M$;%,"K%RVE OF^=-7-)MKPJ+WD@0*F<A,2@2UY,0IJA.:*-&4
M.PI<-71Y-:X&AKJFMJPZG^DZD#X!\13#%;TW=+>TZ/74&,JH(49&0X"I1*S3
MB3@F1*0>P ++Z+W80JH"=\.!V[%+AA73JW"MM&E.#A5*I9%XETJ:DY$$N7-$
M)YNE'!-Z;%N0T,:"KL#>"&#7/)HJG"J<S7?!U2-Q_0ZWOS\^?_Q&!926Y5/0
MJ?P%%+?$"B>(P@!*6>N$]2>'HNJ2F;J]Z4Y/8SR,H1?Z'_HA#L*)FRTOR=LX
M*AZV,/PXZ+53ZQV-AA_ZXUK5IU;UN8<QI%J3H,/"6:O!O7@IU1,5XFFFTM_+
M,O\<<7(\*LWH1A''\6F<?G\VF-8I?'R8_VA258V;)C:4VX+<Q*A-9$0;Q0F
M5<0HKPESG'DM -#%G5W5&+6T4ZUBO!+P?1?.(C6LK5<@K<QDZSDH(:R42FFD
MD0F#BH45VG>5>-=!O,_GB==[FE J0:)1D"T\3XG14A)T7B4G*)/.7$6\UZ]Q
M76%]/SAW>_-<]N.D=S <;UOFRF;;TM49W&%:J<*IPJG"J<+IK'#6:P0M[H;*
M*D>V?(:'\3]9[ZA6SD)6SM]GK1QCE$^&4>(-IM(-(ULY4G/"H@DLT,@3=3N[
MNI&&-X9>+""W<#>?BMWN8'?Y '7%[GJQ>Z[L1J14Z)08D0(, 1F0( @@5.K
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MMYN#0AT9PN8&LQE^P30"=NDBGU]\>F$$E;G0-O1E<P8Y:)7'UNW(:F?B8/M
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MSF>.E8E#:ZU+XY+X*1MZSNNYTB?3$PUX(LMZNO>;:2IOK&C0QTR3<$-+_?-
M.*DZEU=?W,^?ZK+RY2QT(T[P^N-AR3O998S=LOIJNAP!$WPKJM(AO,T:F3OQ
M>8NOZ-N)KJVVR0M>36?.7NM;GTB>Z!)>J6$MOXI1JU:><J?V]9Q:_4S'%:K?
M8!EZ7(?Q]N]S4=-.6YESX%Q2S7/NO?905SB@+SDG*;UH3E+V,.8DA?<U)^E3
MYW78$4;@PTY]<%KBQDP_.FN"4Y_/#@[?PC/V@KU_O<7/XR__VC_9/Q0!/(/N
M_3B.]W:/H_U_?3E;"DX=OH_W#O'9G[]_.<2U#$^^A&^#_1__'.W_=?SC8/?K
MZ<$NWN<?^N#P:WSPQU$8L22C84("RF-"$Y80%L)>JCBC/M-*JR!8++OA.F%,
M)C+(8DKC,,T2S3.N0RYRFHLL61Q^].GSWM[.QR\XY^C3^]_VW[][_V9G_]#;
M>?/FX#,L>?\W[\/![^_?O'_[,Z./+E[,_.)%I.!"%2>1B"A6&84TC0)?Y)&,
MI S6UPQM8AII+S;4)CCTLT!82^Z=5<0,9-6B*KAM,([SX[R@D7X7N[><7TLN
M.,O:!>R,QVA@?C13:Q GWX'UY 4^^=]66\4L;Y<CM O UTL1"C!%*,BMY]/9
M9?B-3TJ 96/RBQ&;WWZW=2;X<*=G&8?GI[=O\(E[!L3#M,DWLB,I^C%4-_'C
M8E_BU#CWNY#.N/0P]&]:B]LUU N*PV5/ M/QS2R29E=6G58O-\?571D;]GCL
MO!EU[RPYB*'3%TL\<XO(^AH+( [T JJ>V7\_563=.]PYW=O]?!31( [B)"62
M,TDHBV* 5I$0"3C%6.(#8O%%J%PGXE<+]'NN#C*GC\S4'S;X4#/REVHR+E\9
MU(%#5UID$O;+2G9E9WWNK@"/"K W:U=BB4D2-GNK@U7GS# 3&VL#;K_M['P8
M6);7)@[HW![=J,^.$?%[8PDV1.V]+N$_Y@;O=CZ]'ABX:5ZN>Y]B;%-^&C/#
M*/;C&LA2M/ZX!LC_,%?LX*QH, 8R)(&/;26=]XG\/Z?I[9@MP.D59RY[;3$T
M,FRMZ,7GZ[*<VD'$+O_)O"YN@74[6'M=K4EQ>6^BZLS&EEM +B>@YY<NCO63
MA]V4V>#2>U&=05/ [_(#G,>P0K%E/'++UTK3"VVLT,K *D.34HFY?1B9[ABJ
MV:">H6/WRZ[8-49IOJ+D@ZV)>;]$D\TK-P'_9J_L6#-I"I"^&7'>7MGS]+0I
MJL9C,K]?QE7=E+2A08H:R8K"K,O317UB\@8X'A0S3 S?^0O,/W.&K1[CQN^N
MO@?2O1N^C5K'M+P376M%NX2^"GZ[&L3OZ A6OZ-;M=ZJ#7N[[X]8F,LPH2F)
M\U 3&DN?\%1%).%)E$0QST6^9-1H/Z1^&/N22C!G:)*G< XA3S)!X0,9/&@U
MPQ+'0T6U?OJ>--UKC=^^,"UI>PE0=E3MT,07F)&0ML?/"Z^M9K&?6CCL X/)
M=L+AAL;U"FS_\>#SH+F5R\5HTBX1)YQ0L1>4'/:J\9I9O_GXF)@NNTL7K$B0
M[N,B9T.C[M0G"IYY :QL\Q<,>60;E;^PTL-RH<=D 8P"E;($OI#@C%L5^9E2
MU%>QS"(II,EU?D#LNWI++L3;5\""<QR(@P6LAK88,S*)0"#J9R:BZ<VP2=+0
M*!_FFZT<MW<SC&F[+2XRY[HG=-?@8T8X[]1^><+.G-[A>D"V>4CF\S[R++V.
M"7/T'HZ8Y!P3IK7,=#GV9UPOO%]HT:S7I'YUD-2NRV0%S[][F\%F_]267#3]
M!%T;2U,>72UUTYF9H+/U8=F:!(Q'EU5E._]72RN<LTK:M,VU;P=@W&!\E\![
M[CM:G7-A>Q<:O^+*%W9FQ*1R?1?<1?8"%!MC1,CY-/__J7M;6#?!;&."N>QP
M.Q%U:B(;E6=? =^HV^K&*&P\4CWJP58HP[,E9=5^K^V#8B-PA9%T&$<O,99T
MYC7Y/:O[9JCOF&AK8NZLF8K\PON]S:C U&WDD(7],8]HJ=&T[L#49",HS;1
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MSVN]6/^%3#K8!KS1%1J^)T'FAWF>\CQ)J68\TUI&3&=<\TBD?KAZ-H!_E=$
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MY<BYS1 =]\W+_['QP7)82*/[<]=;OCY1:HK@NX8B-]F+?>DT,2-_@)#G\[.
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MAK[CRIM5P#?'MM4.]J,4_7Y!;N%R34\12P1U0P4G9[(JC]70D]7L&-YT"-L
MASB!BU#,XF+7GO[7<7DZQJT__/B>I&%B5)O=G8]OR>M_!KC=-K=I4A5J:O4;
M<3+&E1M3&V\_L^ETMI4=,+!DHS-1C ?&4H3=X@7J+/;S=[L[MI?%-]0-2[N_
MGH"78K!C'(20JFS'2^.C-FVC.E]1][G91SPBN]P>0.3GA3P;,C([9[I6.+UV
MB=#,/JTBYDL)P4T$TL.Y+H*8%0^:^\CHK&W?4J.MK]V3/H>^W.!MN$Z'H7OV
M7DU8,<>>+TWES%54\R2-A9!,BS0-:9KZ7,0:-/*<R3ABH/^A:H[-Z(UJOMR5
MGD27=:!W<?!-Z3=_#S%P<7:P<R1@EVD6"*+]+" T1"=Y*F,BHE $*J0JE K4
M[7AEPWCCHRO'8PMW%B6M9%]H?;#$CK^:*I4KT482Z81%BJ:A3T5&61;[0G,_
M2)(,C#B_I8V8-#]<ES8.R]<F3P+;.;01%G'VE$D&"Z*4U$R)/"6:QI10$3.2
MAS(E-%)")U0+IE+,CEL]9  ] JW,BXVJEKM&J='5*"*(9*SR, W#**.^"IB*
MX#<J.8\3/Y=18\A':PSY+47< $4<G^T?'^4JD"$/)(EED!%,6"5<!#Y)<I\R
MFN8Q4QPH(EA/$8WN'@57*/=Y&"*Z"^XWT=K[%M3&W39!!UXYITZCN+YZU%M0
MJO- 2-_7G"8JYSG-5,R$"%F2^BJ_,:%]^:CWTV/#K]^!#;7@7/ X(U'.0D)5
MDA*&$ UR$W"1*YTS8,-H'3 [%S$[/L;TR:GKK>""V$UHK#%WVGRBA>!?/R[8
M#YI?R4,;^YF*5)SF+*>FH7P4Y5E&$\V2).>Q W;:>&B3R-]2U$VGL.U\WSL^
M2N)0\C#EZ((% >^SC# ="1+R+*=<A#1.];-7\3I<UR[0@CUAC'7@4A5,#V&%
M'@?OWP#[+I1B<WZ;"N:K Q'@C@]$SK@6&F20S+(T#%0<:IV'H!AD%Y$-W:;?
MW #94""; /DUBB5H 2EHB+CC6:PD28"5:0KZ(X]#3*U-XW.R;\Y!(Z2A%H@6
M2R [U+E<CN##T"+>E17\.O8^=7DX[\>8$[DQRD1?DV#+>7_SZ4286%68]7>I
M\\YOVMS89;4PK8MA83R&*ZQ-,S&AVQ*3?VKS$QFZ_RIIXI9GQCV*'13*V12K
M)AN[]#.@"5S^:6J[BO<SIAQY.=<L.C>OT.7Q"15!!0^@".JBHJ:%(BA0DU!V
M^)G6$I2.*..9H'&6B"B,*4OYVB*HAP$EB]G%]X$@-N5JH81]R&9CZ]9N0PAM
M?,/E=0D[T<2,&>ETB2:I$5W \R[TE>AT BOQ:OAR"T[ \$N U25J+J9A=C&:
MN83,BQ:-^6<+H](6>K(\'G'5)%3>4_I/<_QF9 'B?D=E0XQ L;H<FU(=9=?I
MK)BZG%5N'!/:PNO#;FQJ9J)-3:?#Q7-'R>5.O4V[Z<L9.RSD"G=X Y0KV:!_
MI_\%ZI4E$/L[-X_M-X7]%<\&WGLX(B,\/X'&/>[TZ0;BEKOJF>:-*Y[<!5S.
M33%BE]D %R7$+?\+^+:6A1'BC\C-8[+=[@%)/X^'MHV][5?6YDW)^<H<DPBW
MF,F&1(ZPMG2"A)^1YC!_Z4[3_=D<+(!B43]WO &WJ\[P4_>C_=2N $/T2"?S
M&7*+L&WQT$TJ0AHU:?=+E-5;S'.D+7.5>VA'ZRL2\H;#/@WVGUS;*3P7!_F7
MEH@WO0SHFS&-N$3L7-\TAU[<C)6;T)L#L(Z[6//ZWB]\-C69<<926B2(WJ/.
M?<OG<W13]U7JOF"]_)[9(94XW7<QQ:]<R'W M' ;1B2SR: Y)*(KS+T%^V&B
M,)-@8,HMW6OA8>*&%U6EOI7N<$WK8_QK0_S=8L_/3=AD.+IPI-5E,SJ!9C3[
M5E8-6[2)G?V#7$[O;/82Z_^&9\N4>GDZ+?3 E3*>,&/*6[T/N[T@-Z_^^CRC
MGV\GXFRZUB;$-S/"'"=(-2+P1+7BZY+/7,H]P616,Z9O;BWN?OUM=[/USNND
M\E.QS9ZO"LA&O 1]6+*S58&KEAL/NV5],'-."K';;8O\!%MRH#_8O7AJGBMX
M[O[Q$<V4$GX8DB2FBE!&?9*K1!#!0YG$*J \2)^]2OS%=B@FP]DD5EF2MMJ2
MF5CA"&79O^%HI2/,;C@R"K%?=N:)UHJ1U6HL\/I79<IT&H46)2@ G)6)B[=I
M3);!I:D?_2=C'!XT@ON<&!8;F8%>O[Q^#G!2#&U): W;T7SQLBO=9/[8G:G#
M\D/7O?P=O.FL4D^.-T2P_\<190''S'D24S\BU!<QR;G6A,=Q'C+FIZFDSU[!
MYE_$'/-LT?"!MGN+;-+#6:"P-WT*<X2$@::1G3,'\HEY]@?,$;3RV&4D]M(B
MYYC,ULVY!W:4.Q\/=?KD[O,YW#\V5?>;0*W[IIS"$NJ![M'NDR//K]B4/@E%
M'L1!0#(_EX0F44+R%$ \RY(XQ=B0IOFS5_EJZG1S\)H2E7EE]\&JA5=.FUR3
M/OX8,R>[5_W5.^SR@@]=0^;[:+G0I/@SLS0[/7/5F,(VA=R.SD+MU^CVH!=C
M>P9K$)G<X7IJJU[;KYYOK!G'E!T+;;Q$:!4U"?MN&6O6X Q]-L!J6Y/F7+>9
M\ZUAT$^_MLU$)J4I?#*-A6=5/7/=0UC_TO;)$UBZ&WG6GUWMU*K6C'&CPX]+
M5RO=7RU\&REPH@P9HK%IXHY"7<(X1#:HRW(\WV6SNX?)_/:PJ^4%C4_F'K7:
M;?"87,&8FGS?#4Q,\H%CKZNG)?,@ _'-@EC2C-)4LX2EN4X5"UD<,U]?D'KZ
M?O_=-B_Y\M+\QY=P__0H$)I2S&7*_8""LIF&A,5)2A*?:94$0>1G'/.2U^<R
M72HQ>97 NWIN\GT0R#85=9%N!!KP">-I3$-*DHR"D1(FC,"YY"0,8Q8D(0\"
ME:.1LB:A_<:2DWF2JU#'4C/&J(A]G@1"17$FM:(!M4; .<G)6Y*X&9+ N6=I
M%L>)EA$)),L)I0@JN<\)8\*GDN8B3AB01)0.XLMF)S\B\;R<GGS?PKJ-V3?Z
M\$^D LHP54$0,Q9*REB0QYK3+$OS+(MDP(*5K:FWG;ANEOF.?6 ^,+LC2;5/
M=)[$A&8,Y+@2OA'KB:)YR+($4P&#G\L$O-.\Y"C+.4TEDWGLTU"K/-*QH(FO
M$D"0*&T:GJ=KJ,K_::)ZL@B^]^,]K/?SC_W=KZ=[?_T1'> 8C9S+/,](% E
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MZHQL<T%$[Q!U8P*T<0WX@_*;?M1I:Y%*_KR*B%?_>UE=D:$,"Z\M=CH/W!0
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M1Z6"T/1"JI)_WC3N>D IIE]2JW\%7#)1Z@TT^0Z*/X,F*I-ONZ"0%"0B3GU
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M5SCR9R\8-X\=A&XV_/@#;VT=8*\5XTJC%!4 4:H9<IPH!']SP2JA4JX3_'E
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M_^R]>7/;R+4^_%50SB2QJT . 8+;^+VIDF5Y1LE8]DCR^)W\,P4"#1$V23
M*)GSZ7]GZ6XT0% B92VDQ%LWB2P!C5Y.G_V<!W%N?'@<0T@2V ]A:0@$C-)
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MJ ?ESU'C::1B):JLMJ-!XHT^<$MC4Q\:.3A=$;S YL [2]!UY'.'P9O!6I,
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M]^'RUCA>DVJAJ*/UF]^=AU<N;<)?A$,GL3$!_I43B8(\],.1R%"JC19AFES
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M^& D^'29_X?3-PVWY='NT\^.]QA4&4^_B( !0@S>3XY^D0-)2(JHI=,R/29
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M+,[DX</RL%"V :0AU=KC:.F>:CH!_1J;-H"*2TQ'>;<HHYNFI'(YR'Z>#R=
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MX5@7;O5'/\VM8]LZAH.PG(.F=8H[_(YV6-\G\B4XK<9_"O_AMA[$N>*G=:Q
M,=T5C$;QH(]@Y8_0/7*@_X)'&/CSJ@T0@ZXHHV(EXX0^)QLM\)X5%][62C4,
M$L2S@H49CQ3?(Y4>>,J*%6$L"D-$XIZV_]K-UO1S'0&5+O,=B/4=TP_ 5#^
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M8_KL&$Y!N4LTGF>H'+#FALFT'RQ;HX EX[X85K3T8Q?F"L.*^)=)#'Q:A'Q
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M+(E55HF'0ID+*A1H9JYCEHL?+$J6A"P^6#^42MCE=_1QT_^ 4MK,YJ$/DG+
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MHVU.[8DUNAQ47;$77)$G9":$;Z1R1O-<^90E,R)7K>F<,!ZF.<F_^:JSG\Z
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M+D% S6<OR(8OIFH4VZJ\TU7,776Z6&:'&!6ERM\5%<VVSG)1E*H*E!!JPZS
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M\3<L$SK8[KZ CS/%$. R$5:6+(@'2D#6/[RH"B8P:!+&LR,LW[ %*R6(*'N
MIQ(-SU/X"@C>*RE0-AW:E?]O+!P%UDP#4;LA2[F:<4!>D,XI 7FPAFGE:7=A
MMI ;!I^/,&7PNTJ\X-6P8"D"@^R(=0:OIVZW1'>H3GV5),1>,AGUY_KD\B$O
MA+I88ATX?>*(99B2[X$I<NE" CQ1\0!1#!O/D/=,WAY!Y&<%ZK\/S+6;B;7-
M";I$KEB.@-IRFQG)]C7O4H"C,)Y17YYJ!$]*L@+C, ?M213D!<N:"WJ.5D12
M._/ <R133_Y6UO_.!ZA],%*=>MB%.69+</)"3;E!PIKE:-.="[][955U=]RU
M3]$-$ ""^0@C\6ST"]#*^[ @VZI/_0R4 JU]@"-L8?(B28  (*PUP>]<,B7!
M3R-,YA,?O$?MAFM%+(>Z$Q%M*N754M0SO"QT[3Q/;'7<O8$3 8[F+5IH8\6L
MYG7[&8FS[]V-D_7:@R+%<(=S8B0=BB^PI=Z(F["B75EV26X("\J69?-<^\!<
MNR3'I\;'^$W<N""BN6*<V?:]1B"B+JH[4M1GT@F*SJ@$.Y*ALU_9H2J+K'9.
M=NU_^SQ0RC&-8QJY@WGO@;DA KG9IYN"?;"""&I?Z.NW>0SH?B',YUTBBZT1
M[ "K[RSJT3FQPN.XRZXE'BCRHD-BP?*,\U-CNZ(]U.C[@7@6=;TA8M^+UNY4
MP]I5(DA*4N?>X[[CR'KHGI"ON%)%_G_X!(1X.<+P@475O_,CR(J(ZL^#%I[O
M(98\5:L6;ZF?R(7P& 33]JU\-W4WI/5/2L)P16FR<&,QK XWILDK;[FVL!*6
M[9WU=U7MR#Y#M$&D,S7PN@M&7+GB)=; \2L +67XJ57_+9'5;B*R7?,X8U31
MIT\"5F#[.R27XC-,8WJCSC$%N;_(5U\6Z;@.\F!SZ9)2]48,D$!GW0T/2Z^6
MBT2KXZE=DI-9SNX4R)N")5*1&N>JUQ+9T4RXFK.D(\PQ G];;3:O&+&YX:-)
MK)0#/U0'3"TDO>[HKC\:FR6.!6TVK5TNXS 9E.D6,P%@:O.<6<G39:6#[7)8
M:A_V':"<2U^@CPA3YPH'3K1(RJJUS)8W":*"DSG"6PW)[\;/Z.,)\P$XW*U(
M.0CC&1C7JOY&):2UBX?TC,.:X&L7#49X2KB\7Y+O?98!K3O*!CR<)V]8#1P'
M*SY5O:FU!:9#->6:M&GAH91RL'6?1XGNT=U2+@:A70HS1#&O\D^=E8,^5/8^
MPY@$Z*#U'%Q]!3Z-L37SJ$NGP*;> P$.XM7K!9=R'QYY2VBV"9D$RX$J.()9
M!RFUV]0*9]SW>J;]G<\MNL23Q[2VVJ,H"5P[Z]++>0];BKAG\I9:R@=%!^2W
M1E?[1$1U:@=.T3%$_57NJF@.9\.NB.#XE0_WMLR].432'1Y(ME0.5F[<)-Z1
MJBKH8ULF;.&!7%=>P(72V8??E(8#==NU[S,M]%?*0M?ML:AMJ?2;G*3YF*JF
M-\NX2;A:J+3N*B)+O)^A3YF#B:S7J#V/]JY]UIRMV=P@>*("?@GV!@9.8KN@
M]!:#!D/]^PE1,!*=V,D=5;KAH;JQMR[B?)5F&+"@_,/:BJJHZNE$O!J2]^(C
M("\QX!W2Q+^/S'#6/;JBJ_%:F$,]?9:XJA5$CY'6%5V**(2KG8?=WC^Z$(N5
M/3.;T[KV83P2BU%K1A;\AE !L67Q]4@M2.T#*EE"XHEZUGZ*420Q':H>/OF2
M.X.L=WS<O<F,/=>D-\L!UYW@#-^,J.)JF&*YYQ^'E=&AL:IG^7=$6KLR#/T)
M./C!J]-""UIP#S\?H/;!9.XX9:53LK85M]G-JHR[]BE:W: JMRKE-J]]()(?
M(XR (RMV?*/,M5_![#Z%][ZK\+8ZKMJG(#[U4>)@R.%&+UF:M2<%/6Q=!)*0
MA]3-WB)_*M6P=N)E80'$9^KE%F&$K"G.E]'V4,4QN7&I4C@#1T54^:=Q<@%^
M#T/<NA[G'Z,89Q0T1[Z,W,CD7V&$JDX"MH?RKR;U51K^0%/&85'%$5[DEU4L
MJLA8 %RWWY^_LS3P\#XWJ@K0U6ZRT\6"B_<$="!U;P3<H"5F01$\"[YO9J$+
M;JJ6 ZZ?:;I=&?V&8@G(P]E#S"GO%]Q!>K_R@=7QUVW.BLO@1J6@=JZGNXFH
M[J%7J9-R[_T+(Z8K![4EMMH]&55*GELS/$=??OI_4$L#!!0    ( )& ;%'+
MH4W'MA0  &O+   5    9&%R92TR,#(P,#DS,%]C86PN>&ULY5U;<QLWEG[/
MK]!Z7A<Q@,8UE61*ODVYRK%=MK.9?6+A<F#UAF)KFBW9GE\_!RW*IB1*HDB
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M;!0T(!0-'FG*,?I7-!IPVFG*:U!A)9I]"I\+<&![B1=V7!<6R<2HT1\'HD7
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M>,3KE6MW=;*GOFX;-1>5:[EU\A/H70Z[7H&;P\50OUQ@\D(* \X2+YU -RZ
M6,LP!?88@$5(!D(5?W<[K'VJ'2AL! KJHQA'7G<#7/-3PH<XCHQ;!*)D)+8!
MBWXJ-) $LPRJ% JLP+)/E0&%V;"MY(M1X,GIO)W!?(X9FV]GHR2^IFM#+A-N
MX\C;7&-\A;(\"&T9#AV!Y?$W@CA,!8B*0:%)2U+5"9DWA[P.H=3W2:@=Z;%&
M"C:1S#7<>4M8H($(DSCQBB>B/5?2FB"3J5++=N.279&,4CH5,9BSQ"3+\R*S
M(C8X("Y1$,&#%;9*=<)FH?4#)%OWTOLM2X^;"+S@"N1LZ%T8_FB'HZ>G\Z$[
MAO[K#%O:+D_.,@SZ(E$,$!R5 A/!U!",_RQMC*14LCJKD6OAV]/L:RN*U%#-
M0_K=)<B"\4 Q(B"><339#>7H*3!YE"9ZS"@;QWB5RKVM4.]IZK<5QW:GQMJ)
MX1(LU6"^FI./('7>'A6&6*T,D1Z$;J1TP*NLC-^);$_3PZT85%8=5UCR\^.K
MDGJ%OU<XY/C69:A',+38UV4P6YYXO-QRY>./MPRC]!G1]P/^.^Z0=6G! ?RK
MR[ME2R=2\EF4;<5YCY[*BW?3818Z>KKB>,_7HSW<6VI <Z)3/J]!%69 CGG2
M",6]%IJ!K[($?@NF(L6$-QQI>M'U:!=GY]%R^/*A=ZB',%K/61Q_6]C2^'\8
M+"UJ?,\E)1K!M1PEE6L]O0%BJ-=$*VJC" U*L4IQ?9WA[%,Z5(J?*TL:'Y8(
MY58I8?@&_O#,M=.\:O:A6SIVM=A3?N+F;9@DJV@R.I$0+,HMTD@, "/X40A4
M21YIE?#EGCCW*>6J1<.:JJO#KXGCLL&4+Q(PG.5#7X8XH2EQD7'3X*!3JK/^
MO8RB6(R_-#"%@:@#@U&I3+EP(S*"X:DG&%XJ&A+8&.H8\>M8]LD";Z[]&R/Y
M#85>]H@,)A#=94"+LN8))"%8$OG2FWSD4.5U,H;I!36-L=$&)T2=K;];8>V3
M.2S(B7*J*+\ L$ QGZ#SUIA1<J+0O6.&:1UQ4C$BN0V&Q9"\$%5-PP62;8?V
M#YAABU.,8P[C<3MKYT-N_^RKO+EF6D.#N7/*I[-CY,32@*Y-4Z,BCEO'*NMF
M=^#:)WNX'3NN\K^D0@H>EY\#-I/+^)_!&4R[\43C!23+02;G%$D4<$X*M-;.
M6IX+F;UUC=7150D?;T6U3]:Q+$/**:-,@=2K-N2>7P!, H_.-< )8PQP6#$2
MIS4CMN%4. >!V2N75-U0#_6MS7U: R^CQVV$5MZE+;EM9F0##C0Q(E\%93SF
M$IHU)%\49#C'?%54V7&[,]XMXK$A8730-,0;A7&E%F@W-1-$1NXB]5%&5R5+
MN<-CW^FZR&X8O2$-;HSH-Y+[@RV :*4:EWP@T0(Z5="!>(DSDGK!+4O4&F_W
M;@%DV[S=-HV27F0])TH$S5&Z1$]!&QU$XAAEU+G@YI:\?8\2V\*LN76=YUZJ
M*#9)_G!]+KU]UGV:O>M.9_$%N.&TSXM9?=Y8>P;G/U_.S@^>'![G(OV)5Q*C
M3,&(CAKGL_6).*"(-R3&E+< H4JPMQ':>P:!=6WM+NE57[<[W#==WA%;<1:L
MX&;?32?-JFWPW36<FGNH^4#VBVGWJ>AVZ;=&ZPKN!O"E-D&Q]2OGU3'K&OHV
M((S%>?;+'RP]^1;ZMHO7IUJ8GL8Q,@I';O81WN%@GJ<$89A@1*6T:!2)'&@^
MZ>1RQ 5H_BT&_]Q8X:M<6[+;81:(7C*$MWUWUJ**GWSY?0[8_]>0\S ,[=EY
M>8DP-DJ)&9G4>9&$V8:8$#GA42@P+ 4*5>ICUX>X3W'/'K-]1=A4@P,E$X]5
M^%ZT,S<+E_'A6(W-%^7X\2XP12DQ# SAWF'"SQL9695L>WV(^[2$]OUS=%L.
M%./H^1#?I.5AOYFMOJ5EHE(4WF%FHHS!662E)]9:D^\(Y]%#8S&KK\'2^X#<
MIR7"[XBGU7A0VYJ^G)VA!"_/)"XI%X"" .]RZF(M<2XPXC&)"5I'8UFM%9PU
M(>Y3*>YWQ-)*'*C-T541B394!1DEH6&\!=*A&&3$.<1<$DY:%G6M!;>-HM+[
M"P.[2.TP+FE1JKG,+Q5*JLG[4-X1SVPD05-) V\LDU4<QS<(^Q1B5V+)BLMG
M-Y%_L<GP#$YZ".THD4F(36.I%<3C[">":XHS$1KBFR!B:*RDHLIQOF40^Q3"
M[H@#&^N@W-511ZZ')^@3QI)UF,W/L?B0WRB6+S]V+A*1N,GO&T&"<LIHE$RZ
M.BYZ-9Q]"AIWQ(P">BG&D>OAP]4[92>,)>; Y9NMA%UP5]- 5%+2>(^X7)5%
MG+NAW3.4J[ZML OR%%9812)=OI-VXH%%"4X3@+R=C0D+\5SD92$E&ZY2B'7.
MRM\%[)YW=?Q%2;2%LLI4+]W Z]?=XKC'<'X1[EAL=7YAT5,THQ_S&4:/UC'X
M2#@&6DAWDXBE,5>FQ@2&-F"O%@W<4.RT,81[WL[Q75-HA\JJ:)NN7'4W\CUZ
M[S$ISN>90WX'&R1+H@%K93"4\RHGZNY$M@ZU]%\K/"JKK;HDNG([WH1)HY/#
MH$TBM8DPRN.X&TLT$[Y1C%EAJRPMK -N'2J9_P=4VD9G%=ETZZ4?$PK@M4F*
MQ)1W*$8!-+HAP" DZ;1+J<HEJ/?$N0['[%^=8^4T62:TRFX9!3%>TW 1X"EN
M?6 YQ70QOW \7_Q@@B'@?<20+Z!3#FL%32L:7VO!C_XU6%!$P+4BZ%57>TXT
M**$<#DLU>1. @2 VEYFY:%EPR7M+-PV75_6W%AEV5F?],,'QUGIXB)T\F:QB
MG ))FN>K8=!$&8TI(&V2;7P4M(E5/,ZF.WD;[)*X+V,5VX?N,/SKM.WAQG?&
M311HYB1M"..CT:84C;9L"$<6")!:>E[EY.GZ$/?J.$,EFEW;9JFCP(>H0J*:
M2IUOT8Z\49@70R!>24>L=DH E_FRI'VJ0KIO" (#=A$ XOP%LN7E?'Z:[RYZ
MDY:*KE%?BW+I^22_=$4(R4E2&M656+ZNPRH" I1-,7)V-8^Z*3RY7\??P5[E
MMNRY'+E4U$N9J.9>\#P'L(&A)S6Q09^J4032:A)E,DSD6/OJ*Y1NH$UISCSP
MWF91SE332,EW[UY'V+]W4\2Y>'L+!)F"D8!!>=XC43$1YU4@4>@HHHG,VTKO
M)+P+VG>P(5J*3I7T585'R_>>3Z@ H#0T)'D': :U)Q8!D$A%"M!H"ZY..'@#
MH'VJ:7L SFRLF\J'I][T']VL_??8DLM[(?/0MR?YMRX-1W!Q!>ME-.N=^UFW
MZ3*G?S8:2(DS4VMV?!AC.SXR?3E+77_.TV<PN'9:4[JW=KM3R:\O@!):>9]-
M0?^E2^_;C[,VM2%G6^=[-#C!WW;3=GQGX :"7[/E,K+=9!B[$U]],3Z(.!]:
MK!_.*X>J"?7#4F72CD2Z:DB[$^C"L;OI^9X_&JFES;5W< QN?MI#1-OT#O+%
MT/C5?*YZOH5YW@VP7:JPJ!!WI_O2?K= K[O4VFZ][N*JHO$&ZBEF*]WYE=2'
M'WLX/XV]B<3O;K2,0.\)?B?R*LW>[3K<D9QWR]EQ77X^=KB)1)>_7D8^-P(J
M/-K7>0$LWQ>X!9]N:ZZX-&X'7,2EY+7!Z_7_F[B)U2T5,OUKP*PGCBW"T]O:
MJRF::N'GRMZ*AQSW[Z6F,'><R*_$\"WXR7]^,ZXV+%;MOB"FP^.Q7TZ9R/NL
M+A]1G>9[86HJI""FFNJK);H=*!L3BPYCW7_G^WU6/;@H;%H 'KJE$<['PI;\
MX7/4</<%(&<PS]H>PM#U6V5Z#XUY)V39L>AW0"9,8T^/SP'FY?]V]F3JPI_O
MPQ%^=WZ._&W?YNV W[H(4R3_/M!I%ZAW0JB=B[\8I;:^4J[:U7&[N"+N>A];
MQH.KVJHECJIQX*6>JL2 Z_=02X /$/M=ZA_M \33*73+Q1P7E1QO3H?YX,;2
MU:*2OF^GM82_U>"++%?E6N&XJ&#<<-_G6AN%%I5NA59C\)N;O1M:JB.(6B;O
M:C_%5RKOTWX=T>UX[?Q*[R].\S6\O[6S]OCT>/SC12UQ0:G>W4D=T=YS<(7N
M:GT%\SG #2^%_0K@%"8J4.&2;_*;,1HB=&#$^3@699MD\;_45+F1:%V VU:-
MW=K/[^A$YN,^$L3GGT,NW3B_\SDQ[W63$@G2!)2%8L0"5<19+P13*3I3I0!\
M([3[5"9=A7=7J\WJZ[3\&T4N@YPH[:RDC<9!6T-$8P,Q03"B(A.-TEY(6V7:
MW8!GGZJF=T*A$GJI7*]X;T<R83OQD]C- WG*JP/<N:\T(=HH*$D))Y>0C!/K
MJ".4)^DELI'1*H?P]L)7+O7SO^#Z#Y^Z"=6-U50+$I/#"6ABOJ@7#:QDB0>;
M4J"Q2MG^/7%^G_[Q'ER[EW_<4H_%/..Z(%_C+/_P":9G\%LW&X[0" AG5 .*
M*&$<$2ZF_$XF2L"(9*1A,K@J[P78%/#WZ5MW0+^M-+M;'KZ#8]>BJ^G?I!<8
M7;IIGCH3R:SD#H5$$T0B:!3$:HP=1'+Y.@D;69WWV6\.>9^.,^T/%[?7;O7W
M_AP?M\.(=:PE&^L>\9$-%R9O:Z[4"VK6!%SF53XW=E:B\.L^S5>77OW"L'&_
M\?"3Z^,FPEKZ=AE9W 2G[%!+\.26UDJ+HCX+7L-X8?9;Z,?[<3>1Q]4FR@CA
M5F 51K[YWL?JAJI(H=;.QY5NWG;8Y-"ZZ;-V>IKIM[03]SZ?A!@/2#S_G-]Y
M #&?!1T?A/BMG<5V7FYMBZFV$UQ5-+4#$98Y<.+G\*_3_ ;MLTT/,UQKH]1A
MD-N@U1C\5D=H5C=51Q1WTF$1E^9_/ ;"O_[P'U!+ P04    " "1@&Q1LOWA
M?RY0  !:4@, %0   &1A<F4M,C R,# Y,S!?9&5F+GAM;.R]67=;.9(N^MZ_
M(F^>UXM,S$.MSCY+Z:':9SE37K:SZ]PG+@P!B5T4Z>+@H7_]#6Q2$T5*F^0&
M2=&NE67+$K7Q(>+;0$0 $?'O__OKU>"GSS">]$?#WWYFO]"??X)A'*7^\.*W
MG__Z^)K8G__W?_S;O_W[_T/(__W]_=N?7H[B[ J&TY]>C,%/(?WTI3^]_.D?
M"2;__"F/1U<__6,T_F?_LR?D/YI?>C'Z]&W<O[B<_L0II\L_'?_-^:299XH
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MSBE0YA&"UZ/QA[)??_PR*B'TLWC91_>@_/P\-S\H"Z?U(1F-OH!B^(>43I!
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M2:7DJ)4,.-.]-<AVD,^?I;U$,19>PM3W!Y,=Y?7@<5W+[W&\2_+D+GKFF1/
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M:IL:.@2S&&O'*%.VCM? 'T)=HD<B@*IMK=K-LXJGCQW;_99F:0@]#Y5NK=6
M*.)!@ J!IP8;Q9PSNDCSTT%$_XHU7![S KK7'3AQ>W3J=_KE>]UE L*B!.(D
MQ/&81(:<[E=*F824^(Z<1@J-0[+K23 PS'1"1]4?D6$)K8B@2G#.BQP_C%4R
M"31CE(HY)P^Y92F3U<O</:KVS:WN/];U:C/UWL6-N?Y^;PTQ)Q4T '(4O0$)
M!8(C AB4+$0#:50EF@*?>-,(K")S:II2<<UMC3-;MV:N/MWDM77=?D=_"8JG
M3BO!0!4?!!(()%4&4!Y](HDPQ*;=*'/@!?\KQ3FBF-FG["YV^;IV&856<;S=
M[&6$(!61$A".PP 9=4!1'F9EY8315EON4M8.219EOP&X>IJ8);(99<<1SY-;
M[I??/L1>:9< ,K=)83*ZX4T++T]D,U06,D\.Z6!96#U+*A"@T$;9;3Q^TQ0#
MX1%R&'N.2<KIUC64RA&3PY$JY9S@YV:##_7"-.^+6> MVX\9\UIAJ\*$JXT(
MX_42**PMP-)@V?5+L33+PQ]_/:R96J'X-]F"=ZX4>?MS?.@PJMN;+U!+ P04
M    " "1@&Q1-<<)2?Z@ 0!B_P$ %    &1A<F4M,C R,# Y,S!?9S$N:G!G
M[+P)N.-DV3_<<V9CAF$9AGT]##MA2),F;3+,0M(M7=(F;=.T11W2;,W>IFG3
M5E9?Q!<0D4505ED$ 05E!Q404%009$=  1&159!]G7_.Z0 ##+[@]WZ?_^N[
MN,_5G"?/\GN6^W[NY4G3-0^N>2RT:3:5284F)B<F]IG8)Q1:\WQH'Z;E>$ZW
MY;2G(ON&0QB9H6<]'YJF3:=KA"9"$^__7_-X_OLMSVLO T&[NZ\@.4UY7]&Q
MP('0!J%]PV!H^:I!6Q -V9MJRJIFKUCRCY_=L&1*DU8LX5$Z3+?C<DNC1JY<
M'A4JXL@0<6G)JI4+E@^6#:RV)7O"U, R[>ZRP8HE,^#+@O1T-KAD:J:*9ZQ8
M0DP73-5H9BKNN/(4NF]TJ0@AZ%0,WQ>*1A <WV<*#D,8&,9 *+(4BBY#PLM@
M>&HM+5FY(+@N=R5E62F16MM=<+=BR=IY^;Z_KQ_9UW%5$,)Q' S#( PO#6HL
M[0YM3Q@LM;N[C$'>QTG(7='5VI[FV%/3]T+3Z7DKEBQ9,+4.C3N2Q _Z:?=<
M<Z87201E4[9DV^L&:PB!ZVL73/V#ANM=^$]IE,Y8ZK]NJ(*:I7Y:<YK^UXTM
M:[TMNUY)5OYURVYEV);!DMQU>JXH!]5W63]0LN]]'J!D/UC&]4)IIMGK>J[@
M.>[Z =>I\*DKVI8^95I!0= H GX@&-.R(8G+%,>U!&^E9@FJ#.IM65T.?IC[
MT:J>YIGRRH]T.B-=A.E]-/?] E.;'M4R4[ #%@^62K(B]$QOR<J$X,JDYJS.
MV*9FRZM3/=.,.Z;CKH[3]=QR<-ST8QV!G^QI9J0?']3R0"B6Q5UY>I4JCF.N
M'&_&S(=K-Q6/3\&!&IG:DQ9$S9[6*WLM!S_>;'V(<B+XK RV+KXT'%L*1RH0
MO S!ER%P<+LL'%X'9%SS8QBT(VG*\!,8^!BC,6Z^3J6/-P^TC"1XPF<9Q$?J
M?@RGTNI935O0S.[GY.7TO[;@=N5I@5ZQY'V)7O*)!FM[FM[:RWQ-\EHK830Z
M,[!ULOY5HY:LJ2UO)89]V&AMUK]JM59HLTPR_6&[3TCR)]O-R/Y*$-=!A"#8
MLM'(EE2")-0DF2>278)(@#&6Z'+I5E]*XR,AC?N9!-VC"0)A#;-  &%BAD@B
MJ#]-26+W70;$?@0[W3@@EB!!($/S23/!0CC+&7BZS U2044R**7+R4&[:6'Q
M9'#3Y-&P:&8I5B/K?-5122P8DDIDQX!$G:#9X,H71F(2JI1,=@:_S%43&:I0
M+H4SQ">(:?+3(YJF\!#*</$ +J"U@/\VE>H1<BA-IZHS]Z,9P$:Z.JK[P6U]
M>F1D5XJ4_)E*RDPEKFYYXWMU9N2<:+8:_/1X6C.#XAK0VGO-_V"$7/W]2L88
MI)&&>HWIU,ST23^X-V;NN]/W\8QD5\V9^_#T2.)IR3)-R7]_ROA,ST:3JGK"
M=!(<]]SDJRW1GV:B/U,NI:NZ, V?F.F4%LU2F9TN3TR7JW0#*I5G -?-K'^L
M4@""S$PWR&E&2%0,5+1 L6HN3;<SB21:K*AJ.5V---/5L!2'V!G @+MNO98U
M,LE"OUDC6TT[F'>Z9(HP_<'J)^T9;JO3G"_H2;2@USU:0P8?8])XA"(T(T_9
M$D?#=,6 "UIXF->3_Q;;/RDVJ8 YVOLWB1$7"/M,LM2D^90IK$<BIY=C1K@_
M MB,!E43.C2-8GP$E-2L@%$>P@5)7?@(:+P\#<*T@HO7Q8U&K:!_=(1D8WK:
MJD"5PF+"Z><C4D0:HNT&3_?JL/JQ0:V_[EBPU]?@<]+[FV/=$?9F]FZB/BA6
MZG"^DNG193+9X!LMB1^$,ZD9QNE->-"7:AE5C)"M.LRI^3(YX@PI_C[P_ZN
M'Z6/R6$^E34;5G78X%&]429Y@:]&!!ZU9V37*K6EM-EO:N1X#9O_DPS&!^5@
MI*9H57O3HZI.[UO8[#6&P>Z!44.HE=I-&%$%'E%G /\'Z5\/D?#T"-?>5-H,
M0J126"_8G<P,8*"2$[% "Y D'6CR@FC/,#SU@; & '2\6B>XF6Q106'(K-<^
M7 Z"_3"YGC7,,3/_[$*[,5Q;'\IRF70!$NWZ^Y76K@E'Q%6"(4B62+.$3,3I
M,6 N$'0BD2$*/A&;KEIBR1R1Q (E3#:(%$+4?=(ATF%"5,D(0?F!GHVGB4PW
M4)WQ*I%U"-N/&T3.(%PU/AR/,"\2?2)!$G2=&/H)EBAP!.PG5*+($5$_T&-,
MG0#\P%"Q(IE@DQ6B9)"4GS2)<I>DU21"5!"RQ*9HHIHA9P!Y-J42O$@VU11$
MU'Q2]=-YHI$A+37=(@2#[+)IE!"3Y)"E2H1DD A+M0DE0P)J)D&H?CQ%9"1"
MJ\?S?@89C]!(QLM^EB/,<+SA9P>$[<1;1*Y(M-6XH^:ZA%N/^VP^3WA<'"'R
M+M'G IT=,'!03V18VB-&:H+U"PP!.8GQ7E8+0R*")#2UR!/13,)5BU$"$Q-A
MGU&#N28 EDT'$I#,$*Q')KK),E&JDFDZ*;(E@,SX24LM.V2^GAP0E<H,(%E,
M!BRH "0;3E$$YY(5)U5FJW62%U.2SZ?)1CW55GF(%+D4Q-9,4JFG2;7.DYJ8
M+OC!VIA&6E ;,=+QTS. -BOTR6[ 1[:IDWV.(GVQ00Z[%,-*# DG*8F0TR1J
M4"XA@R2>H5!60>)$-T/YZC">K&=XM=6+9S(94]4Z,X#Q/)()J[H=9[K9)&&8
M\8J3K?BF$:\96=VWC'C3R8Y\VXPKW5R2=>RX'LY5B78G[B1S%M'IQ;M<+D*X
MH[C?S<\ 9M0N&H>2>8'M$7%4S7>)?B8.)/, ZY<3<8=F_8&8H#A:5X=V@B9H
MF!V-$FRXD%4A(E%U"A(!%Q."4?#]B#P#F%#48M)'>@G#*#8(%$RTNT5/C943
M/82)LYB9"">9FHI'$VB=Z?H@DP!\-EXBK&229NLE$DAFNVROE*@E&:XT Y@<
M!'\<5FJ6 M8)3FE8HIRD*I:SK6PJ:;'E%IG3DUVZC SH1')(5]A!H$H0NM(F
MF502X#BRQ=JII,$)K?)XRJE<F!NU*GZJE*D6R"J?J@4::L#C*9G@ UFS4H;!
M-TF!2;D9'FHUHZE!N,:6)#.%&#6WI913H%A/#UI$.LW59P"UEM9/%[@ZT#+4
M-,<UA(%52C?%1J3D)-.:(W"E=B3=1H1!R>VF!VRS./#T-.(TNZV^0!$9,=<:
ME"FJ*SJ#$3T#2#&<1+4@BJH1DE6*)"C9EU,ME* L1S;)*$#U#"4YP  *-A23
M!$ *<-14F20S:5^UXHEDAB%:5#R5R=2XU@R@4Z:*&:6K98?9:L;):.XP+V5\
M1R_&"U8&975?8_PLB1F5<@G+YKH&K''9;$4UA3A?RXJBB0_K=C;0YZVA$)D!
MS/94.QV7LMF(8W>&BI@CP@XS; URN8P#Q8UTKJ*VA:$EY22B0V@.E+/4CC5T
MF9R?<0N:U\ZA83=<]E/YA-%=:U.&6KX@>HDX1.9K=:\SC+3RK7JO$H_&\Z[8
MBVF8D8><OE$&J3R(^(4*V:5SK ^/DF6:<P:JGH[22F:8T[-CSX%N=X=0@B[0
MX?I(&141&DR&<Z.26<@B83C!50I<&&J-:O&"$H8+H\:PT$'@:$4T"C 1L1-*
MK4BR")?0Z"*MHF/E4#'CQ1J&]A,V6M3K42G1&19[6"Q?\=QBU(E%$[[-I#FL
MG1CI3#F#URMPBY$)()- 5:9# $@":S%P$G1T4!L[G/$"T4C&+;8HD3DNU6&%
M 1DS,CYK9^,>EX^PHW9"X1BB1!22I7 Y5Z+10(ZKU5*CG8H8=:UD2>E.N.F7
M1E5J!E .*T0YT-_EL%8J%Z0LQ9EZ63"S6-*)E&TH-YC>)E A;QE]K1)OTZ(Q
MC%;8;*%LP)6*-"AF.;17<26&2.+C.*6"%IA(E; Y*L7VH&2:JY(E"Z(L3D^5
ME52>X@:%2@TJ=CBPP;%FF:D6O&HN586J8I9/0 VQVC%Y')*2531;FP%$4FJ?
MIZ#Z$#($GC<;O91#!?^$MNE"?+C:-*M]LY:HBBUSQ-?*DB2G(ME:JRTW4U&\
MYN-*O0J,ZD15K<+QL3ZL,X-6!4YK=:6JE?F<6.^3.@L7:W7 ,]@@.&L439/A
M^7)#EBR&%\J-7LMF>+G2 $R'@35>* [:+&P)@I(: Y;3'47H2VX%[MD"B'>K
M\+#?9%M>/0VCS5:V)\"Q9'. ]N4T6!+CGM^R$ZI8:0_,&N6+AC=LVS0I0M"H
M1['<#*!$D>$1Q3E2O0HAP;BDM@<#E,1+L0*2K+5Z,CU <[:5E64I6K([INR7
M8O5(/Z[$4YA:&[44+H4[-814K"PP ^C;F*X@)1"MDY2:T\BXDW)5$8[3F5Q9
M[9<35:08;07&1<U4]!8GISI(O=BR<VD($6,M%,B0F59;HZ-9&K$:8_6E1'.-
MC)O31O&\Z?0Q/5VDATYXH#>T HB@EMZ-,@4'D U"8)OM!&]4@%(GFRD9=J>,
MH(6"$1.X3+:<,YER=0:PAM:R@>3Q-BKFS A?0[(MVLIKC6S68BUE* A9MVJ%
M<TT7]44[8XDX"AFVE)/9;+1G#V!%0\&HD[94.)<:"[;3%+1L)\<[OJ!+'<9J
MIP1C$.60MF!9Z8Z0;_=AN]E1U$XJYPQR1J0C6!TJUV$Z?LZ5A'[;30V[X1R4
M=)M:;P8P+T1;[D#H:[$@V*1X/^JFU*XD#,NQ?+P[TD:NRYI>=@@E8WS.4].P
MW&SZ'JQ%D'RKT2NDT;)KQWMZ+^HUNV/ 7E3&,LUALU_B<3V&Y/I.&0!C>+0/
MU@B13G1]7B$1+*OX7C_!TPPW2%')4;>:'XAZNM1M)@9ABNIC*C[,C\9;K]BU
MT*&NYSRL"P]C3;H@#J%1I5;P1 0>N4VF@ %(.&&S/2^)A9NQ,H/GR7"X4AEX
MI2Q$]ZL5KU:"S!H/%R1Q!A "$O5&07=@?M3 I#8,]_M-M>"G(AE72A9@/M(:
MR8Z'M2-14"WTXCC"55JC8K:">'V]#C N2C$&6.23J!JQ9@#-7N W1VV'[FE8
ME&NVP\5V,]JKN6*Q'XMEFEY2AL68IO>\(D[$L)'/,PD3J^4'()BCL8$]:H-L
M&*?S$,?4QIX#;D5@ )1S &DC'<9  %&)5D'7!B(*1H+#.EBV\5X?S8/>"&PJ
M( @"R'2$:33AK$FD*V-W6P&;1(8=^]BDR@;^+I<D52Y%JD::9.O9N*\&+IN:
M3Q!.+NX[N6F'.4'XTQ\V02!,DL"*"9*NI$BVDASXS?2@*U(#3!G;Y2 Q\_&3
MTZY<(4&$ZT$/]72+*Z5*CO)!^6?X?!1PG0^(!;$#&[C>TV&!GRP11*9$L'0I
MF%J2&$?,%#$],7;=J(M-C7UL/Y,.@A<J3AC!]((*T\[XQRNS1#R8;; D8B;.
M.OF@)!YTD)B.,8*\8$4"C$"-C0%5ND0&,5*FE!FPU60Z"2<UL9[DZ':Z10[X
M :LQ).=1+7K0T+!X::CVDR8[*E6,3FY8CS#Q L?:1K0X*K2DL3YL4)5$N)?)
M9!TZ&V^IC58V6+I..5SU"M4<Z0X1D$E"Q4JX49L^(."A@50S<;X!MX+-[G6;
M/-JO1TJ09$N(/+8I[9A"08 2*29;=8'2,E9.0X:!H -Q RU7S;9<MQJ=IIV%
M91O-Z>T<;[6C6KO3Z75=(=IWIM<WF'XF0;)<<BPV;#T9#Z2B.;UFK62"C$^[
M&,D45RJT,FICH#:20Z=)^2F:*B'E0CQ5S6IB/SG*)DH)M264N2&OU0-%0D:8
M\;E-0<XFU8'$&;XZ,^6LWDBE-<F04EP$ZQ1'_E!MAP%FU,J6#8^N<"A3,J4@
M5FTW:RE(KD&E(#27'(%ON\UQ6 'UFO#[:_"ITT^8V<#$HEK#:O=$NQ%5C$[1
M: N"W<E9G4YTZ+D=H \*:\-;/S$M%LEI.4M@!,XAG5BJ5N]@#)0'A\VX@A%-
MS@.!BM88RC60(",@D1C@B(SYH)](2^"P8N*#!H72X P@6NXQH.V!@U07)R$&
MAX&B9"N(SVAX851E*KU!%<Y]QLLX7OY751"E4P.-P+>*"68?(S [.3*P/E $
M403 &+D>C%X/;K)# .GJV%A]*5B[1H$C&/3C&<]VBFVP%QF,NC$P36*U=D]H
M1Z7_Q1'"N7X"+X.8Y=O@]$+Z"0.Q1-L$!Q&0H2*MV"@!^D0C F:+M4C*G &,
MF+6R5_'Z=%CT!D)Y4%+Z2D3/^#6);V/57",".\-2D:GW#;[E5W2;I,MD#X^/
M^#[[B0', '[V)?_@HBM69!1I4R;$5 S0)[-].%6/%1+C$\XP(\$11,>4)DWQ
MDL/Z34JNB3&F"W;=;*=2Q^DBB-=DS(%<;  6^ [M YXU4IER&G(I+]9C=":"
MCBS%8PHS@$84RV"VBQ?@0ANK84Q2!OB 08-:+UX!&GBO+!A178 88%3)#L%!
M5X$0T!$0!5$5(!5PMZV+)4%OC/H9;LQE+]HM4\Y0PCV\BV=)/2/%$*5((VG<
MMV1+EO!FUR), _!\O6/ ,0ZW :B&0L..;+;R9A?E*2^?3UAR1E:B,X"P',VB
MK3!81<I0+Y*ND@"N!N87A*B^U1LB#;88ZWM!+-%H>:.8,1JVAW9]O)4^>1E[
ML)]6^L&%+P R6.C(-2F+EXNZT!*A<E@O(B0!9(<,J4"HBCO"R,_P,X!,A\G"
M=J/60*%B6<>3P<C[&L:'W;)7QX;1091F<G+,K@\KHV$RL!**)L$8C=92FFW;
M;"0K(R,4X\U!P-!Q)&4P83*6104P[PY!IRL4L7+$PPIPKV$F" K,L%!5@0!
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M)&P3MYI$-?, &'<MV%#@Y)*UQ9"$GJWW>JH^:2HI+^;=TKRL%M>=Z-L?;$9
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MI&G1:')O](W#+ZA^Y&3!")D5$OSPE$3'(9X$*,FAU((]O9/R!F-AK+%X(88
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MC;;(8>S#W/?? ;P##+O5AEE9GU-SX2.#]P'D7NT!EEU/ ML0R:*-FH%P((B
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MFH%F4>[PJV$I46NCN([26? T\@%54D_6$ -4S-QX=2'R/?3[_WT%_B.5]'E
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MLWI-L3W?A:@C?HHWZJ'-%3;T2-1(M>3[;Q&633USU-6Z=/SML/&\P-EX'@_
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M=2<=NZXF72G4 $6X: +H$U6)H>+"#"-9#I$.J_WG>?2,#4D9S-YM;>C5FSP
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ML @QQDM\&=596,VQ9#Z?[5W/_\P\6!=90X)3U+.!A1>Z-<,:!)5L".WD(BU
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M RGMT?N9\#D32(F!I4"GE&=W9[JU:ZFQ7Z?UK;=[_<&:M07?*LL2Z2F5TGU
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MW6SFK#H'%,K7O5E3K4S@@EA=MK@=YX<-U<HS"=_&+<UF<M+!GH\-MY,@7VG
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MUIOF?'2Y6HDA&6$W]D5P["E-.NS\=^=T*2?FG+X^ZG9ZD]$=7[TF1A_PJ;7
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MGZ0N'.R;&H742H=\X%M3FS4]SZQ2.M\OY]L]/-^MAIUEMX=,LF>TQOP/&2+
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M8-,GN9)5\2-HE52_?%/;>E5@Q5X"O*T@S;%+(NMLN@6D'JHV]IKDY"W\CG&
MBUSV\^:Z+^_7^<?_%NA[U*-N$L"*-(V/<V7_?""VU8HN=ESI7#J9<7!\<!R
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MDLZNW;P:WNI!5$.7,>C/F05/#!5&IO@^_U&_4A]YP:2TK].KKE:5;2<XU*K
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M>H<9=&><I?I;.W/LUHS>.:<42#+0WUOXG?N"_R-;&,+]1D12B_7R#QRE_]5
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M;<U66P%J:NY/"M6>=93]]E]%^+-1("#*BV>R8_13WB%>Z67J+1/M"Z;8,-N
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M-SM::+AFZ$J7&5ZC.AQ$$R_;?^=^ZCGN=^0^ZZV] (7SZY,6VC30W9,"@\Y
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M(<$3O?TH<J:L6C#\FX>0Z<T8MS6[<F1[Y]VL3EZ.J,E;$LU*>$+)[%E,/U?
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MAOT?PTFIIU@\\.:Q:%=ZZ O5Z]KC;*>:57OL'XO)E:2ZGU69NQJWB0[G#2>
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MD4_[RW1ER:*)3UKS+N74,*1<\M\>W%TCUE.""_&!\/LI)&7I&)T#"P&.V S
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M^[?_"\+_]>;+1_ N9^M'L5B!MTM!5H*#[]GJ ?R=B^(?0"[S1_#W?/F/[)E
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M_F2A^>K$#%Z*(E\OV7;M>YP?6]#46J97O^2W!7D4Q1.I7U!2:S.A4N0_M,A
MR0QJH4$I-=B*_6^_;55U@/=\=!3GKPP@^%;)_/\Z1I+71EWYNU$1W>EYTLCF
M;$>ZN;;?\N4^3#FSAJGB1_T6U":REP9>R7[&[?QV\ 5<+QMAR9*=&8;ZB=]8
MKBS4IQ7<^<:U1=]/JU7>[Z.IT%5"_03R)1=+M2<YHN#V$Q?9K-F2W*E79W[
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M_!!+EBD;;Q9(+%(1!U!(+X;8BQ2/QE$(DTC$B#/,PLC(]6W2V=2HLI8/B$;
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M%V5<?II&Q*<1AWY*0XA#-9-I*@FD'A<A\M/(0T;GN\>;GYHY4 L(WG5%.9C
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MM!BA<R''K6<X%,8')1$'ZZB'4_NS4%-IL2+WXE9N0JM+'[I:IO+%S(M1B*+
M@\)+?8C].(!IS!,81IP$,O699YA-QJ"SJ?'[-M2<;60$:B-E:'H;X6O@@':(
MVL!TNI547XO>PK<5UB%R%@YCAPB.Y!AN(:E6%G+D0W3E 3;$IM/3>ZZ-\3RZ
MAMKL>&Y-W[GP<K*R^\6JJ"\.\MO%%Z%+62OK4*<#*[8'YE1@/PP"#AE)/8AY
M3&&2X@3&4@C,I$=C27K=3S848&HL_)4]"+Z>EQ/A?;8@BS+0N%*FC%UHJH-G
MROCZHA;02C]]DD+ 1L<R+9YE9(/UT)D9U$,.R, $O[W/?-6,P.\MO/?0KBMJ
M@T%B(_JB.,AU9U,97N?&LR5")R\]V[;C+IO#YWR>L9?JO]OI%E*,@IC[D*
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M*:90^$&0<DG]T"P(HE_W4Z/@5JD[UI;X"BQ$>5)?RPV>\J6Y]Z[GT)@P]I"
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M==6W>;$J9FHKR241''J\K-2="IA$TH>AB+'P& ^CV*A2=V<O4V/'C^*>S*\
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M=W.7@I^-"@ZFI=.86%CIH9 .S%<;D(W<H!4<W*F]6_M5R?*_!P;9P90/!?9
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MUE+42Z,.$#OZU-LDVO-_J55R.(NY:@PM#KV&&IG _-8.RD8/L*,(:#4!NZJ
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M3F:^W,IPI&RMT1X?V[_5;UN\-M3-ULMB;NH@5N<;$Y)E(HVI@HR8P'R>(,W
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MS=Q9;%)<TK*4J[I"W$[]O?^\FI?.#4=O?O( \AOQU ;K1G3P9RN\1R?4';'
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M$!74Q*VEFAE2;0W02,$LE6FL<")8ECKEOSO3T=B(X;AB1V]W_"RV=A3A ['
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M96HX[V[^2;+EFBY?/TW52LKYP\_%P]-B76JGY^&G[NSU08^:;);@F%$:Y[*
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M?$C.EU_HZ273<EK>J5M>A4N;3>W%;,I?Z_]N;9^,I3')"JX1I9HO:!%#D[\
M,I9%/!,B$MBJ@HQ;MV,CYTIJ$]I\KUMM@Z,<_64[O"W]9>\HAO:76P"W(M^
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M/R./H(RS-"XH07EB52*CHX^Q$:R1$F@QP49.AV/Y,S!:1"]<#TYHD@,?P-_
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M5(:P36(QA&U;($C/(469&$:NLM #PN+6XEN!0O8/BOTEV@DD/B[";#FM@K^
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MDT56^2#AGR\GB2?Z7TG@D6M0/FGP6CL*EJW/*?/D_7#WF0_3L!TRNK_.'$#
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M@-FT$) !G);D$RI,5I<4%7^@L&J V\DGR1JG 7)CS VHB0YP]8!;Z 3'NCM
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M$]5T@+F['1(ON,A2&.:"!OJ#8A&6$+P('-#GE(.RB>LF"8T/DS-N6M'P:!I
MZ!U Y\J7?$N\O*$OEY.4?(X%J^^8,QE<1(A9:Q)*0.M5X;K-M)3[I'32_6C
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M9"!(3UQ81ILU)^53DXE@#Y,SKL7K#F\#Z&SLM)Q?Y[,JL;?U7N!ROHBSS-N
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MSWV F+P@%X&B?6^C)QD<QZP]26=OQ<A'LG##Z:Z#8W;[Y\=)B"(;E1-X\B!
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M[[\N=OK%[WQ]MZ"O_C>F35\5G:VI#Y,0R)&EXR48<$8GL-:4&)@Q7C89>=R
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M@4)J:SQXLI>@"@G"*J>MW:;%Z59ZO[7RR)K?1V_S(80XMO:GLQN$LQQ5E$Z
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M)9TL46;P.6O(7EF!3'KATE;FL-/Q]MU KH$^QD;7M86?:.YT=+Z +,Z!$L6
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M_&FAO>*>$S0_GN "0UG5:F%F*I,<+$7=]:8H@5-> V;GN9("C=C.']QO_>W
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M80J+6YU7WUAH9*@,K-1Y(PF/C9;WY_%TFC;IE(66KSF6&RZD#BEID<#F8NB
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MMN@8HH.TIXRGW3%\ 'AY+I.!ZX&?_N8*9K>CY"(-2J%6U;(IGI;$4^>(<%E
M3)Z;[;%D];)+#^@:HB[J!D]="F2@^'H_GC=3C2_+R1YZDE2!,22KA(ZE\HR$
MY"CA931R,E%'7N6@_RW"^CUT/3;"]A;) ""VM5>:<IG\]QP:%W'DHZ<\J$2B
M*_=KL]3$9>-)-L[&)")#/E;QS%^CJM]JS)K@ZDX8@QC<\NIROJ+(H#1#OL@?
MQQ.,>,;^YLMTWN2./Y3,\'R,7L'Y>+X8":NBQ<"'R%3J%Y3(99Q$)-24O>:]
M\G4N;G5$?S^C('O':R4!#TYGWAU=K8/K$66.V:0$B: 3!M3,$<LX.AD2M#3"
M*\NK=#AZG:Q^QD4>'X4'B6/PX-IA4VF62FU9Q(5FBG%]SB0 *)(S-XE[;G4Z
M@NW>?P']3*#L'["51#Q<:'^>3N)ZKSJ::&#E0D$L!4>JB<],(IQ9'75B+(<J
MA[=O4M;/Y,H>P;BG4$X!93ML, K**:XLD0Z0L28Q8DU ^,18&GDRY5V59'*'
M:^AGWN4@D%M)T(/#>!D?,[+6&65\)-$+7UHZ"N*:$7Q91,<5#=)7&8GYE)2>
M1F(>'W([\WUPR-G,(QJY'+B2 ?T';Y$I5C37^0S)&F1,";2M4Q/R/#D]S<P\
M/H+VXO_@4/1/*)$_I+,?^-UKN(1R6+WY8<F[LY&EP2:@BD29,,(OMX8=E9JH
MR!4HFQ+5O#Z^WB:TISF;QT=>QS([G9K;C\O2@_8O7.SM\O;1)NRP\/;MEU2J
MOMUQ=75*< W&I3)E21)EMMPW Q*T*Q^B%LS%C'^=2@GN"T[FAJNK?9-*@]J/
MXWGT-_\#?C82QF8I.2.LZ1YJ5)F>E3QN)#!>\:2$K-*T;G^2^RXQV!L_.UTN
MZ$YJ [#!K5;ZODPL_;6X^@DW/^"OZ63Q;3Y"K1X!#0@1H62-,@3BO*+$*Y:M
M*\.64\4*J=T)[KM<X;C8/%1B)X3,LNNN?DY'-BG<7$*1Y,N5=V#%JRD))IJX
MH#(P[:L$'SO2V7=1P]%QN(]\3@A^HR19T#:B@\M,Z042) F<<9)SP)UE<]"I
M2M^?M@3V7>AP=,#M))']D39=^)OZ2/M[DM9U09 ^_(KXJ^L!%SD9:Q4/1"C)
MRH5M0X*(F217W ]?-/O1[K2_26W?Q0O'P6 GLAJ ZGMA>2/N-43C/,E:Z%+W
M&$@(!O=5"DSYK*F&*G6"+]#3=RU"9Z#J@M__1JF3T98;4"EY,F*]I4^V5WB7
M0/G'_FPNLRC&B^8M?I+>H<N/@,)?V;/'S6N/ZXAMK2GN*+_TX'UG6^\KM;<W
MTSE*[;XA"O?1*HO*R'G4V64\3&#>E\Y*Y7I!-#S7:;JW"Y4'-X:[?]G]P^_[
M)3@FE9#H0VFF$I%)H2.5-2,E;<N=B3[6B?%?)ZOGMH/54/2D\UMWPAFN=7A%
M"7PN?<@6XQ]P0$I]E\?75VNOKZ@7-1<Y1M_*6!)50A1IA:XIEYE0D34W48@@
MJV1-CJ+F[B9 O_"F=2=:R7/FH'!G"D6D")H$[R+Q0LN$_V?&V5LX:_6F4U)<
MN^#BR<#MSM@]@&#HC^5\/"FA7/S7<KRJ^FENX_L0@T+_G$AF!3K\P1,+N" A
MG&$.*.K@*@/V7J"G'VQ5D/AVXX(.V#]0%)5/9P#K6_E4@12,.I)LN4 =2RML
M2S-QRFI EBD?JM0VO$E9SWT,NI!_"TSM+XR^1R/\-49^(A>_S_\83Q<0OWV:
MQ/_<C'@P)D<> C%9!2*A9"4BH*,HA61@K-"TG6E[Y27#P\<!LIQ68&S? 'E%
M/Y_?ST#UG$$4DF1*T=Z7FP!.E"8.661/<TZ2I4.=H/-^VUC4,U9UV-PW;IK[
M=P_VU=V2%OC9?)Q@U1QZ<T,*<"<$I2@)%C](H7"+29O+[5++I;/1FG:Z9K?W
M#M/QV5/BT^.POV]DO9O.IA/_8SQ;SL_&Z1)NQI Q5OX0IY/I[3A^A=AT[SR+
MB_.IGVQ&+%]"!(R=T\@8$R5X2I3Q&5DJ 94Y+5Z MIP%,"SSEKKJ$#J&J<4Z
M0-X1Q3, U_P]A,6G"8:]R\+/3Q-\,LR;+@S-S8_T!6:Q"/8:1MS39((K$[-D
MN<,4RVTF'@CC4F<3K6>J2CZT/8G]5)?4Q61E0?6M##^C;SG_XG\7[V.MS+_<
MX,Z+<;:$M%DF[BH967!E_$)$CY,92:R#0'A&EDG/N1?MQEZT>U\_52-'4&X5
MV#W<[/J?99#'V4\_VW(JVR7/'_SKCG+C+]'34>I[98*:AO?W?7PE]]8*0V)@
M#L._+- E8IHP:H6@2K!*9>3/T'*0FKAGW?T1D)5)^53J.)DI4WX0_\$IA3O!
MQZBS]D&U<X2>>7B_8?VADGRTY0]EW2GL[RX.RUYY6N?[_RA'8<^AB*O@C"V-
M2G,H76(4*O;@'$DJ*QU$ .:&K@\VC_P:OT%:WL!%1NM5"LWFC7$K3GFQG.O;
MRI/K^U>O4AP4)(],61)2.=MAV1(OK"):.6= "!9,E8LE>]([/$VT"X:VO=AC
M"*U'EW8^6XPP(DS+N+B8?879CW&$)F%OP% N4-<FDQ5J;\N)92H2U+7&.*>8
M4VVZ6.+S'P .O]H&VTL$](NBHTA]VJ$(A@&APIOU"N;K='Y0RDO!+'$4HSH)
MBJ,7 "4.B$P _M';<=#!.'I*13]@ZD:P3U%R()?[#J ;I^+BA\>73S:CI5F6
MQN?,2<H2?44G@01>+N69PB(1:<JQO6?\^.&]"_]0>3WQC0]@WB"$__[L\L/'
MRRNVIA^XH-HDQ+_W&I4F(#-DD"0YJX,/V9ILVPO_\</[2?K6%/X!S!M ]K99
MPIKTE*E/1G-BM)&E1Q\:2\H3,2*HY%C@AE<IH7A 0S_YU^[A<2A[!X",_P9_
ML_CV#AEW-5O.%Q^7D]082R4H#> MT:9,RZ69D: EQ_#?9AE#!!JK7)QZ@9Y^
M[R4?TR_M4C##Q-=G?[NI.LDL>B&"(#JPT@8 MPTZ8I(H24U((9:_CX2R>ZKZ
MC8$ZD?O;6-I3"'T[,G^,;VYPQ_T%^-/D__2X"S_BADR->-8:6$9.&;.2>!;1
M-M/DRSU"3;(1:+9+"S'K6CDV+5XV.*SL*]=I128/0 U=PDUS^.EGB]]7:*WG
M/I;%S/_X_? GS48#SE+F3I-8)O-(R22N+"F"\6*Y2V*SM55Z^;8GL=_F"'T8
MPTKB&Q@PU_LV0M ^A% ZD* 'J34EWI3Z22JCU9HKO1V8=0_ (5C"6D)_!5M[
M2*!OB_C9;R8 SQ?CQ1)WXD5>V85-J"J<]31F8@%E+B.UQ!H/&*\Z8VDI G?M
M:E;?>M-PT+*/&*>U>#H )?-(4:..;G3UO7X^OZL7@9"U,JB>1>:XCP+'<-AX
M0;P+G&G<4MI4L7UM">RW2TL?EJ^*Z/K669MBR(_(XN:<^R(W*911IDY!3)8@
MM]"KU$V] 7X)-%C'>')/L@XOZ*J7WM"OCJHCS&G7G!V QKI$P2 !WY!)[^$'
MW$R_ETJWLQFNY;II,_[/\>+;1RCEW3=_3G_ ;%*^^0Z#H.DMS$H@A/OP:GJ1
M\QP6I7?T_-.J4WD:*>FX4M$0&Y"CTEE&G!5EOI-$WIILF*ER);'>DOI-CE4%
M]<#P,("=T6SG!_P=@4^"*AU(2ACARU)K8;6EQ+K,6!1@*G56VR:DWZCT*"@\
MB/=]&]VSE,8KM_8+\FBR&/N;];Y8N\Y7T_O"LQ%3(7@K4?!1ETD-1J"O*]%G
M\4*S$+/*OEW1Y$ZO[=>_JV^>Z\F@;W3=L^GC=/;AUW>8S&'^X69\/5Y]ZQ+&
MMV&)KRIZ>229,=Y)25@*&)D9BO$ZADTD*:VD+$W@MF>]O("NG5[;;W^]^NBJ
M)X,!V+U+-/N3)13'MEQV*!6&Q>9O3/R'7_%F6392N1"(_Z4K_VOD@U7,42!1
M,8]+!%_:<SBB!4L>M#5H^NNX>CO3VF^;OB/Y<'4EV+<*?+]^9Z/!UVI]<^\T
M<AF"48!+8(9(YC2QN4P_LJ;4Q":>H%VEU2LOZ7>(7WWUUA5_AWM1X3,LSJ?S
M^1>8??V&O[+/[83M1W1T)>%5RCJZA_#!S\I4E+N7W!62"P\Y6:>(<X 2MB56
M4R&3C%A!)QO#-UNE^]9+!!UJRK:?>W_?ADOO> 9.A)4(WEC&(GB%*PTB6RTS
M977RKR]2U&^^K!-$;)NA;KA_,DJD24'O=='I^0?542C/45E;K:"0(TK;D0RE
M ;H6D02@@>2<(3J?HK%5&C774BL/CB<PLDSCFV6Y.;;N0S#&2*!QL""M'+#;
M[\N5Y"[RRSLB2<XLSZ4=IRRV.C&,$6QQOU*F2@-5ODI[U^Z7,E!%M@L&7[DC
MU8>\3T8#WJ5:WJ]9=+%<S!>^\1^?YU;SBY#NGU,NVT\GS=,.N#EZ%+KJZ.<C
M\+"Z%PF<!E::#$- GT%22IRDF21E@-O@,7JH,N]Z^.I^=4AMT)]2AI+4'(-X
MY8A/GI$4@S/&4"U9%?9TNXR!JOE=L%=/S>\LYP&D_0Y<\Q^_GW_ JCLFBR)1
M$0B',HTB94-<,IXD5-@)N&$T5JD^K[BFP=S?/3I4M^MF!H*;P6ZAAX7BFE-&
MM2*"TXAQKTC$!670ZP-EN;->VRH-N]XBK.=BG:$@J!6R]Q3G .#Y 5WGZ6^
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M*_8G120(REXNUR@Q.F.<5JC]P$ =WZ5LSC0T \>'AT WR1)YC7RUR#$,\VY
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M 5!+ 0(4 Q0    ( )& ;%%IF.>G5K@! *Z1$  1              "  0
M  !D87)E+3(P,C P.3,P+FAT;5!+ 0(4 Q0    ( )& ;%%JP3YO-!(  (ZT
M   1              "  86X 0!D87)E+3(P,C P.3,P+GAS9%!+ 0(4 Q0
M   ( )& ;%'+H4W'MA0  &O+   5              "  >C* 0!D87)E+3(P
M,C P.3,P7V-A;"YX;6Q02P$"% ,4    " "1@&Q1LOWA?RY0  !:4@, %0
M            @ '1WP$ 9&%R92TR,#(P,#DS,%]D968N>&UL4$L! A0#%
M  @ D8!L437'"4G^H $ 8O\! !0              ( !,C " &1A<F4M,C R
M,# Y,S!?9S$N:G!G4$L! A0#%     @ D8!L45S:CCS8O@  +O@' !4
M         ( !8M$# &1A<F4M,C R,# Y,S!?;&%B+GAM;%!+ 0(4 Q0    (
M )& ;%&!QMV"WVT  'G@!  5              "  6V0! !D87)E+3(P,C P
M.3,P7W!R92YX;6Q02P$"% ,4    " "1@&Q19UXJM$,(  !_/   &@
M        @ %__@0 97AH:6)I=#,Q,3(P,C P.3,P+6YG=BYH=&U02P$"% ,4
M    " "1@&Q1Q1_7R28(  "3.P  &@              @ 'Z!@4 97AH:6)I
M=#,Q,C(P,C P.3,P+6YG=BYH=&U02P$"% ,4    " "1@&Q1,LQV7KL$  "
M$   &@              @ %8#P4 97AH:6)I=#,R,3(P,C P.3,P+6YG=BYH
M=&U02P$"% ,4    " "1@&Q1,GS/8:L$  !T$   &@              @ %+
M% 4 97AH:6)I=#,R,C(P,C P.3,P+6YG=BYH=&U02P4&      L "P#L @
&+AD%

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
